<SEC-DOCUMENT>0001558370-25-003482.txt : 20250321
<SEC-HEADER>0001558370-25-003482.hdr.sgml : 20250321
<ACCEPTANCE-DATETIME>20250321171559
ACCESSION NUMBER:		0001558370-25-003482
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250321
DATE AS OF CHANGE:		20250321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annovis Bio, Inc.
		CENTRAL INDEX KEY:			0001477845
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				262540421
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39202
		FILM NUMBER:		25761547

	BUSINESS ADDRESS:	
		STREET 1:		101 LINDENWOOD DRIVE, SUITE 225
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355
		BUSINESS PHONE:		484-875-3192

	MAIL ADDRESS:	
		STREET 1:		101 LINDENWOOD DRIVE, SUITE 225
		CITY:			MALVERN
		STATE:			PA
		ZIP:			19355

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	QR Pharma, Inc.
		DATE OF NAME CHANGE:	20091202
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>anvs-20241231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.9.0.3 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 3/21/2025 7:32:06 PM -->
<!-- iXBRL Library version: 1.0.9062.16423 -->
<!-- iXBRL Service Job ID: abecbe0c-5c4e-4d84-bdc0-f22bcfa1d89e -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:anvs="http://annovisbio.com/20241231" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>ANNOVIS BIO,&#160;INC._December&#160;31, 2024</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" xs:nil="true" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" name="us-gaap:CommitmentsAndContingencies" id="Hidden__sY3U0j3JEOClaX1AU374Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" xs:nil="true" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" name="us-gaap:CommitmentsAndContingencies" id="Hidden_nehVYZIkkkyD86UwvBXiAw"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityCentralIndexKey" id="Tc_gyAUU2VwqkCQhdTRxalVsA_2_1">0001477845</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentFiscalYearFocus" id="Tc_b2qcEykNfUOP0IJNRr4LKg_3_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentFiscalPeriodFocus" id="Tc_n7aXXn1u4E-qkHV9JFFxiQ_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:AmendmentFlag" id="Tc_tzDbAOWPv0qBVZRnKBykiQ_5_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" id="Tc_l-woCN51Gkqe22neOrHPUA_6_1">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_mZLC-SsCREWJ1bGnJlH22Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_zf0wHy7OGEOHuqg2Y_k6EA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" id="Hidden_gpFqkFDn5Ui6GHkc9wqiBw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" name="us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations" id="Hidden_-uopdWwNhE2Q_pRJNT2atw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" xs:nil="true" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" name="us-gaap:PreferredStockValue" id="Hidden_7SaK4QnVyEqfJCs42II-wQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" xs:nil="true" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" name="us-gaap:PreferredStockValue" id="Hidden_0nCDzmrS8USk-QqhIbWFcA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_lTTopYnhakCO6SzZjzlPOA">10519933</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_AHJWVzGiNUeXAwXQV8zhFw">14141521</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" xs:nil="true" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" name="anvs:NonCashFinancingCostsIncludingChangeInFairValueDerivative" id="Hidden_TFrxFG3gykmZYKFhjgO8zQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" xs:nil="true" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" name="anvs:CashPaidForFinancingCostsDuringPeriod" id="Hidden_Qc2Tvi8YB0WWjmj0gWXuNQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" name="us-gaap:DerivativeLiabilitiesNoncurrent" id="Hidden_cLJWlZQJJUG8Jg1dho1-lA">0</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_CLI8H38dPUa4BbOr2SOSqg" name="us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" id="Hidden_IDmi6EBxm0ykocQlpvyy7w">http://fasb.org/us-gaap/2024#MonteCarloModelMember</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q" name="us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" id="Hidden_MYnYPWwqd0e83MnNL4wIWQ">http://fasb.org/us-gaap/2024#BlackScholesMertonModelMember</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Hidden_sH-lbMPWqkOGFnPa1im7Pg">0.0001</ix:nonFraction><ix:nonNumeric contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Hidden_nIEprH3FlECzxDG_jmJGRg">P5Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" xs:nil="true" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA" name="anvs:NumberOfWarrantsIssuedDuringPeriod" id="Hidden_x2mt2vNGpkmX_I7rt27w1w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" xs:nil="true" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA" name="anvs:ConversionOfWarrantsNumberOfWarrantsConverted" id="Hidden_hS9S4DOFWEOzsGyH4QCjfA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" xs:nil="true" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA" name="anvs:NumberOfWarrantsIssuedDuringPeriod" id="Hidden_IEv4e_C0VEWG-Y-PNjt6jw"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="anvs-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_CLI8H38dPUa4BbOr2SOSqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_f4FMnm-LBE-CzSoyhuwWBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_d8L9-mdvUEO7pQR41LiAvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hOaMIkWJtUezSLsczgZ1uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_QubN3dDRukWsMAmcsNrjCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_xdwCJRelz0CJeBLUaRigFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_15mDcFyvlE6Gb641ZNdHLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bxePodlwPkegkSAB4FKMNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_AedzWyGjZUykRExAVLXYGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mYYWaz1_-0mHQD-w2xRyvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_FuwYvmh-q0yc-mYoMixFEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputConversionPriceMember_naW-EsPsskqjwTlzZs5cbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_anvs_MeasurementInputSuccessRateMember_3aP8WPBeZ02voCIQpI_gMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">anvs:MeasurementInputSuccessRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_j7VLWFmUpEe9bDHG0DciDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_hMBXSD_r90OcUkje1xs0Kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6DnXcoTVUU-mi30CGoncNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9YgeSUKYHkinaLnDH3gT8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zUAgBq5SJEGx67d7VE9u4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6THFqqlMJEyIsnWSUyL9qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_28BkIxJtwUCxsN3Its458Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cpOE3CFuPkqOfWlu_Xn-hw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KVeVvbTwK06JZJKM4d21ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qdFrnkmd3UOa2tLKqyPiAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_bukzSMYfYkGUxtewxBU0ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_pDfDkGHDXUSTWmxUhrtBpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_wwvOa88X1UO_ZTYRVgaRLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_pJBku7_aCk68MVRcc7xViA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:PerformanceBasedVestingConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_OeMNROUv0EC2j9VxF13eMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_WHvnc8vNT0mnAJbraAi9IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_zW8RAM-bpUWV473IHWZYTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_12_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_VGsJvkPfqEiFabjsYECyuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_RldmCmC-GEOG6BsKRZ7jHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hvDUBjTlvU2jxBxrBfn9yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CG9ka-YnN066FFG9Jtzx0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_SrizNFCLl0OrRUDzrcGBsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_61vShh9zukuFEQnE9vaedw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_c12N8aDCj0a8T1KQPkPjgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_drKyELhDW0-wlU15l7Zyuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_gvgCPSCuP0eTU2Ad-DzdLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BZvwU0W_1kq5dnznbxqBTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_CS9mE9iYf0ibvclFxHcf3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_drOFZ18jkU62ofbq5FTKag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_F4sV-r5ZzEW1HxbvXiPFTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:April2023PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_SkKKchrYf066v4UUAPqRkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:March2023AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_2_1_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_a5jUEWlNeEGGlp00_fXhKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:December2024AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_VTb1RU6T3Eu-Tbi6TLPZEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023EquityOfferingAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_q2MkFPGZKUeQUuTkMa5JVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">anvs:GeneratedIn2017AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hoAfWhIToE-9kc4wkiIxvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1b7gLnM7l0uyFch569QwTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RRJXAsbbukC8dIuM3xSztw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b1p2M5EkZEWd2ktBcLEmYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_ZJ9I8gAzMkiGCrkd6nMsRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_Tk2BdOkQEki6zZ7xcxRKFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anvs:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_YF4qvTY1HkiAlLoVQFqtXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anvs:ServiceBasedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_JiqWi9fSuEijFwv_zoQINA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_DplnVEhr1UKyMZzvd2jAOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_eDlqgmZOK0uV7d1yioA33g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_OUKphoR9A0ai9gK2FT1JGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sZy1RM1ObEShrxOTqRKePw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023EquityOfferingAndWarrantIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_gHIzv_4Whk2YABqPEYSDww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qXOmV3N2BkWavNqKGoaRZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_MQP1-VikVEKX6PVp5fZJKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GmXKWrDQdku8NRf1skZHOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_EkA9YeMGEkWI79aNnSvkJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ETg7vggNp0yISA331JxRTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_Ce1DhVkEO0ycmzDj2jbxSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MarkWhiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_iJ4ofV9Y8E6ZohLjT2mgzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MariaMaccecchiniMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_leZDo1RgDkCmAdE8soyXPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:ClaudineBruckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MarkWhiteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MariaMaccecchiniMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:ClaudineBruckMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_rJgoRibFTU2F1Wv9IExzHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_18_2025_MpjKojjXkUSsMLNgxf4KXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_M2DYJkhLdUG7ok90TpIEwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5yKKJ3mp6ECf-Gc5Bz4Sqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_sqRyLfV0qkCQCwu5h2544Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_qlq2NUmLmkOmub_e008yZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-31</xbrli:startDate><xbrli:endDate>2023-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ks4SJs0ZpUGHrUcFBn_hhg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-03</xbrli:startDate><xbrli:endDate>2025-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_KsBP2tMOlkaHzf39vA3zUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_fOusTvtxKkyURMPwViHpkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-15</xbrli:startDate><xbrli:endDate>2024-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_xPM3GLi0RUOkXjtpjkTGoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_NgTaNPhJI0e6-e-ecoGs3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_dh8V_0GTe0Kam8Xht2ZFqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-03</xbrli:startDate><xbrli:endDate>2025-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:December2024AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_27_2023_To_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_Ole6j-8tB0ajoZW3rv8oMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-27</xbrli:startDate><xbrli:endDate>2023-11-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_7_2023_To_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_6Rvkzj0uGUq7zP-I43U2RQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:April2023PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-07</xbrli:startDate><xbrli:endDate>2023-04-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_IQdTVBbE1kuTFDb_-zrMqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:March2023AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anvs:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anvs:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_ZVroRH_FcESsW5ndUBJ8dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_aMlHarrTRUOw2ZPEPhIpaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_26_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_4nudJCrUe0q5HzKyVLPtIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-26</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_NZ9r7_BupkiL0YsEGFb8kg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_25_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_C7P9lxm6_UawTNSEnjwUvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementFixedPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_jFh9SfTd8kas9xGVihV0Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementCommitmentSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_Myild4X83kmqgHCD5Jm5Sw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementFixedPurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_KwF1UY3e6UWazmxYxCohhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-25</xbrli:startDate><xbrli:endDate>2024-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_7gg9fooLjEmkcRZFmQ-9wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_11_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_HZ8IW9wPyES6tf53JMU46Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:December2024AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:March2023AtMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001477845</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q"><xbrli:measure>anvs:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_iNruACJbWkCS-x51NTwMZQ"><xbrli:measure>anvs:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_D_Rt3F2Dcobk-KrJxikqwA4w"><xbrli:measure>anvs:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug"><xbrli:measure>anvs:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:13.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_428571f7_b888_44bc_9019_9b61cc419d8b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:2pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Form&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentType" id="Narr_9eZXt5Ywl0uO0vJowqUXtQ"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_560de5c3_833a_4b71_ad6c_b1899e914aec"></a><a id="Tc_77T8oJuKJUKOHgJ8TeBtsw_0_1"></a><a id="Tc_JVI6sneHC0CMeTJXaC2zUA_2_0"></a><a id="Tc_zUZz9xIctUSaRT3SwfMJ9Q_4_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentAnnualReport" id="Tc_ho0Avlfvb06nrVGBr0DKSA_0_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentPeriodEndDate" id="Narr_5OIHGWzMWE-WVBwsSru6nw"><ix:nonNumeric format="ixt:date-monthname-day-en" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:CurrentFiscalYearEndDate" id="Narr_T9knyJHAA02hYSsb__Tj0Q"><b style="font-size:8pt;font-weight:bold;">December&#160;31</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">OR</b></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:100%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.86%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentTransitionReport" id="Tc_FLySWt_Un0afHqhICwvYiA_4_0"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.13%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><b style="font-size:8pt;font-weight:bold;">Commission file number&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityFileNumber" id="Narr_GZeUfGFdI0mitYBlQKNqXw"><b style="font-size:8pt;font-weight:bold;">001-39202</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityRegistrantName" id="Narr_-xmQCWfBwkaerbJ-VKNhZQ"><b style="font-weight:bold;">ANNOVIS BIO,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Exact name of registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityIncorporationStateCountryCode" id="Narr_nAI_A6fkuk2Ek5j4Kjv46A"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">(State or other jurisdiction of</span><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">incorporation or organization)</span></p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt 3.59pt 0pt 3.59pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityTaxIdentificationNumber" id="Narr_Xm9KrUqyxEme6yLSjumAdw"><b style="font-size:8pt;font-weight:bold;">26-2540421</b></ix:nonNumeric><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">(I.R.S. Employer</span><span style="font-size:8pt;"><br/></span><span style="font-size:8pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityAddressAddressLine1" id="Narr_O6DO-bYmhkuFMGReE6eKWQ"><b style="font-size:8pt;font-weight:bold;">101 Lindenwood Drive, Suite&#160;225</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityAddressCityOrTown" id="Narr_EPS2jNIT70CHJK--uatUYg"><b style="font-size:8pt;font-weight:bold;">Malvern</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityAddressStateOrProvince" id="Narr_m8KrTe8WeUm7Lpr8rl0m0w"><b style="font-size:8pt;font-weight:bold;">PA</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityAddressPostalZipCode" id="Narr_NYT9HaE1mEaG8O90qGON_g"><b style="font-size:8pt;font-weight:bold;">19355</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Address of principal executive offices including zip code)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:8pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:CityAreaCode" id="Narr_3svz2M9SIUmK-GVQT47KJw"><b style="font-size:8pt;font-weight:bold;">484</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">)&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:LocalPhoneNumber" id="Narr_BATpVdljj0SkeNtKRpoZPw"><b style="font-size:8pt;font-weight:bold;">875-3192</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">(Registrant&#8217;s telephone number, including area code)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_1b4e4fcb_93fd_4b50_845d_0ea62902d24d"></a><a id="Tc_JUeaJzh21UKliEAfsdVsjw_1_0"></a><a id="Tc_tc7m60aggEKsSXL1pbBBoA_1_2"></a><a id="Tc_zgC4slpSs0u8Bs-d3yDhTQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:27.96%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:2.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:2.05%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:27.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.05%;border-bottom:1.0pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:33.96%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:Security12bTitle" id="Tc_JRXQjKhL4kOq9UTGvLTxmA_2_0"><span style="font-size:8pt;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:27.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:TradingSymbol" id="Tc_sYFOH76wbEyoS9m8e9YyNg_2_2"><span style="font-size:8pt;">ANVS</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.05%;border-bottom:1.0pt solid #ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:33.96%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:SecurityExchangeName" id="Tc_5wujyYyaUk2TsEOSWFIPnQ_2_4"><span style="font-size:8pt;">New York Stock Exchange</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_LGbQ87MKeEqOAzNLJKlIMg"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act. Yes&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> &#160;</span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityVoluntaryFilers" id="Narr_7Zb2jABfuESJOz0E3mY2OA"><span style="font-size:8pt;">No</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityCurrentReportingStatus" id="Narr_3m9gmA0UfUeEVQoavu5H7Q"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> &#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityInteractiveDataCurrent" id="Narr_mJvwBoSacUSIc1IfLeElDA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span><span style="font-size:8pt;"> &#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Large&#160;accelerated&#160;filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">Accelerated filer&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityFilerCategory" id="Narr_Z4X18ggrGkeyPqO9Nlnrhw"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:8pt;">&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Smaller reporting company&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntitySmallBusiness" id="Narr_HF9hq8zWc0uGXiyRm-HNNA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:26%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityEmergingGrowthCompany" id="Narr_gmkHL0apEUGVaT6qkwYtzw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:22%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:30%;margin:0pt;padding:3pt 0pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;text-indent:0pt;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityExTransitionPeriod" id="Narr_JkKsR_kr7EuTxt4fnBwwIQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:IcfrAuditorAttestationFlag" id="Narr_zqRr-28dw0Cd0-S0JR6wWw"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentFinStmtErrorCorrectionFlag" id="Narr_ve949k9u80uznf4o7QuTzA"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b).&#160;<span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#160;</span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span><span style="font-size:8pt;"> No&#160;</span><ix:nonNumeric format="ixt:fixed-false" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:EntityShellCompany" id="Narr_sij5EfAxEEqCyqKMWGTSpQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">As of June&#160;30, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_6_30_2024_rJgoRibFTU2F1Wv9IExzHg" decimals="0" name="dei:EntityPublicFloat" id="Narr_uzBbE5PjXEGeEnY-gZ3nhA">51,312,050</ix:nonFraction> based on the closing sale price as reported on the NYSE. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt 0pt 3pt 0pt;">The number of shares of the issuer&#8217;s common stock outstanding as of March 18, 2025, was <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_3_18_2025_MpjKojjXkUSsMLNgxf4KXw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_KP9ixp7tdkGYQNcGYg_zeA">19,486,231</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">Documents Incorporated by Reference</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="Tb_b63bLuuEQECPOyz--fYLCw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Certain portions, as expressly described in this report, of the registrant&#8217;s proxy statement for the 2025 Annual Meeting of the Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-indent:36pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:2pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_512c12bd_4ba9_4899_8eb2_e38d59d31656"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 8pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CautionaryNoteRegardingForwardLookingSta"><span style="font-style:normal;font-weight:normal;">Cautionary Note Regarding Forward-Looking Statements.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SummaryofRiskFactors_151760"><span style="font-style:normal;font-weight:normal;">Summary of Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_289954"><b style="font-style:normal;font-weight:bold;">Part I.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_749608"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1Business_749608"><span style="font-style:normal;font-weight:normal;">Business.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_448269"><span style="font-style:normal;font-weight:normal;">Item1A.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_448269"><span style="font-style:normal;font-weight:normal;">Risk Factors.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">28</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_556571"><span style="font-style:normal;font-weight:normal;">Item1B.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_556571"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity_600109"><span style="font-style:normal;font-weight:normal;">Item1C.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1CCybersecurity_600109"><span style="font-style:normal;font-weight:normal;">Cybersecurity.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">77</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_424245"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_424245"><span style="font-style:normal;font-weight:normal;">Properties.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_59244"><span style="font-style:normal;font-weight:normal;">Item 3.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_59244"><span style="font-style:normal;font-weight:normal;">Legal Proceedings.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_448345"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_448345"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">78</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_847922"><b style="font-style:normal;font-weight:bold;">Part II.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Item 5.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 7.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">79</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Item 7A.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Item 8.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Item 9.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_371514"><span style="font-style:normal;font-weight:normal;">Item 9A.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_371514"><span style="font-style:normal;font-weight:normal;">Controls and Procedures.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_404053"><span style="font-style:normal;font-weight:normal;">Item 9B.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9BOtherInformation_404053"><span style="font-style:normal;font-weight:normal;">Other Information.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item 9C.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_953652"><b style="font-style:normal;font-weight:bold;">Part III.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Item 10.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsandExecutiveOfficersandCo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers and Corporate Governance.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_144002"><span style="font-style:normal;font-weight:normal;">Item 11.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item11ExecutiveCompensation_144002"><span style="font-style:normal;font-weight:normal;">Executive Compensation.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Item 12.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Item 13.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Item 14.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item14PrincipalAccountantsFeesandService"><span style="font-style:normal;font-weight:normal;">Principal Accountant Fees and Services.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_494222"><b style="font-style:normal;font-weight:bold;">Part IV.</b></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Item 15.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">92</p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:8.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_558755"><span style="font-style:normal;font-weight:normal;">Item 16.</span></a></p></td><td style="vertical-align:bottom;width:86.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item16Form10KSummary_558755"><span style="font-style:normal;font-weight:normal;">Form 10-K Summary.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">93</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#IndextoFinancialStatements"><span style="font-style:normal;font-weight:normal;">Index to Financial Statements.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-1</p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_225846"><span style="font-style:normal;font-weight:normal;">Signatures.</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">98</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_3bb96cbf_e5fe_4647_a1a8_9b9dddc8973d"></a><a id="CautionaryNoteRegardingForwardLookingSta"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cautionary Note&#160;Regarding Forward-Looking Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains express or implied forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;objective,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; or &#8220;would,&#8221; and / or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form&#160;10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report on Form&#160;10-K include, among other things, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash and cash equivalents balance, runway and needs, as well as financing plans;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of regulatory submissions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks relating to the timing and costs of clinical trials and the timing and costs of other organizational expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks related to market acceptance of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks associated with our reliance on third-party organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitive position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intellectual property position and our ability to maintain and protect our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our results of operations, financial condition, liquidity, prospects, and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the industry in which we operate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trends that may affect the industry or us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should refer to Part&#160;I,&#160;Item&#160;1A &#8220;Risk Factors&#8221; of this Annual Report on Form&#160;10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of the risks, uncertainties and assumptions described under &#8220;Risk Factors&#8221; and elsewhere, we cannot assure you that the forward-looking statements in this Annual Report on Form&#160;10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.</p><a id="SummaryofRiskFactors_151760"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal risks described below in Part I, Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. We believe that the risks described in the &#8220;Risk Factors&#8221; section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the &#8220;Risk Factors&#8221; section and the other information contained in this Annual Report on Form 10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">As a result of our history of operating losses and accumulated deficit, there is substantial doubt on our ability to continue as a going concern and therefore, an increased risk associated with an investment in our company.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our auditor&#8217;s opinion on our audited financial statements for the year ended December 31, 2024 includes an explanatory paragraph relating to our ability to continue as a going concern.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional capital to fund our operations, and if we fail to obtain necessary funding, we may not be able to complete the development and commercialization of our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have limited operating history and no history of commercializing pharmaceutical products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are heavily dependent on the success of buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have concentrated our research and development efforts on the treatment of Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;), diseases that have historically seen limited success in drug development. Further, buntanetap is based on a novel approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequently, obtaining regulatory approval. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are not successful in discovering, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives may be impaired. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical trials, including the enrollment and retention of patients, are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome(s).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for buntanetap or any other product candidates, our business will be substantially harmed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials. Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are further subject to audit and verification procedures that could result in material changes in the final data. Furthermore, undue reliance on interim analyses may be detrimental to our long-term clinical development plans, which could harm our business, operating results, prospects or financial condition.</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market opportunities for buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if we obtain regulatory approval for buntanetap or any of our product candidates, we will still face extensive and ongoing regulatory requirements and obligations. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The successful commercialization of buntanetap and any other product candidates we develop will depend in part on market acceptance; the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies; and our sales, marketing and distribution capabilities. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">A variety of risks associated with operating internationally could materially adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely on third parties for the production of clinical supply of buntanetap and for the conduct, supervision and monitoring of our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner or do not comply with regulatory standards and requirements, it may harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Enacted and future healthcare and other legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and increase the liabilities to which we may become subject, as well as affect the prices we may set or the manner in which we conduct and plan to conduct our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain, maintain and enforce patent or other intellectual property protection for buntanetap or any future product candidates or technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize buntanetap or any future product candidates may be adversely affected and we may not be able to compete effectively in our markets.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to claims challenging the inventorship of our patents and other intellectual property. We may additionally become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. If one or both financial institutions fail, our deposit accounts could be adversely affected due to the loss of or delay in obtaining access to all or a portion of our uninsured funds.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The market price of our common stock has been volatile and fluctuated substantially in the past, and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have been subject to securities class action litigation in the past and could be subject to such litigation in the future. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_7bcedbb8_fbba_462b_8d19_d25631d76536"></a><a id="PARTI_289954"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART I</b></p><a id="Item1Business_749608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item 1. Business.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Company</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins &#8212; APP/A&#946; (&#8220;APP&#8221;), tau/phospho- tau (&#8220;tau&#8221;) and &#945;-Synuclein (&#8220;&#945;SYN&#8221;) &#8212; that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for the communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">In 2021, we completed two Phase 1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the &#8220;AD/PD Trial&#8221;). In the AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination (&#8220;MMSE&#8221;) score between 19 and 28 and early PD patients as those patients at Hoehn &amp; Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn &amp; Yahr scale is a medical assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease severity. In collaboration with the Alzheimer&#8217;s Disease Cooperative Study (&#8220;ADCS&#8221;), we also conducted a trial in 16 early AD patients (the &#8220;ADCS Trial&#8221;). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between 19 and 28. At the completion of the ADCS Trial, the data showed that buntanetap acts as a translational inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">All three clinical trials above were double-blind, placebo-controlled. We designed the studies by applying our understanding of the underlying neurodegenerative disease states and measured both target and pathway validation in the spinal fluid of patients to determine whether patients underlying disease condition improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics (&#8220;PK&#8221;) of buntanetap, our AD/PD Trials also met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, as well as function in PD patients. We believe that the AD/PD Trial represents the first double-blind, placebo-controlled study that showed improvements in AD patients, as measured by Alzheimer&#8217;s Disease Assessment Scale-Cognitive Subscale (&#8220;ADAS-Cog&#8221;) and in PD patients, as measured by Unified Parkinson&#8217;s Disease Rating Scale (&#8220;MDS-UPDRS&#8221; or &#8220;UPDRS&#8221;). ADAD-Cog is an assessment scale that measures cognitive functions and non-cognitive functions such as mood and behavior. More specifically, ADAS-Cog 11 is the cognitive assessment scale used to measure areas commonly seen to decline in AD patients. It consists of 11 specific tasks such as word recall, comprehension, object-naming, etc., in order to produce a scale measurement. UPDRS Part II and III are composed of a 42-item rating scale designed to assess Parkinson&#8217;s disease-related disability and impairment and also evaluate the activities of daily living and motor function. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Following completion of the AD/PD Trial, we submitted our data to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and requested direction to further pursue the development of buntanetap in early PD patients. With the FDA&#8217;s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our &#8220;Phase 3 PD Study&#8221;). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn &amp; Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to periods when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our &#8220;Phase 2/3 AD Study&#8221;). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. Our</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Phase</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">3</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">PD</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Study</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">and</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Phase</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">2/3</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">AD</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">Study</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">each</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">had</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">built</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">in</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;">interim</span><span style="color:#231f20;letter-spacing:0.05pt;"> </span><span style="color:#231f20;letter-spacing:-0.1pt;">analyses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="color:#231f20;">Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively, for which baseline and two-month data was available. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. The study was completed on December 4, 2023, and we released the topline PD Study efficacy data on July 2, 2024. The study data showed that in two subgroups, buntanetap </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">improved UPDRS 2, 3, 2+3 and total. It also showed that in the entire intent to treat (&#8220;ITT&#8221;) population, buntanetap stopped the loss of cognition and that in the 12% of patients that already had cognitive issues, buntanetap improved cognition in a dose-dependent, statistically significant way. We expect to discuss the Phase 3 PD data with the FDA in a Type C meeting during 2025. During that meeting, we plan to propose continued development of buntanetap with an additional, pivotal Phase 3 trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">With respect to the Phase 2/3 AD Study, we disclosed the results of the interim analysis on October 23, 2023, and similar to our PD study, based on the outcome of the interim analysis, we proceeded with the study as planned. The Phase 2/3 AD study was completed on February 13, 2024, and on April 29, 2024, we announced topline efficacy data. The data showed that in early AD patients, buntanetap improved ADAS-Cog11 in a dose-dependent fashion and was statistically significant from placebo and from baseline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">On October 10, 2024, the Company met with the FDA in an end-of-phase 2 meeting to discuss its Phase 2/3 AD data and to agree on a regulatory path forward. Annovis and the FDA have aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy. The Phase 3 AD program will investigate buntanetap in patients with early AD and will consist of one study that first incorporates a 6-month period aimed at confirming buntanetap&#8217;s symptomatic effects, while continuing blinded for an additional 12 months to show potential disease-modifying efficacy at 18 months. The completion of the first 6-month period, if well-designed and well-executed, may be sufficient to support an NDA filing, potentially within one year of the 6-month treatment period initiation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">During the end-of-phase 2 meeting for AD, the FDA raised no concerns with the Company&#8217;s data on buntanetap&#8217;s safety, including impact on liver enzymes, drug interactions, dose selection, pharmacokinetics and population pharmacokinetics. Further, the FDA confirmed that future development can proceed using the new crystal form of buntanetap.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function issues associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has historically encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or &#945;SYN, indicating that doing so does not change the underlying course of neurodegeneration. Our ultimate goal is to develop a disease modifying drug (&#8220;DMD&#8221;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets, if a DMD is developed and approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="color:#231f20;">Our leadership team has substantial experience and extensive industry knowledge and has been successful with respect to meeting clinical timelines, enrollment progression and data readouts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Company Leadership</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Maria L. Maccecchini, our Founder, President and CEO, founded Annovis in May 2008 to develop improved therapeutics for neurodegeneration. She was previously the Founder and CEO of Symphony Pharmaceuticals/Annovis, a biotech company that was sold to Transgenomic in 2001. She was previously the General Manager of Bachem Bioscience, the U.S. subsidiary of Bachem AG, Switzerland. Dr. Maccecchini completed one postdoc at Caltech and another at the Roche Institute of Immunology. Her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cheng Fang, Senior Vice President, Research and Development, has broad scientific knowledge and over a decade of experience working in the field of neurodegenerative diseases. She previously worked at Clarivate Analytics and the Cornell Institute for Medical Research. As a Research Assistant Professor at Boston University, she designed projects that addressed prion diseases and AD. Dr. Fang has a PhD in biology and neuroscience from Pennsylvania State University. She also holds a B.S. in biopharmaceutics from Nanjing University. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Eve Damiano, Senior Vice President, Regulatory, has spent over 35 years in the biotechnology sector, focusing on the definition and execution of regulatory strategies. Ms. Damiano has held various senior management positions throughout her career, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">with experience garnered at companies including Centocor, MedImmune, OraSure Technologies and Vicuron Pharmaceuticals. Ms. Damiano holds a track record in the definition and execution of regulatory strategies. She holds an M.S. from the Drexel University College of Medicine. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Melissa Gaines, Senior Vice President, Clinical Operations, is an accomplished clinical research professional with over 20 years of experience garnered from positions held in academia, contract research organizations and pharmaceutical companies. She was previously Senior Director, Clinical Operations, for Worldwide Clinical Trials, and has over a decade of experience at INC Research. She has demonstrated proven success in leading cross-functional teams as well as driving operational success. Ms. Gaines holds a B.A. in Psychology from Millersville University of Pennsylvania.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Mike Christie, our Vice President, Process Chemistry, has spent over 40 years working in the pharmaceutical industry, with a focus on process chemistry R&amp;D, pilot plant production and good manufacturing practice (&#8220;cGMP&#8221;) operations. He has held senior management positions in both large (SmithKline, Rhodia, Teva) and mid-size (Cephalon) companies, as well as being the founder of a company providing contract process R&amp;D services (later acquired by ChiRex).  Dr. Christie is co-author or co-inventor on several publications and patents.  He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Andrew Walsh, our Vice President, Finance, has over 13 years of diverse finance experience at both public and private companies. Prior to joining Annovis, Mr. Walsh served as Senior Director, Finance and Treasury at Ocugen, a Nasdaq-listed biotech developing gene and cell therapies. There he provided oversight over all areas of finance, including SEC Reporting, FP&amp;A, as well as Treasury. He also previously served as Director, Treasury and Tax at Potters Industries, a private equity sponsored materials manufacturer. Mr. Walsh began his career at KPMG as a member of its tax practice. He holds a B.S. in Accounting from Drexel University, summa cum laude.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Mechanism of Action</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, buntanetap, is designed as an oral translational inhibitor of neurotoxic aggregating proteins such as APP, tau and &#945;SYN. To understand how buntanetap can potentially inhibit translation, we undertook two complementary approaches: a macro approach to examine all proteins in the cell whose translation is affected by buntanetap, and a micro approach to study the mechanism of action using molecular biology, to understand and validate the binding and function.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">First, the non-biased proteomics approach was applied to explore what proteins in the total protein universe were specifically downregulated by buntanetap. We have observed that, in addition to the proteins already known to be reduced by buntanetap, other neurotoxic aggregating proteins - huntingtin protein (&#8220;HTT&#8221;) and TDP43 - were downregulated as well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A detailed analysis of the reduction of these protein levels was conducted in five different laboratories using multiple methodologies. The results observed in the analysis revealed that the mRNAs of these proteins have a special region, an atypical stem loop, that is preserved and responsible for their translation. When this region is bound to an RNA binding protein, the mRNA is not translated. When this region is free, the mRNA is translated. In neurodegenerative conditions, the mRNA coding for these neurotoxic proteins is over-translated, produces high levels of these proteins and causes them to become toxic. Buntanetap was observed to specifically increase the affinity between this special region and the RNA binding protein, preventing the mRNA from being released and translated. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process outlined above leads to lower translation, lower levels of neurotoxic proteins, and less toxicity in the brain. By preventing the overexpression of these neurotoxic proteins, buntanetap is designed to reverse the downstream toxic cascade that leads to neurodegeneration and reinstates homeostasis. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:251.21pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following illustration visually depicts the mechanism of action of buntanetap:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20241231x10k003.jpg" alt="Graphic" style="display:inline-block;height:251.21pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:446.94pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 12pt 0pt;">MOA; Chen XQ et al. Pharmaceutics 09-2021 Iron and Neurodegeneration; Wong f. et al. Frontiers Aging Neuroscience; 03-2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The special region in the mRNA is a 5&#8217;UTR iron responsive element (&#8220;IRE&#8221;) present in all mRNAs of neurotoxic aggregating proteins. The RNA binding protein is the Iron Regulatory Protein -1 (&#8220;IRP1&#8221;) that specifically binds the IREs of neurotoxic aggregating proteins.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">The Toxic Cascade Leading to Nerve Cell Death and Loss of Function</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. Buntanetap and ANVS405, our product candidates designed to treat acute neurodegeneration, including traumatic brain injury (&#8220;TBI&#8221;), have a mechanism of action we believe to be unique. The mechanism of action is designed to inhibit the over-translation of and ultimately reduce the levels of APP, tau and &#945;SYN, which play a central role in the pathogenesis of both AD and PD. This leads us to believe that buntanetap has the potential to be a promising drug for the treatment of both AD and PD. Our approach is innovative in that we do not have a single </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:264.16pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">therapeutic target for a single disease; instead, we are developing a technology platform that has the potential to target the mRNAs of multiple neurotoxic proteins, which are potentially impactful for multiple diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="anvs-20241231x10k004.jpg" alt="Graphic" style="display:inline-block;height:174.83pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:498.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In our AD/PD Trials in human AD and PD patients, we observed that buntanetap reduced levels of neurotoxic proteins, improved axonal transport and synaptic function, reduced inflammation, improved the health of nerve cells and improved cognition and function in mild to moderate AD and PD patients. Further, we have also observed that buntanetap reduced the levels of multiple neurotoxic proteins in animals, reversed the entire toxic cascade and recovered the affected function, be it in the brain, the body, or the eyes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our pipeline consists of: buntanetap for chronic neurodegeneration - including AD, PD and Lewy Body Dementia - as well as within certain combination therapies summarized below; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20241231x10k005.jpg" alt="Graphic" style="display:inline-block;height:264.16pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:444.95pt;"/></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:177pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Buntanetap</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate, buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. Buntanetap has been observed to improve axonal transport in these diseases in preclinical studies by inhibiting the overproduction of neurotoxic proteins that kill nerve cells. In Phase 2/3 early AD patients, we have seen a statistically significant improvement in ADAS-Cog. In Phase 3 PD patients, we have seen statistically significant improvement in cognition for an ITT population, as well as in UPDRS scores for a per protocol population. The drug has further demonstrated improvements of cognition, including memory and learning, in AD mice, as well as movement, including colonic motility and grip strength, in PD mice. Buntanetap was tested in three Phase 1 clinical studies that showed it to be well tolerated. This safety data is applicable to the clinical development of buntanetap for AD, PD, and potentially other chronic neurodegenerative diseases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Below is a summary depiction of our previously completed clinical studies of buntanetap. To date, over 1,000 human patients have been treated in the clinic and the drug has consistently shown to be well tolerated with minimal side effects:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20241231x10k006.jpg" alt="Graphic" style="display:inline-block;height:176.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:451.87pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that buntanetap has the potential to be the only drug to improve both cognition in AD patients, and motor function in PD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANVS405</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after Traumatic Brain Injury (&#8220;TBI&#8221;) and/or stroke. ANVS405 is the same compound as buntanetap, given in cases of acute head and brain trauma. In prior animal studies, ANVS405 was given to rats intravenously after TBI to determine whether ANVS405 would reach the brain in less than 15 minutes, as opposed to 1.5 hours if given orally. TBI rats that were treated with ANVS405 after the injury exhibited enhanced memory and learning and lower microglia activation, a measure of inflammation. The program has previously been funded by a grant from the U.S. Army and has since been completed. We therefore plan to seek additional grant funding to further the development of ANVS405 for acute indications of brain and nerve trauma. If and when we receive such sufficient funding, we plan to conduct a follow-on study to evaluate the effect of ANVS405 administered to TBI rats at various intervals post-injury to determine how long after a TBI a patient can effectively be treated. Our plan is to seek further funding to conduct the toxicology and pharmacokinetics (&#8220;PK&#8221;) studies in animals, file the initial new drug application (&#8220;IND&#8221;), conduct the safety and PK studies in humans and later, continue with Phase 2 and Phase 3 efficacy studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">ANVS301</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 was observed to improve memory and learning in rats of an advanced age by lowering the number of errors from six to three and shortening run times from approximately 75 to approximately 28 seconds. ANVS301 previously finished a single ascending dose Phase 1 clinical trial that was conducted and financed by the National Institutes of Health (&#8220;NIH&#8221;). </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:123.4pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Clinical Trials of Buntanetap</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future Development Plan for Alzheimer&#8217;s Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The future development of buntanetap for AD includes the recently initiated pivotal Phase 3 study for early AD patients. This study was designed to include both a 6-month treatment window to demonstrate symptomatic efficacy, combined with a 12-month extension that will allow the study to achieve an 18-month treatment window that demonstrates disease modifying effects. We also expect future development to include an open-label extension for AD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February of 2025, we initiated the Phase 3 AD study of buntanetap in 750 early AD patients, which will be separated into two cohorts of 375 patients (the &#8220;Phase 3 AD Trial&#8221;). The trial is expected to be conducted at up to 100 sites in the U.S. The Phase 3 AD Trial is a double-blind, placebo-controlled efficacy study which treats early AD patients. The inclusion criteria for early AD is an MMSE score of 21 to 28 and diagnosis according to NIA and NIA-AAA criteria. Patients participating in the trial are age 55-85, have a study partner, are of non-child-bearing age or agree to effective contraception, and have no evidence of suicidal ideation. Additionally, for Phase 3 AD we are incorporating a new biomarker-based inclusion criteria, for a positive reading of pTau217 levels in plasma. pTau217, a phosphorylated form of the tau protein, has been recognized by the FDA as an acceptable early detection biomarker for AD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patients participating in the trial can remain on any drugs they regularly take, whether for AD or for other conditions, as long as they are stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse are excluded from participating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patients are to be randomly assigned to receive either 30 mg of buntanetap or placebo, once per day. Patients will visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 24/72 weeks. As described above, the study plan calls for opening the blind to a select group of individuals who will analyze the data after the 24-week treatment window, in order to evaluate 6-month efficacy of buntanetap. Study participants will remain blinded and will continue participation for an additional 48 weeks so that buntanetap&#8217;s disease modifying efficacy can be evaluated over a total of 18 months. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Below is a visual depiction of the development path and study design for the active Phase 3 AD program: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="anvs-20241231x10k007.jpg" alt="Graphic" style="display:inline-block;height:123.4pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>We expect the 6-month symptomatic component of the combined AD trial to read-out in the second half of 2026. The 18-month disease modifying component is expected to read out in the second half of 2027. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Future Development Plan for Parkinson&#8217;s Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">  </span><span style="white-space:pre-wrap;">As mentioned above, we also intend to propose a pivotal Phase 3 trial for Parkinson&#8217;s patients to the FDA during 2025. Buntanetap has been shown to prevent worsening of cognition in the entirety of our previous Phase 3 ITT population. In the same study, the drug also showed statistically significant improvement in MDS-UPDRS Part II, III, IV, total and MMSE in a per protocol subgroup population. Our plan is to continuing refining a proposed pivotal Phase 3 program design during 2025 and when it is finalized, we will propose a meeting with the FDA to solidify the path forward for clinical development of buntanetap in PD.   </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Similar to the AD program, we also expect to ask the FDA for clearance to add an open-label extension to allow all patients that participate in our pivotal Phase 3 PD program to continue on the medication. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Initiation of the pivotal Phase 3 PD program and open-label extension is also currently contingent on additional fundraising.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 3 PD Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2022, we initiated a Phase 3 clinical trial of buntanetap in 450 early PD patients, which were separated into three cohorts of 150 patients (the &#8220;Phase 3 PD Trial&#8221;). The Phase 3 PD Trial was conducted at 53 sites in the U.S. and 49 sites in the EU. The Phase 3 PD Trial was a double-blind placebo-controlled efficacy study which treated early PD. The inclusion criteria for early PD was Hoehn &amp; Yahr 1, 2 and 3 with less than 2 hours of OFF time, as well as a MMSE score of 22 to 30. Patients participating in the trial were age 40-85, were of non-child-bearing age or agree to effective contraception and had no evidence of suicidal ideation. Patients participating in the trial were permitted to remain on any drugs they regularly took, whether for PD or for other conditions, as long as were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse were excluded from the trial. Patients were randomly assigned to receive either 10 or 20 mg of buntanetap or placebo, once per day. Patients visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 6 months. The study plan incorporated an interim analysis at two months, the results of which were disclosed by the Company on March 31, 2023. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Phase 3 PD Trial&#8217;s primary endpoints were evaluated using the following measures: MDS-UPDRS Part II and III. Specifically, The FDA requested two co-primary endpoints to have an objective primary endpoint (MDS-UPDRS Part III, motor function) and a subjective primary endpoint (MDS-UPDRS Part II, activities of daily living). Together, these co-primary endpoints were intended to provide a more complete picture of the study and treatment results. The secondary endpoints were evaluated using the following measures: the MDS-UPDRS total score, which includes the Part II and III measures we well as mentation, behavior, and mood symptoms, and complications of dopaminergic therapy; the participant global impression of change (&#8220;PGIC&#8221;), a participant-reported outcome which asks how their condition has changed compared to their condition at the beginning of treatment; and the Change on Clinical Global Impression of Severity (&#8220;CGIS&#8221;), which measures the severity of movement impairment as assessed by a site rater.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The study was completed on December 4, 2023, and we released the topline PD Study efficacy data on July 2, 2024. The data showed that in two subgroups, buntanetap improved UPDRS 2, 3, 2+3 and total score. It also showed that in the entire ITT population, buntanetap stopped the loss of cognition and that in the 12% of patients that already had cognitive issues, buntanetap improved cognition in a dose-dependent, statistically significant way. We expect to discuss the PD data with the FDA at an end-of-study meeting during 2025. During that meeting, we plan to propose continued development of buntanetap with a pivotal Phase 3 trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Phase 2/3 AD Trial</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">In February 2023, we initiated a Phase 2/3 clinical trial of buntanetap in 320 mild to moderate AD patients, which were separated into four cohorts of 80 patients (the &#8220;Phase 2/3 AD Trial&#8221;). The Phase 2/3 AD Trial was conducted at 64 sites in the U.S. The Phase 2/3 AD Trial was a double-blind, placebo-controlled efficacy study which treated mild to moderate AD. The inclusion criteria for mild to moderate AD was a MMSE score of 14 to 24. Patients participating in the trial were age 55-85, had a study partner, were of non-child-bearing age or agreed to effective contraception, and had no evidence of suicidal ideation. Patients participating in the trial were permitted to remain on any drugs they regularly took, whether for AD or for other conditions, as long as they were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse were excluded from participating.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Patients were randomly assigned to receive either 7.5, 15 or 30 mg of buntanetap or placebo, once per day. Patients visited the clinic for the first-time dosing in clinic, followed by an at home dosing period of 12 weeks. The study plan incorporated an interim analysis at six-weeks, the results of which were disclosed on October 23,2023. Similar to above for the PD study, based on the outcome of the interim analysis, we proceeded with the remaining AD study as planned after the interim analysis. </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The co-primary endpoints of the Phase 2/3 AD Trial were evaluated using the following measures: ADAS-Cog 11 and ADCS-Clinical Global Impression of Change (&#8220;ADCS-CGIC&#8221;), which focuses on clinicians&#8217; observations of change in the patient&#8217;s cognitive, functional, and behavioral performance since the beginning of a trial. The FDA requested the inclusion of two co-primary endpoints to have an objective primary endpoint (ADAS-Cog, cognition) and a subjective primary endpoint (ADCS-CGIC, activities of daily living). Together, these co-primary endpoints were intended to provide a more complete picture of the study and treatment results. The secondary endpoints were evaluated using the following measures: the ADCS-Instrumental Activities of Daily Living Scale (&#8220;ADCS-ADL&#8221;), which measures 6 basic activities of daily living items, including basic self-care tasks such as feeding, mobility and bathing, and 17 instrumental activities of daily living items, which include a broad range of activities based on cultural norms and gender roles; MMSE; and the digital symbol substitution test (&#8220;DSST&#8221;), which asks individuals to record associations between different symbols and numbers within time limits to assess cognition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Phase 2/3 AD study was completed on February 13, 2024, and on April 29, 2024, we announced topline efficacy data. The data showed that in a subgroup of early AD patients, buntanetap improved ADAS-Cog11 in a dose-dependent fashion and was statistically significant from placebo and from baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 10, 2024, the Company met with the FDA in an end-of-phase 2 meeting to discuss its Phase 2/3 AD data and to agree on a regulatory path forward. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy. The Phase 3 program will investigate buntanetap in patients with early AD and will consist of one study that first incorporates a 6-month study period aimed at confirming buntanetap&#8217;s symptomatic effects and later moving into an 18-month study period designed to demonstrate potential disease-modifying effects. While the overall study will last for the entire 18 months, the completion of the first 6-month treatment period, if well-designed and well-executed, may be sufficient to support an NDA filing, potentially within one year of the study&#8217;s initiation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the end-of-phase 2 meeting, the FDA raised no concerns with the Company&#8217;s data on buntanetap&#8217;s safety, including liver enzymes, drug interactions, dose selection, pharmacokinetics, population pharmacokinetics, and confirmed that development can proceed using the new crystal form of buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;">.<span style="font-style:italic;font-weight:bold;">Phase 1/2 AD/PD Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">In 2021, we completed a Phase 1/2 clinical trial of buntanetap in 14 early AD and 54 early PD patients (the &#8220;AD/PD Trials&#8221;) which were conducted at 12 clinical sites in the U.S.  The AD/PD Trials were double-blind, placebo-controlled studies which treated mild to moderate AD and early PD patients for 25 +/- 2 days. The inclusion criteria for the AD portion of the AD/PD Trials were MMSE 18-28 and age 45 and older. For the PD portion of the AD/PD Trials, inclusion criteria were MMSE 18-30, age 45 and older and Hoehn &amp; Yahr 1, 2 or 3. Patients participating in the trial were of non-child-bearing age or agreed to effective contraception and had no evidence of suicidal ideation. Patients participating in the trial could remain on any drugs they regularly took, whether for PD, for AD or for other conditions, as long as they were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients who had cancer within the prior year and patients who suffered from alcohol or substance abuse were excluded from the trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The AD/PD Trials were designed to assess the safety, tolerability, and PK of buntanetap. The studies met their primary endpoints of safety and tolerability, as measured by the percentage of patients with treatment-emergent adverse events in the buntanetap treatment arms as compared to the placebo groups, and secondary endpoint of pharmacokinetics of buntanetap, as measured by the concentration of buntanetap in plasma. The studies also met exploratory endpoints of measures of biomarkers related to neurotoxic protein cascade, and improvements in cognition in AD patients and function in PD patients. We believe the AD/PD Trials were the first double-blind, placebo-controlled studies that showed improvements in AD patients as measured by ADAS-Cog, and in PD patients as measured by UPDRS.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;white-space:pre-wrap;">The studies were conducted in two parts.  The first part of the AD/PD Trials was in 14 early AD patients and 14 early PD patients. Patients were randomly assigned to receive either 80 mg of buntanetap or placebo, once per day.  The second part of the AD/PD Trials was a dose response analysis performed in 40 early PD patients in which patients were randomly assigned to receive 5 mg, 10 mg, 20 mg, or 40 mg of buntanetap, once per day.  In both parts of the AD/PD Trials, patients visited the clinic for the first-time dosing in clinic, followed by an at home dosing period of 25 +/- 2 days.  We measured levels of neurotoxic proteins, neurotransmitters, neurotrophic factors, inflammation, and nerve cell death in all patients, as well as cognitive and functional improvements.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Safety results showed that buntanetap was well-tolerated in all dose groups. No serious adverse events were reported. The adverse events seen included problems related to CNS sampling: headaches, back and leg pain. PK parameters for buntanetap in plasma of AD and PD patients were similar to those seen in Phase 1 in our single ascending dose (&#8220;SAD&#8221;) and multiple ascending dose (&#8220;MAD&#8221;) studies in healthy volunteers, and in a proof-of-concept study in mild-cognitive impaired (&#8220;MCI&#8221;) patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We observed that buntanetap administration for 25 days lowered secreted APP &#945; and &#946; as well as total-tau and phosphorylated-tau levels in AD patients, and alpha-synuclein levels in PD patients. APP and its downstream products and tau are the neurotoxic proteins involved in AD, while &#945;SYN is the primary neurotoxic culprit of PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CSF was extracted before starting the study at baseline and at time 0 to 6 hours at the end of the study in both placebo and buntanetap treated patients. The values from time 0 to 6 hours were pooled to lower variability and the placebo values were deducted from the treated values. In all but one case, Ab42, we saw that the levels in buntanetap treated patients were lower than in placebo patients. With respect to Ab42, we observed that levels were slightly higher, which is consistent with our hypothesis that Ab42 levels are lower in advanced AD and higher in early AD. We believe that higher Ab42 levels we observed suggest that the course of AD was reversed and the patients improved. Again, CSF was extracted at baseline and for 6 hours after the study and the values of the placebo patients were subtracted from the buntanetap treated patients. We observed that inflammatory markers were generally reduced in both patient populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We observed that buntanetap reduced neurofilament light (&#8220;NFL&#8221;) levels in both AD and PD patients, suggesting a potential improvement in axonal integrity. We also observed that buntanetap reduced neurogranin (&#8220;NG&#8221;) levels in both AD and PD, potentially suggesting more intact synaptic functions. The same CSF as above was used to measure neurofilament light and neurogranin before and after treatment and to compare buntanetap patients to placebo. In both patient populations, neurofilament light and neurogranin are lower in treated than in placebo patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These results suggest that buntanetap has the potential to reduce neurotoxic proteins, rescue axonal transport, reduce inflammation, and protect synaptic functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We performed ADAS-Cogs and WAIS coding tests to evaluate buntanetap&#8217;s effects on AD patients&#8217; cognition. ADAS-Cog11 was performed at the beginning of the study at baseline and at the end at 25 days in the buntanetap-treated and the placebo groups. Although the study was not powered for efficacy, ADAS-Cog11 improved by 4.4 points, a statistically significant improvement of 28.57%. An improvement in ADAS-Cog11, which is reflected by a lower ADAS-Cog11 result, indicates increased cognitive performance. At 25 days, the treated group&#8217;s improvement from baseline was 3.3 points, or 20.71%, better than the placebo group&#8217;s improvement from baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The WAIS coding test measures speed in movement and thinking. Treated AD patients showed a 6.6 point, or 16.17%, statistically significant improvement from baseline. Furthermore, the treated group&#8217;s improvement from baseline was 3.1 points, or 8.8%, better than the placebo group&#8217;s improvement from baseline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In Parkinson&#8217;s disease, we pooled the original 14 PD patients with the additional 40 PD patients and looked at the MDS-UPDRS and WAIS coding tests to evaluate buntanetap&#8217;s effects on PD patients&#8217; mobility and functionality. The 54 PD patients received doses of either 5mg, 10mg, 20mg, 40mg or 80mg buntanetap treatment or placebo, once per day. We observed a statistically significant improvement in UPDRS Part II, III and IV individually. Specifically, Part III of the MDS-UPDRS measures the motor functions and has long been used as a standard to assess drugs&#8217; effects on patients&#8217; mobility.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We combined the two best doses, 10 and 20 mgs, and all doses, and saw an improvement of 3.6 (16.4%) for 10 and 20 mg, and of 2.4 (13.3%) for all doses combined compared to baseline. In the WAIS coding test, PD patients showed a statistically significant improvement both from baseline (17.1% for 10+20mg; 13.3% for all doses combined) and from placebo (27.1% for 10+20mg; 23.3% for all doses combined).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Axonal Transport in Human Nerve Cells</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When the information highway of a nerve cell slows down, the nerve cell is unable to properly communicate with other nerve cells, internal organs and the periphery and it gets sick and dies.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:351pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The transfer of information in a nerve cell is called axonal transport. Axonal transport is responsible for:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Neurotransmitters GABA (anxiety), ACh (cognition), dopamine (movement), serotonin (mood)</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Neurotrophic factors NGF, BDNF, and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All communication within and between nerve cells </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When transport and synaptic transmission are impaired, the cell releases lower levels of neurotransmitters, leading to impaired nerve cell health. The diseased cell is then attacked by the immune system, which is activated when it detects a diseased cell, and it eventually kills the cell. Impairment in axonal transport, therefore, leads to inflammation and eventually to nerve cell death. This is visually illustrated below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;"><img src="anvs-20241231x10k008.jpg" alt="Graphic" style="display:inline-block;height:350.3pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:320.59pt;"/></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">TBI Study in Rats</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">TBI causes severe cognitive and neurological impairment, which can incapacitate the patient, reduce quality of life, and increase the risk of morbidity and mortality. TBI is known to increase the risk for neurodegenerative disorders such as AD and PD. Several studies have analyzed changes in the brain after TBI and identified up-regulation of neurotoxic proteins, such as APP, tau, and &#945;SYN.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In our study, rats were subjected to either fluid percussion injury (&#8220;FPI&#8221;) or sham operation to one side of the brain. Three different ANVS405 doses or saline were given intraperitoneally to rats subjected to FPI for four weeks, with the first dose administered one-hour post-injury. At the termination of the treatment, all of the rats were first tested for their performance in a water </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:204pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">maze, and then they were sacrificed for brain staining of living cells and determination of microglia activation. 10 mg/kg ANVS405 was shown to improve memory and learning as measured by water maze performance. Furthermore, sections of the brain were stained with tyrosine hydroxylase (&#8220;TH&#8221;), wherein TH stains only live cells. The amounts of TH immunoreactivity in the whole striatum of the brain slices were measured. The rats treated with all three doses of ANVS405 showed higher TH staining in the ipsilateral area of the brain than the vehicle treated animals. Thus, ANVS405 demonstrated the ability to protect the striatum following FPI in rats. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because FPI can induce microglial activation, we next checked whether ANVS405 would reverse this pathology. In our study, we found that ANVS405 increased the number of resting microglia and reduced the number of activated microglia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Stroke Mice Model</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap was also tested in a stroke model, in which mice were challenged with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified. After four weeks the locomotor function, behavior, and cognition of these mice were also evaluated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap, in combination with pifithrin-&#945; (&#8220;PFT-&#945;&#8221;) given to mice after the induced stroke improved mice locomotor activity and cognitive function. While both treatments yielded improvements in locomotor and cognitive function, the combined buntanetap/PFT-&#945; treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT-&#945;. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Potential Markets for our Lead Drug Candidate</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With there being a very large potential market for neurodegenerative diseases, most pharma companies have a program studying some aspect of nerve and brain degeneration. Some newer approaches target tau, whose expression is more closely associated with cognitive decline. Similarly, for PD, several companies are trying to inhibit &#945;SYN. So far, we believe that generally, neither drugs attacking tau nor &#945;SYN have shown positive results. Hence there is a substantial need for a new and different disease-modifying strategy. There is more than one neurotoxic protein in the brain of AD and of PD patients, and the same neurotoxic proteins are involved in the pathogenesis of AD and PD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="anvs-20241231x10k009.jpg" alt="Graphic" style="display:inline-block;height:203.55pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:465.75pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of AD patients&#8217; brains display mixed PD pathology and vice versa. Therefore, just attacking one of these proteins may result in no or lower efficacy than attacking them all. To prove that this approach is possible, we are studying the effects of buntanetap on the levels of several neurotoxic proteins and other surrogate markers, in parallel, in both AD and PD patients.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">AD is a neurodegenerative disorder with cognitive, functional, and behavioral alterations. AD is age-related, and its incidence is increasing with the aging of the population. It is estimated that currently 55 million victims of AD or some form of dementia exist in the world and by 2050, the number will grow to nearly 140 million people worldwide. In the United States, it is estimated that there are nearly seven million patients with AD currently and that by 2060, the number of people aged 65 and older with AD is projected to reach nearly 14 million people. Nearly eightfold as many people have preclinical AD as have symptomatic AD and are at risk for progressing to full manifestation of the disease. Disease modifying treatments (&#8220;DMTs&#8220;) that will prevent or delay the onset or slow the progression of AD are urgently needed. Similarly, medications to effectively improve cognition or ameliorate neuropsychiatric symptoms of patients in the symptomatic phases of AD are needed to improve memory and behavior.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The incidence rate of AD increases significantly with age. Individuals between ages 64 to 75 have an incidence rate of 0.4%, which increases to 3.2% for people between ages 75 and 84 and finally to 7.6% for people aged 85 and above. These incidence rates are cumulative as an individual ages, which means that an individual reaching 90 years of age will have a 38% chance of suffering from AD while an individual reaching the age of 95 will have a 76% chance of suffering from AD. AD is becoming increasingly common as the global population ages and as the health systems in developing countries improve. There is a significant need to identify drugs that prevent, delay the onset, slow the progression, or improve the symptoms of AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parkinson&#8217;s Disease Market</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD is also a progressive neurodegenerative disorder with both movement and non-movement symptoms, functional, behavioral and cognitive alterations. PD, like AD, is age-related and is becoming markedly more common with the aging of the world&#8217;s population. PD affects about 1% of the population over the age of 60, while in individuals over the age of 85, this prevalence reaches 5%, highlighting the impact that advancing age has on the risk of developing this condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">PD affects more than 10 million people worldwide, of which nearly one million are in the U.S. While a 2014 study estimated that the incidence in the U.S. will rise to 1.2 million by 2030, a later 2022 study found that there are nearly 90,000 new cases of PD diagnosed each year in the U.S., potentially supporting an even greater future incidence rate. By 2050, the number of worldwide PD patients is expected to grow to up to 30 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The National Parkinson&#8217;s Foundation estimates that the economic burden of PD is at least $25 billion a year in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To date, there are no available treatments capable of curing PD, with current therapies seeking only to ameliorate dopamine-related motor symptoms of the disease. There is a clear and unmet medical need for new DMTs that can slow or prevent PD progression.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.37;margin:0pt 0pt 10pt 0pt;">Mixed Pathologies Market</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the unmet need of AD and PD patients, approximately 50% of patients exhibit mixed pathologies, with some pathologies resembling AD and some resembling PD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Dementia is increasingly being recognized in cases of PD; such cases are termed PD dementia (&#8220;PDD&#8221;). The spread of fibrillar &#945;SYN pathology from the brainstem to limbic and neocortical structures seems to be the strongest neuropathological correlate of emerging dementia in PD. Up to 50% of patients with PDD develop sufficient numbers of A&#946; plaques and tau-containing neurofibrillary tangles for a secondary diagnosis of Alzheimer&#8217;s disease, and these pathologies may act synergistically with &#945;SYN pathology to confer a worse prognosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Another study looked at the incidence of mixed pathologies diagnosed community-dwelling older persons. Those with dementia most often have multiple brain pathologies, which greatly increases the odds of dementia. Specifically, in people with dementia, over 50% had multiple diagnoses (AD, PD/Lewy body dementia, PDD or infarcts). After accounting for age, persons with multiple diagnoses were almost three times more likely to exhibit dementia compared to those with one pathologic diagnosis.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We believe that a therapy that only addresses A&#946;, tau or &#945;SYN is less likely to help people with mixed pathologies. Since buntanetap is designed to inhibit more than one neurotoxic protein, we believe that it may have the potential to slow or eventually stop AD, PD and mixed pathology diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutic Approaches and Competition</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alzheimer&#8217;s Disease Approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Drug development for AD has historically proven to be very difficult. Drugs which have been approved for the treatment of AD include cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine),an N-methyl-D-aspartate receptor antagonist (memantine) and more recently, monoclonal antibody treatments (donanemab, lecanemab). Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a dramatic drug/placebo difference or having unacceptable toxicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Most clinical trials conducted have addressed amyloid targets. Since A&#946; accumulates for years before the symptoms of AD are visible, some pharmaceutical companies are testing their drugs earlier, including in cognitively normal people or those who have genetic profiles that place them at high(er) risk for developing AD. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An increasing number of agents are also directed at tau-related targets. Neurofibrillary tangles are one of two major pathological hallmarks of AD. Correlation studies conducted by Braak and Braak demonstrate that neurofibrillary tangle burden more closely correlates with cognitive decline than amyloid plaque load. Several phase 3 studies conducted with tau approaches have failed. There are still several anti-tau approaches in the clinic. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In summary, at present there are few disease-modifying agents currently on the market and existing treatments show limited efficacy. Previous large efforts to develop a DMD for AD has targeted A&#946;42, but many A&#946;42 approaches to date have failed and again, have shown limited efficacy when treating AD. Further, most companies testing tau have shown negative results as well. As a result, many organizations have pulled out of AD research and are waiting to see if a new or alternative approach may have a better outcome. Since the AD brain contains several neurotoxic proteins&#8212;amyloid precursor protein and its toxic fragments A&#946;42 and IC99, as well as tau and &#945;SYN, we believe an A&#946;42-only approach is not sufficient in order to develop a DMD drug. We believe that a DMD drug needs to target more than just one toxic protein to be efficacious and we are developing buntanetap with this approach in mind. A concerning observation derived from a review of the existing industry AD pipeline is the lack of agents targeting the moderate to advanced stages of AD. With over 15 million people affected by AD dementia worldwide, there is an urgent need to develop more effective symptomatic treatments for moderate to advanced stage disease. The paucity of agents directed at this population represents a significant weakness of the AD drug development pipeline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Parkinson&#8217;s Disease Approaches</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Levodopa (&#8220;L-DOPA&#8221;) was introduced for use in treating PD more than 40 years ago and remains the mainstay of therapy for improving the symptoms of the disease. Unlike dopamine, which cannot cross the blood&#8212;brain barrier, L-DOPA is effectively absorbed into the brain, where it metabolizes into dopamine. It is typically administered five times a day and works well in controlling symptoms for one to five years. Unfortunately, the effects of L-DOPA in any patient diminish with time. There are several other drugs available to treat PD, which also seek to modulate dopamine levels. Combination drug therapy is common in PD. For instance, the use of other drug classes such as the catechol-O-methyltransferase (&#8220;COMT&#8221;) inhibitors and the monoamine oxidase (&#8220;MAO&#8221;) inhibitors allow patients to reduce L-DOPA dosing levels. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The current global market for PD drugs is estimated at $5 to $6 billion worldwide, despite high-volume generics. The most important current therapy for PD, L-DOPA, is prescribed as a generic. While volume growth in the category is expected to remain healthy, dollar growth will likely remain relatively flat as some of the category&#8217;s larger brands contend with generic inroads. The size of the current market reflects the absence of innovative branded therapies more than it does the medical need.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">So far, we believe that only buntanetap and Exenatide are in the later stages of clinical development for disease-modification and no products have yet shown efficacy in PD patients long term. Although several drugs have shown potential neuroprotective ability in preclinical studies, demonstrating these effects in clinical studies remains a challenge. Beyond drug therapies, a few cell and gene therapy approaches are also being explored. Progress across these newer technology platforms has been slow.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis has filed fourteen (14) families of patents and patent applications to prolong the patent life of buntanetap. The pending patent applications invented and filed by Annovis include claims directed to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">method</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of treating neurodegenerative diseases such as AD and PD;</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating and/or preventing acute brain and nerve injuries; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of prevention and treatment of disease states due to metal dis-homeostasis such as AD or PD as well as other acute or chronic neurodegenerative diseases;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating viral and bacterial infections of the brain, including COVID-19;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of inhibiting cancer metastasis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">combinations of buntanetap with some drugs and uses of these combinations to treat neurodegenerative diseases; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a method of treating neuropsychiatric indications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a new composition of matter of Posiphen, Form B or ANVS402; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new methods for making buntanetap and Posiphen Form B.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Solid forms of chemical compounds can exist in different crystalline structures.  One crystalline structure of Posiphen is buntanetap. Annovis, through its research efforts, invented a new crystalline form of Posiphen, known as Form B (&#8220;ANVS402&#8221;).  Form B, or ANVS402, has demonstrated certain improvements over buntanetap and was filed as a new composition of matter patent application.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 9, 2024, our patent portfolio comprised 39 total issued patents plus 18 pending patent applications in various jurisdictions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patents, granted and if granted based on the pending applications, have expiration dates between 2031 and 2045. The first patent application family we filed, which would be expected to expire in 2031, before any patent term adjustments or extensions, covers the use of buntanetap in the treatment of AD, PD and other neurodegenerative disorders such as Huntington&#8217;s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies, frontotemporal dementia, Lewy bodies disease, and chronic traumatic encephalopathy, based on our preclinical research. In August 2019, the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) granted the first of our Annovis patents from this family covering treatment of PD and Lewy body diseases. Subsequently, the USPTO also granted patents covering treatment frontotemporal dementia and Prion&#8217;s disease, tauopathies, chronic traumatic encephalopathy, prion diseases, amyotrophic lateral sclerosis, Alzheimer&#8217;s and Huntington&#8217;s disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The second patent application family covers ANVS405&#8217;s use in acute brain and nerve trauma and would be expected to expire in 2036, before any patent term adjustments or extensions. In December 2020, the EPO approved the whole patent and it has since been approved in most countries filed claiming a method of treating acute nerve and brain injuries by administering ANVS405 before and after the injury. The US patent office instead has asked us to separate the application into four divisional applications covering stroke, traumatic brain injury, nerve injury and spinal cord injury.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The third patent application family relates to the use of the mechanism of action of buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire in 2038, before any patent term adjustments or extensions. The first divisional of this application was approved in December 2022, it covers the prevention of neurodegenerative diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fourth patent application family relates to a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related compounds. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related compounds, which would be expected to expire in 2041, before any patent term adjustments or extensions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fifth patent family application is directed to a method of maintaining heavy metal homeostasis avoiding the effect of toxic levels of a heavy metal in cells in a healthy human or restoring heavy metal homeostasis in a sick human patient. The USPTO granted the first patent in this family on March 7, 2023, which is expected to expire in 2039, before any patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The sixth patent application family relates to treating brain metastasis via administration of buntanetap or related compounds. In September 2023, we filed a U.S. nonprovisional patent application directed to treatment of brain metastasis via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2043, before any patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The seventh patent application family relates to treatment of mental illness via administration of buntanetap or related compounds. In January 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of mental illness via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2044, before any patent term adjustments or extensions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The eighth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antidiabetic agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ninth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and a phosphodiesterase inhibitor. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The tenth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antihypertensive agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The eleventh patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap with two additional therapeutic agents. In August 2024, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The twelfth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an additional therapeutic agent. In February 2025, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The thirteenth patent application family relates to the new Form B of Posiphen (ANVS402); it demonstrates that it can be used instead of buntanetap, including in the foregoing uses of buntanetap of the Company&#8217;s patent portfolio. Posiphen Form B may be the compound of choice in current uses of buntanetap, because it may have advantageous properties such as better stability and higher purity. In 2023, the Company filed with the USPTO two provisional patent applications as to Posiphen Form B. In 2024, the Company filed an International (PCT) as to Posiphen Form B and uses thereof. The &#8220;International Search Report and Written Opinion&#8221; issued by the USPTO in the prosecution of the PCT application was favorable, indicating that the searched claims directed to Posiphen Form </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">B are novel and inventive.  The Company expects to further file patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications involving Posiphen Form B and uses thereof, patents would be expected to expire in 2044, before any patent term adjustments or extensions.  The Company also expects to seek New Chemical Entity status for Posiphen Form B before the US Food and Drug Administration (FDA), and to seek additional regulatory exclusivity based thereon.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fourteenth patent application family relates to new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B. The Company sees this patent application family as providing further protection as to methods that use buntanetap or Posiphen form B, and for Posiphen form B. More in particular, in 2024 the Company filed with the USPTO a provisional patent application directed to these new methods of for preparing buntanetap and Posiphen Form B. The Company expects in 2025 to further file at least an International (PCT) application, claiming priority from that provisional patent application, and directed to the new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B, and thereafter patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications, patents would be expected to expire in 2045, before any patent term adjustments or extensions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that we will fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that provide further coverage of buntanetap or any other product candidate in the United States or in other foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Sales and Marketing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If buntanetap is approved for AD or PD, we plan to enter into sales and marketing agreements with one or several pharmaceutical companies to sell to neurologists, geriatric specialists and to primary care physicians. We also may explore the use of a variety of types of collaboration, co-promotion, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Manufacturing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Buntanetap is a small molecule that is manufactured using a patented process. We do not own, operate, and currently have no plans to establish, any manufacturing facilities. We therefore rely, and expect to continue to rely, solely on third-party contractors for manufacturing clinical supplies for our current and future potential product candidates, and plan to do so for commercial supplies also if any of our product candidates received marketing approval. We also rely on these third parties for encapsulating, packaging and stabilizing clinical trial materials. Presently we are working with a U.S. supplier for the manufacture of cGMP active pharmaceutical ingredient (API) to meet our buntanetap clinical study supply demands.  We have also engaged a backup API manufacturing contractor, with primary operations in China. We also have an agreement with a local U.S. supplier for the encapsulating, packaging, and stability of the clinical trial material.  These arrangements will allow us to enter large and long-term advanced clinical studies. We have only limited supply agreements in place with respect to buntanetap and our product candidates, and these arrangements do not currently extend to commercial supply. We do not have long-term committed arrangements with respect to buntanetap, any of our other product candidates, or other materials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Government Regulation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacturing, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacturing, quality control, safety, effectiveness, labeling, storage, record-keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Government Regulation of Drug Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practice regulations.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an Investigational New Drug application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Approval by an independent institutional review board (&#8220;IRB&#8221;), at each clinical site before each trial may be initiated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (&#8220;GCP&#8221;), requirements to establish the safety and efficacy of the proposed drug product for each indication.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Submission to the FDA of an NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA advisory committee review, if applicable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Payment of user fees and securing FDA approval of the NDA.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) and the potential requirement to conduct post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Preclinical Studies</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical Trials</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes for public dissemination on www.clinicaltrials.gov.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Special FDA Expedited Review and Approval Programs</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To be eligible for a fast-track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast-track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six- and ten-month review periods are measured from the &#8220;filing&#8221; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast-track designation are also likely to be considered appropriate to receive a priority review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, products tested for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act passed in July 2012, a sponsor can request designation of a product candidate as a &#8220;breakthrough therapy.&#8221; A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. Annovis would like to petition the FDA to classify buntanetap as a breakthrough therapy in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation and Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a product with orphan status receives the first FDA approval for a disease or condition, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease if the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Marketing Approval and Post-Approval Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#8220;filing&#8221; of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#8220;filing&#8221; decision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, quality and purity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may refer an application for a novel drug to an advisory committee. While the FDA is not bound by the recommendations of an advisory committee, it considers such recommendations carefully when making decisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing for the FDA to reconsider the application. If and when those conditions have been met to the FDA&#8217;s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Fines, warning letters or holds on post-approval clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Product seizure or detention, or refusal to permit the import or export of products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Coverage and Reimbursement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Significant uncertainty exists as to the coverage and reimbursement status of our lead product candidate, buntanetap, or any other candidate for which we may seek regulatory approval. Sales in the U.S. will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Medicare Part D, Medicare&#8217;s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement for oral oncology products, and all Part D prescription drug plans are required to cover substantially all oral anti-cancer agents. However, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of buntanetap or any other product candidates will therefore depend substantially on the extent to which the costs of our products will be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) and/or the Medicare Administrative Contractors is typically a significant gating issue for successful introduction of a new product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our operations include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provisions of the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act requirements, under the Patient Protection and Affordable Care Act, which require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Regulation Outside of the United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To market our future products in the European Economic Area (&#8220;EEA&#8221;), which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein, and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). There are two types of MAs:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (&#8220;EMA&#8221;) and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product based on scientific criteria concerning its quality, safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Data and Marketing Exclusivity</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Orphan Drug Designation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in development. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of &#8220;clinical superiority&#8221; by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Human Capital</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of February 28, 2025, we had eight full-time employees. We also utilize the services of seven key part-time employees or consultants. We contract with consultants and third parties for the conduct of certain clinical development, accounting and administrative activities. We anticipate hiring of additional employees as we continue to advance our clinical trial programs. None of our employees are represented by labor unions or covered by collective bargaining agreements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our human capital resource objectives include, as applicable, identifying, recruiting, retaining, training, incentivizing, and integrating our existing and new employees, advisors and consultants. We offer competitive compensation packages that are competitive within our industry. We incentivize high performance through an annual bonus program based on organizational performance, for which all employees are eligible. We also offer equity incentive plans, the purpose of which are to attract, retain and reward personnel through the granting of stock-based compensation awards. These awards are granted in order to align employee and consultant performance incentives with objectives that will increase stockholder value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in 2008. Our principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 and our telephone number is (484) 875 3192. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We file annual, quarterly, and current reports, proxy statements, and other documents with the SEC under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC maintains an internet website, www.sec.gov, that contains reports, proxy, and information statements, and other information regarding issuers, including us, that file electronically with the SEC. Copies of each of our filings with the SEC on Form 10-K, Form 10-Q, and Form 8-K and amendments to those reports, can be viewed and downloaded free of charge at our website, www.annovisbio.com, as soon as reasonably practicable after the reports and amendments are electronically filed with or furnished to the SEC. Our website and the information contained on, or that can be accessed through, our website shall not be deemed to be incorporated by reference in, and is not considered part of this Annual Report on Form 10-K.</p><a id="_23d0ec62_0813_44f0_b2d8_ee42556ff20a"></a><a id="Item1ARiskFactors_448269"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our recurring operating losses, negative cash flows from operations, and accumulated deficit raise substantial doubt about our ability to continue as a going concern, if we are unable to obtain additional financings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern for the next twelve months from the date of the financial statements included in this Annual Report on Form 10-K. As of December 31, 2024, we had cash and cash equivalents of $10.6 million and current liabilities of $3.9 million. We believe that we have sufficient resources </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">available to support our development activities and business operations and satisfy our obligations into the fourth quarter of 2025. We do not have sufficient cash and cash equivalents as of the date of this Annual Report on Form 10-K to support our operations for at least the 12 months following the date that the financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing to fund our ongoing clinical trials and future operations, and to continue to execute our corporate strategy. To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, we plan to explore various dilutive and non-dilutive opportunities, including equity and debt financings, strategic partnerships, business development and other transactions. The future success of the Company is dependent upon our ability to obtain additional funding. There can be no assurance, however, that we will be successful in obtaining sufficient amounts of funding, on terms acceptable to us, or at all. Failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on our business, results of operations, and financial condition. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December&#160;31, 2024 contains an explanatory paragraph relating to our ability to continue as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The auditor&#8217;s opinion on our audited financial statements for the year ended December 31, 2024 includes an explanatory paragraph stating that we have incurred recurring losses from operations that raise substantial doubt about our ability to continue as a going concern for the next twelve months from the date of the financial statements included in this Annual Report on Form 10-K. While we believe that we will be able to raise the capital we need to continue our operations, there are no assurances that we will be successful in these efforts or will be able to resolve our liquidity issues or eliminate our operating losses. If we are unable to obtain sufficient funding, we would need to significantly reduce our operating plans and curtail some or all of our development efforts. Accordingly, our business, prospects, financial condition, and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company&#8217;s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $134.8 million. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant additional operating losses for the next several&#160;years, at least, as we advance buntanetap and any other product candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other product candidates, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to progress our development in AD and PD with additional pivotal Phase 3 studies, or conduct clinical trials for any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">scale-up cGMP drug supply manufacturing and complete necessary work to support an NDA for buntanetap in AD or in PD;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">are required by the FDA to complete additional toxicological/pharmacological studies to support an NDA for buntanetap in AD or in PD;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a sales, marketing and distribution infrastructure to commercialize our drug, if approved, and for any other product candidates for which we may obtain marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, scientific and commercial personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts, as well as to support our requirements as a public reporting company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license or invent other product candidates or technologies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under &#8220;&#8212;Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval&#8221; and &#8220;&#8212;Risks Related to Commercialization.&#8221; This will require us to be successful in a range of challenging activities, including completing clinical trials of buntanetap and any other product candidates, acquiring additional product candidates, obtaining regulatory approval for buntanetap and any other product candidates, and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#8217; equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our company will be materially and adversely affected. Furthermore, this could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates, achieve our strategic objectives or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require substantial additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of buntanetap.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The development of biopharmaceutical product candidates is capital-intensive. Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of buntanetap. If we obtain receive regulatory approval for buntanetap or any other product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. We will require additional capital for the further development and potential commercialization of buntanetap and may also need to raise additional funds sooner to pursue a more accelerated development of buntanetap. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reliably estimate the actual amount of financing necessary to successfully complete the development and commercialization of buntanetap or any other product candidates. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Based on our current operating plan, we believe that our current cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could deploy our available capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Our current cash and cash equivalents will not be sufficient to complete development of buntanetap or any other product candidates, and we will require substantial capital in order to advance buntanetap or any other product candidates through clinical trials, regulatory approval and commercialization. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Our ability to raise additional funds may be adversely impacted by </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from factors that include but are not limited to, inflation, progression of geopolitical events (including in the relation to the conflict between Russia and Ukraine and the conflict between Hamas and Israel), diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts, or even cease operations. We expect to finance our cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop buntanetap or any other product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for buntanetap or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical development plans we establish for buntanetap and any other future product candidates, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and cost of regulatory meetings and reviews by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for buntanetap and any future product candidates and our anticipated timing for seeking approval in such jurisdictions&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, CMC, quality and commercial personnel&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of the implementation of commercial-scale manufacturing activities, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products&#894; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any products or technologies that we may in-license or acquire; </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Conducting clinical trials and preclinical studies and potentially identifying future product candidates is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">obtain regulatory approval and commercialize buntanetap or any future product candidates. If approved, buntanetap and any future product candidates may not achieve commerciab success. Our commercial revenue, if any, will initially be derived from sales of buntanetap, which we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, that we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we would be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts, or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, or on less favorable terms than we would otherwise choose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have limited operating history and no history of commercializing pharmaceutical products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were established and began operations in 2008. Our operations to date have been primarily focused on conducting preclinical and clinical studies. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, reliance should not be placed upon the results of any particular quarterly or annual period as indications of future operating performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our tax net operating losses is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred significant net operating losses since our inception. As of December 31, 2024, we had U.S. federal net operating loss carryforwards of approximately $54.1 million. Our ability to utilize these net operating losses to offset future tax liabilities depends on the successful development of our product candidates and future financial performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, our net operating losses may be subject to Section 382 of the Internal Revenue Code of 1986, as amended (&#8220;Section 382&#8221;). Generally, if an ownership change occurs within three years of the closing date of an entity&#8217;s most recent change in control transaction, any existing net operating losses and certain built-in losses would be subject to an additional limitation, pursuant to Section 382. Change in control as defined by Section 382 occurs when there is an ownership change among stockholders owning directly or indirectly 5% or more of our common stock, as well as an aggregate ownership change with respect to such stockholders of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">more than 50% of our common stock. We have not yet conducted a comprehensive study to assess whether a change of ownership as defined by Section 382 has occurred since our inception. If it is determined that we are unable to use our net operating losses to reduce future tax liabilities, our financial condition, results of operations, and cash flows may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inflation could adversely affect our business and results of operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While inflation in the United States has been relatively low in recent years, during 2023 and 2024, the economy in the United States encountered a material level of inflation. The residual impacts of COVID-19, geopolitical developments such as the Russia-Ukraine and Israel-Hamas conflict and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity, including whether inflation will continue and how long, and at what rate. Increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, Isreal and Hamas, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves, or on less favorable terms than we would otherwise choose. In addition, if one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our clinical development goals on schedule and on budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are heavily dependent on the success of buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We do not have any products that have gained regulatory approval. Currently, our lead clinical stage product candidate is buntanetap. As a result, our business is entirely dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize buntanetap in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and may be able to better sustain the delay or failure of a lead product candidate. We cannot commercialize buntanetap in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize buntanetap outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of buntanetap for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that buntanetap is safe and effective for use for that target indication and that the manufacturing </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">facilities, processes and controls are adequate. If the FDA is not satisfied with the quantity and nature of the data we collect, we may be forced to undertake additional preclinical studies or clinical trials to obtain regulatory approval, which will lead to delays in our clinical development plans and cause us to incur additional costs, both of which may have a material adverse effect on our business. Even if buntanetap were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for buntanetap in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other product candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for buntanetap, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize buntanetap, we may not be able to earn sufficient revenue to continue our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competitors may develop alternatives that render any product candidates we develop obsolete&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited financial and personnel resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause it to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product, we may relinquish valuable rights to that product through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business, results of operations, cash flows, financial condition and/or prospects may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could harm our ability to complete or could materially delay our clinical trials, as well as cause disruptions to the FDA and other governmental authorities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our operations and the operations of our suppliers, contract research organizations (&#8220;CROs&#8221;), hospitals, clinical trial sites, regulators, consultants and other third parties with whom we conduct business could be subject to earthquakes, power shortages, telecommunications or infrastructure failures, cybersecurity incidents, physical security breaches, water shortages, floods, hurricanes, typhoons, blizzards and other extreme weather conditions, fires, and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers or suppliers to produce buntanetap and its components and on CROs and clinical sites to conduct our clinical trials, and do not have a redundant source of supply for all components of our product candidate. Our ability to obtain clinical or, if approved, commercial, supplies of buntanetap or any future product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption, and our ability to commence, conduct or complete our clinical trials in a timely manner could be similarly adversely affected by any of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the foregoing. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, buntanetap and our other product candidates may not have favorable results in later preclinical and clinical studies or receive regulatory approval. The historical failure rate for product candidates in our industry is high, particularly in the earlier stages of development. Furthermore, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approval to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reaching an agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining Institutional Review Board (&#8220;IRB&#8221;) approval at each site, or Independent Ethics Committee (&#8220;IEC&#8221;) approval at sites outside the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patients failing to complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing patient safety concerns that arise during the course of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adding a sufficient number of clinical trial sites; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of product candidate for use in clinical trials.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in &#8220;&#8212;Risks Related to Our Dependence on Third Parties.&#8221;</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for buntanetap or any other product candidates, our business will be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for buntanetap or any other product candidate. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. Approval from the FDA and comparable foreign authorities may be delayed or denied for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing the active ingredient in our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. For diseases like AD and PD, the FDA has stated that one single Phase&#160;3 trial is adequate for approval if it demonstrates robust and unquestionable efficacy. However, the circumstances under which a single adequate and controlled study can be used as the sole basis of demonstrating efficacy of a drug are exceptional.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the large number of drugs in development, only a small&#160;percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market buntanetap or another product candidate, which would significantly harm our business, results of operations and future commercial prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have concentrated our research and development efforts on the treatment of AD and PD, diseases that have seen limited success in drug development. Further, buntanetap is based on a new approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequent obtaining of regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Efforts by biopharmaceutical and pharmaceutical companies in treating AD and PD have seen limited success in drug development, and there are few FDA-approved disease modifying therapeutic options available for patients with AD and PD. As a result, the design and conduct of clinical trials of buntanetap or any future product candidate may take longer, be more costly or be less effective as a result of the novelty of development in these diseases. We cannot be certain that our approach will lead to the development of approvable or marketable products. In some cases, we may use endpoints or methodologies that regulatory authorities may not consider to be clinically meaningful and that we may not continue to use in clinical trials or that we may determine after the initiation of the trial to no longer be an appropriate endpoint or methodology. Any such regulatory authority may require evaluation of additional or different clinical endpoints in our clinical trials or ultimately determine that these clinical endpoints do not support marketing approval. In addition, if we are required to use additional or different clinical endpoints by regulatory authorities, buntanetap may not achieve or meet such clinical endpoints in our clinical trials. Even if a regulatory authority finds our clinical trial success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we may conduct for our product candidate. Further, even if we do achieve the prespecified criteria, our trials may produce results that are unpredictable or inconsistent with the results of other efficacy endpoints in the trial. Regulatory authorities also could give overriding weight to other efficacy endpoints over a primary endpoint even if we achieve statistically significant results on that primary endpoint if we do not do so on our secondary efficacy endpoints. Regulatory authorities also weigh the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The majority of drugs approved by the FDA to treat AD and PD to date address only the diseases&#8217; symptoms. Only a small number of new treatments have been approved for AD since 2003. From 2004 to 2025, phase 2 and 3 clinical trials for unique compounds with various mechanisms of action intended to combat AD had a development success rate of just 8%. AD drug candidates have the highest failure rate of nearly 100%, compared to 50% to 80% for all other drug candidates. As a result, the FDA has a limited set of products to rely on in evaluating buntanetap. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of buntanetap for the treatment of AD and PD. We cannot be sure that buntanetap, or any other product candidate we develop, will ultimately prove to be safe and effective, scalable or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe novel treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As product candidates progress through clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize safety, efficacy, yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the manufacturing process being used to produce clinical material for our planned clinical trials is different than that used in prior trials of buntanetap. There can be no assurance that such changes will achieve these intended objectives. These changes and any future changes we may make to buntanetap or any future product candidates may also cause such candidates to perform differently and affect the results of future clinical trials conducted with the altered materials. Such changes or related unfavorable clinical trial results could delay initiation or completion of additional clinical trials, require the conduct of bridging studies or clinical trials or the repetition of one or more studies or clinical trials, increase development costs, delay or prevent potential marketing approval and jeopardize our ability to commercialize buntanetap or any future product candidates, if approved, and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may develop buntanetap and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may develop buntanetap and future product candidates for use in combination with one or more other approved therapies for AD or PD. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we will not be able to market and sell any product candidate we develop in combination with an unapproved AD or PD therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved AD and PD therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patient enrollment and retention in clinical trials depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility and exclusion criteria as defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature and design of the trial protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existing body of safety and efficacy data with respect to the product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to clinical sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing clinical trials being conducted by other companies or institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient consents; and</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting, which could adversely impact the outcomes of our trials and could have safety concerns for the potential patients. Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll our clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and recruiting patients may prove costly. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. If patients are unwilling or unable to participate in our trials for any reason, including the existence of concurrent clinical trials for similar target populations, the availability of approved or authorized therapies, or the fact that enrolling in our trials may prevent patients from taking a different product, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a specified number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, results of early clinical trials may differ from results of later clinical trials due to changes in patient population size. The clinical trials that we have completed to date included a limited patient population, and we may observe differences in the safety and efficacy of buntanetap and our other product candidates as the patient population increases in size. Accordingly, the data that we have observed to date may not be reflective of ongoing and future clinical trial data. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for buntanetap are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are further subject to audit and verification procedures that could result in material changes in the final data. Furthermore, undue reliance on interim analyses may be detrimental to our long-term clinical development plans, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">From time to time, we may publish interim &#8220;top-line&#8221; or preliminary data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to evaluate all data fully and carefully. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Moreover, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim &#8220;topline&#8221; or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, buntanetap and any future product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with biopharmaceuticals generally, it is likely that there may be adverse side effects associated with buntanetap or any future product candidates&#8217; use. Serious adverse events or undesirable side effects caused by buntanetap or any other product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with buntanetap to date, at high doses have experienced adverse events that include nausea, vomiting and dizziness.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If unacceptable side effects arise in the development of our product candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and future commercial prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, if buntanetap or any future product candidates are associated with undesirable side effects in clinical trials or demonstrate characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our development and clinical trial plans based on findings in our ongoing clinical trials. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">It is possible that as we test buntanetap or any future product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread following any regulatory approval, more illnesses, injuries, discomforts and other adverse events than were observed in earlier trials, as well as new conditions that did not occur or went undetected in previous trials, may be discovered. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw approvals of such product;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings on the label, such as a &#8220;black box&#8221; warning or contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and future commercial prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to initially seek approval for buntanetap for AD and PD in the U.S. The precise incidence and prevalence for the conditions we aim to address with buntanetap or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on a number of internal and third-party estimates. These estimates have been derived from a variety of sources, including relevant scientific literature, patient foundations and market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these indications. While we believe our assumptions and the data underlying our estimates are reasonable, we have not independently verified the accuracy of the third-party data on which we have based our assumptions and estimates, and these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, including as a result of factors outside our control, thereby reducing the predictive accuracy of these underlying factors. The total addressable market across all of the potential indications for buntanetap and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each such product candidate which receives marketing approval for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of such product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition and results of operations. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates. Further, even if marketing approval is obtained, we have no experience as a company in commercializing products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, we have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If buntanetap or any future product candidates ultimately receives marketing approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company with the marketing, sale or distribution of biopharmaceutical products and there are significant risks involved in the building and managing of a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain FDA approval for buntanetap or any other product candidates in the United States, we may never obtain approval for or commercialize buntanetap or any other product candidates in any other jurisdiction, which would limit our ability to realize their full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future growth may depend, in part, on our ability to develop and commercialize buntanetap and any future product candidates in foreign markets. We are not permitted to market or promote any product candidate before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for buntanetap or any future product candidates. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we obtain regulatory approval of product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">different regulatory requirements for approval of drugs in foreign countries&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced protection for intellectual property rights&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the existence of additional third-party patent rights of potential relevance to our business&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers and regulatory requirements&#894;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation, or political instability in particular foreign economies and markets&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with export control and import laws and regulations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">foreign reimbursement, pricing and insurance regimes&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty in countries where labor unrest is common&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements with respect to manufacturing of products&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we obtain regulatory approval for buntanetap or any product candidates, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS.&#160;If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on manufacturing such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning letters or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of the products from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, the FDA&#8217;s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as buntanetap or any future product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for buntanetap or any future product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of buntanetap or any future product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for buntanetap from the FDA in PD and AD. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may seek a Breakthrough Therapy designation for buntanetap or one or more of our other product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit, delay or cease commercialization of any products that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The use of buntanetap or any other product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. This risk will be even greater if we commercialize our product candidates, especially if our products are prescribed for off-label uses (even if we do not promote such uses). For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Claims could also be asserted under state consumer protection acts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs or be required to limit, delay or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impairment of our business reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of participants from our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant costs to defend the litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">distraction of management&#8217;s attention and our resources from our primary business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to patients or other claimants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize buntanetap or any other product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased market demand for any product; </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant negative financial impact; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in our stock price.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The product liability insurance coverage we carry or acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. In connection with all our clinical studies, we carry insurance for product liability claims in the United States and in Europe. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of buntanetap or any future product candidates. Although we maintain such insurance, a successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, cyber security liability, employment benefits liability, workers&#8217; compensation, products liability, and directors&#8217; and officers&#8217; insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. No assurance can be given that an insurance carrier will not seek to cancel or deny coverage after a claim has occurred. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If buntanetap is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain quicker regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implement more effective approaches to sales and marketing; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">form more advantageous strategic alliances.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than buntanetap. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for buntanetap, which could result in our competitors establishing or strengthening their market position before we are able to enter the market. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competing products may render buntanetap or any future product candidates we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of buntanetap and any other product candidates we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as buntanetap, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for any approved product candidate. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available, or at an acceptable level, for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules&#160;and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules&#160;and regulations are likely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if buntanetap or any product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, which would adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Buntanetap and any future product candidates may not be commercially successful. If buntanetap or any other product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy and potential advantages compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the indications for which our product candidates are approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effectiveness of sales and marketing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment in relation to alternative treatments, including any similar generic treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to offer our products for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of third-party coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any restrictions on the use of our product together with other medications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product liability claims; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of our products as well as availability, safety and efficacy of competitive drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unfavorable publicity relating to the product.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing buntanetap, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have any infrastructure for the sales, marketing or distribution of buntanetap, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities or collaborate with third parties to perform these services. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator&#8217;s strategic interest in a product and such collaborator&#8217;s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of buntanetap, if approved, for certain markets overseas; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of buntanetap, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for buntanetap we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for buntanetap at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to establish adequate sales, marketing and distribution capabilities, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">A variety of risks associated with operating internationally could materially adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently have no international operations, but our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the burden of complying with multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure by us to obtain and maintain regulatory approvals for the use of our products in various jurisdictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional potentially relevant third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities and difficulties in obtaining protection and enforcing our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in staffing and managing foreign operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limits in our ability to penetrate international markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">certain expenses including, among others, expenses for travel, translation and insurance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Dependence on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our employees and independent contractors, including principal investigators, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely on third-party contract manufacturing organizations (&#8220;CMOs&#8221;) for the production of clinical supply of buntanetap and intend to rely on CMOs for the production of commercial supply of buntanetap, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of buntanetap and any product candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of buntanetap drug substance to enable us to complete our clinical trials, and we have also engaged two CMOs to provide clinical and commercial supply of the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Finding new CMOs or third-party suppliers involves additional cost and requires our management&#8217;s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely and in the future intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, yet we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and our CROs will be required to comply with the Good Laboratory Practice (&#8220;GLP&#8221;) requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management&#8217;s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. Additionally, working with collaborators presents risks, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form&#160;10-K also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Healthcare Laws and Other Legal Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the &#8220;ACA&#8221;) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there may be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal&#160;year. These reductions went into effect in April&#160;2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act (&#8220;FCA&#8221;) which, among other things, impose criminal and civil penalties, including through civil whistleblower or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">qui tam</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g.,&#160;public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any clinical trial programs we conduct or research collaborations we enter into in the EEA may subject us to the General Data Protection Regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we conduct clinical trial programs or enter into research collaborations in the EEA, we may be subject to the General Data Protection regulation (&#8220;GDPR&#8221;). The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the European Union (&#8220;EU&#8221;) to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners&#8217; or service providers&#8217; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to &#8364;20&#160;million or up to 4% of the total worldwide annual turnover of the preceding financial&#160;year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad if and when we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities, and any training or compliance programs or other initiatives we undertake to prevent such activities may not be effective. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions could also adversely affect our supply chain.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and any contract manufacturers and suppliers we engage are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. While the materials we use require operations involving the use of hazardous and flammable materials, including chemicals and biological materials, we do not produce any materials ourselves and contract with third parties for the manufacture and the disposal of these materials and wastes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years.  In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on us due to our tax losses generated during all prior years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">U.S. tax legislation enacted in 2017 has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules&#160;governing NOLs. The legislation could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is remains unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain, maintain and enforce patent or other intellectual property protection for buntanetap, Posiphen Form B or any future product candidates or technology or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize buntanetap, Posiphen Form B, or any future product candidates may be adversely affected and we may not be able to compete effectively in our markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our drug development programs and product candidates. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain and defend patent protection in the United States and other countries with respect to buntanetap, Posiphen Form B, and any future product candidates. Because we have not conducted a formal freedom to operate analysis for patents related to buntanetap since 2008, we may not be aware of patents issued since then that a third-party might assert are infringed by buntanetap, Posiphen Form B, or any future product candidates, which could materially impair our ability to commercialize buntanetap, Posiphen Form B, or any future product candidates. We generally seek to protect our proprietary position, in part, by filing patent applications in the United States and abroad relating to buntanetap, Posiphen Form B, and any future product candidates, manufacturing processes, and methods of use.  If we are unable to obtain, maintain or enforce patent protection, our business, financial condition, results of operations and prospects could be materially harmed.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Changes in either the patent laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our intellectual property, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we currently or may in the future pursue will issue as patents in any particular jurisdiction, will provide sufficient protection against competitors or other third parties, or if these patents are challenged by our competitors, will be found to be invalid, unenforceable, or not infringed.  Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection before public disclosures are made.  Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, third-party collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we may not be able to prevent any third party from using any of our technology that is in the public domain to compete with buntanetap, Posiphen Form B, and any future product candidates or technologies. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable in light of the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to invent or file on the inventions claimed in any of our licensed patents or pending patent applications, or that we or our licensors were the first to make the inventions claimed in those owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patents and patent applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable.  Furthermore, even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain additional patent protection to prolong the patent life of our product candidates, we may not be able to continue development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We seek to protect and prolong our proprietary position by filing patent applications in the United States and abroad related to our development programs and product candidates. If the patent applications we own with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for buntanetap, Posiphen Form B, or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future product candidates. Any such outcome could have a materially adverse effect on our business and our company could cease to exist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Annovis has filed fourteen families of patent applications to prolong the patent life of buntanetap, Posiphen Form B. Unless these applications are approved by the U.S. and international patent offices, the patent life of using buntanetap, and Posiphen Form B is limited. The first patent application family we filed, which would be expected to expire in 2031, before any patent term adjustments or extensions, covers the use of buntanetap in the treatment of AD, PD and other neurodegenerative disorders such as Huntington&#8217;s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies, frontotemporal dementia, Lewy bodies disease, and chronic traumatic encephalopathy, based on our preclinical research. In August 2019, the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) granted the first of our Annovis patents from this family covering treatment of PD and Lewy body diseases. Subsequently, the USPTO also granted patents covering treatment frontotemporal dementia and Prion&#8217;s disease, tauopathies, chronic traumatic encephalopathy, prion diseases, amyotrophic lateral sclerosis, Alzheimer&#8217;s and Huntington&#8217;s disease. The second patent application family covers ANVS405&#8217;s use in acute brain and nerve trauma and would be expected to expire in 2036, before any patent term adjustments or extensions. In December 2020, the EPO approved the whole patent and it has since been approved in most countries filed claiming a method of treating acute nerve and brain injuries by administering ANVS405 before and after the injury. The US patent office instead has asked us to separate the application into four divisional applications covering stroke, traumatic brain injury, nerve injury and spinal cord injury. The third patent application family relates to the use of the mechanism of action of buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire in 2038, before any patent term adjustments or extensions. The first divisional of this application was approved in December 2022, it covers the prevention of neurodegenerative diseases. The fourth patent application family relates to a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">compounds. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related compounds, which would be expected to expire in 2041, before any patent term adjustments or extensions. The fifth patent family application is directed to a method of maintaining heavy metal homeostasis avoiding the effect of toxic levels of a heavy metal in cells in a healthy human or restoring heavy metal homeostasis in a sick human patient. The USPTO granted the first patent in this family on March 7, 2023, which is expected to expire in 2039, before any patent term adjustments or extensions. The sixth patent application family relates to treating brain metastasis via administration of buntanetap or related compounds. In September 2023, we filed a U.S. nonprovisional patent application directed to treatment of brain metastasis via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2043, before any patent term adjustments or extensions. The seventh patent application family relates to treatment of mental illness via administration of buntanetap or related compounds. In January 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of mental illness via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2044, before any patent term adjustments or extensions. The eighth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antidiabetic agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The ninth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and a phosphodiesterase inhibitor. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The tenth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antihypertensive agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The eleventh patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap with two additional therapeutic agents. In August 2024, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The twelfth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an additional therapeutic agent. In February 2025, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The thirteenth patent application family relates to the new Form B of Posiphen (ANVS402); it demonstrates that it can be used instead of buntanetap, including in the foregoing uses of buntanetap of the Company&#8217;s patent portfolio. Posiphen Form B may be the compound of choice in current uses of buntanetap, because it may have advantageous properties such as better stability and higher purity. In 2023, the Company filed with the USPTO two provisional patent applications as to Posiphen Form B. In 2024, the Company filed an International (PCT) as to Posiphen Form B and uses thereof. The International Search Report and &#8216;Written Opinion&#8221; issued by the USPTO in the prosecution of the PCT application was favorable, indicating that the search claims directed to Posiphen Form B are novel and inventive.  The Company expects to further file patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications involving Posiphen Form B and uses thereof, patents would be expected to expire in 2044, before any patent term adjustments or extensions.  The Company also expects to seek New Chemical Entity status for Posiphen Form B before the US Food and Drug Administration (FDA), and to seek additional regulatory exclusivity based thereon. The fourteenth patent application family relates to new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B. The Company sees this patent application family as providing further protection as to methods that use buntanetap or Posiphen Form B, and for Posiphen form B. More in particular, in 2024 the Company filed with the USPTO a provisional patent application directed to new methods of preparing buntanetap and Posiphen Form B. The Company expects in 2025 to further file at least an International (PCT) application, claiming priority from that provisional patent application, and directed to the new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B, and thereafter patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications, patents would be expected to expire in 2045, before any patent term adjustments or extensions. It is possible that we will fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that provide further coverage of buntanetap, Posiphen Form B, or any other product candidate in the United States or in other foreign countries.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our patents may be challenged in courts, in patent offices or before other administrative bodies which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio, along with the unpredictable nature of patent prosecution, may not provide us with sufficient rights to similarly challenge other parties or exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Even if patents do successfully issue and even if such patents further cover buntanetap, Posiphen Form B, or any future product candidate, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Our patent rights may be subject to such priority, validity, inventorship, scope and enforceability disputes. Legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and likely to divert significant resources from our core business, including distracting our management and scientific personnel from their normal responsibilities and generally harm our business. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. If we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of U.S. Supreme Court cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a &#8220;law of nature.&#8221; Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We or our licensors may be subject to claims that former employees, consultants, collaborators or other third parties have an interest in our patent rights, any potential trade secrets, or other intellectual property as an inventor, co-inventor or owner of any potential trade secrets. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, any potential trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become subject to third parties&#8217; claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages, if we are found to be infringing a third party&#8217;s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys&#8217; fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot guarantee that any of our or our licensors&#8217; patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18&#160;months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (&#8220;AIA&#8221;) which was passed in September&#160;2011, resulted in significant changes to the U.S. patent system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files&#160;a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file&#160;a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all of our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">U.S. patents, even those issued before March&#160;16, 2013. Because of a possibly different evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent applications and the enforcement or defense of our or our licensors&#8217; issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent&#160;years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. Furthermore, the requirements for patentability differ in certain jurisdictions and countries. For example, unlike other countries, China has a heightened requirement for patentability, and </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Prosecution of patent applications in other jurisdictions is often a longer process and patents may grant at a later date, and with a shorter term, than in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to prevent third parties from practicing our or our licensors&#8217; inventions in all countries outside the United States, or from selling or importing products made using our intellectual property in and into the United States or other jurisdictions. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and under similar legislation in foreign countries, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we do not have sufficient patent life to protect our products, our business, financial condition, results of operations, and prospects will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five&#160;years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The total patent term including the extension cannot exceed 14&#160;years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO, referred to as Patent Term Adjustment (&#8220;PTA&#8221;). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not address all potential threats to our competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to buntanetap, Posiphen Form B, or our future product candidates but that are not covered by the claims of the patents that we own or license from others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we or any of our collaborators might not have been the first to conceive and reduce to practice or file on the inventions covered by the patents or patent applications that we own, license or will own or license;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ownership of our patents or patent applications may be challenged by third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to seeking patent protection for our product candidates and proprietary technologies, we may also rely on trade secret protection and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture buntanetap, Posiphen Form B, and any future product candidates, and we expect to collaborate with third parties on the development of buntanetap, Posiphen Form B, and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Furthermore, we cannot guarantee that we have entered into applicable agreements with each party that may have or have had access to any potential trade secrets or proprietary technology and processes. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time-consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. If any of our potential trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We have not yet registered our trademarks in the United States or other jurisdictions. Failure to secure such registrations could adversely affect our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not yet registered our trademarks in the United States or other jurisdictions. If we do not successfully register our trademarks, we may encounter difficulty in enforcing, or be unable to enforce, our trademark rights against third parties, which could adversely affect our business and our ability to effectively compete in the marketplace. We have also not yet registered trademarks for any of our product candidates in any jurisdiction. When we file registration applications for trademarks relating to our product candidates, those applications may be rejected, and registered trademarks may not be obtained, maintained or enforced. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties may oppose pending trademark registration applications or seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademark registrations may not survive such proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, any proprietary name we may propose to use with buntanetap, Posiphen Form B, or any future product candidate in the United States must be approved by the FDA, regardless of whether we have registered, or applied to register, the proposed proprietary name as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe, misappropriate or otherwise violate the existing rights of third parties and be acceptable to the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on, misappropriating or violating other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">confusion. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. There could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">In response to an inability to enforce our patent rights, or in the event of successful litigation against us by third parties, or in the normal course of future business operations, we may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. Furthermore, if we or our licensors are unsuccessful in any proceedings sought to enforce our patent rights, such patents and patent applications may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties. Although at this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize buntanetap, or Posiphen Form B, a third party may also hold intellectual property, including patent rights that are important or necessary to the future development or commercialization of buntanetap, Posiphen Form B, or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize buntanetap,</span> <span style="font-style:normal;font-weight:normal;">Posiphen Form B, or our product candidates, in which case we would be required to obtain a license from these third parties. If any of these situations were to occur, such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, contractors, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against any of the foregoing claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our proprietary information may be lost, or we may suffer security breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Certain federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular categories of personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, delays in our regulatory approval efforts, damage to our reputation, costs to recover or reproduce the data and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">If any security breach or other incident, whether actual or perceived, were to occur, it could impact our reputation and/or operations, cause us to incur significant costs and liabilities, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture buntanetap, or Posiphen Form B, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any actual or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of buntanetap, Posiphen Form B, or any future product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities. In addition, a security failure could result in violations of applicable privacy and other laws.  If this information is inappropriately accessed and used by a third party or a team member for illegal purposes, such as identity theft, we may be responsible to the affected individuals for any losses they may have incurred as a result of misappropriation.  In such an instance, we may also be subject to regulatory action, investigation or liable to a governmental authority for fines or penalties associated with a lapse in the integrity and security of our team members&#8217; or patients&#8217; information.  We may be required to expend significant capital and other resources to protect against and remedy any potential or existing security breaches and their consequences.  In addition, our remediation efforts may not be successful, and we may not have adequate insurance to cover these losses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Security breaches could also significantly damage our brand and our reputation with existing and prospective clients and third parties with whom we do business.  Any publicized security problems affecting our businesses and/or those of such third parties may negatively impact the market perception of our products and discourage third parties from doing business with us.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Employees, Managing Our Growth and Our Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the development, regulatory, commercialization and business development expertise of Maria L. Maccecchini,&#160;PhD, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to experience significant growth in the number of our employees and the scope of our operations. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results. Furthermore, we may experience losses related to investments in other companies, including as a result of failure to realize expected benefits or the materialization of unexpected liabilities or risks, which could have a material negative effect on our results of operations and financial condition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We may seek to enter into collaborations, license agreements and other similar arrangements in the future, and may not be successful in doing so.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We may seek to enter into collaborations, joint ventures, licensing arrangements or other similar arrangements with third parties for the development or commercialization of buntanetap and any future product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. These relationships or those like them may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish or maintain a strategic partnership or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us. For example, we may need to relinquish valuable rights to our future revenue streams, research programs, intellectual property or product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into additional agreements with other potential collaborators. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">them with our existing operations and company culture. In addition, if we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on any future collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Furthermore, we may not be able to maintain such collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory. Any delays in entering into new strategic partnership agreements related to our drug candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Collaborations involving buntanetap or any future product candidates would pose significant risks to us, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not perform their obligations as expected or at all&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to any product candidate that achieves regulatory approval may not commit sufficient resources to the marketing and distribution of such products&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws, resulting in civil or criminal proceedings&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly enforce, maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation&#894;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not provide us with timely and accurate information regarding development, regulatory or commercialization status or results, which could adversely impact our ability to manage our own development efforts, accurately forecast financial results or provide timely information to our stockholders regarding our out-licensed product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to invest resources and attention into such collaboration, which could distract from other business objectives&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us regarding ownership of or other rights in the intellectual property generated in the course of the collaborations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborations may be terminated, including for the convenience of the collaborator, prior to or upon the expiration of the agreed upon terms and, if terminated, we may find it more difficult to enter into future collaborations or be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to buntanetap or any future product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition, results of operations and future commercial prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business and operations would suffer in the event of failures involving our information technology systems, or those of any of our service providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), team member misconduct, human error, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of buntanetap or any other product candidate could be delayed. It is not possible to prevent all threats or to our information technology systems and information and those of our third-party service providers, over which we exert less control, and any controls we implement to do so may prove to be ineffective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Disruption, failure or cybersecurity breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We use computers and telecommunication systems to analyze and store financial and operating data and to communicate within our company, with outside business partners, and across international borders. These systems can be subject to technical system flaws; power loss; cyber attacks, including viruses, malware, phishing, ransomware, terrorism, and surveillance, unauthorized access, malicious software, intentional or inadvertent data privacy breaches by employees or others with authorized access, hacktivism, ransomware, physical or electronic break-ins, fires or natural disasters, supply chain attacks, and other cybersecurity issues. We have no assurance that our systems are appropriately redundant to withstand these events. Accordingly, such events could cause adverse </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">effects and material disruptions to our operations or systems or those of our business partners; compromise the security, integrity, availability, and confidentiality of customer information, employee information, strategic projects, product formulas and other trade secrets, other business or personal sensitive data, including third party confidential information in our possession. Release of third party confidential information could materially harm our reputation, affect our relationships with such parties and expose us to liability. Although we have introduced many security measures, including firewalls and information technology security policies and training, these measures may not offer the appropriate level of security. A security breach or other compromise of our information security safeguards could expose our confidential information, including third party confidential information in our possession (such as customer information) to theft and misuse, which could in turn adversely affect our relationships with such third parties and have an adverse effect on our business, financial condition, results of operations and cash runway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. If one or both financial institutions fail, our deposit accounts could be adversely affected due to the loss of or delay in obtaining access to all or a portion of our uninsured funds.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. The balance held in these accounts regularly exceeds the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), standard deposit insurance limit or similar government guarantee schemes. If one or both of the financial institutions in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) and Signature Bank, were closed by state regulators and the FDIC was appointed as the receiver for each bank. The FDIC created successor bridge banks and all deposits of SVB and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. If one or both of the financial institutions in which we hold our funds for working capital and operating expense needs were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market price of our common stock has been volatile and fluctuated substantially in the past and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock is highly volatile. For example, from July 1, 2024 to February 28, 2025, the closing price of our common stock on the New York Stock Exchange ranged from as low as $1.74 to as high as $15.46 and daily trading volume ranged from 67,300 shares to 40,734,200 shares. The market price of our common stock may be subject to wide fluctuations in response to a variety of factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of our clinical trials, and the results of trials of our competitors or those of other companies in our market sector&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to enroll subjects in our future clinical trials&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or unanticipated developments in the completion of our planned clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA&#8217;s review of that NDA;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain regulatory approval of buntanetap or any future product candidates or additional indications thereof, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to successfully develop and commercialize buntanetap or any future product candidates;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the degree and rate of physician and market adoption of any of our current and future product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain additional funding or obtaining funding on unattractive terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to buntanetap or any other product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing, supply or distribution delays or shortages, including our inability to obtain adequate product supply for buntanetap or any other product candidates, or the inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success or failure of our efforts to identify, develop, acquire or license additional product candidates&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">introduction of new products, services or technologies by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed financial projections we provide to the public;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to meet or exceed the estimates and projections of the investment community;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the market valuations of companies similar to ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts&#8217; reports or recommendations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key scientific or management personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us or our stockholders in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in accounting standards, policies, guidelines, interpretations or principles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading volume of our common stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated fluctuations in our financial condition and results of operations&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publication of news releases by other companies in our industry, and especially direct competitors, including about adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory compliance, and product recalls&#894;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or progression of geopolitical events (including in relation to the conflict between Russia and Ukraine or Isreal and Hamas)&#894; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. The market price of our common stock may decline, and our stockholders may lose some or all of their investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our failure to meet the New York Stock Exchange&#8217;s continued listing requirements could result in a delisting of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">If we fail to satisfy the continued listing requirements of the New York Stock Exchange, such as the corporate governance requirements, market capitalization or the minimum closing bid price requirement, the New York Stock Exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders&#8217; ability to sell or purchase our common stock when they wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, or prevent future non-compliance with the listing requirements of the New York Stock Exchange.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have been subject to securities class action litigation in the past and could be subject to such litigation in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;white-space:pre-wrap;">In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. During the year ended December 31, 2021, two securities class action complaints were filed against us and our executive officers following disclosure of interim results from the AD/PD Trials.  Both complaints were voluntarily dismissed without prejudice by the plaintiffs. If we again face such litigation in the future, it could result in substantial costs, a diversion of management&#8217;s attention and resources, and damage to our reputation, which could have a material adverse effect on our business, financial condition and results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our directors, executive officers and certain stockholders own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant control over matters subject to stockholder approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our directors, executive officers, and stockholders affiliated with our directors and executive officers own 14.3% of the current voting power of our outstanding common stock. Therefore, acting together, they have the ability to substantially influence all matters submitted to our board of directors or stockholders for approval. For example, these holders may be able to control the appointment of our management, elections and removal of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these holders may not always coincide with our corporate interests or the interests of other stockholders, and they may act in a manner with which our stockholders may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. So long as they continue to own a significant amount of our equity, these holders will be able to strongly influence or effectively control our decisions. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts. If our financial performance fails to meet analyst estimates or one or more of the analysts who cover us downgrade our common stock or change their opinion of our common stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock would be our stockholders&#8217; sole source of gain on an investment in our common stock for the foreseeable future. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. See &#8220;Dividend Policy&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the New York Stock Exchange, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section 404 of SOX, we are required to furnish a report by our senior management on our internal control over financial reporting. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To comply with Section 404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. We have had a material weakness in our internal control over financial reporting in the past, and cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the NYSE, SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering (&#8220;IPO&#8221;) on January 31, 2020, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and our amended and restated bylaws that became effective upon the closing of our IPO may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing advance notice bylaw provisions for proposals from stockholders for presentation at annual meetings and forum selection bylaw provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our restated certificate of incorporation that became effective upon the closing of our IPO specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders with respect to our company and our directors. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">judicial forum that the stockholder believes is favorable for disputes with us or our directors, which may discourage meritorious claims from being asserted against us and our directors. Alternatively, if a court were to find this provision of our charter inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations. We adopted this provision because we believe it makes it less likely that we will be forced to incur the expense of defending duplicative actions in multiple forums and less likely that plaintiffs&#8217; attorneys will be able to employ such litigation to coerce us into otherwise unjustified settlements, and we believe the risk of a court declining to enforce this provision is remote, as the General Assembly of Delaware has specifically amended the Delaware General Corporation Law to authorize the adoption of such provisions.</p><a id="_07882b5e_ae06_4140_95b2_e142df31e28d"></a><a id="Item1BUnresolvedStaffComments_556571"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B. Unresolved Staff Comments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_9979012c_2f79_43fb_b36c_05a6c2a39006"></a><a id="Item1CCybersecurity_600109"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 1C. Cybersecurity.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Tb__b0TTGRydUaETLhlmCQFXQ" continuedAt="Tb__b0TTGRydUaETLhlmCQFXQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Tb_ejCZZKc_A0Kttijcmw8q9g" escape="true"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Narr_Xwciqb9VSUecfxpSlcqgDg">The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company&#8217;s overall risk management systems and processes</ix:nonNumeric>. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations.</ix:nonNumeric> The Company references the National Institute of Standards and Technology Cybersecurity Framework to help identify, assess, and manage cybersecurity risks and has adopted and tested a formal cybersecurity incident response plan. As part of our risk management process, <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Narr_awz1nfz-Qke0nv6h7W5w9Q">the Company engages a third-party provider to conduct periodic maturity assessments</ix:nonNumeric>. The Company stores data in cloud environments, with security appropriate to the data involved and has adopted controls around, among other things, access and acceptable use, backup and recovery and vendor risk assessment.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Group_MAkmTSKySE6UwMNLn2chsw" continuedAt="Group_MAkmTSKySE6UwMNLn2chsw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Narr_LGmN2N-CtUiI7BUXULHklQ">Our cybersecurity program is managed by the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Tb_tULMHvAjyUuZ4yfiMzQiIg" escape="true">Annovis Incident Management Committee</ix:nonNumeric> (the &#8220;AIMC&#8221;). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. </ix:nonNumeric>The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Tb_0V-WIdET50WBSzIxspel7w" escape="true">Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company.</ix:nonNumeric> From time to time, we engage this vendor to monitor our environment, which includes an outsourced security operations center. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt:fixed-true" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Narr_T1N-C0xI-0-LJriRiTzwoA">We may also from time to time engage partners for periodic penetration testing and vulnerability assessments. We intend to continue to work to formalize our cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.</ix:nonNumeric></p><ix:continuation id="Group_MAkmTSKySE6UwMNLn2chsw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt:fixed-false" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Narr_WpWYeuvycE2jPDUWUPOmJw">we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations, or financial condition</ix:nonNumeric>, although we may be materially affected in the future by such risks or future material incidents. See &#8220;Risk Factors&#8212;Risks Related to Our Business Operations&#8212;Disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations&#8221; for additional information regarding cybersecurity risks.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb__b0TTGRydUaETLhlmCQFXQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Tb_8uKUODbKEECYWwWphZ1aEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Roles and Responsibilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity is an important part of our risk management processes and an area of focus for the Annovis management and Board of Directors. We continue to invest in cybersecurity and enhance our internal controls and processes, which are designed to help protect our systems and the information they contain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The Board has delegated to the Audit Committee the responsibility to oversee the integrity of the Company&#8217;s information technology and cybersecurity risks and to assess the risks and incidents relating to cybersecurity threats. While our <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_PcagFlT33EOfod4oBkvmYw" escape="true">Board and Audit Committee</ix:nonNumeric> oversee cybersecurity risk, management, through <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Group_vGPGrH4-EUeWOQmSC89u0w" continuedAt="Group_vGPGrH4-EUeWOQmSC89u0w_2" escape="true">the <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Tb_WUUBSL0he0mgTHyDakhZ2Q" escape="true">AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee</ix:nonNumeric>.</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt:fixed-true" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Narr_-xOA9b_oWEawCuKw7onboQ"><ix:continuation id="Group_vGPGrH4-EUeWOQmSC89u0w_2">The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually</ix:continuation>.</ix:nonNumeric> Additionally, the Audit Committee regularly meets with members of the Company&#8217;s internal audit function to discuss risk management activities, compliance, best practices, and other related matters.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_57082044_2dfe_46ef_a168_1da1fdfe98e0"></a><a id="Item2Properties_424245"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2. Properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our offices are in Malvern, Pennsylvania, where we have leased and have access to approximately 1,500&#160;square feet of office space pursuant to a short-term lease agreement. We believe that our facilities are adequate to meet our current needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_16a7fb3a_b508_4c6f_9b88_d24f0a0bc206"></a><a id="Item3LegalProceedings_59244"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3. Legal Proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.</p><a id="_80ffd609_90a3_4024_9b69_4de04c801aff"></a><a id="Item4MineSafetyDisclosures_448345"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4. Mine Safety Disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_d015a106_7e47_466c_8f05_1338efe2133c"></a><a id="PARTII_847922"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Market Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our common stock is listed on the New York Stock Exchange under the symbol &#8220;ANVS&#8221;.  Our common stock began trading on the New York Stock Exchange on November 18, 2021.  From January 29, 2020, the date of our initial public offering, to November 17, 2021, our common stock traded on the NYSE American.  Prior to January 29, 2020, there was no public market for our stock.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Holders of Record</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of March 18, 2025, there were approximately 23 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Securities Authorized for Issuance Under Equity Compensation Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information called for by this item regarding equity compensation plans is incorporated by reference to Part&#160;III,&#160;Item&#160;12 of this Annual Report on Form&#160;10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Sales of Unregistered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e596ff97_6069_4240_891b_c4cef01f1856"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the end of this Annual Report on Form&#160;10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form&#160;10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read &#8220;Cautionary Note&#160;Regarding Forward-Looking Statements&#8221; and Item&#160;1A. Risk Factors of this Annual Report on Form&#160;10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</i></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Company Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins &#8212; APP/A&#946; (&#8220;APP&#8221;), tau/phospho- tau (&#8220;tau&#8221;) and &#945;-Synuclein (&#8220;&#945;SYN&#8221;) &#8212; that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for the communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We designed the studies by applying our understanding of the underlying neurodegenerative disease states, and measured both target and pathway validation in the spinal fluid of patients to determine whether patients underlying disease condition improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics (&#8220;PK&#8221;) of buntanetap, our AD/PD Trials also met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, as well as function in PD patients. We believe that the AD/PD Trials represent the first double-blind, placebo-controlled study that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and requested direction to further pursue the development of buntanetap in early PD patients. With the FDA&#8217;s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our &#8220;Phase 3 PD Study&#8221;). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn &amp; Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to periods when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our &#8220;Phase 2/3 AD Study&#8221;). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. Our Phase 3 PD Study and Phase 2/3 AD Study each had built in interim analyses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively, for which baseline and two-month data was available. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. The study was completed on December 4, 2023, and we released the topline PD Study efficacy data on July 2, 2024. The study data showed that in two subgroups, buntanetap improved UPDRS 2, 3, 2+3 and total. It also showed that in the entire intent to treat (&#8220;ITT&#8221;) population, buntanetap stopped the loss of cognition and that in the 12% of patients that already had cognitive issues, buntanetap improved cognition in a dose-dependent, statistically significant way. We expect to discuss the Phase 3 PD data with the FDA at an end-of-study meeting during 2025. During that meeting, we plan to propose continued development of buntanetap with an additional, pivotal Phase 3 trial.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">With respect to the Phase 2/3 AD Study, we disclosed the results of the interim analysis on October 23, 2023, and similar to our PD study, based on the outcome of the interim analysis, we proceeded with the study as planned. The Phase 2/3 AD study was completed on February 13, 2024, and on April 29, 2024, we announced topline efficacy data. The data showed that in early AD patients, buntanetap improved ADAS-Cog11 in a dose-dependent fashion and was statistically significant from placebo and from baseline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On October 10, 2024, the Company met with the FDA in an end-of-phase 2 meeting to discuss its Phase 2/3 AD data and to agree on a regulatory path forward. Annovis and the FDA have aligned on a development path for buntanetap towards the filing of New Drug Applications (&#8220;NDAs&#8221;), one for short-term and one for long-term efficacy. The Phase 3 AD program will investigate buntanetap in patients with early AD and will consist of one study that first incorporates a 6-month study period aimed at confirming buntanetap&#8217;s symptomatic effects, then later transitioning into an 18-month study period, designed to demonstrate potential disease-modifying effects. While the overall study will span the combined 18-month treatment period, the completion of the first 6-month period, if well-designed and well-executed, may be sufficient to support an NDA filing, potentially within one year of the 6-month treatment period initiation.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">During the end-of-phase 2 meeting for AD, the FDA raised no concerns with the Company&#8217;s data on buntanetap&#8217;s safety, including impact on liver enzymes, drug interactions, dose selection, pharmacokinetics and population pharmacokinetics. Further, the FDA confirmed that future development can proceed using the new crystal form of buntanetap.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function issues associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has historically encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or &#945;SYN, indicating that doing so does not change the underlying course of neurodegeneration. Our ultimate goal is to develop a disease modifying drug (&#8220;DMD&#8221;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets, if a DMD is developed and approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function issues associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has historically encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or &#945;SYN, indicating that doing so does not change the underlying course of neurodegeneration. Our ultimate goal is to develop a disease modifying drug (&#8220;DMD&#8221;) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly, these diseases present two unmet needs of the aging population and two potentially large U.S. markets, if a DMD is developed and approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We have never been profitable and have incurred net losses since inception. Our accumulated deficit at December 31, 2024 was $134.8 million. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when we will be able to achieve or maintain profitability, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:36pt;margin:0pt;">The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December&#160;31, 2024, we viewed our operations and managed our business as one operating segment consistent with how our chief operating decision-maker, our Chief Executive Officer, makes decisions regarding resource allocation and assessing performance. As of December&#160;31, 2024, substantially all of our assets were located in the United States. Our headquarters are located in Malvern, Pennsylvania.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development (&#8220;R&amp;D&#8221;) expenses consist of expenses incurred in development and clinical studies relating to our product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses associated with clinical development;</span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel-related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payments to third-party contract research organizations (&#8220;CROs&#8221;), contract manufacturing organizations (&#8220;CMOs&#8221;), contractor laboratories and other independent contractors.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, whereby expense is recognized when the service is performed. Clinical development expenses for our product candidates are a significant component of our current research and development expenses. Product candidates in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size (e.g., patient population) and duration of the clinical trials. We track and record information regarding external research and development expenses for each study or trial that we conduct. We often use third-party CROs, contractor laboratories and independent contractors to help us complete clinical studies. We recognize the expenses associated with third parties performing these services for us in our clinical studies based on the&#160;percentage of each study (or study activity) completed at the end of each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses in 2024 were primarily related to the wind-down and analysis of our Phase 3 study in early PD patients and our Phase 2/3 study in AD patients, as well as preparatory work for our pivotal Phase 3 AD study program in early AD patients. Our research and development expenses in 2023 were primarily related to the execution of our Phase 3 study in early PD patients and our Phase 2/3 study in AD patients. We expect that our research and development expenses in 2025 and for the next several years will continue to remain elevated as a result of costs associated with completing our Phase 3 trial for AD, our planned Phase 3 trial for PD and other subsequent planned activities leading up to a potential NDA filing(s) with the FDA. These expenditures are subject to numerous uncertainties regarding timing and cost to achieve completion. Completion of our clinical development and clinical trials may take several years or more and the length of time generally varies according to the type, complexity, novelty and intended use of our product candidates. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing and uncertain nature of our research and development, we are unable to accurately determine the duration or completion costs of our development of buntanetap. As a result of the difficulties of forecasting research and development costs of buntanetap as well as the other uncertainties discussed above, we are unable to determine when and to what extent we will generate revenues from the commercialization and sale of approved product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative (&#8220;G&amp;A&#8221;) expenses consist primarily of salaries, benefits and other related costs, including public company costs as well as stock-based compensation, for personnel serving in our executive, finance, accounting, and administrative functions. Our general and administrative expenses also include professional fees for legal services, including patent-related expenses, consulting, tax and accounting services, insurance, rent and general corporate expenses. We expect that our general and administrative expenses will increase as a result of the continued clinical development and potential commercialization of our product candidates. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $54.1 million, which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning 2032. The remaining federal NOL carryforwards generated beginning in 2018, do not expire. NOL carryforwards generated beginning in 2018 are permitted to offset 80% of taxable income in future years. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million, which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the &#8220;IRS&#8221;) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code. This could substantially limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">changes may further affect the limitation in future years. We have not yet conducted a comprehensive study to assess whether a change of ownership as defined by Section 382 has occurred since our inception.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Years ended December 31, 2024 and 2023</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Operating expenses and other income (expense) were comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:45.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 19,995</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 38,791</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,796)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,699</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,244</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 455</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 26,694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 45,035</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (18,341)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 332</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 668</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (336)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,853)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> -</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,853)</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,626</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,837)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,463</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,105</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (11,169)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 13,274</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 24,589</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 56,204</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31,615)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses decreased by $18.8 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. The decrease was primarily the result of our Phase 3 PD and Phase 2/3 AD studies being active during the majority of 2023, whereas 2024 study activity was minimal because the aforementioned trials had been completed. This decrease related to timing of study costs was primarily offset by increases in statistics, bioanalytical and CMC costs during the year ended December 31, 2024. Year-over-year increases for these items took place as we analyzed data from our completed Phase 3 PD and Phase 2/3 AD studies and performed preparatory work for our pivotal Phase 3 AD study. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses increased by $0.5 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. The increase was primarily a result of warrant exercise commissions expensed during the current year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interest Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Interest income decreased by $0.3 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. The decrease was primarily the result of lower cash and cash equivalent balances on hand year-over-year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Financing Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financing costs were $1.9 million for the year ended December 31, 2024. We did not incur any financing costs for the year ended December 31, 2023. The change was attributable to issuance costs as well as changes in derivative fair value associated with our ELOC financing with an ELOC Purchaser, described further below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Change in Fair Value of Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Change in fair value of warrants was a gain of $3.6 million for the year ended December 31, 2024 compared to a loss of $11.8 million the year ended December 31, 2023. This change was attributable to the fair value remeasurement with respect to our liability-classified Canaccord Warrants during 2024. The current year loss recorded in the statements of operations was primarily </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">driven by warrant exercises made at higher stock prices during the third quarter of 2024, triggering remeasurement. The remaining change in fair value was primarily driven by the change in our stock price during 2024. For the year ended December 31, 2023, the change in fair value was primarily attributable to issuance of the liability-classified Canaccord Warrants and the increase in our stock price during the fourth quarter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock and warrants. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of December 31, 2024, our principal source of liquidity was our cash and cash equivalents, which totaled $10.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Financings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">March 2024 Registered Direct Offerings </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">On March 15, 2024 and March 21, 2024, we entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, we issued 0.4 million shares for net proceeds of $3.9 million registered direct offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">April 2024 ELOC Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 25, 2024, we entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of our common stock. The term of the agreement was until the expiration of our active S-3 Registration Statement, unless earlier terminated or exhausted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Upon execution of the ELOC Purchase Agreement, we agreed to issue 33,937 shares of common stock as commitment shares to the ELOC Purchaser. In addition to the commitment shares referenced above, as of the year ended December 31, 2024 we have sold 2.0 million shares of our common stock under the purchase agreement and received net proceeds of $14.6 million. There are no shares remaining to sell under this agreement after December 31, 2024.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">January and July 2024 Warrant Exercises</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;width:36pt;"></span>During July of 2024, 0.8 million of our Canaccord warrants were exercised at $9.00 per share in a series of transactions. The exercises resulted in gross proceeds of $7.5 million. There were also 0.1 million warrants exercised in January of 2024, for gross proceeds of $0.5 million. Total warrant commissions payable to Canaccord for these exercises totaled $0.5 million, which was expensed in the Statements of Operations for the year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">December 2024 ATM</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 11, 2024, we entered into an Equity Distribution Agreement (&#8220;Distribution Agreement&#8221;) with Oppenheimer &amp; Co. Inc. (&#8220;OpCo&#8221;), relating to the sale of shares of our common stock. In accordance with the terms of the Distribution Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as our agent or principal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, we have sold 26,788 shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">February 2025 ThinkEquity Offering</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February 3, 2025, we entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">of common stock and one warrant to purchase one share of common stock (the &#8220;ThinkEquity Warrants&#8221;), at a per unit price of $4.00 (the &#8220;Offering&#8221;). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. We have agreed to suspend sales of our Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Future Capital Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that our current cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of our operations. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these financial statements are issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur significant operating losses for the foreseeable future. We also expect these losses to further increase, as we ramp up our clinical development programs and begin activities for commercial launch readiness. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for buntanetap or any other future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical development plans we establish for buntanetap and any other future product candidates, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we discover or in-license and develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the outcome, timing and cost of regulatory meetings and reviews by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for buntanetap and any future product candidates and our anticipated timing for seeking approval in such jurisdictions&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property and proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, CMC, quality and commercial personnel&#894;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of the implementation of commercial-scale manufacturing activities, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval; </span></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products&#894; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#894; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any products or technologies that we may in-license or acquire.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section of this Annual Report on Form 10-K titled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes our cash flows from operating, investing and financing activities the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (21,895)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (39,967)</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26,692</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,344</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,797</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (22,623)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2024, cash used in operations was $21.9 million compared to $40.0 million for the year ended December 31, 2023. The decrease in cash used in operations was primarily the result of our Phase 3 PD and Phase 2/3 AD studies being active during the majority of 2023, whereas 2024 study activity was minimal because the aforementioned trials had been substantially completed in 2023. The reduction in clinical activity during 2024 significantly reduced our operating cash burn year-over-year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect cash used in operating activities to once again increase in 2025 as compared to 2024, due to an expected increase in our operating losses associated with continued development of our product candidates (i.e., pivotal Phase 3 AD Program) as well as planned increases in our personnel count. </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $26.7 million during the year ended December 31, 2024, which was primarily attributable to proceeds from issuance of common stock and warrants for capital raises, including our ELOC and ATM facilities, as well as proceeds from exercises of our Canaccord Warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $17.3 million during the year ended December 31, 2023, which was primarily attributable to proceeds from issuance of common stock and warrants for capital raises, including proceeds from our equity financing with Canaccord as well as proceeds from exercises of our Canaccord Warrants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Off-Balance Sheet Arrangements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We have based our management&#8217;s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses, fair value of warrants and stock-based compensation. The clinical development cost to advance any of our product candidates to marketing approval is substantial and involves numerous risks and uncertainties associated with pharmaceutical product development.  As a result, we are unable to accurately predict the timing or amount of increased expenses and, as a result, clinical development expense could be materially different as the costs are incurred. In determining warrant fair value, we maximize the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. We measure and record stock compensation expense using the applicable accounting guidance for share-based payments using the Black-Scholes option pricing model to value option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. These assumptions used in calculating the fair value of stock-based awards represent our best estimates and involve inherent uncertainties and the application of judgment. As a result, if factors change and we used different assumptions, stock-based compensation expense could be materially different for stock-based awards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are more fully discussed in Note 2 to our audited financial statements appearing at the end of this Annual Report on Form 10-K, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Research and Development Expenses and Clinical Trial Accruals</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">As part of the process of preparing the financial statements included elsewhere in this Annual Report on Form 10-K, we are required to estimate and record expenses, for which a large portion are research and development expenses. Research and development expenses include, among other categories - development, clinical trials, and regulatory compliance costs incurred with research organizations, contract manufacturers, and other third-party vendors. We rely on third-parties to conduct our clinical studies and to provide many of these services, including data and project management, statistical analysis and electronic compilation. At the end of each reporting period, the estimation process involves identifying services that have been performed on our behalf by third-parties, estimating and accruing expenses in our financial statements based on the evaluation of the progress to completion of specific tasks and the facts and circumstances known to us at the time of the estimate, and assessing the accuracy of these estimates going forward to determine if adjustments are required. We periodically collaborate with our third-party vendors to assist in determining our estimates. Payments for these activities performed by our third-party vendors are based on the terms of the individual arrangements with our third-party vendors, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as applicable. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates. Any changes to estimates will be recorded in the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">period in which a circumstance causing a change in estimate becomes known and the impact of any change in estimate could be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Stock-Based Compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We account for our stock-based compensation awards in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). We have issued stock-based compensation awards that are stock options, in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the statements of operations based on their grant date fair values. We use the Black-Scholes option-pricing model to determine the fair value of options granted. We recognize forfeitures as they occur. Expense related to stock-based compensation awards are recorded to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent our best estimates and involve a number of variables, uncertainties, assumptions, and the application of our judgment, as they are inherently subjective. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in our Black-Scholes option-pricing model for stock options are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term.</i> As we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee options is determined using the &#8220;simplified&#8221; method, as prescribed in SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility.</i> The expected volatility is based on our historical volatilities and that of similar entities within our industry for periods commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate.</i> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends.</i> The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense was $3.8 million and $4.6 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had $2.4 million of unrecognized stock-based compensation expense, related to service-based options, which will be recognized over a remaining weighted-average period of 1.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Valuation of Common Stock Warrant Liabilities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of Common Stock Warrant Liabilities is determined using a Black-Scholes option-pricing model. Determining the appropriate fair value model and calculating the fair value of Common Stock Warrants requires considerable judgment. Any change in the estimates used may cause the value to be higher or lower than that reported. The Common Stock Warrants are not traded in an active market and the fair value is determined using valuation techniques. The estimates may be significantly different from those recorded in the financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the statements of operations each reporting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="background:#ffffff;">Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><i style="font-style:italic;background:#ffffff;">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </i><span style="background:#ffffff;">(&#8220;ASU 2023-07&#8221;) on an annual basis, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, </span><i style="font-style:italic;background:#ffffff;">Segment Reporting</i><span style="background:#ffffff;">. This guidance is effective for </span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;background:#ffffff;">fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.  See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company&#8217;s financial statement disclosures but is not expecting material impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">In November 2024, the FASB issued ASU 2024-03, </span><i style="font-style:italic;background:#ffffff;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&#8220;</i><span style="background:#ffffff;">ASU 2024-03</span><i style="font-style:italic;background:#ffffff;">&#8221;)</i><span style="background:#ffffff;">, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">JOBS Act</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Section&#160;107 of the JOBS Act also provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B)&#160;of the Securities Act for complying with new or revised accounting standards. In other words, an &#8220;emerging growth company&#8221; can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</p><a id="_35d05536_6f9a_4348_9a70_64e47fa1a961"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This item is not required for smaller reporting companies.</p><a id="_a07e4a16_9ebe_4257_b1bb_b34a5a99ad54"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8. Financial Statements and Supplementary Data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial statements, accompanying notes and Report of Independent Registered Public Accounting Firm are included in this Annual Report on Form&#160;10-K beginning on page&#160;F-1, which are incorporated in this Item&#160;8 by reference.</p><a id="_d5c364f9_e0ce_4369_8374_76a9d8f55e11"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_5e72ec9f_f0f9_49fb_a155_733d21c00538"></a><a id="Item9AControlsandProcedures_371514"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A. Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Evaluation of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Our management, with the participation of our Chief Executive Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15I and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer, as our interim principal financial and accounting officer, to allow timely decisions regarding required disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Management utilized the criteria established in the Internal Control &#8211; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) to assess the effectiveness of our internal control over financial reporting as of December 31, 2024. Based on the assessment, management has concluded that, as of December 31, 2024, our internal control over financial reporting was effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As an emerging growth company, management&#8217;s assessment of internal control over financial reporting was not subject to attestation by our independent registered public accounting firm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_1931961b_f46c_46ab_aab3_a144a84b8d9b"></a><a id="Item9BOtherInformation_404053"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B. Other Information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the three months ended December 31, 2024, the following directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408(c) of Regulation S-K:</p><a id="Tc_XLP9WOvH-kGDF0MOwPpNdg_1_0"></a><a id="Tc_TMc2aRyDkU-NTPKcu8qNaQ_1_1"></a><a id="Tc_qUSquiYvdUOsTRXbtpxTGA_1_2"></a><a id="Tc_54Djm6tHgk-6dMdQ-Iz-sA_1_3"></a><a id="Tc_mQ3z-uT2p0ifEfL5NuN2XA_1_4"></a><a id="Tc_X_YPSSmwEk-v_Puk2ZBikg_1_5"></a><a id="Tc_v5ivrRJPtUinYMHzkZK4Tg_2_0"></a><a id="Tc_ENTWXzEHl0C_yfrWbi2tfA_2_3"></a><a id="Tc_xDIj3gb0ek-1BUOn3JK68g_3_0"></a><a id="Tc_XBU_owNO8UedGvet2b-iIg_3_3"></a><a id="Tc_5jPls8b5GEW4zbL7qGXAJg_4_0"></a><a id="Tc_E2GxUVnUf0-5-lfLkSGwZw_4_3"></a><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw" name="ecd:MtrlTermsOfTrdArrTextBlock" id="Tb_AZfLcVbpC0WRVBz9jvrZzg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name and Title</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Action</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan</p></td><td style="vertical-align:middle;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aggregate Number of securities to be sold</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan Expiration Date</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw" name="ecd:TrdArrIndName" id="Narr__ObGNECrf02PTBwEmGfwzw">Maria Maccecchini</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw" name="ecd:TrdArrIndTitle" id="Narr_KLs44pzbbkeJboIWwQoDew">CEO &amp; Director</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Tc_ybgv80D-NkGToYEIwRMOjg_2_1">Adoption</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw" name="ecd:TrdArrAdoptionDate" id="Tc_5S_Ct9I16k-TxpBIzIYfqA_2_2">17-Dec-24</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_iJ4ofV9Y8E6ZohLjT2mgzg" decimals="INF" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Tc_R0SaoOnd4keKo-cRg_qoJw_2_4">270,000</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw" name="ecd:TrdArrExpirationDate" id="Tc_H66Ab4f4mESniNLjUs0EHw_2_5">16-Sep-26</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw" name="ecd:TrdArrIndName" id="Narr_hl8Lsh2FUEygYpChCwCavw">Claudine Bruck</ix:nonNumeric>, <ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw" name="ecd:TrdArrIndTitle" id="Narr_m6ePN7UNcUGJ3tqPn32lKQ">Director</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Tc_xfr4NfZyGk2p0YdUmKcGHQ_3_1">Adoption</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw" name="ecd:TrdArrAdoptionDate" id="Tc_uqg95aJH6k6P490w_08MXQ_3_2">17-Dec-24</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_leZDo1RgDkCmAdE8soyXPw" decimals="INF" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Tc_Ulirflvd40-h0-zn040hGA_3_4">21,426</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw" name="ecd:TrdArrExpirationDate" id="Tc_qNbKySPvnEKpVSxK9w_VsQ_3_5">31-Dec-25</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA" name="ecd:TrdArrIndName" id="Narr_J_tBfNWV3kmjShadweRPrw">Mark White</ix:nonNumeric>,&#160;<ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA" name="ecd:TrdArrIndTitle" id="Narr_kRIvNWVmsEar-UynUDsDmw">Director</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA" format="ixt:fixed-true" name="ecd:Rule10b51ArrAdoptedFlag" id="Tc_lG6E1yeXOkaahYnmT6r_Ww_4_1">Adoption</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA" name="ecd:TrdArrAdoptionDate" id="Tc_p5fArviih0GMgW2t94qyuA_4_2">17-Dec-24</ix:nonNumeric></p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_Ce1DhVkEO0ycmzDj2jbxSg" decimals="INF" format="ixt:num-dot-decimal" name="ecd:TrdArrSecuritiesAggAvailAmt" scale="0" id="Tc_cRR5ixkHLESvXP0C-90WeA_4_4">51,426</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA" name="ecd:TrdArrExpirationDate" id="Tc_tVGLLWDIy0eKzX7ybUeFLQ_4_5">30-Sep-26</ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_f4b0d1f3_d735_4ad5_85b5_a1a44f8e74ce"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt;"><span style="font-weight:normal;">Not Applicable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_1219e48f_a0aa_4c51_adc9_8727889f38cb"></a><a id="PARTIII_953652"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART&#160;III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Item10DirectorsandExecutiveOfficersandCo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;10. Directors, Executive Officers and Corporate Governance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;10 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.</p><a id="_3cf80943_fa3d_47e9_b439_9249fd4d6282"></a><a id="Item11ExecutiveCompensation_144002"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11. Executive Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;11 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.</p><a id="_aea24304_a5c0_48ed_8ff6_7fad3d1758a9"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;12 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Equity Compensation Plan Information</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">securities&#160;to&#160;be&#160;issued</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;securities&#160;remaining</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">upon&#160;exercise&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">available&#160;for&#160;future&#160;issuance&#160;under</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">outstanding&#160;options,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise&#160;price&#160;of&#160;outstanding</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">equity&#160;compensation&#160;plans&#160;(excluding</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Plan category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">warrants and rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options, warrants and rights</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">securities reflected in column (a))</b></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(b)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(c)</p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,336,020</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.39</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 354,299</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equity compensation plans not approved by security holders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 310,733</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8.99</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:35.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,646,753</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 11.11</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 354,299</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2b496288_1cc9_4603_9bc4_fcbb3890b36e"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13. Certain Relationships and Related Transactions and Director Independence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;13 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.</p><a id="_24ec80de_4d71_4aae_8104_1ddf37609d34"></a><a id="Item14PrincipalAccountantsFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14. Principal Accountant Fees and Services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We incorporate the information required by this Item&#160;14 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a0bfeb48_3701_4a27_a3e4_d85874e5a2c8"></a><a id="PARTIV_494222"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15. Exhibits and Financial Statement Schedules.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Documents filed as part of this report:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statements. The financial statements as set forth under Item&#160;8 of this Annual Report on Form&#160;10-K are incorporated herein.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules. All financial statement schedules have been omitted because they are not applicable, not required, or the information is shown in the financial statements or related notes.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits. See (b)&#160;below.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Exhibits:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br/><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></th></tr><tr><td style="vertical-align:bottom;width:12.05%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">3.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit&#160;3.1 to the Current Report on Form&#160;8-K filed February&#160;6, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">3.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920011925/tm206971d1_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit&#160;3.2 to the Current Report on Form&#160;8-K filed February&#160;6, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465923072250/tm2318997d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed June 16, 2023.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919005362/a2239691zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Specimen Certificate evidencing shares of the Registrant&#8217;s common stock. (Incorporated by reference to Exhibit&#160;4.1 to Amendment No.&#160;3 to the Registration Statement on Form&#160;S-1 filed September&#160;20, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.2</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465923113281/tm2329368d4_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant Agreement (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 1, 2023.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.3</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Warrant (Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on February 5, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.4</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_ex4-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Warrant Agency Agreement (Incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed on February 5, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">4.5</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20241231xex4d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.1+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465920038326/tm2013055d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Employment Agreement dated as of March&#160;24, 2020 between the Registrant and Maria Maccecchini. (Incorporated by reference to Exhibit&#160;10.1 to Form 10-K filed March 25, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.2+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919003982/a2239177zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Annovis Bio,&#160;Inc. 2018 Equity Incentive Plan. (Incorporated by reference to Exhibit&#160;4.</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">3</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;"> to the Registration Statement on Form&#160;S-8 filed February 14, 2020.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.3+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465924054167/tm243000d1_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Annovis Bio, Inc. 2019 Equity Incentive Plan (Incorporated by reference to form DEF 14A filed April 29, 2024.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">10.4</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000104746919004651/a2239387zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement dated as of December&#160;19, 2014 among the Registrant and the signatories thereto. (Incorporated by reference to Exhibit&#160;10.5 to Amendment No.&#160;1 to Form&#160;S-1 filed August&#160;8, 2019.)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:13.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br/><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:86.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description of Exhibit</b></p></th></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.5+</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465923040275/anvs-20221231xex10d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Non-Qualified Stock Option Award Agreement for the Annovis Bio, Inc. 2019 Equity Incentive Plan. (Incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K filed on March 31, 2023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465924127439/tm2430444d2_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Distribution Agreement, dated December 11, 2024, by and between Annovis Bio, Inc. and Oppenheimer &amp; Co. Inc. (Incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed on December 12, 2024)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000110465925009279/tm255497d1_ex1-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Underwriting Agreement, dated February 3, 2025, by and between Annovis Bio., Inc. and ThinkEquity LLC (Incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed on February 5, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">19.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20241231xex19d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Insider Trading Policy</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20241231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst &amp; Young LLP</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">31.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20241231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">32.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="anvs-20241231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0pt 7pt;">97.1</p></td><td style="vertical-align:top;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1477845/000155837024004393/anvs-20231231xex97d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Clawback Policy (Incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed March 29, 2024)</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Labels Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"/><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:12.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:1.85%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:86.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File &#8211; the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">+</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">Indicates management contract or compensatory plan.</p></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Financial Statement Schedules:</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_2f34f4bc_b4c6_4b27_a9c6_8f151368177b"></a><a id="Item16Form10KSummary_558755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16. Form&#160;10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Not Applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_87fb33f4_a3ea_4f88_b5c6_365d11cb93e4"></a><a id="IndextoFinancialStatements"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">ANNOVIS BIO,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page(s)</b></p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Report"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID No. <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:AuditorFirmId" id="Narr_vTEG5hLyGUqJX-onutFJWg">42</ix:nonNumeric>)</p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BalanceSheets_148726"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2024 and 2023 </span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofOperations_7171"><span style="font-style:normal;font-weight:normal;">Statements of Operations for the&#160;Years Ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StockholdersEquityDeficit_933195"><span style="font-style:normal;font-weight:normal;">Statements of Changes in Stockholders&#8217; Equity (Deficit) for the&#160;Years ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#StatementsofCashFlows_169542"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the&#160;Years Ended December 31, 2024 and 2023</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:88.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NotestoFinancialStatements_177435"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:top;width:3.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_26a11564_5c4c_49ac_9622_bb9d02426ef7"></a><a id="Report"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">To the Shareholders and the Board of Directors of Annovis Bio, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">We have audited the accompanying balance sheets of Annovis Bio, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations, changes in stockholders&#8217; equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">The Company's Ability to Continue as a Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management's evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:AuditorName" id="Narr_hBDQMOOKOE6tGBs_zboWZQ">Ernst &amp; Young LLP</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="dei:AuditorLocation" id="Narr_LCX9LwxUjkig-HEUe137Lw">Philadelphia, Pennsylvania</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 21, 2025</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c17fc8ed_5f06_42ab_905c_73547c96fe63"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="BalanceSheets_148726"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_6c5307e4_e7b3_4da2_9c91_7be2f777aa9f"></a><a id="Tc_C-Si-DY3Aku_DXTdzWSgIg_1_2"></a><a id="Tc_LxhC3izfeUG47Jc_jKpiBA_2_2"></a><a id="Tc_-2QHcBdQJUSkwQ9VwJxIIg_2_5"></a><a id="Tc_Yfju9LsRO0iFCUpqNoOqdg_4_0"></a><a id="Tc_4okozoq2JEaY0PSkZo78Fg_5_0"></a><a id="Tc_hI7JfK8U4UCQVLf-vKsDBQ_6_0"></a><a id="Tc_Qh0C_gxHGkmTZIdvVtMEzQ_6_2"></a><a id="Tc_4DIYzDA9Pk61udkuhDA-jw_6_5"></a><a id="Tc_2isvHkxc4Ue1JbwfSusocg_7_0"></a><a id="Tc_PaY_9ydUr0W7-d8Koaadfg_8_0"></a><a id="Tc_l_ff99g4jkmGD6qRLI57ZQ_8_2"></a><a id="Tc_wPrxFWHNl0mr1IFOKWQtVg_8_5"></a><a id="Tc_RYen0DfRM06aDrS2hVMLfA_9_0"></a><a id="Tc_Fw-Rb2K-2kyWN0hlnlKA1w_10_0"></a><a id="Tc_3UuYeixcrkGpMxEnDR7ldA_11_0"></a><a id="Tc_44zc5iVQ6UmXiEMXWldtIw_11_2"></a><a id="Tc_K2f7btfdUkeWSqrajKbFpA_11_5"></a><a id="Tc_KZfllDxn1UWzHxRWTmNriA_12_0"></a><a id="Tc_WB9q1UkPh0GtgfP6fQ3taw_13_0"></a><a id="Tc_deCPgQhQ7EiTAUOPOWqDMw_14_0"></a><a id="Tc_9QNHuc0tNUGd37YKm9_hLw_15_0"></a><a id="Tc_p91VYlg7GEuI47ypz9SG0A_16_0"></a><a id="Tc_6OU6yCXQTEuE8ZXl_yreJw_17_0"></a><a id="Tc_SPV6UBltQEqRgC4AbmLpQA_18_0"></a><a id="Tc_FxT8pJVJlUeaIchR5mJsiw_19_0"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5_2"></a><a id="_6d558747_ea69_4a32_bf17_e8e414c7e7b5_3"></a><a id="Tc_FCCvSmr4d02uR8deVYuZZQ_20_0"></a><a id="Tc_bJdMn39erU2nbCzedKXoqA_21_0"></a><a id="Tc_1jVuvvFMg0itK_y3L4iq2Q_22_0"></a><a id="Tc_J4jFAr8OQU-3cB3pyXPHtQ_23_0"></a><a id="Tc_l00XTCpzRUO6NXTtTrIVUw_24_0"></a><a id="Tc_HMRbt3C3skaaXrunCOhJAg_24_2"></a><a id="Tc_01a3h9Uov0KzeGUeM1y8SA_24_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_xTKiXVH0IEm5utC4fkqWug_6_3">10,551,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_yxKQZ8ATBUilys5cFEJzDw_6_6">5,754,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_zoRDbhuV3E2_9DaQOhb-eA_7_3">3,373,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_B2xXhmNCGUeaIKn0PAvJlw_7_6">4,453,544</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_-fJW6ZisP0mC2uK4fyQnXQ_8_3">13,925,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="0" id="Tc_BpiU7dtJoUeyrea7CEGthQ_8_6">10,208,264</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_XsuzLj6390yI7f2TxnBBXQ_11_3">2,305,974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_mXsse8YrWUyRFtiR5dVvZw_11_6">1,292,837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_Xvpxi1qpdkOExCRyGcANbQ_12_3">1,575,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_WXuGuaFcIEu-j6LJXLnU6Q_12_6">2,986,273</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_wqojjvD0ek6FvexVh3JGvg_13_3">3,880,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_ZgC3gtWgI0u4e4BlOp49Zw_13_6">4,279,110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_vsW4KCuokkyJLzjUYdk4FA_15_3">737,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_vOaQL750dEaUAHQTDSGxVg_15_6">13,680,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_aER42V7yVkiA6uGCSfoOLQ_16_3">4,617,987</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="0" id="Tc_5agQ9jlQPEW2rMYbugYBfQ_16_6">17,959,110</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies (Note 6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity (deficit) :</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_DuWQVtF3UU-Hsb7YUbH4dQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_LSmlXMdvbUqwSmPX9lkejQ">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_TUehyiNOV06qs36Pr1OkYA"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_bZpGJqoceky4Kxkae7vqUg">2,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_AsrARDHjZ0GrvAmMCsu9Uw"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_iCM_Zy0kUEWKG8vWOSXI2w">0</ix:nonFraction></ix:nonFraction> shares issued and outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_7SaK4QnVyEqfJCs42II-wQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_0nCDzmrS8USk-QqhIbWFcA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock - $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_SjpeJxvjUEiwqG4znBGUpg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_F0tuYz6aSEuYFOdgeJakeA">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_KlEIdhbpT0OSt7mE7unaoA"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_R_lQZADQ7kqzkXHO7bpVbA">70,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_hldh8T_uRUSDOSnephNAAQ">14,141,521</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_mFzN1qQdrkWAk-wfZ1hRdg">10,519,933</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_lTTopYnhakCO6SzZjzlPOA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and <span style="-sec-ix-hidden:Hidden_AHJWVzGiNUeXAwXQV8zhFw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2024 and December&#160;31,&#160;2023, respectively</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_wgK_jfRWFUqM6MsjjceyYw_20_3">1,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_WgTghecSkEeAk-N_1qqbTg_20_6">1,052</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_QnoFcYa7tEqXGKX9ryJp9g_21_3">144,155,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_wxnpJKbDnke-AEhpCqftoA_21_6">102,507,189</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_UFXwBOH-zEmw3dPup1rALA_22_3">134,849,462</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_9j9xwJgHUUaZ7djhxtS_HQ_22_6">110,259,087</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="white-space:pre-wrap;">Total stockholders&#8217; equity (deficit)  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Sl0XjoBqK0G_JVvYRhuRsA_23_3">9,307,646</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_chggbXaAYUu3-9gsjIew0A_23_6">7,750,846</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total liabilities and stockholders&#8217; equity (deficit) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_ssqaSkYOS0O1ffxkLHpJVg_24_3">13,925,633</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_6L8tjagfs0GKNOs-8QP7hg_24_6">10,208,264</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_c0e81e3e_6f3c_4089_9a03_341ab9f49507"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StatementsofOperations_7171"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d4963940_5a91_40ff_8386_48669054e401"></a><a id="Tc_uqR-PIEK7U2cYzJ2beIqkQ_1_2"></a><a id="Tc_YFanfZ6ZxUS-b1Ka_RYdfA_2_2"></a><a id="Tc_AfqKSzbqRkeqx_E92c-IpA_2_5"></a><a id="Tc_VzGRR4Ti0kyUMJ6byagOng_3_0"></a><a id="Tc_rjms0jwdZEOmttzW0OAmEA_4_0"></a><a id="Tc_48HNKW6HjkGmWadGcz7XrA_4_2"></a><a id="Tc_H3njCidUWEe9y3xn0vFOgQ_4_5"></a><a id="Tc_x-zlbfaSzEmTVpxFTKBWAA_5_0"></a><a id="Tc_m1riEOaAW0uYTV5qhvbUxQ_6_0"></a><a id="Tc_ZOTQMmeXP0ims8dXx7_h_Q_7_0"></a><a id="Tc_A_LPl3XE4UOLw_pUNOeOZQ_8_0"></a><a id="Tc_yq9F7w-zZkaVFLumrpD0TQ_9_0"></a><a id="Tc_Jyv-mM1tOEyxW-vUFap5kQ_10_0"></a><a id="Tc_O79SVR9jK0CY8gYE6svSlQ_10_6"></a><a id="Tc_WqqiCIpew0ygpV-szvMUYw_11_0"></a><a id="Tc_QXvMDn9niEWJyECok8m8Wg_12_0"></a><a id="Tc_oNe0kThfHUuZq_guqQ5ZMg_13_0"></a><a id="Tc_bgZDi6KZTUKdY7c_xEShAA_13_2"></a><a id="Tc_qNeWo0U9A0iDXgzPXPEdqA_13_5"></a><a id="Tc_l7Dj1ClYEUKJiAfuFSky7Q_14_0"></a><a id="Tc_LKhUqfBC6Eye89OB8gZlmQ_15_0"></a><a id="Tc_JKFQCXNtG0yGG26cM0-KLg_15_2"></a><a id="Tc_6xNAtr0KdUGLSGg6d_iWoA_15_5"></a><a id="Tc_5WWMT3MRaUu2pZrplEnliA_16_0"></a><a id="Tc_UQkNKHsaSkmg9Vl7YM0KNQ_16_2"></a><a id="Tc_0JSwMQsITk-X--tVBCmt1Q_16_5"></a><a id="Tc_9OxnSO-jO0-62A7tS84kpA_17_0"></a><a id="Tc_ThGynAW17UqZ8NH2fAbliw_18_0"></a><a id="Tc_qwqTqisvGUOrXncuePllvQ_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:27.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_qJ1T_MAClEmS9Zw-Q7wOeQ_4_3">19,995,447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_RK9gQEbwAk2_3RupDO-u2A_4_6">38,790,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Or6WTwjBVUqb8hBSbxXZjQ_5_3">6,699,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_pe7ioVNAyEOFQ6j3SEJ26w_5_6">6,244,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_F4SDBO4FzU-JitskOfD-mA_6_3">26,694,928</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_vc2pXWYUPUmLLppeIW4kag_6_6">45,035,011</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_GL__h5RBEUS15ObLLLcaoA_7_3">26,694,928</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_avwvPrW22UmtJSTBGuIRZQ_7_6">45,035,011</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other income (expense):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_-rslyupWQ0W4hbjVqUjkGA_9_3">331,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_LVqlhor5WEqWr2Nj5SgF_A_9_6">667,898</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other financing costs (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:FinancingCostsFromIssuanceOfShares" scale="0" id="Tc_ECLMZvQnn0-BzHi0kJEFdA_10_3">1,853,189</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Change in fair value of warrants (Note 7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:GainLossOnChangesInFairValueOfWarrantLiability" scale="0" id="Tc_o93JXnC6f06tZwK2AylFeA_11_3">3,625,893</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="anvs:GainLossOnChangesInFairValueOfWarrantLiability" sign="-" scale="0" id="Tc_qw6AQ-D4xUqZ67JJXicFAA_11_6">11,837,200</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total other income (expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="0" id="Tc__wIAPg9-Hk28_dg1Iq5jaA_12_3">2,104,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="0" id="Tc_K6xSO2npQ0usj5hBrfjxKw_12_6">11,169,302</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_WHBDJEPj60SNnPDYGMIVMA_13_3">24,590,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_tS_HjhFdwEGx9t-BFlhopQ_13_6">56,204,313</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share (Note 9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_wY5xhyTDZkKVRjw11qG4Sg_15_3">2.02</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_uvANdMN5SUmhJw_xJinP2g_15_6">6.23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_KTgooy1m5EWfa3HrfEOVfA_16_3">2.31</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_nzxVhpsaLUShX4-3z1eGUA_16_6">6.23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average number of common shares used in computing net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_sHc_lUQfqECSg2c6rFBIJQ_18_3">12,182,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_3w4nY36q-kGBCGGLBxurtQ_18_6">9,023,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_i1GGZrXka0yuSqvHuEapuA_19_3">12,235,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_jDnT7hQ8ykqoX9sQSZ833g_19_6">9,023,138</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_6dae9a6c_6b09_4a29_a7f9_e7fe0bf4a26e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StockholdersEquityDeficit_933195"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Changes in Stockholders&#8217; Equity</b><b style="font-weight:bold;"> (Deficit)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_eed35834_721c_46ca_810a_d8274a4740b2"></a><a id="Tc_eJ1ANi1A50yW43zXW1-OOw_1_2"></a><a id="Tc_TeJvxQeARkWJTHnjrx_NIg_2_8"></a><a id="Tc_YwY7ifaz6EuB53NDnXzOZQ_2_14"></a><a id="Tc_64MYHXmnmkmbZ6cfuN3OXw_3_2"></a><a id="Tc_7DTUV1zvFE2DVvXwJtlrFA_3_8"></a><a id="Tc_Vy2PEngPAkKgvblY5tIEVg_3_11"></a><a id="Tc_JyjEWhm3q0CPMlEVCOkq3Q_3_14"></a><a id="Tc_IY_QNQPRzEuaToPG5sOWXw_4_2"></a><a id="Tc_ukVvEgoIaUGiqA_-8EUPuQ_4_5"></a><a id="Tc_iUVDjagdcU2dGiepioGd1g_4_8"></a><a id="Tc_BerAmVEtNUuUDPCSWrKABQ_4_11"></a><a id="Tc_gaTXmLZKwE2fQsE-kibPNw_4_14"></a><a id="Tc_FKnLpE8-JkWltZueIzE76w_5_0"></a><a id="Tc_Zbvd6TvuLUe5CSf_RuhdLQ_5_5"></a><a id="Tc_D58-aPHtyUCHZmLIQjYHJw_5_8"></a><a id="Tc_TeNbmOjP_0Czj60F-eTUxQ_5_11"></a><a id="Tc_-UUTVeq0zUK8wruaD02_Ww_5_14"></a><a id="Tc_uP61L4dfNkysQeVkNKTVfA_6_0"></a><a id="Tc_jpxQfbh4I0KVGP9OfQ6Npg_6_12"></a><a id="Tc_URrrzu-EyEW0DstZBptmdg_7_0"></a><a id="Tc_N-AZ_sNCDUanOVqvF9zMbA_7_2"></a><a id="Tc_P_ud0AOR9Ueqrbp1FlXRig_7_6"></a><a id="Tc_-xvO-Lrai06uEon3qhCmLA_7_12"></a><a id="Tc_zO5e-FH09EiD0QeGH74u-A_8_0"></a><a id="Tc_Fe8jFEDLYUus3w_PNOP5rQ_8_12"></a><a id="Tc_vsERr4MYY02I6nABqHlIXw_9_0"></a><a id="Tc_dbt8t1pJv06rGc9vKRdWHw_10_0"></a><a id="Tc_ehDulFCX806JLJuqzQ9AtQ_10_2"></a><a id="Tc_YGt4KGTJO0m7KER9IylpLg_10_6"></a><a id="Tc_kXJdJtwnHEyAetzUkzIhqA_10_9"></a><a id="Tc_Go6UKbE-yk2bdZrO4ELZjw_11_0"></a><a id="Tc_4PAM3VSUYk-UEdSHAp2K1w_11_5"></a><a id="Tc_-G20g5rDIUCJjXKhyC16zA_11_8"></a><a id="Tc_dE8w32l3hEa7DJtCQtv1Jw_11_11"></a><a id="Tc__cFBeVVAUEitjB95NJsvag_11_14"></a><a id="Tc_CtqcBnhuBUSrlIvZ_c-QOA_12_0"></a><a id="Tc_RhjTLljNCUiIhZo_WXiWYg_12_12"></a><a id="Tc_KhPij44Kf0mfeRBYGGOZjA_12_15"></a><a id="Tc_VBDX09blUEKh7dGZB_S2pg_13_0"></a><a id="Tc_bD_bXKCrTkC8NCMTXXSV0g_13_2"></a><a id="Tc_B5wWBJp68UOV8wfdgqvQog_13_6"></a><a id="Tc_fjOM_tfpC0eiJzzNOkqsTw_13_12"></a><a id="Tc_X62K_qD090aMKuDa9euLYA_14_0"></a><a id="Tc_Pu2tHQ933ki4QriggO9hXw_14_12"></a><a id="Tc_sJmRK02ku0eK_oX27k4Qew_15_0"></a><a id="Tc_48TqJNIzHUGFm-3bxDkULg_15_12"></a><a id="Tc_1oDVELqibUS7jIptIDxCiQ_16_0"></a><a id="Tc_PF2K6mzQzkOMGOiPV0chsQ_16_12"></a><a id="Tc_z1FuRneTzUmJbqW1qcJ9vQ_17_0"></a><a id="Tc_5sEFck_zpkaVNdbrdG7bJA_17_12"></a><a id="Tc_S8rWvLpZaEWXMeQPVLwM9Q_18_0"></a><a id="Tc_tGQGCHYSlk-kCI8gZaB24A_18_2"></a><a id="Tc_lyA5QkHkSEaP866Fuy4I1Q_18_6"></a><a id="Tc_QDBWmJe2xUKCAYxSuLQu-w_18_9"></a><a id="Tc_QQEKjtbj40Cw5imkiL1mKA_19_0"></a><a id="Tc_u8PWnvy1NEKz0bxO7lb0og_19_5"></a><a id="Tc_ISYJknwZjE6dEGiBQKvZVw_19_8"></a><a id="Tc_P20Vyaxa1UC5K41JZJ46yQ_19_11"></a><a id="Tc_bIcs-QvrnkOthIej3Z5kbw_19_14"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="14" style="vertical-align:bottom;white-space:nowrap;width:57.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Stockholders&#8217; Equity (Deficit)  </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Deficit) </b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_YsL1IVTeFU2-KWLdoidb8w_5_2">8,163,923</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wenbNeSaSkKOpM4UxJGRkw_5_6">816</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cpOE3CFuPkqOfWlu_Xn-hw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_6Z2237vO4kWWJqPQQ8YxDA_5_9">82,377,488</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_28BkIxJtwUCxsN3Its458Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_EgPN17s1XESvjdGyU-APyg_5_12">54,054,774</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2022_gHIzv_4Whk2YABqPEYSDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_7u4hH1oMBEmrKhM1GZgldA_5_15">28,323,530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_O5Amq599ykycXShQ_QSVuw_6_2">59,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_d2eiSL9Ag0eZtlJdZkgA6A_6_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_-HJNbLMWOkONJgE3DebvDg_6_9">8,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_nqbeu-bwlEWmwvaRx_3WZQ_6_15">8,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_66OnjXVg20-zJIra7LzzBQ_7_9">4,628,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_aoiDQF1lTkC-tUQIVRTMNQ_7_15">4,628,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of common stock warrants, inclusive of warrant reduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_25dQDaDDm0ujzIckt09WQA_8_2">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_SnyyD_OVQkGVeLNZLSkxJA_8_6">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_5BPVNfoCYEWM3qqFnr8RKg_8_9">1,056,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_7qkoGM5qt0-xwYpUbhMC-w_8_15">1,056,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock, net of issuance costs and warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" scale="0" id="Tc_jUNQQ_xrS0u3WLRzEcNvMQ_9_2">2,246,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA" decimals="0" format="ixt:num-dot-decimal" name="anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" scale="0" id="Tc_VGuX7VSYQ0KGqvngOFYp3w_9_6">225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w" decimals="0" format="ixt:num-dot-decimal" name="anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" scale="0" id="Tc_IqlIfEeVrEuRZ_KLaCUFjQ_9_9">14,436,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" scale="0" id="Tc_Rsgw_iOVTkOqneNzi5plAw_9_15">14,436,945</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b1p2M5EkZEWd2ktBcLEmYQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_KH-LqvKYn0uKd2rJVjp-Wg_10_12">56,204,313</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_GeLlIbZFHUiWMotIzKNl8Q_10_15">56,204,313</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qdFrnkmd3UOa2tLKqyPiAg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_xeHZ_O2AJkqNX8NrL6wPDw_11_2">10,519,933</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qdFrnkmd3UOa2tLKqyPiAg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_THZ6FDPdB0uoPJBKRp_PGQ_11_6">1,052</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6THFqqlMJEyIsnWSUyL9qw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_TXVeoQ6B-EOtT_bTZnIxww_11_9">102,507,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zUAgBq5SJEGx67d7VE9u4A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Duz8ie88N0aNiAoq7qv7Bw_11_12">110,259,087</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_YtIwz7b2SkKOPlry5gAgZw_11_15">7,750,846</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cashless exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" scale="0" id="Tc_cKQHxAzPXke29ruqX_f7iQ_12_2">220,339</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" scale="0" id="Tc_ATc1mXeSkE6IKjiWi32iqA_12_6">22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" sign="-" scale="0" id="Tc_vbHT_rXPAUKajRxt1tnBeQ_12_9">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_6LsLeit-rUCBiSekr37Mzw_13_9">3,836,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="0" id="Tc_ZvxVA1pTGEq66uWskJltLQ_13_15">3,836,770</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Exercise of common stock warrants, inclusive of warrant reduction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Tc_AnQkPU1QGEiuIj3WkkeMvw_14_2">891,667</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_stlXvQhCxkK7DoxGmWs3xg_14_6">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_zaEWnKHl-UyDCeD-2OzbHA_14_9">17,342,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodValueWarrantsExercised" scale="0" id="Tc_-Y31fYVbHEG72tl4PhjseA_14_15">17,342,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodSharesEquityDistributionAgreement" scale="0" id="Tc_RWKsCMB4B0yEMjqKUE--0A_15_2">26,788</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="0" format="ixt:num-dot-decimal" name="anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_zOPqa2WPpUiBsma9slfAhg_15_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg" decimals="0" format="ixt:num-dot-decimal" name="anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_Mcc-lxMl4U-e0wkZSsxiNA_15_9">156,766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_g46RUfzFkEWdvNxGdVzC0w_15_15">156,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to ELOC, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodSharesEquityLineOfCredit" scale="0" id="Tc_PSCWOoAAdkaELUgpyWs2LA_16_2">2,051,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="0" format="ixt:num-dot-decimal" name="anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_6XJHnuZAt0Ktf6sS7NNaXg_16_6">205</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg" decimals="0" format="ixt:num-dot-decimal" name="anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_k1J94S0GV0SZ760ARUOpXw_16_9">16,438,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_6EnNcD8_S0CVlk_VVV0gag_16_15">16,438,217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Issuance of common stock pursuant to registered direct offering, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:StockIssuedDuringPeriodSharesRegisteredDirectOffering" scale="0" id="Tc_rzG60fkKOkqMamHijx6SsA_17_2">431,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA" decimals="0" format="ixt:num-dot-decimal" name="anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_nj--_fpwRku2qm4H67uEvw_17_6">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg" decimals="0" format="ixt:num-dot-decimal" name="anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_UwjSq5drh0qZz1GZnUyF-Q_17_9">3,874,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" scale="0" id="Tc_Cmz2-jw-5UOyHuMWK0tyOw_17_15">3,875,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RRJXAsbbukC8dIuM3xSztw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_KVaGMR0OI0iMEGyVGx8rBQ_18_12">24,590,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_SLz9lemAO0GgOsI6Qcok9Q_18_15">24,590,375</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Balance, December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KVeVvbTwK06JZJKM4d21ew" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" id="Tc_eHqsqPZ9nEGe3rqZtVwOZg_19_2">14,141,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KVeVvbTwK06JZJKM4d21ew" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_pRWULPa3lUKMBEGUebcTKg_19_6">1,414</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9YgeSUKYHkinaLnDH3gT8A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_hW0lYdYsBUCmXYwi43AMRw_19_9">144,155,694</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6DnXcoTVUU-mi30CGoncNQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_GfnKcsypYUy0hM13u9RXRA_19_12">134,849,462</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.97%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_8sBgTGqTOUKvUzEYw8DkUQ_19_15">9,307,646</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5236ffa7_1362_47f5_b2b8_8257f50fbb39"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNOVIS BIO,&#160;INC.</p><a id="StatementsofCashFlows_169542"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_2988c841_52ab_4bd5_a283_472ccbafd74a"></a><a id="Tc_1jVO8vWQ3EuM4Z78KLoSgg_1_2"></a><a id="Tc_XwXfoqylNEqUYkCWFgc8GA_2_2"></a><a id="Tc_468qQTN8ik-P8FvvaD-mbQ_2_5"></a><a id="Tc_zIa_tHYIXkOUHQ4YlIlaOg_3_0"></a><a id="Tc_FIqbwoTj80yjx6i9iVDc9A_4_0"></a><a id="Tc_FW_lTOutz0-RTafLcWQfRA_4_2"></a><a id="Tc_lGJepiczPkaEhKyqELD8HQ_4_5"></a><a id="Tc_sZ1l4Hkf-EynrdETFJrmnw_5_0"></a><a id="Tc_vCaBOgI1NkabB6viqbVItg_6_0"></a><a id="Tc_vfN89TxHL0Ga7ImT4Y8UsQ_7_0"></a><a id="Tc_QMp2pMxtJUiGLtbPYAs4tA_8_0"></a><a id="Tc_QeF4B0Pat0Wy_QSFCBIAlA_9_0"></a><a id="Tc_qKFE2QTypk-OVQZNcvkcDg_10_0"></a><a id="Tc_rGCTdY2EqEuOcZ5buo9kKA_11_0"></a><a id="Tc_TsHSMZaHsUWWQC-Y5Ou9cQ_12_0"></a><a id="Tc_LU0Sbku79k201GXVikvJSg_13_0"></a><a id="Tc_Ysl_yj0IIEKHOdLqp2KBfw_14_0"></a><a id="Tc_cmZoz-hQbk6wSh86Y7xIzw_15_0"></a><a id="Tc_NlR51UXjQkWvKmsC17MHzw_16_0"></a><a id="Tc_o1JwW4IFGkyQmd0-i2Xt3g_17_0"></a><a id="Tc_Iza8mIj4W0OPeLJQtgV4JA_17_3"></a><a id="Tc_k1O6o9LjwESHMGcdpFZeKg_18_0"></a><a id="Tc_XBQIlbAysUCUG0uJ71Tlrg_19_0"></a><a id="Tc_Q7WIaypiaEmwf6PkKT6w5g_20_0"></a><a id="Tc_AYqc6iVR4ES8U3X3HwojAg_21_0"></a><a id="Tc_wPw0oCXLDkqInVWt4-GqrQ_21_2"></a><a id="Tc_Oi2PBRpnT0uXBXkS68PtqQ_21_5"></a><a id="Tc_DRLoCJXKU06zWBhpn9ZvZw_22_0"></a><a id="Tc_fWPvL6tQbUqt8jCFXfu7YA_23_0"></a><a id="Tc_NuQzKbjZ9Ueql-HSF-abkg_23_2"></a><a id="Tc_o_a1FD2s4U22WSfHiFPKdg_23_5"></a><a id="Tc_afhDj7v0jk6hV8xGzavSyg_24_0"></a><a id="Tc_DkSEOrKh4EmNs9G-KldLYw_24_2"></a><a id="Tc_No5S6QWjPkS1VCoFSJivqQ_24_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_6fmCQGSCy06jeFH4f0E30w_4_3">24,590,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_T0RLH1D35UmnsM2e7QYa7A_4_6">56,204,313</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_ufGguxb5iEio7VcGkOu3Yg_6_3">3,836,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_gkifeqH70kid6YvjURPdjA_6_6">4,628,406</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Change in fair value of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_Eesi0Ur8dEadga0gRlcGZg_7_3">3,625,893</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Tc_hZmsClEPe0-6bQhKxeG4Gw_7_6">11,837,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Non-cash other financing costs, including change in fair value of derivative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:NonCashFinancingCostsIncludingChangeInFairValueDerivative" scale="0" id="Tc_XxNxmfW4Sku_e4Xtd-kibA_8_3">1,803,189</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_TFrxFG3gykmZYKFhjgO8zQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc__i14K6PJRkGWPQUkevuyYQ_10_3">1,079,827</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_EF49sNSIr0OhjwvLx1gtbQ_10_6">3,190,832</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_RxYQ7a5F-U6-pQxJ1DE-4Q_11_3">1,013,138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_hhs60V6nv02KoMHZPYHv8A_11_6">2,668,417</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_rLQcPAa2XkWupzocSeE7uA_12_3">1,411,260</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_I_kQ86TI5k-An7wrWN-5kA_12_6">751,012</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_zNPWxDNU2EWhitIwwNMXsg_13_3">21,894,604</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_75xt4gQ52UWFoxJqgjPuwg_13_6">39,967,304</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of common stock, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_GVtpGtmdtU-TE4HUrOSKMQ_15_3">18,666,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Tc_3FlHcTO_k0CU2nmGd9HwpA_15_6">16,885,946</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Tc_D0ovMEBEnEe6umrqd3FHdQ_16_3">8,025,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Tc_vpAomu_q2E2ZyN_6XvrqUg_16_6">450,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_BGejPE9WW0qlkoroQNXHJA_17_6">8,385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_S2ZoVWWoY0G86HkTY4_QnA_18_3">26,691,800</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_vm7SygZSG0ysOKEooGjqqA_18_6">17,344,331</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net increase (decrease) in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_POHs2imFt0qYI5cR8w5CHw_19_3">4,797,196</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc_xtA08qww6EWxmqnmL893Yw_19_6">22,622,973</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, beginning of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_59QwpxS0K0S4gh6BujCRKw_20_3">5,754,720</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2022_gHIzv_4Whk2YABqPEYSDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_cqNFsq8mB0i_iuXWu76qXw_20_6">28,377,693</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_kqX9eKoAxEOij83CObWnJA_21_3">10,551,916</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_8tsRQnfv_k-r0XMlUe6j0A_21_6">5,754,720</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Supplemental disclosure of cash flow information:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other adjustment to value of warrants related to exercises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:NonCashTransactionValueOfConsiderationWarrantExercises" scale="0" id="Tc_3RIsgNRtg0OqPksij2de_g_23_3">9,317,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="anvs:NonCashTransactionValueOfConsiderationWarrantExercises" scale="0" id="Tc_8zUP7pVVqEm6FsIRZfnRgQ_23_6">606,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash paid for financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="anvs:CashPaidForFinancingCostsDuringPeriod" scale="0" id="Tc_OOTLmgrwqk6-e2lzxEvBRg_24_3">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Qc2Tvi8YB0WWjmj0gWXuNQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e0d6f2ee_6700_43d4_a41e_b09858eac750"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Annovis Bio,&#160;Inc.</b></p><a id="NotestoFinancialStatements_177435"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">December&#160;31, 2024 and 2023</b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_2ya8qszncEOFP2UEqUUpJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Nature of Business and Management&#8217;s Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Annovis&#8221;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#8217;s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="-6" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="Narr_D81ivNpGvkO953Wo8vXxIw">no</ix:nonFraction>t generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#8217;s primary source of capital has been the issuance of common stock and warrants to purchase common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the Company&#8217;s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2024, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_ZaiNUliM-0KLkWqDdkZeUw">10.6</ix:nonFraction> million and an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_Kn7b2skhjUStOVhINb2t9Q">134.8</ix:nonFraction> million. The Company&#8217;s net loss was $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_YRBVz9_QCEG82S_eUmG6Kg">24.6</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="6" id="Narr_YIW-0ztlUU-gqa2wg7ivdg">56.2</ix:nonFraction> million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company&#8217;s operating loss was $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="6" id="Narr_nvyKQ8VGeUmVRu_e3BhifA">26.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="6" id="Narr_VwbRFiuhPEOynoFxgdWNSQ">45.0</ix:nonFraction> million for the years ended December 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2024, combined with cash raised in the first quarter of 2025 in connection with its December 2024 ATM with OpCo and February 2025 stock offering with ThinkEquity, is not sufficient to fund operations for the period through one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management&#8217;s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, management concluded that such plans do not alleviate the substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.<span style="white-space:pre-wrap;">  </span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_CbbHt9xrd0aBVTPrTywZ4Q" continuedAt="Tb_CbbHt9xrd0aBVTPrTywZ4Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:BasisOfAccounting" id="Tb_QmMAGxwZBkqWBeAb3Go64w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:UseOfEstimates" id="Tb_Q9MM7Zcry0eCF2eQiu2vYQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_akrr3GrH4Em5lSYnW7Rqtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company viewed its operations and managed its business as <ix:nonFraction unitRef="Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_0WCv9nLf90-shOm6FwbptA">one</ix:nonFraction> operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_CLJX_8J43kuJw42iMIeEfw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_9GocUodF3UisAqaqASVHBg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashFDICInsuredAmount" scale="0" id="Narr_sWOYE78BP0Ct8cDe8IjaOg">250,000</ix:nonFraction>. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#8217;s financial condition, results of operations, and cash flows.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" id="Tb_4PqnW7uJpUuC_mqaAlspDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (&#8220;ELOC&#8221;) Purchase Agreement are expensed as incurred as prescribed by ASC 815. </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:DerivativesEmbeddedDerivatives" id="Tb_xmaX4EfZZE2gixtY7njRdw" continuedAt="Tb_xmaX4EfZZE2gixtY7njRdw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 &#8211; <i style="font-style:italic;">Derivatives and Hedging</i>. An embedded derivative </p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CbbHt9xrd0aBVTPrTywZ4Q_cont1" continuedAt="Tb_CbbHt9xrd0aBVTPrTywZ4Q_cont2"><ix:continuation id="Tb_xmaX4EfZZE2gixtY7njRdw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that requires separation is accounted for as a separate liability or asset from the host agreement.  The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 &#8212; Stockholders&#8217; Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was </span><span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span></span> because the ELOC facility had been exhausted and all shares from the equity line had been sold. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:DerivativesPolicyTextBlock" id="Tb_4MeJwfQBcUObxjSYJ7H1xQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h)&#160;Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_QSLKZ1gN1kWdycpkIr4c1Q">1,250,000</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> shares of common stock and (ii) warrants to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_MJtSBJgDg0qmbivpT6uWzg">1,250,000</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_XSxOlsqMe06H8wfrDtF1Iw">9.00</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> per share (&#8220;Canaccord Warrants&#8221;). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" id="Tb_pTBC1l1RrEWmWfNdTxN3dg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i)&#160;Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company&#8217;s contracts with its vendors and are realized in the ordinary course of business.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="anvs:IntangibleAssetsPatentCostsPolicyTextBlock" id="Tb_D7Uv7Fy4XUGUN0NrkLGOVg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(j)&#160;Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_4SQNkCl-aUWAcpqvI7Ygkw" continuedAt="Tb_4SQNkCl-aUWAcpqvI7Ygkw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(k)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_0Qq5gBsvJESLEK9fPGMTqw">10</ix:nonNumeric> years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#8217;s Black-Scholes option-pricing model represent Management&#8217;s best estimates and involve a number of variables, uncertainties, assumptions, </p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CbbHt9xrd0aBVTPrTywZ4Q_cont2" continuedAt="Tb_CbbHt9xrd0aBVTPrTywZ4Q_cont3"><ix:continuation id="Tb_4SQNkCl-aUWAcpqvI7Ygkw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the application of Management&#8217;s judgment, as they are inherently subjective. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model for stock options are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term. </i>As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the &#8220;simplified&#8221; method, as prescribed in SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility.</i> The expected volatility is based on historical volatilities of Annovis and similar entities within the Company&#8217;s industry for periods commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate.</i> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends.</i> The expected dividend yield is <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_hvMnx9x9hEiyNEcWSUZwIg">0</ix:nonFraction>% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_azsBqmodskOTiNPqfBQqxw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(l)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.      </span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_eA-aBXOCaU-EvYZy5T7m1Q" continuedAt="Tb_eA-aBXOCaU-EvYZy5T7m1Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(m)&#160;Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;) on an annual basis, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, <i style="font-style:italic;">Segment Reporting</i><span style="white-space:pre-wrap;">. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.  See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(n) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes</i> <i style="font-style:italic;">(Topic 740): Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company&#8217;s financial statement disclosures, but it does not anticipate material impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_CbbHt9xrd0aBVTPrTywZ4Q_cont3"><ix:continuation id="Tb_eA-aBXOCaU-EvYZy5T7m1Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (</i>&#8220;ASU 2024-03&#8221;<i style="font-style:italic;">)</i>, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. <span style="white-space:pre-wrap;">The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.  </span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7751c273_da10_4c97_843e_a4dca186eb03"></a><a id="Tc_1kM0oENEoUOfGkwTxpfLbA_1_5"></a><a id="Tc_Tc9QcpRuFkG9wokcCE9TXg_2_5"></a><a id="Tc_SHMzVFIj7kqxuydq2TIxHg_3_2"></a><a id="Tc_wDDKtkN2vkmiMw01HqIswg_3_5"></a><a id="Tc_gUUITaA6AkymPsGan3I0ig_3_8"></a><a id="Tc_qGVjPsRImUmdrzOpoEPlrw_3_11"></a><a id="Tc_lIGNmVO4rE2usMDys9T8ag_4_0"></a><a id="Tc_qFwYUdXkkkmXsUPO5TloRw_5_0"></a><a id="Tc_Aa19bXVw30GNAamI1GRLrg_5_2"></a><a id="Tc_5TcwPpIx2kqF_mVZC79fUA_5_5"></a><a id="Tc_aZb54OQcqUqg1aYKnrQrSw_5_8"></a><a id="Tc_oqnY5LwxWE2V3d4KGVdHZg_5_9"></a><a id="Tc_Gvl44RFsAkC5H8HmPpBvSQ_5_11"></a><a id="Tc_8f70iMNL0kqHoJ5WeXDRdg_5_12"></a><a id="Tc_wI8CBzPHhEqqcVp5wWJUPQ_6_0"></a><a id="Tc_UxV2rLCOz0qQhiYR9bB8IQ_6_2"></a><a id="Tc_bVkxonz8s0i5jX2GqL0vjg_6_5"></a><a id="Tc_eFCWH-an9E60tpXnak8dTg_6_8"></a><a id="Tc_kLK-mHXFQ0abnnChLMauEQ_6_9"></a><a id="Tc_7-eWIbzX80O3PKjqZkNreA_6_11"></a><a id="Tc_YbOygfVQi0CTB8h52wlUHA_6_12"></a><a id="Tc__mTlHZaJDEi8rE812PQJ7g_7_0"></a><a id="Tc_cgutMoB3AE2WCSgs9I9HSA_8_0"></a><a id="Tc_pMHOwSdYGE6zgsHkMzegGw_8_2"></a><a id="Tc__QiaHWU-2UW9uTLEM5udYA_8_5"></a><a id="Tc_5hQ1h8DFEEqzpEWqSrYMAA_8_6"></a><a id="Tc_6aCHME7_rU2gqGqbV9RQ_A_8_8"></a><a id="Tc_mPbSVJ5l8UWvlt2ucJ-O2A_8_9"></a><a id="Tc_MUS52cWcN0SRNj5owqadiA_8_11"></a><a id="Tc_HIK_NYfDR0OD4WD7P6zwow_9_0"></a><a id="Tc_r_t4NaW6vEaBqJlGZLmDEQ_9_2"></a><a id="Tc_RQ0Ho3W9Pkqd9xZw4G8Q8Q_9_5"></a><a id="Tc_JJVyq4coikagfLkFDyMMvA_9_6"></a><a id="Tc_1-T8cOHBrEiogB9_MCf-KA_9_8"></a><a id="Tc_S8pBj_HK0k-z5C5BKuulUw_9_9"></a><a id="Tc_tK4VJ32lmEevjydoPpPCUg_9_11"></a><a id="_b3030a14_ed0e_4b05_8ce0_2007a6c6ff0a"></a><a id="Tc_amaNYnBw80yq7iNujHA1qQ_1_5"></a><a id="Tc_d9rVefhkjka_Q2bE_BL8CQ_2_5"></a><a id="Tc_iwpjQgLIFUWT-hsjHKlEZg_3_2"></a><a id="Tc_nDwPZmSKREir4P_ioM-9Uw_3_5"></a><a id="Tc_YqllBd7ZdEGjcQCLHJUgwA_3_8"></a><a id="Tc_kOJrVvHqekW82jvXZEK1EA_3_11"></a><a id="Tc_zfD3czSMgU69qA6vC0xsTw_4_0"></a><a id="Tc_9RMhgtzzY0m6T7e2gOz1Jg_5_0"></a><a id="Tc_wCWppK6vVUSQAVhVIuuXTQ_5_2"></a><a id="Tc_jbguRFBWCEeU4tPxh08awA_5_5"></a><a id="Tc_7BF4S6LsBEm94WPPBYlrbQ_5_8"></a><a id="Tc_mxzL6Ypo-Ey2wKqFAJSupw_5_9"></a><a id="Tc_U-Sbsw906Emt5d_pE6a3ww_5_11"></a><a id="Tc_rCY1xJe6wk6bHrDcmS3PJQ_5_12"></a><a id="Tc_jDTae_vuQkiRS6ckTBW8RQ_6_0"></a><a id="Tc_-M_VBC1UdUm3rlMAMjJRNw_6_2"></a><a id="Tc_bIIaQcUxXESRjFhvOvqSNA_6_5"></a><a id="Tc_KGaPUq6d2EuDXMKi249W_Q_6_8"></a><a id="Tc_3wEXrMO4MEyKG9mkERqF2Q_6_9"></a><a id="Tc_yP051txKK0afsvIR5rYRcg_6_11"></a><a id="Tc_7OOfMFP0p0yuJ3FXiA1OJw_6_12"></a><a id="Tc_w4EBR1Nz0UmPTl3Ltr_mkg_7_0"></a><a id="Tc_DkoZPAUox0Ki0J9RU2h3KQ_8_0"></a><a id="Tc_Wu-wKBrYkk2b2hDaWJ7T5A_8_2"></a><a id="Tc_gigEoj0CBEmQIpLUqi-ltQ_8_5"></a><a id="Tc_vGwBAjYu3UqOWInNMibPgg_8_6"></a><a id="Tc_Ijc-UaOoIUa5BHcgNiOe1Q_8_8"></a><a id="Tc_Ltuoe8ZEUkWHCsfRbcpjvg_8_9"></a><a id="Tc_emriIihuikC05vdJSrFaeQ_8_11"></a><a id="Tc_VT-TCPOsAUu3hUFLNOPQIg_9_0"></a><a id="Tc_zKQYROGktEyAnIw-idJSoQ_9_2"></a><a id="Tc_H0x2o812iEacK84V_Sz2Ig_9_5"></a><a id="Tc_vdwvhvQbkkOHUeaToslrYQ_9_6"></a><a id="Tc_B-xEMXvZYkq_GEqb1_rxdg_9_8"></a><a id="Tc_6rgfL-SR0kKGMGgeJey95g_9_9"></a><a id="Tc_I395WRxrZEu4AIbw8zddhw_9_11"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_psXdKsjBeEWI-adUvnYmeg" continuedAt="Tb_psXdKsjBeEWI-adUvnYmeg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="Tb_O-4cS8kHhkGNfUsdc72mLQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_qXFf6q3HTk2rXHlNNFNClQ_5_3">491,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qXOmV3N2BkWavNqKGoaRZw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_D0t0mDEUhUONrc0n6ASgxA_5_6">491,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_AOcLimvqAEyzGqYXwfXgRg_6_3">491,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qXOmV3N2BkWavNqKGoaRZw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_ByAqj5Otu0myQZNggtC_Ig_6_6">491,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_fMVAM4eQFkO8juuUN3DmAA_8_3">737,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_M2DYJkhLdUG7ok90TpIEwQ" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_c1BVM7InqES7ae4KAsyx2Q_8_12">737,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_eSdvyxiVo0-8_zOqEbJHew_9_3">737,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_M2DYJkhLdUG7ok90TpIEwQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_YUmw9_EbYkWsnU0egISkbA_9_12">737,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_LJ6zmM-HlUaAEfcPr_2vMg_5_3">5,136,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_MQP1-VikVEKX6PVp5fZJKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="0" id="Tc_Fehse2exuUq622TyZnIWJw_5_6">5,136,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_PYQQQ5oEv0y5zOtk0RvwAw_6_3">5,136,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_MQP1-VikVEKX6PVp5fZJKQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" id="Tc_zDD5fcveEUedE0gnoVkwug_6_6">5,136,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_mZVQuF0Ku0Kp90l0ePHoUg_8_3">13,680,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5yKKJ3mp6ECf-Gc5Bz4Sqw" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_jXayop0hjUmRgBQnMem51w_8_12">13,680,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_qzZg3B6eCEiej4aLrIjwig_9_3">13,680,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5yKKJ3mp6ECf-Gc5Bz4Sqw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" id="Tc_X1zR7_N8lkaYx0juVVlf_w_9_12">13,680,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any financial instruments into or out of Level 3 classification, during the year ended December 31, 2024 or 2023. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_eb0d6932_1de6_42cf_9c5a_ce611a670450"></a><a id="Tc_qSo9QbRRl0G_jhBG1YwupQ_1_2"></a><a id="Tc_H2JJLvQ9BUC6uGr_xAS4cw_1_5"></a><a id="Tc_0hUUhSaFrE6EW-o0NnDr4Q_2_0"></a><a id="Tc_SWsmYIuU60Sy1mWkkJO4JQ_2_2"></a><a id="Tc_WG4ZrLrk7ku8cBy3c__SgQ_2_5"></a><a id="Tc_DR_kD3Vk50WDTWwHdDg7Yg_3_0"></a><a id="Tc_Dv9Nip-I8kiwbd6nGpRIrw_3_2"></a><a id="Tc_PHy4NyuQKEGZjoVKkSiXGg_3_5"></a><a id="Tc_9gnx9tq9hU6onogV363bvw_4_0"></a><a id="Tc_x6lkHT7B4E6wIXWPBsHPQA_5_0"></a><a id="Tc_kgZuS6PPw0mwjr27HbYbzQ_5_3"></a><a id="Tc_RNrfQIzHfkGd89Sg7oowJw_5_4"></a><a id="Tc_Qulx4IXj5UKjeXGXQcrmqw_5_7"></a><a id="Tc_7AX6Wek6JE69O2IISZXjBw_6_0"></a><a id="Tc_pfHdf8m0dEGIFC3UECZ2Hw_6_4"></a><a id="Tc_u1p3eHnxqky0mA5RJpYRrQ_6_7"></a><a id="Tc_UUpq8Ll7KkyH3KTeaqUusA_7_0"></a><a id="Tc_P6oIx_PQqUu9X1lmDX0BTw_8_0"></a><a id="Tc_Ha0vPCv4jUObomqVGmg2EA_8_2"></a><a id="Tc_8GfRhJWUsEaLM7xk8UNeSA_8_3"></a><a id="Tc_tLq5BcxG-ESMpytH5vjo_w_8_5"></a><a id="Tc_E0W-PcOQY0msXYK_2j8yeQ_9_0"></a><a id="Tc_gYe0rr6sVUeTiwPeQs3pYg_9_4"></a><a id="Tc_ukMWHTACQEGqCcBtCRQS2A_9_7"></a><ix:continuation id="Tb_psXdKsjBeEWI-adUvnYmeg_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Canaccord Warrants</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The common stock warrants issued in connection with the Company&#8217;s equity financing in November 2023 (&#8220;Canaccord Warrants&#8221;) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock. The Canaccord Warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense), net in the statements of operations until the warrants are exercised, expired, reclassified, or otherwise settled. From their date of issuance until the period ended June 30, 2024, the fair value of the Canaccord Warrants was estimated using a <span style="-sec-ix-hidden:Hidden_IDmi6EBxm0ykocQlpvyy7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Monte Carlo</span></span> simulation model, given the performance conditions outlined further below. However, during the quarter ended September 30, 2024, the Company determined that certain performance conditions could not be met and that going forward, their use as inputs for determining fair value was no longer appropriate. As such, after the period ended June 30, 2024, the fair value of the Canaccord Warrants is estimated using a <span style="-sec-ix-hidden:Hidden_MYnYPWwqd0e83MnNL4wIWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Black-Scholes</span></span> option-pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in both a Monte Carlo simulation model and a Black-Scholes option-pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on an implied asset volatility calculated and believed to be reasonable for the Company over the holding period remaining. The risk-free interest rate is based on the market yield of U.S. Treasuries over a term commensurate with the remaining term to expiration. Any changes in these assumptions can change the associated valuation significantly.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_ZJ9I8gAzMkiGCrkd6nMsRg" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="Tb_yGbzEJrX10i2gpRrA4h7ng" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_xdwCJRelz0CJeBLUaRigFA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_qD-EHwj9UES1AO8D3VnUow_2_3">9.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_FuwYvmh-q0yc-mYoMixFEA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_8REf8WIBskGegv3r-B4ywA_2_6">9.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_f4FMnm-LBE-CzSoyhuwWBg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_Ft6YPQHz70ipwmpWnIiqcA_3_3">5.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_15mDcFyvlE6Gb641ZNdHLg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_4HvzKenH3k2aTExxJC30dA_3_6">18.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_OUKphoR9A0ai9gK2FT1JGw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_J_LHWXm3FkqIb9tl5D6TKA_4_3">308,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sZy1RM1ObEShrxOTqRKePw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_wrwJQee5mUyUgihWYikKkQ_4_6">1,200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Phase III data probability of success</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_anvs_MeasurementInputSuccessRateMember_3aP8WPBeZ02voCIQpI_gMg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_VjwTwVL0sUO6stfjyIfz7Q_5_6">60</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hOaMIkWJtUezSLsczgZ1uw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_dPPTcggzT0mu7-XtC6S-wA_6_3">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_AedzWyGjZUykRExAVLXYGw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc__3d5GVLR60qBixNDPCfhlw_6_6">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (time to expiration in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_QubN3dDRukWsMAmcsNrjCQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_N15_S1yJ2kKsCkHRFQuC3Q_7_3">3.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mYYWaz1_-0mHQD-w2xRyvw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_P7RHYElR8keYJMOYA5eh_w_7_6">4.84</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redemption hurdle price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputConversionPriceMember_naW-EsPsskqjwTlzZs5cbA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="Tc_W6upCxcZrUKh4yiIFc4fHQ_8_6">14.25</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_d8L9-mdvUEO7pQR41LiAvg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_zZ63hGwPE0KUbJBCMvT3bA_9_3">4.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bxePodlwPkegkSAB4FKMNQ" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="Tc_F_3xUhuoAkm7yWrhHfRhiQ_9_6">3.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Canaccord Warrants were exercisable immediately at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_AwAgUiCdJ0ef-xPkh1V9kQ">9.00</ix:nonFraction> per unit, and redeemable at the Company&#8217;s option, in whole or in part, at a redemption price equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw" decimals="3" format="ixt:num-dot-decimal" name="anvs:ClassOfWarrantOrRightRedemptionPricePerShare" scale="0" id="Narr_2LQboc7bvU-4kxVmlH31Bw">0.001</ix:nonFraction> per Warrant upon <ix:nonNumeric contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_qlq2NUmLmkOmub_e008yZg" format="ixt-sec:durday" name="anvs:WarrantsThresholdPeriodOfNoticeForRedemption" id="Narr_6X7k6wW1jECSyDPwQPP1Eg">30</ix:nonNumeric> days&#8217; prior written notice, at any time after:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson&#8217;s Disease; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which (a) the closing price of the Company&#8217;s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_utyCAlQi7Um3z2sbN5SxIQ">14.25</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and (b) the average daily trading value (&#8220;ADTV&#8221;) of the Company&#8217;s common stock is equal to or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw" decimals="0" format="ixt:num-dot-decimal" name="anvs:AverageDailyTradingValue" scale="0" id="Narr_NrVG2_U_Xk2AmZKzRgLd1A">2,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_D_Rt3F2Dcobk-KrJxikqwA4w" contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_qlq2NUmLmkOmub_e008yZg" decimals="INF" format="ixt-sec:numwordsen" name="anvs:ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" scale="0" id="Narr_WRwrzocHxUCa3savkHhZBg">two</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> consecutive Trading Days. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson&#8217;s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met. As such, the probability of success and redemption hurdle price inputs were no longer used in the Black-Scholes option-pricing model outlined above for the year ending December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Warrants were exercisable immediately and will expire on November 2, 2028, <ix:nonNumeric contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_Ds6eVKWWl0eeKaE1Z0VWTA">five years</ix:nonNumeric> from the date of issuance. See Note 7 &#8211; Stockholders&#8217; Equity (Deficit) for additional background.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_e2f40308_e030_4ffc_a1fa_89cd4218e3d3"></a><a id="Tc__I9HORF_fUqqJN80CpI2Zg_1_2"></a><a id="Tc_Rgd4eWMZGE6bOhzgoK1wdA_2_2"></a><a id="Tc_fy7iNsDtek6ECwCY-ABCxA_2_5"></a><a id="Tc_eSaRVDfc5UWUUf4xFbya9Q_3_0"></a><a id="Tc_jzyt33Kv9UuOBfMKgfPRHg_3_2"></a><a id="Tc_HBjsrSWpBkC0WuM73yalzQ_3_5"></a><a id="Tc_zgMSj6g2fU2GeTZ7KU7tdA_4_0"></a><a id="Tc_IKDNyreskUGnCriYoAlu8A_5_0"></a><a id="Tc_zQkBnQVMJUqsCcDS9HOFJw_6_0"></a><a id="Tc_NevhF7bZqUO4ieG3oqReXQ_7_0"></a><a id="Tc_Iv4w07sVKUK94Ny8BiEZSw_7_2"></a><a id="Tc_tVTa2zNNkEOUu2X2iOsoxA_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" id="Tb_yXdkoXOuqUmCKWd6GJ2d5w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Prepaid Expenses and Other Current Assets</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_BWrTCP0jcUeI6Ep3K88uJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_z39v_TfzQkyP750LpCqD_g_3_3">2,998,811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:PrepaidResearchAndDevelopmentExpenseCurrent" scale="0" id="Tc_AdOxja32m0OXY61g5u1BQg_3_6">4,391,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_5KcpNur4kEqfHQZFQegsjQ_4_3">346,313</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherPrepaidExpenseCurrent" scale="0" id="Tc_-utUy42iWEalmA9u6MeOwg_4_6">23,455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_zZg8awRnLEmIvKSAZFTi2w_5_3">21,098</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PrepaidInsurance" scale="0" id="Tc_fVvZu0EVjkeB4sTMN2rZqA_5_6">18,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_BR26F0Tuj0Sb13vZIxIW-A_6_3">7,495</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="0" id="Tc_fr2nUqQ_oUWJfhsxJFvTLQ_6_6">20,796</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_p22wIs7mAEujBrZlrapV9w_7_3">3,373,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" scale="0" id="Tc_a2iDv650IkOWt2eRDfbfbQ_7_6">4,453,544</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_e2f11d62_794e_4757_be42_1181d1517d2d"></a><a id="Tc_cRI098FSdU2V-x7Voyr-pw_1_2"></a><a id="Tc_Byy2WRgXnkKRYSshTZVwXA_2_2"></a><a id="Tc_HHmboIBGLkmvo1QPh26ucw_2_5"></a><a id="Tc_PbqFv9Q6uEac9Xaaf1kFXA_3_0"></a><a id="Tc_1XA4NNAfDEK_81BwjbcSfw_3_2"></a><a id="Tc_-O34dvQ1n0WFB__NckxIBg_3_5"></a><a id="Tc_5kEb4YgLM0OkdfH1buzKAw_4_0"></a><a id="Tc_x_cNLHbVtkuxxVn0-dwmoA_5_0"></a><a id="Tc_z3Ko6ctv6U6knPdZFeBrVQ_6_0"></a><a id="Tc_hi2tkzkVdE6SIQZarxi-wA_6_2"></a><a id="Tc_eKV8UedxLEmHWBrBOMXrxA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_DhjGtlBZ20qP6g142OVuAw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Accrued Expenses</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_TZKe8-4XtkCCIYq-U4GmaQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:AccruedClinicalLiabilitiesCurrent" scale="0" id="Tc_K5gtFvCKLkqJyFRCqtIYaA_3_3">948,695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:AccruedClinicalLiabilitiesCurrent" scale="0" id="Tc_ktj1rZ6vFUW80wPF1nVPgA_3_6">2,645,589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_oZuipQU1LEeMwKSa0g7r1Q_4_3">364,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_huShGDO1306b4XBJEkqSoA_4_6">96,848</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_inHK2f3DYkaB1Tjmq8V2Rw_5_3">261,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_xPRR5UuBlkmHdysmdsLtIA_5_6">243,836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_xdIWu3zNW02UAz2UqVscfg_6_3">1,575,013</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_HiMYzsHFd0ayIIjF1HOGtg_6_6">2,986,273</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_PZFyYbITMEOCN_dAyt_7Lw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has entered contracts with CROs and CMOs related the Company&#8217;s clinical trials.  The contracts require upfront payments, milestone payments, and pass-through cost reimbursements, to be made. While the contracts are generally cancellable with (written) notice, the Company is obligated to make payments for services rendered through the termination date of the project with any applicable CRO/CMO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains <ix:nonFraction unitRef="Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt-sec:numwordsen" name="anvs:NumberOfShortTermLeases" scale="0" id="Narr_euBDri2pC0SW7HW-7IcKXg">one</ix:nonFraction> short-term lease associated with occupying its corporate headquarters. Total rental expense was $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_6zvBV-f4_EWZi3hdP5PEQg">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_tVBV60S160eJK7SmbzSC0Q">0.1</ix:nonFraction> million for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has an agreement with its Chief Executive Officer that provides for severance payments upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreement was estimated to be $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_NgTaNPhJI0e6-e-ecoGs3g" decimals="-5" format="ixt:num-dot-decimal" name="anvs:MaximumAggregateSeverancePayments" scale="6" id="Narr_oDbtIoEUVkGye0sIeBLdKQ">1.1</ix:nonFraction> million&#160;at December&#160;31,&#160;2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For both the years ended December 31, 2024 and December 31, 2023 the Company did not have any pending legal actions deemed to be material.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_JTYhfhAaJ0uCnYvA9TA2pA" continuedAt="Tb_JTYhfhAaJ0uCnYvA9TA2pA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7) Stockholders&#8217; Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt-sec:numwordsen" name="anvs:NumberOfClassesOfStockDesignated" scale="0" id="Narr_aZYonHsct0y5ecBeXMWAsw">two</ix:nonFraction> classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:CommonStockAndPreferredStockSharesAuthorized" scale="0" id="Narr_t0HCOHvVe0q8u73ZdJGJwg">72,000,000</ix:nonFraction>, each with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_mQDQIqHJgEmgTLjZESgIRw">0.0001</ix:nonFraction> per share. Of these shares, <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_9s08Q9fIFU6h3NIVxs0ejg">70,000,000</ix:nonFraction> is designated as common stock and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr___laxYrVNUmJ5gzft8bsng">2,000,000</ix:nonFraction> is <span style="-sec-ix-hidden:Hidden_sH-lbMPWqkOGFnPa1im7Pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preferred</span></span> stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to <ix:nonFraction unitRef="Unit_Standard_Vote_iNruACJbWkCS-x51NTwMZQ" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt-sec:numwordsen" name="anvs:NumberOfVotesForEachShareOfCommonStock" scale="0" id="Narr_tGvUYXsk1EWqcz3Q2rnItA">one</ix:nonFraction> vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series. There was <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_fHoxrrmeT0yrgm4f7KpiTg"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_gxps20pko0WPFEzbNMf-Hw">no</ix:nonFraction></ix:nonFraction> preferred stock issued or outstanding as of December 31, 2024 or December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;IPO Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the closing of the Company&#8217;s Initial Public Offering (&#8220;IPO&#8221;), the Company granted its underwriters <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="6" id="Narr__LaNXL0tVkuMcrng8lQiQQ">0.1</ix:nonFraction> million warrants to purchase shares of Company common stock (&#8220;IPO Warrants&#8221;) at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_yTfoupuR-EKa4U3rEfnWFw">7.50</ix:nonFraction> per share, which was <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w" decimals="2" format="ixt:num-dot-decimal" name="anvs:PercentageOfExercisePriceToShareOfferingPrice" scale="-2" id="Narr_cnWH11o32EOzwzy9M8bkog">125</ix:nonFraction>% of the IPO price. The IPO Warrants have a <span style="-sec-ix-hidden:Hidden_nIEprH3FlECzxDG_jmJGRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five-year</span></span> term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders&#8217; equity. At both December 31, 2024 and December 31, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_SPqsTvoSZEmCmTaTfjmmuQ"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_eRSkNG2PQ0GJ3T9rUWnfTg">2,400</ix:nonFraction></ix:nonFraction> of the IPO Warrants were outstanding. <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_7gg9fooLjEmkcRZFmQ-9wg" decimals="INF" format="ixt-sec:numwordsen" name="anvs:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_0H63oquw4UyuwRUZryDIRA"><ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA" decimals="INF" format="ixt-sec:numwordsen" name="anvs:ClassOfWarrantOrRightNumberOfWarrantsExercised" scale="0" id="Narr_igS9_KYQok6YSu8lgUTIvw">No</ix:nonFraction></ix:nonFraction> IPO Warrants were exercised during the years ended December 31, 2024 or 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(e)&#160;March 2023 ATM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Company, entered into an At the Market (&#8220;ATM&#8221;) Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221; or &#8220;March 2023 ATM&#8221;) with BofA Securities, Inc. (&#8220;BofA&#8221;) and ThinkEquity LLC (&#8220;ThinkEquity&#8221; and, together with BofA, the &#8220;Sales Agents&#8221;), as sales agents, pursuant to which the Company could offer and sell, from time to time through the Sales Agents, shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_CVkGciS4UE22bP11ntKprw">0.0001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ" decimals="-5" format="ixt:num-dot-decimal" name="anvs:AtMarketEquityOfferingCommonStockAuthorizedValue" scale="6" id="Narr_L1wi9xnM7EOCcrvzK26faA">50.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.</p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a8d6c987_a4a9_4209_9bcd_dab9c7075e8f"></a><a id="Tc_qZvs0VNYL0iRc_DrOimn2w_1_0"></a><a id="Tc_xsh-6flS50SvxAlmjXcozw_1_1"></a><a id="Tc_z7pSi2yTREW8rDy4eefi2g_2_0"></a><a id="Tc_w88oxdejDEaTCufMOqRQKQ_3_0"></a><a id="Tc_l29fVH4Tu0S_J7MY_eL7wg_4_0"></a><a id="Tc_MAmbZZJtcESh7TfPorrpbQ_5_0"></a><a id="Tc_Is6BAwllek2Hbt81U65dGQ_6_0"></a><a id="Tc_s0lM7ebCnkCES_jVfZPxAw_7_0"></a><a id="Tc_gQb04Fgp1kqZqFZu6O79gQ_7_1"></a><a id="_58cfa9f3_0150_4d0d_8d40_2161d4d1c35a"></a><a id="Tc_zmcriyq4H0qrx1hjSMjmng_1_4"></a><a id="Tc_Qv0K9wszHU6u0AVVXwEA3w_1_10"></a><a id="Tc_d6JRCdJGFEiAWqFEUC0k3g_1_12"></a><a id="Tc_FDvwkc16kUeV-w4ufA9-xg_2_4"></a><a id="Tc_NqrPM5hHRkCRwy9EMWNW_Q_2_8"></a><a id="Tc_E2BESkvrekKTjk8nUX0G8Q_2_10"></a><a id="Tc_Jnfvafxft0e3Gpkfo-vXug_2_12"></a><a id="Tc_hQ0-2XxNik2U_k5-c-Mbkg_2_15"></a><a id="Tc_xS8AzbCMmEq4F24AZ755tg_3_2"></a><a id="Tc_l6JTcUHTn0Sut8g76eY_Xw_3_4"></a><a id="Tc_wCDzjjlb8Ei4sgNjvyOQLQ_3_6"></a><a id="Tc_12VH1ZcTwU-2VpJicUoAZQ_3_8"></a><a id="Tc_sTo8Q21LR0OsmOozWkkQhg_3_10"></a><a id="Tc_3D25-EalYk-3cpfb5sCIGg_3_12"></a><a id="Tc_xYAOGwMFm0uIGwmd2yUn2Q_3_15"></a><a id="Tc_-5YtCyVbb0S_s-Z6sbiS4w_4_0"></a><a id="Tc_ewmhImPCakmfcSbju6l8HQ_4_2"></a><a id="Tc_DUBEm4Wy4UuS-sk4lbF9aQ_4_12"></a><a id="Tc_h_MTJKQ9pUqDOUoRszL8Ww_4_15"></a><a id="Tc_zw3ATFqlB06oqoMvIp5L_Q_5_0"></a><a id="Tc_xjhS4cqcbUeaY1p2SvX1ng_5_2"></a><a id="Tc_ugqRe9hgQEq-D-oK6wMIwQ_5_12"></a><a id="Tc_fP0992jdrUqMlBBNPkoS0g_5_15"></a><ix:continuation id="Tb_JTYhfhAaJ0uCnYvA9TA2pA_cont1" continuedAt="Tb_JTYhfhAaJ0uCnYvA9TA2pA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to termination of the Sales Agreement, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_3_31_2023_To_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_IQdTVBbE1kuTFDb_-zrMqw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_PsmbNpj0C0ObyGeYVDF30Q">0.7</ix:nonFraction> million shares of Common Stock pursuant to the Sales Agreement at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_SkKKchrYf066v4UUAPqRkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_6YvBhNP1C0O5mg5x_bFT9g">10.88</ix:nonFraction> per share, for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_3_31_2023_To_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_IQdTVBbE1kuTFDb_-zrMqw" decimals="-4" format="ixt:num-dot-decimal" name="anvs:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_kvyzhbXCXE2-yN-HT6vNRw">7.6</ix:nonFraction> million before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(f)&#160;April 2023 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_4_7_2023_To_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_6Rvkzj0uGUq7zP-I43U2RQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_wbcWet4x20OZRwKTbvVhfw">0.1</ix:nonFraction> million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_F4sV-r5ZzEW1HxbvXiPFTA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_OkLQHH8WTEedgn6fZmbGew">12.61</ix:nonFraction> per share, for aggregate proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_4_7_2023_To_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_6Rvkzj0uGUq7zP-I43U2RQ" decimals="-5" format="ixt:num-dot-decimal" name="anvs:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_NgwkzEjlwkuwy4ysnlpV-A">1.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(g)&#160;November 2023 Equity Offering and Warrant Issuance</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" id="Tb_O2tjUjZ63kq4NfMwWsvLow" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_oXu4gOW5b0aq3bImbwhyKA">1,250,000</ix:nonFraction> shares of common stock and (ii) warrants (&#8220;Canaccord Warrants&#8221;) to purchase an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_o7wY3msp40S62Ye6fu7TRA">1,250,000</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_UVMHD8swFkqZI0fOGkjWTQ">9.00</ix:nonFraction> per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire <ix:nonNumeric contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_LiG6GXn_GUe5deH7s3MCFw">five years</ix:nonNumeric> after the date of issuance. The Company received $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_JdWBrcrFjUWKlj61OPGT-g">6.8</ix:nonFraction> million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Canaccord Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_A17qsEMG7kWF8gX6ytMu8w_1_2">2,449,001</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ" decimals="INF" format="ixt:num-dot-decimal" name="anvs:ConversionOfWarrantsNumberOfWarrantsConverted" scale="0" id="Narr_di9CdQsJ50ukDwqST9CsmQ">50,000</ix:nonFraction> warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ" decimals="0" format="ixt:num-dot-decimal" name="anvs:IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" sign="-" scale="0" id="Tc_sMEeh4dSdkeZSHTkyWaN_w_2_2">606,201</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_bfgLrAGyV0iABzpyim53oQ_3_2">11,837,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_sqRyLfV0qkCQCwu5h2544Q" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_NP8xCeFc6UW4zI63Lqz2RQ_4_2">13,680,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="0" id="Tc_LOFm2j34rEShoTLnJ2mc3Q_5_2">3,625,893</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:ConversionOfWarrantsNumberOfWarrantsConverted" scale="0" id="Narr_T0Qym4GXqUmK81ktBgSIrg">891,667</ix:nonFraction> warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA" decimals="0" format="ixt:num-dot-decimal" name="anvs:IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" scale="0" id="Tc_hKg25v-oI06NbAj6Mr88Wg_6_2">9,317,107</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q" decimals="0" format="ixt:num-dot-decimal" name="anvs:WarrantLiabilityNoncurrent" scale="0" id="Tc_ag4eVItPmkekFDIC1EWZBA_7_2">737,000</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h)&#160;Warrant Summary</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Tb_pDXO4LdpA0O0ZPZh2FgbMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had the following common stock warrants outstanding:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised&#160;or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IPO warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_vz0vaspnWEemAWApXcg-RA_4_4">2,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_ocX4sCgjxE2JSSfZYbGv7Q_4_10">2,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_y-8e4eKtYkmZe28AaeFBQg_4_13">7.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 29, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Canaccord warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_sqRyLfV0qkCQCwu5h2544Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_kFLoXCgQqkiTsrQsgtzzmA_5_4">1,200,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA" decimals="INF" format="ixt:num-dot-decimal" name="anvs:ConversionOfWarrantsNumberOfWarrantsConverted" scale="0" id="Tc_as5eG-jTdESCnZKcX1pCcQ_5_8">891,667</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Tc_QpqPIEXJ-k-7E2L6l_oSyQ_5_10">308,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Tc_COteFyIwUE-WbCnD0nQF6Q_5_13">9.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 2, 2028</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i)&#160;November 2023 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 27, 2023, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_11_27_2023_To_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_Ole6j-8tB0ajoZW3rv8oMQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_2KjV3M1EQUmJ1XAPE0t3WA">0.2</ix:nonFraction> million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_drOFZ18jkU62ofbq5FTKag" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_1acsP8UdAEW_j6zExGiHyg">6.10</ix:nonFraction> per share, for aggregate proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_11_27_2023_To_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_Ole6j-8tB0ajoZW3rv8oMQ" decimals="-4" format="ixt:num-dot-decimal" name="anvs:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_4A0WKRG_WEqf_aHrV0guug">1.3</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(j) March 2024 Registered Direct Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 15, 2024 and March 21, 2024, the Company entered into <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew" decimals="INF" format="ixt-sec:numwordsen" name="anvs:NumberOfSaleOfStockTransactions" scale="0" id="Narr_abvsQzY_OUSuHOcjDns2DQ">two</ix:nonFraction> separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_n8reVvdpW0GMnGI8PeHmbA">0.4</ix:nonFraction> million shares for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_4Sp_C6pVukWRrJqQxFFShg">3.9</ix:nonFraction> million in registered direct offerings.</p></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_JTYhfhAaJ0uCnYvA9TA2pA_cont2" continuedAt="Tb_JTYhfhAaJ0uCnYvA9TA2pA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(k) April 2024 ELOC Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 25, 2024, the Company entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog" decimals="INF" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementSharesAuthorized" scale="0" id="Narr_jAzSYmbpZkKpB0mAhSgdNQ">2.0</ix:nonFraction> million shares of shares of the Company&#8217;s common stock. The term of the agreement was until the expiration of the Company&#8217;s active S-3 Registration Statement, unless earlier terminated or exhausted. Due to certain pricing and settlement provisions, the ELOC Purchase Agreement qualified as a standby equity purchase agreement and included an embedded put option and embedded forward option. The Company therefore accounted for the ELOC Purchase Agreement as a derivative measured at fair value, with changes in the fair value recognized in the statements of operations within other financing costs. The Company initially recognized a derivative liability of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="Narr_fXb4VcGwyUGkl1nsV23doQ">1.7</ix:nonFraction> million related to the purchased put option at inception of the ELOC Purchase Agreement. The Company then expensed the difference between the discounted purchase price of the settled forward and the fair value of shares on the date of settlement as a noncash financing issuance cost. The Company recognized $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_xPM3GLi0RUOkXjtpjkTGoQ" decimals="-5" format="ixt:num-dot-decimal" name="anvs:NonCashFinancingCostsFromIssuanceOfShares" scale="6" id="Narr_7CKgE8z8-kmiCmacXtInPg">1.3</ix:nonFraction> million of noncash financing costs during the year ended December 31, 2024 related to the discounted purchase price of the settled forward and the underlying fair value of the shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the ELOC Purchase Agreement, the Company agreed to issue to the ELOC Purchaser <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_jFh9SfTd8kas9xGVihV0Yw" decimals="INF" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementTotalCommitment" scale="0" id="Narr_-sPXYz3CA0aNi_31XtUHCA">33,937</ix:nonFraction> shares of Common Stock as commitment shares (the &#8220;Commitment Shares&#8221;). The fair value of the Commitment Shares was $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_NZ9r7_BupkiL0YsEGFb8kg" decimals="-5" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementTotalCommitmentValue" scale="6" id="Narr_jBo75y6ar0-E1RCxsWGj2Q">0.5</ix:nonFraction> million, which was expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The Company also incurred issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_VTb1RU6T3Eu-Tbi6TLPZEw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="6" id="Narr_utco3D1JsECvS6ElJ7564A">0.1</ix:nonFraction> million, consisting of legal costs incurred in connection with the ELOC Purchase Agreement, which were expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The ELOC Purchaser agreed that during the term of the Purchase Agreement, neither it nor any of its affiliates would engage in any short sales or hedging transactions involving the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ELOC Purchase Agreement, on any business day (the &#8220;Purchase Date&#8221;), if the Company&#8217;s stock price is greater than or equal to $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_EfLOirszWUyVpVR0cKNriw">5.00</ix:nonFraction> per share, the Company could direct the ELOC Purchaser to purchase common stock. The ELOC Purchaser&#8217;s committed obligation under any single Fixed Purchase could not exceed the lower of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_4_25_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_C7P9lxm6_UawTNSEnjwUvQ" decimals="INF" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementTotalCommitment" scale="0" id="Narr_WWVBJrn7GEaLwyLLrSjDkw">25,000</ix:nonFraction> shares of Common Stock or $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_4_25_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_C7P9lxm6_UawTNSEnjwUvQ" decimals="0" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementTotalCommitmentValue" scale="0" id="Narr_eFchJ_y7s0Sh7fDg5tAsAg">250,000</ix:nonFraction> (&#8220;Fixed Purchases&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company could also direct the ELOC Purchaser, on any trading day in which the Company submitted a Fixed Purchase notice for the maximum amount allowed for such Fixed Purchase, to purchase an additional amount of the Company&#8217;s common stock (a &#8220;VWAP Purchase&#8221;). The ELOC Purchaser&#8217;s committed obligation under any single VWAP Purchase could not exceed a number of shares of Common Stock equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g" decimals="2" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" scale="-2" id="Narr_8wVmyCg1OE2uLZO4br-1-Q">300</ix:nonFraction>% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g" decimals="2" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" scale="-2" id="Narr_rZwzBZlMsk6puB3kghHGDQ">30</ix:nonFraction>% of the trading volume in the Company&#8217;s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date (&#8220;VWAP Purchase Maximum Amount&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company could also direct the ELOC Purchaser, on any trading day for which a VWAP Purchase had been completed and all of the shares had been placed, to purchase an additional amount of the Company&#8217;s common stock (an &#8220;Additional VWAP Purchase&#8221;). The ELOC Purchaser&#8217;s committed obligation under any single Additional VWAP Purchase was the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_KwF1UY3e6UWazmxYxCohhw" decimals="2" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" scale="-2" id="Narr_3Lp3hwPP9kWnHLaa3_uIcw">300</ix:nonFraction>% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (&#8220;Additional VWAP Purchase Maximum Amount&#8221;). The applicable pricing structure for each purchase type is outlined below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for Fixed Purchases (&#8220;Fixed Purchase Price&#8221;) equals <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_Myild4X83kmqgHCD5Jm5Sw" decimals="2" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementPurchasePricePercentage" scale="-2" id="Narr_7tH6vitzskmubXZW1fKYDQ">95</ix:nonFraction>% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the daily volume weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock on the NYSE for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for VWAP Purchases (&#8220;VWAP Purchase Price&#8221;) equals <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g" decimals="2" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementPurchasePricePercentage" scale="-2" id="Narr_KnhheG0-REK7Ymz4sx4_oA">95</ix:nonFraction>% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the VWAP during the applicable VWAP Purchase Period during the applicable VWAP Purchase Date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date.</span></td></tr></table></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_319092ae_e91e_4c5a_b0df_20f4c3f69e03"></a><a id="Tc_EzwFMOIjb0-TMjSBfpssKQ_1_0"></a><a id="Tc_Cc69IUDEq026bTcs_IvZeQ_2_0"></a><a id="Tc_2gpJdskYdkqEmz7hTXRKtA_3_0"></a><a id="Tc_NdSIHkunMk6YCyF90_D_ww_4_0"></a><a id="Tc_nxDaM6s2-0eb1yzWX7zHzQ_5_0"></a><a id="Tc_w3XuqYPwM0qN9Edpx6Ge5g_6_0"></a><a id="Tc_rrLNTtyvnUifdiLtBiA3ZQ_7_0"></a><ix:continuation id="Tb_JTYhfhAaJ0uCnYvA9TA2pA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for Additional VWAP Purchases (&#8220;Additional VWAP Purchase Price&#8221;) equals <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_KwF1UY3e6UWazmxYxCohhw" decimals="2" format="ixt:num-dot-decimal" name="anvs:CommonStockPurchaseAgreementPurchasePricePercentage" scale="-2" id="Narr_er8Iu4HnaU2R-a221PVLlw">95</ix:nonFraction>% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the commitment shares referenced above, a total of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_hMBXSD_r90OcUkje1xs0Kw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_hPQMAVDs4UyPFtiNDSzgnQ">2.0</ix:nonFraction> million shares of the Company&#8217;s common stock were issued under the ELOC Purchase Agreement during the year ended December 31, 2024, for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_hMBXSD_r90OcUkje1xs0Kw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_gazuGztm20qjkbcmU9vrBw">14.6</ix:nonFraction> million. The facility was fully exhausted during 2024 and no further shares are available to issue as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following is a roll-forward of the ELOC derivative liability from date of execution to December 31, 2024: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at April 25, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_lGxezDs1Z0iMzCsFBeTirg_1_2">1,697,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_4_26_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_4nudJCrUe0q5HzKyVLPtIw" decimals="0" format="ixt:num-dot-decimal" name="anvs:FairValueAdjustmentOfDerivativeLiabilities" scale="0" id="Tc_qKOYVeJw8EGW_ENwHZ88Cg_2_2">1,192,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_eDlqgmZOK0uV7d1yioA33g" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_MtqXG_vzdU2ut3XH4ZIAVA_3_2">505,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_aMlHarrTRUOw2ZPEPhIpaw" decimals="0" format="ixt:num-dot-decimal" name="anvs:FairValueAdjustmentOfDerivativeLiabilities" scale="0" id="Tc_2wyEoX1Az025OS_lU814xQ_4_2">62,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_DplnVEhr1UKyMZzvd2jAOg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_iRfoO3p-rkOXI4Y6yZKVuQ_5_2">442,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_10_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_ZVroRH_FcESsW5ndUBJ8dg" decimals="0" format="ixt:num-dot-decimal" name="anvs:FairValueAdjustmentOfDerivativeLiabilities" scale="0" id="Tc_-jksFCxY0UyHU_XkM7WuwA_6_2">442,500</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_JiqWi9fSuEijFwv_zoQINA" decimals="0" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="Tc_38dsLiTZY02GN8jm01irBg_7_2">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(l) December 2024 ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 11, 2024, the Company entered into an Equity Distribution Agreement (&#8220;Distribution Agreement&#8221;) with Oppenheimer &amp; Co. Inc., (&#8220;OpCo&#8221;) relating to the sale of shares of the Company&#8217;s common stock. In accordance with the terms of the Distribution Agreement, The Company may offer and sell shares of its common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_11_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_HZ8IW9wPyES6tf53JMU46Q" decimals="-5" format="ixt:num-dot-decimal" name="anvs:AtMarketEquityOfferingCommonStockAuthorizedValue" scale="6" id="Narr_z_9FSoykpUuUaqevgSPwTA">50.0</ix:nonFraction> million from time to time through or to OpCo, acting as agent or principal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the year-ended December 31, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_gpQFYjs3FUenHVaL9XwsJQ">26,788</ix:nonFraction> million shares of common stock pursuant to the Distribution Agreement for gross proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw" decimals="-5" format="ixt:num-dot-decimal" name="anvs:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_QIW-s4d3LkOdOYjawouulQ">0.2</ix:nonFraction> million before commissions.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_l3-QgLezUEK56PFSmYolqw" continuedAt="Tb_l3-QgLezUEK56PFSmYolqw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company&#8217;s IPO on January&#160;31, 2020, the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) became effective, succeeding the Company&#8217;s previous equity incentive plan. <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_WHvnc8vNT0mnAJbraAi9IA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_xUMejuiwhEeko_fplfkDdw">No</ix:nonFraction> new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 12, 2024, the 2019 Plan was amended to increase the number of shares authorized from <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_RldmCmC-GEOG6BsKRZ7jHA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_MW3hdYtBdEyxgPBkAnS4sA">2,000,000</ix:nonFraction> to <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_6_12_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_VGsJvkPfqEiFabjsYECyuw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_JxvRv-LM6UuHQ1teP6gmug">3,000,000</ix:nonFraction>. As of December 31, 2024, the 2019 Plan contained <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_zW8RAM-bpUWV473IHWZYTw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_JLfQXlW1H0OnKCgnhttwUQ">354,299</ix:nonFraction> shares available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board, except when they are below previously approved thresholds allowing the Company&#8217;s CEO to grant awards on a discretionary basis. The Company&#8217;s stock options generally carry a maximum term of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_SrizNFCLl0OrRUDzrcGBsg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr__KSUpA8_1k2Bt72Oc5GJbA">10 years</ix:nonNumeric> after date of grant and are exercisable in cash, or as otherwise determined by the Board. </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a4456cfd_febf_4932_a3a9_41f2f19988e1"></a><a id="Tc_O7XsbcZaFE-_C6WB2rtuIA_1_2"></a><a id="Tc_BfBdC-jstEKfQJNxoiBp4A_2_2"></a><a id="Tc_GvYtiwO5okSZ-dR3M2T5iA_3_2"></a><a id="Tc_Wt4zcr2oy0ydxDtyG9wXsQ_3_5"></a><a id="Tc_me_78jtEr0K8FHJ1iBc5pA_4_0"></a><a id="Tc_LIkJDWyhtkuaWazPucQhgw_4_2"></a><a id="Tc_MUxgpgEuZEKVj4bjZtILSg_4_5"></a><a id="Tc_f9MHs116XUSqf0urPnhtAw_5_0"></a><a id="Tc_OZKUamQxRkOu_-fI7G8M_Q_6_2"></a><a id="Tc_D74VDOe-zkOUShYzevblCw_6_5"></a><a id="_527ec98a_8eb6_4454_8602_719f7a8d2029"></a><a id="Tc_TbWJF9grRk2Jas__sixTkw_1_7"></a><a id="Tc_QpP7pUCHZkKzYauLRtjbZQ_2_7"></a><a id="Tc_3Swt-BjOLkyAmaHMa3FQtA_3_7"></a><a id="Tc_s8VOgv7P00SMaWdB4-dZ-Q_3_9"></a><a id="Tc_SlNl1aQpxEWeAk5ryO8KFQ_4_4"></a><a id="Tc_uSpYXNKXh0GrfiZypDxssw_4_7"></a><a id="Tc_6kNBxy0xy0CYz9pJTWe1zQ_4_9"></a><a id="Tc_EnMU2N00KUOlCSkdLyypyg_5_2"></a><a id="Tc_ZgmvGDXwCUmJNsSXWWLB8g_5_4"></a><a id="Tc_tGTPmdkuMkiEQu-u96xdJw_5_7"></a><a id="Tc_0p6BqiAJVUaP6PvbFVFYLA_5_9"></a><a id="Tc_Gqr32KQml0SYeLK2xMV0Qw_6_2"></a><a id="Tc_wqZhkc3tB0eHHh9KdoUQrw_6_4"></a><a id="Tc_pVGdrKSQiUmXb_4DebSkSQ_6_7"></a><a id="Tc_VFeJMKEKAkO7TmzGjHpo2A_6_9"></a><a id="Tc_F5o_DEZCK0igu9WxL0jpsw_7_0"></a><a id="Tc_PyBleJV8oEi2rQ1q0Q2Qug_7_4"></a><a id="Tc_Hy_cgQ1o3EWaZtcRbDiP3w_7_9"></a><a id="Tc_3EiuTAe2XEiWvRT43O6C3g_8_0"></a><a id="Tc_5VjnFTpCxE2vcdU7-YPNag_8_10"></a><a id="Tc_hxHUsK18-EK4sUXc112_cg_9_0"></a><a id="Tc_sGFb4kJ_Z0qFJ2ER9_vaLw_10_0"></a><a id="Tc_2oL3VcKm6ESyo54e7VXOfw_10_10"></a><a id="Tc_5KTHRcmkgkWsrVsdiBOQ0g_11_0"></a><a id="Tc_yoYx035EKk6vD1RjkpkpYw_11_4"></a><a id="Tc_5IAHm_XdEk-1Ndc9AOx_Pg_11_9"></a><a id="Tc_vh9KM5Gxp0Wnlffxhnwkfg_12_0"></a><a id="Tc_CehCJ_DDjEOWeb13Sxgugw_12_4"></a><a id="Tc_bGrvyhlVFEeCo2E3r2se-Q_12_9"></a><a id="Tc_Afwr-zFh-EqQFQ3KFGIj2w_1_2"></a><a id="Tc_CLxorMfKoESRYaZ1z1oi8Q_1_4"></a><a id="Tc_Gp_SdduGUUyklAuDC_rzxQ_2_2"></a><a id="Tc_WDI5obGSykOTG4uqz1ml9w_2_4"></a><a id="Tc_YgJAAOQk8UaNvfLjPuNhAQ_3_0"></a><a id="Tc_zh-TfnLK7E6JWhK0vOYK4A_3_3"></a><a id="Tc_8m-n373RBUOwagpUKi8Jsw_3_5"></a><a id="Tc_h-S3h9c8LEefFYii1oG3uA_4_0"></a><a id="Tc_5w2np0nbmkWt3aPhxogxBw_5_0"></a><a id="Tc_Lgom9OxxLEG1Mf-bTPLwKg_5_3"></a><a id="Tc_ovHAebf2AUSIKx0iQXYWQQ_5_5"></a><a id="Tc_BxYcddPtgEekycm5iYYodg_6_0"></a><ix:continuation id="Tb_l3-QgLezUEK56PFSmYolqw_cont1"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_CEEslxFJpU6DNpROhNwFbg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2024 and 2023 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_gvgCPSCuP0eTU2Ad-DzdLg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_EfPlOpf-y0q7iT1sADGOhg_4_3">2,510,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_CS9mE9iYf0ibvclFxHcf3Q" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_qfcFExYY9EytFWukloul1Q_4_6">2,414,867</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_drKyELhDW0-wlU15l7Zyuw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_UVqUVbW_q0ubUZMIfK6s7A_5_3">1,326,326</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BZvwU0W_1kq5dnznbxqBTQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_goNSsf2SskiIgyaV6v8SiA_5_6">2,213,539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_eiBsSVvKSEuf2IKcKmeqLA_6_3">3,836,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_AD9elYj_B0iixujaG2QZoQ_6_6">4,628,406</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_pF8sDXjakEaFWve35xHS0g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_yp-CnhVA_kePJEceVdmF8g_7_2">1,954,774</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_hhvkvSllnkSgTzqg-6YMrA_7_5">13.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_2M8gbdLitkK0dEdsO3spJQ_7_7">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_k6tD9L4Gv0CLw7-NmM3-eA_7_10">17,863</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_giiNWqe59EGh05TcgWpGwQ_8_2">870,494</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_JdZo7G8JEUmZsvcAFeYLcg_8_5">6.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_MYQqoeDDvEGi6u0xv9iu2A_9_2">300,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_1qF47NV95E-se17smOxP3Q_9_5">3.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="Tc_OGPBWWrv_0uIR7EtwKjLJQ_9_10">570</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_4lAhwdu7pk6olljWPB7VUQ_10_2">189,248</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_tnAmacDie0aoVFJfjklBbg_10_5">20.61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_yjnaNohni0ugT3eU2CKqSw_11_2">2,336,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_LLIu8pJY_kah8IfTEDf5sg_11_5">11.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_Q_Yq8WQ2IEK-4Qry-1Qcvw_11_7"> 7.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_mUsGU-MQ2E2hCiGy2Qvn7w_11_10">1,298</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_l3VdcxnJdUWfFAmd8szOsQ_12_2">1,824,122</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_NXYEeXKu9k6SavoyQmcyqA_12_5">12.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Da0wWLZ4vEuWO1TWXU345A_12_7"> 6.8</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="Tc_OTzBFnY-qEqtIb51RPbh0Q_12_10">1,298</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_pOCOiyl28kG_-iQcvDXcgg">5.16</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_TuHidDg_u0e5v2HvO8pZdw">7.39</ix:nonFraction>, respectively. During the year ended December 31, 2024 the Company received <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_5x1wQ8hYhkuhP-UAKR1LMQ">no</ix:nonFraction> cash proceeds from the exercises of stock options. For the year ended December 31, 2023, the Company received $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_DMJEqZ4mhUqYrB7pvsKxoA">8,385</ix:nonFraction> cash proceeds from the exercises of stock options. As of December 31, 2024, there was unrecognized stock-based compensation expense related to unvested stock option awards, related to service-based options of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_Tk2BdOkQEki6zZ7xcxRKFQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_bxV4grRy9k67-_3LN8D4mA">2.4</ix:nonFraction> million, which will be recognized over a remaining weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_YF4qvTY1HkiAlLoVQFqtXg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_dXVHJqvbI0qlOua6rVmh3g">1.0</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2024 and 2023, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_ukPe2r-5eE6641R3h94O1g">870,494</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_-vH-Wqn_B0Wd_9RVnzr5gQ">367,329</ix:nonFraction> options, respectively. Under the grant agreements for the 2024 stock option grants, <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_wwvOa88X1UO_ZTYRVgaRLA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_5WJ8ZvI4s0mBztSTuASlQg">382,282</ix:nonFraction> of the options vested immediately and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_61vShh9zukuFEQnE9vaedw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_obCU2l4prkOsVN7LaHDBxg">468,212</ix:nonFraction> of the options vest in substantially equal quarterly installments over <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_61vShh9zukuFEQnE9vaedw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_56hJSO8exEyJvuV2USIOhw">two years</ix:nonNumeric> from the date of grant. There are also <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_pJBku7_aCk68MVRcc7xViA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_9JX-vGLI1E65viwVYLVRUQ">20,000</ix:nonFraction> stock option grants that vest as consulting services are performed and awards are earned. Under the grant agreements for the 2023 stock option grants, <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_OeMNROUv0EC2j9VxF13eMQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_g4G-bugfVEOdl_P7TMbstg">94,624</ix:nonFraction> of the options vested immediately, and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_c12N8aDCj0a8T1KQPkPjgA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_5zspahtyo0GEYjfVBAy08Q">272,705</ix:nonFraction> of the options vest in substantially equal quarterly installments over <ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_c12N8aDCj0a8T1KQPkPjgA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_Eswnv-B_BU2MnDqWms_ADg">two years</ix:nonNumeric> from the date of grant. All of the options have a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_bsEw1QGgaUmpo8DgtWSSPw">10</ix:nonNumeric>-year term prior to expiration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The assumptions utilized in the fair value calculations for stock options granted during the years ended December 31, 2024 and 2023, respectively, were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_yiA16hibj0aDPOQapllMzA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_joyh8rYp80urzRompmylDQ_3_2">4.18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_ptXT5IpcH0G5O6So8aeImA_3_4">4.17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_LP4-2WE6W0eGJqt2guo6jQ_4_2"> 5.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_0OGJAFNaMkCtrmAKMskagA_4_4"> 5.5</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_fuEwyShDKESaAPD_4ta36g_5_2">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_Ibzd6z47A0ij0eUYIA-Z2Q_5_4">120</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hvDUBjTlvU2jxBxrBfn9yg" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_jN5uJX6xZUO9OYEsAaiHrA_6_2">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CG9ka-YnN066FFG9Jtzx0g" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_w_rrfNchgkKmUUd-W4Jnuw_6_4">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended December 31, 2024, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_pDfDkGHDXUSTWmxUhrtBpg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_yXXEyx4L3kCBXPu3t2PDFg">20,000</ix:nonFraction> non-qualified stock options to a member of its Board of Directors in consideration for the member&#8217;s agreement to serve as a consultant to the Company. The options were issued in one tranche, at a grant price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_pDfDkGHDXUSTWmxUhrtBpg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_ffT7COWgEU23gST2AMnxug">5.27</ix:nonFraction> per share. <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_bukzSMYfYkGUxtewxBU0ew" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_aKmrnVvev0CE_b4_5hoszw">8,069</ix:nonFraction> of the awards became vested during the year ended December 31, 2024. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_a7af27e9_4fa4_42d2_832d_baa68f46b0b1"></a><a id="_29bf67f4_b74a_4ae8_99ab_bc73a8a13f22"></a><a id="Tc_1yrgSVoEhU-YsPxQAOvPBg_1_2"></a><a id="Tc_XUgHivrSZE6NpLjKhjWg2w_2_2"></a><a id="Tc_IfufF-mLz0qCaQBSdx-gTQ_3_2"></a><a id="Tc_-zOVq3jeTkSsZJSgWEIUKg_3_5"></a><a id="Tc_OjdMddsEj0WgwFOLvtQl8A_4_0"></a><a id="Tc_hFgcbHd6Qku0NKUtaSgY9Q_5_0"></a><a id="Tc_zpbI5NYlpES3el0b3-t5jg_6_0"></a><a id="Tc_ma6GcfSYkkCwRjH3_caeRg_6_2"></a><a id="Tc__bff_S4zFEqZcIzRZYhIlQ_6_5"></a><a id="Tc_nt84Ca03yEWM6gk68ig2CA_7_0"></a><a id="Tc_hRuoSykh0UKA2pCu2gj0xQ_8_0"></a><a id="Tc_RwiMadLnMkGzwWOZuqBrXA_9_0"></a><a id="Tc_QPzreKmfQUCRpmO0L1qWrQ_9_2"></a><a id="Tc_-YgSf7v2mUSL4-5xAwKZGA_9_5"></a><a id="Tc_xaoJXoccUkupvtHB_hRdDw_11_0"></a><a id="Tc_gOfcQzV94UavQTnp5x4OVQ_12_0"></a><a id="Tc_IvXAe3DppUqnREmob2WcDw_13_0"></a><a id="Tc_E-_QiVYWnkysM0sOYuHHTQ_13_2"></a><a id="Tc_majuEVYChkq-9uUwrhHf7g_13_5"></a><a id="Tc_I7WVcUBtO0mJ7iRtzCygsQ_14_0"></a><a id="Tc_lYEZPcizR0qtrbP097jz0Q_14_6"></a><a id="Tc_RYq-YDu4qEu1F0WmCUX8qg_15_0"></a><a id="Tc_n9QsEx-ZVki48Tgr9UCE6A_15_2"></a><a id="Tc_3JGOuItCIk6SAAqpS72VjA_15_5"></a><a id="Tc_AgMss6PY00mKN5O7tpHLjA_16_0"></a><a id="Tc_1Ya-qwxP-UCGtAf-gy-lLA_17_0"></a><a id="Tc_QRC3pMaWqE6mvElYEZv8Zw_18_0"></a><a id="Tc_w8gnmHxz60iCGDJDNd7vdw_18_6"></a><a id="Tc_DzKKhoZ0okafynJJbUebsQ_19_0"></a><a id="Tc_tUsvC7I0Y02naCP51vNWiw_20_0"></a><a id="Tc_IjKk-Nj3H06EN-tmriaO5A_20_2"></a><a id="Tc_9FpkINUK0UiJJesaA6ZTDA_20_5"></a><a id="_6b388e06_9166_4c7f_83bd_1dc1116e7a7d"></a><a id="Tc_987JswXw-Ea1neR1DpFSIw_1_2"></a><a id="Tc_Gc_MOmWhU0OXQOv4KYiEiA_2_2"></a><a id="Tc_1Cn4e6VZl0Sf7yPj6_asbA_2_4"></a><a id="Tc_aA3fDiLppE-MQEYinIkwMw_3_0"></a><a id="Tc_igGFH70DQkGpPKirhcwX5A_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_v1L7uT0G8EW20MhXPz-u8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the&#160;years ended December 31, 2024 and 2023, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_d6HLT-IoNUeeue5ZEHhZww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share &#8211; Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_ElbTNkIwgEOQ_5gmEOsx-w_6_3">24,590,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_rD6rma5w_0i2Vk36vi-W0Q_6_6">56,204,313</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_lR0jkmlsW0O-9PqETc0S3A_8_3">12,182,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_Sd4xNFaVTk6-9-BIndwuoA_8_6">9,023,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_ZmUbzqp4y0ShSu3wx39dwA_9_3">2.02</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_BQg9e8TR5ECTkf-V22RkGw_9_6">6.23</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share &#8211; Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_MxlCYJGQME6UwKYZ_aJ1OA_13_3">24,590,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_orKzN5WNfESLmvdeBFfiMg_13_6">56,204,313</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Less: gain from change in fair value applicable to dilutive liability-classified warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DilutiveSecurities" sign="-" scale="0" id="Tc_IsGiSpZmuUaXATLaG-YEqw_14_3">3,625,893</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Numerator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="0" id="Tc_KleS4OMgGEm9dvvCzG1RLQ_15_3">28,216,268</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="0" id="Tc_jtacJWsZvUadL6oZXF6FZw_15_6">56,204,313</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Denominator for basic net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_JzbbjrxP4UKgpjaghVHR8g_17_3">12,182,475</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_oCKlNKFkSkSHkXRPLuLmrA_17_6">9,023,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Plus: incremental shares underlying &#8220;in the money&#8221; liability-classified warrants outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="Tc_5Hebx7WEtkeEYrHeTtcuYg_18_3">52,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Denominator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_y-sc5TjEkEGbklT-Tkhi0Q_19_3">12,235,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_17Bz9mD_WE-HU2KKUxrxcw_19_6">9,023,138</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Diluted net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_tBvNehq9hE-i_MTEHrsitQ_20_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_tBvNehq9hE-i_MTEHrsitQ_20_3_2">2.31</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_T1PgaMNzOEuN74Ad_DMM6g_20_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_T1PgaMNzOEuN74Ad_DMM6g_20_6_2">6.23</ix:nonFraction></ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_KpvIkuVGtEOmj-hfytE28w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YOSOVaVa9EaMhSFwK4tVEg_3_2">2,336,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ETg7vggNp0yISA331JxRTQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_C0TWBcJmP0CfEKPiRiJ_tA_3_4">1,954,774</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GmXKWrDQdku8NRf1skZHOw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_-wsSFV1GWUiDnjiWdS8Wvg_4_2">2,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_EkA9YeMGEkWI79aNnSvkJg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_VI1YOt4VyEi5Wntmwoeobg_4_4">1,202,400</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d"></a><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d_2"></a><a id="_dc22ecab_c6bc_46a5_9a4d_1b51576b8d6d_3"></a><a id="_07c8df1f_3d00_49e5_92f7_79c54f4e1f70"></a><a id="Tc_vOFhZyM3tEyi8FFrmX-MZw_1_2"></a><a id="Tc_RqrmuRj3ZEO20Uovz5t-iw_2_2"></a><a id="Tc_AROSqkE9B0aFa9Le31ccgw_3_2"></a><a id="Tc_2kajBV-Ea0GaEIHcLqpVvg_3_4"></a><a id="Tc_r7IhdC4QK06BV4tr_0DL9g_4_0"></a><a id="Tc_v_6Ypw8HBEe2_lNmIYbXCQ_4_3"></a><a id="Tc_jzRUFRP_1kC_742VQwb0aQ_4_5"></a><a id="Tc_qfoq4f7kZUGTbD8NfTLTvQ_5_0"></a><a id="Tc_dpTmKNAboUGeHAF3u_vMyg_5_3"></a><a id="Tc_5Pc2uKRx9UWEh-i3nbOCqA_5_5"></a><a id="Tc_3_QCmDy95UyYc7AlCkk3EA_6_0"></a><a id="Tc_x3nSkOLwBkuLC8SEaW_lBA_6_3"></a><a id="Tc_n04aV3LLbUqFb7z3q9mWJw_6_5"></a><a id="Tc_3H9yZvuudUWBGvOxoo9ubQ_7_0"></a><a id="Tc_811a8VBs3EeFhxsBLK8gTA_7_3"></a><a id="Tc_7LLM8ONElkOgdCZj8LbG7w_7_5"></a><a id="Tc_OhJqEBq8sEeG8xWHCXQyMw_8_0"></a><a id="Tc_osZs-iQCR0KFqK5sWJGPgg_8_3"></a><a id="Tc_sE34Bv-P8kGgIHu_6Gq7cw_8_5"></a><a id="Tc_8iISJ0s5jkCmkdrNp_BhOQ_9_0"></a><a id="Tc_9Ivl63285UuinUmNtzrEhA_9_3"></a><a id="Tc_jnJ3CriZE02dcuxEN-6Dkg_9_5"></a><a id="Tc_R8vl03K20ESo9_sAwhMW1g_10_0"></a><a id="Tc_Y0ItuCpSikOMwM72g1V4RQ_10_3"></a><a id="Tc_BIXqORsU4EGQAqyV_8dEgw_10_5"></a><a id="Tc_HQr-4drqZ0emuycZMAFFIA_11_0"></a><a id="Tc_uizaOSvdIU6tO7bMybAvTw_11_3"></a><a id="Tc_jXfUZx1YtEuBINvHfJf32g_11_5"></a><a id="Tc_dnekyx7RrU2jQRReQL1t9A_12_0"></a><a id="Tc_lJ1CXitqn0GlPPVCzBq0qA_12_3"></a><a id="Tc_aPt7C-I4pkKhvYhxz3cvCg_12_5"></a><a id="_389210ad_9421_4357_88c5_da91bd84dd12"></a><a id="Tc_9j3kz2p0H0uX4Go0piVzeA_1_2"></a><a id="Tc_mYnOK3sPHUWbxAj7wEhuKA_2_2"></a><a id="Tc_ZBUdPx5MtkG-bormWsLJWA_2_5"></a><a id="Tc_yHsLbNq_bU214nwf0DPc1w_3_0"></a><a id="Tc_XEJYiafh3UG5_gC2rX0-QQ_3_2"></a><a id="Tc_WdxR2io8IE2WuHaJWgGtlQ_3_5"></a><a id="Tc_yURLAdx1FUyzvjS9mmWIfA_4_0"></a><a id="Tc_TlBP5T1CnkWdduIgYziW7Q_5_0"></a><a id="Tc_HnyWS4V_S0u5NLlCnluxYA_6_0"></a><a id="Tc_SLy-a4b8ckGsf32Tzu-UfA_7_0"></a><a id="Tc_ylpo5XWG1ECZbs7eQuyUCw_8_0"></a><a id="Tc_K7BdJFJQFUusRXuuGOkyaQ_9_0"></a><a id="Tc_2OY7t0P3tku2G62PMMlQrQ_10_0"></a><a id="Tc_n-TdZ-C-Yk6DyxMNKR0cEg_11_0"></a><a id="Tc_CJSUq-2ZmEWD-J4p09wqQw_11_2"></a><a id="Tc_gHeiHS3AykSmIogM13JAZQ_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_10nsTLkOnEap71jrw-xqVA" continuedAt="Tb_10nsTLkOnEap71jrw-xqVA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was&#160;$<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="Narr_NMlX6XlqAki3kmLhVr4HFA"><ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" scale="0" id="Narr_KYfY0hMtS0ivR0y1eHGkYQ">0</ix:nonFraction></ix:nonFraction>&#160;for the&#160;years ended December 31, 2024 and 2023.</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_Lqs2y-_pGUqcoBszfcL3wg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2024 and 2023 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc__jeZiRzBOEeHwv8BXS2_wA_4_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_EJFBopEwfESFoX52dRfIUg_4_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_WQUsO4_NnEOUUtNVv3Fpcg_5_2">4.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_FzfNsNxCHUKF-PCjqTFV8A_5_4">3.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, change in rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="Tc_5vFGwl_dhEmf3I_ocqP1kg_6_2">0.0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" sign="-" scale="-2" id="Tc_AgyfgibOfUeqrRmzwnE5_Q_6_4">3.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_Cx-D6S7k-UWRKc-22ixR-w_7_2">1.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_fb0WtJejC0uoOVUi5mWgOQ_7_4">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc__11y7jl_106xYzWTF4qJtQ_8_2">4.3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_710FhQVJxUibooxlOIDhAA_8_4">4.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_Cn6UEH8GwU2GpGkRlXyEag_9_2">0.0</ix:nonFraction> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="Tc_E7uejL07_kSVuhPfhNvV4Q_9_4">0.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="Tc_oEA4kMv8vkGuu5fYh5cboQ_10_2">1.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" sign="-" scale="-2" id="Tc_scDqicZTN0mzLcHdTvG8LQ_10_4">4.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_RTYEd6wHB0CoGKvO_GAioA_11_2">28.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_z3lAIguMOUGURgUEjM3BGQ_11_4">20.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_1HB32Q5ExEi3lNUjJdx8LA_12_2">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_bzEqx6uJd0-0GBOvKQdUBg_12_4">0.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_MDAfMcFoN0KqmneavXg9jg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_UtyLZQcw30iOo_-W-Cc1dQ_3_3">13,634,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_4Osnvwn3K0Sw-yvN319eNw_3_6">9,607,158</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" scale="0" id="Tc_wVejGrDABECAg58ElvpY7Q_4_3">4,390,635</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" scale="0" id="Tc_T0AMKxOpbkO5cjYnW7ZGJw_4_6">4,245,472</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc_aR-MexVzvEWyY4vLZDyRzA_5_3">1,137,406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" id="Tc___Ihqa_RUkCm9Y1xgeX_pg_5_6">1,334,494</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" scale="0" id="Tc_tFQ-Szw_80ukldp5xVGdOQ_6_3">12,802,738</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" scale="0" id="Tc_VxX6EIHGHkaASTqNqNwuWg_6_6">10,793,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_T32wF8siQkuDEAUMhtSrPA_7_3">5,198,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" id="Tc_eJqIzegR2kKBeP30joI_fQ_7_6">4,132,475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_hfEp0hU0nUyosTgyGNaI3w_8_3">76,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="0" id="Tc_x2pqIH2JlEqHWHiGV6sNgA_8_6">14,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_GuWQIwUeykiJVQF1B-ZkKg_9_3">37,240,555</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_uv8-P_KpJkadVlKcnGGvsw_9_6">30,127,594</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_NzkmX4ts6UeRKUEzYxO5Ow_10_3">37,240,555</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_64wtvH8dYE-FcU0qzBlGfA_10_6">30,127,594</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_9G55xtyVaE6_Z0o34knp1g_11_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww" decimals="0" format="ixt:fixed-zero" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_gOIrwivLa0Sw-lBrVR0YuA_11_6">&#8212;</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1b7gLnM7l0uyFch569QwTQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_eG7_KkVExUiOIdzSZ-2C6Q">54.1</ix:nonFraction> million which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_q2MkFPGZKUeQUuTkMa5JVg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_6jnfkjjGVkiU1Zd1vNeZrA">2.8</ix:nonFraction> million will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hoAfWhIToE-9kc4wkiIxvA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="6" id="Narr_af6yqCjhI06JRgQWoJICRw">56.6</ix:nonFraction> million which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2024 and 2023 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company recorded a net change in valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_yFYaebNRkEGfsNgW7hspKw">7.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_fMmYO5WFuU-7b00LQWGKLg">11.7</ix:nonFraction> million in the&#160;years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had federal research and development tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_j7VLWFmUpEe9bDHG0DciDQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="Narr_zcVe1syDXkOg2HFsfyUHjg">5.2</ix:nonFraction> million available to reduce future tax liabilities, which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of </p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_10nsTLkOnEap71jrw-xqVA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax&#160;years from 2021 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the tax authorities may adjust the tax attributes upon their examination of the future period in which the attribute was utilized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="0" id="Narr_d9W-X9bXlkWJ8I16kSK9_A">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="0" id="Narr_2bUfs75wZE-jm6cm4C10gw">no</ix:nonFraction> amounts have been recognized in the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_fOusTvtxKkyURMPwViHpkQ" format="ixt-sec:duryear" name="anvs:ResearchAndDevelopmentAmortizationPeriodTerm" id="Narr_0edVWphNEkyOXvdh9rjDhQ">5</ix:nonNumeric>-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a <ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_KsBP2tMOlkaHzf39vA3zUA" format="ixt-sec:duryear" name="anvs:ResearchAndDevelopmentAmortizationPeriodTerm" id="Narr_pR19sC_3skujyjo_6eHVWg">15</ix:nonNumeric>-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="font-weight:normal;"> </span><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f89d7bd1_d6e0_4478_a3aa_712dfaa85857"></a><a id="Tc_H8TZ4Gwfu0mYAEkGJrW3bw_1_1"></a><a id="Tc_8bMAoq0hOEy_S0Mhxp4hzw_2_1"></a><a id="Tc_sYbqZP3U6kiHUwUMwyuSgg_2_4"></a><a id="Tc_5wOWcIztpE2uXWk0E9rjzg_3_0"></a><a id="Tc_IQYMf6EqwUKLmJlqQ4dHmg_3_1"></a><a id="Tc_OFv10El6NEmTsnXtbDi4xA_3_4"></a><a id="Tc_Y0z0S3r3j0SNQ8OW4b1msw_4_0"></a><a id="Tc_o2yCDtsEBkiOFRY_qxu8kw_5_0"></a><a id="Tc_99Q6YExXVk2uyZx_XXtzZg_6_0"></a><a id="Tc_EEXz736HuECkH4R3-iYAIQ_7_0"></a><a id="Tc_97sNFTsXlEqnjFgJ_L1BxQ_8_0"></a><a id="Tc_uncxn1sqGEmw4dS-0khcYw_9_0"></a><a id="Tc_KMhuMj_PBk2P65x_e7ugBg_10_0"></a><a id="Tc_qsK96mcZC0iQuKIpfNQIjw_10_1"></a><a id="Tc_9O_u5ZmVZEO4MtOuC8qFKw_10_4"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_ajk1E3lrMkidXIEFIWhQkg" continuedAt="Tb_ajk1E3lrMkidXIEFIWhQkg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">(11) Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2008. The Company&#8217;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. This presentation is consistent with how the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on net loss as reported on the statements of operations. The CODM uses net loss to monitor actual operating results, assess cash runway, and benchmark against the Company&#8217;s competitors. The measure of segment assets is reported on the balance sheets as total assets. The Company&#8217;s assets are held in the United States.</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Tb_s0tpbpm24k6C_IfEbTl_SQ" continuedAt="Tb_s0tpbpm24k6C_IfEbTl_SQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">When evaluating the Company&#8217;s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company&#8217;s segment information as reviewed by the CODM:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to clinical-stage product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="anvs:ProgramExpensesRelatedToClinicalStageProductCandidates" scale="0" id="Tc_yK8K5UyBRE-mVnWr68hU-A_3_2">16,723,518</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="anvs:ProgramExpensesRelatedToClinicalStageProductCandidates" scale="0" id="Tc_Q4nF-B81uEG5nQ8x0C52rw_3_5">35,104,702</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to preclinical and discovery programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="anvs:ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" scale="0" id="Tc_L4XD--dj-0GAoNRReuCv8A_4_2">568,214</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="anvs:ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" scale="0" id="Tc_Mn7imuau9UmQv8acOOWItw_4_5">583,154</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_L0ELPV-sQES9bHhQeBm6rA_5_2">6,525,586</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="0" id="Tc_nsTJS1ImpUuzMedHV_rFog_5_5">6,444,920</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="anvs:GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" scale="0" id="Tc_1xZfmNlaDku3qoefyCFO2g_6_2">1,687,276</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="anvs:GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" scale="0" id="Tc_SvymXOfdaUWmCSjFhLfzIQ_6_5">2,152,485</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items&#185;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="0" id="Tc_nyVEovh_506zN88fkzKUVw_7_2">1,190,333</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="0" id="Tc_mmJDkhLQlkOWew1nhA076g_7_5">749,750</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_SxdVjTWrgkePz8aZd9sMeQ_8_2">331,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Tc_yVSGHuxhdE-a2A8AK-YxGg_8_5">667,898</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-cash income (expense) items&#178;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="0" id="Tc_xn5WtOmQR0KkES8eRMd8rQ_9_2">1,772,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" sign="-" scale="0" id="Tc_qvvyCUEy30Clijy4hPRorQ_9_5">11,837,199</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_xVx_RPdRPE219MLxapWcqA_10_2">24,590,374</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_aNvY_Dqt2k-pf0viuRRrPw_10_5">56,204,313</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_ajk1E3lrMkidXIEFIWhQkg_cont1"><ix:continuation id="Tb_s0tpbpm24k6C_IfEbTl_SQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">&#185; Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">&#178; Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.</span><span style="font-weight:normal;background:#ffffff;"> </span></p></ix:continuation></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_wKhI6fmBkUO4edwP7kWh7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2024, the Company sold <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="Duration_1_1_2025_To_2_1_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_a5jUEWlNeEGGlp00_fXhKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="Narr_HQbYw2qHhE2FIWPcwX_SKQ">0.1</ix:nonFraction> million shares of its common stock under its ATM with OpCo, which the Company entered into in December 2024. The Company received net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_1_1_2025_To_2_1_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_a5jUEWlNeEGGlp00_fXhKg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_C8AYIII7UEG2XsuAGoeU2g">0.5</ix:nonFraction> million after deducting commissions and fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg" decimals="-5" format="ixt:num-dot-decimal" name="anvs:SaleOfStockNumberOfUnitsAuthorizedForIssuance" scale="6" id="Narr_PG3at6Iqe0Wcqk0v__Z3-Q">5.3</ix:nonFraction> million units of the Company. Each unit sold consisted of <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg" decimals="INF" format="ixt-sec:numwordsen" name="anvs:NumberOfSharesIncludedInEachUnit" scale="0" id="Narr_eTfpqZGp2E6CAQwnHKiUug">one</ix:nonFraction> share of common stock and <ix:nonFraction unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q" contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg" decimals="INF" format="ixt-sec:numwordsen" name="anvs:NumberOfWarrantsIncludedInEachUnit" scale="0" id="Narr__qXlNUwImUacWSVBH5jBmw">one</ix:nonFraction> warrant to purchase one share of common stock (the &#8220;ThinkEquity Warrants&#8221;), at a per unit price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="Narr_8zEIN5U6J0G1eKtsZvGGqg">4.00</ix:nonFraction> (the &#8220;Offering&#8221;). Aggregate gross proceeds from the Offering were $<ix:nonFraction unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A" contextRef="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_dh8V_0GTe0Kam8Xht2ZFqA" decimals="-5" format="ixt:num-dot-decimal" name="anvs:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_yN8B3h0RpkWMUKxjVBYYvw">21.0</ix:nonFraction> million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw" contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_M41DdH_XvE6ymphnzTr4oA">5.00</ix:nonFraction> per share, are immediately exercisable and expire <ix:nonNumeric contextRef="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_dh8V_0GTe0Kam8Xht2ZFqA" format="ixt-sec:durwordsen" name="anvs:WarrantTerm" id="Narr_BqSLh64bvUiWUhAYHOCl_A">five years</ix:nonNumeric> from the date of issuance. The shares of Common Stock and Warrants were issued separately. The Company has agreed to suspend sales of its Common Stock under the OpCo ATM Facility for a period of <ix:nonNumeric contextRef="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ks4SJs0ZpUGHrUcFBn_hhg" format="ixt-sec:durwordsen" name="anvs:SaleOfStockAtMarketOfferingTemporarySuspensionTerm" id="Narr_JgEfJYf8jkSYi7NQ3biTVA">six months</ix:nonNumeric> after the closing of the Offering.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2e467744_5e6e_4477_972d_bb30d190cd78"></a><a id="SIGNATURES_225846"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the requirements Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ANNOVIS BIO,&#160;INC.</p></td></tr><tr><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:top;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:&#160;</p></td><td colspan="2" style="vertical-align:top;width:47.1%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ MARIA MACCECCHINI</p></td></tr><tr><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;</p></td><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:49.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:41.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 21, 2025</p></td></tr></table><a id="Power_of_Attorney"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:18pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Signature</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:middle;width:18.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MARIA MACCECCHINI</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;white-space:nowrap;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2025</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Maria Maccecchini</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(principal executive officer; interim principal financial and accounting officer)</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MICHAEL HOFFMAN</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chairman of the Board and Director</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2025</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Michael Hoffman</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ CLAUDINE BRUCK</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2025</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Claudine Bruck</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ REID MCCARTHY</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2025</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Reid McCarthy</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:46.63%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ MARK WHITE</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;white-space:nowrap;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 21, 2025</p></td></tr><tr><td style="vertical-align:top;width:46.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mark White</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:1.86%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:18.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>anvs-20241231xex4d5.htm
<DESCRIPTION>EX-4.5
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 07:32:02 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Exhibit&#160;4.5</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (the &#8220;Amended Certificate&#8221;), our amended and restated bylaws (the &#8220;Amended Bylaws&#8221;) and applicable provisions of Delaware corporate law. You should read our Amended Certificate and Amended Bylaws, which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our authorized capital stock consists of 70,000,000 shares of common stock, par value $0.0001 per share, and 2,000,000 shares of preferred stock, par value $0.0001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Voting</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The holders of our common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. There is no cumulative voting. An election of directors by our stockholders shall be determined by a plurality of the votes cast by stockholders entitled to vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Dividends</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Subject to the rights of holders of all classes of our stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive proportionately any dividends when and as declared by our board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Liquidation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to receive on a pro&#160;rata basis our net assets available for distribution to stockholders after the payment of all debts and other liabilities, subject to the rights of holders of all classes of our stock outstanding having rights that are senior to or equivalent to holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Other</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Holders of common stock have no preemptive, subscription, redemption or conversion rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All of our outstanding shares of common stock are fully paid and nonassessable, and any shares of common stock to be issued upon an offering pursuant to this prospectus and the related prospectus supplement will be fully paid and nonassessable upon issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Preferred Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will fix the designations, powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereon, in the certificate of designation relating to that series. The applicable prospectus supplement will contain the terms of and other information relating to the preferred stock which will include, as applicable:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the title and stated value;</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of shares we are offering;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the liquidation preference per share;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the purchase price; the dividend rate, period and payment date and method of calculation for dividends;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the procedures for any auction and remarketing, if any;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the provisions for a sinking fund, if any;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any listing of the preferred stock on any securities exchange or market;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">voting rights, if any, of the preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preemptive rights, if any;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on transfer, sale or other assignment, if any;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether interests in the preferred stock will be represented by depositary shares;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a discussion of any material United States federal income tax considerations applicable to the preferred stock;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our board of directors may authorize the issuance of preferred stock with voting, conversion or other rights that could adversely affect the voting power or other rights of the holders of our common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-style:italic;font-weight:bold;">Authorized but Unissued Shares</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Stockholder Meetings</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Requirements for Advance Notification of Stockholder Nominations and Proposals</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder&#8217;s notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Delaware Anti-Takeover Statute</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are subject to Section&#160;203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three&#160;years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Choice of Forum</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Court of Chancery of the State of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent permitted by law, for:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any derivative action or proceeding brought on our behalf;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any action asserting a breach of fiduciary duty;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; or</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">or any action asserting a claim against us that is governed by the internal affairs doctrine.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our amended and restated bylaws will not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find either choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-style:italic;font-weight:bold;">Advance Notice Requirements</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board ofdirectors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder&#8217;s intention to</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">bring that business before the meeting. Although our bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Warrants to Purchase Common Stock</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants to purchase an aggregate of 1,250,000 shares of common stock (&#8220;Canaccord Warrants&#8221;). The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company&#8217;s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days&#8217; prior written notice, at any time after:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson&#8217;s Disease; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which (a) the closing price of the Company&#8217;s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (&#8220;ADTV&#8221;) of the Company&#8217;s common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days.</font></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson&#8217;s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="white-space:pre-wrap;"> On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the &#8220;ThinkEquity Warrants&#8221;), at a per unit price of $4.00 (the &#8220;Offering&#8221;). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Transfer Agent and Registrar</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">National Securities Exchange Listing</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our common stock is listed on the New York Stock Exchange under the symbol &#8220;ANVS.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>3
<FILENAME>anvs-20241231xex19d1.htm
<DESCRIPTION>EX-19.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 07:32:02 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 19.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ANNOVIS BIO, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INSIDER TRADING POLICY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">(Adopted July 31, 2019)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This Insider Trading Policy is designed to help persons understand the federal securities laws relating to insider trading and describes certain prohibited transactions in securities of Annovis Bio, Inc. (the &#8220;Company&#8221;) and, in certain cases, the securities of other companies. It also provides general guidelines with respect to maintaining the confidentiality of information that has not yet been publicly disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This policy is intended to promote compliance with federal securities laws. However, each person is ultimately responsible for ensuring that he or she does not violate state or federal securities laws or this policy. Violation of the securities laws can result in significant civil and criminal penalties (including fines and jail) and other liabilities. In addition, persons who violate this Insider Trading Policy will be subject to appropriate disciplinary action by the Company, up to and including dismissal.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This Policy contains four Sections:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"><i style="font-size:11pt;font-style:italic;">Section I. General.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This section contains the general Insider Trading Policy of the Company, applicable to every director, officer, employee and associate (including consultants) of the Company (each a &#8220;Covered Person&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-size:11pt;font-style:italic;">Section II. Additional Trading Restrictions for Insiders.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Directors, officers and other personnel whom the Company designates as regularly having access to or generate material, non-public information (the &#8220;Insiders&#8221;) are subject to additional restrictions on the purchase and sale of the Company&#8217;s securities, which are set forth in Section II.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><i style="font-size:11pt;font-style:italic;">Section III. Certification.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Please read this Insider Trading Policy carefully and sign and return the attached certification.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Please contact the Chief Financial Officer with any questions about this Insider Trading Policy, who will coordinate with the Company&#8217;s attorneys with respect to questions that arise in connection with this policy. Please keep a copy of this policy for future reference.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SECTION I</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">GENERAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">INSIDER TRADING</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The insider trading laws prohibit persons from buying or selling securities while in possession or aware of material, non-public information (as defined below) or passing on such information (&#8220;tipping&#8221;) to others who buy or sell securities. These laws apply to trading in the Company&#8217;s securities while in possession or aware of material, undisclosed information and also to trading in the securities of other companies about which the person has acquired information in the course of his or her employment or association with the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">This policy applies to all types of securities transactions, including purchases and sales of stocks, bonds, debentures, options, puts, calls, and other securities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">RESTRICTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-size:11pt;font-weight:bold;">Insider Trading Restrictions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">If any Covered Person is in possession or aware of material, non-public information relating to the Company or any of its subsidiaries, or information that might affect the market value of securities of any other company that is obtained in the course of employment by, service as a director of, or other association with, the Company or any of its subsidiaries, neither that Covered Person, any related person (e.g., spouse, parent, child or sibling) nor any person living in his or her household may buy or sell the Company&#8217;s securities or the securities of such other company (including options or other derivative securities related to such securities), or engage in any other actions that would take advantage of, or pass on to others, that information. This prohibition continues whenever and for as long as the Covered Person knows material, non-public information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-size:11pt;font-weight:bold;">Additional Prohibited Transactions</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The Company considers it improper and inappropriate for any Company personnel to engage in short-term or speculative transactions involving the Company&#8217;s securities. It is also the Company&#8217;s policy that Covered Persons may not engage in any of the following activities with respect to the Company&#8217;s securities at any time: (i) &#8220;short&#8221; sales (sales of securities which are not owned by the seller at the time of the sale), (ii) sales &#8220;against the box&#8221; (sales of securities which are owned at the time of sale but are not delivered promptly), and (iii) buying or selling puts or calls or other derivative instruments based on the Company&#8217;s securities. In addition, it is generally illegal for any director or executive officer of the Company to engage in short sales or sales against the box.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"><b style="font-size:11pt;font-weight:bold;">Transactions By Family Members</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The same restrictions that apply to a Covered Person also apply to his or her family members or to other persons living in his or her household. Each Covered Person is expected to be responsible for his or her related family and household member&#8217;s compliance with the terms of this policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">DEFINITIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;Material&#8221; information is any information for which there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold the securities of a company. In other words, any information, which reasonably could be expected to affect the price of the stock to which it </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">relates is &#8220;material&#8221; information. This can be positive or negative information. It is important to remember that materiality will always be judged with the benefit of hindsight. When in doubt, a Covered Person should assume that the information is material, and treat it accordingly.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">While it is impossible to provide a complete list, some examples of information that could be &#8220;material&#8221; are:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">financial results, reports or projections;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">early indications of clinical trial results;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">known but unannounced clinical trial results;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">known but unannounced analyses of clinical trial results;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">news of a pending or proposed merger, acquisition, divestiture or tender offer;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">securities offerings, changes in dividend policy or declarations of stock splits;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">changes in dividend policy;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">calls, redemptions or purchases of a company&#8217;s own securities;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">significant changes in the Company&#8217;s operations;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">changes in top management;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">initiation or settlement of significant litigation or governmental investigation or other governmental action;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">significant developments related to intellectual property;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">industry information;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">substantial changes in accounting methods; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:11pt;">changes in debt ratings or problems relating to debt service or liquidity.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">&#8220;Non-public&#8221; information is any information which has not been disclosed generally to the marketplace or the investing public. Information becomes public when it has been released through appropriate channels, such as a press release or governmental filing, and enough time has passed after such a release for the investing public to receive and evaluate the information. The appropriate interval following public disclosure will depend on the nature and complexity of the information. As a general rule it would be appropriate to refrain from trading for at least three business days after the initial release of the information. At that point, and not before, the information is considered &#8220;public.&#8221; All information that a Covered Person learns about the Company (or any other company in connection with his or her employment or service as a director) is potentially &#8220;insider&#8221; information until publicly disclosed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">&#8220;Tipping&#8221; is the passing along of material, non-public information to others. Penalties for tipping can apply whether or not the Covered Person derives benefit from another&#8217;s actions. Recommending or hinting that </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">others buy or sell securities when the Covered Person possesses or is aware of material non-public information, even without telling them why, can still be unlawful.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SAFEGUARDING CONFIDENTIAL INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Treat all sensitive, non-public information about the Company (or any other company) as confidential and proprietary to that company. Do not disclose such information to others (such as family members, relatives, business or social acquaintances) who do not have a legitimate need for such information in connection with the Company&#8217;s business. Treat all such information carefully and avoid inadvertent or indirect disclosure of it. Even within the Company, confidential information should be distributed to or discussed with others only on a need-to-know basis, and those people should be told that the information is confidential. Be careful that conversations are not overheard on elevators, airplanes or other public places; do not leave confidential documents on conference tables, desks or otherwise unguarded; and take whatever steps are reasonably necessary to keep confidential information from being disclosed. This prohibition applies also to inquiries about the Company that may be made by the financial press, investment analysts or others in the financial community. Such inquiries should be referred to the Chief Financial Officer or another authorized representative of the Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">STOCK OPTIONS, WARRANTS, ETC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The exercise of stock options in accordance with their terms, standing alone, is not considered &#8220;insider trading&#8221; under the Company&#8217;s policy, but please note that &#8220;exercise and sell&#8221; or &#8220;cashless exercise&#8221; transactions (i.e., the concurrent sale of stock acquired upon the exercise of an option to cover the option price, withholding for taxes and/or broker&#8217;s commission) or any similar transaction involving a sale of the Company&#8217;s securities into the market or otherwise involving a third party and the Company would be covered by this policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Please note that, in all instances, this policy applies to sales of stock acquired upon the exercise of stock options.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SECTION II</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">ADDITIONAL TRADING RESTRICTIONS FOR INSIDERS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The general Insider Trading Policy in Section I applies to all Covered Persons. Insiders are subject to certain additional restrictions on transactions in the Company&#8217;s securities to reduce the risk of securities law violations or the appearance of impropriety with respect to such transactions. This Section II outlines those procedures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">PRE-CLEARANCE OF TRADES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Insiders must pre-clear with the Chief Financial Officer at least one day in advance of each proposed purchase, sale or other transfer of Company securities, other than purchases or sales pursuant to a plan known as a &#8220;Rule 10b5-1 Plan,&#8221; as to which an Insider should consult a financial advisor or attorney if the Insider is interested (see the section below regarding Rule 10b5-1 Plans). Insiders requiring pre-clearance will be notified by the Company. The purpose of this additional pre-clearance requirement is to allow an Insider to confirm that the status of corporate disclosure does not preclude lawful transactions involving the Company&#8217;s securities. Unless such confirmation is received, the transaction should not be undertaken. &#160;After receiving clearance to engage in a transaction, the Insider should either complete it (including settlement) within one week or submit a new request. Any advice will relate solely to the restraints imposed by this policy and will not constitute advice regarding the investment aspects of any transaction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">Even if pre-clearance is received, the Insider and any family member sharing the household with the Insider may not trade in the Company&#8217;s securities if the Insider is in possession of material, non-public information. The procedures set forth herein are in addition to the general provisions included in Section I and are not a substitute for those provisions. These restrictions are also in addition to the legal requirements that may otherwise apply to an Insiders&#8217; transactions under Section 16 of the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;) and Rule 144 under the Securities Act of 1933.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">EXCEPTIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">10b5-1 Plans</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">SEC Rule 10b5-1 under the Exchange Act provides a defense from insider trading liability if trades occur pursuant to a pre-arranged &#8220;trading plan&#8221; that meets specified conditions (a &#8220;trading plan&#8221;). A trading plan must be a binding contract, an instruction or a written plan that specifies the amount, price and date on which securities are to be purchased or sold, and it must be established at a time when the Insider does not possess material non-public information. If such a plan exists, the Insider can claim a defense to insider trading liability if the transactions under the trading plan occur at a time when the Insider has subsequently learned material non-public information. Arrangements under the rule may specify amount, price and date through a formula or may specify trading parameters that another person has discretion to administer, but the Insider must not exercise any subsequent discretion affecting the transactions, and if the Insider&#8217;s broker or any other person exercises discretion in implementing the trades, the Insider must not influence the broker&#8217;s or other person&#8217;s actions and the broker or other person must not possess any material non-public information at the time of the trades. Trading plans can be established for a single trade or a series of trades.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">It is important to document promptly the details of a trading plan. Please note that, in addition to the requirements of a trading plan described above, there are a number of additional procedural conditions that must be satisfied before a person can rely on a trading plan.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">SECTION III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:11pt;">The undersigned hereby certifies that he/she has read and understands, and agrees to comply with, the Company&#8217;s Insider Trading Policy.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:40.38%;margin:0pt;padding:1.39pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Date: ______________________</font></p></td><td style="vertical-align:top;width:59.61%;margin:0pt;padding:1.39pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Signature:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">_____________________________________________</font></p></td></tr><tr><td style="vertical-align:top;width:40.38%;margin:0pt;padding:1.39pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.61%;margin:0pt;padding:1.39pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;">Name: ____________________________________________</font></p></td></tr><tr><td style="vertical-align:top;width:40.38%;margin:0pt;padding:1.39pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:59.61%;margin:0pt;padding:1.39pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>anvs-20241231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 07:32:02 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="color:#333333;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#333333;">We consent to the incorporation by reference in the following Registration Statements:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#333333;">(1)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#333333;">Registration Statement (Form S-3 No. 333-276814) of Annovis Bio, Inc.,</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#333333;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="color:#333333;">Registration Statement (Form S-8 No. 333-236457) of Annovis Bio, Inc. pertaining to the 2018 and 2019 Equity Incentive Plans, and</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;"><font style="color:#333333;">(3) &#160; Registration Statement (Form S-8 No. 333-280417) of Annovis Bio, Inc. pertaining to the Amended and Restated 2019 Equity Incentive Plan;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#333333;">of our report dated March 21, 2025, with respect to the financial statements of Annovis Bio, Inc., included in this Annual Report (Form 10-K) of Annovis Bio, Inc. for the year ended December 31, 2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#333333;">/s/ Ernst &amp; Young LLP</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="color:#333333;">Philadelphia, Pennsylvania</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="color:#333333;">March 21, 2025</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>anvs-20241231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 07:32:03 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">INTERIM PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">I, Maria Maccecchini, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">I have reviewed this Annual Report on Form 10-K of Annovis Bio, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#39;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#39;s internal control over financial reporting that occurred during the registrant&#39;s most recent fiscal quarter (the registrant&#39;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#39;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant&#39;s auditors and the audit committee of the registrant&#39;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#39;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">(b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:11pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#39;s internal control over financial reporting.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 21, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Maria Maccecchini</p></td></tr><tr><td style="vertical-align:bottom;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td></tr><tr><td style="vertical-align:bottom;width:50.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:47.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>anvs-20241231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.128.0--><!--Created on: 3/21/2025 07:32:13 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Annual Report of Annovis Bio, Inc. (the &#8220;Company&#8221;) on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:54pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.</p></td></tr></table><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 21, 2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Maria Maccecchini</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maria Maccecchini</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:51.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:45.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>anvs-20241231x10k003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %/ E0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA<J\@5AV-)M+<:3EHD6J*I_VK;?\]5H_M6V_YZK4\\>Y?LY]F7**I_VK;?\
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M2;-)# =\AN'$K#?\PRRX#<8Y^E=--QG)13U/SIX#+L91Y*22LKW32E;SO?\
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M-C!SDD>E=II,\EWI=G/,/WLD2NW'<BL,XC452,IM:I'B5>3V<52ORIO?N_\
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M@@C';%2?'?XM)\#OA=JWB[^PK_Q$UD$BAT[38\L\CL$C#$#Y$W%06P>H !)
MKK_#.L+XD\.:3JR1/ NH6D-T(I5*M'YB!MI!P01G&#Z5R8S,,3BW[23M&^B1
MOA<%A\->FE>5M6S\]/B;X9M/A9\6M?\ #5A=RW&GVP1XGN&!=5>-) K'^(KO
M(W=2 "><UQ7B6]CN].E4R+E1O!SR/>O39OB9HVF?'SXG:IK!,R2:MLMML.\X
MAE9, X.WA%YQ6?XX^-^B-INGPZ5:*2^HI?W,TUNO^C!9(GX4I^\DPKJ7S@@M
M\OS<?H6&G4]E3YU=V5W\CX>O&'M9\NBN]/F?2/[#_B277O@F+69BW]E:C/:Q
MD]!&P290/8>:17T#7AO['FEI#\,]8UJ%"EEK_B"^U&S!39FVWB*,A>P(CSBO
M=*_-,?;ZU4Y=KL_0L"W]6I\W8;13J*X#NN2Z>/\ B86W_75?YUH>*1G5?^ ?
MU-4M/_Y"%M_UU7^=7_%'_(3_ . _U-=,?X$O5'')_P"T1]&8U%.HKF.RXVBG
M44!<;5+6M;T_PUI5SJ>JWL.GZ=;+OFN;A]J(/\3T ')/ K0 +$ <DU\1_%7X
MCS?&[XKS:9;W##P?H%R8+>*-L+=3J2KS-ZG(95]%&1R]>E@,%+&U>1.R6K9Y
M^-QD<)3YGJWL>G?$#XPP^.]:\/W&AZ9+<:?HWG:BJZ@FU;F0%4B)0$$+NR<$
M@\<@5Q6K?M0_%:UOGD&G:-<PALF+[&<G\IL_SI;_ %C3=.M-7-K<6\GV6.VL
MS%;.&*;5=V! /R_/(0<]UKSB75K][)=6GT;4(-&D?:FIM;R?9R2<#]YMV\GC
M.:^WPV7X:4+.*:OI<\;.,?BZ4Z.';<>2$=+6UFN=Z?\ ;UODCZ!^%W[8&C>*
M]2AT?Q58#PMJ<K"..Y\TM9NY. K%@&B)/ W94GC=GBOH4C!P:_-[Q9IT&KV;
MN%4W*J=K8!#C'*GU!%>N?![]JN'P?\/9;3Q9K=G#+H\+VVGPZ@["XU-WV"UA
MCP"TC(PD1L#.TQD\Y)\/-,HC12JX?;J@R[-95&Z=?Y,^D_C-::3??"+QI;Z_
M?W&EZ%+I%RE_=VCA)4@,9W[&((#$94<'[V!S67^SGX(D^'/P+\#^'YOMBW%I
MI-OYT5].TLD,C(&>/+<A58D!>B@8' KGO"UCJ_[0(TKQ'XFB33?!%G.ES8>&
MT^:34+F,@I<7S<KL5@&2W0LH(#.S$!1[222<GDU\U.\(^SZWU/>IOVL_:I:6
MLAM%.HKG.NXVBG44!<;13J* N-HIU% 7)M-'_$QMO^N@KTN/_5K]!7F^F_\
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M8[<'I6#;ZZUEXUT.:***><7MN46X021%O,3 9""&7(&0>HXK)EU554*#@ 8
MKIOV>?!\_P 5OV@O".CQ1&6UAO4O[PXR$MX&$KD_7:J?605M5453;ELC.G=S
M5C]&9/V4/ -C=7=YH%OJ'@_6))WFAU;PW>-97%L6.2B[!LDCSDA)ED7DC&,
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ME1^5.HH"XW\JXWXH?"G0/BSX?FTW6[19',9BBNH\)/&I979%DP617**&VX)
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M8%+10;"8%&!2T4 )@48%+10 F!398(KB)XIHTEBD4H\<@RK*1@@@]01VI]%
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M .9XN,P/MY>T@]?S/C_XFZ9/X1N/#/BNQ?8UG,D4TO[B.,2;E*.[$B21F<(
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M%%%>J>>%%%% !1110 4444 %12]14M12]10-;C****#0**** "BBB@ HHHH
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MIU% #<48IU% #<48IU% #<48IU% #<48IU% #<48IU% #<48IU% #<48IU%
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K "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>anvs-20241231x10k004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %? ^<# 2(  A$! Q$!_\0
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M&[M)X[FUG02131,&1U(R"".H-6X245)K1D\R;M?4GHHHJ"@HHHH **3- .:
M%HHHH **** "BBB@ HHHH **** "BBLWQ!XETCPGIKZCK>JV6C6"$*UUJ%PD
M$2D] 7<@#/UII.3LA-I:LTJ*@LKVWU*TANK2>*ZM9D#Q30N'1U/(*L."#ZBI
MZ6PPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **3.*,T +1110 4
M444 %%%% !112$XH 6BDS2T %%%% !163XC\7:%X/M([K7M:T_1+:1Q$DVHW
M4=NC.>BAG(!/M6I'(DT:R1NKHPRK*<@CU!JN5I7MH*ZO8=1114C"BBB@ HKE
M]>^)_A/POXGTGPYJ_B'3M.US5<_8K"YN%26?M\JGU/ ]3P,UU%6X2BDVK7V)
M4D[I/8****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&V&B5XUW$'L<<9I4\)/$X>A"$W[\I))[+;7_ #"5>-&K4E*/PI._5GK/C?\
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M$?CE\3X]&\$_#B[N_#<,#2S^*9M.C@A@F&"B@$=#SSG=G^''-?4-0V=E;Z?
M(;:".WB7I'$@11^ XJ>N#$U:=6=Z4>5+N[OUO_DCJI0G"-IN[]+!1117(;!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 51UO1[7Q#H][IE]$)K.[A:":-APRL,$?K5ZB
MFFT[H-]#\^-!U;QW_P $]/%NKZ=?^'K[Q=\(=1N&N+>^L%W269)[]E('!5L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTKH_%=[)\./B_<^+M3TS4M1T+4M*BTU;[2[*2]DT^2.5G*O'$K2".0,/F4$
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M3D#!SZ&M/3_$EOXD\&>+M+T_Q#XR\4WLNE2E(=>T&6S"G:1A&-K"&8D],DT
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M!;\;_!7Q$EI?^+;MH?%7B2;6M+U2_P!*TV#R()[2R)"P0I([%I!N:0%V^9E
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MP2/.LFQ29-Y 4GJ,5JZI\1/BO\,M/T3Q5XLN?#^L>']0GAAN]-T^U>&:R$I
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M:!X+:+4C;1>'M9TN82W, ; 9+DL%+,.F.*Z&W^(7Q'^*WBOQ-!X&O=$T#1=
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M]L]JA'C/3I;O1H("]RNJJS031XVC R=W-5?B5HEUXB\)S6-C$)YWDC(1F"Y
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M?;4A^R2-'L82*W) SGBH+GX-:_;-\--/T_4IM.30[*>"\U:R,9>%V4?=5_O
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M@TR*6-8]1A*C<&?EHR1E1TZ\UWJE@G-I/1>;[K]/D>=[;,%34K:OR5]ORO\
M,]-\0_&/1M'.E0Z?:W_B74=4MQ=VEAI$/F2O"1Q(<D!5^IJ&R^-%CJVA7=[I
MV@:Y>W]C.MO>:-';*MY;,03ED9@-O'4&N>E\(:_X,\3Z1XG\,>'TU&U.CQZ5
M=:%)=)%/ J8*F.0Y5B.A]>M;/PV\'ZY%XB\4^+?$-K#IFI:TD<$6F02B7R(H
MU(7>XX+$]<5A*EAHPYM_GK>^UO0Z56Q4JG+M\M+6WOZ]"KI7[0%CJOAK4?$
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MX?$O4B?PL]!7I3J:O2G5]@>2M@HHHH&%%%% !1110 4444 %>3>+?^1AO/\
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M<LE%+I_P2HQEI=GHM%%%<1N%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %6]*_Y"=K_P!=!_.JE6]*_P"0G:_]=!_.KA\2]2)_"ST%>E.I
MJ]*=7V!Y*V"BBB@84444 %%%% !1110 5Y-XM_Y&&\_WA_*O6:\F\6?\C#>?
M[P_E7=@_XAYV.^!>ID5Y)^TE\4M9^%'A/0M2T1;5KB\URTT^4747F+Y4KX;
MR,''0UZW7F_QT^$,WQD\.:1I<.J1Z4UCJUMJ9EEA,H<1-NV8!&"?6O6J7<7R
M[GDTW'F7-L>;:9^U3)IW[5_B3X7>(DM[31%BB_LK41'LVSF/>T<KDX.X XZ=
M*YOPM^V%K/CWQ/\ %X:+:6L7A_PQHSWVC3SP,6NW0E3*22-T98'  '3K7;^,
M/V1-$^(?B3XAWOB34#<Z?XK:SDAAM(C'/8R0#&Y9"2"3[ <&I#^RQ;V.M^,9
M](U6#3=*UOPO%X;M; 6S-]D5 0)"V[Y\YZ8!SGFN?EJWU>AU7H?.QYEX-_:3
M^*&D0_##6_%FH>#?$6B>-;J*T_LW18)+?4;,R9PV"[!P,<\4NK_M"_%F35/B
MIJ>EZYX%LM"\$:@]NNFZS:R)<7D:KNPLHDP&/(SCK7K_ ,%/V4O /P<TO0I;
M?PUHUUXJTZW6.37UM")I7[NNYCM)]N:\]\2?L"^&O&,_C_4M6N[.?Q#K^I#4
M=,U9;1O,TTC&$8%L2*2!D8&14<E516I2G0;;:+EY^TAXT^)6J>!_"WPYT_2M
M&\1:]HJZ[?WVOI)-!I\'3:L:X+L2#C/;%1P?&SXK:9=^.O .K6_A^?XB:+I7
M]M:3J5A;R?8M2@'56B8[D?@]ZZOQK^SKKVLZAX7\6>'?&4/A;XBZ)8+I[ZE;
MZ:)+"]BQ@I);L>%XX /%:WPA^!-_X+\6:UXT\8^)SXT\;:M MK-?+9K:VUO;
M@Y$,,0SM7U)/-6HS<M62Y4E'1'%7O[4.I^*O 'PND\'1V1\7>-+I+9X;F,R1
MV8C/^E,R @_+@@9]17GVJ_M5>,&^*_C/PS+\2_A_X)M]'U);*SMO$&DW,MQ=
MJ5'S*T;8ZG'..M>I_!_]D73?A-\9_$?CF+5A?VMZ93I>E>0473?-8-+M)8@[
MCZ 5G+^S?\1_#?C_ ,8^(/"/Q#\.:59^([X7LEIJ7A<7TD9"A0!(S_R I6JM
M:C3HIE?Q7\3OBWK/Q[3X=^#M:\*6"PZ!%JDUYJVERS)*Y^]MV."%)Y&1P*[G
MX"?&#Q#XVUGQ5X0\:Z79:=XP\,3)'=2:6[-:74;C*2QAN5SW4US'C#]G?XA7
M_P 6H_B!X7^(^E>']9?2(M*NC<Z!]J63;]YT4N%7)Y [5W7P3^!\7PE;7-3U
M#7KSQ9XKUZ<7&J:W>HL9F(&%1(UX1!V%5!5%+4B;IN.ECB/VH?C[XK^&VKZ-
MH'P_TNTUOQ T$NK:E!<1F3R;"+!<@ C#-SC-;7Q)^+WB2+X,Z+\3/ 4-EJNE
M1QQ:AJ6G7,1:2:S('F>4P/RNG/KG%96K?L>Z#X_^)'B?QAX^U&ZUZYU(I#8V
MVFW5QIZ65JHQY3&.0>83U)/'M639_LBZU9?#J/X;Q>.EC\ _VNUW)9K:.;M[
M(G<+/S2^-N>IQR*'[3F?;H/]U9+[Q/"G[46LZ]\/O&OQ:N=.CMOAO8P8T.P,
M6V]O7& TDC[B%4L< 8]ZQ]:^+_QV^'?@.P^)WBB#P?>^$Y#%/?>'M.@F2\LK
M:0C:PG)VNR@@D8KMO#O[)NG>&X?&_AFVU-!\,O$T&/\ A&EA8/83D8,D$N[
M4X!VD=:YUOV4?'6OZ/I_@WQ7\6GUKX;V$B%=,ATA(+ZZC0YCBGN,G<HQS@<U
M#52W];CO2OI:WZ%#7OVS)O!O[1D/AG6+&-OA[>6%G,NL1PL'LI9P"AF;.-A)
MQT&*Z[X9_M%W&J_#SXE>+/$TUBEEX8U.ZM[=[5-BO"@_=@\G<S$@9'7-:LW[
M,VD:I\0_&&LZM+;7_AWQ#HEOHK:*;<J84BZ,'S@GICC(Q7G.@_L+-H7PME^'
M4?C(OX5N]>_M2^06K+<7%L/NVV\/\I]7'7TJK54[^HKTI*VVQTG[-?Q_\7>/
MIO$.B?$'2[;1?%%M;)J^GP6\)C2:PE4M&V"3DC@&NR_9B^*.L?&#X7)XAUU;
M5;]K^ZML6<1C39'*57@D\X'/-<E8?L<Z%X(^(F@>*_ 6J7GA^>S26UU&WU&[
MN-06^MG7'E@R2$I@X(QQQTJM\(?V>?BI\'TMM*TWXHZ'+X4COY;R337\-YF=
M))"[H)C)D'GKVIP]I&W,A3]E*[BSKOVD_$/Q&\%>"=0\4>"-5\/65GH]G)=7
MMMK-A)<R7&#P(RK +U[UY3XH^-'QD\$? '3/&^IZUX0O-1UV[T^*P6VTF5(K
M5)R0WG!G^8CCD'UKZ-^*?@I_B/\ #CQ'X72\6P?5K-[073QEUBW8^8J"">G3
M->=_$G]FX_$3X%>&OAS-K%O%'I4MDT]U);,Z7*0?>38&!&X9'4XS53C-MV8J
M<H**4EU,#X9_&KQU:?'.'X:>-KSPQXFDO=*.J6VK^%HWB6WP0#'.C,V"<\&L
MGP]^U5X@U3X^C39],M4^%FH:E/X?TW5TC/FR7\2@DE\XV,=P'N*V]!_9,C^&
MGBGQ;J/PWU+3/"VG^(M)^Q/82Z>TQM+@# FA<."%P22A[X-<U<?\$]/!D7P^
MM--TO4]1LO%]H8[F'7WO;AX5NU8,9OLOF;!DYX'//6HM525C2]%W)?$7[85W
M\/\ ]JS5O 7B6SAC\$*MK#'K$4+ V5Q*H*^>^<;&.1G QCZUAZE^UOXTM?@I
MK'BJ&VTMKJ+Q9+H8U,V<DEII]H&XN)DC)9\#TZUZ?;_LMVNL>-?'6L^+M0M/
M$%AXNTBTTR\L%M&C*O"N#*'+'DGYEXR#W-9'PU_9<\4?!GX37'A'P7\0HM-O
M/[6EU"*]NM(6ZBEA;@6\\;MR,=64CD4K5;O70%*C;ST,&Y^/GC'1/V>?'/CJ
MW\<^!/'MQID44FG7?AZUD1$)8!UN(7?(//'2F^%/V@?B'X5\=^ -*\<:GX.\
M3:9XQM9)XSX<BDAO-.*1>83*C.P*XXSQR#4R_L6ZAJ?A'XEQ:QXKTT^*/&\,
M,$]SI6C"RT^U6-@PVVZ-EF/.6)S7K'PL_9N^'OPDM[6;1?">D6NM+:+:W.IP
M6W[V?Y0'.6)*ANX!I*-1M= <J-FK'D/A[XM_'/XP^&=6\?>!H/"6D>$[>6<:
M9H^LV\TMYJ44)(9FE5@L1;:V*H>*?VJ_%_BW2O@S-X$?1?#L_CF2Z@NWU^W:
MYBLY81\PRK+QD,,]^*Z&/]E?QSX0MM6\-_#_ .*[^&? 6JS2RR:7<Z4MS=V0
ME),J6L^X;0V3U'&:N^*/V*_#&OV_PLT=9()O"G@QIS<:5J,+3-J8D')9U9=I
MW?,33M5'S4?(I> ?BS\5?B'>^._!-KJG@V#QEX4NX-WB*UM9KC2[N"1&8J(@
MVY9 0,\X'-6?V3?B3\6/C%IG_"4>*=6\+MX<6XNK$V&FZ9+#=&6*38'\PN5V
MG!XZ\BNU^ GP!B^ :>*=*T>^M9?"^I7S7NGV0M-ES9EAAHWE!_>J.-I(R!Q5
M_P#9Z^#DOP-^'[>&IM5CUAVO[F]^TQ0&$8ED+A=I)Z9QG-7"-33F9G.4.5J)
MZ;11174<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>F> ?^0"O_71J\SKTSP#_ ,@$?]=&K@QG\->IWX+^+\CI****\8]P*9+_
M *M_H:?3)?\ 5M]#2>S \U;J?K24YOO'ZFFU\<]SUUL%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5;T
MK_D)VO\ UT'\ZJ5;TK_D)VO_ %T'\ZN'Q+U(G\+/05Z4ZFKTIU?8'DK8****
M!A1110 4444 %%%% !7DWBW_ )&&\_WA_*O6:\F\6?\ (PWG^\/Y5W8/^(>=
MCO@7J9%%%%>T>*@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "O3/ /_ " 5_P"NC5YG7IG@'_D
MC_KHU<&,_AKU._!?Q7Z'24445XQ[@4R7_5O]#3Z9+_JW^AI/9@>:MU/UI*<W
M4_6FU\<]SUUL%%%%(845!?W+V=C<3QPM</%&SK$GWG(!(4>YZ5\@_L_?M/\
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M/&J_#,:S;W$U\EZIU**U,:*9R<$IG)VC Z\XKVW-&ZFZU1MNXU%+8^3?'7[
M>C^-_A]\.=+?6HK#Q5X/2& :[%:DK>0H^XQO'NSCT))P:Z;5?V,="^('Q-\3
M^,/'^J7FNS:@D5KIUMI=W<:<+*U1<&-C&X\S<>3GCVKZ,)S1NJOK%7N2J<5L
M?)=[^P@+[X=Z1X#N?%$%[X3TGQ(=8L[*ZM9'9;0YW6C-OR?]_P#2OH#X:_!;
MP+\'H;F+P7X5T[PXETP:<V<6'EQT#.26('IFNTW4;JF=:I45FRE%)W/(OA?\
M!IOAU;_$>-]:BO\ _A+=1GOD*6Y3[*)$*[3D_,1G.1BO/K?]C&6P^%O@K1=.
M\8OI'C7P=<S76E>)[2SRH,C%BDD+'YD.<$9KZ>W49]A1[:HM;B<$SS+X2^"/
MB/X=N]0OO'_Q$A\7S7**D-EIVDI8VEMM_B4<L6/?)Q4'QJ^"DWQ<UCP)>Q:O
M'I@\,ZPFJLDD!D-P ,; 01M/N<UZIFCI4\\N;GZCY5:QX+\8_P!DO0/CC\8=
M#\5^*FM=2T/3]-FL7T6>%\RNYRLJR*PVE?3%<G'^Q;>1_!ZW^%9\66J>#8]:
M^W2);6+07-Q9;MWV:216P6S_ ,M.N*^IB<T'FK5>I&R3T$X)NY\Y:9^Q=H/P
M_P#B=X<\9?#_ %.[T*:QCEM=1M=5N[G41>VSKCRU,DA\LC@CM[5S>M_L!Z1X
MH^ LG@/5=<1];@U&ZU'3O$%O:LK6QFD+&,INRRX.",\]:^L=U&XU7UBJM4Q>
MSB?/?BKX!_$B;PMHOA[PW\0M!@T6UTF+3+K2M?\ #*7]O(57:9DRVY6/H>*R
M] _8LL?#VA_##24U\7]EX2N[N[O$NK4[;_[0I5T10V(DY.!SQ7TQNHS4JO42
MT!01\UZ=^Q'X:\(VGAFU\)W\FFQZ5XE_X2"YDO$,TER,$+"",;0HX'H*V=)_
M9S\4^%+WXGZEX9\?1:'JWB[5TU2WN1I8N%M5"X,,B.V)%;N1BO>\T;J?MZO<
M.1'S-X(_93\5Z+XO\2^-]3\>Z79^.=3T[^S;2^\->'8K*UMAD'S7A+8E<XZG
MU-.\+?LJ>*+KXIV7COQYXTT76=5TRRGL[,^'O#R:89C(I4R7+J<R$9Z=*^E\
M^U .*;Q%1WO^0>S1\RVG[%_V3X/>%_#4'B^33O%GA?4I]4TCQ-8V@_<RR.6*
MM$Q.Y"#@C/.*VO!'[.7BJ[^)>F>//BEX\@\;:UHT$D&D6FG:6MA9VA<8:4KD
MEG([]!FOH#-&:3Q%0/9H^4=9_8'T7Q/\![GP#K&M)-K$6I7>IZ;X@MK0HUF\
MSEBFTMED(.&&>>M?1?PZ\)MX$\!^'_#KW*WCZ78Q69N%38)"BA=P4YQG'2NC
MSFDK.=6I47+)Z%**CL%%%%04%%%% !1110 4444 %%%% !1110 4444 %6]*
M_P"0G:_]=!_.JE6]*_Y"=K_UT'\ZN'Q+U(G\+/05Z4ZFKTIU?8'DK8****!A
M1110 4444 %%%% !7DWBW_D8;S_>'\J]9KR;Q9_R,-[_ +P_E7=@_P"(>;CO
M@7J9%%%%>T>,@HHHI6N!X'XA_9BN-<UKXO7Z^(8(1X\T^*RCC-JS&R*@#<QW
M?/TZ#%8'CS]A_1O&-I\.+N'58]-\2^$H[6";4DMB4U"&''RN@(.<C*DDXKZ:
MQ2GD5DZ46;*M-;,\"\3_ +.WB[2?B)KOB_X7>/8/!MQXAVG5]/U+2UOK:611
M@31C(*/C\*9XV_92;XH2?#Q?'7B1/&47AR2:34?M]GY1U+>/NXB91&!VZGBO
MH$' Q2 XH]E!Z"]K-'S3:_L=_P!A_"?X@?#O0]>L]/\ #_B&X^TZ?OL&::P)
M(+)(P;]\HQQGD5L^%O@M\6]#T6\TNZ^)7AJXM'TU["V-EX42UEA;9M21I%;<
MV/3O7OIYHSBCV41^VJ=3Y6G_ ."?GA"U\!6-AI.KZK8>+K)H[J'79+^XEA%V
MK;FE^S%]F&/8<^]=%\5_@#\2_B?;7FEWGQ%\/7/A[4($BN+34?"L=Q-;$* [
M6\I;*ECDC=R":^B-U)1[*&P_;5+W;/F37OV2/$ECXO\ "^N>"/&^FZ/)H>AI
MHBKKNB#4O.0=7(+!03^E:GCS]G?X@>.=$\$33?$#1K7Q;X6U&2_BU2'P_MM7
MW+M51;AP!C]:^A\TNXT>Q@'MIGB7P[_9_P!:T[XDI\0/B!XV?QQXIM[9K.Q^
MSZ<EA9V43'YMD2DY8]R370_%_P #>//%TUFWA'QCI6B6J1M'=:5KFA1ZE:7.
M?XB"00PZ>E>EY]A03FG[-6Y2?:2OS=3Q3X9?LVI\.O@UXC\%'68[Z[U[[3+<
MWB6:PVT<LP(/EP*<*@SPN:CU#]G%[S]F"+X21ZW#!,EE':'55M"(R5<,6\L'
M/./6O<,TE+V41^UG>]SYW\9_L<Z-XE^(G@#QO9:BFEZ]X<, O72#,>II$N%W
M $;6_P!HYXXJHG[$/AGQ/JWBS7/'NI7OB/7O$%W),\^GWEQ8PQ0D8CB\M'P^
MWC[V<U])T4.E!]!^WJ;7/EN?]B8>(M-^&ND^+/$5IXET;P<]PC6EQ:2*;VV<
MGRXBP?(*# SWQ7O?@GX7^%/AKH%QHWA'0+#P[83!B\5E%MWL5QN8G)8_4UU-
M'2JC3C'5$RJSDK-GA7@S]FJ?PG^SSXA^&3^((;B;5OMFW4UMF5(O.<L,INR<
M=.O-9NK?LLZG;Z=X%U/PIXS/AKQWX4TQ=*CU<60GM;R #E)8&.=I/(YXKZ'/
M-%)THL%6J;G"_"GPIXU\+V%\_C?QN/&6IW<PD'D:>EG;6J@8V1(.<=_F-9_C
M?X12^+OC#X$\;+JB6L?AF.Y1K)H2S7'FK@$-G"X]P:]*HS5<B:LR>=WN?/\
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M-)2MU/U-)7QSW/76P4444AA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !5O2O^0G:_]=!_.JE6]*_Y"=K_ -=!
M_.KA\2]2)_"ST%>E.IJ]*=7V!Y*V"BBB@84444 %%%% !1110 5Y-XM_Y&&\
M_P!X?RKUFO)O%G_(PWO^\/Y5W8/^(>;CO@7J9%%%%>T>,%%%% !1110 4444
M %%%% !1110 448-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>F> ?^0"O_ %T:O,Z],\ _\@$?]=&K@QG\->IWX+^+\CI****\8]P*
M9+_JG^AI]-E_U;?0TGL!YHW4_6DI6ZGZFDKXY[GKK8****0PHHHH *^,?$_[
M9/C;1?@Q\4/%MKIFDW.J>&/&7_"/6-OY#^7-!YJK\XWY+D'J"!GM7V=7R[J/
M[%EQJ'PT\=>$_P#A+($?Q-XN7Q0MV;)B+<"59/)*[OF/RXW CZ5T4>2_O^1G
M._0=X9_;#_X6)XI^#]IX=MK:V@\37MUI_B#3KU&-WIMQ#%N:+J-IW="0<C\:
MXOPS^U+\1O&WC?Q3IEOXW^$OA2'2_$$VCV^F>(_.2_N41\*R@3#=G.,@=:]1
MUG]C[0I/VEO#/Q?T6_71[ZQ8OJ>FI 3%?R>6464$$!'P>20<\=ZUOA+^ROX;
M\ 7_ (KU#6K'1?%6I:SK\^M6]Y=:5&9K17((B#N"?E(SD$?2MW*@E>*O_G<S
M2F]RQ\'OB_KOCOXP?%;PGJD-E'9>%+BSAM'MHV5W\V(L^\ECGD<8 XKEOVIO
MVC?%7PGUG2-"\!Z%:>(=;%I/K>JQ708B#381\Y4*00['A<\<'BHY_P!G#XF>
M'/BSXY\9>!OB=HOAZ#Q7/#-<V.H>'/MSIY2;5 <R #N>!WIEQ^Q-H_CCQUXC
M\7_$G7;WQ-K.J10VT#:/=7&EQVT"1[6CVH_S!FRQ!X&<8I+V,9<TGI;8/>LT
M-_:._:SG^%7PH^'OC[PQ96^LZ7XBO[9)H9%+N;:2,NPCVD8<8(SSR#Q6;\=O
MVUK;P=/\.K/P+%::[<>*)K:YGFG5I$L[&5PH9@I&'9CM&3U4\'%3Z5^QA>Z=
MX(\'^$G\6V]UHGA7Q3_;VG1S63LXM,L?L;$MR1N^_P!.O%3:G^PIX6L-$O[+
MPM?OI%Q?^([?79I[N+SA''%)O%K&%(VQ@EB/3/M5Q^K*UWW&^=[$GAW]KAT_
M:O\ %GPG\206EAI=N(TTC4T1EW3>6)&BE<DKDC=MX'2I/@'^U=<?'#XU^/\
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M=>HTDWL/D2N?/O@_]E-O"7[-6O\ PU&OB]US7(9OM_B"XB9O/GD_Y:,I.X@
M8QFF_ SX%?$GX4ZAHD&I>*_!>H^'["W%M)#IGA86E[,@7 S<;B<^I/6OH7-%
M)UJC33>XN2.YY)\=?@3=?%&_\.>(O#OB-_"/C;PY*TNFZJ(!<1;6^_'+$2-R
M&N1\1_ 'XG_$?X5^./"_CGXEZ;JUWX@MTM[46&BBVL[#:P)8*#O<MCG)Q7T3
MFDI1JSBDNPW&Y\[?"SX#_$OP3"NF:MXM\&7FA#39-.:/2?"PL[MP8RB,TP;)
MQU/K5;X+_ 7XO_";3-*\-CXD>&K[P;9-(KV*^'G6Z>-]Q*B8R<')ZX[5])45
M;KS=[VU\A*"1\R?!S]G;XO?!FWBT72_B7X;D\*#4)KQ[.3P\[7)61RS*)3)P
M>>#BJ/C']E#Q[\4O$^DR^-O'/AG5-(T[4H]0CO;'PLEKK+"-MR1FX#8 Z D=
M<5]59I*/;U+\VGW![.(BKM4*,D 8YI:**YS0**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *MZ5_P A.U_ZZ#^=5*MZ5_R$[7_KH/YU</B7
MJ1/X6>@KTIU-7I3J^P/)6P4444#"BBB@ HHHH **** "O)O%O_(PWG^\/Y5Z
MS7DWBS_D8;W_ 'A_*N[!_P 0\W'? O4R****]H\8**** "BBB@ HHHH SO$>
MDG7O#VIZ8L@A:\M9+<2$9"EE*Y([]:^?+K]C:SF_9ST_X<QW.D1ZY;&(MXA&
MEKO?;+O/;?R./O5]*49J)0C+<TC.4/A/F7QK^RWXOOOBY)XX\->*O#5G))I%
MOI3VGB#P_P#VBN(UP74%@ 3^=7_$W[+FK?%;6/!TOQ#\4P7FG>'K>0"U\,P2
M:69+EC\LJ%&_=A1P M?1?6DQ4>QBVR_;3LO(^7YOV+/[&TOXC:%X8\3RV?AW
MQAIZPM;:J\MY-!= \SF1FRX(X(//O7?_  7^'?Q3\ 2:7IWB7QSH.O>&=/M%
MMHK*PT1K:?Y0 A,I<YQCGCFO8J*%2BG="=6;5GJ>1?#/X%7/P_T?XAV4NKPW
MC>*K^YO(WC@91;B5"H5@3\V,]JX9_P!C>T;]G&+X<BZT8:ZC*W_"0C2QO.)=
M_7[_ $X^]7TMFBG[.(*K-.Z9Y#\9?@(WQ6\(>#-'74;:TE\/ZC:7S33VYD$J
MQ !D4#[N[%>MR0^9;/%P-R%/ID8I^:,U2BEJB')M)/H?*&J?L&Z;XA^!ESX'
MU3689=;BU&YU'3==@MV0VK3.6*,I.67!P1GWK7\8?LJ>)[_4_AYJ?A[Q1H%G
M?^%-$_LAAK6BF_@N,]7$98 >V<XKZ8HK-T8&JKS74^<_&_[+^N_%GP)X7\.^
M-M<\/WRZ3K(U"X32](:QMKBWQCR1$C?*3W;-=)\$/V:M/^ GC'Q9/X;>RC\)
MZV4FBTMK=C<VD@&&03$DO$>RGI7M%&:KV4;W)=:;5NA\[_!O]D"R^$WQEU_Q
ML-8_M'3YS+_8VE&-E&F"5]\N,G')]!6/-^R_\0=%^('C+Q!X8\7>$(+;Q#J)
MU P:YX9^WRPG  42,PQT[5]09HS4^QA:P_;3O=G+>+/ =O\ $'X=7_A3Q*ZW
M4&I67V6\EM4\H,V!ET7^'# $#V%>7?#[X0?&#P9>Z%I=U\7+*\\'Z0ZA+>+0
M56_NH%&%AEE9BN,8RP&>*]ZS16CA%N[(52459'RSH_[+/Q$\(^*O%6I>'/&/
M@R.TUO5Y=6\O6?"_VV>%G/W5D9N, #IWYKH?%'P$^(P^,>J>/_!OCS0M#N]3
MTVVT^Z@U+17N\^4.67#@#)R?I7T+14>RB7[:;/G+7_@#\4[OXEZ?X]T;XA>'
MM/\ $2Z''H]])=:$\T,Y5BS.D8<; 3C SQ6AXW^$GQ?\8:39V<WCOP=J,36G
MD7UGK/A,7%L\N3F:(%B5)! P>.*]]HH]E$%6DK?Y'GWP'^$4/P-^&&D^$(=1
M?5?L>]Y+IX_+#N[%FVH"=J@G '85Z#116J7*K(Q;;=V%%%%,04444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>F> ?^0"O_71J\SKT
MSP#_ ,@$?]=&K@QG\->IWX+^*_0Z2BBBO&/<"F2_ZM_H:?39?]6_T-)[ >:-
MU/U/\Z2E;J?J:2OCGN>NM@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "K>E?\A.U_P"N@_G52K>E?\A.
MU_ZZ#^=7#XEZD3^%GH*]*=35Z4ZOL#R5L%%%% PHHHH **** "BBB@ KR;Q;
M_P C#>?[P_E7K->3>+/^1AO?]X?RKNP?\0\W'? O4R****]H\9!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRUM+GP_<Z5/)?20,T<PM!A@J@Y&[MGI62E3;2E;?\!M2W3,OQ/\ &/XF>/\
MXR>*_ 'PELO#5E#X1$*:QKWBKS94:XE4LEO#%$03P.6/3GIWXGQ1^V9XN\/?
M ;XD:M=^&],T[XG> M9M='U33-SSV,S2RJJRQ'(;:X)P"<@COD5Z#XT_9_\
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MT?\ "&'_ )^O_'/_ *]=311]2H?RB]K/N<M_PAA_Y^O_ !S_ .O1_P (8?\
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M?<Y;_A##_P _7_CG_P!>C_A##_S]?^.?_7KJ:*?U*A_*+VL^YRQ\&G_GZ_\
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H_P"O72Z!I']BV MO,\WYBV[&*TZ*B=:=16DS2%"%-WB@HHHK$W/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>anvs-20241231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (2 WP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?XU9H **** "BBB@ HHHH **** "BBB@ J*YF%M;RRD;A&A;'K@9J6JNI_\
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MO]GQ+3P?H>@Z9XK\6?$.ZT*SFCM3%:0?)&QFD7)+-\W SCTQBO9+C]H3XO\
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M,H6=>>JD].>HJ[X;^#'A#2VU,ZWX)^-GC/[9I;Z,@\0W/V@6MHW_ "SC'FC
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MQQ-XUE^''Q:\:>,WC,*:[XJ"WUS"A[(6D^7CCCH.!BO=O^&DKO\ Z)3X]_\
M!=%_\=KAK_O&K:M+5]Q'M59<&/\ A)[W[N?L<'U^_-7E/_#25W_T2GQ[_P""
MZ+_X[6?%^T?=C7[I_P#A5OCLDVL(\O\ LZ/(^>7G_6]#_0US<DA'O5?G=_P4
MPN?#</QR^",?C.XN8/"+O<#4_LQDW&+<,\1Y8]N@KZG_ .&DKO\ Z)3X]_\
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MS_MM> DZV>M_^ T?_P <J!_VY?A^G6SUS_P%C_\ CE5]3Q'\C"S/HBLR$_\
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M;2_NX04+94$]O2NB^,D'B;P]^T]?2>%#9IXF\7>!+C3M!FU&4Q6ZWT$NX@L
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MD!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!RUJL3+_ )]2^X+GRQ<5FW'6OJ^3XC?LV#[VGVW_ (!2U7?XD_LRC[VG6O\
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M[4?_ #XG]P<WD?FRW2FGI7Z7GXD_L)#_ )ES3?\ P67-)_PLK]A$?\RYIO\
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MIN\G=DA1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!YY\>?B\GP.^'-SXJ;1KCQ \=U:V<6GVTR0O+)/,D* ._RCYG'
M6N1\(_M.K-XYN_!_C_P??_#/78M*DUN+^U+ZVN;6>SC8+)(L\+LH*$\@XP.:
MD_;$^&?B'XN?!*Z\-^%X9I=6FU339E:WGCADBCCNXI))%:0A<JJLP]<< GBN
M-\3_ +)VL>'_  CXSUWPUXKU/QK\5;S0Y=)TK5?&DZ7$<$3,&>%5"!%WX(W%
M3R1G@4 >PZ/\??AOK^@ZOK>G>-]#O=)TB/S=0O(;U&CM4_O2'/RCW-<Q)^TO
MH.J?$?P5X?\ #-SIWB32/$!ODFUBSO0R6LEO&LA7 !#$AQGD8R*^.]%_94^-
M5[H?Q7GU/PSJ8O/$O@QM)L[;5M?T^ZN'NQ)D1L\/EQJ",D9R .K \5[-\=/V
M2M?^)S?"7P_X>>?P5H6E:3=6>KZAHKP1/;%[9$"!=P+!F7!* \#J,YH ]IN?
MCOINI^-?"%IX;UWPKJ?AW5#J"7MU)JF+D-;(K,+9 ")=NX[^1M&/6M?PS^T-
M\,O&>N6VC:%X[T'5M5N5+P6EI?1O)*!UV@'G%?-^@?!SXI7^N?!R/6/ UIH\
M?@:RU_1;NZTZ]M?LES');)%:W,,8DWJLQ'*LH96#%@ 0:71/V8?$VC?L]_!3
M1K;P?:6_C#P[XIL]3U58Y[9)(80\QN',P?#Y5QD*S$YX!Q0!]-:'\</A_P")
MO$=WH&E>,=&U#6;02-/8V]XCRQA/OE@#QM[^E)X7^.7P]\;7-_;Z#XST75Y[
M"-I;J.SO4D:%%^\S 'H,')KXU\/_ +,?Q?U*\\5>$M-\/M\./!>IZ5JUG+/J
MFM6FJQF6XC80FR,2"XC7S#E_,(RIP.>*ZWPC\$?B3XFU[PC+JWPUT?X=6_@K
M0;W2OM.GZK;W#Z[)):^2@C$8&R'(W_O2&SCCK0!]'Z%^T/\ #GQE</9>&/&F
M@^(-5:U:[@L;/4(V>9 NX$8/0\<]JYGP%^U-X9OOAGX0\1?$&^TGX=:UXBM3
M=Q:+J&I(SB,R,L;*Q"E@RA6!P,;L=J\C\*_LS^)/#G@/]EVUM?"5K8ZSX0N(
M9/$I@EME>W4VCI-N</B7,C<["V<YZ<U-^U;\'?B%KOQ-LM?^&G@>:YU8Z3'I
MD>OV^N6<%K$JR.PBNK.XC.^)2P(,66.2,<"@#ZJ\1^,]"\'^'I=>US5[/2=&
MB4.]_=S+'"H/0[CQSFOGK5_VR[75]3^)EIX-F\+7UEX4TS2[^UU_4]9\K3[A
MKN8QNDKJA\O;M(')W,5'&:W_ -H_X6^,?'GPS\"R:7IVF^)/$7A;6;+7+O0I
MY1;VNK>3%(DD"LPVKDR;UW#;E%SCJ/G#Q?\ L\?%SXB6'[0>IGX5V?@^Z\9Z
M3H4&DZ-::O92F26WN]\PD=75%<+\Q)PIZ L: /M1OC=X$MO%5KX4N_%VBP^*
MIV2-=)%XIF,C#(4+U)/;C)JQIGQE\"ZSXOF\*V/B[1[OQ'$65]+AO$:=2OWA
MM!SD=Q7RI??!+XKZ;^T/'J7@[P<?#NB7VN6]]K&M7FN6=YIUS;KM$S+:LGVB
M.X*#"[2%#8.X=:X3X1_L6_$_PK\0?#6D:]#K4^C>'-5DU.W\30^(K,6$I#NZ
M$6HA^T[FW .K,!RWSGB@#[?\/_'/X>^*_$<^@:/XST74M:@#F2QM[U&E4+][
MY<]N]-\/?'?X=^+-3O\ 3]&\:Z)J5[81O-=0VUZCM"B'#LV#P >IKX6\-?LQ
M?'K4/BMX/UGQ7X=GO(='U:Z-_+_;M@NG3PR13*'M8(D66*(Y12&)?YL[#R1H
MZ)^RO\9]=T/Q-X*L=$;X=>#)=%N;"&/6M9L]39Y25,"6DMNGFQQ94[_.Y((X
M)% 'W/X&^+/@SXF-=KX4\3Z7XA:T(%PNGW2RF+/3< >*\T^)O[4*?#SQ;X^T
MZ+0#JVG>"/"K>)-6N8[GRY-YW&*W12I!+*C'<6XXX->4_LA?L[^./!GQ3N?%
MGC72M>T6;3](.D6S:GXALK^.[5G4L$BMH5VQC8"ID8,,XV\DBG\4/!FL^)?B
M9^U%X+TNR-YX@\7>![=]%@>5(OM9,,L)16<A1ARH)) &[F@#U7PM^U??3^(/
M"VE^,_AMK'@=/%4#2Z'?37]K>V]VRQ>=Y;&%R8V* D!AV/2N=\-?MM:MK'@"
MS^(5]\'O$5C\.;@NS>(+;4+.[,,2R-&TKVZ.)0@96R=O &<5J?##]D9/#L/A
MG7O%7BKQ-XR\0Z)INS3K'7;Z.2WTR=X/+<1*@"DC)4,2>.AKR/X8>%?V@M)_
M9OM?@E_PI^#06>UNM.F\6ZKXDLIK6**::1VD%O [R,0LG"^HY(H ^FOA[\<8
M?&_Q9\7>"GLX;?\ LS3[#6M*OX;CS%U.PNE8>:!M&TI)&RD<C#(<\D#U2OD_
MX,^"8O#W[8E]IFE3-=:9X&^&6F>&;N=C]ZXENFFB!_VO+A)]MP]:^L* "O$Y
MO^3P(_\ L36_]*Q7ME>)S?\ )X$?_8FM_P"E8K2'7T ];N>]9-SWK6N>]9-S
MWIQ S+GJ:R;GJ:UKGJ:R;GJ:Z(C1E77>LNY[UJ77>LNY[UT1&9-SWK+N*U+G
MO67<5O$9DW'6LJYZUJW'6LJYZUT1 R[GO65<]36K<]ZRKGJ:Z(C,NYZ&LFYZ
MFM:YZ&LFYZFNF(S*N>M9=ST-:ESUK+N>AK>(S)N.]9=UWK4N.]9=UWKHB!E7
M'6LJYK5N.M95S71$HRKKI63<5K772LFXKHB!F7/>LJXZUJW/>LJXZUT1&C)N
M.M9=UTK4N.M9=UTKHB,RYOO5">M33?>J$]:U8QAZTUJ<>M-:H :U1GK4C5&>
MM0(93#TI],/2I8="-J8W6GM3&ZUFR1K4T]*<U-/2H8#&Z5&>M2-TJ,]:S8#*
M:>M.IIZU+ 8>],/2GGO3#TJ&!&W2FGI3FZ4T]*S8#&Z5&>M2-TJ,]:A@,/6K
M>DZUJ'A_4(K[3+VXT^\C.4GMI3&ZGV(-5#UIK=:AZB/K[X*?\%0?B]\*6M[3
M6KBW\>:(F%:VU?*W"K_L3KSG_>#"OOKX*?\ !3WX/?%9K>RU>]F\"ZU)@?9M
M9P(&;T6<?*?^!;3[5^(K5&XSQUKRZV H5=;6?D19,_IOTO6+'7+..[TZ\@OK
M6092:WD#HP]B*N5^$_[)'A#]IR^U6VG^$<>N6&G[ANN[MS#I@'^T9/E8>R@G
MVK]HOA%9>/K'P?;1?$?4=&U/Q& /-FT2!XH?_'CR?< #VKYK$X98=V4D_P R
M&K';4445PB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "J,FAZ=+J\6JOI]J^J0Q-!'?-"IG2,G)0/C<%) ) .
M.*O44 %%%% %*QT33M,N[Z[L["UM+J^D$MW/!"J/<.%"AI& RQ"@#)SP *NT
M44 %>)S?\G@1_P#8FM_Z5BO;*\4EQ_PV#%GI_P (<W_I6*TAU] /6KGO63<]
MZWY#;_Q$57D.G?QE/UH3L!RMSU-9-SU-=O(=&_C,?XDU6D/AW^-H?S:M5/R&
M>>77>LNY[UZ=(?"G\;6__?357D;P7_$UM_WTU;*I;HQGD=SWK+N*]GD/@+^-
MK3\6>J\A^'7\3V?XL]:JM_=8'A5QUK*N>M?0,A^&/\3V/_?<E5I#\*/XI-/_
M .^Y/\:V6(_NO[@N?.=SWK*N>IKZ9D;X/_QR:=^+R?XU6D;X+?Q2:9^+R_XU
MJL3;[#^X=SY;N>AK)N>IKZRD/P.YW2Z5_P!_)?\ &JLC? 7^.72?^_DW^-;+
M%V_Y=R^X=SY"N>M9=ST-?7VI-\!?.L?*FT@)Y_[[]Y-]S8_O_>VTYV_9S_BE
MT;_O[-_C6RQO_3N7W!<^*;CO67==Z^X9#^S5_'-HGXRS_P"-5Y&_9A_CFT+\
M99_\:U6._P"G4ON"Y\(W'6LJYK[ZD;]EG^.;0?\ O]<?XU7D;]E#^.?P_P#C
M-<?XULLP_P"G4ON*YC\^+KI63<5^BDC?LC_Q3^'OQFN/\:K2-^Q]_'/X<_[_
M -S_ (UJLR_Z<S^X.;R/SAN>]95QUK]*Y&_8V_BN/#?_ '_N?\:S1_PQLVJ3
M[[CPT;7R8]G[^Y^_N?=_%Z;:V69V_P"7,_N'S>1^:%QUK+NNE?J0T'[%+=9?
M#)_[;W7^-1-8_L2-U?PP?^WBZ_\ BJU6;)?\N9_<'-Y'Y43?>J$]:_5DZ5^P
M^>2?"_\ X$77_P 53/[)_8=]?"W_ ($77_Q55_;"_P"?,_N#F\C\ICUIK5^K
M1TG]ASU\+?\ @1=__%4ATG]AOU\+?^!%W_\ %5/]KK_GS/[@Y_(_*1JC/6OU
M>.D?L->OA;_P(N__ (JD_LG]ACU\+?\ @1=__%5/]KQ_Y\S^X.;R/R?IAZ5^
ML/\ 9/["_KX6_P# B[_^*I/[(_86]?"O_@1=_P#Q5+^UH_\ /F?W!S>1^3;4
MQNM?K,=(_85]?"O_ ($7?_Q55H-(_8:^UW/F'PIY7R^7_I%WZ<_Q5']K1_Y]
M3^X7-Y'Y0-33TK]:/[)_82/?PK_X$7?_ ,52'2?V$?7PI_X$7?\ \54O-5_S
MZG]P<WD?DJW2HSUK];#I/["'KX4_\"+O_P"*I/[)_8.]?"G_ ($7?_Q51_:B
M_P"?4ON#F/R1IIZU^M_]D_L&^OA/_P ";O\ ^*I#I/[!GKX3_P# F[_^*I?V
MHO\ GU+[A<Q^1Q[TP]*_<+P5^R;^RS\1],&H>%_"GAS7K,C)DL+^:7;_ +P$
MN5/L<5T7_# _P _Z)IIO_?\ N/\ XY7/+.:*=G!_A_F',C\%VZ4T]*_>G_A@
M7X ?]$TTW_O_ ''_ ,<H_P"&!?V?_P#HF>F?]_[C_P".5']LT?Y7^'^8<R/P
M3;I49ZU^\6L_L&? *VL&DC^&NFJXDC&1-<'@NH/_ "T]#5S_ (8#_9^_Z)EI
MG_?^X_\ CE2\XH_RO\/\PYD?@<>M:WA7P=KOCO6HM(\.:/?:[J<OW;33[=II
M#[D*#@>YXK]V_P#A@']GW_HF6F?]_P"X_P#CE>L_#[X6>$/A1I']E^#_  YI
MWAVQ/+1V$"QESZNW5C[L2:RGF\+>Y%W\Q<Q^3'P6_P""37Q*\<M!>^-KRV\$
M:8V&:W8B>\8>FT?*OXD_2OO3X+_\$[O@Y\'&M[L:"OB?6(L$7VM@3@-ZK&?E
M'Y&OIRBO&K8ZO6T;LO(B[([>WBM84A@C2&) %6.-0JJ!T  Z5)117 (****
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MC.PYQD@&(9OC1\4_CA\5M,\*?%JV\&Z+X4O[.UM-*G\,6U^DOF6<4QW2LRN
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M;H?RO\/\PYT?A4>E,;I7[R?\,%? '_HFFE_]_9__ (Y2?\,$_ '_ *)GI?\
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M-=!2:L 4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 4444 %%%% &;XA_Y!;=/];%U_ZZ+[&M*LWQ#_R"V_ZZQ=L_\M%K2H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&\4^,_#_@:PBOO$>NZ
M;X?LI91!'<ZI>1VT;R%68(&<@%B%8XZX4GM3O#/C#0?&MBU[X>UO3M>LU?RV
MN-,NX[F,-_=+(2,^U?,?_!1:SCU#P;\)+>:3PY%')\0;-6?Q="LNE ?8+_\
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M)+'UH ]#B8O&C,-K$ D>E.HHH *\(UJ9X/VMHGC8JW_"($9'_7U7N]>"Z_\
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M^_[YC_\ B*K/^TA\31T\8W__ 'Q%_P#$5P,O>JDG2I^KT?Y%]R.2>59?_P!
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M9@./B#J?_?$/_P 15:3]L+XT#I\0]4_[XA_^-UY1)T-59>II?5Z/\B^Y')+
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M$\MQSP,\E>.?IW%EOB+\,!U6V_\ !>__ ,16JQ4U_P NF=L,]Q*_Y@JGW/\
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M_/B7]?(YY<48U_\ ,MJ_<_\ Y$^"Y6'J*JRL,GD5]]-\<?V?1UCL/_!++_\
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M=9OB$9TMN,_O8N,X_P"6B^X_G^?2M*N<X@HHHH **** "BBB@ HHHH ****
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M, G)XXKDO$?[6?PJT#X=^(_&D'C+2]=TG08C)=)I%Y#/,S8)6-%+@%WQA02
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI9_;H^#*]?%,W_@LNO\ XW3#^W;\%AU\53?^"RZ_^-U^5DO0U5DI?V30[O\
M#_(PEPC@%]J?WK_Y$_5H_MY?!0=?%<W_ (*[K_XW3#^WQ\$EZ^+)O_!7=?\
MQNOR=DZ&JLO4T?V30[O\/\CG?"N!7VI?>O\ (_6D_M_? ]>OBV;_ ,%=W_\
M&Z:?^"@?P-'7Q=-_X*KO_P"-5^1DM59.GXU/]E4.[_#_ ".>7#&"7VI?>O\
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M_P#6J!_V*OB"W1M,_P# G_ZU+Z]AO^?B.6?$>4/_ )B8?>?.\M59>IKZ*?\
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M^ _Y_1^\^2Y:JR=/QKZV?_@FS\66_BT7_P #?_L:@?\ X)I_%L]&T3_P-_\
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MCX>\'>-8O"N@QZ[KOB.Q@LKP>+M8O;N.\6%V:,22L[R*5WMAE.1A?05]"44
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M% !1110 4444 %%%% &;XA_Y!;9 /[V+[W3_ %BUI5F^(3C2VY4?O8OO=/\
M6+[C^?Y]*TJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ7(ZQ]C_ '?I_C6C6;IY!U74L$$YCS@#/W>] &E1110 4444 %%%% !1110
M4444 9WB#_D&-@@?O8NH)_Y:+Z UHUF^(2!I;9( \V+[P&/]8OK6E0 4444
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MP";Y="L#XN^S;QH_]H'[-YW_ #S^T>7G;_M;/PH<&O\ AP.GHKPW_A.OC_\
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M66[T[7VOI#)D87RS F 1GG/;I61XW\3_ !7TKX@ZA#X2\"Z%K^DBTM]EU?\
MB!K.0\R$YC%N^/F+#[W0 ]Z.1WM^J ]@HKPW_A.OC_\ ]$H\*?\ A8/_ /(E
M>EZUJGBNV\""]TS0K"]\6?9XG.DS:@8K;SCM\Q//\LG"Y;#;.<#@9H<&O^'
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MZU=7Z^./"&D>&8(T0VLFF:TU^9F).X,##'M &.><YKOJEJSL 4444@"BBB@
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M44 %%%% !6=8?\A74N#UCZ]/N_2M&LW3Q_Q-=2XQS'SD'/R_7C\A0!I4444
M%%%% !1110 4444 %%%% &;X@&=+;@G][%P.O^L7V-:59OB'G2VXS^]BXR!_
MRT7U(K2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "OBCXR:7XE_9>^+<_COPPK2^&-
M;FWW=MC]TLC'+1/Z9.2I]R*^UZSO$/A[3O%6BW>DZK:1WNGW2&.:"495@?\
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MO_C?>^*OB[)<WD?AW7I(;/0--G9E6&UA3YI"AX#M(SY8=0HH Z[Q9^U=\*?
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MC\1_[?#_ /$5YG>UB7'WJ]BEDF7RWI?B_P#,\BKG6/CM5_"/^1["W[35PO\
MS+L7_@:?_C=1-^U!<K_S+<7_ (&G_P"-UXQ)UJM)U-=JR'+?^?7XR_S/.GG^
M9+:K^$?\CV*^_:8N;J6S?_A'85^SS><!]L8[OD9<?<_VO?ITJ5OVK+D#_D68
MO_ X_P#QNO$).M5GZ&MX\/Y8_P#ES^,O\SCEQ'FJVK?A'_(]T;]K&Z7_ )EB
M'_P./_QNHF_:WNA_S*T/_@>?_C=>$256>NB/#F5/_ES^,O\ ,XI\3YNMJ_\
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MXI+&VDBG?S)4:%2LC?WF&.3QU-#:/8/;26S6-LUO*VYX3"I1SZD8P3P*N44
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M/$1 TILG \V+GC_GHOK6G0 4444 %%%% !1110 4444 %%%% !1110 4444
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M(3^!8/&.D2^+ER#I"W2F?(&2N.[ 9.WKQTKO*_/WP=^QWXTT_P =:9HVO_\
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M@K,A_P"1EO.#_P >D'.>/ORUIUEP?\C->=/^/.#OS]^7M7(=IJ4444 %%%%
M!1110 4444 %%%% !6=8?\A74NO6/O\ [-:-9UA_R%=2Z=8^_P#LT :-%%%
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M?\GA1?\ 8G-_Z5BO:J\5D_Y/"B_[$YO_ $K%:0Z^@'M5%%%9@%%%% !1110
M4444 %%%% !1110 4444 96M F[T;IQ>>_\ SRD]/ZUJUDZYM^V:+G9G[;QN
M )SY,O3/?Z>]:U !1110 4444 %%%% !69"/^*EO#V^R0>O]^7\*TZRH-O\
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M=6TO3M7GT&_O+62"#5+9 \EJ[*0)54\$J>0#Z5^</BZ?XG:!^U!X=^$/A_\
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MXA?(BU[2[Z:[!VC=O>*X1#SG&%'&*.76UT!ZS17@XT_]IW/.O?"7'_8$U/\
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MO96L%I;J8PL4$811\OH !5'X+G%3)YS_ .$R$X^KT^2U?WLVJ***#YH****
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ML)=5GM/^$JN0(X8Y=WV=<G<SCU_V*^N*S(3_ ,5->#/_ "Z0<?\  Y:+(?\
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MI;<X_>Q<_P#;1:TJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ K)TCP_I>DZIJ][8Z;9V5YJ,RS7MQ;P+')=.J!5:1@,N0H !;)P ***N.S
M_KJ!K4445 !1110 4444 %%%% !1110 4444 %%%% #617*EE!*G(R.AQUIU
M%% !1110 4444 %%%% !30BARVT;B "V.<?Y)HHH =1110 4444 %%%% !11
M10 4444 %-50&8@ $]2!UHHH =1110 4444 %%%% !1110 4444 -=%=<, P
MR.",TZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>anvs-20241231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %B XD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZGXL>-+.:Q2,Q1EYQ"-Y9@1\S \ \5[_ %^6_P#P4\<2?ME_LWNO*M/:$?\
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MDF3YGF.D:8XQP2W7J.E 'TY1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_L^:?X'^ 2_#K6!#>"^MIH]5DMB=DLDH(<HQ / P%) /R@X%>,Z;^S-\<_
M'A_4/ _@[X@:*/ ]XT@1[^-Q=VT<GWU0"-L9R>C8R21M)KOC5HMR5.R::2NO
MLKY;O<\N=#$*,'54I)IMJ+LU)N_=:):(XOXE_&O4/CC^PUJ&JZQ'&NLV.L6]
MA>21+M29U96#@=B589 XSG&.E=!XT^(_B;P?>_LTZ3HNM76FZ;JMI:QWUM"P
M"7"[H%PWX,1^-=UXF_8\GL_V9)/AGX5U*TDU6:^BOKC4-3+Q1S2!@6.$5R.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^\;:O>V7Q4^&]E!=S0V=
M[+J N8$<A)@EJ67<.^#R,]Z]!KS/X@?\EC^%7_7;4_\ TD->F5M/X8>GZLYZ
M3;G4]?\ VU!1116)T!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%>']3N
M[CXK^,;&2YEDL[:PTUX8&8E(V<W.\J.Q.U<^N!7:UP/AG_DLWCK_ +!VE?SN
MJ[ZM:F_R7Y(QHN\7ZO\ -A11161L%%%% !1110 4444 %%%% !1110 4444
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M&OPT^%=QX_N/%FCZOH@5_L?]FZG;2-J$BC)BMR9 LDF.=H.:Y[XR_"77=?\
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MX;_:;_:JTC2[6.RTVPUP6MK:PC"0Q)>WRHBCL H 'TH _26BO,OCK^TA\/\
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M^C?%KPZUJ1Y5I8VB3V]QN7#B6V?;LV[P49"<D?-P00#VNBBB@ HHHH ****
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MA'^RQXL\ _L(Z[\%=0U#1IO%-_H>K:;%>6T\K6(DNDE6,L[1!]H,@W$(2,'
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M\ Z_X T(K/HOA_6M7OK<-=X'^E721VDBR.AR(UW%5X;&[D>U_#2Y^(MQ#?\
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M#X>_ 2T\&^,IO&6N>)];\<^+#:&QAU37'BQ9VY8,T<$42)'&&(!8A=S;1DG
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M#DQAQN'X5S>E_$O0=7\>:[X0M[H_VQHMM:75TK !-EP91'M;/S',+Y';CUH
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M]:?61:QV@-CJ'DQB-"2N%VGGYCS4GP%_8(^%W[./CS_A+O"/]N?VO]EDL_\
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MC((([&@#XI\.^$O#W[/NE>&7^*OP*BMWTVZM(9_B7H=U%?(]VTJ(EU.VY+I
M\A7<65AEL'(KO/ ?P,^'=S^U]\4Y9/!>AR/9:7H&I6K-8QDPW,DE^SS)QP[,
MB$L.25'I7;P?L@^%9'L+?5_$OC7Q+H-A<17,'A_7/$4]U8;XV#Q;T8YD5&52
M%=F&5'%=%X[_ &>= \<^-T\6KK'B/PUKC6B6%U<>'-6DL?MMNCETCF"?>"EF
MP>"-S 'F@#A_ K"+]NOXJQN0LDWA#0Y(U/!=1-=J6'J >*CO-=?3_P!KOX@3
MZ<B7VIZ=\.K69;13DM(+JX9$('/S8'YUZ%\3_@#X=^*'B#3/$,U[K/ASQ/IT
M+VL&N>'-0>QNS;L=S0NR\21YY"L" 22,9-0_##]G+PA\)?%6H^)=%_M.YU_4
M[1;34-2U6_DN[B]VN7$DLDA+,_.,YP%    H \<_9C^ WP_^,/P"\*>.O&6E
MVOC3QCXHL$U/5?$5^2UVMS)EG2*0$& 1,2BK'M"[.,&O-O@_\/9]8_9/UG6?
M#=[-KGBGP+X[U;7M"U%Y-\UT]O<L)(V;^+SH#+&?4N#SBOH[4OV0_!MUJ6K2
MZ?J_BSPYI.KSO<ZCX?T'7[BSTVYD<YD)A0C9OR=P0KNR<U9TW1M$_97\+0Z#
MX.\!^)-<T6]O+J]^SZ#%%<"UED8-L*M(A5&)(7 (&.2.M '(7_CO3_VF?B=\
M,]&\/,+[P=IME;^.]7NARA=LC3;5A_>,GF3,IY'V=?<5W7[7%Q+:_LO_ !4D
MA)5QX;OAN7JH,+!C^ )/X5A_L?\ P0D^#7P]U6?4-)@T+7O$^K76N7NEV\OF
MQZ>LLC-#:*_=8HR%XXR6QZGU?XA>$8/'_@/Q'X9NB!;ZQIUQ82$] )8V0G_Q
MZ@#P+]K#PW'KWP7^&&A175QIMM=>*M M//L9#%+'$7VGRW'*G;D CD9R*Y_]
MIGX-^#?@5X/\,^//A_H-KX3\3Z1XGT>(:AIH,<EU!/>Q03PSMG,J.DC9WY.>
M<YKUGX?>";KXF?!?P!9?$'2K[2O$'AVXM)YX#($+WMDQ19@1D-%(4\P#NKC/
M-=Q\3OACHOQ;\,+H&OK.VGK>VM^!;2^6_FV\Z31\X/&^-<CN,T >1_'BP\-7
M'CE7U;X,^.?'EU]DC']J^'G06P7+8CYO(CN')/R_Q#DUUO[/-KHUKI&KC1OA
MWXF^'D9G0R6WB5E,ER=O#Q[;B;@=#R.>U>MT4 > ?L56D%U\ [-IH8YFA\2>
M()(S(@8HW]L7@W#/0\GD>M5M&AE^-/[5VI:U))YGA/X80-I=C&.4GUJX0-<R
M^A,,.R/V:5_0BO8/AS\.M(^%OA9?#^AB=-/6ZN[P>?)O?S+BXDN).<=-\KX'
M88%0_"_X8:+\(_"YT/0Q<O!)=W%_/<WLOFW%S<32-)++(^!N8LQY^E 'G<@%
MO^VU&8N&NO  6XQW$>H,8\_C))^M>Y5XU\.O"VNZM^T'\1_'FMZ?)IM@EM9^
M&=!CFP'GM8-\\UQ@=%>>=E7N1'R.E>RT %%%% !1110 4444 <#X9_Y+-XZ_
M[!VE?SNJ[ZN!\,_\EF\=?]@[2OYW5=]6M3XODOR1A1^%^K_-A11161N%%%%
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M'O%&C>+M.^WZ%J]CK5AO,?VK3KE+B+<.J[D)&1D<5IT %%%% !1110 4444
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M9)Y6P@PP^8A=A;>-I'WL5RG@-_B=^S5IMYX&L_AM>?$?PU%>W=SH.LZ%J-K
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M2?CW\&_@UX1_:STWX1:3XPUSP3H6G3(GB'Q-XCU![A2[(KB*!4C 7Y6 WO\
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MI49VEAR!0!W54KS6].T[4-/L;N_M;6^U!WCL[::94DN61"[K&I.7*HK,0,X
M)/ KRSXE?&W5M&\9^&O 7@K0K?Q#XYUNRDU1X[ZY:WLM-L4*JUQ<2*K-@NP1
M5526(/0"O(/&'BWQS<?M:_L]:!XY\-:?IURFH:S>6FK:%>/<V-RG]D72M&?,
M1'CE4X."""&!#<$  ^OZ*\W^#OQ1OO'USXPT?7=,BT;Q)X8UF;3;JTAD+I)
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MOJX'PS_R6;QU_P!@[2OYW5=]6M3XODOR1A1^%^K_ #84445D;A1110 4444
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MQG\'8?A#\'K:*?P!IOPX\0:I*;O5='TJ_FNX1*/E1MTCN02@7*AB!ZFO>**
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M:&23Y \2J7('#Y -<=\>_%?Q9^-7P#\2^"]%^#VLZ/XDU/3C!?3ZM>6BVB
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M454I<SN1"/(K>OXNX4445)84444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>anvs-20241231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #8 [$# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **^3OVN_B)\9?@O+)XF\,7HO_![[0\4=I T
MED^,8;=&25)Z-GJ<<<9^7])_X*!?%W74+6&HQ7.."J6UKN!]QY6:F'M*LG&G
M!MKLCCJXNG1=IW1^J-%?E[_PW%\;_P#GH?\ P#MO_C-'_#<7QO\ ^>A_\ [;
M_P",UO[#$_\ /F7W&']HX?N?J%17Y>_\-Q_&_P#YZ'_P#MO_ (S1_P -Q_&_
M_GH?_ .V_P#C-'L,3_SYE]P?VCA^Y^H5%?E[_P -Q?&__GH?_ .V_P#C-!_;
MC^-X_P"6A_\  2V_^,T>PQ/_ #YE]P?VCA^Y^H5%?E[_ ,-Q_&__ )Z'_P
M[;_XS1_PW'\;_P#GH?\ P#MO_C-'L,3_ ,^9?<']HX?N?J%17Y>_\-Q?&[_G
MH?\ P#MO_C5!_;B^-V?]:?\ P#MO_C-+V&)_Y\R^X/[1P_<_4*BOR]_X;B^-
M_P#SU/\ X!VW_P 9I/\ AN+XW_\ /4_^ =M_\9I^PQ/_ #YE]P?VCA^Y^H=%
M?E[_ ,-Q?&__ )ZG_P  [;_XS0/VX_C?_P ]#_X!VW_QFCV&)_Y\R^X/[1P_
M<_4*BOR]_P"&X_C?_P ]#_X!VW_QFC_AN/XW_P#/0_\ @';?_&:/88G_ )\R
M^X/[1P_<_4*BOR]_X;B^-_\ ST/_ ("6W_QFC_AN/XW_ //0_P#@';?_ !FC
MV&)_Y\R^X/[1P_<_4*BOR]_X;B^-_P#ST/\ X!VW_P 9J[X6_P""CGCGP9XW
MT8^/8)+_ ,.SN5NX8(8$E2,\>8NV,%BI(.W(S@BIE2KP7-.E)+O8J./H3DHI
MGZ:T5E>%O%.D^-O#UAKNA7\&J:1?Q":VN[=MR2(>X_D0>000>:U:@]$****
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MM96.@_$"UO+ZVN;RTCGL/$F@3&VFN(",QE@Z'/!X)4,!QG'%=3\"?V:_#'P
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M_P"36/C)_P!B9K/_ *0S5ZK7E7[6/_)K'QD_[$S6?_2&:@#)_8H_Y-'^$/\
MV+-C_P"BEKVNO%/V*/\ DT?X0_\ 8LV/_HI:]KH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH KZAI]MJUC/97L$=U:3H8Y895#(ZD8((/45^5
M7[;_ .Q'=_"K49_&G@NWDN?#$[[IK9!N:T8G[I_V?1OP/.,_J[5;4=.M=7L+
MBQOK>.[L[A#%+!,H9'4C!!!ZBJC*5.2J0=FC"M1C6CRR/Y\=.U$3+M;@C@@]
M0:T:^H_VWOV*+WX2ZO/XQ\'6TESX5N7S)$F6:T<G[C>W]UN_0\XW?)>G:B)E
MVMPPX(/45]G@L;'%1[26Z/DL1AY4969HT445Z9QA7KOP9^/W_"HO 'Q-\,_V
M%_:W_":::NG?:OMGD_8\1SIOV^6WF?Z_.,K]WKSQY%143A&I'EEL7"<H/FCN
M=_K7QS\8>(?A9HGP\OM3,WAC2)S<6T&W#D\[59NK*NYMH/3/L,>PZS^VU_:_
M[3.@_%S_ (0SRO[+TQM._L?^U-WFY69=_G>2,?Z[IL/W>O/'R_164L/2EO'O
M^._WFD:]2.S[?AL>[P_M0^3\-/BKX1_X1G/_  G6K2:I]L^W_P#'ENE5_+V>
M5^\QMQG*]>E=1HO[9>D:GX$\/:%\1?A?I7Q!U#PY$(=*U2ZNS RHH 595V-O
M&%7/(#;1D9YKR3X(? SQ!\??$FH:)X<N-/M[RQL'U&5M1E>-#&KHA *HQW9D
M7C&.O->=UG["A)N-M5KN^UOR1I[:M%*5]'ILO4]H_:<_:0D_:2U_0-5F\/Q^
M'Y=,L/L3QQ7?GI*V\L77Y%V#GA?FQZFE_9Y_:-3X)Z?XJT/5O#$'B_PKXFMT
M@U#3)KDV[':& *R!6QP[ C&>F",5XM16OL*?L_96]TS]M4]I[6^I]"_#S]J^
MR^'M_P",=(B\!6.H_#+Q+/Y\O@Z[O&=;9L*,QSE"<_*O)7^%<8*YJE\9OVHD
M^('@"Q\ >$?!]EX \$6T_P!JDTZTG,\ES+DD-)(57(R<XP3D#).!CP>M^X\!
M>([3P=:^+)M%O(O#5U.;:#56B(MY)1NR@?H3\C\?[)J/848R4VM?7K_G^)7M
MJKBXIZ>G3_+\# HHHKJ.8**** "H;BW6="",U-12:N&Q[9^R-^USK/[,?B<:
M=J)GU3P%?R@WNGJ<M;,>#/"#T8=UZ,!ZX-?L'X2\6Z1XZ\.:?KV@ZA#JFD7\
M0FM[NW;*2*?Y$="#R""#7X%7-LLZ$$5[A^R-^USK7[,?B8:?J!FU3P%?R@WN
MG@Y:V8\&>#/1AW7HP]\&OC\?@'AVZM)>[U7;S7E^7H?08+&[4ZA^SE%9'A+Q
M;H_COPWI^OZ#?PZII%_$)K>Z@;*NI_D1T(/(((-:]>0?0!1110 4444 %%%%
M !7E7[6/_)K'QD_[$S6?_2&:O5:\J_:Q_P"36/C)_P!B9K/_ *0S4 9/[%'_
M ":/\(?^Q9L?_12U[77BG[%'_)H_PA_[%FQ_]%+7M= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !115?4-0MM*L;B]O;B*TL[>-I9IYW")&B
MC+,S'@  9)- %7Q(FE2:!J*ZX+8Z.8'^V?;,>3Y6/FWYXQC/6OQ2^+?@?PEX
MK^+NLM\-Y+F#PTLY,=Q=I\I'<CG.W.<$\D8R,U]#?M3_ +5&H_M":W-X0\'S
M2V7@2UD_?W?*-?LI^^W<1C^%3UZGG 'S;XD\1VVB67]CZ/PHXEF'5C7L97A)
MUJBQ+T@MN\O_ +7\_3?YK'XN,W[.GTZG)ZOI$&BW)MH;[[<5X+B/:!^IKWO]
M@GPUI'BS]HO3-.US2K+6=/>QNG:TU"W2>(D1Y!*.",CZ5\[$EB23DGO7<_!?
MXPZS\"O'=OXLT&VL+O48(9(%BU&-WA*NNTY".ASCIS7U->$ITI1ANT>51DH5
M(RELF?;_ ,(-8^%7QQU_XC^"M1^$'A[2]#\*K)=VEQ8Q!+N:.&4JV^50'W-@
M'ANA*G/6N'&I>"/VD_V7?B9K2?#;0/!6L>$ D]A<Z) L;;,;@K,%!;(5U;.0
M<@@ BOG'X9?M%^)/A3XB\7:SI-CI5Q=>)K>:VO$O8I62-9'+L8PLBD')XR6_
M&J?@+X[:_P##OX<^,_!>FVFFSZ7XJC6*]FNHI&GC"A@/**NJ@_,?O*U>?]4G
M%MQ[QMJ_G]YW_6HM)2\[Z+Y'TWXSO/!G[(?PK^&(LOAKX?\ '&K>*=.&I:EJ
M_B&V%P'RD;-'$2#M'[W QP %)#$DUW5O^R7\.=;_ &H/#-RFC"P\.:EX7?Q+
M+X6<D(MPLD48CVYR$_?!BG3,;#[IVCYB^&_[:?CCX>>#K#PQ/IGA_P 7:3II
M#:<GB.Q:X>RQ]T1LKJ<#MG) X!  %<S>?M2?$6^^,$'Q+DUO'B6!?)BVQ 6Z
M0<_N!'T\L[CQUR2V=W-3]6KZV=GKK=ZWVTZ6*^L4-+JZTTMM;?7K<^TOV/OC
M=H?Q9^(_C"UL?A=H7@FYT_2)OL][HUJ('%N98P;>?: &;(1@<#&QL <UY_\
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M?>N39ZC%.P91_<?MN [=^HKD_#]IIOB2!)+;QE>12,.8;B5D<>WH?P)KNP>
MQ>.BY45'3=.6J_ \+$YK'"RY:D&?LI17Y"_\(,/^AON?_ AJ/^$&'_0WW/\
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M\W_\CNNHJF?T:4G"<'<_1FBOSF_X9ST+_H;=3_\  QO\*/\ AG/0O^AMU/\
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MLU/_ ,#&_P */["S'^6/WO\ ^1#_ %CP_P#*S]&:*_.;_AG30O\ H;-2_P#
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M=3_\#&_PI?\ AG/0O^AMU/\ \#&_PH_L+,?Y8_>__D1?ZQX?^5GZ,T5^<O\
MPSGH7_0VZG_X&-_A2_\ #.>A?]#;J?\ X&-_A1_868_RQ^]__(A_K'A_Y6?H
MS17YR_\ #.>A?]#;J?\ X&-_A1_PSGH7_0VZG_X&M_A2_L+,?Y8_>_\ Y$?^
ML>'_ )6?HU17YR_\,YZ%_P!#;J?_ (&M_A1_PSEH7_0VZG_X&-_A3_L+,?Y8
M_>__ )$/]8\-_*S]&J*_.7_AG+0O^ANU/_P,;_"E_P"&<M"_Z&W4_P#P,;_"
MC^PLQ_EC][_^1#_6/#_RL_1FBOSF_P"&<]"_Z&W4_P#P,;_"C_AG/0O^AMU/
M_P #&_PH_L+,?Y8_>_\ Y$7^L>'_ )6?HS17YS?\,YZ%_P!#;J?_ (&-_A7'
MZP_B3]G?QMI_B3X?ZW=ZK-8K_IEA>S&2"^B/+1'T.!P>QK.>2YA3BYN":79M
MOY*R-J6?X:K-0::OU/U)HKS?X#?'?PW^T%X%A\1>'Y3'*A\F_P!-F/[^QG ^
M:.0?J#T(Y%>D5XJ=]4?3)IJZ"BBBF,**** "BBB@ HHHH **** *^H:A:Z38
MW%[>W$5I9V\;2S7$[A(XT499F8\   DDU^9?[5/[5FH?M!:S/X3\(W$FG^ ;
M23]_>,3&=0(/WWSC$>?NH>O#'G 7Z3_:X^%'QE^.P/AOPS-IFB^"D(:5)+PB
M?4)!R#* ,!%/W4R<D;FYP%^59/\ @F?\7I4"-K&F^6.B"\PH_#94TI4G5_VA
M/E71+?U\OS]-_,Q7MJB]G35EW/!]=\26VEZ?_96A_P"KZ27 '+GOS7$&-V))
M!)/>OJL?\$Q/BOWU73/_  +_ /L:/^'8GQ7_ .@KIG_@7_\ 8U]/_;-%:*+^
MX\;^SZA\I^2_I1Y+^E?5G_#L3XK_ /05TW_P+_\ L:0_\$Q?BQVU;3/_  +_
M /L:?]M4?Y7]P?4*A\J>2_I1Y+^E?5?_  [$^+/_ $%=,_\  O\ ^QH_X=B?
M%C_H*Z9_X%__ &-']M4?Y7]S#ZA4/FV#Q=XCMO#%QX;AUS4XO#MQ()IM(2\D
M6TEDRIWM"#L+953DC/RCT%5_#^O:SX3U:'5-#U.]T;4X=PBO=/N'@FCW JVU
MT((R"0<'D$BOIK_AV+\6/^@KIG_@7_\ 8T?\.Q?BQ_T%=,_\"_\ [&E_;%#;
ME?W%?4:N^IX3IOQG^(^BI<+I_CSQ18K<3O=3+;:S<QB69SEY&VN,LQY+'DGK
M6)XF\8^)?&MQ'/XAUW5->GC!"2ZG>27+*#UP78D5](_\.Q?BS_T%=+_\"_\
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MQCU#3+M-KQ..5/9E/9AV(K\EOVD_V9O$'[-?B@R*)-1\*W<A-GJ"+QCKL?\
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M>)??G_9V[O:N>\#? KQS\2=*OM1\.:#)J=M97*VDX6:-'24X^78S!N-PR<8
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MMY_I]YUFL^-_#>H>$SIEKX*MM/U/RHD_M5+MF?<I4LVS;CY@".O&ZLOX:?\
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M*P_Y^DH_X2*P_P"?I*_2K_AW?\)/^>&J?]_H?_C5'_#N[X2?\\-4_P"_T/\
M\:I?ZR8C_GU^/_ #^PEW/S5_X2*P_P"?I*/^$AL/^?I*_2K_ (=W?"3_ )X:
MI_W^A_\ C5'_  [O^$G_ #[ZI_W^B_\ C5'^LF(_Y]?C_P  /["7<_-7_A(K
M#_GZ2C_A(K#_ )^DK]*O^'=_PC_Y]]4_[_1?_&J/^'=_PC_Y]]4_[_1?_&J/
M]9,1_P ^OQ_X ?V$NY^:O_"16'_/TE'_  D5A_S])7Z5?\.[_A)_SPU3_O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_'O1/VK+/PU\*_A/%<^+-3N=4CO9KQ+62*&(*CH!\Z@@#S"S.0%4+U.3B/\
M:\'B#XC>./AY^S]X*M5\1W/AO3X;S4;=IA%'/+'  JR,64*!$"<Y'^O '.*W
M^LRI*JJ<G-:*+WU?2_6VYY*R.ECZN!J8VC'#S?/*K%+D7LX6:DXOX+_#T3W/
M0?V,OVF/'WC'X@ZCX'^*MR'UF^TRWUG19'M8K<O"T8D*XC50VZ-U<<9&QP>F
M!]FU^9G[0C_'+PCXO\'?&3Q5X!T7PQ_PB<L%H)]#NU=982YVQ2*)7(0AG3(
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M: !48C..G<U\?ZAK_CJR^-OPA^''C^$_VKX(\0V]E;W3L6::VDN;<Q_,?O(
MGRMW5E&/EKZ*\?Z[IOAK_@I[X:U'5]0M=*T^'26\V[O9UAB3-C<*-SL0!DD
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MQ2ESJMO8Q1W4ZD@D/*%W,"57@G^$>E;M%/ECHK;$NO5;E)S=Y;ZO7U[E#7=
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5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>anvs-20241231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (V @8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D/ I:0]* $W4;J2ODKXL_\%"-.^$WQ7\<
M^$I_AIXJU_2_!0LY-=U_15CFALXKF%)4D="00H#D<D?<- 'UMNHW5S<OQ&\+
MVOA?3/$=YK^G:=H>I0Q3VE]?W*6\4R2*'0@N1R5(..M<%^T/^TGH?[/G@OP_
MXCNX8]9MM:U:UTRW2"\CCRLQQYX8Y#(HP3CL1S0![#NHW5B67C?PYJ5]!96F
MOZ7=7LY=8;>&\C>20JH9PJALG"LI..@(/>G:?XRT#5]9N](L=<TV]U:S_P"/
MFPM[N.2>#G'SQ@EEY]10!L[J-U8VI^,_#^B:M:Z7J.NZ;8:G=*7M[*ZO(XYI
ME'4HC$%AP>@[57G^(7A6UM8KF;Q+H\-M+'YT<TE_$J/'O";P2V"N\A<],G'6
M@#H=U&ZL/4?''AS2-6&E7_B#2[+4S"UP+*XO8XYC$H)9]A8-M !).,  T_4?
M&.@:/H<>M7^N:;8Z-(%*:C<W<<=NP;[N)"0ISVYYH V=U&ZO(_A9^T)8_%/X
MO_%/P-9Z;Y$?@8Z7_P 35+M98M06]MWF5D4*-H4)C.YLYSQ7H7A_QKX>\627
M4>AZ]IFLR6K;+A=/O(YS"WHX0G:>#UH VMU&ZO(/VG?VA8/V<O -CK,>AR^*
MM?U?5;;1-%T""X%O)J%Y,V%C$FUMH"ACG:>0!WKSSXQ?MLW/PN\92^#])^&6
MM>/?$^CZ+'KGBBW\/W*M!HT#+D@2N@,S8R0-BEEP>,D  ^HMU&ZN5^%OQ)T3
MXP_#S0/&GAR9Y]%UJT2[MC*NUU!ZHXR<,K J1D\J>37B&B_ME:EXN^+VM>#O
M"_PD\3>(]&T3Q)_PC6I>*K.6'[%:S*Z+,[ G=B,/N(ZX'O0!],[J-U>-?M5?
MM'6W[,?PU@\3/HW_  D>H7NHV^EV.E?;DL_/FE) +2N&"* "2=IQQG Y'<^%
M?B+I6OZ?H:WE]I>G>(-1MT=]%CU.&YDBG,*RR0JR'$I0'.Y1@J-W0T =9NHW
M5SJ?$;PG)=7=LGB?1FN;29;>XA&H1%X96.%1QNRK$@@ \T[5OB!X7T%KA=3\
M2:1IS6\B0S"[OXHC%(X)1&W,,,P!(!Y.#B@#H-U&ZLA/%NAR:_\ V&FLZ>VM
M^5Y_]FK=1FY\O&=_EYW;<=\8J/4/&WAW2-;M=&OM>TRRU>[Q]GT^XO(X[B;)
MP-D98,W/H* -O=1NKD/B[\2=/^#WPR\2^--4C:>ST6QDNS;QG#W#@8CA4X/S
M.Y5![L*MZ9XWL-FA66N76GZ#XGU.TCG_ +"FOXVG5RH+H@.UI K;EW!>=N<"
M@#I-U&ZL36?&WAWPYJ-G8:MKVF:7?7AQ;6M[>1PRSG./D5F!;GCBKNLZYIOA
MS3I=0U;4+72["+'F75[,L,2?5F( H O;J-U>7_&7XR77@+X)ZY\0_!FC6?Q%
MBTJV:^:SL]56%9[=.9GCF6.4,R*&;;CG:1G. >J^&GQ TKXK?#[P[XQT.0R:
M3KEC%?6^_P"\JNH.UAV922I'8@B@#I@<FG4T=:=0 4444 %%%% !1163HWBO
M1O$5UJ%MIFIVM]=:?.UM>00RAI+>1205=>JGCOU[4%QA.47**;2W\O4UJ***
M" HHHH **** "BBB@ HHHH **** "BBB@#YK_:4\4_'+1/'5C!\,M.FN]!;3
M8WG>.RAF N?-E##<XS]P1\=.:\F_X6#^UO\ ] 2Z_P#!5;?X5]VT5#C?J?>X
M'BBA@\-##RRZA4<5;FE"\GYMWW/A+_A8/[6__0$NO_!5;?X4?\+!_:W_ .@)
M=?\ @JMO\*^[:*7+YG=_KEA_^A5AO_ /^"?"7_"P?VM_^@)=?^"JV_PH_P"%
M@_M;_P#0$NO_  56W^%?=M%'+YA_KEA_^A5AO_ /^"?"7_"P?VM_^@)=?^"J
MV_PH_P"%@_M;_P#0$NO_  56W^%?=M%'+YA_KEA_^A5AO_ /^"?"7_"P?VM_
M^@)=?^"JV_PH_P"%@_M;_P#0$NO_  56W^%?=M%'+YA_KEA_^A5AO_ /^"?"
M7_"P?VM_^@)=?^"JV_PH_P"%@_M;_P#0$NO_  56W^%?=M%'+YA_KEA_^A5A
MO_ /^"?"7_"P?VM_^@)=?^"JV_PH_P"%@_M;_P#0$NO_  56W^%?=M%'+YA_
MKEA_^A5AO_ /^"?"7_"P?VM_^@)=?^"JV_PKN_@?XQ_:)U7XHZ+:^.]+N+;P
MK)Y_VR5]/@B"X@D,?S*,C]X$Z5]94AZ4^7S.7%<5T,30J4%EF'@Y)KF4+-75
MKIWT:W7F-K\??VM?!&KZW^U'^TEXGAOM;G\'^&[SPK-XN\-Z1?26PU;29+*,
M3;@APQCV C<"%#NW&*_8*BK/SX_*_P#:Q_LD_M%>#=?U?5_"^E_!V?P3;1^#
M=0\5^'[C6=" ."\:11, DY3:P9P?D"C@A:YWQ5\)=)A_8J\&7L^K6GC3P_>_
M$NUET%VT:YL(]/L[F3;<6L$=R2_D.T>1@D$$\DYK];KBVBNHC'/$DT9ZI(H8
M'\#4@&!@<"@#\Y/@Q\)434?VRM3\ Z+;V_Q!TS4K_1_#%U;H%GLE^R,$BMF_
MY9D_* 1CE4SP!7C_ (.'PIU70O@#HGP1T34K+]HS3=;T]_$$D=E=0W=H$!&I
MM?R. C1%LY&3\IQ@#*U^O=1I;Q1RR2K$BRR8WN% 9L=,GO0!^5GCN'X4>&/B
MK^T99_M!^%M7UCXBZUJEU<>#KG^S[JY>ZTPQ_P"A)8R1@K&\> "Q*@8 )^5A
M5']DSP'H'Q ^)W[*]AXDTJWUBQMOA]JE]':WB!XO.34KDQN5/!VD[AGH0#U
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MR\'U%>3_  ]^$,,WQ!_;-O/ ^AV\7CO0X4TKPG-;H!-I^[394$=J?^6;, J
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MU_X*K;_"C_A8/[6__0$NO_!5;?X5]VT4<OF'^N6'_P"A5AO_  #_ ()\)?\
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M7WANX^R7%U<O9SRE=P&-H-L<+C;^]R02%QY%J?[2'Q-N_P#@G1XG:?QQKO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDR/N[OE /ORL31_&^@>(?$&N:%IFL6=_K&AM$FIV5O,'ELVE4O&)5'W2R@D
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MX8MOB1<>/!97$_BB6V:T6ZN;^XFCMXF$8=8('D,4&_R8MQC12VP%L\U2\4_
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MO0!3$5\D,OV-XW>X^;/78*8+8K;Q3R1;K\ G8Q].]7&LS+9'[.ZPQI)L=D/
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MTL5NH=,CA\T ><:]8RB$K&5> (S1L#RIQTKZ5_X(]Y/[/?CW=U_X3R^S_P"
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MD>U,1GN;HK-;1#:RL<!F[8]: /';'XT^'O&'B&^T*VNYX;VTG$+));%%Y/\
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MX=_Y'OQ=_P!N?_HHUU=8^F:')8>(=:U%I5=+_P C:@'*;$*G/US6Q0 4444
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M4 ?03?"/P*]QXBN&\%^'FG\1IY6M2G2H-VJ)S\MR=F9AR>'SUI=1^$W@G5O
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M+7]F_P"(H^('B.-] \O3+)_'%]9ZP;ZW*:L=:,36L"()/,1D*L',JHH*+M+
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M$9-_@W4 /^F?_HQ:\0)FAFW#:1Z$\U[C\0_^1.U#M_J__1BUXHR&4YVX8=Z
M(PD3'S-A1C39 LC@9YIZ%@Y# '\:)5#MG9MQWH 88PG?!]*3!_V?SIV-_;\:
MC=!_"30 [;N.#C\*1MQ.".!WI4 49)P:0%7<#=D=3B@!NQ6..3]!4<A!(W*<
MBK$KHYVQCY>F:A\C'?- #9#TR,;N*3R#$?DP7'(%/&"=K''O2.50%02QQU%
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MJ-AEB)6D2555E\KANM $*)DF0MG%-$,C,60 \]ZG3 !2($CWIS$+P$)8^AH
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M]Q(K73POK1.3I%^OM]F?_"C_ (1;62__ "";[_P&?_"@#&@5F)7L*;LVR9<
MCWK7?PSKJ,=FCWY'_7L_^%#>%=9EQNT>_'?_ (]G_P * ,Z95?:&'RGICBFI
M^Z4\;@.U:7_"+:V2/^)1?@>]L_\ A3QX5UER2=)OQC_IV?G]* ,=9/WP*H1Z
MYI'422MN?/L*U;GPQKS.H71[['<_9G_PIW_"(:T0<:1? ^OV9_\ "@# D9AD
M!2H^E"Q,X^5,FME?"NN1(<:/J#D_].K_ .%*?"FMX_Y VH#/I;O_ (4 8T<:
MJ.F#ZYS3QE3E9,'T K37PEK:1L!HVH>W^BO_ (4R3P=K+Q*/[&U'=ZBVD_PH
M Q?MR03.K(Y8]2_RTLEP53)"2QGLKY-2:YX)\10PA[/1-2E;O_HTC'^5+;>$
M/$T]@AFT;40X_@^Q2*?_ $&@#.BEFAFWQPL8#U ZU;-PUQ$\<;>7GH#VK9M?
M"VN1PC.B:CGT^RO_ (4K>%-?968Z)?*>P%J_/Z4 <_9P7$((FGWK_=Q5@J'P
M2N<=A6C!X;\0NY5_#^H*/[WV63_"K"^%-<QSHNH#_MU?_"@#&><C 50"/45
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M>YS\E[[7OK9V9]F45^=G[+GAF]^*,UOJNK_&*_T34+/5HHX-$N;]GDOE78^
MK3*2&)*X"GIWZ5]!?ML^+=8L_"WA3P?X;O)[/Q!XHU>.V@>VF:)RBD C<IR
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MLCU5[.,W2+@KA9<;@,,1@'H3ZT^4\V7%%%XF=?V3M+#>PW6_*H\WIY;GQ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR@%#N#9- 'U#X5^*7ACQOXH\4>'M$U(ZAJGAF>.UU9$MI5BMYG7<(Q*R"-W
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MW4>J3PPI!Y D^=4C;S'?,+ @L,'@"ON'X1_\DI\%_P#8%LO_ $0E '64444
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MG_WZC_\ CE(?V@?#JG!L]3SZ>5'_ /'* /3:*\P'[0?ATD_Z%J@Q_P!,H_\
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M [&, ]:.]* 6!YR:.BD$9H 3O2$9IRC Z8H;K0 S:#1@+G'6E8]NU$8 !Q0
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MS4?PW_X'K7VG_P *2^'?_0@^&/\ P36W_P 11_PI+X=_]"#X8_\ !-;?_$4
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M6W_Q% 'Q6/VF?A-N'_%Q_#7_ ('I1_PTS\)=QS\1_#?_ ('I7VI_PI+X=_\
M0@^&/_!-;?\ Q%'_  I+X=_]"#X8_P#!-;?_ !% 'Q9_PTS\)/\ HH_AO_P/
M6C_AIKX2?]%'\-_^!ZU]I_\ "DOAW_T(/AC_ ,$UM_\ $4?\*2^'?_0@^&/_
M  36W_Q% 'Q6O[3/PEW'_BX_AO'_ &$$I?\ AICX2G_FH_AK_P &"5]I_P#"
MDOAW_P!"#X8_\$UM_P#$4?\ "DOAW_T(/AC_ ,$UM_\ $4 ?%G_#3'PE_P"B
MD>&O_ ]*</VF?A+C_DI'AK_P/2OM'_A27P[_ .A!\,?^":V_^(H_X4E\._\
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M(@^F V?PK<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6MO://\ ;$CD9A$R2K#$63:&%R VXA, 'H/@[X*^#? 5_'?:)I#6MXDEU/\
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M<'A!]1F\.V_]M>'-.N9O%NEV[/+Y&H+</9V]E"ZY(\ZXCDD#E7Q#&#M/FH:
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MJI!&!70^"_ .C> ;6\ATF.Y:2]G^TW=W?WDUY<W,FU4#233,SMA550"<*%
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M/D'GYFR44 :V@>&]-\+VUU;Z9;?9HKF[GOYAO9R\\TC2ROEB3R[L<= ,
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:9C)Y:[8Q@DA0 3PH'4GJ:TZ** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>anvs-20241231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 anvs-20241231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &9 Z8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[+QW^W;X[\3:3H-SX?TC5- ,]M;W5N87D7=:CSBO;S"K/[[L\]:]O_;@\?\
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MI#Q-^WE\)/#'B&\TF35+^_:SE,%Q=V%B\UO&X.""XX/((R,CTS5#6?$%E?\
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M1D'@CCH:^"+']I?QWX3_ &)+#QKI%Y8:=KK>+&T]GM=+MHHC 8W8KY2H$!)
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M]7#8"G&*]+_8\^-?B_XE+XZ\+>/1;3^*O!FI#3[J]M45$N 6E4'"@+D-"_(
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M#XH>$[_X@WW@JUU>"3Q7:0"YN=.6-PZ1\88MMVG[R]^]=;7Y_? C4_$_AO\
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M[)OIKMU\SF?#V:5,/'"5ZL(\OM)1IM^]:-^=JT7NX65WK:Z5KL^UZ1E#J58
M@]0>]?"'C_\ :\\5^,/BKXIT#PYX^\/_  OT/P[,;:.XU6R^U3ZE*I(;JCA5
MRIZ 8&.3GB+7/VVO&FJ_LM:MXGTZ6TTOQIH6NV^E7=Y;6ZRVUW$X8B6-) 0
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M&R?+;ELNUK/J?-_PJ_9:\56?Q7;XE?%#QI'XR\56UF]GIPMK8006JLK*6V@
M9VNXP !\Y/)KJ/V7?V?+WX#>%/$>CZKJ5IK']K:E)>@V\;*JHR@;"&ZGBO<*
M*J&%I4VI16JOU[[W,<5GN.QE.=*I)<LE%644DE"[BHI)62;>W<^/3^QO\1_
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MY4<>GK'@+]C;4XU^(&M>/_&4GB3QKXPTN329M4MH?+2UA< ?(O'/R)P   H
M%?3BZ?:I>/=K;0K=NNUIQ&!(PXX+=<<#\JL5C# TU)RGK=M];:^7?S/2Q/%.
M+J4:=##I0480@W:+D^2WVK7Y6U?EO8^%]4_8.^(NN?"JU\ 77C?PY#HFF3>=
M9-;:1LGG.]C^_E'S$ .V .IQG.!7MGB7]G#4]=^/GPZ^($>L6D5EX7T\6<UF
MT;&2<[6&5/0#YN]>^45<<%1ALNW5]-CGK\3YEB'><E]O:,5_$5I[+=VW^X\2
M_9U^ 6H?!7Q!\1M0OM5MM23Q1K#ZG"ENC*8%+R-M;/4_..GI7FNO_L=^,_"?
MCKQ%K?PI\;:=X=TW7[AKJ[TO5]+BNTAE8DDQ%T; R21@#'3D 5];T53PE)P4
M+;;:N^OF<]/B#'T\14Q/,FZB2DG&+BU%)*\6K:65GN?./CO]DJY^(WP.T/PG
MK7B@2>+]'N1?VOB2WM%A(G&?O(N,C! SU^53VKSWQ'^QU\7OB1JWA34O'/Q6
MLM>E\/:A%/;VPL?*B\I65G/R*N9&V*,D'CO7VA14SP5&>Z?3J];;7[F^'XFS
M+"JU.4=Y-7A%N/-\7*[>ZGU2LC&\9^&8/&O@_7/#US-+;6^K6,]A)- <21K+
M&R%E/J V17QI<_L)?$2Y^%DGP[/C;PW'X=@F,]M-'H^V[F._<!++UP,D\<YP
M,XK[DHK2MAJ==WFO+?H<F6YYC<IBX862M=2UBG:2V:NG9ZGS5XI_94UCXD:G
MX TGQ;KUI<_#SPK8P1OH5HDBOJ%RD87S)6/&S(&%';/]XX7X>_LF7WASP#XW
M^&>OZ_'KOPVU@NVE6I#"\TW+;EPQX.U@K =-RYQR:^E**GZI1YN:VOZ6M;T\
MC5\0YBZ2H*=HJS222M)2YE)::2N]9;M:;'Q=-^Q5\4M<\+V7P]UWXNI=_#*T
MD3;816"K<O$C!D0OC)P0, L0,#C@5ZK<_LRR6_[0_P .O'FE:A;6?A_PCHKZ
M.FELC&9U\F>-2&Z8'G+U_NFO?**F.#HQV7;JWMM\C2MQ+F->ZE))-332C&*?
M.K2;22O)KKN>$:U^SE>ZU^TO=?$J35X(]*N/#[Z*UBB,)P64J7#=.]>+6W["
M7C_3OAUKGP^L_''A^/PK>3/<1SOH^;Z0E@RH\O4+E5)VG/& <$BON"BB>"HS
M;;6]^KZ[CP_$V9891C3DK14$KQB[<E^5ZK=7>I\Q^)?V2]7URQ^!D$>O641^
M'L4,=T6B<_:]BQ ^7Z9\L]?6OI#6-+AUO2+[3KC=]GO('MY-IP=KJ5./P-7*
M*WIT84[\JWM^"L>5BLSQ.-5-5I7Y+VT2MS2<G^+/ECX)_LN?$3X/Z?KOA,>.
M]/U+P!>6M[%!I[6&V=9ITVK(SXR,'&0&(Y/'3';_  %_9VN?A9\ +[X;ZQJ\
M=\UZ+R.2]L%9-J3J5RN[G< :]PHK.GA:5.W*MDUN]F=V+S_'8Q3562]YQD[1
MBKRC>S=EOJ[OKU/AL_L)?$,?#"\^'<?C?PY'X:$QG@G71\7DIW;@LLO4+WXR
M>@SBO4]9_97U;4_$'P*U!=<LD3X=VT<%VAB?-V56(9C]/]6>OK7TC16<<#1B
MK)=NKZ.Z.NMQ3F=9J4I*]Y/2,5=SCRR;LM6TSP_QY^S_ *CXN_::\"_$^'5;
M6WL/#UB]I+821L992?.Y4C@#]Z.OH:\I^(G[(_Q:^)\=_H_B#XA^'=1T*\N/
M,:[E\/Q"_C3?N"+(%W#' ^_TXSBOL:BJGA*52][ZN[U?]=#GPW$6/PCINFXW
MA%1BW&+:2;:LVM'=O7[]D?G[\=_A1J<7[5?P3\%^%/$-SH6H:?X8\BQUMH_,
M>)X!=,K,.A#;,$=,,>#TKVCX7_LK^*4^+2_$?XK^-(O&WB"TM'LK"&VMA!!
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M (W<D XR*]$^%O[5MK\3OVDOB-\(X_#DNGW'@Z$2OJK78D2ZRR+@1[ 4^_\
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M,X)SC!^YOAO\2O#7Q<\(67B?PEJT.LZ)> ^5<PYZ@X96!P58'@@@$5Q/Q?\
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MS&!G;C<S'.,\]:SOBC\$?!'QHM],B\9^'X-;&F2M/92/(\4ENS##;'1E8!@
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MB@ HHHH *^?_ -OG0=2\3?L@_$O3-(TZZU74KBPC6"SLH&FFE/VB(X5%!).
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M\*D+ 8R0,T@/CG]G!_%O[-UMX<T#Q5X1_P")W\6O&VJZQ<66G7B-%X>5[=9
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M]!QCZUZ/(E43<GL<<*B<7[J+>E:CJ]]*I(V!&_>$RY'3GM3O$6KW6A6+7O\
MI=P(1O:WM55VE']T9Q^M9\WBE-&U"XL9XY$C,@B63;N+EN@"J,_C6AKEC:ZM
MIRRW"W6WRMNQ.&/L5QD?E3E4?(U!ZHBRC)2DM#E/$GC_ %?2M*>[!6&3=N2*
M0D!U R5R.AP#ST'-,\#_ !1/C/2[?4X;L^1=VR21HN"0[9Z$'#*.F[CI7(?%
M+46TNZO;N62T32Y+%(TAO(G7R922)&+#Y6'EY&T8.?K7DG[(VA:EIOP]FUG1
M(93X<@UW4DLX+PYDFLP4\IX_FVC:=X(XZ$<$5X4L96A7ERMM+H>['"T98:-1
MJS>Q]&^./&EQX;TN\U)M5D5+2$3%(V4*>.0PP>N/6LS1_B:_BS1Q<V5],A-O
M%>)LEV!PV0%R1G'&#[USNL>!++Q-I@>33Y9[QI'G,BW)#W#L%^_P!@[0 #NX
M''OYSX<\9OX2TS^RIK:[N(;&_%E#JMG$LRS122'<F6P596&#U ZCKBHJXVK3
MJ*4W9,TI82G4I/D5Y(YG]JOQ=\1_!7]E:OX?\8^(+&TE?9/;V['85/&1N!VL
M#T'3U(KN/AI\4/%=WX9TV'6==O;R[G0V[S*ZF<'JCE1]UBO(&,^YR*[#XE^$
MF\=:!:Q6$T5Q<Q,ES)9W $J3J?OQ,'&W:X[X.#CJ*X?X4?"O1]+N;O4/"NH9
ML4GD74]-N+822QN 2T9VD893TR.F,5R55BO:I1D[,]6%3!3PW+*FE)>1[U\/
M_$EW=W,NC7FH74UY"H:*:<A6G0C)8#J<9P?0@CM6U<W&LV-[)";IY(RH:-A]
MX#N#ZY/0XZ5XF_C6XU^^MI+"Q9+FUNHEM;Y(G5R#P5F7&5!P1G[I_.O;(;RX
MU.W,\T?V9EQ@,>0.Y/K7TF"Q'M[PN].K/D\50]BT[*QG>*?&DV@^'VOKA[A8
M('$=W-",LB%@ID&.@!/)[5Z#:2JUK$R.98S&I60MG>,<'/?-<,EM;7_G6-TD
M<J/%L>)FQYB'J,=""./IVK?\.VD6F6<5G:3[K>%-D<$CG* =!R.@'%=Z<HR=
MW='!4BFM#R+XUW?BD:Y;S:!XDO\ 2Y+8;FLXBHAF0<G.0<$=.O(KM?A1XXD\
M76JR3W,CS-"&:-SP&'#8[_TK;\5Z':ZL@DFMWBER%62,AQR.]<#X;\%OX(NW
M2/5'N4GEDDBDEPOE9_AP.P^M>A*<)07*M28VDK,]*UV/5;22*?3YA)"9/WT<
MS_=7'53BM59)KFU)0D28&-IQ60]TYMUMY7,IB"JQS]XGTJ[I_P!KM@=Y1X2/
ME/\ $/3\*X^;704HM(YWQ#K^I::K)$9!*00)"!M0]B?KZUY['XM\566K7WVV
M6Y2W4*T.7W!B/OKT';D5W'C:2XNE6T6U8AI MQ(O&V,]1P<D'^E9_B/3;N^T
MLP0HOEQ*K6LBH0^]>@.."".*XZT9UG[DFK?B>C0E""O**9ZCITWVFSBE_OJ&
M_,59JCHC,^DVI==K&-<KZ<"KU>I&_*KGDNU]#FO'ZLV@?*,GS5./SKS0J[3Q
MSLOR8P,'\Z]0\;PO-HRA&*L)E.1U[U\[ZS'K-OXMDL#*YM+N)C Y;*K(/O#V
M]JX:UE.[=CLH)M.QW@Q'(TC*!O4*#G)SGG^8ISHC1JR)\Z_+C%8^B:;=:5HJ
MP3RF:8');N/_ -6:V(I)8%3Y@48<MT(]><UE-:V3N)/2[);M(4;,RJX9=K#U
M]JJK;N\96,I'$#N50.!4TP#QM(&WIC=R:6TES&D,A C(+[EYXJ5&VQ#;2N4'
M66ZF\O+$L3DGC-74MQ';['P(SD/D'=^%,TURM^[*?,5>$/I5R[E#9'S;2P.'
M/4TI7BRU)V*4]D+ZS%E*I6.567CH0:J^$/#.F^$$FCLBY9V!<R<]OY5KI#).
MJI'D29.XJ>,=_I55F>.X<&0GGIT ';_]=7&<N1P3T,W'6X^X#W%Z\H((P%!5
M>/6DMHV6-< %.<D'H:FA(2(HK;E//)& ?7=1AQ#+*<<=/I62<K60XZ#PY%K(
MF44=\CFJH8)&TJKPO53WI'G9UXP58XPO)%3^7)$,/'@YZ'KBG;E6I:DF0+'O
M1=RY=FRIQP!W%<+\0++4-3UNUM-.>9WEB:,M V!&>VX=Z[\ML*@G'.1CO6OI
MBVQMGN?+42J3]:4G+HRJ=3D=[7.9T6WN=/TN*VOPWGH C2 ??(Z$CL:NQ":
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M&%)UF^7H>W:)JQU.VEDF,;!01YH< D@]"O;'KWJGK6EVFMZ>\?F[ED4A)8W
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M>OYU;MY$BN1YA#+C:P(^]GI31(EO=JP<X# ,&X)'TJ+V=B9*R&2"6TA195#
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M3-XQCB(RCLS\_?VFM9C^&GQKTW4[#RS:"U>5K&<;<>:3\Z@?C\W8XXQ7GO\
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M]:U[_P 0^'7\ZQ\;W,"1RW26 64CYI3]WCJ W7!&/2NML/A]I>A7?G:<< @
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MN3ZE%.VV8*C1$#  ZX-:LY\EW8E3O.<*!T]/SH!HR-1T6SUJS\C5;:.Y56W
M,/NC/;T/%6X;:.UA011B. )\B( %4#H!^%+-*"#A6;C)P.M.E#?9OF78GW3Z
M#'XU?,TN5@D%K:O?2CD+ST)[=\5@>/81]BS'>/:L#G:C#Y_KWH\9^.;+P-I4
MMS<E6D/S)&S'I^=?)^N_M/)XO\5/86[DR$X7:W 'H*\_$3GM!7/;P&!G6?M'
ML>[Z1XG-G=&.0%P?1LDFO1--U-;GRV+;68#  _.O(_AXMK-;VTMY,7>9CM(
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M-+%'(9[5& _O#+$\C()XW5[WHWBW4]<T9;G1K"&U22037%PO"RGIMVHP<Y
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MJ=UD\V3RI8SG=TQ_C3;Z>YU57!G\J)F'('S'CK7OVOL>6E9%^TCMI--,4O\
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MVE_I]U:10G#$QMU_+FO6/!?AV'2K&XN;6TN);J1#&C*A8J#_ !$=J_1C5/\
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M<636Y5]C>: NT^A/OVKZFGF%"JKQDCX*KD&*A*SB>?%"6QBKUC8R/,@VDCT
MYKL]-\ &_NW@AFBGN>%6)"<EL]/>O0?#O@#4?AG#H7C#7[",V5RYEM+9]I>9
M4;!8I_=##!I5\?"$7RZOMW-\+P_5E.,JVB;_ "/I#X1M\/\ PY\';/3/&'A2
MYTF]G4M'JT]@896PN[*2D;N2,#'KZ5XQ\4/$UAJ>LD@:C?K!&I@N[E(R^-W
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M0*])\?>(I7MHK>VOC<O?2JWD*K,\?/((R>#@8]:\PCL$OO$5Y#=[DN(W (1
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MH9Y)Y)[>ZA<C$D#D<'.!C)P>H%>\7+7UG9B>*$K=,WFF!)AA>Q#'N.]?E_\
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M)>';+1=7NIM:U>VB1KB\51 MS.3SM /'!Z=.*;XHUGQX+SRM-LH(+",-MN9
MDKL<<?+NS^AKZ".(C&BG-._4\&5!SFU':^ES2G\$::DYU1K2*.XE97W _,?4
MD'IVK2DT>!-0BB%P/.:/>Z-CY_\ =/!(]J\5TGXRWVKWES;:U)!X<UK3SL=I
M) T$[ @,?*8Y"LO0,!S6WXJ_:#B\.^(O#NDS:+-J-OJB,1J=K<6_V2RVGYA(
MSN'.!@_*#GI7/''8:KOHUW.QX+%P:BE>_8^C+-2ENBL<D  GUXJ>J>D7"W>G
M03)]V1%8'UR!5ROHXM22:/GFK.S.;\?1B70@K %?.7/ZUYS<6J+-"95(CQ@A
M3P17I7C<%M&7!(_?+T_&O.[P[$! SG@#/(KS\1\9TTGI8YS5+U=0+1QV[ ;M
MI'0D#IV%7].M_P"RM)6-BPE9B_KC)Z9J:2)G<%@0IY'/2K:SP."K)E5Y+ <Y
MK!U?=Y#3V:O<B6_<!8/)QGH0<_C5AY0F3YOE,J_PGK[46TB21N=I8X&#_P#J
MI9M-%Q;AY%SCD'&"?IZUB[O8I6ZCX[B(HDA8,&;)R?:EFU2U^T 2*%S\J8;#
M$^H'?IBLB#PW:O>O*2[2,, >9U^E1'P=IUK)'<1VB3W"-F.25V=@.^,GBD^8
MM*GW-BXA?SHW#21'G]WCL?6JTB?OH'51C)4^W''ZU<MY<?ZQR&/W@!D@"HY0
M 6'RAB>"!R*TC>QE>Y.EL\,UPL3 ,"&^8\*?\G]*MX"FS=<D$$$!<<CVZU5T
MM6EO#N)?=@$XS4TTAMY&C& !(2&4]#GKGZ4GH2U<769_M2CR@JRXP00<D>]<
MY>:797T,T-VFZ%N&)7KGMFNBN&4QB2-M_P NTL>2:SM6U%["Q<QVHG)QE/+Y
M_/K1S66I4%*^CL>(?$G]E;P#XD\PM8W,4TV6#PR<9SP1GTKY7^)'[#\.GO<+
M;7DDD>"\>W&Y,=L]#7Z-6-PVI6Z2^2T3/@F-AR:Y_5O"K:@96V1%%;Y7W')4
M]B*Z*=:=*#=*3BST:>+G&:C6]Z)^7OA/X21^$+^YC(,LH3$K3QEGC^A' S[5
MZ)\.O &H:Y]I:UMI)(6)*L%.W(.,C_"OM?3OA'IU[,[W<*.-V"N.6],FNWTS
MP=I6@1""SM$@C4\D*!V[>M<LJM7$+GJN[/<EFM'#15.A&QX-\+X=4T+5K>PD
MM6@M, .^#SQ_GBOI6RO(KO3[6U5-X9L[@.?J!ZTRW\/1:C SQF&/ ."W+#CJ
M>*Y#1/#<?@_49KW^T;J5)&)D$\Y=#V&,].>PK&$7!*+>AX=>K#%MSM:1VEO"
M8+EG&^-E!!W,.>M364L$5^9VW1 !E6.0[L^OY<57FN3=2B=&+ A2-IY/''M5
MJ6\CGM3YRH;D?*1QGIU]#6C5W<\VS.9U+QM>W.N&TBMV$:R##J<8_&NC>UGD
MMVNF;+]?]K'M5"WCMY)4DACVLN<$CK5J/5KHR-$%PF< /T6M9.+2Y58B$'>[
M'QF6%&.\+$XPP!ZYILL,#Q/B19-J[022,?0?C^E+':%94RR;2 >?YXJ#?M))
M."21M0=:S6K-%&Q&MN]Y<)$J\[<X(QDUH2:)+M5^C8V[!GCFKEC8/9*UPY"[
MAD_-TXJO>:C-(\:[3&H?A@<@XI-]";'I=%%%?0G&-(^;.>W2N:\<RSVVE-,A
MC\J,9*R=":Z4G!]JY/QK/'J]A<:7#&T]T2 HQP"?>M*?QH"G\+ E]X8%Z8EC
MDFD9\ =.>U;]_H:ZU<0_;55[>!M\:?[7J:\Z^&4>N>%]9NM-U1)'M]_##E%!
MZ5Z\CJZ@J0P/<5M73C4;3W)BK(\2^-5\-&>"R0MF?E,=QW'Y5R>@:A%;Q2%%
M99MG'F#K7J/QC\-?VS96-S&,/;N<N!D@$5Y%I)M[V>XLA<LZP$@MW!KU,+*,
MZ-@EK)'8-#!'96,\$?\ I;-G<IQ@U,K^??1-.Y>59,<'BLBWLVMQ;I/=97[J
MX.<>];;0Q+:KL.YAU8#FI;[FR(M9OI[&W9HXU,BD]/XC4#ZA.MBUQ);;CL#$
M-W]:MW$XDVK%"9BH&>>YJ*Z9Q9R)<,2@X,1Z 5*20-7.4UOQ7!X<6>\$1E>1
M 4B3^E8=A_;NOZ/>:U%!*;:/+!.YJ[IS6MQ>3OJ2;K=Y3%"L:9[?H*^B_#NE
MV&FZ'9V]O#&8C&,[4R#QSFMJM58>-VKMF&K9\:66@^(?%&NQVME9R7 EP3NS
MA.>]=P/AMJ^F^*+2WU*$+M VQ(?ED/UKZ)N;_0O!<C>9$FG"X;>\I4*,GU->
M/_$3XF6>I^/]&_LW5;?[):2!)) W))//UIT\54K2Y81LK$36FYTFO_#./Q'%
M;V4L;V>XHR<#Y-ISQ3O$'PPU>6[A,$RSP0%7C5^AQU%>G3:GIODV[W%S!^\
M,;%QR?:HHM;M-3U1K&SO%DGMOFFCC[9'&37EK$54;61\S_$*?58=<OFN\6TU
MNH:&-5PIQVJS\,O%4^OV;O( UW&WSXSM%>J?$GPUJ'B3Q+:6EMIZSVLB$2S.
M  E>1:/H4WP[\73Z>6*^:^6SRF#TKU83C5@EUL0KQ.ZMA/=S237%LL<N"GF
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M07N\NO92%0L"3SZ8KU[P3X!\?WVBG3=*.H>#M&6[<7VIH1+YF\ B2&) "1C
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MJTEBTD+"*96(^8[3@CG_ .M26^@-6*[^;D%F"AAC.T X[YQU]J;=%A%CY@V
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M_BQ2^FQ6EJ\TUSM4%U*[N#\V=U?GIX<\!-K(EN<JS0R+9S6EKYLEW< $;I$
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M]&U)P]WIUO<N.AEC#8J67PUILMDUF;2-;1E*M"B[5(/48%:1R>-.I[6+U?\
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MH **** "BBB@ HHHH **** "BBB@ HI"0.II: "BBB@ HHHH **** "BBB@
MHI 0>]+0 4444 %%%% !1110 4444 %%%% !129&<=Z6@ HHHH ***3I0 M%
M)UI: "BDR#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7M;L_#6AZAJ^HS+;
MV%A;R7-Q,YP$C12S$_0 U^7/P,_;?^*[?M >&O'?C>_G'P2^(>N:AHFD6DP
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M9E_9[\4?L^7O[/GB;Q1KMS_:%GINNZ19-/I5VET&'FS2JI7"[SU/W0H;;C-
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M_8"\,:SX-_9(^'VCZ_I-]H>KVMK(L]AJ5L]O/$3,Y >-P&4X(/([T 9OQ?\
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M3XC>#;[X*>)OB59:YJDFH:-KWA>S:Y@N<@JJ3E5;9Q@D'D?-P1S0!M_M,?\
M!3+4M'F^$>H_"W3M7_L#7YQ<:A->:+N^V0^8J-:P%AS.I5P0O]]""<BON[X3
M?$5/BOX!TOQ3'HFK>'4OA(1INN6QM[N':[)\\9Y7.W(]B#7P[^VCX1^*WQ4^
M$GP'^(Q^%UY:ZYX2UI=2U?P=HTGVRZMX=T178J+D\0C*@$KO&>A(]HO?VN/B
M+J5Y\+)?#_P&\6?V5XJU"6TU5M8M9;>?2(TD51)(@0A058R!G*@A2!D] #ZI
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KQ+]H']D+P)^TAJFE:MXDFUS3-<TN%K>TU30
M=3>TGBC9MS*.J')[E<^]>VT4 >'_ +/G['/PX_9LO]2U7PO::A?>(=27R[O7
M-;O#=7DJ9!V[B  ,@$X49P,YP*]PHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\HN_P!FGPA>_M#6/QGD;4?^$QL[!M.C47 ^R^44
M9#F/;G.'/.ZO5Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR5\S&W"GG=^%9GAG]O?X6>*/&UAX<ADUBS_M"40V>J7M@8K.X<G"A6+;@"2
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MO]/@$T7E@*=[?,&QAQT!/M69\*/VR_A]\6_%Z^%[(:MH>MS*7M;77+,6YNU
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M4>ZO9^B/E<=D^#HYSA<%334:C@I1;U7-*SLVD]5KJKIG.6O_  4.^$]SJEA
MQUVWTZ[*(-9GTTK9Q.P!*,^[.5/!(4C(."1S79?%G]KCP!\%_$FEZ-XCFO\
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MKN_,]$^-'[5?@7X&ZM:Z/K,FH:IKURGFII.C6WVBX"=G8$J%'!ZG)]*S;/\
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M"..,UY!^R+KT_P ,?'?Q ^%_B'P]K>GZ[K^N74UEJ*61-K&AC?#-)_"#M&"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>anvs-20241231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 7:32:22 PM-->
<!--Modified on: 3/21/2025 7:32:22 PM-->
<xsd:schema targetNamespace="http://annovisbio.com/20241231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2024" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:anvs="http://annovisbio.com/20241231" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>995200100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations">
        <link:definition>995200200 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>995200400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" id="DisclosureFairValueMeasurementsHierarchyDetails">
        <link:definition>99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" id="DisclosureAccruedExpensesDetails">
        <link:definition>99940501 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" id="DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails">
        <link:definition>99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" id="DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails">
        <link:definition>99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" id="DisclosureIncomeTaxesDeferredTaxesDetails">
        <link:definition>99941002 - Disclosure - Income Taxes - Deferred taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSegmentInformationDetails" id="DisclosureSegmentInformationDetails">
        <link:definition>99941101 - Disclosure - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>995200105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" id="StatementStatementsOfChangesInStockholdersEquityDeficit">
        <link:definition>995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans" id="DisclosureNatureOfBusinessAndManagementSPlans">
        <link:definition>995210101 - Disclosure - Nature of Business and Management's Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>995210201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>995210301 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>995210401 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpenses" id="DisclosureAccruedExpenses">
        <link:definition>995210501 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>995210601 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>995210801 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>995210901 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>995211001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211201 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>99930303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesTables" id="DisclosureAccruedExpensesTables">
        <link:definition>99930503 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>99930803 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>99930903 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>99931003 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails" id="DisclosureNatureOfBusinessAndManagementSPlansDetails">
        <link:definition>99940101 - Disclosure - Nature of Business and Management's Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" id="DisclosureFairValueMeasurementsCanaccordWarrantsDetails">
        <link:definition>99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>99940601 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails" id="DisclosureStockholdersDeficitEquityOverviewDetails">
        <link:definition>99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" id="DisclosureStockholdersDeficitEquityIpoWarrantsDetails">
        <link:definition>99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" id="DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails">
        <link:definition>99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" id="DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails">
        <link:definition>99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" id="DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails">
        <link:definition>99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" id="DisclosureStockholdersEquityWarrantSummaryDetails">
        <link:definition>99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" id="DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails">
        <link:definition>99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" id="DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails">
        <link:definition>99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" id="DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails">
        <link:definition>99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" id="DisclosureStockBasedCompensationSummaryOfPlansDetails">
        <link:definition>99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" id="DisclosureStockBasedCompensationStockOptionActivityDetails">
        <link:definition>99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" id="DisclosureStockBasedCompensationAdditionalDisclosuresDetails">
        <link:definition>99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" id="DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails">
        <link:definition>99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" id="DisclosureIncomeTaxesAdditionalDisclosuresDetails">
        <link:definition>99941003 - Disclosure - Income Taxes - Additional disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941201 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquity" id="DisclosureStockholdersDeficitEquity">
        <link:definition>995210701 - Disclosure - Stockholders' (Deficit) Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995211101 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables" id="DisclosureStockholdersDeficitEquityTables">
        <link:definition>99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://annovisbio.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99931103 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="anvs-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd" />
  <xsd:element id="anvs_NumberOfClassesOfStockDesignated" name="NumberOfClassesOfStockDesignated" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_CommonStockAndPreferredStockSharesAuthorized" name="CommonStockAndPreferredStockSharesAuthorized" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_NumberOfVotesForEachShareOfCommonStock" name="NumberOfVotesForEachShareOfCommonStock" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_PercentageOfExercisePriceToShareOfferingPrice" name="PercentageOfExercisePriceToShareOfferingPrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" name="DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" name="AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" name="PrepaidResearchAndDevelopmentExpenseCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" name="PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="anvs_NatureOfBusinessAndLiquidityAbstract" name="NatureOfBusinessAndLiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_MaximumAggregateSeverancePayments" name="MaximumAggregateSeverancePayments" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="anvs_EquityIncentivePlan2019Member" name="EquityIncentivePlan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_EquityIncentivePlan2018Member" name="EquityIncentivePlan2018Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_GeneratedIn2017AndPriorMember" name="GeneratedIn2017AndPriorMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" name="ConversionOfWarrantsNumberOfWarrantsConverted" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" name="IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" id="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" id="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PerformanceBasedVestingConditionsMember" id="anvs_PerformanceBasedVestingConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" id="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketEquityOfferingCommonStockAuthorizedValue" id="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClassOfWarrantOrRightNumberOfWarrantsExercised" id="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GrossProceedsFromIssuanceOfCommonStock" id="anvs_GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WarrantsThresholdPeriodOfNoticeForRedemption" id="anvs_WarrantsThresholdPeriodOfNoticeForRedemption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AverageDailyTradingValue" id="anvs_AverageDailyTradingValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" id="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsExercised" id="anvs_StockIssuedDuringPeriodValueWarrantsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MeasurementInputSuccessRateMember" id="anvs_MeasurementInputSuccessRateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" id="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="March2023AtMarketEquityOfferingMember" id="anvs_March2023AtMarketEquityOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="April2023PrivatePlacementMember" id="anvs_April2023PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="November2023EquityOfferingAndWarrantIssuanceMember" id="anvs_November2023EquityOfferingAndWarrantIssuanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" id="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="November2023PrivatePlacementMember" id="anvs_November2023PrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsClassifiedAsEquityMember" id="anvs_WarrantsClassifiedAsEquityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WarrantsClassifiedAsLiabilitiesMember" id="anvs_WarrantsClassifiedAsLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfWarrantsIssuedDuringPeriod" id="anvs_NumberOfWarrantsIssuedDuringPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ClassOfWarrantOrRightRedemptionPricePerShare" id="anvs_ClassOfWarrantOrRightRedemptionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CommonStockPurchaseAgreementMember" id="anvs_CommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockPurchaseAgreementSharesAuthorized" id="anvs_CommonStockPurchaseAgreementSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DisclosureOfEarningsPerShareBasicAndDilutedAbstract" id="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarningsPerShareBasicNumeratorAbstract" id="anvs_EarningsPerShareBasicNumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarningsPerShareBasicDenominatorAbstract" id="anvs_EarningsPerShareBasicDenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarningsPerShareDilutedNumeratorAbstract" id="anvs_EarningsPerShareDilutedNumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EarningsPerShareDilutedDenominatorAbstract" id="anvs_EarningsPerShareDilutedDenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FinancingCostsFromIssuanceOfShares" id="anvs_FinancingCostsFromIssuanceOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NonCashFinancingCostsFromIssuanceOfShares" id="anvs_NonCashFinancingCostsFromIssuanceOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CashPaidForFinancingCostsDuringPeriod" id="anvs_CashPaidForFinancingCostsDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockPurchaseAgreementCommitmentSharesMember" id="anvs_CommonStockPurchaseAgreementCommitmentSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockPurchaseAgreementTotalCommitment" id="anvs_CommonStockPurchaseAgreementTotalCommitment" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" id="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockPurchaseAgreementFixedPurchaseMember" id="anvs_CommonStockPurchaseAgreementFixedPurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" id="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockPurchaseAgreementTotalCommitmentValue" id="anvs_CommonStockPurchaseAgreementTotalCommitmentValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" id="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" id="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockPurchaseAgreementPurchasePricePercentage" id="anvs_CommonStockPurchaseAgreementPurchasePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="WarrantLiabilityNoncurrent" id="anvs_WarrantLiabilityNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GainLossOnChangesInFairValueOfWarrantLiability" id="anvs_GainLossOnChangesInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValueAdjustmentOfDerivativeLiabilities" id="anvs_FairValueAdjustmentOfDerivativeLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NonCashTransactionValueOfConsiderationWarrantExercises" id="anvs_NonCashTransactionValueOfConsiderationWarrantExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NonCashFinancingCostsIncludingChangeInFairValueDerivative" id="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" id="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" id="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedClinicalLiabilitiesCurrent" id="anvs_AccruedClinicalLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfShortTermLeases" id="anvs_NumberOfShortTermLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="December2024AtMarketEquityOfferingMember" id="anvs_December2024AtMarketEquityOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SecondaryOfferingMember" id="anvs_SecondaryOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockNumberOfUnitsAuthorizedForIssuance" id="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfSharesIncludedInEachUnit" id="anvs_NumberOfSharesIncludedInEachUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfWarrantsIncludedInEachUnit" id="anvs_NumberOfWarrantsIncludedInEachUnit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="WarrantTerm" id="anvs_WarrantTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MariaMaccecchiniMember" id="anvs_MariaMaccecchiniMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ClaudineBruckMember" id="anvs_ClaudineBruckMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MarkWhiteMember" id="anvs_MarkWhiteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" id="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" id="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" id="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" id="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" id="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesEquityDistributionAgreement" id="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodSharesEquityLineOfCredit" id="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodSharesRegisteredDirectOffering" id="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IntangibleAssetsPatentCostsPolicyTextBlock" id="anvs_IntangibleAssetsPatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SingleReportableSegmentMember" id="anvs_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" id="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProgramExpensesRelatedToClinicalStageProductCandidates" id="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" id="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ResearchAndDevelopmentAmortizationPeriodTerm" id="anvs_ResearchAndDevelopmentAmortizationPeriodTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfSaleOfStockTransactions" id="anvs_NumberOfSaleOfStockTransactions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ServiceBasedOptionsMember" id="anvs_ServiceBasedOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SaleOfStockAtMarketOfferingTemporarySuspensionTerm" id="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>anvs-20241231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 7:32:22 PM-->
<!--Modified on: 3/21/2025 7:32:22 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementBalanceSheets" roleURI="http://annovisbio.com/role/StatementBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementStatementsOfOperations" roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementStatementsOfCashFlows" roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://annovisbio.com/role/DisclosureSegmentInformationDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781823404087715" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781823404087715" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638781823404087715" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638781823404087715" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638781823404097730" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638781823404097730" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638781823404097730" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781823404097730" xlink:to="us-gaap_LiabilitiesCurrent_638781823404097730" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638781823404097730" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781823404097730" xlink:to="us-gaap_AccountsPayableCurrent_638781823404097730" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638781823404097730" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638781823404097730" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638781823404097730" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent_638781823404097730" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638781823404097730" xlink:to="anvs_WarrantLiabilityNoncurrent_638781823404097730" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638781823404097730" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies_638781823404097730" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781823404107701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638781823404107701" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638781823404107701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781823404107701" xlink:to="us-gaap_PreferredStockValue_638781823404107701" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638781823404107701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781823404107701" xlink:to="us-gaap_CommonStockValue_638781823404107701" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638781823404107701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781823404107701" xlink:to="us-gaap_AdditionalPaidInCapital_638781823404107701" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638781823404107701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638781823404107701" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638781823404107701" order="4" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Statements of Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_638781823404117700" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638781823404117700" xlink:to="us-gaap_OperatingExpenses_638781823404117700" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638781823404117700" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638781823404117700" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638781823404117700" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638781823404117700" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense_638781823404117700" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638781823404117700" xlink:to="us-gaap_InvestmentIncomeInterest_638781823404117700" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_FinancingCostsFromIssuanceOfShares" xlink:label="anvs_FinancingCostsFromIssuanceOfShares_638781823404117700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638781823404117700" xlink:to="anvs_FinancingCostsFromIssuanceOfShares_638781823404117700" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GainLossOnChangesInFairValueOfWarrantLiability" xlink:label="anvs_GainLossOnChangesInFairValueOfWarrantLiability_638781823404127697" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638781823404117700" xlink:to="anvs_GainLossOnChangesInFairValueOfWarrantLiability_638781823404127697" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638781823404127697" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="us-gaap_ProfitLoss_638781823404127697" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638781823404127697" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="us-gaap_ShareBasedCompensation_638781823404127697" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638781823404127697" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638781823404127697" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative" xlink:label="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_638781823404137719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_638781823404137719" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781823404137719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781823404137719" order="5" use="optional" weight="-1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638781823404137719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638781823404137719" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638781823404137719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823404127697" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638781823404137719" order="7" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823404137719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823404137719" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823404137719" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823404137719" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823404137719" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638781823404147700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823404137719" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638781823404147700" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638781823404147700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823404137719" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638781823404147700" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638781823404147700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure_1" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638781823404147700" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent_638781823404147700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure_1" xlink:to="anvs_WarrantLiabilityNoncurrent_638781823404147700" order="1" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638781823404157709" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638781823404157709" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638781823404157709" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance_638781823404157709" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638781823404157709" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638781823404157709" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638781823404157709" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="us-gaap_SecurityDeposit_638781823404157709" order="4" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued Expenses (Details)">
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedClinicalLiabilitiesCurrent" xlink:label="anvs_AccruedClinicalLiabilitiesCurrent_638781823404157709" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="anvs_AccruedClinicalLiabilitiesCurrent_638781823404157709" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638781823404167699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638781823404167699" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638781823404167699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638781823404167699" order="3" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823404167699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss_638781823404167699" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638781823404167699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_DilutiveSecurities_638781823404167699" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823404167699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823404167699" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_638781823404177729" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_638781823404177729" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781823404177729" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781823404177729" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781823404177729" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781823404177729" order="2" use="optional" weight="1" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781823404177729" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781823404177729" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638781823404177729" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638781823404177729" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781823404187700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781823404187700" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638781823404187700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638781823404187700" order="6" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638781823404187700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638781823404187700" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781823404187700" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781823404187700" order="8" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Income Taxes - Deferred taxes (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638781823404197727" order="1" use="optional" weight="-1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross_638781823404197727" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781823404197727" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781823404197727" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781823404197727" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638781823404197727" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781823404197727" xlink:to="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638781823404197727" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781823404197727" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781823404197727" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638781823404197727" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781823404197727" xlink:to="us-gaap_DeferredTaxAssetsOther_638781823404197727" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781823404207701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638781823404197727" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781823404207701" order="6" use="optional" weight="1" priority="2" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://annovisbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Segment Information (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_638781823404207701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_638781823404207701" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_638781823404207701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_638781823404207701" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638781823404207701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="us-gaap_LaborAndRelatedExpense_638781823404207701" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_638781823404207701" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_638781823404207701" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638781823404217699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638781823404217699" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638781823404217699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="us-gaap_InvestmentIncomeInterest_638781823404217699" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638781823404217699" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_2" xlink:to="us-gaap_OtherNoncashIncomeExpense_638781823404217699" order="7" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>anvs-20241231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 7:32:22 PM-->
<!--Modified on: 3/21/2025 7:32:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementStatementsOfChangesInStockholdersEquityDeficit" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsCanaccordWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityIpoWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersEquityWarrantSummaryDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://annovisbio.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="anvs-20241231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://annovisbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis_1" xlink:title="us-gaap_AwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardDateAxis_1" xlink:to="us-gaap_AwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardDateAxis_1 To us-gaap_AwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended" xlink:title="Individuals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember" xlink:title="ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MariaMaccecchiniMember" xlink:label="anvs_MariaMaccecchiniMember" xlink:title="anvs_MariaMaccecchiniMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="anvs_MariaMaccecchiniMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To anvs_MariaMaccecchiniMember" order="1" priority="0" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClaudineBruckMember" xlink:label="anvs_ClaudineBruckMember" xlink:title="anvs_ClaudineBruckMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="anvs_ClaudineBruckMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To anvs_ClaudineBruckMember" order="2" priority="0" />
    <link:loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MarkWhiteMember" xlink:label="anvs_MarkWhiteMember" xlink:title="anvs_MarkWhiteMember" />
    <link:definitionArc xlink:type="arc" xlink:from="ecd_AllIndividualsMember" xlink:to="anvs_MarkWhiteMember" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:ecd_AllIndividualsMember To anvs_MarkWhiteMember" order="3" priority="0" />
  </link:definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" xlink:label="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" xlink:label="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" xlink:label="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" xlink:to="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:label="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023EquityOfferingAndWarrantIssuanceMember" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_November2023EquityOfferingAndWarrantIssuanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CashFDICInsuredAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="anvs_WarrantLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MeasurementInputSuccessRateMember" xlink:label="anvs_MeasurementInputSuccessRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="anvs_MeasurementInputSuccessRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputConversionPriceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="anvs_ClassOfWarrantOrRightRedemptionPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="anvs_ClassOfWarrantOrRightRedemptionPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsThresholdPeriodOfNoticeForRedemption" xlink:label="anvs_WarrantsThresholdPeriodOfNoticeForRedemption" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="anvs_WarrantsThresholdPeriodOfNoticeForRedemption" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AverageDailyTradingValue" xlink:label="anvs_AverageDailyTradingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="anvs_AverageDailyTradingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" xlink:label="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LeaseCostAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfShortTermLeases" xlink:label="anvs_NumberOfShortTermLeases" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="anvs_NumberOfShortTermLeases" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract" xlink:to="anvs_MaximumAggregateSeverancePayments" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsEquityMember" xlink:label="anvs_WarrantsClassifiedAsEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_WarrantsClassifiedAsEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_March2023AtMarketEquityOfferingMember" xlink:label="anvs_March2023AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_March2023AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_April2023PrivatePlacementMember" xlink:label="anvs_April2023PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_April2023PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023PrivatePlacementMember" xlink:label="anvs_November2023PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_November2023PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_December2024AtMarketEquityOfferingMember" xlink:label="anvs_December2024AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_December2024AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" xlink:label="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" xlink:type="extended" xlink:title="99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023EquityOfferingAndWarrantIssuanceMember" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_November2023EquityOfferingAndWarrantIssuanceMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" xlink:type="extended" xlink:title="99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_WarrantLiabilityNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" xlink:label="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xlink:type="extended" xlink:title="99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsEquityMember" xlink:label="anvs_WarrantsClassifiedAsEquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_WarrantsClassifiedAsEquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfWarrantsIssuedDuringPeriod" xlink:label="anvs_NumberOfWarrantsIssuedDuringPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NumberOfWarrantsIssuedDuringPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" xlink:type="extended" xlink:title="99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfSaleOfStockTransactions" xlink:label="anvs_NumberOfSaleOfStockTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NumberOfSaleOfStockTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" xlink:type="extended" xlink:title="99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMember" xlink:label="anvs_CommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_CommonStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementCommitmentSharesMember" xlink:label="anvs_CommonStockPurchaseAgreementCommitmentSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="anvs_CommonStockPurchaseAgreementMember" xlink:to="anvs_CommonStockPurchaseAgreementCommitmentSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementFixedPurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementFixedPurchaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="anvs_CommonStockPurchaseAgreementMember" xlink:to="anvs_CommonStockPurchaseAgreementFixedPurchaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="anvs_CommonStockPurchaseAgreementMember" xlink:to="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="anvs_CommonStockPurchaseAgreementMember" xlink:to="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementSharesAuthorized" xlink:label="anvs_CommonStockPurchaseAgreementSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockPurchaseAgreementSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashFinancingCostsFromIssuanceOfShares" xlink:label="anvs_NonCashFinancingCostsFromIssuanceOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_NonCashFinancingCostsFromIssuanceOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementTotalCommitment" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockPurchaseAgreementTotalCommitment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementTotalCommitmentValue" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitmentValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockPurchaseAgreementTotalCommitmentValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProfessionalFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" xlink:label="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" xlink:label="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementPurchasePricePercentage" xlink:label="anvs_CommonStockPurchaseAgreementPurchasePricePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_CommonStockPurchaseAgreementPurchasePricePercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" xlink:type="extended" xlink:title="99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMember" xlink:label="anvs_CommonStockPurchaseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_CommonStockPurchaseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="anvs_FairValueAdjustmentOfDerivativeLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="anvs_FairValueAdjustmentOfDerivativeLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="anvs_EquityIncentivePlan2019Member" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="anvs_EquityIncentivePlan2018Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ServiceBasedOptionsMember" xlink:label="anvs_ServiceBasedOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="anvs_ServiceBasedOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PerformanceBasedVestingConditionsMember" xlink:label="anvs_PerformanceBasedVestingConditionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_VestingDomain" xlink:to="anvs_PerformanceBasedVestingConditionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Income Taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="anvs_GeneratedIn2017AndPriorMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ResearchAndDevelopmentAmortizationPeriodTerm" xlink:label="anvs_ResearchAndDevelopmentAmortizationPeriodTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="anvs_ResearchAndDevelopmentAmortizationPeriodTerm" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SingleReportableSegmentMember" xlink:label="anvs_SingleReportableSegmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="anvs_SingleReportableSegmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SecondaryOfferingMember" xlink:label="anvs_SecondaryOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_SecondaryOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_December2024AtMarketEquityOfferingMember" xlink:label="anvs_December2024AtMarketEquityOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="anvs_December2024AtMarketEquityOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" xlink:label="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfSharesIncludedInEachUnit" xlink:label="anvs_NumberOfSharesIncludedInEachUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_NumberOfSharesIncludedInEachUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfWarrantsIncludedInEachUnit" xlink:label="anvs_NumberOfWarrantsIncludedInEachUnit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_NumberOfWarrantsIncludedInEachUnit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantTerm" xlink:label="anvs_WarrantTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_WarrantTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" xlink:label="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>anvs-20241231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 7:32:22 PM-->
<!--Modified on: 3/21/2025 7:32:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Act File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Financial Statement Error Correction [Flag]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Documents Incorporated by Reference [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document incorporated by reference</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Security Deposits, and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Interest, and Employee-Related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities:</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_WarrantLiabilityNoncurrent" xlink:to="anvs_WarrantLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_WarrantLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_WarrantLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="anvs_WarrantLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="anvs_WarrantLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_WarrantLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies (Note 6)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value (dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of preferred shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income (expense):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_FinancingCostsFromIssuanceOfShares" xlink:label="anvs_FinancingCostsFromIssuanceOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_FinancingCostsFromIssuanceOfShares" xlink:to="anvs_FinancingCostsFromIssuanceOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_FinancingCostsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the charge against earnings during the period for transaction costs related to the issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_FinancingCostsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing Costs from Issuance of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_FinancingCostsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financing costs</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GainLossOnChangesInFairValueOfWarrantLiability" xlink:label="anvs_GainLossOnChangesInFairValueOfWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GainLossOnChangesInFairValueOfWarrantLiability" xlink:to="anvs_GainLossOnChangesInFairValueOfWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GainLossOnChangesInFairValueOfWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gain (loss) from changes in fair value of warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GainLossOnChangesInFairValueOfWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Changes in Fair Value of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GainLossOnChangesInFairValueOfWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other income (expense), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract" xlink:label="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract" xlink:to="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Earnings Per Share, Basic and Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average number of common shares used in computing net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator for diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Changes in Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Stockholders' Equity (Deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" xlink:label="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" xlink:to="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock issued as a result of the cashless exercise of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Cashless Exercise of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options (or share units) exercised during the current period in a cashless transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cashless Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cashless exercise of stock options, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of stock issued in the cashless exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock warrants, inclusive of warrant reduction</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued as a result of the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of common stock warrants, inclusive of warrant reduction, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" xlink:label="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" xlink:to="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued during the period, net of issuance costs and warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of Stock Issued During Period, Net of Issuance Costs and Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs and warrant liability</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" xlink:label="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" xlink:to="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period, excluding warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues Excluding Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock, net of issuance costs and warrant liability, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued under terms of an equity distribution agreement during the period, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Distribution Agreement, Value of Stock Issued During Period, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" xlink:to="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued during the period under terms of an equity distribution agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Equity Distribution Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued under terms of an equity line of credit, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Line of Credit, Value of Stock Issued During Period, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock pursuant to ELOC, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" xlink:to="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued during the period under terms of an equity line of credit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Equity Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock pursuant to ELOC, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:to="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of new stock issued under terms of a registered direct offering, net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Registered Direct Offering, Value of Stock Issued During Period, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock pursuant to registered direct offering, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:label="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:to="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares of stock issued during the period under terms of a registered direct offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Registered Direct Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock pursuant to registered direct offering, net of issuance costs, shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative" xlink:label="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative" xlink:to="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash financing costs, including change in fair value of derivative.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Financing Costs, Including Change in Fair Value Derivative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash other financing costs, including change in fair value of derivative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash proceeds after deducting underwriter discount and fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashTransactionValueOfConsiderationWarrantExercises" xlink:label="anvs_NonCashTransactionValueOfConsiderationWarrantExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NonCashTransactionValueOfConsiderationWarrantExercises" xlink:to="anvs_NonCashTransactionValueOfConsiderationWarrantExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NonCashTransactionValueOfConsiderationWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The value of the noncash consideration recognized as a reduction in warrant value related to exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NonCashTransactionValueOfConsiderationWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Transaction, Value of Consideration, Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NonCashTransactionValueOfConsiderationWarrantExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other adjustment to value of warrants related to exercises</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CashPaidForFinancingCostsDuringPeriod" xlink:label="anvs_CashPaidForFinancingCostsDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CashPaidForFinancingCostsDuringPeriod" xlink:to="anvs_CashPaidForFinancingCostsDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CashPaidForFinancingCostsDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash paid during the current period for financing costs related to the issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CashPaidForFinancingCostsDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Paid for Financing Costs During the Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CashPaidForFinancingCostsDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for financing costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Management's Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Management's Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:to="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expenses and Other Current Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (Deficit) Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccounting_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic and Diluted Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:to="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for issuance costs associated with equity issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Associated with Equity Issuances [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance Costs Associated with Equity Issuances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesEmbeddedDerivatives" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives, Embedded Derivatives [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research, Development, and Computer Software, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IntangibleAssetsPatentCostsPolicyTextBlock" xlink:label="anvs_IntangibleAssetsPatentCostsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IntangibleAssetsPatentCostsPolicyTextBlock" xlink:to="anvs_IntangibleAssetsPatentCostsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IntangibleAssetsPatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for the treatment of patent costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IntangibleAssetsPatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible Assets, Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IntangibleAssetsPatentCostsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recent Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canaccord Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of quantitative information regarding Level 3 fair value measurements inputs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued expenses</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" xlink:label="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" xlink:to="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of changes in common stock warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Changes in Common Stock Warrant Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of changes in common stock warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of common stock warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions used to determine fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of shares excluded from the computation of diluted weighted-average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of income tax provision (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of significant components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock, Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' (Deficit) Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Liquidity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Business and Management's Plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023EquityOfferingAndWarrantIssuanceMember" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_November2023EquityOfferingAndWarrantIssuanceMember" xlink:to="anvs_November2023EquityOfferingAndWarrantIssuanceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the November 2023 Equity Offering and Warrant Issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2023 Equity Offering and Warrant Issuance [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2023 Equity Offering and Warrant Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, FDIC Insured Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, Federally insured limit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability, ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability, beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares which may be purchased with warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock option contractual term (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reported Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimate of Fair Value Measurement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets measured and recorded at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities measured and recorded at fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Exercise Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Share Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing stock price</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MeasurementInputSuccessRateMember" xlink:label="anvs_MeasurementInputSuccessRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_MeasurementInputSuccessRateMember" xlink:to="anvs_MeasurementInputSuccessRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_MeasurementInputSuccessRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement input using probability of success rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_MeasurementInputSuccessRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Success Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_MeasurementInputSuccessRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Phase 3 data probability of success</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term (time to expiration in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputConversionPriceMember" xlink:to="us-gaap_MeasurementInputConversionPriceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputConversionPriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Conversion Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputConversionPriceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption hurdle price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants classified as liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Classified as Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Canaccord warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, measurement input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="anvs_ClassOfWarrantOrRightRedemptionPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:to="anvs_ClassOfWarrantOrRightRedemptionPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ClassOfWarrantOrRightRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ClassOfWarrantOrRightRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Redemption Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ClassOfWarrantOrRightRedemptionPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redemption price per share</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsThresholdPeriodOfNoticeForRedemption" xlink:label="anvs_WarrantsThresholdPeriodOfNoticeForRedemption" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_WarrantsThresholdPeriodOfNoticeForRedemption" xlink:to="anvs_WarrantsThresholdPeriodOfNoticeForRedemption_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_WarrantsThresholdPeriodOfNoticeForRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold period of notice of warrants for redemption.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_WarrantsThresholdPeriodOfNoticeForRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Threshold Period of Notice for Redemption</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_WarrantsThresholdPeriodOfNoticeForRedemption_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold period of notice for redemption</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing price of common stock</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AverageDailyTradingValue" xlink:label="anvs_AverageDailyTradingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AverageDailyTradingValue" xlink:to="anvs_AverageDailyTradingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AverageDailyTradingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of average daily trading value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AverageDailyTradingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average Daily Trading Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_AverageDailyTradingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average daily trading value</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" xlink:label="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" xlink:to="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the threshold consecutive trading days for which average daily trading value is traded.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Consecutive Trading Days of Which Average Daily Trading Value is Traded</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold consecutive trading days</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of warrants (in years)</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research and Development Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid clinical expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid insurance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Deposit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security deposits</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedClinicalLiabilitiesCurrent" xlink:label="anvs_AccruedClinicalLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AccruedClinicalLiabilitiesCurrent" xlink:to="anvs_AccruedClinicalLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AccruedClinicalLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AccruedClinicalLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_AccruedClinicalLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued clinical expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued professional fees and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title and Position [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Commitments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfShortTermLeases" xlink:label="anvs_NumberOfShortTermLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfShortTermLeases" xlink:to="anvs_NumberOfShortTermLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfShortTermLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of short-term leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfShortTermLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Short-Term Leases</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfShortTermLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of short term leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rental expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Compensation Arrangements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employment Agreements</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_MaximumAggregateSeverancePayments" xlink:to="anvs_MaximumAggregateSeverancePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Aggregate Severance Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_MaximumAggregateSeverancePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate severance payments</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfClassesOfStockDesignated" xlink:label="anvs_NumberOfClassesOfStockDesignated" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfClassesOfStockDesignated" xlink:to="anvs_NumberOfClassesOfStockDesignated_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfClassesOfStockDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of stock designated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfClassesOfStockDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of stock designated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfClassesOfStockDesignated_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of classes of stock designated</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:to="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of shares permitted to be issued by an entity's charter and bylaws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock And Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common and preferred shares authorized</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfVotesForEachShareOfCommonStock" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote for each share of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Votes for Each Share of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of vote for each share of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Table]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsEquityMember" xlink:label="anvs_WarrantsClassifiedAsEquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_WarrantsClassifiedAsEquityMember" xlink:to="anvs_WarrantsClassifiedAsEquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_WarrantsClassifiedAsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants classified as equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_WarrantsClassifiedAsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants Classified as Equity [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_WarrantsClassifiedAsEquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of exercise price to the share offering price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Exercise Price to the Share Offering Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of exercise price to the share offering price</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Number of Warrants Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_March2023AtMarketEquityOfferingMember" xlink:label="anvs_March2023AtMarketEquityOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_March2023AtMarketEquityOfferingMember" xlink:to="anvs_March2023AtMarketEquityOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_March2023AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the March 2023 ATM Equity Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_March2023AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2023 At the Market Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_March2023AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">March 2023 ATM</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_April2023PrivatePlacementMember" xlink:label="anvs_April2023PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_April2023PrivatePlacementMember" xlink:to="anvs_April2023PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_April2023PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the April 2023 Private Placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_April2023PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">April 2023 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_April2023PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">April 2023 Private Placement</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023PrivatePlacementMember" xlink:label="anvs_November2023PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_November2023PrivatePlacementMember" xlink:to="anvs_November2023PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_November2023PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the November 2023 Private Placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_November2023PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2023 Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_November2023PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">November 2023 Private Placement</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_December2024AtMarketEquityOfferingMember" xlink:label="anvs_December2024AtMarketEquityOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_December2024AtMarketEquityOfferingMember" xlink:to="anvs_December2024AtMarketEquityOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_December2024AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the December 2024 ATM Equity Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_December2024AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2024 At the Market Equity Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_December2024AtMarketEquityOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">December 2024 ATM</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" xlink:label="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" xlink:to="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At the Market Equity Offering, Common Stock, Authorized Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate offering price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GrossProceedsFromIssuanceOfCommonStock" xlink:to="anvs_GrossProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The gross proceeds from the additional capital contribution to the entity through the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross proceeds from issuance of common shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" xlink:label="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" xlink:to="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the period in the fair value of warrants attributable to the exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Fair Value of Warrants Attributable to Exercise of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of warrants converted in a noncash (or part noncash) transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Warrants, Number of Warrants Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised or Expired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants exercised</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfWarrantsIssuedDuringPeriod" xlink:label="anvs_NumberOfWarrantsIssuedDuringPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfWarrantsIssuedDuringPeriod" xlink:to="anvs_NumberOfWarrantsIssuedDuringPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfWarrantsIssuedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfWarrantsIssuedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Issued During the Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfWarrantsIssuedDuringPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Securities Purchase Agreement with an institutional investor</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfSaleOfStockTransactions" xlink:label="anvs_NumberOfSaleOfStockTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfSaleOfStockTransactions" xlink:to="anvs_NumberOfSaleOfStockTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfSaleOfStockTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of sale of stock transactions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfSaleOfStockTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Sale of Stock Transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfSaleOfStockTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of transactions</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMember" xlink:label="anvs_CommonStockPurchaseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementMember" xlink:to="anvs_CommonStockPurchaseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to a Common Stock Purchase Agreement (the "Purchase Agreement") with an Equity Line investor (the "ELOC Purchaser").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="anvs_CommonStockPurchaseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ELOC Purchase Agreement</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementCommitmentSharesMember" xlink:label="anvs_CommonStockPurchaseAgreementCommitmentSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementCommitmentSharesMember" xlink:to="anvs_CommonStockPurchaseAgreementCommitmentSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the "Commitment Shares" issued under terms of a Common Stock Purchase Agreement (the "Purchase Agreement") with an Equity Line investor (the "ELOC Purchaser").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Commitment Shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementCommitmentSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitment Shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementFixedPurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementFixedPurchaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementFixedPurchaseMember" xlink:to="anvs_CommonStockPurchaseAgreementFixedPurchaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementFixedPurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Fixed Purchase shares issued as defined under terms of a Common Stock Purchase Agreement (the "Purchase Agreement") with an Equity Line investor (the "ELOC Purchaser").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementFixedPurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Fixed Purchase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementFixedPurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Purchase</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" xlink:to="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Volume-Weighted Average Price (VWAP) shares issued as defined under terms of a Common Stock Purchase Agreement (the "Purchase Agreement") with an Equity Line investor (the "ELOC Purchaser").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Volume-Weighted Average Price Purchase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VWAP Purchase</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" xlink:to="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to additional Volume-Weighted Average Price (VWAP) shares issued as defined under terms of a Common Stock Purchase Agreement (the "Purchase Agreement") with an Equity Line investor (the "ELOC Purchaser").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Additional Volume-Weighted Average Price Purchase [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional VWAP Purchase</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementSharesAuthorized" xlink:label="anvs_CommonStockPurchaseAgreementSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementSharesAuthorized" xlink:to="anvs_CommonStockPurchaseAgreementSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares of authorized under terms of a common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of authorized shares under terms of the agreement</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashFinancingCostsFromIssuanceOfShares" xlink:label="anvs_NonCashFinancingCostsFromIssuanceOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NonCashFinancingCostsFromIssuanceOfShares" xlink:to="anvs_NonCashFinancingCostsFromIssuanceOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NonCashFinancingCostsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of non-cash financing costs attributable to shares issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NonCashFinancingCostsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-Cash Financing Costs from Issuance of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NonCashFinancingCostsFromIssuanceOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash other financing costs</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementTotalCommitment" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementTotalCommitment" xlink:to="anvs_CommonStockPurchaseAgreementTotalCommitment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate number of shares of committed under terms of a common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Total Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total commitment shares</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementTotalCommitmentValue" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitmentValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementTotalCommitmentValue" xlink:to="anvs_CommonStockPurchaseAgreementTotalCommitmentValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitmentValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate value of shares of committed under terms of a common stock purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitmentValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Total Commitment Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitmentValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of total commitment shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of shares issued, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" xlink:label="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" xlink:to="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum purchase of shares in a single transaction as a percentage of the Fixed Purchase Notice shares directed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Maximum Purchase of Shares as a Percentage of Fixed Purchase Notice</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum percentage of shares directed by Fixed Purchase Notice</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" xlink:label="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" xlink:to="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold percentage of trading volume.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Threshold Percentage of Trading Volume</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage of trading volume</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementPurchasePricePercentage" xlink:label="anvs_CommonStockPurchaseAgreementPurchasePricePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_CommonStockPurchaseAgreementPurchasePricePercentage" xlink:to="anvs_CommonStockPurchaseAgreementPurchasePricePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_CommonStockPurchaseAgreementPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The purchase price as a percentage of the lesser of certain criteria as defined in the purchase agreement..</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_CommonStockPurchaseAgreementPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock Purchase Agreement, Purchase Price, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_CommonStockPurchaseAgreementPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price, percentage</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="anvs_FairValueAdjustmentOfDerivativeLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_FairValueAdjustmentOfDerivativeLiabilities" xlink:to="anvs_FairValueAdjustmentOfDerivativeLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_FairValueAdjustmentOfDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense (income) related to adjustment to fair value of derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_FairValueAdjustmentOfDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_FairValueAdjustmentOfDerivativeLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlements and changes in fair value of ELOC derivative liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityIncentivePlan2019Member" xlink:to="anvs_EquityIncentivePlan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to the Company's 2019 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityIncentivePlan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EquityIncentivePlan2018Member" xlink:to="anvs_EquityIncentivePlan2018Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pertaining to the 2018 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EquityIncentivePlan2018Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2018 Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of Income Location, Balance [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at end of the year (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at beginning of the year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at end of year (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ServiceBasedOptionsMember" xlink:label="anvs_ServiceBasedOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ServiceBasedOptionsMember" xlink:to="anvs_ServiceBasedOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ServiceBasedOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangement awarded for meeting service requirements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ServiceBasedOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service-Based Options [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ServiceBasedOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service-based options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Director</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate vesting of awards under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate Vesting [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Immediate vesting</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests in Equal Quarterly Installments Over Two Years [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vests in equal quarterly installments over two years</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PerformanceBasedVestingConditionsMember" xlink:label="anvs_PerformanceBasedVestingConditionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_PerformanceBasedVestingConditionsMember" xlink:to="anvs_PerformanceBasedVestingConditionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_PerformanceBasedVestingConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to performance-based vesting conditions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_PerformanceBasedVestingConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance-based vesting conditions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_WeightedAverageMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized stock-based compensation expense related to unvested stock option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average recognition period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated fair value of options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected option terms (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - Basic:</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareBasicNumeratorAbstract" xlink:label="anvs_EarningsPerShareBasicNumeratorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareBasicNumeratorAbstract" xlink:to="anvs_EarningsPerShareBasicNumeratorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareBasicNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareBasicNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareBasicNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareBasicDenominatorAbstract" xlink:label="anvs_EarningsPerShareBasicDenominatorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareBasicDenominatorAbstract" xlink:to="anvs_EarningsPerShareBasicDenominatorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareBasicDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareBasicDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic, Denominator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareBasicDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share - Diluted:</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareDilutedNumeratorAbstract" xlink:label="anvs_EarningsPerShareDilutedNumeratorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareDilutedNumeratorAbstract" xlink:to="anvs_EarningsPerShareDilutedNumeratorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, Numerator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareDilutedNumeratorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilutive Securities, Effect on Basic Earnings Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: gain from change in fair value applicable to dilutive liability-classified warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator for diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareDilutedDenominatorAbstract" xlink:label="anvs_EarningsPerShareDilutedDenominatorAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_EarningsPerShareDilutedDenominatorAbstract" xlink:to="anvs_EarningsPerShareDilutedDenominatorAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_EarningsPerShareDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_EarningsPerShareDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted, Denominator [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_EarningsPerShareDilutedDenominatorAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Denominator</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plus: Incremental shares underlying "in the money" liability-classified warrants outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Income Tax Expense (Benefit), Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State provision (benefit) for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal income tax benefit at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local tax, change in rates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock compensation</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:to="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Amortization of Research &amp; Experimental Expenditures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Section 174</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Jurisdiction [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Domestic Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Tax Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outside of the U.S.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GeneratedIn2017AndPriorMember" xlink:to="anvs_GeneratedIn2017AndPriorMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GeneratedIn2017AndPriorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to tax years 2017 and prior.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GeneratedIn2017AndPriorMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Generated in 2017 and prior</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research Tax Credit Carryforward [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carryforward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognized income tax interest and penalties</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ResearchAndDevelopmentAmortizationPeriodTerm" xlink:label="anvs_ResearchAndDevelopmentAmortizationPeriodTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ResearchAndDevelopmentAmortizationPeriodTerm" xlink:to="anvs_ResearchAndDevelopmentAmortizationPeriodTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ResearchAndDevelopmentAmortizationPeriodTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time for amortization of research and development expenses, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ResearchAndDevelopmentAmortizationPeriodTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Amortization Period, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ResearchAndDevelopmentAmortizationPeriodTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">R&amp;D amortization period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segments [Domain]</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SingleReportableSegmentMember" xlink:label="anvs_SingleReportableSegmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SingleReportableSegmentMember" xlink:to="anvs_SingleReportableSegmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to a single reportable segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single Reportable Segment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_SingleReportableSegmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Single reportable segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" xlink:to="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of program expenses related to clinical-stage product candidates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program Expenses Related to Clinical-Stage Product Candidates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program expenses related to clinical-stage product candidates</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" xlink:to="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of program expenses related to preclinical and discovery programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program Expenses Related to Preclinical and Discovery Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Program expenses related to preclinical and discovery programs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Labor and Related Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel-related expenses (including stock-based compensation)</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" xlink:to="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses classified as professional and consultant fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense, Professional and Consultant Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative professional and consultant fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Other Segment Item, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other segment items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Noncash Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-cash income (expense) items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SecondaryOfferingMember" xlink:label="anvs_SecondaryOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SecondaryOfferingMember" xlink:to="anvs_SecondaryOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SecondaryOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary sale of stock to the public.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SecondaryOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Secondary Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_SecondaryOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" xlink:label="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" xlink:to="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of units authorized for issuance. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at a per unit price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Number of Units Authorized for Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of units to be sold</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfSharesIncludedInEachUnit" xlink:label="anvs_NumberOfSharesIncludedInEachUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfSharesIncludedInEachUnit" xlink:to="anvs_NumberOfSharesIncludedInEachUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfSharesIncludedInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares included in each unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfSharesIncludedInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Included in Each Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfSharesIncludedInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of common shares included in each unit</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfWarrantsIncludedInEachUnit" xlink:label="anvs_NumberOfWarrantsIncludedInEachUnit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_NumberOfWarrantsIncludedInEachUnit" xlink:to="anvs_NumberOfWarrantsIncludedInEachUnit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_NumberOfWarrantsIncludedInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants included in each unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_NumberOfWarrantsIncludedInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Warrants Included in Each Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_NumberOfWarrantsIncludedInEachUnit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of warrants included in each unit</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantTerm" xlink:label="anvs_WarrantTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_WarrantTerm" xlink:to="anvs_WarrantTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_WarrantTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time in which warrants may be exercised, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_WarrantTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrant, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_WarrantTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of warrants</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" xlink:label="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" xlink:to="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of time for temporary suspension of sale of stock under the At the Market Equity Offering Sales Agreements after the start of the secondary public offering, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, At The Market Offering, Temporary Suspension, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary suspension of ATM offering</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock, Consideration Received on Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds from sale of stock</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MariaMaccecchiniMember" xlink:label="anvs_MariaMaccecchiniMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_MariaMaccecchiniMember" xlink:to="anvs_MariaMaccecchiniMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_MariaMaccecchiniMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Maria Maccecchini.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_MariaMaccecchiniMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maria Maccecchini [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_MariaMaccecchiniMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maria Maccecchini</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClaudineBruckMember" xlink:label="anvs_ClaudineBruckMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_ClaudineBruckMember" xlink:to="anvs_ClaudineBruckMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_ClaudineBruckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Claudine Bruck.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_ClaudineBruckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Claudine Bruck [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_ClaudineBruckMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Claudine Bruck</label>
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MarkWhiteMember" xlink:label="anvs_MarkWhiteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="anvs_MarkWhiteMember" xlink:to="anvs_MarkWhiteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="anvs_MarkWhiteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Mark White.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="anvs_MarkWhiteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mark White [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="anvs_MarkWhiteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mark White</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>anvs-20241231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.9.0.3 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/21/2025 7:32:22 PM-->
<!--Modified on: 3/21/2025 7:32:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementBalanceSheets" roleURI="http://annovisbio.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementStatementsOfOperations" roleURI="http://annovisbio.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementStatementsOfChangesInStockholdersEquityDeficit" roleURI="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#StatementStatementsOfCashFlows" roleURI="http://annovisbio.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNatureOfBusinessAndManagementSPlans" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurements" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssets" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureAccruedExpenses" roleURI="http://annovisbio.com/role/DisclosureAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquity" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensation" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNetLossPerShare" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxes" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSegmentInformation" roleURI="http://annovisbio.com/role/DisclosureSegmentInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSubsequentEvents" roleURI="http://annovisbio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureAccruedExpensesTables" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityTables" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNetLossPerShareTables" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesTables" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSegmentInformationTables" roleURI="http://annovisbio.com/role/DisclosureSegmentInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNatureOfBusinessAndManagementSPlansDetails" roleURI="http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsHierarchyDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureFairValueMeasurementsCanaccordWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureAccruedExpensesDetails" roleURI="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityOverviewDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityIpoWarrantsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersEquityWarrantSummaryDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" roleURI="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationSummaryOfPlansDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationStockOptionActivityDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureStockBasedCompensationAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" roleURI="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureIncomeTaxesAdditionalDisclosuresDetails" roleURI="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSegmentInformationDetails" roleURI="http://annovisbio.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="anvs-20241231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#CybersecurityRiskManagementAndStrategyDisclosure" roleURI="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://annovisbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638781823404997700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638781823404997700" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638781823405007709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638781823405007709" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638781823405007709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638781823405007709" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638781823405007709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638781823405007709" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638781823405007709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638781823405007709" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638781823405007709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638781823405007709" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638781823405017728" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638781823405017728" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638781823405017728" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638781823405017728" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638781823405017728" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638781823405017728" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638781823405017728" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638781823405017728" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638781823405017728" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638781823405027711" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638781823405027711" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638781823405027711" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638781823405027711" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638781823405027711" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638781823405027711" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638781823405027711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638781823405027711" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638781823405037701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638781823405037701" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638781823405037701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638781823405037701" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638781823405037701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638781823405037701" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638781823405037701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638781823405037701" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638781823405037701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638781823405037701" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_638781823405037701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_638781823405037701" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638781823405047704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638781823405047704" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638781823405047704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638781823405047704" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638781823405047704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638781823405047704" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_638781823405047704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_638781823405047704" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638781823405047704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638781823405047704" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638781823405047704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638781823405047704" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638781823405057701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638781823405057701" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638781823405057701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638781823405057701" order="35" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638781823405057701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638781823405057701" order="36" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638781823405057701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638781823405057701" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638781823405057701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638781823405057701" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638781823405067708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638781823405067708" order="39" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638781823405067708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638781823405067708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638781823405067708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781823405067708" xlink:to="us-gaap_AssetsCurrentAbstract_638781823405067708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781823405067708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638781823405067708" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781823405067708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638781823405067708" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638781823405077701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638781823405067708" xlink:to="us-gaap_Assets_638781823405077701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638781823405077701" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781823405077701" xlink:to="us-gaap_AccountsPayableCurrent_638781823405077701" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781823405077701" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638781823405077701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638781823405077701" xlink:to="us-gaap_LiabilitiesCurrent_638781823405077701" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638781823405077701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent_638781823405077701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638781823405077701" xlink:to="anvs_WarrantLiabilityNoncurrent_638781823405077701" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" xlink:to="us-gaap_Liabilities_638781823405087701" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" xlink:to="us-gaap_CommitmentsAndContingencies_638781823405087701" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638781823405077701" xlink:to="us-gaap_StockholdersEquityAbstract_638781823405087701" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781823405087701" xlink:to="us-gaap_PreferredStockValue_638781823405087701" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781823405087701" xlink:to="us-gaap_CommonStockValue_638781823405087701" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781823405087701" xlink:to="us-gaap_AdditionalPaidInCapital_638781823405087701" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781823405087701" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638781823405087701" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781823405087701" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781823405087701" xlink:to="us-gaap_StockholdersEquity_638781823405087701" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638781823405098119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638781823405087701" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638781823405098119" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="995200105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638781823405098119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638781823405098119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638781823405098119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638781823405098119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638781823405098119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638781823405098119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638781823405098119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638781823405098119" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638781823405098119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638781823405098119" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638781823405107707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638781823405107707" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638781823405107707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638781823405107707" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638781823405107707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638781823405107707" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638781823405107707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638781823405107707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638781823405107707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638781823405107707" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638781823405107707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638781823405107707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638781823405107707" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638781823405107707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638781823405107707" xlink:to="us-gaap_OperatingExpenses_638781823405117712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638781823405117712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638781823405117712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638781823405117712" xlink:to="us-gaap_InvestmentIncomeInterest_638781823405117712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_FinancingCostsFromIssuanceOfShares" xlink:label="anvs_FinancingCostsFromIssuanceOfShares_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638781823405117712" xlink:to="anvs_FinancingCostsFromIssuanceOfShares_638781823405117712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GainLossOnChangesInFairValueOfWarrantLiability" xlink:label="anvs_GainLossOnChangesInFairValueOfWarrantLiability_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638781823405117712" xlink:to="anvs_GainLossOnChangesInFairValueOfWarrantLiability_638781823405117712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638781823405117712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638781823405117712" xlink:to="us-gaap_NonoperatingIncomeExpense_638781823405117712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823405227697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638781823405227697" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract" xlink:label="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_638781823405227697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_638781823405227697" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638781823405227697" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_638781823405227697" xlink:to="us-gaap_EarningsPerShareBasic_638781823405227697" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract_638781823405227697" xlink:to="us-gaap_EarningsPerShareDiluted_638781823405237694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638781823405237694" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638781823405237694" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823405237694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_638781823405237694" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781823405237694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" xlink:type="extended" xlink:title="995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638781823405237694" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781823405237694" xlink:to="us-gaap_StatementEquityComponentsAxis_638781823405237694" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638781823405237694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781823405237694" xlink:to="us-gaap_CommonStockMember_638781823405237694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781823405237694" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638781823405247694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781823405237694" xlink:to="us-gaap_RetainedEarningsMember_638781823405247694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638781823405237694" xlink:to="us-gaap_EquityComponentDomain_638781823405247694" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638781823405237694" xlink:to="us-gaap_StatementLineItems_638781823405247694" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638781823405247694" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_StockholdersEquity_638781823405247694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_SharesIssued_638781823405247694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638781823405247694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638781823405247694" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781823405247694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions" xlink:label="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_638781823405247694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_638781823405247694" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions_638781823405247694" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod_638781823405257878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_638781823405257878" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodValueWarrantsExercised_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="anvs_StockIssuedDuringPeriodValueWarrantsExercised_638781823405257878" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_StockIssuedDuringPeriodValueWarrantsExercised_638781823405257878" xlink:to="anvs_StockIssuedDuringPeriodSharesWarrantsExercised_638781823405257878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability" xlink:label="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_638781823405257878" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability" xlink:label="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability_638781823405257878" xlink:to="anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability_638781823405257878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405257878" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement_638781823405257878" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405257878" xlink:to="anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement_638781823405257878" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405267694" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit" xlink:label="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405267694" xlink:to="anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit_638781823405267694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts" xlink:label="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405267694" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering" xlink:label="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts_638781823405267694" xlink:to="anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering_638781823405267694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_NetIncomeLoss_638781823405267694" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_StockholdersEquity_638781823405267694" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_638781823405267694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638781823405247694" xlink:to="us-gaap_SharesIssued_638781823405267694" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638781823405277694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="us-gaap_ProfitLoss_638781823405277694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638781823405277694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="us-gaap_ShareBasedCompensation_638781823405277694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638781823405277694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638781823405277694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative" xlink:label="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_638781823405277694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative_638781823405277694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781823405287713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781823405287713" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638781823405287713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781823405287713" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638781823405287713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638781823405287713" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638781823405287713" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638781823405277694" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638781823405287713" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638781823405287713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638781823405287713" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823405287713" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638781823405287713" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638781823405287713" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638781823405287713" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638781823405287713" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638781823405297700" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638781823405287713" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638781823405297700" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638781823405297700" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638781823405297700" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387818234052977001" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6387818234052977001" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638781823405297700" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashTransactionValueOfConsiderationWarrantExercises" xlink:label="anvs_NonCashTransactionValueOfConsiderationWarrantExercises_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638781823405297700" xlink:to="anvs_NonCashTransactionValueOfConsiderationWarrantExercises_638781823405297700" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CashPaidForFinancingCostsDuringPeriod" xlink:label="anvs_CashPaidForFinancingCostsDuringPeriod_638781823405297700" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638781823405297700" xlink:to="anvs_CashPaidForFinancingCostsDuringPeriod_638781823405297700" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans" xlink:type="extended" xlink:title="995210101 - Disclosure - Nature of Business and Management's Plans" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638781823405307698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638781823405307698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638781823405307698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638781823405307698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="995210301 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638781823405307698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638781823405307698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="extended" xlink:title="995210401 - Disclosure - Prepaid Expenses and Other Current Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock" xlink:label="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_638781823405317782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock_638781823405317782" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpenses" xlink:type="extended" xlink:title="995210501 - Disclosure - Accrued Expenses" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638781823405317782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638781823405317782" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="995210601 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638781823405317782" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638781823405317782" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquity" xlink:type="extended" xlink:title="995210701 - Disclosure - Stockholders' (Deficit) Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638781823405328182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638781823405328182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="995210801 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638781823405328182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638781823405328182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="995210901 - Disclosure - Net Loss Per Share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638781823405328182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638781823405328182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="995211001 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638781823405328182" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638781823405328182" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995211101 - Disclosure - Segment Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638781823405338172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638781823405338172" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211201 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638781823405338172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638781823405338172" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting_638781823405338172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccounting_638781823405338172" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638781823405338172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638781823405338172" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_638781823405338172" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_638781823405338172" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638781823405348100" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638781823405348100" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock" xlink:label="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock_638781823405348100" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_638781823405348100" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock_638781823405348100" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock" xlink:label="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock_638781823405348100" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IntangibleAssetsPatentCostsPolicyTextBlock" xlink:label="anvs_IntangibleAssetsPatentCostsPolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="anvs_IntangibleAssetsPatentCostsPolicyTextBlock_638781823405348100" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638781823405348100" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638781823405348100" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638781823405348100" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638781823405357813" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="99930303 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405357813" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405357813" xlink:to="us-gaap_FinancialInstrumentAxis_638781823405357813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638781823405357813" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638781823405357813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638781823405357813" xlink:to="us-gaap_WarrantMember_638781823405357813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405357813" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405357813" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638781823405357813" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405357813" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_638781823405357813" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638781823405368128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405357813" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_638781823405368128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638781823405368128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_638781823405368128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesTables" xlink:type="extended" xlink:title="99930503 - Disclosure - Accrued Expenses (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638781823405368128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638781823405368128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables" xlink:type="extended" xlink:title="99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_5" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock" xlink:label="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock_638781823405378116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_5" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_638781823405378116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638781823405378116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638781823405378116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637250488103173191" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638781823405378116" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="99930903 - Disclosure - Net Loss Per Share (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638781823405378116" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638781823405378116" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638781823405378116" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="99931003 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638781823405388159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638781823405388159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638781823405388159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637250510374017182" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638781823405388159" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99931103 - Disclosure - Segment Information (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638781823405388159" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_638781823405388159" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - Nature of Business and Management's Plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NatureOfBusinessAndLiquidityAbstract" xlink:label="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638781823405397838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638781823405397838" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638781823405397838" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" xlink:to="us-gaap_NetIncomeLoss_638781823405397838" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_NatureOfBusinessAndLiquidityAbstract_638781823405397838" xlink:to="us-gaap_OperatingIncomeLoss_638781823405397838" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405397838" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_1" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405397838" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405397838" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405408332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405408332" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405408332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023EquityOfferingAndWarrantIssuanceMember" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405408332" xlink:to="anvs_November2023EquityOfferingAndWarrantIssuanceMember_638781823405408332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405397838" xlink:to="us-gaap_ClassOfStockLineItems_638781823405408332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_NumberOfOperatingSegments_638781823405408332" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_CashFDICInsuredAmount_638781823405408332" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405408332" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405408332" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638781823405408332" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405408332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405408332" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781823405418103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781823405418103" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638781823405418103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405408332" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638781823405418103" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" xlink:type="extended" xlink:title="99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637538572007802700_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405418103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637538572007802700_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405418103" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638781823405418103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405418103" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638781823405418103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638781823405418103" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638781823405418103" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638781823405418103" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638781823405418103" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_638781823405428680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638781823405418103" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638781823405428680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405418103" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781823405428680" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781823405428680" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405428680" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405428680" xlink:to="us-gaap_FairValueInputsLevel1Member_638781823405428680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405428680" xlink:to="us-gaap_FairValueInputsLevel3Member_638781823405428680" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638781823405418103" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405428680" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405428680" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_638781823405428680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638781823405428680" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638781823405428680" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638781823405428680" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638781823405438086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract_638781823405428680" xlink:to="us-gaap_AssetsFairValueDisclosure_638781823405438086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_638781823405438086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638781823405428680" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_638781823405438086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent_638781823405438086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638781823405438086" xlink:to="anvs_WarrantLiabilityNoncurrent_638781823405438086" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_638781823405438086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract_638781823405438086" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_638781823405438086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" xlink:type="extended" xlink:title="99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637538572007802700_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781823405438086" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637538572007802700_3" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781823405438086" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781823405438086" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781823405448074" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638781823405448074" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405448074" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638781823405448074" xlink:to="us-gaap_FairValueInputsLevel3Member_638781823405448074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781823405438086" xlink:to="us-gaap_MeasurementInputTypeAxis_638781823405448074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis_638781823405448074" xlink:to="us-gaap_MeasurementInputTypeDomain_638781823405448074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="us-gaap_MeasurementInputExercisePriceMember_638781823405448074" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="us-gaap_MeasurementInputSharePriceMember_638781823405448074" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MeasurementInputSuccessRateMember" xlink:label="anvs_MeasurementInputSuccessRateMember_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="anvs_MeasurementInputSuccessRateMember_638781823405448074" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_638781823405448074" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember_638781823405448074" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="us-gaap_MeasurementInputExpectedTermMember_638781823405448074" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputConversionPriceMember" xlink:label="us-gaap_MeasurementInputConversionPriceMember_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="us-gaap_MeasurementInputConversionPriceMember_638781823405458082" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain_638781823405448074" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_638781823405458082" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781823405438086" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638781823405458082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638781823405458082" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638781823405458082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781823405458082" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember_638781823405458082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_638781823405438086" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList" xlink:label="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_638781823405458082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList_638781823405458082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_638781823405468071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638781823405468071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405468071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClassOfWarrantOrRightRedemptionPricePerShare" xlink:label="anvs_ClassOfWarrantOrRightRedemptionPricePerShare_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="anvs_ClassOfWarrantOrRightRedemptionPricePerShare_638781823405468071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsThresholdPeriodOfNoticeForRedemption" xlink:label="anvs_WarrantsThresholdPeriodOfNoticeForRedemption_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="anvs_WarrantsThresholdPeriodOfNoticeForRedemption_638781823405468071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="us-gaap_SharePrice_638781823405468071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AverageDailyTradingValue" xlink:label="anvs_AverageDailyTradingValue_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="anvs_AverageDailyTradingValue_638781823405468071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded" xlink:label="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded_638781823405468071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded_638781823405468071" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638781823405478234" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_638781823405458082" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638781823405478234" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidResearchAndDevelopmentExpenseCurrent" xlink:label="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638781823405478234" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_PrepaidResearchAndDevelopmentExpenseCurrent_638781823405478234" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_638781823405478234" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_638781823405478234" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance_638781823405478234" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_PrepaidInsurance_638781823405478234" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638781823405478234" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_SecurityDeposit_638781823405478234" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent" xlink:label="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638781823405478234" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent_638781823405478234" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureAccruedExpensesDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - Accrued Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedClinicalLiabilitiesCurrent" xlink:label="anvs_AccruedClinicalLiabilitiesCurrent_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="anvs_AccruedClinicalLiabilitiesCurrent_638781823405488079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638781823405488079" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638781823405488079" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent" xlink:label="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent_638781823405488079" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - Commitments and Contingencies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2" xlink:to="us-gaap_OtherCommitmentsTable_638781823405488079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638781823405488079" xlink:to="srt_TitleOfIndividualAxis_638781823405488079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638781823405488079" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638781823405488079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="srt_ChiefExecutiveOfficerMember_638781823405488079" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638781823405488079" xlink:to="srt_ChiefExecutiveOfficerMember_638781823405488079" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsTable_638781823405488079" xlink:to="us-gaap_OtherCommitmentsLineItems_638781823405498071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638781823405498071" xlink:to="us-gaap_LeaseCostAbstract_638781823405498071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfShortTermLeases" xlink:label="anvs_NumberOfShortTermLeases_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638781823405498071" xlink:to="anvs_NumberOfShortTermLeases_638781823405498071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638781823405498071" xlink:to="us-gaap_OperatingLeaseExpense_638781823405498071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementsAbstract" xlink:label="us-gaap_DeferredCompensationArrangementsAbstract_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems_638781823405498071" xlink:to="us-gaap_DeferredCompensationArrangementsAbstract_638781823405498071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MaximumAggregateSeverancePayments" xlink:label="anvs_MaximumAggregateSeverancePayments_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementsAbstract_638781823405498071" xlink:to="anvs_MaximumAggregateSeverancePayments_638781823405498071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfClassesOfStockDesignated" xlink:label="anvs_NumberOfClassesOfStockDesignated_638781823405498071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="anvs_NumberOfClassesOfStockDesignated_638781823405498071" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockAndPreferredStockSharesAuthorized" xlink:label="anvs_CommonStockAndPreferredStockSharesAuthorized_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="anvs_CommonStockAndPreferredStockSharesAuthorized_638781823405508071" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638781823405508071" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638781823405508071" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_CommonStockSharesAuthorized_638781823405508071" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_PreferredStockSharesAuthorized_638781823405508071" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfVotesForEachShareOfCommonStock" xlink:label="anvs_NumberOfVotesForEachShareOfCommonStock_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="anvs_NumberOfVotesForEachShareOfCommonStock_638781823405508071" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_PreferredStockSharesIssued_638781823405508071" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638781823405508071" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_PreferredStockSharesOutstanding_638781823405508071" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_3" xlink:to="us-gaap_ClassOfWarrantOrRightTable_638781823405518066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638781823405518066" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638781823405518066" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638781823405518066" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638781823405518066" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsEquityMember" xlink:label="anvs_WarrantsClassifiedAsEquityMember_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781823405518066" xlink:to="anvs_WarrantsClassifiedAsEquityMember_638781823405518066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable_638781823405518066" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638781823405518066" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405518066" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PercentageOfExercisePriceToShareOfferingPrice" xlink:label="anvs_PercentageOfExercisePriceToShareOfferingPrice_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" xlink:to="anvs_PercentageOfExercisePriceToShareOfferingPrice_638781823405518066" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638781823405518066" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638781823405518066" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638781823405527719" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:label="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems_638781823405518066" xlink:to="anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised_638781823405527719" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" xlink:type="extended" xlink:title="99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_4" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405527719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405527719" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405527719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405527719" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405527719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_March2023AtMarketEquityOfferingMember" xlink:label="anvs_March2023AtMarketEquityOfferingMember_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405527719" xlink:to="anvs_March2023AtMarketEquityOfferingMember_638781823405527719" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_April2023PrivatePlacementMember" xlink:label="anvs_April2023PrivatePlacementMember_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405527719" xlink:to="anvs_April2023PrivatePlacementMember_638781823405527719" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023PrivatePlacementMember" xlink:label="anvs_November2023PrivatePlacementMember_638781823405527719" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405527719" xlink:to="anvs_November2023PrivatePlacementMember_638781823405527719" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_December2024AtMarketEquityOfferingMember" xlink:label="anvs_December2024AtMarketEquityOfferingMember_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405527719" xlink:to="anvs_December2024AtMarketEquityOfferingMember_638781823405537695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405527719" xlink:to="us-gaap_ClassOfStockLineItems_638781823405537695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405537695" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638781823405537695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_AtMarketEquityOfferingCommonStockAuthorizedValue" xlink:label="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405537695" xlink:to="anvs_AtMarketEquityOfferingCommonStockAuthorizedValue_638781823405537695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405537695" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405537695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405537695" xlink:to="us-gaap_SaleOfStockPricePerShare_638781823405537695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock_638781823405537695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405537695" xlink:to="anvs_GrossProceedsFromIssuanceOfCommonStock_638781823405537695" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" xlink:type="extended" xlink:title="99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_8" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405547698" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405547698" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_November2023EquityOfferingAndWarrantIssuanceMember" xlink:label="anvs_November2023EquityOfferingAndWarrantIssuanceMember_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405547698" xlink:to="anvs_November2023EquityOfferingAndWarrantIssuanceMember_638781823405547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405547698" xlink:to="us-gaap_ClassOfStockLineItems_638781823405547698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405547698" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405547698" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405547698" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638781823405547698" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405547698" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405547698" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405547698" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638781823405547698" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823405547698" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405547698" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823405547698" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" xlink:type="extended" xlink:title="99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_6" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405557695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405557695" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638781823405557695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638781823405557695" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638781823405557695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781823405557695" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember_638781823405557695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405557695" xlink:to="us-gaap_ClassOfStockLineItems_638781823405557695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405557695" xlink:to="anvs_WarrantLiabilityNoncurrent_638781823405557695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405557695" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_638781823405557695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants" xlink:label="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_638781823405557695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405557695" xlink:to="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_638781823405557695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants_638781823405557695" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_638781823405567687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantLiabilityNoncurrent" xlink:label="anvs_WarrantLiabilityNoncurrent_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405557695" xlink:to="anvs_WarrantLiabilityNoncurrent_638781823405567687" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" xlink:type="extended" xlink:title="99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_10" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_10" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405567687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405567687" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638781823405567687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638781823405567687" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638781823405567687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsEquityMember" xlink:label="anvs_WarrantsClassifiedAsEquityMember_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781823405567687" xlink:to="anvs_WarrantsClassifiedAsEquityMember_638781823405567687" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantsClassifiedAsLiabilitiesMember" xlink:label="anvs_WarrantsClassifiedAsLiabilitiesMember_638781823405567687" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638781823405567687" xlink:to="anvs_WarrantsClassifiedAsLiabilitiesMember_638781823405567687" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405567687" xlink:to="us-gaap_ClassOfStockLineItems_638781823405577691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405577691" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638781823405577691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfWarrantsIssuedDuringPeriod" xlink:label="anvs_NumberOfWarrantsIssuedDuringPeriod_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405577691" xlink:to="anvs_NumberOfWarrantsIssuedDuringPeriod_638781823405577691" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ConversionOfWarrantsNumberOfWarrantsConverted" xlink:label="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405577691" xlink:to="anvs_ConversionOfWarrantsNumberOfWarrantsConverted_638781823405577691" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_6387818234055776911" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405577691" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_6387818234055776911" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405577691" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405577691" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" xlink:type="extended" xlink:title="99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_11" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_11" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405577691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405577691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405577691" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405577691" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405577691" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405587694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405587694" xlink:to="us-gaap_PrivatePlacementMember_638781823405587694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405577691" xlink:to="us-gaap_ClassOfStockLineItems_638781823405587694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfSaleOfStockTransactions" xlink:label="anvs_NumberOfSaleOfStockTransactions_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405587694" xlink:to="anvs_NumberOfSaleOfStockTransactions_638781823405587694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405587694" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405587694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405587694" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638781823405587694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" xlink:type="extended" xlink:title="99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_14" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_14" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405587694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405587694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405587694" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405587694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405587694" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405597695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMember" xlink:label="anvs_CommonStockPurchaseAgreementMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405597695" xlink:to="anvs_CommonStockPurchaseAgreementMember_638781823405597695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementCommitmentSharesMember" xlink:label="anvs_CommonStockPurchaseAgreementCommitmentSharesMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_CommonStockPurchaseAgreementMember_638781823405597695" xlink:to="anvs_CommonStockPurchaseAgreementCommitmentSharesMember_638781823405597695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementFixedPurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementFixedPurchaseMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_CommonStockPurchaseAgreementMember_638781823405597695" xlink:to="anvs_CommonStockPurchaseAgreementFixedPurchaseMember_638781823405597695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_CommonStockPurchaseAgreementMember_638781823405597695" xlink:to="anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_638781823405597695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember" xlink:label="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_CommonStockPurchaseAgreementMember_638781823405597695" xlink:to="anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_638781823405597695" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405587694" xlink:to="srt_RangeAxis_638781823405597695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781823405597695" xlink:to="srt_RangeMember_638781823405597695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638781823405597695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781823405597695" xlink:to="srt_MinimumMember_638781823405597695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405587694" xlink:to="us-gaap_ClassOfStockLineItems_638781823405607711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementSharesAuthorized" xlink:label="anvs_CommonStockPurchaseAgreementSharesAuthorized_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_CommonStockPurchaseAgreementSharesAuthorized_638781823405607711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405607711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NonCashFinancingCostsFromIssuanceOfShares" xlink:label="anvs_NonCashFinancingCostsFromIssuanceOfShares_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_NonCashFinancingCostsFromIssuanceOfShares_638781823405607711" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementTotalCommitment" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitment_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_CommonStockPurchaseAgreementTotalCommitment_638781823405607711" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementTotalCommitmentValue" xlink:label="anvs_CommonStockPurchaseAgreementTotalCommitmentValue_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_CommonStockPurchaseAgreementTotalCommitmentValue_638781823405607711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalFees" xlink:label="us-gaap_ProfessionalFees_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="us-gaap_ProfessionalFees_638781823405607711" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405607711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405607711" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638781823405617691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638781823405617691" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638781823405617691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="us-gaap_SaleOfStockPricePerShare_638781823405617691" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice" xlink:label="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice_638781823405617691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice_638781823405617691" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume" xlink:label="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume_638781823405617691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume_638781823405617691" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementPurchasePricePercentage" xlink:label="anvs_CommonStockPurchaseAgreementPurchasePricePercentage_638781823405617691" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405607711" xlink:to="anvs_CommonStockPurchaseAgreementPurchasePricePercentage_638781823405617691" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" xlink:type="extended" xlink:title="99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_13" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638781823405627711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_13" xlink:to="us-gaap_ScheduleOfStockByClassTable_638781823405627711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405627711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405627711" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405627711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405627711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405627711" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405627711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_CommonStockPurchaseAgreementMember" xlink:label="anvs_CommonStockPurchaseAgreementMember_638781823405627711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405627711" xlink:to="anvs_CommonStockPurchaseAgreementMember_638781823405627711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638781823405627711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638781823405627711" xlink:to="us-gaap_ClassOfStockLineItems_638781823405627711" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405627711" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405627711" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405627711" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="anvs_FairValueAdjustmentOfDerivativeLiabilities_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405627711" xlink:to="anvs_FairValueAdjustmentOfDerivativeLiabilities_638781823405637715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638781823405627711" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent_638781823405637715" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405637715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405637715" xlink:to="us-gaap_PlanNameAxis_638781823405637715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638781823405637715" xlink:to="us-gaap_PlanNameDomain_638781823405637715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityIncentivePlan2019Member" xlink:label="anvs_EquityIncentivePlan2019Member_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638781823405637715" xlink:to="anvs_EquityIncentivePlan2019Member_638781823405637715" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EquityIncentivePlan2018Member" xlink:label="anvs_EquityIncentivePlan2018Member_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638781823405637715" xlink:to="anvs_EquityIncentivePlan2018Member_638781823405637715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638781823405637715" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405637715" xlink:to="us-gaap_AwardTypeAxis_638781823405637715" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781823405647703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638781823405637715" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781823405647703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638781823405647703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781823405647703" xlink:to="us-gaap_EmployeeStockOptionMember_638781823405647703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405647703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405637715" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405647703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638781823405647703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405647703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638781823405647703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781823405647703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405647703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638781823405647703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781823405647703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405647703" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781823405647703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405657702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405657702" xlink:to="us-gaap_IncomeStatementLocationAxis_638781823405657702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638781823405657702" xlink:to="us-gaap_IncomeStatementLocationDomain_638781823405657702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638781823405657702" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638781823405657702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638781823405657702" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638781823405657702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405657702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405657702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638781823405657702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405657702" xlink:to="us-gaap_ShareBasedCompensation_638781823405657702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638781823405667702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638781823405667702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638781823405667702" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638781823405667702" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387818234056677021" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6387818234056677021" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638781823405667702" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638781823405667702" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638781823405667702" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638781823405677712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638781823405677712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638781823405677712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638781823405677712" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638781823405667702" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638781823405677712" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638781823405677712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638781823405677712" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638781823405677712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_638781823405677712" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638781823405677712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638781823405677712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638781823405677712" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638781823405687703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638781823405677712" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638781823405687703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638781823405687703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638781823405677712" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638781823405687703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638781823405687703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638781823405677712" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_638781823405687703" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638781823405687703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" xlink:to="us-gaap_AwardTypeAxis_638781823405687703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638781823405687703" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638781823405697712" xlink:to="us-gaap_EmployeeStockOptionMember_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ServiceBasedOptionsMember" xlink:label="anvs_ServiceBasedOptionsMember_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOptionMember_638781823405697712" xlink:to="anvs_ServiceBasedOptionsMember_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" xlink:to="srt_TitleOfIndividualAxis_638781823405697712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638781823405697712" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638781823405697712" xlink:to="srt_DirectorMember_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" xlink:to="us-gaap_VestingAxis_638781823405697712" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638781823405697712" xlink:to="us-gaap_VestingDomain_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638781823405697712" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_638781823405697712" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember" xlink:label="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_638781823405697712" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638781823405697712" xlink:to="anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_638781823405697712" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_PerformanceBasedVestingConditionsMember" xlink:label="anvs_PerformanceBasedVestingConditionsMember_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638781823405697712" xlink:to="anvs_PerformanceBasedVestingConditionsMember_638781823405707708" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" xlink:to="srt_RangeAxis_638781823405707708" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638781823405707708" xlink:to="srt_RangeMember_638781823405707708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638781823405707708" xlink:to="srt_WeightedAverageMember_638781823405707708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638781823405687703" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638781823405707708" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638781823405707708" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638781823405707708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638781823405707708" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638781823405717709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638781823405717709" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638781823405717709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638781823405717709" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638781823405717709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638781823405717709" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781823405717709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638781823405717709" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638781823405717709" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638781823405717709" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638781823405727744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638781823405707708" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638781823405727744" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638781823405727744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638781823405727744" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638781823405727744" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638781823405727744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638781823405727744" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638781823405727744" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638781823405727744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638781823405727744" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638781823405727744" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638781823405727744" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638781823405727744" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638781823405727744" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638781823405737694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareBasicNumeratorAbstract" xlink:label="anvs_EarningsPerShareBasicNumeratorAbstract_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638781823405737694" xlink:to="anvs_EarningsPerShareBasicNumeratorAbstract_638781823405737694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicNumeratorAbstract_638781823405737694" xlink:to="us-gaap_NetIncomeLoss_638781823405737694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareBasicDenominatorAbstract" xlink:label="anvs_EarningsPerShareBasicDenominatorAbstract_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638781823405737694" xlink:to="anvs_EarningsPerShareBasicDenominatorAbstract_638781823405737694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareBasicDenominatorAbstract_638781823405737694" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823405737694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_638781823405737694" xlink:to="us-gaap_EarningsPerShareBasic_638781823405737694" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781823405737694" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareDilutedNumeratorAbstract" xlink:label="anvs_EarningsPerShareDilutedNumeratorAbstract_638781823405737694" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781823405737694" xlink:to="anvs_EarningsPerShareDilutedNumeratorAbstract_638781823405737694" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedNumeratorAbstract_638781823405737694" xlink:to="us-gaap_NetIncomeLoss_638781823405747720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedNumeratorAbstract_638781823405737694" xlink:to="us-gaap_DilutiveSecurities_638781823405747720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedNumeratorAbstract_638781823405737694" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638781823405747720" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_EarningsPerShareDilutedDenominatorAbstract" xlink:label="anvs_EarningsPerShareDilutedDenominatorAbstract_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_638781823405737694" xlink:to="anvs_EarningsPerShareDilutedDenominatorAbstract_638781823405747720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedDenominatorAbstract_638781823405747720" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638781823405747720" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedDenominatorAbstract_638781823405747720" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_638781823405747720" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedDenominatorAbstract_638781823405747720" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638781823405747720" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638781823405747720" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="anvs_EarningsPerShareDilutedDenominatorAbstract_638781823405747720" xlink:to="us-gaap_EarningsPerShareDiluted_638781823405747720" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" xlink:type="extended" xlink:title="99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781823405757707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_2" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781823405757707" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638781823405757707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781823405757707" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638781823405757707" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638781823405757707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638781823405757707" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638781823405757707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638781823405757707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638781823405757707" xlink:to="us-gaap_EmployeeStockOptionMember_638781823405757707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638781823405757707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638781823405757707" xlink:to="us-gaap_WarrantMember_638781823405757707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638781823405757707" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781823405767738" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638781823405767738" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638781823405767738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations_638781823405767738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations_638781823405767738" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251282146734479" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638781823405767738" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781823405767738" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638781823405767738" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_638781823405777708" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638781823405777708" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638781823405777708" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_638781823405777708" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_638781823405777708" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638781823405777708" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638781823405777708" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638781823405767738" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638781823405777708" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" xlink:type="extended" xlink:title="99941002 - Disclosure - Income Taxes - Deferred taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251288811670906" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251288811670906" xlink:to="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638781823405787704" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638781823405787704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment" xlink:label="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment_638781823405787704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures" xlink:label="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures_638781823405787704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638781823405787704" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsOther_638781823405787704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsGross_638781823405787704" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638781823405787704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638781823405787704" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_638781823405787704" xlink:to="us-gaap_DeferredTaxAssetsNet_638781823405797707" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" xlink:type="extended" xlink:title="99941003 - Disclosure - Income Taxes - Additional disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637251306845174076" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637251306845174076" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638781823405797707" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638781823405797707" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638781823405797707" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638781823405797707" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638781823405797707" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638781823405797707" xlink:to="us-gaap_DomesticCountryMember_638781823405797707" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638781823405797707" xlink:to="us-gaap_StateAndLocalJurisdictionMember_638781823405797707" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember_638781823405797707" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638781823405797707" xlink:to="us-gaap_ForeignCountryMember_638781823405797707" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638781823405797707" xlink:to="us-gaap_TaxPeriodAxis_638781823405807706" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_638781823405807706" xlink:to="us-gaap_TaxPeriodDomain_638781823405807706" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneratedIn2017AndPriorMember" xlink:label="anvs_GeneratedIn2017AndPriorMember_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_638781823405807706" xlink:to="anvs_GeneratedIn2017AndPriorMember_638781823405807706" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638781823405797707" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638781823405807706" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638781823405807706" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638781823405807706" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638781823405807706" xlink:to="us-gaap_ResearchMember_638781823405807706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638781823405797707" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="us-gaap_OperatingLossCarryforwards_638781823405807706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638781823405807706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638781823405807706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638781823405817705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638781823405817705" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405817705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405817705" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638781823405817705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638781823405817705" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638781823405817705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638781823405817705" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ResearchAndDevelopmentAmortizationPeriodTerm" xlink:label="anvs_ResearchAndDevelopmentAmortizationPeriodTerm_638781823405817705" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638781823405807706" xlink:to="anvs_ResearchAndDevelopmentAmortizationPeriodTerm_638781823405817705" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="99941101 - Disclosure - Segment Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781823405827856" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781823405827856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638781823405827856" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781823405827856" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638781823405827856" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638781823405887703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638781823405827856" xlink:to="us-gaap_SegmentDomain_638781823405887703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SingleReportableSegmentMember" xlink:label="anvs_SingleReportableSegmentMember_638781823405887703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638781823405887703" xlink:to="anvs_SingleReportableSegmentMember_638781823405887703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638781823405887703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638781823405827856" xlink:to="us-gaap_SegmentReportingInformationLineItems_638781823405887703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToClinicalStageProductCandidates" xlink:label="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_638781823405887703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="anvs_ProgramExpensesRelatedToClinicalStageProductCandidates_638781823405887703" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms" xlink:label="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_638781823405887703" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms_638781823405887703" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638781823405897704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="us-gaap_LaborAndRelatedExpense_638781823405897704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees" xlink:label="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_638781823405897704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees_638781823405897704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638781823405897704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638781823405897704" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638781823405897704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="us-gaap_InvestmentIncomeInterest_638781823405897704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense_638781823405897704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="us-gaap_OtherNoncashIncomeExpense_638781823405897704" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638781823405897704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638781823405887703" xlink:to="us-gaap_NetIncomeLoss_638781823405897704" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://annovisbio.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941201 - Disclosure - Subsequent Events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638781823405907706" xlink:to="us-gaap_SubsequentEventTypeAxis_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638781823405907706" xlink:to="us-gaap_SubsequentEventTypeDomain_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638781823405907706" xlink:to="us-gaap_SubsequentEventMember_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638781823405907706" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638781823405907706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638781823405907706" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SecondaryOfferingMember" xlink:label="anvs_SecondaryOfferingMember_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405907706" xlink:to="anvs_SecondaryOfferingMember_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_December2024AtMarketEquityOfferingMember" xlink:label="anvs_December2024AtMarketEquityOfferingMember_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638781823405907706" xlink:to="anvs_December2024AtMarketEquityOfferingMember_638781823405907706" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638781823405907706" xlink:to="us-gaap_SubsequentEventLineItems_638781823405907706" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance" xlink:label="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance_638781823405907706" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance_638781823405907706" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfSharesIncludedInEachUnit" xlink:label="anvs_NumberOfSharesIncludedInEachUnit_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="anvs_NumberOfSharesIncludedInEachUnit_638781823405917704" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_NumberOfWarrantsIncludedInEachUnit" xlink:label="anvs_NumberOfWarrantsIncludedInEachUnit_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="anvs_NumberOfWarrantsIncludedInEachUnit_638781823405917704" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="us-gaap_SaleOfStockPricePerShare_638781823405917704" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_GrossProceedsFromIssuanceOfCommonStock" xlink:label="anvs_GrossProceedsFromIssuanceOfCommonStock_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="anvs_GrossProceedsFromIssuanceOfCommonStock_638781823405917704" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638781823405917704" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_WarrantTerm" xlink:label="anvs_WarrantTerm_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="anvs_WarrantTerm_638781823405917704" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm" xlink:label="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm_638781823405917704" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405917704" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638781823405917704" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638781823405929643" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638781823405907706" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638781823405929643" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" xmlns="http://www.xbrl.org/2003/linkbase">
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638781823405929643" xlink:to="anvs_MariaMaccecchiniMember_638781823405929643" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638781823405929643" xlink:to="anvs_ClaudineBruckMember_638781823405937710" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_AllIndividualsMember_638781823405929643" xlink:to="anvs_MarkWhiteMember_638781823405937710" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="ecd_AllIndividualsMember_638781823405929643" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MariaMaccecchiniMember" xlink:label="anvs_MariaMaccecchiniMember_638781823405929643" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_ClaudineBruckMember" xlink:label="anvs_ClaudineBruckMember_638781823405937710" />
    <loc xlink:type="locator" xlink:href="anvs-20241231.xsd#anvs_MarkWhiteMember" xlink:label="anvs_MarkWhiteMember_638781823405937710" />
  </presentationLink>
  <presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="extended" xlink:title="995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 18, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANNOVIS BIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2540421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">101 Lindenwood Drive, Suite&#160;225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Malvern<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">875-3192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANVS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,312,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,486,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Document incorporated by reference</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Certain portions, as expressly described in this report, of the registrant&#8217;s proxy statement for the 2025 Annual Meeting of the Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001477845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,551,916<span></span>
</td>
<td class="nump">$ 5,754,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,373,717<span></span>
</td>
<td class="nump">4,453,544<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">13,925,633<span></span>
</td>
<td class="nump">10,208,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,305,974<span></span>
</td>
<td class="nump">1,292,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,575,013<span></span>
</td>
<td class="nump">2,986,273<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,880,987<span></span>
</td>
<td class="nump">4,279,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">737,000<span></span>
</td>
<td class="nump">13,680,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,617,987<span></span>
</td>
<td class="nump">17,959,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively</a></td>
<td class="nump">1,414<span></span>
</td>
<td class="nump">1,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">144,155,694<span></span>
</td>
<td class="nump">102,507,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(134,849,462)<span></span>
</td>
<td class="num">(110,259,087)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">9,307,646<span></span>
</td>
<td class="num">(7,750,846)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
<td class="nump">$ 13,925,633<span></span>
</td>
<td class="nump">$ 10,208,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">14,141,521<span></span>
</td>
<td class="nump">10,519,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">14,141,521<span></span>
</td>
<td class="nump">10,519,933<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 19,995,447<span></span>
</td>
<td class="nump">$ 38,790,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,699,481<span></span>
</td>
<td class="nump">6,244,408<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">26,694,928<span></span>
</td>
<td class="nump">45,035,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(26,694,928)<span></span>
</td>
<td class="num">(45,035,011)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">331,849<span></span>
</td>
<td class="nump">667,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_FinancingCostsFromIssuanceOfShares', window );">Other financing costs</a></td>
<td class="num">(1,853,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GainLossOnChangesInFairValueOfWarrantLiability', window );">Change in fair value of warrants</a></td>
<td class="nump">3,625,893<span></span>
</td>
<td class="num">(11,837,200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">2,104,553<span></span>
</td>
<td class="num">(11,169,302)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,590,375)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract', window );"><strong>Net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (dollars per share)</a></td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="num">$ (6.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (dollars per share)</a></td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="num">$ (6.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of common shares used in computing net loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">12,182,475<span></span>
</td>
<td class="nump">9,023,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">12,235,444<span></span>
</td>
<td class="nump">9,023,138<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_FinancingCostsFromIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for transaction costs related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_FinancingCostsFromIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GainLossOnChangesInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from changes in fair value of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GainLossOnChangesInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 816<span></span>
</td>
<td class="nump">$ 82,377,488<span></span>
</td>
<td class="num">$ (54,054,774)<span></span>
</td>
<td class="nump">$ 28,323,530<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">8,163,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">8,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">59,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,628,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,628,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of common stock warrants, inclusive of warrant reduction</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">1,056,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,056,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of common stock warrants, inclusive of warrant reduction, shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability', window );">Issuance of common stock, net of issuance costs and warrant liability</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="nump">14,436,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,436,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability', window );">Issuance of common stock, net of issuance costs and warrant liability, shares</a></td>
<td class="nump">2,246,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,204,313)<span></span>
</td>
<td class="num">(56,204,313)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">102,507,189<span></span>
</td>
<td class="num">(110,259,087)<span></span>
</td>
<td class="num">$ (7,750,846)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="nump">10,519,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Changes in Stockholders' Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions', window );">Cashless exercise of stock options</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod', window );">Cashless exercise of stock options, shares</a></td>
<td class="nump">220,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,836,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,836,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised', window );">Exercise of common stock warrants, inclusive of warrant reduction</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">17,342,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,342,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of common stock warrants, inclusive of warrant reduction, shares</a></td>
<td class="nump">891,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts', window );">Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">156,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement', window );">Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs, shares</a></td>
<td class="nump">26,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts', window );">Issuance of common stock pursuant to ELOC, net of issuance costs</a></td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">16,438,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,438,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit', window );">Issuance of common stock pursuant to ELOC, net of issuance costs, shares</a></td>
<td class="nump">2,051,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts', window );">Issuance of common stock pursuant to registered direct offering, net of issuance costs</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">3,874,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering', window );">Issuance of common stock pursuant to registered direct offering, net of issuance costs, shares</a></td>
<td class="nump">431,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,590,375)<span></span>
</td>
<td class="num">(24,590,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 1,414<span></span>
</td>
<td class="nump">$ 144,155,694<span></span>
</td>
<td class="num">$ (134,849,462)<span></span>
</td>
<td class="nump">$ 9,307,646<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance, shares at Dec. 31, 2024</a></td>
<td class="nump">14,141,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued under terms of an equity distribution agreement during the period, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued under terms of an equity line of credit, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued under terms of a registered direct offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period in a cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued during the period under terms of an equity distribution agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued during the period under terms of an equity line of credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period, excluding warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued during the period under terms of a registered direct offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the cashless exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of stock issued in the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period, net of issuance costs and warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (24,590,375)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,836,770<span></span>
</td>
<td class="nump">4,628,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrants</a></td>
<td class="num">(3,625,893)<span></span>
</td>
<td class="nump">11,837,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative', window );">Non-cash other financing costs, including change in fair value of derivative</a></td>
<td class="nump">1,803,189<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,079,827<span></span>
</td>
<td class="nump">3,190,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,013,138<span></span>
</td>
<td class="num">(2,668,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(1,411,260)<span></span>
</td>
<td class="num">(751,012)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(21,894,604)<span></span>
</td>
<td class="num">(39,967,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">18,666,797<span></span>
</td>
<td class="nump">16,885,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">8,025,003<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,385<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">26,691,800<span></span>
</td>
<td class="nump">17,344,331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">4,797,196<span></span>
</td>
<td class="num">(22,622,973)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">5,754,720<span></span>
</td>
<td class="nump">28,377,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">10,551,916<span></span>
</td>
<td class="nump">5,754,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NonCashTransactionValueOfConsiderationWarrantExercises', window );">Other adjustment to value of warrants related to exercises</a></td>
<td class="nump">9,317,108<span></span>
</td>
<td class="nump">606,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CashPaidForFinancingCostsDuringPeriod', window );">Cash paid for financing costs</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CashPaidForFinancingCostsDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period for financing costs related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CashPaidForFinancingCostsDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash financing costs, including change in fair value of derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NonCashTransactionValueOfConsiderationWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the noncash consideration recognized as a reduction in warrant value related to exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NonCashTransactionValueOfConsiderationWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Management's Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business and Management's Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of Business and Management's Plans</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1)&#160;Nature of Business and Management&#8217;s Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio,&#160;Inc. (the &#8220;Company&#8221; or &#8220;Annovis&#8221;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#8217;s disease (&#8220;AD&#8221;) and Parkinson&#8217;s disease (&#8220;PD&#8221;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#8217;s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#8217;s future operations are dependent on the success of the Company&#8217;s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#8217;s primary source of capital has been the issuance of common stock and warrants to purchase common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the Company&#8217;s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2024, the Company had cash and cash equivalents of $10.6 million and an accumulated deficit of $134.8 million. The Company&#8217;s net loss was $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company&#8217;s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company&#8217;s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2024, combined with cash raised in the first quarter of 2025 in connection with its December 2024 ATM with OpCo and February 2025 stock offering with ThinkEquity, is not sufficient to fund operations for the period through one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management&#8217;s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, management concluded that such plans do not alleviate the substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.<span style="white-space:pre-wrap;">  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2)&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#8217;s financial condition, results of operations, and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (&#8220;ELOC&#8221;) Purchase Agreement are expensed as incurred as prescribed by ASC 815. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 &#8211; <i style="font-style:italic;">Derivatives and Hedging</i>. An embedded derivative </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that requires separation is accounted for as a separate liability or asset from the host agreement.  The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 &#8212; Stockholders&#8217; Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was </span><span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span></span> because the ELOC facility had been exhausted and all shares from the equity line had been sold. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h)&#160;Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock and (ii) warrants to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-style:normal;font-weight:normal;">$9.00</span><span style="font-style:normal;font-weight:normal;"> per share (&#8220;Canaccord Warrants&#8221;). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i)&#160;Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company&#8217;s contracts with its vendors and are realized in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(j)&#160;Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(k)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#8217;s Black-Scholes option-pricing model represent Management&#8217;s best estimates and involve a number of variables, uncertainties, assumptions, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the application of Management&#8217;s judgment, as they are inherently subjective. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model for stock options are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term. </i>As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the &#8220;simplified&#8221; method, as prescribed in SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility.</i> The expected volatility is based on historical volatilities of Annovis and similar entities within the Company&#8217;s industry for periods commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate.</i> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends.</i> The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(l)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.      </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(m)&#160;Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;) on an annual basis, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, <i style="font-style:italic;">Segment Reporting</i><span style="white-space:pre-wrap;">. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.  See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(n) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes</i> <i style="font-style:italic;">(Topic 740): Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company&#8217;s financial statement disclosures, but it does not anticipate material impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (</i>&#8220;ASU 2024-03&#8221;<i style="font-style:italic;">)</i>, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. <span style="white-space:pre-wrap;">The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3)&#160;Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;2&#8212;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level&#160;3&#8212;Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any financial instruments into or out of Level 3 classification, during the year ended December 31, 2024 or 2023. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Canaccord Warrants</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The common stock warrants issued in connection with the Company&#8217;s equity financing in November 2023 (&#8220;Canaccord Warrants&#8221;) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock. The Canaccord Warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense), net in the statements of operations until the warrants are exercised, expired, reclassified, or otherwise settled. From their date of issuance until the period ended June 30, 2024, the fair value of the Canaccord Warrants was estimated using a <span style="-sec-ix-hidden:Hidden_IDmi6EBxm0ykocQlpvyy7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Monte Carlo</span></span> simulation model, given the performance conditions outlined further below. However, during the quarter ended September 30, 2024, the Company determined that certain performance conditions could not be met and that going forward, their use as inputs for determining fair value was no longer appropriate. As such, after the period ended June 30, 2024, the fair value of the Canaccord Warrants is estimated using a <span style="-sec-ix-hidden:Hidden_MYnYPWwqd0e83MnNL4wIWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Black-Scholes</span></span> option-pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in both a Monte Carlo simulation model and a Black-Scholes option-pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on an implied asset volatility calculated and believed to be reasonable for the Company over the holding period remaining. The risk-free interest rate is based on the market yield of U.S. Treasuries over a term commensurate with the remaining term to expiration. Any changes in these assumptions can change the associated valuation significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Phase III data probability of success</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (time to expiration in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redemption hurdle price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company&#8217;s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days&#8217; prior written notice, at any time after:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company&#8217;s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson&#8217;s Disease; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which (a) the closing price of the Company&#8217;s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$14.25</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and (b) the average daily trading value (&#8220;ADTV&#8221;) of the Company&#8217;s common stock is equal to or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> consecutive Trading Days. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson&#8217;s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met. As such, the probability of success and redemption hurdle price inputs were no longer used in the Black-Scholes option-pricing model outlined above for the year ending December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Warrants were exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. See Note 7 &#8211; Stockholders&#8217; Equity (Deficit) for additional background.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4)&#160;Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,998,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,391,219</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 346,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,455</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,074</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,796</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,373,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,453,544</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5)&#160;Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 948,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,645,589</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,848</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,836</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,575,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,986,273</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6)&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has entered contracts with CROs and CMOs related the Company&#8217;s clinical trials.  The contracts require upfront payments, milestone payments, and pass-through cost reimbursements, to be made. While the contracts are generally cancellable with (written) notice, the Company is obligated to make payments for services rendered through the termination date of the project with any applicable CRO/CMO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains one short-term lease associated with occupying its corporate headquarters. Total rental expense was $0.1 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has an agreement with its Chief Executive Officer that provides for severance payments upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreement was estimated to be $1.1 million&#160;at December&#160;31,&#160;2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#8217;s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For both the years ended December 31, 2024 and December 31, 2023 the Company did not have any pending legal actions deemed to be material.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' (Deficit) Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7) Stockholders&#8217; Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company&#8217;s initial public offering (the &#8220;IPO&#8221;) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are two classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 is designated as common stock and 2,000,000 is <span style="-sec-ix-hidden:Hidden_sH-lbMPWqkOGFnPa1im7Pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preferred</span></span> stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of December 31, 2024 or December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;IPO Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the closing of the Company&#8217;s Initial Public Offering (&#8220;IPO&#8221;), the Company granted its underwriters 0.1 million warrants to purchase shares of Company common stock (&#8220;IPO Warrants&#8221;) at an exercise price of $7.50 per share, which was 125% of the IPO price. The IPO Warrants have a <span style="-sec-ix-hidden:Hidden_nIEprH3FlECzxDG_jmJGRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five-year</span></span> term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders&#8217; equity. At both December 31, 2024 and December 31, 2023, 2,400 of the IPO Warrants were outstanding. No IPO Warrants were exercised during the years ended December 31, 2024 or 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(e)&#160;March 2023 ATM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Company, entered into an At the Market (&#8220;ATM&#8221;) Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221; or &#8220;March 2023 ATM&#8221;) with BofA Securities, Inc. (&#8220;BofA&#8221;) and ThinkEquity LLC (&#8220;ThinkEquity&#8221; and, together with BofA, the &#8220;Sales Agents&#8221;), as sales agents, pursuant to which the Company could offer and sell, from time to time through the Sales Agents, shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;), having an aggregate offering price of up to $50.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to termination of the Sales Agreement, the Company sold 0.7 million shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7.6 million before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(f)&#160;April 2023 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2023, the Company sold 0.1 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(g)&#160;November 2023 Equity Offering and Warrant Issuance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (&#8220;Canaccord Warrants&#8221;) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Canaccord Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,449,001</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 50,000 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (606,201)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,837,200</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 891,667 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,317,107)</p></td></tr><tr><td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h)&#160;Warrant Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had the following common stock warrants outstanding:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised&#160;or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IPO warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 29, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Canaccord warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (891,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 2, 2028</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i)&#160;November 2023 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 27, 2023, the Company sold 0.2 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $6.10 per share, for aggregate proceeds of $1.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(j) March 2024 Registered Direct Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 15, 2024 and March 21, 2024, the Company entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, the Company issued 0.4 million shares for net proceeds of $3.9 million in registered direct offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(k) April 2024 ELOC Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 25, 2024, the Company entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of the Company&#8217;s common stock. The term of the agreement was until the expiration of the Company&#8217;s active S-3 Registration Statement, unless earlier terminated or exhausted. Due to certain pricing and settlement provisions, the ELOC Purchase Agreement qualified as a standby equity purchase agreement and included an embedded put option and embedded forward option. The Company therefore accounted for the ELOC Purchase Agreement as a derivative measured at fair value, with changes in the fair value recognized in the statements of operations within other financing costs. The Company initially recognized a derivative liability of $1.7 million related to the purchased put option at inception of the ELOC Purchase Agreement. The Company then expensed the difference between the discounted purchase price of the settled forward and the fair value of shares on the date of settlement as a noncash financing issuance cost. The Company recognized $1.3 million of noncash financing costs during the year ended December 31, 2024 related to the discounted purchase price of the settled forward and the underlying fair value of the shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the ELOC Purchase Agreement, the Company agreed to issue to the ELOC Purchaser 33,937 shares of Common Stock as commitment shares (the &#8220;Commitment Shares&#8221;). The fair value of the Commitment Shares was $0.5 million, which was expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The Company also incurred issuance costs of $0.1 million, consisting of legal costs incurred in connection with the ELOC Purchase Agreement, which were expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The ELOC Purchaser agreed that during the term of the Purchase Agreement, neither it nor any of its affiliates would engage in any short sales or hedging transactions involving the Company&#8217;s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ELOC Purchase Agreement, on any business day (the &#8220;Purchase Date&#8221;), if the Company&#8217;s stock price is greater than or equal to $5.00 per share, the Company could direct the ELOC Purchaser to purchase common stock. The ELOC Purchaser&#8217;s committed obligation under any single Fixed Purchase could not exceed the lower of 25,000 shares of Common Stock or $250,000 (&#8220;Fixed Purchases&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company could also direct the ELOC Purchaser, on any trading day in which the Company submitted a Fixed Purchase notice for the maximum amount allowed for such Fixed Purchase, to purchase an additional amount of the Company&#8217;s common stock (a &#8220;VWAP Purchase&#8221;). The ELOC Purchaser&#8217;s committed obligation under any single VWAP Purchase could not exceed a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) 30% of the trading volume in the Company&#8217;s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date (&#8220;VWAP Purchase Maximum Amount&#8221;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company could also direct the ELOC Purchaser, on any trading day for which a VWAP Purchase had been completed and all of the shares had been placed, to purchase an additional amount of the Company&#8217;s common stock (an &#8220;Additional VWAP Purchase&#8221;). The ELOC Purchaser&#8217;s committed obligation under any single Additional VWAP Purchase was the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (&#8220;Additional VWAP Purchase Maximum Amount&#8221;). The applicable pricing structure for each purchase type is outlined below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for Fixed Purchases (&#8220;Fixed Purchase Price&#8221;) equals 95% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the daily volume weighted average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock on the NYSE for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for VWAP Purchases (&#8220;VWAP Purchase Price&#8221;) equals 95% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the VWAP during the applicable VWAP Purchase Period during the applicable VWAP Purchase Date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for Additional VWAP Purchases (&#8220;Additional VWAP Purchase Price&#8221;) equals 95% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the commitment shares referenced above, a total of 2.0 million shares of the Company&#8217;s common stock were issued under the ELOC Purchase Agreement during the year ended December 31, 2024, for net proceeds of $14.6 million. The facility was fully exhausted during 2024 and no further shares are available to issue as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following is a roll-forward of the ELOC derivative liability from date of execution to December 31, 2024: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at April 25, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,697,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,192,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 505,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 442,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (442,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(l) December 2024 ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 11, 2024, the Company entered into an Equity Distribution Agreement (&#8220;Distribution Agreement&#8221;) with Oppenheimer &amp; Co. Inc., (&#8220;OpCo&#8221;) relating to the sale of shares of the Company&#8217;s common stock. In accordance with the terms of the Distribution Agreement, The Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as agent or principal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the year-ended December 31, 2024, the Company sold 26,788 million shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company&#8217;s IPO on January&#160;31, 2020, the Company&#8217;s 2019 Equity Incentive Plan (the &#8220;2019 Plan&#8221;) became effective, succeeding the Company&#8217;s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 12, 2024, the 2019 Plan was amended to increase the number of shares authorized from 2,000,000 to 3,000,000. As of December 31, 2024, the 2019 Plan contained 354,299 shares available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board, except when they are below previously approved thresholds allowing the Company&#8217;s CEO to grant awards on a discretionary basis. The Company&#8217;s stock options generally carry a maximum term of 10 years after date of grant and are exercisable in cash, or as otherwise determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2024 and 2023 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,510,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,414,867</p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,326,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,213,539</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,836,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,628,406</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,954,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,863</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 870,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 570</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (189,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,824,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $5.16 and $7.39, respectively. During the year ended December 31, 2024 the Company received no cash proceeds from the exercises of stock options. For the year ended December 31, 2023, the Company received $8,385 cash proceeds from the exercises of stock options. As of December 31, 2024, there was unrecognized stock-based compensation expense related to unvested stock option awards, related to service-based options of $2.4 million, which will be recognized over a remaining weighted-average period of 1.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2024 and 2023, the Company issued 870,494 and 367,329 options, respectively. Under the grant agreements for the 2024 stock option grants, 382,282 of the options vested immediately and 468,212 of the options vest in substantially equal quarterly installments over two years from the date of grant. There are also 20,000 stock option grants that vest as consulting services are performed and awards are earned. Under the grant agreements for the 2023 stock option grants, 94,624 of the options vested immediately, and 272,705 of the options vest in substantially equal quarterly installments over two years from the date of grant. All of the options have a 10-year term prior to expiration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The assumptions utilized in the fair value calculations for stock options granted during the years ended December 31, 2024 and 2023, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended December 31, 2024, the Company issued 20,000 non-qualified stock options to a member of its Board of Directors in consideration for the member&#8217;s agreement to serve as a consultant to the Company. The options were issued in one tranche, at a grant price of $5.27 per share. 8,069 of the awards became vested during the year ended December 31, 2024. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the&#160;years ended December 31, 2024 and 2023, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share &#8211; Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share &#8211; Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Less: gain from change in fair value applicable to dilutive liability-classified warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Numerator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,216,268)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Denominator for basic net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Plus: incremental shares underlying &#8220;in the money&#8221; liability-classified warrants outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Denominator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,235,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Diluted net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,954,774</p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,202,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was&#160;$0&#160;for the&#160;years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2024 and 2023 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, change in rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,634,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,607,158</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,390,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,245,472</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,137,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,334,494</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,802,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,793,442</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,198,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,132,475</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 76,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,553</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,240,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,127,594</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,240,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,127,594)</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had U.S. federal net operating loss (&#8220;NOL&#8221;) carryforwards of $54.1 million which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2024 and 2023 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company recorded a net change in valuation allowance of $7.1 million and $11.7 million in the&#160;years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had federal research and development tax credit carryforwards of $5.2 million available to reduce future tax liabilities, which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#8217;s tax&#160;years from 2021 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the tax authorities may adjust the tax attributes upon their examination of the future period in which the attribute was utilized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">(11) Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2008. The Company&#8217;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. This presentation is consistent with how the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on net loss as reported on the statements of operations. The CODM uses net loss to monitor actual operating results, assess cash runway, and benchmark against the Company&#8217;s competitors. The measure of segment assets is reported on the balance sheets as total assets. The Company&#8217;s assets are held in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">When evaluating the Company&#8217;s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company&#8217;s segment information as reviewed by the CODM:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to clinical-stage product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,723,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,104,702)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to preclinical and discovery programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (568,214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (583,154)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,525,586)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,444,920)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,687,276)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,152,485)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items&#185;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,190,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (749,750)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 331,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 667,898</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-cash income (expense) items&#178;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,772,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,837,199)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,590,374)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56,204,313)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">&#185; Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">&#178; Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.</span><span style="font-weight:normal;background:#ffffff;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2024, the Company sold 0.1 million shares of its common stock under its ATM with OpCo, which the Company entered into in December 2024. The Company received net proceeds of $0.5 million after deducting commissions and fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the &#8220;ThinkEquity Warrants&#8221;), at a per unit price of $4.00 (the &#8220;Offering&#8221;). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. The Company has agreed to suspend sales of its Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (24,590,375)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name and Title</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Action</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan</p></td><td style="vertical-align:middle;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aggregate Number of securities to be sold</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan Expiration Date</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Maria Maccecchini,&#160;CEO &amp; Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17-Dec-24</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">270,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16-Sep-26</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Claudine Bruck, Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17-Dec-24</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21,426</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31-Dec-25</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mark White,&#160;Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17-Dec-24</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51,426</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30-Sep-26</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=anvs_MariaMaccecchiniMember', window );">Maria Maccecchini</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Maria Maccecchini<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">CEO & Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">17-Dec-24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">16-Sep-26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">270,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=anvs_ClaudineBruckMember', window );">Claudine Bruck</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Claudine Bruck<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">17-Dec-24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">31-Dec-25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">21,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=anvs_MarkWhiteMember', window );">Mark White</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mark White<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Director<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">17-Dec-24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">30-Sep-26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">51,426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=anvs_MariaMaccecchiniMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=anvs_MariaMaccecchiniMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=anvs_ClaudineBruckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=anvs_ClaudineBruckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=anvs_MarkWhiteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=anvs_MarkWhiteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company&#8217;s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations. The Company references the National Institute of Standards and Technology Cybersecurity Framework to help identify, assess, and manage cybersecurity risks and has adopted and tested a formal cybersecurity incident response plan. As part of our risk management process, the Company engages a third-party provider to conduct periodic maturity assessments. The Company stores data in cloud environments, with security appropriate to the data involved and has adopted controls around, among other things, access and acceptable use, backup and recovery and vendor risk assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cybersecurity program is managed by the Annovis Incident Management Committee (the &#8220;AIMC&#8221;). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company. From time to time, we engage this vendor to monitor our environment, which includes an outsourced security operations center. We may also from time to time engage partners for periodic penetration testing and vulnerability assessments. We intend to continue to work to formalize our cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations, or financial condition, although we may be materially affected in the future by such risks or future material incidents. See &#8220;Risk Factors&#8212;Risks Related to Our Business Operations&#8212;Disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations&#8221; for additional information regarding cybersecurity risks.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company&#8217;s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Roles and Responsibilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity is an important part of our risk management processes and an area of focus for the Annovis management and Board of Directors. We continue to invest in cybersecurity and enhance our internal controls and processes, which are designed to help protect our systems and the information they contain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The Board has delegated to the Audit Committee the responsibility to oversee the integrity of the Company&#8217;s information technology and cybersecurity risks and to assess the risks and incidents relating to cybersecurity threats. While our Board and Audit Committee oversee cybersecurity risk, management, through the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually. Additionally, the Audit Committee regularly meets with members of the Company&#8217;s internal audit function to discuss risk management activities, compliance, best practices, and other related matters.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Board and Audit Committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cybersecurity program is managed by the Annovis Incident Management Committee (the &#8220;AIMC&#8221;). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Annovis Incident Management Committee<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a)&#160;Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S.&#160;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b)&#160;Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c)&#160;Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d)&#160;Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e)&#160;Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#8217;s financial condition, results of operations, and cash flows.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock', window );">Issuance Costs Associated with Equity Issuances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f)&#160;Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Issuance costs incurred in connection with the Company&#8217;s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (&#8220;ELOC&#8221;) Purchase Agreement are expensed as incurred as prescribed by ASC 815. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Derivative Liability</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g)&#160;Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 &#8211; <i style="font-style:italic;">Derivatives and Hedging</i>. An embedded derivative </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that requires separation is accounted for as a separate liability or asset from the host agreement.  The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 &#8212; Stockholders&#8217; Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was </span><span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span></span> because the ELOC facility had been exhausted and all shares from the equity line had been sold. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h)&#160;Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock and (ii) warrants to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-style:normal;font-weight:normal;">$9.00</span><span style="font-style:normal;font-weight:normal;"> per share (&#8220;Canaccord Warrants&#8221;). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i)&#160;Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company&#8217;s contracts with its vendors and are realized in the ordinary course of business.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IntangibleAssetsPatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(j)&#160;Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(k)&#160;Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, <i style="font-style:italic;">Compensation&#8212;Stock Compensation</i> (&#8220;ASC 718&#8221;). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#8217;s Black-Scholes option-pricing model represent Management&#8217;s best estimates and involve a number of variables, uncertainties, assumptions, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the application of Management&#8217;s judgment, as they are inherently subjective. If any assumptions change, the Company&#8217;s stock-based compensation expense could be materially different in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Company&#8217;s Black-Scholes option-pricing model for stock options are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term. </i>As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the &#8220;simplified&#8221; method, as prescribed in SEC&#8217;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility.</i> The expected volatility is based on historical volatilities of Annovis and similar entities within the Company&#8217;s industry for periods commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate.</i> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends.</i> The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(l)&#160;Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.      </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(m)&#160;Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280): Improvements to Reportable Segment Disclosures</i> (&#8220;ASU 2023-07&#8221;) on an annual basis, which requires public entities to disclose information about their reportable segments&#8217; significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, <i style="font-style:italic;">Segment Reporting</i><span style="white-space:pre-wrap;">. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.  See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(n) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes</i> <i style="font-style:italic;">(Topic 740): Improvements to Income Tax Disclosures</i> (&#8220;ASU 2023-09&#8221;), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company&#8217;s financial statement disclosures, but it does not anticipate material impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (</i>&#8220;ASU 2024-03&#8221;<i style="font-style:italic;">)</i>, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. <span style="white-space:pre-wrap;">The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.  </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IntangibleAssetsPatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IntangibleAssetsPatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for issuance costs associated with equity issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -SubTopic 15<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481051/815-15-35-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480526/815-10-35-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5B<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480588/815-10-25-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 15<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481116/815-15-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-40/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/730/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at  </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Canaccord Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of quantitative information regarding Level 3 fair value measurements inputs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Phase III data probability of success</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (time to expiration in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redemption hurdle price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,998,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,391,219</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 346,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,455</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,074</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,796</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,373,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,453,544</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 948,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,645,589</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,848</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,836</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,575,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,986,273</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock', window );">Schedule of changes in common stock warrant liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (&#8220;Canaccord Warrants&#8221;) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#8217;s control or not deemed to be indexed to the Company&#8217;s stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Canaccord Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,449,001</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 50,000 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (606,201)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,837,200</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 891,667 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,317,107)</p></td></tr><tr><td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of common stock warrants outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had the following common stock warrants outstanding:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised&#160;or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price&#160;per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IPO warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 29, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Canaccord warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (891,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 2, 2028</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in common stock warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock-based compensation expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2024 and 2023 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,510,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,414,867</p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,326,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,213,539</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,836,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,628,406</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company&#8217;s stock option activity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,954,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,863</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 870,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 570</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (189,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December&#160;31,&#160;2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,824,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions used to determine fair value of options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share &#8211; Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share &#8211; Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Less: gain from change in fair value applicable to dilutive liability-classified warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Numerator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,216,268)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Denominator for basic net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Plus: incremental shares underlying &#8220;in the money&#8221; liability-classified warrants outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">   Denominator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,235,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Diluted net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of shares excluded from the computation of diluted weighted-average shares outstanding</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,954,774</p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,202,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of income tax provision (benefit)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2024 and 2023 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, change in rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As&#160;of&#160;December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,634,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,607,158</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,390,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,245,472</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,137,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,334,494</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,802,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,793,442</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,198,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,132,475</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 76,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,553</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,240,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,127,594</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,240,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,127,594)</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">When evaluating the Company&#8217;s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company&#8217;s segment information as reviewed by the CODM:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to clinical-stage product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,723,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,104,702)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to preclinical and discovery programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (568,214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (583,154)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,525,586)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,444,920)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,687,276)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,152,485)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items&#185;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,190,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (749,750)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 331,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 667,898</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-cash income (expense) items&#178;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,772,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,837,199)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,590,374)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56,204,313)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">&#185; Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">&#178; Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.</span><span style="font-weight:normal;background:#ffffff;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Management's Plans (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NatureOfBusinessAndLiquidityAbstract', window );"><strong>Nature of Business and Management's Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">10,551,916<span></span>
</td>
<td class="nump">$ 5,754,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">134,849,462<span></span>
</td>
<td class="nump">110,259,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">24,590,375<span></span>
</td>
<td class="nump">56,204,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="nump">$ 26,694,928<span></span>
</td>
<td class="nump">$ 45,035,011<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NatureOfBusinessAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NatureOfBusinessAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash and cash equivalents, Federally insured limit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option contractual term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023EquityOfferingAndWarrantIssuanceMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares which may be purchased with warrants | shares</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023EquityOfferingAndWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023EquityOfferingAndWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Hierarchy (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">$ 737,000<span></span>
</td>
<td class="nump">$ 13,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">491,006<span></span>
</td>
<td class="nump">5,136,677<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">491,006<span></span>
</td>
<td class="nump">5,136,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">737,000<span></span>
</td>
<td class="nump">13,680,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">737,000<span></span>
</td>
<td class="nump">13,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">491,006<span></span>
</td>
<td class="nump">5,136,677<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured and recorded at fair value</a></td>
<td class="nump">491,006<span></span>
</td>
<td class="nump">5,136,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability</a></td>
<td class="nump">737,000<span></span>
</td>
<td class="nump">13,680,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities measured and recorded at fair value</a></td>
<td class="nump">$ 737,000<span></span>
</td>
<td class="nump">$ 13,680,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Canaccord Warrants (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2023 </div>
<div>USD ($) </div>
<div>D </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember', window );">Canaccord warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList', window );">Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:BlackScholesMertonModelMember<span></span>
</td>
<td class="text">us-gaap:MonteCarloModelMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ClassOfWarrantOrRightRedemptionPricePerShare', window );">Redemption price per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantsThresholdPeriodOfNoticeForRedemption', window );">Threshold period of notice for redemption</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Closing price of common stock</a></td>
<td class="nump">$ 14.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AverageDailyTradingValue', window );">Average daily trading value | $</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded', window );">Threshold consecutive trading days | D</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Closing stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Phase 3 data probability of success</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Term (time to expiration in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Redemption hurdle price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.039<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AverageDailyTradingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of average daily trading value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AverageDailyTradingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ClassOfWarrantOrRightRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Redemption price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ClassOfWarrantOrRightRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold consecutive trading days for which average daily trading value is traded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_WarrantsThresholdPeriodOfNoticeForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period of notice of warrants for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_WarrantsThresholdPeriodOfNoticeForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=anvs_MeasurementInputSuccessRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=anvs_MeasurementInputSuccessRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputConversionPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidResearchAndDevelopmentExpenseCurrent', window );">Prepaid clinical expenses</a></td>
<td class="nump">$ 2,998,811<span></span>
</td>
<td class="nump">$ 4,391,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid other</a></td>
<td class="nump">346,313<span></span>
</td>
<td class="nump">23,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">21,098<span></span>
</td>
<td class="nump">18,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">7,495<span></span>
</td>
<td class="nump">20,796<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,373,717<span></span>
</td>
<td class="nump">$ 4,453,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PrepaidResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PrepaidResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">$ 948,695<span></span>
</td>
<td class="nump">$ 2,645,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">364,717<span></span>
</td>
<td class="nump">96,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees and other</a></td>
<td class="nump">261,601<span></span>
</td>
<td class="nump">243,836<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 1,575,013<span></span>
</td>
<td class="nump">$ 2,986,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfShortTermLeases', window );">Number of short term leases | lease</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rental expense</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsAbstract', window );"><strong>Employment Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_MaximumAggregateSeverancePayments', window );">Maximum aggregate severance payments</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_MaximumAggregateSeverancePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_MaximumAggregateSeverancePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfShortTermLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of short-term leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfShortTermLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - Overview (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Vote </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfClassesOfStockDesignated', window );">Number of classes of stock designated | $</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockAndPreferredStockSharesAuthorized', window );">Number of common and preferred shares authorized</a></td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Number of common shares authorized</a></td>
<td class="nump">70,000,000<span></span>
</td>
<td class="nump">70,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Number of preferred shares authorized</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfVotesForEachShareOfCommonStock', window );">Number of vote for each share of common stock | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockAndPreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockAndPreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfClassesOfStockDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of classes of stock designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfClassesOfStockDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfVotesForEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of vote for each share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfVotesForEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - IPO Warrants (Details) - IPO warrants - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares which may be purchased with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_PercentageOfExercisePriceToShareOfferingPrice', window );">Percentage of exercise price to the share offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_PercentageOfExercisePriceToShareOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of exercise price to the share offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_PercentageOfExercisePriceToShareOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - ATMs and Private Placements (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 27, 2023</div></th>
<th class="th"><div>Apr. 07, 2023</div></th>
<th class="th"><div>Apr. 04, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 11, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_March2023AtMarketEquityOfferingMember', window );">March 2023 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AtMarketEquityOfferingCommonStockAuthorizedValue', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_April2023PrivatePlacementMember', window );">April 2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023PrivatePlacementMember', window );">November 2023 Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_December2024AtMarketEquityOfferingMember', window );">December 2024 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_AtMarketEquityOfferingCommonStockAuthorizedValue', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_AtMarketEquityOfferingCommonStockAuthorizedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_AtMarketEquityOfferingCommonStockAuthorizedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from the additional capital contribution to the entity through the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_March2023AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_March2023AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_April2023PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_April2023PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_December2024AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_December2024AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net cash proceeds after deducting underwriter discount and fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,666,797<span></span>
</td>
<td class="nump">$ 16,885,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023EquityOfferingAndWarrantIssuanceMember', window );">November 2023 Equity Offering and Warrant Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares which may be purchased with warrants</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net cash proceeds after deducting underwriter discount and fees</a></td>
<td class="nump">$ 6,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023EquityOfferingAndWarrantIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_November2023EquityOfferingAndWarrantIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,625,893<span></span>
</td>
<td class="num">$ (11,837,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability, ending balance</a></td>
<td class="nump">$ 13,680,000<span></span>
</td>
<td class="nump">737,000<span></span>
</td>
<td class="nump">13,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember', window );">Canaccord warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability, beginning balance</a></td>
<td class="nump">2,449,001<span></span>
</td>
<td class="nump">13,680,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="nump">11,837,200<span></span>
</td>
<td class="num">(3,625,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="num">$ (606,201)<span></span>
</td>
<td class="nump">$ 9,317,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted', window );">Number of warrants exercised</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">891,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantLiabilityNoncurrent', window );">Warrant liability, ending balance</a></td>
<td class="nump">$ 13,680,000<span></span>
</td>
<td class="nump">$ 737,000<span></span>
</td>
<td class="nump">$ 13,680,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants converted in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfWarrantsNumberOfWarrantsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the fair value of warrants attributable to the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_WarrantLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_WarrantLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Warrant Summary (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsEquityMember', window );">IPO warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfWarrantsIssuedDuringPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted', window );">Exercised or Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember', window );">Canaccord warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfWarrantsIssuedDuringPeriod', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted', window );">Exercised or Expired</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="num">(891,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance</a></td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">308,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ConversionOfWarrantsNumberOfWarrantsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants converted in a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ConversionOfWarrantsNumberOfWarrantsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfWarrantsIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfWarrantsIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=anvs_WarrantsClassifiedAsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,666,797<span></span>
</td>
<td class="nump">$ 16,885,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Securities Purchase Agreement with an institutional investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfSaleOfStockTransactions', window );">Number of transactions</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued | shares</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net</a></td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfSaleOfStockTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of sale of stock transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfSaleOfStockTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementMember', window );">ELOC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementSharesAuthorized', window );">Number of authorized shares under terms of the agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability</a></td>
<td class="nump">$ 1,697,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 442,500<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NonCashFinancingCostsFromIssuanceOfShares', window );">Non-cash other financing costs</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Value of shares issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementCommitmentSharesMember', window );">Commitment Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementTotalCommitment', window );">Total commitment shares</a></td>
<td class="nump">33,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementTotalCommitmentValue', window );">Value of total commitment shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementFixedPurchaseMember', window );">Fixed Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementPurchasePricePercentage', window );">Purchase price, percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementFixedPurchaseMember', window );">Fixed Purchase | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementTotalCommitment', window );">Total commitment shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementTotalCommitmentValue', window );">Value of total commitment shares</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember', window );">VWAP Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice', window );">Maximum percentage of shares directed by Fixed Purchase Notice</a></td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume', window );">Threshold percentage of trading volume</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementPurchasePricePercentage', window );">Purchase price, percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember', window );">Additional VWAP Purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice', window );">Maximum percentage of shares directed by Fixed Purchase Notice</a></td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_CommonStockPurchaseAgreementPurchasePricePercentage', window );">Purchase price, percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum purchase of shares in a single transaction as a percentage of the Fixed Purchase Notice shares directed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockPurchaseAgreementPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The purchase price as a percentage of the lesser of certain criteria as defined in the purchase agreement..</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockPurchaseAgreementPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockPurchaseAgreementSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of authorized under terms of a common stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockPurchaseAgreementSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold percentage of trading volume.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockPurchaseAgreementTotalCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate number of shares of committed under terms of a common stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockPurchaseAgreementTotalCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_CommonStockPurchaseAgreementTotalCommitmentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of shares of committed under terms of a common stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_CommonStockPurchaseAgreementTotalCommitmentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NonCashFinancingCostsFromIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of non-cash financing costs attributable to shares issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NonCashFinancingCostsFromIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementCommitmentSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementCommitmentSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementFixedPurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementFixedPurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' (Deficit) Equity - Changes in derivative liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementMember', window );">ELOC Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' (Deficit) Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, beginning balance</a></td>
<td class="nump">$ 1,697,500<span></span>
</td>
<td class="nump">442,500<span></span>
</td>
<td class="nump">$ 505,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_FairValueAdjustmentOfDerivativeLiabilities', window );">Settlements and changes in fair value of ELOC derivative liability</a></td>
<td class="num">(1,192,500)<span></span>
</td>
<td class="num">(442,500)<span></span>
</td>
<td class="num">(62,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liability, ending balance</a></td>
<td class="nump">$ 505,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 442,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_FairValueAdjustmentOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_FairValueAdjustmentOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of plans (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 12, 2024</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">354,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member', window );">2019 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member', window );">2018 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anvs_EquityIncentivePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,836,770<span></span>
</td>
<td class="nump">$ 4,628,406<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,510,444<span></span>
</td>
<td class="nump">2,414,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,326,326<span></span>
</td>
<td class="nump">$ 2,213,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of the year</a></td>
<td class="nump">1,954,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">870,494<span></span>
</td>
<td class="nump">367,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(189,248)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of the year</a></td>
<td class="nump">2,336,020<span></span>
</td>
<td class="nump">1,954,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of year</a></td>
<td class="nump">1,824,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of the year (in dollars per share)</a></td>
<td class="nump">$ 13.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">20.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of the year (in dollars per share)</a></td>
<td class="nump">11.39<span></span>
</td>
<td class="nump">$ 13.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of year (in dollars per share)</a></td>
<td class="nump">$ 12.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">7 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">1,298<span></span>
</td>
<td class="nump">$ 17,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 1,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value</a></td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 7.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">870,494<span></span>
</td>
<td class="nump">367,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 6.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember', window );">Immediate vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">382,282<span></span>
</td>
<td class="nump">94,624<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember', window );">Vests in equal quarterly installments over two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">468,212<span></span>
</td>
<td class="nump">272,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=anvs_PerformanceBasedVestingConditionsMember', window );">Performance-based vesting conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 5.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director | Immediate vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">8,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Weighted average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Estimated fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.18%<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option terms (years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">123.00%<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anvs_ServiceBasedOptionsMember', window );">Service-based options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average recognition period (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=anvs_PerformanceBasedVestingConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=anvs_PerformanceBasedVestingConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anvs_ServiceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anvs_ServiceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EarningsPerShareBasicNumeratorAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (24,590,375)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EarningsPerShareBasicDenominatorAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">12,182,475<span></span>
</td>
<td class="nump">9,023,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per common share</a></td>
<td class="num">$ (2.02)<span></span>
</td>
<td class="num">$ (6.23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EarningsPerShareDilutedNumeratorAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (24,590,375)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Less: gain from change in fair value applicable to dilutive liability-classified warrants</a></td>
<td class="num">(3,625,893)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Numerator for diluted net loss per share</a></td>
<td class="num">$ (28,216,268)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_EarningsPerShareDilutedDenominatorAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic</a></td>
<td class="nump">12,182,475<span></span>
</td>
<td class="nump">9,023,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Plus: Incremental shares underlying "in the money" liability-classified warrants outstanding</a></td>
<td class="nump">52,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net loss per share</a></td>
<td class="nump">12,235,444<span></span>
</td>
<td class="nump">9,023,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted</a></td>
<td class="num">$ (2.31)<span></span>
</td>
<td class="num">$ (6.23)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareBasicDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareBasicDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareBasicNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareBasicNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareDilutedDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareDilutedDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_EarningsPerShareDilutedNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_EarningsPerShareDilutedNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Potential shares excluded from calculation (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,336,020<span></span>
</td>
<td class="nump">1,954,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">1,202,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of income tax provision (benefit) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations', window );">Federal provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations', window );">State provision (benefit) for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax benefit at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local tax, net of federal benefit</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">State and local tax, change in rates</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(3.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credit</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Change in fair value of warrants</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.90%)<span></span>
</td>
<td class="num">(20.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 13,634,896<span></span>
</td>
<td class="nump">$ 9,607,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,137,406<span></span>
</td>
<td class="nump">1,334,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">4,390,635<span></span>
</td>
<td class="nump">4,245,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures', window );">Section 174</a></td>
<td class="nump">12,802,738<span></span>
</td>
<td class="nump">10,793,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D credit carryforwards</a></td>
<td class="nump">5,198,123<span></span>
</td>
<td class="nump">4,132,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">76,757<span></span>
</td>
<td class="nump">14,553<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">37,240,555<span></span>
</td>
<td class="nump">30,127,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(37,240,555)<span></span>
</td>
<td class="num">(30,127,594)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional disclosures (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Net change in valuation allowance</a></td>
<td class="nump">$ 7,100,000<span></span>
</td>
<td class="nump">$ 11,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Recognized income tax interest and penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 54,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ResearchAndDevelopmentAmortizationPeriodTerm', window );">R&amp;D amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. federal | Generated in 2017 and prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 56,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Outside of the U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ResearchAndDevelopmentAmortizationPeriodTerm', window );">R&amp;D amortization period</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ResearchAndDevelopmentAmortizationPeriodTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time for amortization of research and development expenses, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ResearchAndDevelopmentAmortizationPeriodTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=anvs_GeneratedIn2017AndPriorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=anvs_GeneratedIn2017AndPriorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 331,849<span></span>
</td>
<td class="nump">$ 667,898<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,590,375)<span></span>
</td>
<td class="num">(56,204,313)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=anvs_SingleReportableSegmentMember', window );">Single reportable segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ProgramExpensesRelatedToClinicalStageProductCandidates', window );">Program expenses related to clinical-stage product candidates</a></td>
<td class="num">(16,723,518)<span></span>
</td>
<td class="num">(35,104,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms', window );">Program expenses related to preclinical and discovery programs</a></td>
<td class="num">(568,214)<span></span>
</td>
<td class="num">(583,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Personnel-related expenses (including stock-based compensation)</a></td>
<td class="num">(6,525,586)<span></span>
</td>
<td class="num">(6,444,920)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees', window );">General and administrative professional and consultant fees</a></td>
<td class="num">(1,687,276)<span></span>
</td>
<td class="num">(2,152,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="num">(1,190,333)<span></span>
</td>
<td class="num">(749,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">331,849<span></span>
</td>
<td class="nump">667,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash income (expense) items</a></td>
<td class="nump">1,772,704<span></span>
</td>
<td class="num">(11,837,199)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,590,374)<span></span>
</td>
<td class="num">$ (56,204,313)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses classified as professional and consultant fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ProgramExpensesRelatedToClinicalStageProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of program expenses related to clinical-stage product candidates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ProgramExpensesRelatedToClinicalStageProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of program expenses related to preclinical and discovery programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=anvs_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=anvs_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 03, 2025</div></th>
<th class="th"><div>Feb. 01, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_December2024AtMarketEquityOfferingMember', window );">December 2024 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm', window );">Temporary suspension of ATM offering</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance', window );">Number of units to be sold</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfSharesIncludedInEachUnit', window );">Number of common shares included in each unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_NumberOfWarrantsIncludedInEachUnit', window );">Number of warrants included in each unit</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price per share</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common shares</a></td>
<td class="nump">$ 21.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anvs_WarrantTerm', window );">Term of warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Events | December 2024 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross proceeds from the additional capital contribution to the entity through the issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfSharesIncludedInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares included in each unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfSharesIncludedInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_NumberOfWarrantsIncludedInEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants included in each unit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_NumberOfWarrantsIncludedInEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time for temporary suspension of sale of stock under the At the Market Equity Offering Sales Agreements after the start of the secondary public offering, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units authorized for issuance. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at a per unit price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anvs_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time in which warrants may be exercised, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anvs_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anvs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_December2024AtMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_December2024AtMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anvs_SecondaryOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anvs_SecondaryOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>78
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( /J)=5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( /J)=5J_^"3_\0   "L"   1
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M 8Q<G0#'EXS)W8:ZP/YSJ]O_ E!+ P04    " #ZB75:0$IR.L,$  #3$@
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MQ\'?JL"S(8T?Q%19#>6,8Z=<I8!1@W7I].\Z=8&4K]1Y%S$6H]*N5%^T@TL
M?OI+5)=6NWB\E[ =+]HK>M'G6?3J&='[*_7%NU1'];,KJ7PL8 ]ZCLJN!F7/
M5R]*_$3%0AWLS]5JN3I\0=[!:/R!R#OX?QB?11_N%LVY]"&VNJ"3&9(E4KBA
MV>F//^R_77Y\0?'#4?'#EZ3_=XJ_*'JWXJ_W?U+?W?/'']ZO]M]]['=69\[Y
M&Q/5N?%S]:N#YUZGFA3/6BT_7OBFU>Y>WO8_*A^&@7Y9/_"3NM51&5?XT/J@
M$Y4*J7S6!F/5ZJ\<",OW<]4AOH)BZ5;?1E:1GZ\2YO/+)\)G'6@QZH1_6A4P
MW13:OHD)%J@R=!O56IV8Z521]5.Z+($"[-TH1UWP)6W($31A2HE=42OH=V;_
MJ E4%48(2A,)7*%>#U9]&@UBT"YUN#8N>O?L@LMQP4)]A3')WYE"%3H6NB0
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M8;_.@6@TC$;[=C*YY@)JH 5AQZIQP%  >!70+SB%H?_(95D[B(+)8>WX9H:
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M2:SR/,QXCH:V.(B+Q,F9<=BPM4^P#/L^J2=OC4/Z/JT=#<[6C7 /AF<';"'
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MJ'7?H?&#<ZN\-N,&(<?B,Q?=MKV>NE 0)9@9D6C'PP+>ZB1MYHXM6AV.'&P
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MW?JKZ97_6-@L]Y]</W(]0\VQ5$RQ== [.>J G;K/F/X"E>P^':*NK,K<S[D
MSC4MP/.I@KOA@A34WY(O_PM02P,$%     @ ^HEU6O06+%&U @    <  !D
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M>/TJ(]\=AKJ'Z)IT $$V<)Q)MS),V,L&O"^<B]L'<; [D<[_ 5!+ P04
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M)8ZSW49DVB11;$ _2F)Y3Z#>YKQ,$.Z%A(TJ+\'FWDN@+-$>]0U2^1.E@1S
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MA(M.E4U'QY.VRAKW"]0V:>@&0:R'[.?\5N=8DD4[+"-BDRG8985V!#A!/%=
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ME6_IXT9 KU'B GB_RG-EOR "]ZO*-_\&4$L#!!0    ( /J)=5H=!3%5DP@
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MCA(G43QGUW_5TN[8396)RFUU6_"*G1(]$2;1*T=&LVX<OWK![D3&2\%$*UZ
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ML#U-?7=_<; F#>/TBXS'R,J?.R33,8UG\R 9S0Z9)E$X^7IQOV!;5*X@16D
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MREI5NM>5X'  $>#[0BG;#FB#[O\@E_\#4$L#!!0    ( /J)=5I^B( 6G 0
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M7<M9[YU7H>P=O]GC@;CTX?57N]J^/'P=WIEUMX<WC[]+BZQT(E=+B(Z&L^E
MV/ V+_SP9LUOT!;&>U/PUY4B!M,-N+XTQC<_:(/VE>K5?P%02P,$%     @
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MN.:)U R"W<1GR=(&/'+B9X%K%#G>@/651?=M!ZR@>Z>>_P-02P,$%     @
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M=XO^[^\/F@"B:83>F(H!S<LUIE,0T'-,4S1?KP6L3?%'GBQU@FG#$L)<,,5
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MKA1/BLL-T B$J:"?KSA7GP730'7Z-_L/4$L#!!0    ( /J)=5H\I3,X$0(
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MSK=#G#;^_0$3$OS^06MW#$*!Z44K?P%02P,$%     @ ^HEU6L'A%A;D"@
M)BT  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL[5I9;QLY$OXKA :8
MG0$4VU+.26P#=HY= Y--8'LW#X-]H+HIB6MVLX=DV]'\^OVJR#XD2^TXGEU@
M9O-B]T'675]547UX8]V57RH5Q.?"E/YHM RA>KF_[[.E*J3?LY4J\69N72$#
M;MUBWU=.R9PW%69_>G#P;+^0NAP='_*SC^[XT-;!Z%)]=,+712'=ZE09>W,T
MFHR:!^=ZL0ST8/_XL)(+=:'"/ZJ/#G?[+95<%ZKTVI;"J?G1Z&3R\G3R@C;P
MBG]J=>-[UX)4F5E[13=G^='H@"121F6!2$C\NU:OE3%$"7+\FHB.6IZTL7_=
M4'_'RD.9F?3JM36?=!Z61Z,7(Y&KN:Q-.+<W?U-)H:=$+[/&\U]QD]8>C$16
M^V"+M!D2%+J,_^7G9(@OV3!-&Z8L=V3$4KZ101X?.GLC'*T&-;I@57DWA-,E
M>>4B.+S5V!>.7Z]FRGF5U4Z'E3C7_DJ\ER7\ <L'(<M<8+4,:K$2;[3/C/6U
M4X?[ :R)P'Z6V)Q&-M,=;"93\=Z68>G%VS)7^3J!?<C<"CYM!#^=#E)\H[(]
M\7@R%M.#Z9,!>H];0SQF>H^_QA#CU@ICMLE?[;5RI2PS)7[Y&83$65"%_]<V
MNT2N3[9SI9Q[Z2N9J:,1DLHK=ZU&Q]]_-WEV\&I IR>M3D^&J-_AW(_.9LI[
MY0626YS0E=?E8BS.<KS6\Q7?D+J\"7?B<HG,#U[\<JD^!W%J;':U5>EAL0:C
M['*IQ&M;5+)<B:7T0N:V"BH752MMKKQ>E'@4K-!)5,C)\C.M@DGC7U!.2R,<
M^$%)9PN1K5DD1'7&XF:ILZ603@E=0@H2):=+BR6M.-]_]V(Z>?[*"W*^-)%N
M8L9Z^)6G,& 96G'WH)'UJB>_+C-3YPJ8YBM;XA78T!99)B68F)VS+(@RPV]A
M\'B3A!9)N$:9L<AL.8_VD(8?1%U(429_+;61,TWOB+JMG<@!&?Q2EQ'@"2B3
M&C"IL?#YC0Y+8<'*;5H4$A 15 C'.UG7SGN 5^44<L2SH'_G-=A\5OJ@0QT4
M27$1P%ZZ/%KM4F7+TAJ+.%B/W7=.%HKPG9@NE:EN>7[<=_VZFZ.T]+H?4'0?
ME.=+P=J;C7UP%'/I/%496>XA540E76B,N!D&R=/C?NP(52[P'MSQ5+O\$1%8
MT=)KL'"D%=R7UQFVP\0VUQE9.\K11<6&A5$='"4$>5&7 NA<(U#*:^ULR<O'
MT7NM1K("QPHN#*J)G[3YVIKK9)2^D2!4<"@QR U;ESF,7%!,Q'" )N6"#)]E
M3>K1917DS"A1>S5&P<RNZHI?.951XL1@O%9E;I/I.O7VQ ?8<]T)$!CY6 CM
MDXUS,5NQY"=E">MYQ%-R4P]28*%"AZ"4^(&64NI.#UZ=G+U_S9>35S]&2](3
MP; +^6.<9K I @,LD]LU:4,0630P2,L4)2=,Z=4C5.S-D*NLT1EBD_JBH&*E
M(+TS>,[H>)LY2U8#D""L D6@[PD%Q3;YL[M4:/H93EM-V;Z!&Y4-$06VPUW:
M&8W69YD9T-%SS1A+;"@ B$*WFK'*H)6#7[0%5?T;I_6XRQ$&*Y])PR_V6O=X
M\8.>X^WJ1P;:W&8U"0P>I%N+=4Y5U@6R<H>8,7P6M9'.(.J7V)\WD5WJQC.J
M"Z%^CIU=LH-UIKITTY2(5VJUEL=;XVY/?%*\JL0V9BDW%F8I&4E(HZ@T (#@
M*@TQ.CB+$([<#CHB_DPA/!VQ(4OWL6(/:(=2%=#\<I+B/_)8)0@AW7R3/WB-
M?-2  =:@E_I-34O%AFR()<%C60;CM=)WX"TR#FE6N)"0V'@;BV9?DD:*9)+8
M.[20A5E!A4B/L97<R.E>&RQNBL\:GGV*-;?,$P9B3\W<&K2/T*Q_4[N=-$YJ
M$KL<+C"V6@^@F#U=3-P*"";[B.&(0,I3+]\K*#&RSLJ8^=<IS^3.3&OR)=8
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M\F>W$L/<[U#BIU:)G^YO];8"G?3*Y'E7(G]N2^2MM5BVT%0/X;/=J@W+-,<
M,*3;Y* [8CZXKW:G%DC/C85VBHMASU-W(=@=['J'L^?6I-[FO.F_* &IX5D7
M2O. A"J&V9.,]@7G.XDPP080@1;/T1+[=E)OCB>*]8/.VYKS#-2??&+SROWG
MFI",0^62-8M=?=OZ-:<T?>CKXVH?M/GXK)D[B4X?..,PT*$1[E?-1!!GZZ@
M&8Q_4*'BWYP>I0ZI@]'QSFFJ&6DV,8W:1/3-)M_2[,5F/?*GVI0KZK-3T\0F
M1W_;/_NA9Z[O>,X6%BF][3 ZR;-9;-9LL3[.[SIDI'H2JR'S;Y]WARAQ**'>
MWVXOB0B)I3;1RU%?(K"I7J/(;4'&/4O3#.JXO6UFT:T#"5NCJ SOD>T)T[K'
M;G.ZLP#S7<-@;4:)-;9WL'1[UFLB<D/SWBQ:*(7-[41SRT300OQ:(YL5'1W-
MI->I25G?=_KAC4#D&: K<2UK E,,/VVC:E;CK0RZ8ZD>Q8)G);\[IIK&@HDU
MTRZ? V!BJQ$YFZ;E7&/@&O?.$,<853P!$KW.5#H#C\V"2_,$8I?:_*'>8-+[
ML7#R=4C>L[@3%_4L:^_/-^+L'C _+,O.O!C2=-II.KVOIJE;8"W.&!8HA?^+
M^@]+^*?(Y"%?=;_<3@9_1-WF*RK\)%6O=[W3W,-,OOTR\>V7B0?^,O'M_/C;
M^?'_V_GQ$,!WG[%,'O0=B_4ZR@R[M/;W:Y5W]Q!\!^L[!OQ)=_0X>=#9XY?H
M<%<!&Q;@BXK2D*K=F>7D(8>6;]M?0=?K\[U4'1;@C_\3\) ?NJ.\R;W/\K;W
ML#TO/"#\[CCN^],,G_^3V7,H +JCT<F]ST;OB3GGW/.0?>*<,X"C7W=0NM_[
M=+50;L$?Z'HN?2%^Q=H^;3\"/HF?OG;+XQ?$[Z5##^QAR#FV'NP]!QZZ^%%N
MO FVX@]A9S8$6_#E4DF  2W ^[E%(J8;8M!^&GW\'U!+ P04    " #ZB75:
MQ!3F6C82  #;-@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6RM6VUO
MX[@1_BM$6K0.X#AV]O7V)4"2S;8I]NX6F]OV,RW1-B^RY!,E.^ZO[S,SI$0Y
MLG+7%EAL+(L<#F>>>27]85>4#VYE3*4>UUGN/IZLJFKS[OS<)2NSUFY2;$R.
M-XNB7.L*C^7RW&U*HU.>M,[.+Z;3U^=K;?.3RP_\W=?R\D-15YG-S==2N7J]
MUN7^VF3%[N/)["1\\<TN5Q5]<7[Y8:.7YMY4WS=?2SR=-U12NS:YLT6N2K/X
M>'(U>W<]>TT3>,0_K=FYZ+.BK<R+XH$>[M*/)U/BR&0FJ8B$QI^MN3%91I3
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M%6O^N#+ :4D#\'Y1 -?^@19H?L]V^1]02P,$%     @ ^HEU6G^N\T.<!
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MW.SLA"R(-DNY]U0I@61U4,&\T/='7D$H=Y)Y;5O+9"XJS2B'M42J*@HBGU;
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M""03V$M*HPOQ=0FD$ R;LN+;&3G[E/AN</'?UJ4REV !H=Z [(HX')EBFD=
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MO$!IN)*@,;ONO0XO;B9NO5_P)\>-V?L/SI*54E_=X'UZW0N<(!286,? Z/&
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M@.L ]7[)F-Q-] ;=ET7R&U!+ P04    " #ZB75:(&FA[*4#   2#@  &0
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MW,LM8PH]9FDN+T9;I7;GDXF,MBRC<LQW+->_W'*14:47Q=U$[@2C<164I9/
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MW:?I.]=;JL<W&,544=UV^(9NDC113^584A91Q&3_,0\[2PL[30L[3_M_.-[
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M'[>,QDR4*^C?;SE7SPOEBV7MJXJK?P%02P,$%     @ ^HEU6@;>I8&M @
MN@<  !D   !X;"]W;W)K<VAE971S+W-H965T,S8N>&ULK55=;YLP%/TK%INF
M5MK*A_D('4%JDU7;P[2H6;=G%VZ"5<#,=I+VW\\V%-% JTC;2V+C>\X]Y]J^
M3@Z,/X@"0*+'JJS%W"JD;"YM6V0%5$1<L 9JM;)AO")23?G6%@T'DAM05=J>
MXX1V16AMI8GYMN)IPG:RI#6L.!*[JB+\Z1I*=IA;KO7\X99N"ZD_V&G2D"VL
M0=XU*ZYF=L^2TPIJ05F-.&SFUI5[N8ATO GX1>$@!F.DG=PS]J GW_*YY6A!
M4$(F-0-1?WM80%EJ(B7C3\=I]2DU<#A^9K\QWI67>R)@P<K?-)?%W)I9*(<-
MV97REAV^0N<GT'P9*X7Y18<V-O0LE.V$9%4'5@HJ6K?_Y+&KPP#@^J\ O [@
MG0K '0 ;HZTR8VM))$D3S@Z(ZVC%I@>F-@:MW-!:[^):<K5*%4ZF*PX-H3GZ
M\JC.A0"!2)VC'[( CA8[SJ&6Z$H(D *=+4$26HIS] G=K9?H[/UY8DLE01/9
M69?NNDWGO9)N"=D%PNY'Y#F>/P%?G ['+^&V,MZ[]WKWGN'#_^I^RFE+[4]3
MZ]MW*1J2P=Q2UTL WX.5?GCGAL[G*=__B>Q%%7!?!?P6>U^%3"W0C)0(NG),
MN6ZI D.E6\0^]>)X-G/=Q-X/#8WC?!R[GAOW<2^T^KU6_R2M3&_2E+X6'@[R
M8C_$+CZ2-P[SL!\$T^*"7EQPDCA:BQTG=093 H-Q9M>)9T?ZQE'NS(G\:7UA
MKR]\4]\:LAVG\DGUN88).GVLPU'FR(^#(WGC(,^)XG!:7M3+B]Z4]Y-)=?B:
MKH@PO)-FNU4_;.\D>?5.1J-3AW&$(S<ZTC^.\_T !_YQ@>U!9]6OVG?"MVIW
M40D;A70N(D7!VY>BG4C6F&9[SZ1JW698J,<5N Y0ZQO&Y/-$]^_^N4[_ E!+
M P04    " #ZB75:)9>T5X0"  #R!@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6RME5]OFS 4Q;^*Q::IE;;RWR$=06J35=O#I*A=MV<'+L&JP<QV
MDO;;SS84I0F-\K"78.-[#K]CXDNZX^))5@ */=>LD3.G4JJ]=EV95U 3><5;
M:/1*R45-E)Z*M2M; :2PHIJY@>=AMR:T<;+4WEN*+.4;Q6@#2X'DIJZ)>+D%
MQG<SQW=>;]S3=:7,#3=+6[*&!U"/[5+HF3NX%+2&1E+>( 'ES+GQK^?8U-N"
MWQ1V<F^,3)(5YT]F\J.8.9X! @:Y,@Y$7[8P!\:,D<;XVWLZPR.-<'_\ZGYG
ML^LL*R)ASMD?6JAJYB0.*J D&Z;N^>X[]'EBXY=S)NTOVG6UX<1!^48J7O=B
M35#3IKN2YWX?]@1^](X@Z 7!N8*P%X0V:$=F8RV((EDJ^ X)4ZW=S,#NC57K
M-+0Q;_%!";U*M4YE-WDN-E"@;\_Z?R%!HHL%*$*9O$1?T./# EU\O$Q=I9]D
MZMV\=[WM7(-W7!>07Z'0_XP"+XA&Y//SY>%;N:OS#2&#(61@_<(S0XX%ZARB
M<0=SEJYE2W*8.?JP2!!;<+)/'WSL?1V+]Y_,WH0-A[#A*?<A;*X7:$X8@A.I
M.ZO86ID#O\VF48*G<>IN]_,<EP4XBN-D.M2]08T&U.@DZI*\",X8(DVA.P(C
M2F.OH(&2JE':S@WO880XFOB3 ]KCLBE.HF2<-1Y8X[.VM16\!&F:F-[:$O2)
M,?1<52#&D.,CE@#K%^T?((^416$2XG%F/##CD\R_N-*0I"<_]3_ 1R_8CR>Q
MYX<'G,=UP33!P20\ '7W.I+Y&OPD8DT;B1B46NE=3;2%Z#IL-U&\M4UJQ95N
M>798Z8\2"%.@UTO.U>O$]+WA,Y?] U!+ P04    " #ZB75:WM\_JN4"   O
M"0  &0   'AL+W=O<FMS:&5E=',O<VAE970S."YX;6RM5EUOVC 4_2M7635U
MTD0@?*J#2 4Z;=+8JE;=GDURDUB-[<QV@$K[\;,=R*"%;)UX26S'Y]QS[/A>
MC]="/JH,4<.&Y5Q-O$SKXLKW590A(ZHE"N3F2R(D(]IT9>JK0B*)'8CE?M!N
M#WQ&*/?"L1N[E>%8E#JG'&\EJ)(Q(I^FF(OUQ.MXNX$[FF;:#OCAN" IWJ-^
M*&ZEZ?DU2TP9<D4%!XG)Q+ON7,U&=KZ;\)WB6NVUP3I9"O%H.Y_CB=>V@C#'
M2%L&8EXKG&&>6R(CX^>6TZM#6N!^>\?^T7DW7I9$X4SD/VBLLXDW\B#&A)2Y
MOA/K3[CUT[=\D<B5>\*ZFMOO>1"52@NV!1L%C/+J33;;==@#!*,3@& +")X#
M@A. [A;0=48K9<[6G&@2CJ58@[2S#9MMN+5Q:..&<KN+]UJ:K]3@=#@3C%%M
MMD4K(#R&F>":\A1Y1%'!Y1PUH;EZ!Q= .2QHGINU5V-?F]"6P(^V8:95F.!$
MF$X "\.<*;CA,<:'!+[17 L/=L*G02/C'*,6=#OO(6@'/7BXG\/EQ3O(T6SI
M$7FS?R?K[L@:1';KU>TZWNX)WB]6SM'EJG"]XSA[=*]402*<>.9L*I0K],*W
M;SJ#]H=CYLY$=F"Q5UOL-;&'7TNV1 DB 94)J4&C9-4V*/AU<C^F%>G D=I,
MLPH[8W^U;ZHQ['^:ZM>F^HVF[LQY(#G@QB3+X_HK?*>W9Z#=>F[A+Y,.I UJ
M:8-&:;.,8@(W&XQ*FP#A6Y+0".4QC8U$K_W'SD1VX'E8>QXV'J,;5N3BR28I
MN$XEHDM7QQP/S^GX3&0'CD>UXU'C+B_(AK*2 4F-WY1H!(4KE(1'" 5Y.KD
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M:*S(;#/!HAFD,<#QJ<#]4G5,65:7X>%_4$L#!!0    ( /J)=5K(Q@@900,
M "X,   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;*U7:V_:,!3]*U8V
M;:NTD@>! H-(A71:)W5#K;9^-LD-L9K8S'9(^?>SDY!!&U*8X /QZQS?<V)?
M+N.<\2<1 TCTG"943(Q8RM7(-$400XI%AZV JIF(\11+U>5+4ZPXX+  I8GI
M6%;?3#&AAC<NQN;<&[-,)H3"G".1I2GFFRDD+)\8MK$=N"?+6.H!TQNO\!(>
M0/Y:S;GJF35+2%*@@C"*.$03X]H>^4.]OECPFT N=MI(*UDP]J0[M^'$L'1
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M\SZ:'M5;/R3-@=)<*,VK:.=?_:J\@A8+4+2V5TVQP-(7"WH\9NI)O;6"KAZ
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MT+T+#@5=B<V,F#[$#X&[\'U_OIRO[,,YQ(Z)_F(Q6T[]9F(+T*P!-.L'-/@
MZ&+2N\90)F.*;4<2:['U&[;^R)O8'Y/CF&+;D<1:'.<-QWE_CI8F0WE,9$)1
MGC!,Q>=_&A7 2L@_WR;>S,%/>SMM>A<<RF8DL1:;1<-F,8S-,6%A@C7$$]D!
M*4H1)E@W15AWJ(0<JZW<>:PM7DFNUYVAY$82:Y%;-N26O>1N'T&$3"(DP;"L
M08)]>);_.G^7S\#TKC84S$AB+3"N\Z-J='K1_ ,B.P="+EA.GH *V57JW?R'
MVJPR[2P2>RV'0AM+K4WMK-9V?W:M4:]XGG;^PNG8E?VN#08YDEH%TC[K7S(0
M>],'2F*BK^K[9K3J-3>ZU]3]S[-Q[$'?FL[+_B%3-;#OJ=BS7)(48I1TKN9(
M3%0]876C>&&ZI!U7V'.9RP3[:!!Z CZ/.5>G&[U TYD'WP%02P,$%     @
M^HEU6@RP/T^P P  J!   !D   !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
MM5AM;^(X$/XK5FYUMY6VS2L!>A!I2WJZ^["KJM7>?C;)0*PZ-FL;Z/[[LY,T
M#<3-M8CE XF3>1[//&/&'F9[+AYE :#04TF9G#N%4IMKUY59 2665WP#3+]9
M<5%BI8=B[<J- )Q7H)*Z@>?%;HD)<Y)9]>Q.)#.^590PN!-(;LL2BY\W0/E^
M[OC.\X-[LBZ4>> FLPU>PP.H;YL[H4=NRY*3$I@DG"$!J[GSV;]._=  *HM_
M">QEYQZ94):</YK!/_G<\8Q'0"%3A@+KRPX60*EATG[\:$B==DX#[-X_L_]5
M!:^#66()"TZ_DUP5<V?BH!Q6>$O5/=__#4U (\.7<2JK;[1O;#T'95NI>-F
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M[ 6K#]/K&T'+ZK3XE@I!B^HR0U!N250!^7Y#J7B\416T_])8_@]02P,$%
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MV"!:JD1(_B];HR*ANB=4ZHE8(L5D5I@&*F&(NLZA?4_3@\J"[<JR<N[+T!Q
MP@@0S,K!>9.#<Y!IX+Q3N8/I?#;QC^KWJMONN,)W6XS'N ,BW6837[=JFUG#
MG3?#G;L/.9&_CFF1(*&/*(DV/*=YS/,MBD6ABKZ!S[L##WW?[PS<V>_0PPL2
M1H!@EMZ!WR[L_6>>Y/69S8NB/%YC[Z5VDX;6W)IFE02_)W,1:+<$BF;+?>"C
M J?<7VA:LH[:KU"NS;[^UFSJ(YZ=/M[=_,%)"+JGSWC:FP7(?@D4S<X";K.
MG5FXEEQKO-/'?96&7IUQM\ =E11W)T-K"BB-0-%L@5M'&3B]T7(ELHRKZ@K
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MY/YUC/V&$KOJ?8-;H93(JH\)H[K$F0;Z]XT0ZFG#=-"\%+/\'U!+ P04
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M+ #OKZ0T]P/[@/H?Q^P74$L#!!0    ( /J)=5H"ZFDR>P,  .D2   9
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M4%E!/%\2PI\+LH$FN^7_ U!+ P04    " #ZB75:C_7BZNT"   *"P  &0
M 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6RM5MMNFT 0_945K:I4:L+5V$XQ
M4FSW]A IBI7V>0UC@P(LW5W;Z=]W=L$$NQ@U$I)E]C+G<,XPL!,<&'\6"8 D
M+WE6B)F12%G>FJ:($LBIN&$E%+BS83RG$J=\:XJ2 XTU*,],Q[)\,Z=I882!
M7GO@8<!V,DL+>.!$[/*<\C]SR-AA9MC&<>$QW292+9AA4-(MK$ ^E0\<9V;#
M$J<Y%")E!>&PF1EW]NW"MA1 1_Q,X2!:8Z*LK!E[5I,?\<RPE"+(()**@N)E
M#PO(,L6$.G[7I$9S3P5LCX_L7[5Y-+.F A8L^Y7&,ID9$X/$L*&[3#ZRPW>H
M#8T47\0RH?_)H8ZU#!+MA&1Y#48%>5I45_I2)Z(%L/T+ *<&..< [P+ K0&N
M-EHIT[:65-(PX.Q N(I&-C70N=%H=),6ZC&N),?=%'$R7$D6/5_/,1$Q6; <
MJT-0G=]KLDHHA^NUWHK:6_"BQD"NEB!IFHF/&/RT6I*K]Q\#4Z(H16U&M8!Y
M)<"Y(,!VR#TK9"+(ER*&^)3 1#>-)>=H:>[T,BXANB&N_8DXEN-U"%K\/]SM
MD>,V&78UG_O&#'>EJF+RNIG4&WTK2AK!S,!75@#?@Q%^>&?[UN<NFP.1G9CV
M&M->'WMM^G+M=)FO&$>:47U]]J$[<?WQV K,?=O7OW&>[TP\RV_B3B2/&LFC
M7LG?H !.,T*+F- 87[542$[51Z9+;"_76Y_40&0GMOW&MC]8>?I#FAZ([,3T
MN#$]'KP\*T:_57;.R+8\SSLKSXXXS_8F_KB[/">-Y$FOY$=, N51HNLSACT>
MP"4>I[)+:B_36Y_30&0GIJ>-Z>E@Q3D=TO1 9">F;>OU3+8&+\^:LOU9M%W'
MQ]]9?78$.H[MCMSI68&:K:XB![[5S99 0;M"5J=QLUHU='/5T*FNY&P=&[T[
MW=Z8KS15EWA/^38M!,E@@Y36S1A5\:KQJB:2E;IW63.)G9 >)MBL E<!N+]A
M3!XGZ@9-^QO^!5!+ P04    " #ZB75:"-C%&:X$  #B%0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U,"YX;6RU6%USHS84_2L:NM-)9C8&"0S8M3WC.+OM
M/FR;23:[SS+(-A- KB3'R;^O!!@P8,5VG3S$?.@>G7/U<0\:;2E[YBM"!'A-
MXI2/C940ZZ%I\F!%$LQ[=$U2^69!68*%O&5+DZ\9P6$6E,0FLBS73'"4&I-1
M]NR>349T(^(H)?<,\$V28/9V2V*Z'1O0V#UXB)8KH1Z8D]$:+\DC$4_K>R;O
MS!(EC!*2\HBF@)'%V)C"X0S9*B!K\3,B6UZ[!DK*G-)G=?,M'!N68D1B$@@%
M@>7/"YF1.%9(DL>_!:A1]JD"Z]<[]*^9>"EFCCF9T?A7%(K5V/ -$)(%WL3B
M@6[_(H6@OL(+:,RS_V!;M+4,$&RXH$D1+!DD49K_XM<B$;4 U#\0@(H U RP
M#P3814"6.3-GELFZPP)/1HQN 5.M)9JZR'*314LU4:J&\5$P^3:2<6+R*&CP
M?',K$Q&"&4WD[. XR^\-R%X!NJ[2'8DW<'5'!(YB?BU;/#W>@:M/U^ 3, %?
M848XB%+PE$:"?Y8/Y?6/%=UPG(9\9 K)5O5I!@6SVYP9.L ,(O"=IF+%P9<T
M).$^@"EEEEK13NLMTB+>D: ';/@9( LY'81FQX?;&CIVF7H[P[,/X/V]2>:$
M ;H CUGNNE*4(SC="&J)#_D:!V1LR#7,"7LAQN3WWZ!K_=$E[T)@>V*=4JRC
M0Y_\LQ%<R(D0I4N !9B3992FZD;*%RL"W@AF70G(4=T,56U)+Q,XZ#N>)\?O
MI:Y-V_N9VOJEMKY6VY\,IZ(Y0W/Z_19]W[.<09-]NYGM>C8:E,WV>+DE+U?+
MZ\LK84'$NYFYK2YO;$O]-:AINS@SL5XIP-,*D!OU@D0'4NNU!4!_@!R_(4#;
MQ9D"_%* ?\JL)VGXWGSW6ZJ0;;L6:@Y+NUUS7>P1'I2$!\=,&3R/28WP(;*#
M-@D?.1"A!EEMGV<. ;2J"F=I]]E?62F7]6WZ0IBT)F"W+L ]BP+269FL2^Z[
MET+;UU^K\/!_;[W@2A;KD,8Q9ARL957*ROEU9V[RWOSZJ-L]!S;&7$_J7-&H
M$HV.V9-/T94#0E@3YO:LEBYMO^?JJCP#U%;I:D\_19G=5F;WH-U4]A'^ %8&
M >H=0KG9GZ+,:2M#5L]M#=I'V -8^0.H-PCZ,G"*WGY;+X0]>]#4VW]GC>X+
MJ0P%/,I1=)2'4T3D?4"GS@[UFG5;3^7<,:NL!_1.JQH/1'T5JR&<R<\2)C^(
M-C@&/PA+.D5>R'84N?@($P,K%P./MS%JG-6 \^ZQU0-Y>2BP09)_VD$?A/BM
MZ]-G]@Z46T#!' JX'4#[<BL/!(\W0>_(U0/M. Z.D?L1)@E5)@GI3=)TN61D
MB04!W^3DCE(>!> GCC>=]@A=U!Y="FU?>66/D-X>:;^2BMA^;:OJ>TTOKN_@
M7 &5U4%ZJU-;G9T24-NEHT%SMRU:U85"SW?M[HJ!*K^"CO(K:BUUDK/;W7:0
MNZ@S,6NG90EAR^P0D8. ;E*1'R:53_.#RELXG&7G>8WG4SB<9L=V9@63GWY^
MQTR:; YBLI"05L^3 EE^H)C?"+K.SN3F5 B:9)<K@D/"5 /Y?D&IV-VH#LIC
MW<E_4$L#!!0    ( /J)=5H*HQ]1+@8  'LD   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;+5:6W/B-A3^*QK:Z61G&K!DKBEA)K=.]V&GF:2[^ZS8
M!Z*);;&2@-#ICZ]\P<(@E, J>2#&Z'PZGW2.].DR7G'Q(I\!%'I-DTQ>MIZ5
MFE]T.C)ZAI3*-I]#IG^9<I%2I;^*64?.!="X,$J3#@F"?B>E+&M-QL6[>S$9
M\X5*6 ;W LE%FE*QOH:$KRY;N+5Y\<!FSRI_T9F,YW0&CZ"^SN^%_M:I46*6
M0B89SY" Z67K"E_<A*/<H"CQC<%*;CVCG,H3YR_YE\_Q92O(/8($(I5#4/UO
M"3>0)#F2]N-'!=JJZ\P-MY\WZ'\6Y#69)RKAAB??6:R>+UO#%HIA2A>)>N"K
MOZ BU,OQ(I[(XA.MJK)!"T4+J7A:&6L/4I:5_^EKU1!;!J1WP(!4!F3'  \.
M&(2505@0+3TK:-U212=CP5=(Y*4U6OY0M$UAK=FP+._&1R7TKTS;J<FCXM'+
M^;5NB!C=\%1'AZ1%^YZCJSAF^2--4,QDE'"Y$"#1V2THRA+Y21?Y^GB+SG[]
M-.XH[4H.V(FJ:J_+:LF!:C%!7WBFGB6ZRV*(FP =S:$F0C9$KHD3\1:B-@KQ
M[X@$I&MQZ.;]YJ'#G;!NU[# "X]L5UM3E4A=.U*>QQ=R3B.X;.E$E2"6T)K\
M]@ON!W_8:'H":Y#NUJ2[+O3)]R)I-&.Z!*$' 303-%,HI@K0E#*!EC19@*T)
M2MQA@9N//,M)KXW[X\YRF]I^H4$['-6%&B[W:I=[3I?O!8\ 8HFF@J<(7D%$
M3 +B4R3S'D1\GO>:M/E< O>VW EV'-XO,0R'/;O#_=KAOM/AOTN'RJ;=S9S2
ML1*@OUWM(.B.NCO>[1<+^X.0'&C00>W?P.G?/R#2O/GHBHH8G;$,K8$*:1TC
MW$@X*$UM4>ZT/#'*AS7#X7%17D?-7+#(&M[#O<CMMP.\TQ_.6D_D-*HYC9S#
MU9U43,^)FI3)T[P7'>$_\CEJ>0)K<,>!F0,#9X_>O<ZUJM#D8[9D,60Q6C-(
MK+E5(8T<6>^N[%0R6Q,Z=I+YG*80LWS(78+NU6QFI>'$.+;W?*$U&1/#F'B;
M:RLH7\0]H36)&XV!G;/Y>^:""J$QR@\)&9+=H-TO-^KV2=<^&6"C"+!;$GS3
M,2B1G@7@QT(+2?TA%(ADK5])19-$KPCT[UR/I$BM^,$!_]I=S=']Y@FMV2A&
M<^">OX!UZI>CB7M":Q(WV@7_M'C!^[*DVQ\2O!>P^^7(@ R" _(*&_V"W;+C
M6SEJHCD(QNTNN@'(8=ERBF63AA$IV*U2[D$4B_PL@O.G(M*JZ0!%/"L7=O9$
M\R1#*L(?(6JP4378+6N.2C2O@L876G,M;!0-<2N:=R1:A=!(H$#_[>29NZ)3
MB1@U0]QJYI8)+<VXL#+P*F)\H36)&A%#_(D8XE7$^$)K$C<BAORTB"'[XL0:
MJA^Q]T&,U"%'[GZ\O2XDMGT/,MCE]1%JA1BU0MQ;))L41/^A=ZTMW'!'1^='
M*!9B% OI^TM+I_@YFK@GM"9Q(X.(6XN\)RT'^QM-07^T&[T?L5=#C XB;AUT
ME\X3O@9 14^BDI:5C5?AXPNMR=H('^)]/X=XU3^^T)J;[T;_A-YV=,*W=W2<
M19H>&F$3NH6--2[U$+L[BUA=]BI\?*$U&\((G] M?$X(U="K_O&%UN2_=5#D
MUC\/3+Z<3X6.!*8'6EV#0D(WAY5WB80;9P[MH(N'NP%[J.#@0-@:D1.Z14Z=
M6&7W(.UQ*M'9X3W^-_!ZY9(7A2@MSP/Q$,5T;5T]OQ.J7T&Y>L>(G] M?FJ^
M2Y[HB3]A:FUEV=L;(7 [/TAL=HNUU($N,1(E=&^J/.J09/4JWY4V7O6)+[0F
M:Z-/PH&_ U9/$J0B_A&")C2")G0+FJ^9EN-\EK%_-?/BD++J^6C[^!Y>\V=
M I)B;%4<+;)<M&^,-@E<G-/9PV6X=WQ)NH%EW>5V^-0&,5HG=&J)_757U3X%
MO7(7[XUSR#<JP(6I-12\JIS.UC6.%,2LN-TB=;\N,E5>A*C?EC=HKO'%37'1
M9.?]%;ZX*NZ3= Q,>2WG"Q4SIE5] E,-&;0'NG=%>=.E_*+XO+@L\L25XFGQ
M^ PT!I$7T+]/.5>;+WD%]7VCR?]02P,$%     @ ^HEU6E0F/6<&!   JP\
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MC74:B;;RMQW%:UL\[[G2I=@V2_U8 F$,]'S!=:WL.F:!_OF5_@%02P,$%
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M$/XK&M]-IYWI863 $ J>(>1>^J%WF=#<?5;L!6MJ6YPD(.G<CZ\D&QLGCCC
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M;F>HRI7G%X_Y0+*UN;M[8%*RU#S&0)1>T1/4]R5C<C_0#LKKW^ '4$L#!!0
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M"/9=ZQ^&EZLOKU9?C7W[#U!+ P04    " #ZB75:$R?LNN\!  "E(@  &@
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M>SX;?B"Y>@502P$"% ,4    " #ZB75:1L=-2)4   #-    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( /J)=5J_^"3_
M\0   "L"   1              "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( /J)=5J97)PC$ 8  )PG   3              "  >,!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ^HEU6HNGSG=L"   >C4
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M965T-2YX;6Q02P$"% ,4    " #ZB75:G,=^HJ %  #Z%0  &
M    @(%7)   >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @
M^HEU6HKZ<WEF"0  #A@  !@              ("!+2H  'AL+W=O<FMS:&5E
M=',O<VAE970W+GAM;%!+ 0(4 Q0    ( /J)=5JOCY,2-1$  !XP   8
M          " @<DS  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4
M    " #ZB75:%ZX8W6<)  !7'@  &               @($T10  >&PO=V]R
M:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ^HEU6O06+%&U @    <
M !D              ("!T4X  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q0
M2P$"% ,4    " #ZB75:U4#;E)@"  !,!@  &0              @(&]40
M>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( /J)=5H\@?-A
MK@0  )T*   9              " @8Q4  !X;"]W;W)K<VAE971S+W-H965T
M,3(N>&UL4$L! A0#%     @ ^HEU6K-HQZ:<$   83D  !D
M ("!<5D  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    " #Z
MB75:'04Q59,(   3&0  &0              @(%$:@  >&PO=V]R:W-H965T
M<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( /J)=5I^B( 6G 0  'H.   9
M          " @0YS  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#
M%     @ ^HEU6N=;)'EY"@  7AT  !D              ("!X7<  'AL+W=O
M<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #ZB75:BOXMA4H&  "S
M#@  &0              @(&1@@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM
M;%!+ 0(4 Q0    ( /J)=5HO_=%2" 0  "P)   9              " @1*)
M  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ^HEU6J_S
MF01& @  FP4  !D              ("!48T  'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6Q02P$"% ,4    " #ZB75:;0C32D($   )%   &0
M    @('.CP  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (
M /J)=5H\I3,X$0(  -T$   9              " @4>4  !X;"]W;W)K<VAE
M971S+W-H965T,C$N>&UL4$L! A0#%     @ ^HEU6L'A%A;D"@  )BT  !D
M             ("!CY8  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"
M% ,4    " #ZB75:Q!3F6C82  #;-@  &0              @(&JH0  >&PO
M=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( /J)=5I_KO-#G 0
M ,<2   9              " @1>T  !X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL4$L! A0#%     @ ^HEU6I$IH*W$ @  YP8  !D              ("!
MZK@  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    " #ZB75:
M84IB%:<"  !,!@  &0              @('ENP  >&PO=V]R:W-H965T<R]S
M:&5E=#(V+GAM;%!+ 0(4 Q0    ( /J)=5J,\K@D,04  *(-   9
M      " @<.^  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%
M  @ ^HEU6O2\@K6T!   )0X  !D              ("!*\0  'AL+W=O<FMS
M:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #ZB75:O+,W@E0$  #;#0
M&0              @($6R0  >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+
M 0(4 Q0    ( /J)=5I2G4AQL@0  "H,   9              " @:'-  !X
M;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ ^HEU6B^(L(55
M!   \0D  !D              ("!BM(  'AL+W=O<FMS:&5E=',O<VAE970S
M,2YX;6Q02P$"% ,4    " #ZB75:,L#46N@"  !E"   &0
M@($6UP  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( /J)
M=5H@::'LI0,  !(.   9              " @37:  !X;"]W;W)K<VAE971S
M+W-H965T,S,N>&UL4$L! A0#%     @ ^HEU6M#5O$!V P  '1$  !D
M         ("!$=X  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4
M    " #ZB75:56G1!-X&  "V.   &0              @(&^X0  >&PO=V]R
M:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( /J)=5H&WJ6!K0(  +H'
M   9              " @=/H  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL
M4$L! A0#%     @ ^HEU6B67M%>$ @  \@8  !D              ("!M^L
M 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " #ZB75:WM\_
MJN4"   O"0  &0              @(%R[@  >&PO=V]R:W-H965T<R]S:&5E
M=#,X+GAM;%!+ 0(4 Q0    ( /J)=5K3*7C2, ,  )(+   9
M  " @8[Q  !X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @
M^HEU6LC&"!E! P  +@P  !D              ("!]?0  'AL+W=O<FMS:&5E
M=',O<VAE970T,"YX;6Q02P$"% ,4    " #ZB75:>6R/-4$&   +0   &0
M            @(%M^   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4
M Q0    ( /J)=5J$4K%+F@,  *4/   9              " @>7^  !X;"]W
M;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ^HEU6@RP/T^P P
MJ!   !D              ("!M@(! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX
M;6Q02P$"% ,4    " #ZB75:"IC,&OL#  #>&   &0              @(&=
M!@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( /J)=5I0
M.!2O80,  "0-   9              " @<\* 0!X;"]W;W)K<VAE971S+W-H
M965T-#4N>&UL4$L! A0#%     @ ^HEU6I,L7B$U!@  (#,  !D
M     ("!9PX! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /J)=5H*HQ]1+@8  'LD   9              "
M@?PC 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ ^HEU
M6E0F/6<&!   JP\  !D              ("!82H! 'AL+W=O<FMS:&5E=',O
M<VAE970U,BYX;6Q02P$"% ,4    " #ZB75:)C&&'-,"  "*"0  &0
M        @(&>+@$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0
M   ( /J)=5KIK>3JW@,  &0.   9              " @:@Q 0!X;"]W;W)K
M<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ ^HEU6LB3(:LZ P  *@H
M !D              ("!O34! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q0
M2P$"% ,4    " #ZB75:!TT*43@$   *%@  &0              @($N.0$
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( /J)=5I-"/!!
M_@,  ! .   9              " @9T] 0!X;"]W;W)K<VAE971S+W-H965T
M-3<N>&UL4$L! A0#%     @ ^HEU6N6/21Z:!   GAP  !D
M ("!TD$! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    " #Z
MB75:?[A=F&8#  "P%@  #0              @ &C1@$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( /J)=5J7BKL<P    !,"   +              "  31*
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /J)=5J$[&<#W@0  +DF   /
M          "  1U+ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #ZB75:
M$R?LNN\!  "E(@  &@              @ $H4 $ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    " #ZB75:8B/G&-@!  !((@  $P
M        @ %/4@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     0@!"  42
(  !85 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>129</ContextCount>
  <ElementCount>287</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>54</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200200 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit</Role>
      <ShortName>Statements of Changes in Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - Nature of Business and Management's Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans</Role>
      <ShortName>Nature of Business and Management's Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - Stockholders' (Deficit) Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquity</Role>
      <ShortName>Stockholders' (Deficit) Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995211101 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995211201 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureAccruedExpenses</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</Role>
      <ShortName>Stockholders' (Deficit) Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99931003 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99931103 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - Nature of Business and Management's Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails</Role>
      <ShortName>Nature of Business and Management's Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails</Role>
      <ShortName>Fair Value Measurements - Canaccord Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureAccruedExpensesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - Overview (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - IPO Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails</Role>
      <ShortName>Stockholders' Equity - Warrant Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails</Role>
      <ShortName>Stockholders' (Deficit) Equity - Changes in derivative liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails</Role>
      <ShortName>Stock-Based Compensation - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and diluted net loss per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails</Role>
      <ShortName>Net Loss Per Share - Potential shares excluded from calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of income tax provision (benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>99941002 - Disclosure - Income Taxes - Deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>99941003 - Disclosure - Income Taxes - Additional disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails</Role>
      <ShortName>Income Taxes - Additional disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>99941101 - Disclosure - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSegmentInformationDetails</Role>
      <ShortName>Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="anvs-20241231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>99941201 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annovisbio.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://annovisbio.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>anvs-20241231.xsd</File>
    <File>anvs-20241231_cal.xml</File>
    <File>anvs-20241231_def.xml</File>
    <File>anvs-20241231_lab.xml</File>
    <File>anvs-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="anvs-20241231x10k.htm">anvs-20241231x10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>anvs-20241231x10k003.jpg</File>
    <File>anvs-20241231x10k004.jpg</File>
    <File>anvs-20241231x10k005.jpg</File>
    <File>anvs-20241231x10k006.jpg</File>
    <File>anvs-20241231x10k007.jpg</File>
    <File>anvs-20241231x10k008.jpg</File>
    <File>anvs-20241231x10k009.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="391">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "anvs-20241231x10k.htm": {
   "nsprefix": "anvs",
   "nsuri": "http://annovisbio.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "anvs-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "anvs-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anvs-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "anvs-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anvs-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "anvs-20241231x10k.htm"
     ]
    }
   },
   "keyStandard": 225,
   "keyCustom": 62,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 27,
   "memberCustom": 25,
   "hidden": {
    "total": 25,
    "http://fasb.org/us-gaap/2024": 15,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://annovisbio.com/20241231": 5,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "contextCount": 129,
   "entityCount": 1,
   "segmentCount": 54,
   "elementCount": 551,
   "unitCount": 8,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 391,
    "http://xbrl.sec.gov/dei/2024": 39,
    "http://xbrl.sec.gov/ecd/2024": 20,
    "http://xbrl.sec.gov/cyd/2024": 15
   },
   "report": {
    "R1": {
     "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://annovisbio.com/role/StatementBalanceSheets",
     "longName": "995200100 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "us-gaap:Assets",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical",
     "longName": "995200105 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://annovisbio.com/role/StatementStatementsOfOperations",
     "longName": "995200200 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit",
     "longName": "995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit)",
     "shortName": "Statements of Changes in Stockholders' Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows",
     "longName": "995200400 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans",
     "longName": "995210101 - Disclosure - Nature of Business and Management's Plans",
     "shortName": "Nature of Business and Management's Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements",
     "longName": "995210301 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "longName": "995210401 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://annovisbio.com/role/DisclosureAccruedExpenses",
     "longName": "995210501 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "995210601 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquity",
     "longName": "995210701 - Disclosure - Stockholders' (Deficit) Equity",
     "shortName": "Stockholders' (Deficit) Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensation",
     "longName": "995210801 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShare",
     "longName": "995210901 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxes",
     "longName": "995211001 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://annovisbio.com/role/DisclosureSegmentInformation",
     "longName": "995211101 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://annovisbio.com/role/DisclosureSubsequentEvents",
     "longName": "995211201 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R22": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:BasisOfAccounting",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables",
     "longName": "99930303 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables",
     "longName": "99930503 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables",
     "longName": "99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables)",
     "shortName": "Stockholders' (Deficit) Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationTables",
     "longName": "99930803 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables",
     "longName": "99930903 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesTables",
     "longName": "99931003 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://annovisbio.com/role/DisclosureSegmentInformationTables",
     "longName": "99931103 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails",
     "longName": "99940101 - Disclosure - Nature of Business and Management's Plans (Details)",
     "shortName": "Nature of Business and Management's Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
     "longName": "99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)",
     "shortName": "Fair Value Measurements - Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:WarrantLiabilityNoncurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
     "longName": "99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details)",
     "shortName": "Fair Value Measurements - Canaccord Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw",
      "name": "anvs:ClassOfWarrantOrRightRedemptionPricePerShare",
      "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
     "longName": "99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
     "longName": "99940501 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:AccruedClinicalLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:AccruedClinicalLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "longName": "99940601 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:NumberOfShortTermLeases",
      "unitRef": "Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:NumberOfShortTermLeases",
      "unitRef": "Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
     "longName": "99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details)",
     "shortName": "Stockholders' (Deficit) Equity - Overview (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:NumberOfClassesOfStockDesignated",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "anvs:NumberOfClassesOfStockDesignated",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
     "longName": "99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details)",
     "shortName": "Stockholders' (Deficit) Equity - IPO Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
     "longName": "99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)",
     "shortName": "Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
     "longName": "99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)",
     "shortName": "Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw",
      "name": "us-gaap:WarrantsAndRightsOutstandingTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
     "longName": "99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)",
     "shortName": "Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww",
      "name": "anvs:WarrantLiabilityNoncurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw",
      "name": "anvs:WarrantLiabilityNoncurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails",
     "longName": "99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details)",
     "shortName": "Stockholders' Equity - Warrant Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
     "longName": "99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)",
     "shortName": "Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew",
      "name": "anvs:NumberOfSaleOfStockTransactions",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
     "longName": "99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)",
     "shortName": "Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog",
      "name": "anvs:CommonStockPurchaseAgreementSharesAuthorized",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog",
      "name": "anvs:CommonStockPurchaseAgreementSharesAuthorized",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
     "longName": "99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details)",
     "shortName": "Stockholders' (Deficit) Equity - Changes in derivative liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_26_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_4nudJCrUe0q5HzKyVLPtIw",
      "name": "anvs:FairValueAdjustmentOfDerivativeLiabilities",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
     "longName": "99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details)",
     "shortName": "Stock-Based Compensation - Summary of plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_12_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_VGsJvkPfqEiFabjsYECyuw",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)",
     "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_gvgCPSCuP0eTU2Ad-DzdLg",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
     "longName": "99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details)",
     "shortName": "Stock-Based Compensation - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
     "longName": "99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)",
     "shortName": "Stock-Based Compensation - Additional disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
     "longName": "99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)",
     "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails",
     "longName": "99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)",
     "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails",
     "longName": "99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)",
     "shortName": "Income Taxes - Reconciliation of income tax provision (benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails",
     "longName": "99941002 - Disclosure - Income Taxes - Deferred taxes (Details)",
     "shortName": "Income Taxes - Deferred taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
     "longName": "99941003 - Disclosure - Income Taxes - Additional disclosures (Details)",
     "shortName": "Income Taxes - Additional disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://annovisbio.com/role/DisclosureSegmentInformationDetails",
     "longName": "99941101 - Disclosure - Segment Information (Details)",
     "shortName": "Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A",
      "name": "anvs:ProgramExpensesRelatedToClinicalStageProductCandidates",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941201 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw",
      "name": "anvs:GrossProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ks4SJs0ZpUGHrUcFBn_hhg",
      "name": "anvs:SaleOfStockAtMarketOfferingTemporarySuspensionTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anvs-20241231x10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r44",
      "r47",
      "r819"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r621"
     ]
    },
    "anvs_AccruedClinicalLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical liabilities.",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees and other",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r621",
      "r883"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r767",
      "r768",
      "r769",
      "r770",
      "r830",
      "r886"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r668",
      "r678",
      "r711"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r660",
      "r671",
      "r681",
      "r714"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r706",
      "r715",
      "r719",
      "r727"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "anvs_April2023PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "April2023PrivatePlacementMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the April 2023 Private Placement.",
        "label": "April 2023 Private Placement [Member]",
        "terseLabel": "April 2023 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r82",
      "r92",
      "r111",
      "r147",
      "r154",
      "r179",
      "r183",
      "r222",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r380",
      "r384",
      "r419",
      "r469",
      "r536",
      "r588",
      "r589",
      "r621",
      "r635",
      "r789",
      "r790",
      "r842"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured and recorded at fair value",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r611"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_AtMarketEquityOfferingCommonStockAuthorizedValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "AtMarketEquityOfferingCommonStockAuthorizedValue",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering.",
        "label": "At the Market Equity Offering, Common Stock, Authorized Value",
        "verboseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r664"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r664"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r664"
     ]
    },
    "anvs_AverageDailyTradingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "AverageDailyTradingValue",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of average daily trading value.",
        "label": "Average Daily Trading Value",
        "terseLabel": "Average daily trading value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "us-gaap_BasisOfAccounting": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccounting",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r91",
      "r578"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r60",
      "r108"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r60"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash and cash equivalents, Federally insured limit",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CashPaidForFinancingCostsDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CashPaidForFinancingCostsDuringPeriod",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period for financing costs related to the issuance of shares.",
        "label": "Cash Paid for Financing Costs During the Period",
        "terseLabel": "Cash paid for financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Executive Officer [Member]",
        "terseLabel": "Chief Executive Officer"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Stockholders' (Deficit) Equity",
        "verboseLabel": "Summary of Significant Accounting Policies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r149",
      "r268",
      "r269",
      "r270",
      "r272",
      "r275",
      "r280",
      "r282",
      "r505",
      "r506",
      "r507",
      "r508",
      "r600",
      "r750",
      "r763"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Warrants",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares which may be purchased with warrants",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised.",
        "label": "Class of Warrant or Right, Number of Warrants Exercised",
        "terseLabel": "Number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Number of warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_ClassOfWarrantOrRightRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ClassOfWarrantOrRightRedemptionPricePerShare",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redemption price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Redemption Price Per Share",
        "terseLabel": "Redemption price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "anvs_ClaudineBruckMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ClaudineBruckMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Claudine Bruck.",
        "label": "Claudine Bruck [Member]",
        "terseLabel": "Claudine Bruck"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies (Note 6)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r76",
      "r470",
      "r523"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r250",
      "r251",
      "r574",
      "r786",
      "r788"
     ]
    },
    "anvs_CommonStockAndPreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockAndPreferredStockSharesAuthorized",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock And Preferred Stock, Shares Authorized",
        "terseLabel": "Number of common and preferred shares authorized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r629",
      "r630",
      "r631",
      "r632",
      "r767",
      "r768",
      "r770",
      "r830",
      "r881",
      "r886"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to additional Volume-Weighted Average Price (VWAP) shares issued as defined under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").",
        "label": "Common Stock Purchase Agreement, Additional Volume-Weighted Average Price Purchase [Member]",
        "terseLabel": "Additional VWAP Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementCommitmentSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementCommitmentSharesMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the \"Commitment Shares\" issued under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").",
        "label": "Common Stock Purchase Agreement, Commitment Shares [Member]",
        "terseLabel": "Commitment Shares"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementFixedPurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementFixedPurchaseMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Fixed Purchase shares issued as defined under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").",
        "label": "Common Stock Purchase Agreement, Fixed Purchase [Member]",
        "terseLabel": "Fixed Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum purchase of shares in a single transaction as a percentage of the Fixed Purchase Notice shares directed.",
        "label": "Common Stock Purchase Agreement, Maximum Purchase of Shares as a Percentage of Fixed Purchase Notice",
        "terseLabel": "Maximum percentage of shares directed by Fixed Purchase Notice"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").",
        "label": "Common Stock Purchase Agreement [Member]",
        "verboseLabel": "ELOC Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementPurchasePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementPurchasePricePercentage",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The purchase price as a percentage of the lesser of certain criteria as defined in the purchase agreement..",
        "label": "Common Stock Purchase Agreement, Purchase Price, Percentage",
        "terseLabel": "Purchase price, percentage"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementSharesAuthorized",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of authorized under terms of a common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement, Shares Authorized",
        "terseLabel": "Number of authorized shares under terms of the agreement"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold percentage of trading volume.",
        "label": "Common Stock Purchase Agreement, Threshold Percentage of Trading Volume",
        "terseLabel": "Threshold percentage of trading volume"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementTotalCommitment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementTotalCommitment",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate number of shares of committed under terms of a common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement, Total Commitment",
        "terseLabel": "Total commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementTotalCommitmentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementTotalCommitmentValue",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate value of shares of committed under terms of a common stock purchase agreement.",
        "label": "Common Stock Purchase Agreement, Total Commitment Value",
        "terseLabel": "Value of total commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Volume-Weighted Average Price (VWAP) shares issued as defined under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").",
        "label": "Common Stock Purchase Agreement, Volume-Weighted Average Price Purchase [Member]",
        "terseLabel": "VWAP Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Number of common shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r524"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r524",
      "r542",
      "r886",
      "r887"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r472",
      "r621"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ConversionOfWarrantsNumberOfWarrantsConverted",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.",
        "label": "Conversion of Warrants, Number of Warrants Converted",
        "negatedLabel": "Exercised or Expired",
        "verboseLabel": "Number of warrants exercised"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r738"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r738"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r740"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r740"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r653",
      "r742"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r651",
      "r740"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r644",
      "r733"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r734"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r645",
      "r734"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r732"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r732"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r643",
      "r732"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r646",
      "r735"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r648",
      "r737"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r648",
      "r737"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r649",
      "r738"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652",
      "r741"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r650",
      "r739"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r647",
      "r736"
     ]
    },
    "anvs_December2024AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "December2024AtMarketEquityOfferingMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the December 2024 ATM Equity Offering.",
        "label": "December 2024 At the Market Equity Offering [Member]",
        "terseLabel": "December 2024 ATM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementsAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangements [Abstract]",
        "terseLabel": "Employment Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Schedule of prepaid expenses and other current assets",
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).",
        "label": "Deferred Tax Assets, Amortization of Research &amp; Experimental Expenditures",
        "terseLabel": "Section 174"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred taxes",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "terseLabel": "Deferred taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development",
        "terseLabel": "Capitalized R&amp;D"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r359"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability, Noncurrent",
        "periodEndLabel": "Derivative liability, ending balance",
        "periodStartLabel": "Derivative liability, beginning balance",
        "terseLabel": "Derivative liability",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_DerivativesEmbeddedDerivatives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesEmbeddedDerivatives",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Embedded Derivatives [Policy Text Block]",
        "terseLabel": "Derivative Liability",
        "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r2",
      "r3",
      "r4"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Common Stock Warrants",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r35",
      "r36",
      "r37",
      "r38",
      "r114",
      "r128"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Less: gain from change in fair value applicable to dilutive liability-classified warrants",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Director"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r882"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r298",
      "r328",
      "r329",
      "r331",
      "r605"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "DisclosureOfEarningsPerShareBasicAndDilutedAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Disclosure of Earnings Per Share, Basic and Diluted [Abstract]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r664"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r664",
      "r707"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Document incorporated by reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "U.S. federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (dollars per share)",
        "verboseLabel": "Basic net loss per common share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r130",
      "r132",
      "r139",
      "r140",
      "r141",
      "r146",
      "r375",
      "r378",
      "r395",
      "r396",
      "r467",
      "r479",
      "r580"
     ]
    },
    "anvs_EarningsPerShareBasicDenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EarningsPerShareBasicDenominatorAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Basic, Denominator [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_EarningsPerShareBasicNumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EarningsPerShareBasicNumeratorAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Basic, Numerator [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (dollars per share)",
        "verboseLabel": "Net loss per share, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r132",
      "r139",
      "r140",
      "r141",
      "r146",
      "r375",
      "r378",
      "r395",
      "r396",
      "r467",
      "r479",
      "r580"
     ]
    },
    "anvs_EarningsPerShareDilutedDenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EarningsPerShareDilutedDenominatorAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Diluted, Denominator [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_EarningsPerShareDilutedNumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EarningsPerShareDilutedNumeratorAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Earnings Per Share, Diluted, Numerator [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r143"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r142",
      "r144",
      "r145"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r608"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax benefit at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r343",
      "r367",
      "r608"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r608",
      "r766",
      "r822"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "State and local tax, change in rates",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r608",
      "r766",
      "r822"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r766",
      "r822"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Change in fair value of warrants",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r766",
      "r822",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development credit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense."
       }
      }
     },
     "auth_ref": [
      "r766",
      "r822",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r766",
      "r822",
      "r823"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local tax, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r608",
      "r766",
      "r822"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": {
       "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related benefits",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average recognition period (in years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense related to unvested stock option awards",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r87",
      "r100",
      "r101",
      "r102",
      "r115",
      "r116",
      "r117",
      "r119",
      "r124",
      "r126",
      "r128",
      "r148",
      "r223",
      "r224",
      "r243",
      "r284",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r477",
      "r495",
      "r496",
      "r497",
      "r512",
      "r562"
     ]
    },
    "anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued under terms of an equity distribution agreement during the period, net of issuance costs.",
        "label": "Equity Distribution Agreement, Value of Stock Issued During Period, Net of Issuance Costs",
        "terseLabel": "Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_EquityIncentivePlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EquityIncentivePlan2018Member",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pertaining to the 2018 Equity Incentive Plan.",
        "label": "2018 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_EquityIncentivePlan2019Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EquityIncentivePlan2019Member",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.",
        "label": "2019 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued under terms of an equity line of credit, net of issuance costs.",
        "label": "Equity Line of Credit, Value of Stock Issued During Period, Net of Issuance Costs",
        "terseLabel": "Issuance of common stock pursuant to ELOC, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r657",
      "r668",
      "r678",
      "r711"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r665",
      "r675",
      "r708"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r418",
      "r598",
      "r599"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "anvs_FairValueAdjustmentOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "FairValueAdjustmentOfDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of derivative liability.",
        "label": "Fair Value Adjustment of Derivative Liabilities",
        "negatedLabel": "Settlements and changes in fair value of ELOC derivative liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "terseLabel": "Change in fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r409",
      "r611"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r399",
      "r409",
      "r611"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r614"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r614"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements inputs",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r614"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r411",
      "r436",
      "r437",
      "r438",
      "r598",
      "r599",
      "r601",
      "r602",
      "r603",
      "r611",
      "r614"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r598",
      "r599"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r466",
      "r611",
      "r615"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r288",
      "r293",
      "r399",
      "r409",
      "r436",
      "r601",
      "r602",
      "r603",
      "r611"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r399",
      "r400",
      "r401",
      "r402",
      "r409",
      "r438",
      "r598",
      "r599",
      "r601",
      "r602",
      "r603",
      "r611",
      "r614"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r397",
      "r399",
      "r400",
      "r401",
      "r402",
      "r408",
      "r409",
      "r411",
      "r436",
      "r437",
      "r438",
      "r598",
      "r599",
      "r601",
      "r602",
      "r603",
      "r611",
      "r614"
     ]
    },
    "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "Federal provision (benefit) for income taxes",
        "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r341",
      "r342"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r266",
      "r280",
      "r392",
      "r416",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r478",
      "r595",
      "r611",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r779",
      "r780",
      "r781",
      "r782",
      "r831",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838"
     ]
    },
    "anvs_FinancingCostsFromIssuanceOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "FinancingCostsFromIssuanceOfShares",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the charge against earnings during the period for transaction costs related to the issuance of shares.",
        "label": "Financing Costs from Issuance of Shares",
        "negatedLabel": "Other financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Outside of the U.S.",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r715"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r715"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r715"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r715"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r715"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "anvs_GainLossOnChangesInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "GainLossOnChangesInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from changes in fair value of warrant liabilities.",
        "label": "Gain (Loss) on Changes in Fair Value of Warrant Liability",
        "terseLabel": "Change in fair value of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r546"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "GeneralAndAdministrativeExpenseProfessionalAndConsultantFees",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative expenses classified as professional and consultant fees.",
        "label": "General and Administrative Expense, Professional and Consultant Fees",
        "negatedLabel": "General and administrative professional and consultant fees"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_GeneratedIn2017AndPriorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "GeneratedIn2017AndPriorMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to tax years 2017 and prior.",
        "label": "Generated in 2017 and prior"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross proceeds from the additional capital contribution to the entity through the issuance of common stock.",
        "label": "Gross Proceeds from Issuance of Common Stock",
        "terseLabel": "Gross proceeds from issuance of common shares"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r640",
      "r641",
      "r664"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r246",
      "r247",
      "r403",
      "r405",
      "r410",
      "r492",
      "r494",
      "r547",
      "r577",
      "r613",
      "r852"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r247",
      "r403",
      "r405",
      "r410",
      "r492",
      "r494",
      "r547",
      "r577",
      "r613",
      "r852"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r343",
      "r344",
      "r354",
      "r362",
      "r608",
      "r827"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r343",
      "r344",
      "r354",
      "r362",
      "r608",
      "r827"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r338",
      "r343",
      "r351",
      "r352",
      "r353",
      "r355",
      "r361",
      "r368",
      "r369",
      "r370",
      "r371",
      "r510",
      "r608"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Recognized income tax interest and penalties",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r339",
      "r340",
      "r355",
      "r356",
      "r360",
      "r364",
      "r504"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the fair value of warrants attributable to the exercise of warrants.",
        "label": "Increase (Decrease) in Fair Value of Warrants Attributable to Exercise of Warrants",
        "terseLabel": "Exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Changes in Stockholders' Equity (Deficit)",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r706",
      "r715",
      "r719",
      "r727"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r731"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r731"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r642",
      "r731"
     ]
    },
    "anvs_IntangibleAssetsPatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "IntangibleAssetsPatentCostsPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the treatment of patent costs.",
        "label": "Intangible Assets, Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      },
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r157",
      "r183",
      "r588",
      "r762"
     ]
    },
    "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.",
        "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]",
        "terseLabel": "Issuance Costs Associated with Equity Issuances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "negatedLabel": "Personnel-related expenses (including stock-based compensation)",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r111",
      "r222",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r381",
      "r384",
      "r385",
      "r419",
      "r522",
      "r581",
      "r635",
      "r789",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity (deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r77",
      "r474",
      "r621",
      "r764",
      "r783",
      "r839"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and stockholders' equity (deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r90",
      "r111",
      "r222",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r381",
      "r384",
      "r385",
      "r419",
      "r621",
      "r789",
      "r842",
      "r843"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities measured and recorded at fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r832"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_March2023AtMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "March2023AtMarketEquityOfferingMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the March 2023 ATM Equity Offering.",
        "label": "March 2023 At the Market Equity Offering [Member]",
        "terseLabel": "March 2023 ATM"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_MariaMaccecchiniMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "MariaMaccecchiniMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Maria Maccecchini.",
        "label": "Maria Maccecchini [Member]",
        "terseLabel": "Maria Maccecchini"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_MarkWhiteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "MarkWhiteMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Mark White.",
        "label": "Mark White [Member]",
        "terseLabel": "Mark White"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_MaximumAggregateSeverancePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "MaximumAggregateSeverancePayments",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.",
        "label": "Maximum Aggregate Severance Payments",
        "terseLabel": "Maximum aggregate severance payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_MeasurementInputConversionPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputConversionPriceMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Conversion Price [Member]",
        "terseLabel": "Redemption hurdle price",
        "documentation": "Measurement input using price per share at which convertible share can be converted into common stock."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Exercise Price [Member]",
        "terseLabel": "Exercise price",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Term (time to expiration in years)",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Volatility",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free rate",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Closing stock price",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "anvs_MeasurementInputSuccessRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "MeasurementInputSuccessRateMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using probability of success rate.",
        "label": "Measurement Input, Success Rate [Member]",
        "terseLabel": "Phase 3 data probability of success"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r614"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r614"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r294",
      "r336",
      "r402",
      "r464",
      "r491",
      "r493",
      "r500",
      "r514",
      "r515",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r575",
      "r576",
      "r594",
      "r600",
      "r604",
      "r614",
      "r615",
      "r619",
      "r623",
      "r791",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "anvs_NatureOfBusinessAndLiquidityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NatureOfBusinessAndLiquidityAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Nature of Business and Liquidity [Abstract]",
        "verboseLabel": "Nature of Business and Management's Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      },
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails",
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit",
      "http://annovisbio.com/role/StatementStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r62",
      "r78",
      "r89",
      "r97",
      "r98",
      "r102",
      "r111",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r127",
      "r128",
      "r137",
      "r222",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r375",
      "r378",
      "r396",
      "r419",
      "r476",
      "r544",
      "r560",
      "r561",
      "r633",
      "r789"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Net loss per share - Basic:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Numerator for diluted net loss per share",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r141"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]",
        "terseLabel": "Net loss per share - Diluted:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NonCashFinancingCostsFromIssuanceOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NonCashFinancingCostsFromIssuanceOfShares",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash financing costs attributable to shares issuance costs.",
        "label": "Non-Cash Financing Costs from Issuance of Shares",
        "terseLabel": "Non-cash other financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NonCashFinancingCostsIncludingChangeInFairValueDerivative",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of non-cash financing costs, including change in fair value of derivative.",
        "label": "Non-Cash Financing Costs, Including Change in Fair Value Derivative",
        "terseLabel": "Non-cash other financing costs, including change in fair value of derivative"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NonCashTransactionValueOfConsiderationWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NonCashTransactionValueOfConsiderationWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the noncash consideration recognized as a reduction in warrant value related to exercise of warrants.",
        "label": "Non-Cash Transaction, Value of Consideration, Warrant Exercises",
        "terseLabel": "Other adjustment to value of warrants related to exercises"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r661",
      "r672",
      "r682",
      "r706",
      "r715"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_November2023EquityOfferingAndWarrantIssuanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "November2023EquityOfferingAndWarrantIssuanceMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the November 2023 Equity Offering and Warrant Issuance.",
        "label": "November 2023 Equity Offering and Warrant Issuance [Member]",
        "terseLabel": "November 2023 Equity Offering and Warrant Issuance",
        "verboseLabel": "Common stock warrants"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_November2023PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "November2023PrivatePlacementMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the November 2023 Private Placement.",
        "label": "November 2023 Private Placement [Member]",
        "terseLabel": "November 2023 Private Placement"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NumberOfClassesOfStockDesignated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfClassesOfStockDesignated",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of classes of stock designated.",
        "label": "Number of classes of stock designated",
        "terseLabel": "Number of classes of stock designated"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r773"
     ]
    },
    "anvs_NumberOfSaleOfStockTransactions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfSaleOfStockTransactions",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of sale of stock transactions.",
        "label": "Number of Sale of Stock Transactions",
        "terseLabel": "Number of transactions"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NumberOfSharesIncludedInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfSharesIncludedInEachUnit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares included in each unit.",
        "label": "Number of Shares Included in Each Unit",
        "terseLabel": "Number of common shares included in each unit"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NumberOfShortTermLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfShortTermLeases",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of short-term leases.",
        "label": "Number of Short-Term Leases",
        "terseLabel": "Number of short term leases"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NumberOfVotesForEachShareOfCommonStock": {
     "xbrltype": "integerItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfVotesForEachShareOfCommonStock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of vote for each share of common stock.",
        "label": "Number of Votes for Each Share of Common Stock",
        "terseLabel": "Number of vote for each share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NumberOfWarrantsIncludedInEachUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfWarrantsIncludedInEachUnit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants included in each unit.",
        "label": "Number of Warrants Included in Each Unit",
        "terseLabel": "Number of warrants included in each unit"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_NumberOfWarrantsIssuedDuringPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "NumberOfWarrantsIssuedDuringPeriod",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued during the period.",
        "label": "Number of Warrants Issued During the Period",
        "terseLabel": "Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "negatedLabel": "Operating loss",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r582",
      "r772",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Expense",
        "terseLabel": "Rental expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Income taxes",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business and Management's Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Nature of Business and Management's Plans",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r74",
      "r501",
      "r502"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Income (Expense)",
        "terseLabel": "Other non-cash income (expense) items",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid other",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r784"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r659",
      "r670",
      "r680",
      "r713"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r683",
      "r716"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r662",
      "r673",
      "r683",
      "r716"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r706"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "anvs_PercentageOfExercisePriceToShareOfferingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "PercentageOfExercisePriceToShareOfferingPrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of exercise price to the share offering price.",
        "label": "Percentage of Exercise Price to the Share Offering Price",
        "terseLabel": "Percentage of exercise price to the share offering price"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_PerformanceBasedVestingConditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "PerformanceBasedVestingConditionsMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to performance-based vesting conditions.",
        "label": "Performance-based vesting conditions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r417"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r268"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Number of preferred shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r524"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r268"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails",
      "http://annovisbio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r524",
      "r542",
      "r886",
      "r887"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r471",
      "r621"
     ]
    },
    "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.",
        "label": "Prepaid Expense, Security Deposits, and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "verboseLabel": "Prepaid insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r596",
      "r784"
     ]
    },
    "anvs_PrepaidResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "PrepaidResearchAndDevelopmentExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research and Development Expense, Current",
        "terseLabel": "Prepaid clinical expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Securities Purchase Agreement with an institutional investor",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net",
        "verboseLabel": "Net cash proceeds after deducting underwriter discount and fees",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Proceeds from exercise of warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r13"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional Fees",
        "terseLabel": "Issuance costs",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r588",
      "r633",
      "r884",
      "r885"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97",
      "r98",
      "r105",
      "r111",
      "r118",
      "r124",
      "r127",
      "r128",
      "r222",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r375",
      "r378",
      "r379",
      "r382",
      "r383",
      "r396",
      "r419",
      "r468",
      "r475",
      "r511",
      "r544",
      "r560",
      "r561",
      "r609",
      "r610",
      "r634",
      "r760",
      "r789"
     ]
    },
    "anvs_ProgramExpensesRelatedToClinicalStageProductCandidates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ProgramExpensesRelatedToClinicalStageProductCandidates",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of program expenses related to clinical-stage product candidates.",
        "label": "Program Expenses Related to Clinical-Stage Product Candidates",
        "negatedLabel": "Program expenses related to clinical-stage product candidates"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of program expenses related to preclinical and discovery programs.",
        "label": "Program Expenses Related to Preclinical and Discovery Programs",
        "negatedLabel": "Program expenses related to preclinical and discovery programs"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r287",
      "r294",
      "r324",
      "r325",
      "r326",
      "r336",
      "r402",
      "r439",
      "r448",
      "r464",
      "r491",
      "r493",
      "r500",
      "r514",
      "r515",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r575",
      "r576",
      "r594",
      "r600",
      "r604",
      "r614",
      "r615",
      "r619",
      "r620",
      "r623",
      "r627",
      "r787",
      "r791",
      "r835",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r287",
      "r294",
      "r324",
      "r325",
      "r326",
      "r336",
      "r402",
      "r439",
      "r448",
      "r464",
      "r491",
      "r493",
      "r500",
      "r514",
      "r515",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r575",
      "r576",
      "r594",
      "r600",
      "r604",
      "r614",
      "r615",
      "r619",
      "r620",
      "r623",
      "r627",
      "r787",
      "r791",
      "r835",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r654",
      "r665",
      "r675",
      "r708"
     ]
    },
    "anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued under terms of a registered direct offering, net of issuance costs.",
        "label": "Registered Direct Offering, Value of Stock Issued During Period, Net of Issuance Costs",
        "terseLabel": "Issuance of common stock pursuant to registered direct offering, net of issuance costs"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_ResearchAndDevelopmentAmortizationPeriodTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ResearchAndDevelopmentAmortizationPeriodTerm",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time for amortization of research and development expenses, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Research and Development Amortization Period, Term",
        "terseLabel": "R&amp;D amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r577",
      "r588",
      "r850"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research, Development, and Computer Software, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination."
       }
      }
     },
     "auth_ref": [
      "r785",
      "r820",
      "r888"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research and development tax credit carryforwards",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r655",
      "r666",
      "r676",
      "r709"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r656",
      "r667",
      "r677",
      "r710"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r663",
      "r674",
      "r684",
      "r717"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r70",
      "r473",
      "r498",
      "r499",
      "r509",
      "r525",
      "r621"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r115",
      "r116",
      "r117",
      "r119",
      "r124",
      "r126",
      "r128",
      "r223",
      "r224",
      "r243",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r386",
      "r388",
      "r389",
      "r391",
      "r394",
      "r427",
      "r428",
      "r495",
      "r497",
      "r512",
      "r886"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r147",
      "r155",
      "r156",
      "r177",
      "r183",
      "r187",
      "r189",
      "r190",
      "r285",
      "r286",
      "r465"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "SaleOfStockAtMarketOfferingTemporarySuspensionTerm",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time for temporary suspension of sale of stock under the At the Market Equity Offering Sales Agreements after the start of the secondary public offering, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sale of Stock, At The Market Offering, Temporary Suspension, Term",
        "terseLabel": "Temporary suspension of ATM offering"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from sale of stock",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "SaleOfStockNumberOfUnitsAuthorizedForIssuance",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of units authorized for issuance. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at a per unit price.",
        "label": "Sale of Stock, Number of Units Authorized for Issuance",
        "terseLabel": "Number of units to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureAccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in common stock warrant liabilities.",
        "label": "Schedule of Changes in Common Stock Warrant Liabilities [Table Text Block]",
        "terseLabel": "Schedule of changes in common stock warrant liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of deferred tax assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of income tax provision (benefit)",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r608",
      "r822"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of stock-based compensation expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r833"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment information",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r71"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions used to determine fair value of options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r66",
      "r68",
      "r69",
      "r70",
      "r93",
      "r94",
      "r95",
      "r149",
      "r268",
      "r269",
      "r270",
      "r272",
      "r275",
      "r280",
      "r282",
      "r505",
      "r506",
      "r507",
      "r508",
      "r600",
      "r750",
      "r763"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of common stock warrants outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "anvs_SecondaryOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "SecondaryOfferingMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secondary sale of stock to the public.",
        "label": "Secondary Offering [Member]",
        "terseLabel": "Public offering"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": {
       "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "terseLabel": "Security deposits",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r758"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r147",
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r190",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r248",
      "r249",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r585",
      "r588",
      "r589",
      "r597",
      "r624",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r147",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r166",
      "r168",
      "r169",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r187",
      "r188",
      "r190",
      "r583",
      "r586",
      "r587",
      "r588",
      "r590",
      "r592",
      "r593"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Information",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "negatedLabel": "Other segment items",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r168",
      "r169",
      "r183",
      "r588"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r186",
      "r189",
      "r584",
      "r585",
      "r591"
     ]
    },
    "anvs_ServiceBasedOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ServiceBasedOptionsMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting service requirements.",
        "label": "Service-Based Options [Member]",
        "terseLabel": "Service-based options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://annovisbio.com/role/StatementStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Estimated fair value of options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r324"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Shares authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period in a cashless transaction.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cashless Exercises in Period",
        "terseLabel": "Cashless exercise of stock options, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of year",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of year (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "verboseLabel": "Exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted",
        "verboseLabel": "Options granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of the year",
        "periodStartLabel": "Outstanding at beginning of the year",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of the year (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of the year (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r308"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Weighted average exercise price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r302",
      "r321",
      "r322",
      "r323",
      "r324",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335"
     ]
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.",
        "label": "Vests in Equal Quarterly Installments Over Two Years [Member]",
        "terseLabel": "Vests in equal quarterly installments over two years"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immediate vesting of awards under share-based payment arrangement.",
        "label": "Immediate Vesting [Member]",
        "terseLabel": "Immediate vesting"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Closing price of common stock",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Term of award (in years)",
        "verboseLabel": "Stock option contractual term (in years)",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option terms (years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable (in years)",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssued",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r109"
     ]
    },
    "anvs_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to a single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single reportable segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Income Tax Expense (Benefit), Continuing Operations",
        "terseLabel": "State provision (benefit) for income taxes",
        "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r765",
      "r821",
      "r829"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r343"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82",
      "r88",
      "r147",
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r167",
      "r168",
      "r169",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r190",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r245",
      "r248",
      "r249",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r585",
      "r588",
      "r589",
      "r597",
      "r624",
      "r851",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r54",
      "r55",
      "r87",
      "r100",
      "r101",
      "r102",
      "r115",
      "r116",
      "r117",
      "r119",
      "r124",
      "r126",
      "r128",
      "r148",
      "r223",
      "r224",
      "r243",
      "r284",
      "r365",
      "r366",
      "r372",
      "r373",
      "r374",
      "r376",
      "r377",
      "r378",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r394",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r427",
      "r428",
      "r429",
      "r477",
      "r495",
      "r496",
      "r497",
      "r512",
      "r562"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r148",
      "r428",
      "r465",
      "r503",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r628"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Changes in Stockholders' Equity (Deficit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r148",
      "r191",
      "r428",
      "r465",
      "r503",
      "r513",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r524",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r628"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r658",
      "r669",
      "r679",
      "r712"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesEquityDistributionAgreement",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued during the period under terms of an equity distribution agreement.",
        "label": "Stock Issued During Period, Shares, Equity Distribution Agreement",
        "terseLabel": "Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesEquityLineOfCredit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued during the period under terms of an equity line of credit.",
        "label": "Stock Issued During Period, Shares, Equity Line of Credit",
        "terseLabel": "Issuance of common stock pursuant to ELOC, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r51",
      "r70",
      "r505",
      "r562",
      "r572"
     ]
    },
    "anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period, excluding warrant liability.",
        "label": "Stock Issued During Period, Shares, New Issues Excluding Warrant Liability",
        "terseLabel": "Issuance of common stock, net of issuance costs and warrant liability, shares"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesRegisteredDirectOffering",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued during the period under terms of a registered direct offering.",
        "label": "Stock Issued During Period, Shares, Registered Direct Offering",
        "terseLabel": "Issuance of common stock pursuant to registered direct offering, net of issuance costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised",
        "verboseLabel": "Exercise of stock options, shares",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r51",
      "r70",
      "r308"
     ]
    },
    "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of stock issued as a result of the exercise of warrants.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants, inclusive of warrant reduction, shares"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the cashless exercise of stock options.",
        "label": "Stock Issued During Period, Value, Cashless Exercise of Stock Options",
        "terseLabel": "Cashless exercise of stock options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Value of shares issued, net of issuance costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50",
      "r51",
      "r70",
      "r512",
      "r562",
      "r572",
      "r634"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "verboseLabel": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r54",
      "r55",
      "r70"
     ]
    },
    "anvs_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of stock issued in the cashless exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Exercise of common stock warrants, inclusive of warrant reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets",
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity (deficit)",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r54",
      "r55",
      "r64",
      "r526",
      "r542",
      "r563",
      "r564",
      "r621",
      "r635",
      "r764",
      "r783",
      "r839",
      "r886"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' (Deficit) Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Stockholders' (Deficit) Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r110",
      "r267",
      "r269",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r281",
      "r284",
      "r393",
      "r565",
      "r566",
      "r573"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Events",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Events",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r431"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r432"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails",
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails",
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r705"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded": {
     "xbrltype": "integerItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold consecutive trading days for which average daily trading value is traded.",
        "label": "Threshold Consecutive Trading Days of Which Average Daily Trading Value is Traded",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r778",
      "r841"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails",
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r704"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://annovisbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r266",
      "r280",
      "r392",
      "r416",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r478",
      "r611",
      "r612",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r622",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r779",
      "r780",
      "r781",
      "r782",
      "r831",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r83",
      "r84",
      "r85",
      "r86"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Net change in valuation allowance",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period, net of issuance costs and warrant liability.",
        "label": "Value of Stock Issued During Period, Net of Issuance Costs and Warrant Liability",
        "terseLabel": "Issuance of common stock, net of issuance costs and warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "anvs_WarrantLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "WarrantLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://annovisbio.com/role/StatementBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/StatementBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer.",
        "label": "Warrant Liability, Noncurrent",
        "periodEndLabel": "Warrant liability, ending balance",
        "periodStartLabel": "Warrant liability, beginning balance",
        "terseLabel": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables",
      "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "verboseLabel": "Canaccord Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r629",
      "r630",
      "r631",
      "r632"
     ]
    },
    "anvs_WarrantTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "WarrantTerm",
     "presentation": [
      "http://annovisbio.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time in which warrants may be exercised, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Warrant, Term",
        "terseLabel": "Term of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Warrants, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term",
        "verboseLabel": "Term of warrants (in years)",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r835",
      "r836"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingValuationTechniqueExtensibleList",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]",
        "documentation": "Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "anvs_WarrantsClassifiedAsEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "WarrantsClassifiedAsEquityMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants classified as equity.",
        "label": "Warrants Classified as Equity [Member]",
        "terseLabel": "IPO warrants"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_WarrantsClassifiedAsLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "WarrantsClassifiedAsLiabilitiesMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails",
      "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails",
      "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants classified as liabilities.",
        "label": "Warrants Classified as Liabilities [Member]",
        "terseLabel": "Canaccord warrants"
       }
      }
     },
     "auth_ref": []
    },
    "anvs_WarrantsThresholdPeriodOfNoticeForRedemption": {
     "xbrltype": "durationItemType",
     "nsuri": "http://annovisbio.com/20241231",
     "localname": "WarrantsThresholdPeriodOfNoticeForRedemption",
     "presentation": [
      "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold period of notice of warrants for redemption.",
        "label": "Warrants, Threshold Period of Notice for Redemption",
        "terseLabel": "Threshold period of notice for redemption"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted average"
       }
      }
     },
     "auth_ref": [
      "r402",
      "r448",
      "r575",
      "r576",
      "r614",
      "r844",
      "r846",
      "r849"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "terseLabel": "Plus: Incremental shares underlying \"in the money\" liability-classified warrants outstanding",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Denominator for diluted net loss per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r141"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails",
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted-average common shares outstanding, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r141"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://annovisbio.com/role/StatementStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average number of common shares used in computing net loss per share"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "15",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5B",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480588/815-10-25-5B"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480526/815-10-35-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "SubTopic": "15",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481051/815-15-35-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-40/tableOfContent"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/730/tableOfContent"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001558370-25-003482-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-003482-xbrl.zip
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M9WNSM& &)?=$7@H/E>LNYK*.@MR2JV["_%T=-GGM)+FU_NM_ %!+ P04
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M"G">AL^TF<3.1!XC"WE=@DP76D&>8_R'".4=) A;S#D(!!2>0_\_^VY[EHC
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M\29KQAG\SO\\LDGOY_\#4$L#!!0    ( /J)=5I4K[,&?BL  !:\ @ 5
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M]_0)]5@:JG3I8$SQ_VW\R4M L24)9L'2+B*4]@!Y9I$2K!.?E-JAY9>BG4^
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M^XD1=\'0^R8K'NQW#  %PX/K9,\L@[-F[(-SO'U:O?*$O&44_)D@,ST<:6P
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M]2O"4CJ#5ON0O3 FYK">M92/Z'N)>JBF&4;(N]9A#%5-,_)&/UH$-$:$N8^
M("\NRFZ[W+CS4_M-_G)T)QN^/-9QN''G<(3C<(3C<(1CA",</52Y&=Q H@,&
MD.AH=VY#1Q"$6.:POK:^_5]6EF^4JZ)6ZL>:9$WV8<%L1@F<Z/^[.QRS:WW
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M#$6R?6WQ-DT [I2N(F5PG;0(',:*2:UD:FF 6.0P)'C!G'?)73-9*T-J"2R
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M1$X;^*Q!*GMLBNPJ%H9JM.F,S#"#^MPVKC!_+D[8AX39]1Y]T;N\?\ G5$4
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MD0._005=+QP811';7 U$RP,,UKV6QCF7QEG>:L"I%?N-'=<WYQCF^JJE1H[
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M=/*>PU[OSDMS_3DP75!W/Y39TQA?W%=:\KKPL#[EAU5WXF(DW\K^!#<A08&
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M=?9 _OI7?_E-1&C(IY4'[K3[-'F0Y;AYU4O!F*2,L]U'O.R:H  IJ2YP<?A
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MR(@1C$C!8$7>>1&_\>CNT$ZC>^L97E>?17JT_H2OM</BO-K0^5]/OS9=\'J
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MTAX#3C=FJ;;##YJ;"1B^19F-ND2,5O:#K !S&[^7C<:=EI[I-OL?!7>[5<8
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M+7A V2M:P*5=^+*HM&!!KA2E^1@!;.PCE$7%BP&KY:.;QZE?Q3 Z$*E:>RT
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M6-V%/@(5D"97M%43%%\[,/K%\5/P#3CX;X(Y60(IC9B@YRX"&P=Z5Z\;$,0
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MU7/":GRGV?65RY0<_Y+GN+/;#+?@._F)ZH82JCP$ "F@6,L35B:1LS/I2,@
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M[L$*QFA0:,6&$7"3XK9WD]="IO)Q]MO>1UGWVSPZ[_2UD$GG2Y/&@PWSJD.
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MJ"@]0 \A*Y*6B_QXB;9XUPZ,=$8S2X["NLF@!YP*9X%"/G?R*%QG\^<N"ET
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M3AY9UKQO6E-D*4O(;6(;PYIPD-VGKBZN2WIG7,297N'L5"S(:B&T'H@GI[?
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MA#B%C$ET +;J"S!XT W BW(K__ ,V+5LTD-"PI6UN:TR9FN -DRX;Z2'0"T
MQ0$;-F/C<(I'?J)A 7[O0<#Z;'TUR]RR@\>!%E%B)H!O?PA<5=FTOZ)Q\5@2
M"Q&);+/C[?CR0L5OWGX$90^QIOGV]%_KL7?"DT<L?],X).$K I%6CPJ?+L[<
M5V=8(8/0;+PCKQ 0<-W@M]7[1+&?G16+#_GY0Z5Z?=INC?\0W>^+C:TW\<4L
MY53GKL'/06(B*UI]1.&N0<!.C[O\! 4]QZ9TTZ9,B'1)I"0UDC 85T36F8;"
M"Z,+#RXM]<B:1X,!:0@VK$ZO#>49*D_W(;.<%IM&9A/@4>Y)#X7[(,Y)2YLD
M/P0Z_%^^1THTQH"T 3>[T8WPZNL?E_:5X>H1Q70B"I95'6D_!)@=631Q>9>Q
M:S63W9C(=I5U/C";:J_4[D1+TO4D4R[.'L_(KN+-V+2!U2W6H!IS23-1,!["
M?<SUBHG&_4WQ%!>-V\C@+F8,B=1.2$<Q*7HD)D1OBWAS_BTP.60R!4C63)L:
MIF3@4-1$Q@*-" $M>_%4[;95!)W[L+O>L;O:0Z^J \"276+I 92%>V^&MNDZ
MU%U :T#0-ZIPQ:X@I>GN3!Q13+\2TL]?,/I^5,>Z4AI0G>A6Q_<5\_[^9M1I
MV=6+VF#6CU=NID%4EVNE#1%Y=,HTS:)%QUA?3#L ]$HCH\[&*4<9G=Y>UN33
MVT'W$6>A2M!1/)T\BD*9_A6@;RGZX5U7=25>=U67IZ';PJ)T)-,&"8F)@41T
M1S^'\C.NQ;*#P\C-_4&T25<YC2P1SZSI=7O)6._"=8N7Q7RC/G^,1/JW%WFR
MVIB 94Q:=2P7?THI]#RV'$34-.JN(&HZ39W LS$4:B(B2"$#LM2>9_&I'F\[
M>D; C"US-E]8='[D*L!<8%<0"56,J=O"<X0 ?H=D44$Q!T-!75E/RR,E>%Y,
MH4$$(*_:7"[[D7Z\[:;O]EG<C :7C3% KZH\>QO>LYV!O_8.R^#<EC/L-MU)
M&;BR\OED[=>)*RD$A'K-@KYG4(IJCS4T9[5ZWC;"X'VDKQVB^/HA+A4]AG__
MGU>5*PK<.+MT5^J F/"T:C/J$PEP@K0IFMO\:"J=/H[&_;)%/D#HY;GT<E]A
M\7%1PNAP8S#]O-\W!O_8V?W "2DJ2]$>5%9"F6X\G<ETT[A'S)%86DEDE)B4
M3"272R%1(F_OON UC65=#UI9^_1"Z\WF+HI"O23DZ[5VL=9N;36D\[WQFB]?
M8+24D9V)'W]"&8"GV=YK&=WK<\P3Q[',6HKY>/9YQ4B>"(MY??61!AK@C]Q0
M]>4+[//$/'*!"R!K7C,=W,0#8JB1OHG2-R6?+DQSQ#*4WL<X%ZT+T+S@MR_P
M#B*\!Z&U.+M88Z[O1!93O;X05BQB8XGPT;U%S&9-*+6)0^^*8WSMTCU#@;=,
M>,^6W6<4+5<GO\S-?E.U1R4D.Z9E=Z6$E$INKO_S(F_@#=(D--*DP-O\^/;_
M6IC$]G:I#SO\S][AC6RS7>Y&B8J?B*]7.'YJ/_L:D>4(97[WUW[NW,2[R\01
MPWNW%<?>M%NWOSG3R>-8_#M/, SPVP'W"2ET?8Y3)BJ_Y"5R=%/Q3%),OT^9
M@)8$Z2.ZPY=@? >4\!K9=SWJP(U#A=0#-_XSN'$V:-[%X^EH,O-^CBQE]YPC
M;XT:W\G"C:;W"M\'UGQ@S=^"-><ZAH5M4YM@I>6@?A^BEL!AWDTDDHF4] $V
MG=MS-KT3RBS:%&BC@M?JOO/O5&JO-L&!?Q_X][?@W_G\O(<MGH<V[R9%41(_
MHESG]YQK;Y$>2RT=^/.W95\'_GS@S[OB1]&&98YA@)B8^E'R_\0'7-'1_>;-
MVZ+%HIF]9\H'IT>HX'I@RG\$4XY=X '2"!N1,2TU34SZ3#2^^>:<UW'FV'YS
MYJT2A+8E!!H[<.EOR\0.7/K I7?%E.)5U< MU,?.O*#:D,[M0J)O/)Z.?4B+
MCN\WK]X!6:!%@34I!-K\KGQ[#\(G#RSNSPN2+7?3\50F&GUGE.Q^A\FF,GLE
MJ XZUH$!?0<=*U&EE8GZIM7TJT78K'!)\<$E4VYB[0.J5F*_5:W=48<U3.MO
M--?+=/"[S5D?1^0)C1;;")3B$*I0,Q4J<AB*P*X)%1JN)0^1S4KPL'<#E^WM
MO3)W$!"AVB@' ?%'"(A4U2_$;(-IZ-HVI%X;2I97 C7[I0\(B-1^"XC=4:>Z
M7O]ZT0'E^ME *=:27ZTW;QH**^D.SS2Q[6JL7'!]C%DMK8,D^+Z,\B )#I)@
M9[PN>PGUEE6'UO4AW(7\J?&_/*?A1R3!GF=U[(X\P78I5P^T''37"MF>Z3H"
M-RT@-V3?.7WZP.E#!?@#I_\C.'W:5R<7]9,(WVFYX[%&_T+6_ .</KW?C'YW
MU%EH\8N6*<-?:IM>SG[@[-^6\1TX^X&S[XIW9?+T>@\;&(U"5$<TL##C,W#7
M6Y;>6?4!SI[9;\Z^.^KPAJ%2-_#SI;;9-7NL=0?1RYT,[T]:()^\L) ,"WW_
M( *^+8<\B("#"-@9D\M"N6G+U$!II4&Z"HT?BZ6DA/21$.C,GCMP=D$8KT7*
MQ!=M'ECWM^5L!]9]8-T[XU"Y.EST5S;8G49P+TY<C(N)V$>X]IY7Z=@R36AC
M0J"U?6?5&7&O\'Y@U0=6_2U8=7YAJ >O/R#LQCAW+=565/DC7'O/JW3LCCR+
M=I>OA8"6!:]I=NLQO>2X8>$)W(16-NPQOP[YN[+\/4B(>)I9!!?[4"S^>^?!
ME+N91"R9>'<BS'YGPF2DO1)[7[IE0Z;"'9C4ARBP!VA?KC4F%E0+T^J[R%"*
M,RR[$)-5[_=5&=/O\N8'E#Q)W&\E;W?D\=L]$OQF!:]=ZFO->U?4"J<FH1*<
MGNW]@=E!,(0<_0?!<! ,C/-)/EO*F_H8&S:_Q3P>%\7H1T3"OE]&L@/"+"1
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MI)-ER9O((DD"0]!47XU>*/\\"8V?3_-3Z*7;N *5^6B>A7^[C0W>3XO[V:D
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M#3"U$6);^AY8+&<&E''@UT2-N1H:2N"8N;7";)B[F/O5C+9YO8^CU:R+SMC
ML8*ZA02M(N+IX>K)G>*6X;@/.-",*;I]KZL)]\IX8RJJSD_-5F >F-^P:%.S
M]KYYI&_X>]B3"*,E4[3>K"RC[8.T">6QO2 &S4J&^R1_GX-DR'UGEI%6)Z(*
M A!W.5=:]MXK .6XI/H)7Z$:9[PTIF5B3\!/>>%A95O:_3ZIGV_8T'V_\X!&
MRYGJ&R+[49OX460K0DN0UGBZ5AE9?6(W80JY8W?[/U8S9+J(!F=D+T(_^ AU
M!6FY8MJQ34S4CXHW'7^4DB:7OIT%L<&@_+8D(2(G"RVHPWK5+ 1B/VNU7&VG
MMV7_4\L6AS\>)5(&WU<R;T/_Q(L2Q]4A78+@3%@9 X_\H3+&X7%J<D^.U]%_
M24TBGD//@16ESY+BPV$T@/4J!$^+1%Y"=; _4'\P(JP/%A[X1.N/ R-Z=-+[
MCQ_WW"X?9:O;V]D-,>RL7618UX?-<H4[%+2WG3@[:7IP:R&O]WO/0Z;PEHOU
MN\:1W."^<U+:5^>_NH&&R.5^1/7A3]5#/G,Y9*C,A)\$ NS_%4HA5Y74U->J
M(<(<N5X.P2^D)&(UCD\%!GY?!E3BL YC$_EK&C=*@Y:<T4($+-%YWXCXVO3$
MZM3 ),U$UJFH._!JV >!T*]UY<82#1XVZ%PTY,HSB=O3->,=N;U\EM<$SV<C
MT=)FVYJWLW$$X)V_C%%^TT8,^<#,H";L\EU+RW T;5[$9$HZ'X<N4VDJO&OG
MD'%3Q)-)R IF-'\_G]H>2.;3)V=P/:.8:'K,S\ISK7.\FTI./Y8 FMFD;2+X
M71,&2@2 $I[AKF46?/$[GVX)\7AKE,G TKD.64(^7C+0]G>)&_K.-O(&3RA>
M-RT_1#%4.&<:=3KD5>"3[O-<6/%CWRA9!X<=3M*G *4??52--4J3WCYT2="8
M]F\>2J":T)8Y.>[H\\#G*O5Y]X<Y<0_1!^@;_^](_I][BN/UAUM[(N>_DD^+
M[Z;;&_(#^=*5Y99'B#WM]\H'5,OD0XA4$+A1AX\J, CTQBZ.J^JF+6T;J'JA
M,J%*MRK!'!&+A_:/ )V+K9$"3LT^['__%>#[NPKPK@+\UZT ?TQGJSB4AF2)
MD_TQV%1MR%[0M5 SPX-"_+W]WBMP9 LQ=\N;E$- P>GBI+6^07D:K3JQD\2]
M_%GBB9V]N@3O :H5D[^3\SX;7A'^Z_:SLA<[>^Q"O7TXV0!,SL "WK13V=Y;
MC-B2XS-,PKBXY5>29\*];US"VH;;33AL%:S+4\_,+9T"IM&XX?LOH^_'=-VD
M&G;Q6S5UCY'S@%#OC%0*U1AY1WK([LU*SE>U)_<BN+1)ION[G059@B^A,O%Q
M0AL;Y2Z-)KL.%$ONK,4I*T34.:.,FJFKTXL+E1WOF0+Y@R?Q$4A8^YXIE*?T
M=?PXT-VMR7-D4Q>W[#6K<NDL#?4-[*N)'X<Q\.VXM32J;I#!S[.9B65I,08#
M4+^^6Z_3O>MKV6?0\[EA9M\+JIM<A 6)T26&RZG[E,[=Q6?57$R3K(>//^;U
MGET^IQ%QOT!.&LZ4"!LT"V1O-&&L-?Z%+^C)K"^D/GN O?A &URU(04$+PE
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M?B(P8_F$];"<A$4PX'9)7W@_]S2A2OOEEG3&R1\7@]I9F"RN=X6,?^"58W'
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MAP=W =U5Z@]>"S_Y0JS_N)A:5HTO4$%CPOI^+Z]_"(7C*-=\^@4PC'<-H&)
M0]14,A$N3X/YCXHZ-_YX!*M>VL1>XZL-(2NN8 "\F\H=@K\CAQ6'W.B90.7!
M2E'ND) 8'#D:ZY,.ZVFPZCVMLTR(Y>1?L=0TI[X[?K;49@("]@%_LP$$K"A
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MM)->&H=6#GS/TTR($'*D0MVBO>KSA)S%T^?.XR&RI(7:2;I\8]% 0QN.*.O
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M=U.+9JN"Z@L%N R+N8E+<-FGZVZ_UY[$C-$-3V4TN' 6R% ]1&0^RA?.] F
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M!-=JRY=L.3]_C$H0=<@#TOIB0W_1UJP]T\>/[1Y%=0WE+_U\$)@X^*B#<N;
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M:3!0&]H E>B/SX"5@@ZC6+#9F] [:!1)I$V\F0%"0LC)9HZ"URF?&Z#I1$U
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M(TM 8TRD$"$:&%N"/9>'T$<N]V!9IPL"+K,+?ZG+';0M F&*\M%,"6?2)9T
M*^XC5'B.Z9TD;P[X8ER31:6Y],\%KP S/631I<RQ!_D3E;,W$N6\ A)55:R'
M037=O=%G+<(7=2Z)9"5&AJ'= 8Q.7RU%]3K2*1<L\-/ONFK+HX6R*3&A_<D7
M,[9:@A*_D3+S#K,^?P7._3O&N5_+1G[!:-??KVC7%>WZX:)='P'7O"RXD>OT
M1[:^R .Z1/EFCR<*+&K7W RW9P:!;E(0:()T-"3\@0):)]PB\\_/85&388<E
MV.$")[2A,_JM::%S[P7+9Q61I@QC)FQXQ*L!18+5/=B23-#Y1 <;L2;0W!)
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M CTK8;NIP$3EVN7OQK!^'LP7LS!^<VK)EU0PZ6R<\ _7GFA [R<6G=:&ZFS
MX0E64J2A*/W*C6L<$B_<UNA>2LSY=RW;8J6GZL7+^\224_N$5GF)&<&"3(?3
M!F9[9=$ZF*3/U(CA>!0-D6!]-LVC:LGSJEW_*LMBS)^7*)0FPEIID<+_7\HN
M0UDU2W(7,T?_/U6*A<GB,GLA2/H:6,(C7J/[L6*PO7V?3IK_MC^0ZA%B]_OW
M&$KC3\>H:'W@KGWKDHD"Y..XFW,XA^9WGZN_AF[%/!*?)5683 R$T<)?#M4(
M==G4F)FMSD)Q SK@]TVLD_#YW+DCUZ:4IT^@&'A9] %TLK)-\_K\3"W-4,(.
M9(I"#2"4*X'SD(I#=*H_9+RYU^?=V-B$_:$[(KQVAE#8;QD$124P G,!_5Z
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M.OBKLD9DP*AD8MB&*7X#V&\&:TN@^#2&'AR[6)!_#)SC.!VXOM@,\!4#A^1
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M7D#@&<>4.R)P]G3PG,6C?XCFK<@_T@Q:@C)&^X!C>1YZ:CLJ0/D@ATM&1>H
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M"_[)^M@E2523>$H(S,T1K->TWJ>J>%)B5!O,8"A;M=,A)<L[394<UV% G#N
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M!W/1CY1BG\DK?JO+H#"ZUL[23&$E>OSX))$#P@[_C'C!'UXMV*.CCJNFHU'
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M^E.]92EJ#G4X_9<+=2(SRHEC&P^^.3O$?/&H#,Y7D?**P7<UT.2"4OJ \\B
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M61$Q)=9N^?Q+91XA>_5SV7R2LI&Z73@<8-6T^&0QH.0TVU-C*1PM!_.&<5J
M;,I:D>R ]Y&_H@&B]LIMXT6D*(2E1SSD=_$"42Q%$+Y->\O)'<M)%2V/4_*J
M6LH]GY1+I\#XC0%@/!E$DLH[1 %K/7#)+OF<I=7;ANEE,M+@2\EWP*8?)?$(
MU,@A+)7B- )$'0IUSS0J*/FR:@'1=7F@9)!D*'=(%.*$RKP0FR3S"*(?8">
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MP0AUPG7]SWI8TTMIJ[U@ ".UOOTA-JX2.0+WL!#(!W[+]3&,:3@GM^"AK4/
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M,5\72YLNVWO=4NQX8CZ'\MWL<--WG+X TNFE34IB(CLY/1F%!J1TFN[V]?3
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MKK8&47XJ +$4/QU'*FXZ;C%74=!8>'%Y9G+>U8I;PN@\#W^YO6;^%":3"&[
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M_3'B=<V86V$S;';[ZWIL36E#3?>^:-B"^M6::FOM>"V]=E*;:-9LW'37=\C
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MM&^DZ;L,W)4'E:9@^LY&MER?KKD8_L7PM5BKWBDPTK0]\B&^6;QJ@BL*C0^
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MYO@;#WN&!]X^/$,-L7L,#P__Q4XWR[:0;B<"(4HSAW$8:<X VU;85"SU";Y
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MOC16VG#F[^"=.X9B6D1*^P;/3'NI<#HC%048<5)DE1%C;E3.R@VY7MVC"LO
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M>0YDI['9V5@2NOX^]V$]7Q^=_(;D=S?3X!_Q0\_#''9OM(CR78F0=[J&7Y1
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M?+M48+\%B)R(?J\^S4)F\OH[$C8Y:?:$9\B?3[25"I.*00IE'HCM*(2IXSC
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MFT+6\EP'W6J%8PJEZR2H=(YE+):Q(8WLJE\36U?!KO&R1418_MZT_ 5^$&]
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M'(*,NQ_;'WQJQ"_L,Y^(X%C?,L7W+# _@&W7['MAHNVAS*>(Y?<0E;14#Y&
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M$J@_H^/G#A$!/W>YSLT?J!I/0+$=(F5JVVF1]X@<T_AET3A[K31NJ:,!5.V
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M%L4'8UDE@4@!!LA\CU%EEA0E65)(1F982NE*/5;B2.$N6(CC;.2>@?@JOQW
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MP0Q2BI#,N8F*.Z-R?J_[#""KZ3AH-F.-E.X.XQ)7S#DSI>^WW>. A#M5X^;
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MFC&*CA)9L=]1XC0;0TWW>C66,:XR>AC54DI9Y/FTMV2SU/JT:+=I)1EOC7.
M7C3RB=C3HN85*EYTCIKN 4*EDLH/W>Z0)1-S3A^/] (USOL>U[VQ>F*Y9<Z6
M5#&57Y'=14DPNJ3E.USV6"%;>\J-S'EGF.*U5$:/5_*S3G..FNX!0IDFFTME
MH5"-!)=GJ5PGQ_++"FJZ#PC=K.I$*S/;')7<018,F0XWZOK=;@#!=^=L3.?
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MZ!D7R<)$BP.:OH&Y?_Y"6GS!*0#=C=J-1%RO@9'-"(^KN4PQR"O 1$24%4K
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M_\"$C=/2>.JYUTS.[^X6A5FB:%3:CR.U/6X!C6-K.L$F0CQ[^C36RZDN).9
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MFH<(H[LA:]<&!3Y"J'^ERR96#CS54G;C(^_7 !F9G_)?OF3[QKV]-?9-B&/
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M+[!-)I+W:DIVR@2\.6W;O,$Y!@PY 5)UC93ERR#Y+8F %6,_=(E7X0+==IT
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M;2EQB.S/(79*21IA>:8Z\W9)L-\='JIJD"ZJ.BUS&&+KDEDH@* 6-K%\6OC
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M<MDS#H<(4XY*Y!D9 ^<R9RY.ZR[M,!NX>F>N\\1VMKSK23',WMTZ\L-6KUZ
MDO1@DI)M][,$R0?T"4_W7%/DHWG+#OQWXW[ 1?\&E8G*P5^T^!M_!_"?C?[]
M 7VQ_H2OJW\QE*5?#R.OJ#OC$FV=FU"2G7T%J "^6(H.Z?>JIV]COUA)]&&_
MVV>]@>VF';;KIMC0IQD>!7.' (8;FX/@6_C%_.3^\C:0AIZ18TUW[+8QMEJ
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M/XF>0I/S3K(6181&HXN*)9H5_^MD7/+*CG>TO\I'NQ,N )<_M9<_'E+4CQ"
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M*?RU;\3MF5@'LO&,)X*^GZH@0B2'L<-A6[EZH*O[*Q1VN,B6OQ=1G$5M-M,
M:)HX95;V.1C9,"RLY<HJ6( JHO;C2C8G1 ^VE6WB&4G^;9#>IZ:K9F-E&7^O
MKBVI@@Q*,?,3UO+LWX<@(W_@_OZ+62$=N<HWQ,:,G0":8))78W./:#*P0?PR
MA-5S_*'&B!B_!-@N]&(UD&DJ]@1.Z<DR3/+C" DFMLL,_!S\, &_#9./(4OD
M>7[' I+7-04T>S I)(0?*<'+AH@! *_I;WY?)>",,,0RV3_R-I$7GX(!R]8.
M#2)!G.#?(70!0)SCZ]6D+=3%B:".X<V>F.$VE BV#%ZEX[_C*T7,3[2>(]5
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MGTJ]^"Y!D8.JQL;(EA<-G4@+C[#P$0XW@]MR_WX6+4X7E6':5.+Y1+>:&<1
MUXRRJ5 T>D9U\\K()N > ?<X!_<XB[IJ/&ZX=HUK# N=B;YN=!?M*FI^-/=8
MZ:N;%D+Q66_3&\N3_H,\K4Y;F'N :AGBV3/V?@U\FI<\:G,B&(BI5"I0"B9
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MJ[+I]3*3XR;38JYYD\#>")K;8924<Q#8P\G2*/BQ0":@Q_XX \!5XOXE(97
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MR4/QA\2*5Y8&]F2*)X<?O$H3=!7COC?A!65#NT4U*/B :C&L[4TM^GBWXLT
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MK-&Q=V0W$>R[QI*NZ^%<O+'-L0AH#^*+7*\T62NU*L\T]7%T5*L]TPOYH];
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MFVA#!\)R@6&=%)O\<&XUUGVNUFDY^9HPR6@6E6G\^&,O]&/VM(#!FTA*PDU
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MB=5GTROG8_;QI^"AN)PWY^%RA>DX^09I@SHC31WIQQ_Z+!X>0\G356V'#(?
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M(4A><@V^DQ@-[/3[M]._'D@"Z_T>K/>O1S>!31_8](%==R&Z^5J6?A*>CY=
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MQ&6D(1L^"FD2*P3@V\1-."-$DP\A1),A2-/H#SJTX*W0?_\5N8(?Z22"O\Q
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M#+F5G"29L3R$O)VIUQJ\H:J5->1M "6E 5]OFPZX; K)M<.9."O"?XR7-"-
M3/&&!7[[?^SN#&UD[,Z-GO++,$:=YN\MK(*1_9MW;-W_ ">_N)]X>3;NFIW$
M&V\-^L3+X"'^C0YHF_Z^O/>1[L%?5\_!T(]DXKEL)E&>GW@^4C8C2*<^T/Q_
MAU&&T>^A"7@EC,3V/X9N88?@-[X:@K1^\$P/%_C%_E)^:.FJ8P,_WXIP#WKI
MO*J3V9CNPC=DG\"S;/[W@VEE\6?3R@)$?!8B(H^)9Y,: TQ\$B;H1R*03?>
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M]1%#<7<-$P,:#1@FZ'C0LAQ7XWCVZ,YY '0GH!&*]B$;$!W>X3MR3-8SOK9
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M)AZB$GZ?ZZO%92K )E #]B_J5YWSCO:><&"@<) -!]4L_)[2X6YL%DCAKE!
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M_<<?,D+YVRQ#2M(0NER\K)M1(A&,OD2+\-IVHJ^3K;+;R:<Z31NAG5[G:TK
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M,DE5NO/'CY _OF>S,S4T-^#[JP,$)<MKV?P,Y*QA(CF*[-2CM%_+,:(=*\P
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ME-7;7BSI&_(*_F=D3[0__Q]02P,$%     @ ^HEU6EM#^T1I9P  0V\  !@
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M>NP& )_&B8;TKP3XCX2$_#1&= Q,+&R<IPHUSP#(2"@HR*@H?T?]5.KW5 Y
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M7,%7I9Y("?Z03V%\0>);&=&EJ&6WFS"I<G4/'*!>/BB^?>LYM.)?NM(DA36
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MF.=+/'[!YJ$/G6O>,Z0'N31$@!,5?#>"&"Q_?#_%=Z\>;EA9F^%FXYW@X.N
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M]GZLGAO5\G-6_*]3MO.@[D9*S]0N[]8H-K08]:J4D=3?\E_X;F8W7@6L2=C
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MG14=P:B$Z3T6ML/S,M:QE^_3+6CH$/!\VXFYN5U!CU(GDH/67*(1XMH'?0_
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M?3')[^685U$1.'U4'G4P$,6SJ:+%\BUZI.9U?Y_B.;-Y(J7_1%S5Q>^=GD>
MU6JQ(F=PO$==6XX?387CR=WY-5>?.ZP\(-MSS7#21$*SIY;2I:32\$MC95.#
M;.*FR M_?4IBI=#((N$SP!@Y].MYYK,\P1*+>MOY:>I Z:TBZ.0C($8*1UQA
MC;1FYH[IIT+A'BEACIP-A1Y] T3$<#C#:/VG/7E)0%I\=!X0'2$-EPKRYSS1
MF[QS.3[MDSD);K)2%5=RM/,DOXL&7Z%&-JS[9AM*$*?7G-<;+7$7>LFT7B[=
M^]CZ3IM0EH5EG0C;%1NN1M>%;Q],>Y4U__2=/AZ#MT7XB^Y5;"^15R?ZZ/W!
M27^S\JNZ2G,ZO9'@BFS3H:O^7@!A<[PGBP >7\Z_G80I?3TXXQA9S_*:K<.+
MFA!JH@:( HA=26;M*%]EPA=%7X@I_:J=V'])'CTQ2A+.<,/Z&<T:$1LYJR/8
MUJFDV#5+CG*=<G*B=Y.<+C]9QRY&87;\J5W3C<O+@X<SJV&:ZD"(O2=F49N!
ME4#F$4!3D+HR)9/4GX;A:=3=T[26?2>MB9AUA1E K&6S<(L>_$"A<7SYB&0?
M.=?Z1T  %%'\".@#U6(+;H17#+R:;[+)[K!#1KK-NROY7?<E1#RO;Z)9Z\YH
M!EXSA=/E2)6=4#:7/?]=+M8EO9ND6V_AM0C39P!3H6GD)PJK*/ZDV+4S=/KF
MR##LZV#^=Y]IN!:IA]K10DDTNJ;>L?ZVL8-DO_T4G -O84N,RNRZ"E#H28L*
M->E7/2%0A8S52&/T,D-IA _XDQKB+*B=F!MPDER>#04VO).TA:W[SAL&&%U"
M3R0Y5%9[YZK%?A2T$M8CNUKIK6M]</F,8ZZB.:[Z*AN^I<'Y7*:WV8R1N6JB
M=KRVQ+9*H#?!_M!Y7C!^5X[BGO60;<,RS5 U^[PBB??]/PN=Q5XLWJ[K7O(O
ML/OR#["[%S=_^)L-^%?V\O01$"+WY<>=^@L98MV?GG 98C6D?Y.VHVB90<DL
MQ,O_.QG!U[)K]6O-HJR=^N7!F,&_F^YM"<"$OWON$-8U?V9?EM^2[ A_L)!A
MM3YUKWGXKCC#2;&5NTP\6JQ13LA\X.N5\ /FK(ET_?&48F68DM;X*7#_: WL
MLM+7/>!/Z-FY-EQ;[PPS[L*+:,ZHR#9?)?/-XH@:)OE,!6MMT@PA.54]Z"LH
M""M!\'5?:O2!BQF[7G;O40V>?.[O0/7)LUJ+6WE)C:SL9V;AV1@550.[G_\:
M9W9NA7'SVP_?:2BL\"V/XFB)[\P><W7J:<OTW>%-FFD(5F5SQER][8;GV$IO
MH_(;6B<'_X2 5?*VRCO%JFCZIM>/@&.>+XZ3=F4_'(+'W7;9VE85Y1%UN;8K
MN:/QJ_JYVTF ]ZT!2=C+!5W7LQY@.E'Z+T;1TMB\D@G=B FI*GZA+$A?=<"?
MF$-@PB/@;28"SW'[*E#I$U]_F65Y^9OQ=%0K:52Z0+Y 8J>,MG3V"0:=K0TU
M0#L %[OP\DNDU=>?8 LCO;67W#33*5_F='_-,QB.D>H':U^3#PYC6&E&/C!@
M'[:Q;C4#<X8LB.OJ[#5V5P"$C;WIKR773R%(L$;1C5)&%ELW#:.**<<-N0V5
MG K!^K"KT)E?XNJ/ %JDO_8_P/_T'H32W?7P"N5O),A?#"&G0X88^MV;DQYC
MSW-@*NF31"4C1C-E ?L;__QSF4LSA=8[[2>G6CU]?AM!=:OG^-'A^5 &#([2
MQWJEH]E!TUMF 8N3U8M-GU,GMDJ.!M#D76:)E!6?JG:W8=NW5=G$9)^,A:3G
M'=_OKYMTL,%1Q!*=V(A*2GH2B(2GOI%!M$5NXKL:[S/#75](Z4TN#%CY88\1
M.F01_KX-^N;7 15'=)1O2W(=<U;ES%\WYD]5",V-I)0$,._4VLAJ]0\> KZ1
MK[T 85PZS\QW ''S)YHUQ77(!(4BZ2+;?AB(D)BNSP_A/3A*S]=XQW?I%LNH
MJ'D8@!MVS/EP!?EP**:*@2",H<;F7##5(P!_=O_@]Q4K:T'LSS][,Q#[R4.+
MQB Q)29MR6 :Z4L!#YKI3?[5 T9K+WM%Q6TP\;Z/>HR]C-%_W""OV19:P")]
MU,C^/7D-'#%W_D^NU-\HA$LWY)3HGRB$]D>Y&W ;\'0<DFYT@OD(" N]P[A)
MV8DY-BT1><(C$*"LE;I*7PWY9;E%R?^KSWK8*5<,$)E=DFG[;/D/G9YG"NX8
MWH+3UJA?2=Y@B=#[3@&K=^QD'&-UT#58I#_)I]2@S; 67)GW'#(Z$=6Q\+8J
MII[2,?(=CU;R$_3M.Z7LA\-WB:]/B360=%]FIF.I>3'A-JQ37@"?<264_'DO
MAV;,=_0-TMOJW10BA?8P1\IB?L+NG3@=!Q/Y_EV?_H,+96^.P,)*9"*[K (T
M[T[.WH&_^(4N[^MW0PBW>S[C@=YT3RU#J:G=T>TWNV7,<UKA*<:96LWEJ4HY
M[D+L&\\-N51DV<)/>I*C%Q9R-@[^O <<U1T1]"AAPWX+('$T1DW=N_/PHZY0
M1X>V^*@;54HR-N6TA99/@+2!;+B6U/@RX/)AI IN,ELJ6<#YC8\N"IPJU]:R
MVIIAOB$B8V]:]?Y4QKUB&'-/17WJ.3])B$N-2_LHAD-F@LO2J_K(WCFM]IUO
MPGW>=1XE[)A_A"5KQF2H$-%W?8%@"Y'D6XO;3,T;@LXJL*:*,P>3T-!S1^G@
MCEP8&RZ/<K>W@\A#C7]ZW8L*Q)/8KY,EK==O,J6I9!@$P]TEBOIJ%'1?/1GR
MM8?EF#629;DKLFVVH,E>KJPU1(]'['W/D^:M_*MYPW[X_J-YO9#^B^8]]#^=
M#H>Z3-MR4GT;EV7NP7BM_O0/(%8/YWF-1FS^F??UH2W*!M=\JD[<MJ=25V*E
MTF5I,<./-_%&L@RCA+SA&5I=_N@402P?7HM BW]RH&=:@&VSP'5A=.1/B.7U
M0\*I=?+S.YM[*$/R^".@TE?XP?7KB5&[W%P_9N5;-C#!%K^GJ]H+M0MH>9%D
M#+]B"!E.\!YY@Y1^3>%"_+FU;AB_Z4&+<&\PX[#-\)>QUW^V_;ZN//B5AE=.
MKU?%'I1K9V?PU:SY8V>>+;=XZ[#QZ1\?1#<&'?  !61);4?GB+UMZB]%2%I$
MTU(D8A+2)<'J[7M)/";SC;44Y"1FNP2H.G(A B$AXQ8)50P,W5M34(H[68(U
M8^/9+I$_L8XER*'5X\Y2SR#Y[R5)]+Z:X7B):[JEO$,ARC0"-NV<HY2YW=K;
M.;C<LESRA.2[E!B5E44J.XGA'IAT365T+<P:9B$D.20F=B^^+&ZO Z]M"!\!
MEC2%"P_D96 FN>IQ#M\(^7<*TZDB-I(_?5*:PC>*M8=D*L:Q%45_Y42JAV\)
M83/WD&<!W( &[2=<=Q#H;=M,7=^2:=D'Q#=KQ%\_:NS)C]KI? 10>%,0_SWL
MYGM]L*#(XCY>^[G^7X??D)S9(KZ6<6QDV.AEARDU5;1KHS!D=C;/6V>?B*D-
MA83*Z0P+1K735PV*5>PBP?T;!.I.!(]K,VWR:(=,AY(Q[GG?DP(CB(%O0.7'
M)DDTZ06]R)^'>97]=+1#(NV:WR<LJYY)>O!VBZC^D=F9O8L6,SVVR@BS#D_V
M$MSX$4GP43?ICRWD^)MG@=Z:F@[U:X);Y1#'^V_^Z"V05>LJDJBH[@E@+''%
M#9+14<<]U@2AVZ>VMH\#M(\ <+3JKCRT)#C-;'@LPTY$GW@L6$ 5QQAG1%*G
MI@&%ZKL5@_H=NRCWI7ATMZXIO(VRJ[2_5K<B2DIKF];B5/F(BJ;M,$.N?K.I
MIC9\E8OS'7YH1;E0+Y @N[[.BQ E>VN!9OG>G*V_Q\QV3;<MKRDC&OA<$_M^
MT>+/0D[#$\0-7%^LC2CNGUBD2ZRKA[3PXI<LE;>V]$E(E[>!?;6]GW=IN6XU
M2E9&V>H&IKW+20)3@=)@J^I_#QRB=?_-VN+$S4'Z#MKN74VW=,5?2ZV:/0*0
M'@I*YKB>-/#?ASH7)ZF/  3!A< D<*5-RT4),7[.QYS_Y!EMBCK\<UK1Z'\(
ML<1@LR"%)@)2+%]9:?#Z[%<@>OIQK@@A=!BQ%S!06#]3WG_=9IQ^IWUK;D=Z
M/$1?$+=-@5L52]J?(G<_%4[(5^%O.X3>S[#9FO:2AH"N]>/]=U>1YK=0S]0^
MW0"]X0/P1PN[2)\\.GU<<VL;[?EUN,*UDO!JZ_=Y8^$HAJQ&^KD1@R]Z9K-W
M3>$Q8SJ/ #$OO;7R[">35@](92$XS'S2*K_\^AS5STN==W?$&6P$)I0=7W0K
M$Q=5RG;A1O)BEKN?=1"*D58WQOT!7ENO>3]0!]W,9K^EHG*>OAW[5AKBT<+W
M+6YOW^"F'Y\(+IAYE11[0WI7FA7?C4-,P0[H*U,"'U\SN(/VH&(H5^8D\S5M
M+?$9<H4M=G:2SZHG-IZ+U2P,.D<QDZM^PH!X[V2(AJO JC#A]D+E(6XA41YE
MA )S/H::_2IQ4H\ (BG3?-?+F0K]]F\=E#U$T21R)(++WH*S80;->V+]%\4:
M7QBS_K5D7%+_8_(;!$+O(-(/B/)=J?HV:2.)P$= X=_LZM^LR8SI<?^)"\$_
M <H8YO\2H&P9TRXE,=DJ^:WE09L3SBSXGYNR6ZVT>TX(Q_:4AT+VF=J3>7W%
M3:7IA"S3)!3/KV3S\:,=F8K;H'1$%,C%9T7"FTJ$BZX1)(+K:.:=Z!*([J^_
M0!)3N/3A-446+"I=KQCL=ITI_M!'8QT&?P$R#.V")1:_*G6AQ/K)J& 1S:_\
MH.83EO@V-/GA4D7PU,<//8.[U49;DF!VB@C)^I83H^'^WG-K7^BGC,]QW&6W
M$G4=J4%\&*XF>XD'G?,+3[,&(P?J%PW0'&:)CV>9MRJ-\3"=:PXRN,5FS%?3
M:MTP?^"=R?2Y3P>*I^&MC\KDOG7@Y/ /2!;'XD;5V5 SN/75VKU1Q(X!*;!6
M,%,PHG"7[(&X94+G'C<Q</> Q$$NTXSH:_)W1P9[P#<,= R43[2EDP++X4!\
M5PZ(UF2-GXM,U71U]\-$:_2>K0^$DY I95\6A5W8;'0EB/XS*&'&G^N.Y'@F
M3* [B9*X-N7CKR6_E"$5?1.65W'"W<64!1XA*1P]LANX0A;A!"@6B1&7;7%G
MRK490 QRIL::0$_:3.VP/ MGQEM:O6D/^4BSX2^0:90[0T-0-1=L?W'[QFAV
MB;K:L&&?-@Y2M<>#2J9:\ BP!:L-959=OW7,\-3GS7N1'PIQ.U&%%V26&_S4
M;<0QWLGP:T[Z?YKYSK FFVY=$!&1)AIZ54!*Z$B3$A&EB(!TZ4VZ@-*E"PH8
M0I=>@B!%JK30:RA*[TCO50()D! A@0.^^]OO^UU[GW*=Z_PX/V8],Y-G9K)F
MUJQRSR1\EE%'/[47'/+X5"B^\=\*HT;>@ 7^LAQ8A;Z?7+A=A5*>:9)J *Q7
M1_JMUSPJ<>MWUKTZ/\'2U.3%#;C6/ 1"0A%.5)%-AI:6!0Z42K7.SMZ6KE\7
M%>V3D+1UE#;^(L8A=\V/W,BNT+]T=I.'R#(BA9@#AT'D'H4"@M4(;C54:>;L
MG+G)G,/BR[MBK^[&?K^:Y[\=T: ?I<-_^M%D,S- !E.(A'V^EQUC73@C#WU;
M-#-?VI%3K685PZ$>-2W26P'KD G3"?E"X)#5]\3=G*+)VPDEUM8 ^EB"$*S>
MJKFNUAQU\*&N)O'%E]A>0O8'#RJ%28K2MNWY+D.X*X5]5*66/I%GH/!+"V6P
M?U'"!O^'A>H^)[B^ P\"].9D@D7,KH572ESB0XP$%TY^+L">)/676)"#_Y,Z
M@W4!CNBK)+6]+*VBJP<TV[3'=Q>&QLBZWIJUWAF5YS2G^ZV_;)5)NG>#&%3$
MN+6/4XG;GJ88-MCZJ<(=EM=7DXQCZ\1F/(;69IYF^:&2NT84!)JKJ.[W;BC>
M?.6B@AP8DF+X"6+<PM&A!'N[9WIY^>UN?J_\<7_X6GJ?+KE_/_&ZO)*T5-L.
MR5,4#^X)R<>+%<^4?-9T4\T.(. 2\9*\?Q28-)>]'N@S3(Y&F*LK+T&IYNOC
M ^[-J!HI J6OTKK'=RX=STVS4&HXE?8*"LJEYG.0ZMSX^M3<A4]M!-:J^&AH
MQ34\+WY>?\?$Y$'$2WL&[<?.V,07$/JA)*S+J0:?/K9BN3Z1?3X V)O]6]6:
MUZ+DN5*G]0=W?C_- /CB+2.L$'PI_G[ZJ_M]KPT<9DQNZ2(&A4DY!85)OS.4
M4H#: ]G&AM\RJE??>>V6O68YTL-Y1,'\DC+4HH>(IDM0]R15T+K;\\))V#IF
M1#3-Z/6I>=OW>>AV]P4+FQK+,3G=5#A#^]$J;+G),![LL]G/V(3V-SA#]*?H
M.+YW2C/5LN1R2''S2_\RR_^6HJ6[24! ^6"EB1^A=+1H#!K&N.4CQ,<4JG4J
ME( ;]^66+S,\P]=&-+KH<Q]R5IT3Q'P'+5Z:O)$SZ!\S6&P8<U07=%E5,W*6
M 9H_)V"\B$)L=J*]<39;MI?MRIPIW_U;-TQFDJ<&3F\<H#=LJN.-7P8\W0'J
MJBZL2+IGG&TO;[,OAQW<7 J=HMG]64Z#+Q/8!)':-$0[Y-36-(*=0AH@7K&?
MR*GV%6,6*:6B7G=%M*_ <ET=F([E^"N47LSP^;D+PG8\6XGN2QU1O5]@^$A
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M($,/T9<7()V240;P4NY.+X-9_E)G<9G8Z^.TQ*+ ,')2.4UVNWJ&C988P8'
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M03K.2K;MV,L;&Y6:=:U/5W=[3DQ ^S=V;^\)C3:7D, YOG?C5#P!6F9?-SX
MM!X2_RL]$?Y!(_!$4DM!:R[F$EN$^-T0V>6Y3WX)9EYD>KYE$_U=37 )2.:R
M=ER4", [@V2_')SW+*-7%O1X.44+/3SE%(G:6;M;/+%5IZP_?=)?-*- [VO4
M,HDZ#\0'?HGVM[NX0%1@6\9Q !6=G+)=D36#$2P&\"&8_1:AW#7?8>\E%#:#
M6-,A/#-KJ$K38TIW*&XN<(R-?,]L86%GK-OHE8XJL_M">WT6#^+] "^'8-%
M Z?V;&KPDETT?)FJ&P0)%$=EPI++<5+?QNY'Q).*"SPVN4_A4O70)L91A@5Q
MK,AS^B561?Q(G?G"\3$ER366*(@HX!GO&-MTG/LA57TZ(Z!T3@ T+WCX-Y-4
MT/_]/!"LZ;,V7MBGW&V\DP>E\F2%9WMZ10_RG,!HZ=+3WH8'W>S+@=;.1+5,
M++U EXF" Q<=)4ZU+.IZ>4\#"F<13T)6>0H0F%S7&EHR2+DTM@8I!E^D]>A6
M^_XAO^"&B5S>''M1CSNGE8@L..]9R6<E43^K9F[7&J: HEQN$I]TK7(=*BV]
M7&X&@31Y/1"IO!CN7OQCI";8V&"$(]Z:(G-O^GJ8S.N=_B_6_O'7HK3H(%_O
M05U15:N3B=[.UD'(7YKC+IM9"Q/7J6ZEVK[O!7RSR.8+86G9^=:^T5) ;QD7
M>I37C@9E>O@YX;2>84 U$YK':3?3]^WH=N9,C /V;'T"-[6:ACVVT9$\U?-&
MQAY^C5*VA]JD3T.VRG$/F2'')4.W_*61!1!71'G-/H6#T<1Z)?URUMG(/8]'
M;KJT)!!,6?(E+\69$IF3X1\&2B??"\-9JD7@Y X D<+'T>(WBK(M"$@("+OY
M9(!DIJ*+WZMJ0@;)DPY*5UZ,<7_M"!9UG+R<3FUNA4\ZF%.MVIG$\#?_D8LD
M[ID)ZAG_HSL\R['X/[B[4<A$T.CG56S/8?&#MH%-W+4&:QS=CL7BOL'GS">@
M/U\EK?N8X:]LX3<3&P"^9=P9D]/^=Z^]1DG)3L7&]()+T1[M,Z9$]#^T&S_%
M'<!(VYD/S25W%BOE<Y?5K2@4EPL^[OE+@9&/8 / ;V%7/S9-"62.?M^OA>1
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M)^*+(2!QB7&4A=@W1:J7]Q#(7)/F_,*()Z?Y=L8_#SK^?TOGT_\#4$L#!!0
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M&^DXO9;\S,Z=Q\0[M/SY1GJU[#SQ)6/0<*V_TJW><@X2M^&^#+@!#-OB[M\
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MU)\;J-(#_F=@_"P(NR]R6?K7>";;B7#M$,=K5($[1SO,F0XT>(1E!9Y9'-X
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M(@D\3B;H"4$R_,GANFX,<E"*DGV?B.JB4%B^2MI+GC# '(U^I#HG"I.6.7@
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M_#TC'ILP@:W9Y+KYP$J<^&KN?CS3'G(M2I'5'SPIF4CEC*"]SIC"RZEE"/P
M'=BQ0[=&OZB[F]O2X1_M!&'T11AQ?MTY!).2 D&1K5X[*\XKC[J"^Q(3GG:T
MNA)X-*<D QC.]_%)=N7E5?M93,X=1%B!D),A2:'B+$9J0:E?@VZD)PE<I(5;
MQ QU__QX4=@W7>@,J[J>01I772S2G&HEAQ;*ID>65'EWW !4T%0X/J^O+.H_
M)TC,^QNE74Y_/'ZN*TU3PW!"W ^+/%=B4')T<>R9>U7A]V.;-&TC@2#)Q)I
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MGW,N:S..?Z"VU<DQLZOKL'\J]QTAWC[JUEIT7B;.'^OAV;,W &-_QTM3EQM
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M8\^O[;KZ+MC7-K93!@?JIK/@*1,NL&NCOL[Y,ZK5TM;T;<2=MJA6;>B?P0>
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MY_*3+N$KP8AEX&3@O986Z V@P76MT;*D3O;SA?6,=^#'KC2C?0I@^GFWU<&
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MN%'6N_+-:88M)$/#9=N^WL\)B(M03W=UK^" A"#G<TKSVE]^&8 =>7%T%=4
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MKWCTO_N-D^M#DG6RXY3Z90.3W#^A*,BUV>>BW^;X#;O(T:V3>QTMY*-+QV(
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MLD?6"*G4='EF#?E; 2KUW_U_@O^*I 0"B89A9=$:VXZ$)X3]\GK82,LIO,!
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M?V*4Y&H(_]CV/8'@-6 XC^2_\/*=84UUW;:Q@4@3Z5T%*2(@O8.-+B @A!I
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M@,;H,[.I'[7%P'N+LIW'%]>JF^+>+]XM]DR4?ZOCS-\WRC ?^ "?&P4)!!=
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M;V9L:7S\J^S<"^8OUA:>!Y)G#JN\S63OI,SWKA!R*+T7[*G=;CH:P:)(@8
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M9?+U5!TV*.-/SDP^ 3-J@0<U?59U<V=<3UK[LR=@&8=Z#>D<G9$**PVTK6O
MT^05.;5QSB@^\MIB$MK)%E\$*?BJ='ET5''BA+)/F6.)/'CUWLRIR'?<EI53
M[[@,BPNHKOGPT3SUG*X,#%C1N[5CAL62HE9:LNFM&NT<I<XD0"8%G'*-,82!
MC<_K^2S^BL<IS4[>.T5[I47/C6 .N_S?LK::MUPC&\&@VY6XW2C/\FW#L^2^
M.5%I4UZ.+R?^^['^,]2%1.\)T4-A94HLI<5WB!0_W8]M^>POV@$12H#;R85'
MB['3[0DH>K]56$2&/Z5EOK-')Y<(R\TX\9NSMV$4/(<(9I.Q0%^\^,S3[U)(
M:G.H3U_?-GO6XC.K!UTPH?RNF('1<J\O>5KOT'MMQ]/3(,N1Z$/WF\D_S<QU
M9(*R-KUF8*Q3BIKEFR>^[P)5$9I%WVXWYNI%\,>*L7):<*6-0V?ZF8*OX%))
MMR?A"+-I.E;HJRO#[.\Y*?K4_-91YX"GA,<!?O@KO2?U10'E3L8-OEO"N4>N
M^3;F[VZ(6P(7;'.FI@+!N+8"S%XD\YQQQN5%T%=<6E3VBX>F##EZG)>*9-%I
M9NX)W47G ,HD76B=5N%ZW71O"%Y/-7._JW*.U>T5GO_CD<)[GU3+F,:]P8&=
M>.*T<B0>'JCIR^OO$(;2#')BG#<=A%'1L="EU5?Q![^1/Q-*BEQ)+T4GQ(!8
M)P]>\>)2)89\A;,TR'_808_:.A=-5E:\UJN(=+CY'B[&F?5F%$ZM "8W5=@<
M?33?(W25DETS31C@(DW.SY.Y#76Y'_8F[: =0YQ)&CK\Y"9N&%>WB1SS4Q(-
M[J_>:J?S.C-8[4WL=?.(0S>Q"<'1[G<H4+\V)F881Q8"?292M'&MBSGA%=O5
MT&CFG/'Q$=DYZ]+CALL=#ILZGB>C$40GM-Y-Z):7"FTWTH10^"?),JCNSBEO
M'%??+2&/1R/0+R+!U."C8=R$WL2A8.W/[[]*0O>-J\4RPF?5%X&G'9_BL^_S
M/*5&K17LD_;26S(>Z KWC<4T+^OM^?WA+,KMVZ,:1>OH638'#$LKB;N#_1Q\
M78W7!4>D^RL='GB(Q=<QA>.+AUY.0VI;U1]-$V4"_&./*,K-KS)_8)V++7S[
M@]MK9>:* \ZP1X;K\K3+KG0N4W%S9K4ST#,RYJ7CB*UP_ O&U:MO_/8L.9JM
M8MON0<N[9N1G(N_@ZC,^+P:U&8.G&M.WK5N,;"F[2CQT:"+8L*I;B(9YG0?-
MB_%2>+<T*7ML4<.,>5NZJ"G1A[GMGOP- G>O8&E98?63([R]P&)]1>P57-,>
MUE@J(=X?$E%2:K;5S-2$40@2_N8?1TIQY@V=C5RR2)9)6A!Q-_9JIW1.S^4X
M1-)I.A=H-HYAX3:YWRQJO_RLG/\4KS CF.^XI$ PY6K)=VQCK\,+QV$7CC.#
M/[L9T/)^\S#V4LPN:3XL?8G;GP7;%9'. J.]W5_$PW</U[#U.0X.OOBP1[4Q
MW<"LHA35F9$AB,T;X8+$L\G4E%3^JQYBB8^W7I80T 7=://E6\(1>=)Q9/F9
M+C+72V.*'6;75=/7KKBGQ.Y'KR*":<&#N)UN&(WAUY3GF<9-,U)I\Z>5%@.O
MPBD&7_5?JNK@6B^8(EY:5=@+@ZP,U@X4H\:]%5Y6-T>_?(:JC7_1]=QAS1K%
M*#OJ6J=-&SX^OK-<=$QJU8!^LF^(J\5.S\- D0$86"P3&_/[XN]>6'8@7@WN
M$B.\V)8 @%67;K5^>$LC-S_=G,W>(WVR$?EY^D[H-J6?C<1U5[38\\\.=Q)_
MTS)N4!<0NM$S"8%Z99O^5X/OCRL^?N"KPP:ZU]I;NYWU1ALWX(\?0*I.T)3#
MT%X0X^FE"6#F[+OIZ0F_I()$*(U_?-J@<;; E]^0XH;3@TV?%^5FNJ")(!?X
M1G&K+OFCL[P#2R?)G8\'2KZ:XW6LX:V(<C^7XCE-2L@-4Y957KIDP;F$_C,%
MG:G#>6G<\GL12*UVF!OLBYEY8>43=85X;A^Q4:T-91;BU38]"FCP?*__2.F:
MT_Y9(30()%K-6_:S=*'@@=SB3&E%J^_*7ISH.B'!NV0;*!_HGY-O'_8\VF1:
M2>U6P1N'M0)>.W5=U(Q_4:BGDQ)SUFZ[7M)&@$NGH4$]<M#*[>LY0&(B\"D^
M06UL)(TF%PS#6*J_;&#V26=[IOP:2<&AX?'(Z"0S8FA5-1Z>9[FT-4?6% "S
ME9]?<AR;O[]D+G9U+>D#-<J;K&DK\ Z2(-%SHAY%%$,?3$)T$[C2O/,TO9+T
M+A??^/!3SI@G[W#'7(4:Q8U0Q8@R$!IZI"NW,M-KDSJ9/E[-M[HK,!F^M!K:
M<]AK<]_$L3L+EM/0-GT@;^3RLLP#^WM\>HG4>J,9B+UTT2."]?$ 7%^[6\'L
M8UZLGZ38]9\"G:8W(]>J_0/89L>4!0?+.X4G2;1XII17Z0E04=&\N%?>E(V
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M,KVB45%Q.3P*X]S(!53>!>24@B :U.5]E81%ILK1%>*<A(H-Y.K74MK+EFM
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MY;&"@D>OJ@F &,[G 5I;7C1<"R;</RR4I!_!Z6]?X(?_OB3IXY$M.5S7WW4
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M-=<O7OQD=>(BB^*Y]:33-\YTA/;R"5Q6.0 Y@",S^8 R"HX;R4OVC2;]A)I
MY2S'%@7X=KWR7Z4]8)0%J64R^MMU+.MF Y0.:R$:IC7#]W<KL:> 7;%/$>OC
MD=OA<E2+D$W$KI]X^HDQ*/UQPI9,BGQF\MBU)7FEK;B]HGG@(36;M(:MD[%S
M*UI 7VRLT'X7KU-=D2"[+$34Y'L4L_X%:NS6X39A/M$T2%<MHUXQ3EWIB!*M
MJ,YT&L[14>.VO&1_6I/_]0KWM0=4#Z,%^*?0U8P9+".@3;=P\\E"FK3!)HC>
M7F9JRN5=D$^?)#MY&PY >G4/B+AE<1*"A76_JWET+<<2#L1-6Z4&5-61^#RT
MZ\S;V6,_!9MB[^T^[%C\.AK8OCW5FLF_5\(/<SX <:+$:,*<R3Q65;'RL;KG
M4KRG3..SDCHE$I1<9KP+U(_L#X]"^-05@ /0C8KRB@JJ[POG,J??;=QV-4=U
ML>*/W>^_'/N\DC[4(+D7O0&+0 L#21BRKMD\@>;2EM']L33\:]7@DR#?5;-3
M%R)GO?GX#"?W.Y5XC/$4%;H0V<+MC/E2 V\%]4?ZQ<[TL0[N[9PO-E4?Q083
M$XU0T*2:G]+H.9-F,+'+BO:[/;G?QX5G5(^J6"_R78!]^,'5A%4=^Z.ZL^EG
MIV4LCPR4U7G0=+:"J6L=_ R?.5.FP?IT88-)*U-+W?RI<\=D^$)36)]\.A;8
M'S/T&T?5QYS\282$33>E]A2\!0IO5%76E ]+2Y=(2[YX=^*>!1>QENI5>;[;
M?RURG\42B:.$!^U?:"AF%FNI,%$L'6/RA3DZ/3^>5!8*B@OA$5&];!(U,!TA
M(E8];])8OEHV ^']4^_>]DR&>MK, 8B%N%BJGL*6W>U.5PW^AC:<5/ZRECHG
MO:]*1U'#6R;THZ8$^^A<L&"1.ZNKWDS2Y5*Y+HZS-G2RK]SS&T(<BSR]R]WY
M (X,:[T68-&HLR+4SB.O>KOF<?/#F5,X'-I=/Y_O<17#KA!=<P0JZ7!X1,*!
M=@58F'$;VZZZY+F+0PZ5MY*"=6);72C<#/%Z4K'X?)V]26CK]A>4WZXKOF6:
M>+ANV@ORM0Y IP]/B0%)MS23.VD]GY[M4[YZ57;-,GSN*/9W6%ZGX1X"U87T
MVR_NZQQ!O$5H-K?K< AUOW#]82\2\3A0\[AQPUZ*?"R"7((G2^HA GI9%@5X
ML"TN;^N.)<6JPE[K*9_OX#YFG[AEL??&9N^-/(9UP;AF:<G7/._=5A=&D37A
MQOGS#QYK3UU?E1DH2\M>WIO<D(+2B<L!@>P&EO9-_\^(88ZO_>_$,-OY9'"[
M=!3;?E\JOF7MF"7R9O.@7K_M< ZN]>4WO]F7#V25._3ODE ZNPAD@3H+@&BM
M,&[@[]M$-)[3>;O(Y1^4$*AX[<T)Y->/+N$EGHB!!F%T.YH;J*=A3&G8:&&L
MX:>Z 2[=RL'F.PGF7^4B1S0>G9I_QY&(W__BOUI Q7[>/U-&0R?:!9 D=58J
M4J,=T\AO3OA>^7CB" [WID8IU[WS84,XRHI7XM6/O7=TASPZ$ZTC-HOF\!SE
MX).S[>0@%E:\JM[-%S)3U*S928D/OHS Q6$XU=GS0S8;(RK0YX;I$+RE!;'3
MC_2C*GBQ<PZ4+7OG;E4GB%RYZ3:^VY$I \#)TR>1:1WFQ_M'A#0(50-ULA6G
MGGZ=B%850J\K;Y[_D PO8XRI>QA(JMH7INN$MPGP]XE&D4=O#6S<_AAE)@32
MM _\UAUS1IR8?WTN!_]I$*4"=!8#M>TPSHW:]T^31YM-+DIP1BFR7-P66;\@
MEADH8^V0O3^\KTB3;L& M+)^^NO^;I4^/_E]8J)H@OR1$"5Z(??EB2ON:@S=
M/FB9O32H?:8*S;Z6^ILLV1A2C#*-JJF/74V0VG]4J],\$38RT2&_I[]UJ[0,
M")PI%FN>$JVCKD72!5<4WY"/G'U5COV6^?0V*0G[E*:[:QW2,>ZZ@Z5QQ>W+
MHZX 9A3\6:!9^L0BFQ,GQ'G03=XG@]-,5C:A>5Y9X%T8(AU@V+T!M)!#E[VL
MD4NDAK+3"PEP2\?4X_5]0X*/WAR)_F3PHJFD8GW&K17#0X?24L+I7C3548LT
MJ])=_AHSQP(7)[M>V>., 3*KLL>UJ/DS)JUP4'$RK@"YUJ*:&>3R9$23V-4<
MZ>1S<?ERSG=&R0ZC)>V"23-'^85?M02O'KH$C4(9(5 _S).]?=5/#*-4'-?K
MB#>UO-Q0?;=_6!:NBM<R""EL:&;0%"%L=-X#4,B\)O:41TY#MAO_YR_,9S\:
M=UB>BZ+6,VYI =A<@$?_2&4[$\*-H5<XC]RK1]WI\*5]V<V$74NG7).+VCD#
M":_@<6A1I%IC]X-L!%*)+K57IW\4W'R'Q5L.#QI9O!ER#_"C@Y/K_JR"QN;I
MTPVLR/H-7GYC?39=I:WBC!SI.@W(U%66CF/,F5X#]6R:>_FS-&RKI'UO2\+"
M[WVNZ&8Q>%GUK\Y7W>49<;?<CYR7B!FL@^V*ZF0Y04X6"=.$N21F="+S7Q$2
MCZ"%CW$P^'6.-CAE@O=B-S#A!R VNA<9<V81-[X#CRSO+-)\V9=LH2W,Z)7M
ML/IDWA7&$VU<3?AYN-*M]$QF("M@RB%H^<W#\N-WG#IGCM*'7]VD6GVE7:N'
M-[9O;N><F!'0NKN)'P\GC^!I::2V]L;B%J?CW_US)U]:R%]*N_CR U5[GB$U
M9:9QF4;J#4$S]9=_RG/\O;.%8[A-W#!_XJ$OH>@Y\='29[.$B:2__(-F,K.!
M&4_E:KO&C'0AG,)/-;NQN+W:CC-+Z9%]XK,4]7Z]+6]3#MWCISV&IQEM%8Q"
MV6@9\H'2FA7U5-%8#X0=V<7\^I1=T>]C$<UGW8_2:H7JX<#TKE$7U9:""ZI3
M>>;BIA3BTV4D\H,:\\;E#>ZQ=JWRJ70'H4;SCN@M!FIR&6GZ+#[*)U#?A*97
M*?];R;R^>*6MCD4BP2#V8V!Q65QUCX0/[,F"PJ3.(7N4HK&4-)Y((A705?Q8
MS>3M:9;TTF#3%3N0_R\YH]U1ST;/XEF-@OUAV2GT, ^X^0 $)A*G'(OY"@L6
M8XJVJQY,78P,FO@5K.2S9 8YBG'AE>;6H@!0UXH:R>DPD:JJV!G-VS5EL5&K
MUUM_M+#DG)GUL%)Z<0!Z8B5$FH]0%[ &_!XX/JV[+$5\4AO3Z?%>6_D'\?KU
M8X&JI[_TPVRFF1K>Y+:0$8.%DT[$S78"WU;\,P%OS\[&Y8%@O=DOQW;BU[36
MW#S0Y)%[?I]AQ)(ULG0S!@*LMW%>=>+!A.-=.260+W."CUW_@J_Z-?M2S6?!
M"-W;"$$YT6Y*L_U4%QTHGSZ#'.%5WM2]R*GU2Z0\0^GF:G7G9:1+7H$S_%-;
M>R$)>PYPAG-HG7E!AK!CW)RO6IC7N8E4GB]GYHW3DMP@$S;@8[]O4QE;#T#,
M0._G'<)6O'IZJ84S)[%XLOW=UH0]Z&12QKK @*Q:P/WZXE&;KK$EVU2J26LC
M-O,",%V"/+WZF[2#!1?G=N]]4^1ZI,O<(?+X6_I5RU\MW'FZNX\0/-+/41Z%
M4PN*2CO#V&A<,Y$CA#=+)_+443EQX8U.X1C?!>L6$CP$3&J,LY8%0H@?++7(
M3#HZ=H.M(N9@X4<)VRT."VWNX%V(J3/Z.*TRG*"+UDRSHK$!<2WW2RO'I=(\
M7MH*RER(HF2^Z74N,4\>_&8Y-%'[2VX5_4?G""/#3U:V\>J?6E3GIHEL^-M4
M41=[V8DNK2\N0;X)WZFF"/$O2;? *E!+M-$.')BN;^N21QR;M#3_J5J3?<5(
MEY5S%]J:H(1[%6.KTJYJHI._WSVE<DCX44J!-!VR;F.TMQO+]^+-L*2\GTM/
MRKY?:M9Q'U>+V&!?N;6EWD_7S:,;?*2=R:K<FI(=;B2L/ EFX"-:-EV-*=+_
M]GGGT=D[[PDFGTRRINM\I\M,6B=-*(Q-]4QM_D/&'Q>5IOQ>)]\QE"DUOO%<
M6RB4?VE(H@?CT!N"IZJ1%"-GJA4T1BQT6<$51:(71!>X]Q?$SD_&$7X.CS+]
M*G'I42F?W?8]Y*]%S_^J]?G?-;P.E9'^G&MO"R^/OT<%TY]K[7D[S_S)]Y$!
M2)/I<0E1E_#G?Q_]FZ(U4!:^Z;8AG_GY65D@13?7K0Z=E]"@LNJ_]"@K2ISY
M#_H0=[KT]GBV:$(4R#)53EL#)*7+W2W";@8RG/O;6X<O0-7=W'^R7E3+.\B_
M^G],9_R?T"KM/Z'5WYW/<IJZAYUJ>OP[";>/2;WTED$TIE\#Q"W_YUN?_'DV
M][?73_[^^*<S[O_I=/S#U/S;?)CLUR@\R_B;O06VE&UR0@Y #*TU8;AFO5\9
M:" [JM@[,<.POL&%TG\SM.1L,73SKD$*_HOJ^.\&#9.7Z.%I3H7>8-QQ@CX'
MX"G!34 $1#M>T-543(!,?8M/:#(58/ ?UE#1UO!A\S6YAH[:?HUZ"I11L6U3
M9\J PGQ QX0Z&N5F.UB\B3V]3=5Q\!#\>LKF5<97_R<\,^ 5.THWG(R/12F!
ML6AVI"P_FX6+U$!'VWW+O=(51DVK!)MJBO(BXIU-OF2Q+0S!MA(E,8\A.FP]
MIV&:7U%'0F>Z>5I:K67K*U,,ZX/MO-A]C6FK5?'7!8/U;LYO%C:RHB60\Z:
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MM$R^6#)\6O;Z^;GD*(GTOO])4.E? W8>%/J;T$-6,$MO]WW<@90"-L#LI\1
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M(9KR[XUU!A?EO.[%<LH\"Q[M8X$X80KC:%? .1=H[NRQV]48$Y^6(M7-^]+
M7S:@9:?JAP;1%DQ91QL;:(O*/T^=:W/@T67WQR<EXB8BX\ZZE^38F/:4ONG9
M)Y6_OT-X5:.Y)%++M!D:->YVW]]"X?W[9F<A>_7YPX%OW<4VDR^22@N6BE8H
MGS83):=,.8!=6[?<0T]3D8D4QLVT\2,%1(T,]Z=WQ096ADY8?SC0FMP6V<+L
MEZZ,(\(G4NR'\3MQ^^V!Z^/(?1Y9AS'@FT&'1&/5?WLEN/'NH@SH4W1[2$$V
M%;=TD!A=0>'&BCA*V5E09PO\GLM6R5^+_:)Y1*50B/.MB^6!;?T\!WAI85!4
M"Y];BP9>5KVN $A#[IT7;[LOAH %(OH9A3ZO_67N>F+HGM6S4/0]O"KZ*J!/
M1NZ>QP@7-LB$Y !E'^?I0;C(7VA5N""KHY)O#\*N"]VK]=QK&HNI<&) L8"E
MV21#;<O/7==&-+)SO5-@(U,]A$%AG'!P3=TZS3A+RT]L.%'$L*/1'Y'LP#S=
M]")5@[[5IRZ2U:=>9P6Z:A[PJT1UWX9273\S!^)H\"USCIO:,#6G);+0G4S&
M:Z8K@RSIW^XA^:)(+2AP8)NS-JLHRSM4#6T/U))+A#]C]B@VR#CG 29S6UI;
MEC0H3FZ"<BZ,UIR45+J#?&NMV+,54V45.SUCNUCG&),[#],II]G#A(;]M[[*
MTB_9JPHKYQE<S_\DD\49-(HL"NUALIN'5K 0D$X4Q:KU\HP#.<C*A0R3ZCR)
M]\ZU[;Q4X0,%D)4L!2Z'[:BKPWAN.]3^AO,GI?066\U040XC)R7\GN@YM';6
M"R1DWQO7G+F2KZNWC%P@H;>DN)JG$QU/FR8.,HX!,9[$S"FS5>QRIK%5LZE&
ML@SOO@XUW[UFM3/K# _<LA)MJQW.AU=$"35]$!O2AN3HDB2,'LT-:U^5%>FK
M.#\C8F5_@S?$H*@DC 4J>Y9"Y2(18D[V<BE%8"-.UAL\#3EF8+."D--E@13S
M97%':P^+K;5K64:UE8R5]9(H[24[ 8*-EF-V-BIP9.$#^?Q0(6.M7F7.?>Z8
M>C)8IM(E"#:RK02D/:A%]]BND],3&7+@YH>5QA9-,+GTM@]'4HQPEZAUG?3K
M0WK<7QX]9E+5SVK*5"G8M4.D*[<YR.NQVH)(SZOCCNDS=]!&O&7M[<Z^M<VE
M/7M\3K6'+-J1N9;&7,@0+L#-A*K3C;U[TG3/0KAU_^'R5[KNO),K5A$^>V!W
M.C37"L&<H=WXHQA!@-SN"*>%8*/1GB0E/@;\EPR7<#OK]W;[KN[,OO[.2. B
M+$K*_4-",9/R2"&#KNU\G@4*B_6PI2Q-E: >S <%/J+)Z7E:A2@OR(E4!P[^
M^KSZ>/'RNX>G#@A5-IX57@I5 <9HHNSM+NJ-%V<<*Z4NB2<F/)OPT)IM)"'5
MC8+]5"(3Q;*C(UUE7NAHKLZ%TR@,H9Z6#LQ.;3[BT8 "3U-QE*4@ AQ]K0JI
M3 *KU5\XY';+T;?AHR3]2".DPZF<$N?%/(*+QO PG)V)V+V.\]3YNK:LTOS,
M+KZSAT#Z!Z\<3!J5TL/P^Q7BBZ?(+AN[_4JBWP)Y- YZ&("A>E/:OMJA8:6$
M/B7EXH XRZTKG5.Y7MKYU4T2&LH7K>0D_=[[9?0N[Z %O\;L7(5 4+^AU.D8
M 8\@;76138>BSFA$<=F-K^'5*CO*W2T2:WN%%[4(S7 Q@$ /HNG?T[8AVX5@
M6NN6GW37+SJ;B%#/SCY^J6C@:Z;%^SC)FMT,LT!N/!0I-!?5M 6H[+(SPH$G
MYRW>ALCR]K]3XA0[%IY47Q5D:7AYPM!RFBIA/J4*;66!Q)A'4"P062Z6L8.:
MUM5B>0DX?RZCO9%4HG[9,^9RF5W+OO-"KS]A38)ND]!F6ZZH^I;I'7A9C]%0
MB4$U2LR'G2,(_Q"+7R>_OG\WT/FRK-57PC/,9_<;&?R%(' "W(T%$I^'BYQD
M@2 ,.=HS'#%$O[7T?,9L>O'\LR^="P;M[^>,<U4,.,]*\8<L/AR!7X\K,IJY
MG:"M (_GS"-CQ!9%QD>J29X3Y_;>R4F]\3[IZ,8ET+GX==G-/2:)CT>JLO"W
M11L#C7\/'5,@;UO,M(9*551721\=6?$W%9Q/_]Q.,:R)W"%S(3Y>:DHL; \9
M?VO--=GOA2W$1@3O3G-;"LCSP%00PD./W[Q-^[Q>AWA=,^*EG>P\].3ZB=R"
M\(AT7MT3/3,[%A]O*^3R>JB',S.47."N<V"W;0^KQLX-[+EOE[GXYUL-27O\
MEY>Y_+B=7L)?E[ED_\O'!1=H2-)LR0P\%L?#T+B&=%/"QE ^5C;<Z8^/?EF[
MB_L QQIG8V!#-0G3U(6+AN_%2Z&RI$PDY-%'@P]/5GTY_VYT1[K$Y4116N%+
MAXXIM8C:1G(OC"]T=(2I2&.!6N$\0*.2F@WZM/87&X<#\NGJI2$L4(.)0_#,
M^KQ]9,*6.PK;AN/$'T.1?QWPWW("]"O%EBL>>A/1%WG(?,>GDDW\VK5&[=EM
MVY%PTFDI$["P!]\=6:9,BGTUSM1"J- T8812?SJUM/NT[7;22@!X%^,*=:VJ
MVMD32=8Y)U'@(M);UJEVQ4GI+ER#9T*XVV-D:-$D8O7+ 6I^QW3T!TD@E0CF
M03&GFX,>2RM6!,=)E/!J=RD5_#(=\_2WQR4UQ7M'Z:5 M1MUW0Q("7&;\<1Q
MSV]6U*''S??/#&6=3'?]>#@V;84K:!-,=%KJHE*(W'8E_"@KD\&UJBH!HQ<Y
M]9USWF)A2X9A=UZWH2+R&4*C^H.KIZ!7ZP=-L8C*ZN&<D2-5R49WGJIX"QCM
M]A),5-'L53LU;'?<(F>J,+".T@&-A@@P#_;.3$?8>D>X''ER;1?S12$JOQM%
M4GE^(^)0?)@=5\IX;:,N/0^XEP>(MF,0U)44!!F[T[%EN]:-.]G3KEY$N]?;
M=[^)9E./0@TM_S5<; *MG]XQS8]VRD<YMVHEY ;6M26^R,]LA%&N;CA<%GC3
M4NG)D-W.2FG2<HM3UK8HQ(D"3]L*.VR'WNT4FS),%6R3-AD"T3(*+B/MF&&S
MN:G#N+FO\HL0R$IE;S2$GZ$Z$UT4 %U>5"U<L%)]JF+[?M<;EP/8Q]4<\%34
M7 MDG-"!VZNM?_@I:I1H>7>Q\&)^1[;'K2GE/!7%3-]LZV)K?IW%(1;(%3MV
M&;VC@;9K;;:!>:@1OW.DW4K/J=1&V?#,#IV8Y39?)W[V.\[I&!R/M_+U_H8K
M,^ZK&VN: 3LWL1'=;21*2)OE]8U?^+GRC.@9]J)EP]"&X1H@GU;0#A'5#B;B
M./1G'I126TOU9$:OU0K9B]K/:"/NS2?O"M)?6J>E.27 ]M;7XP<B8TKF;P^X
M9V1E)6^\$&Z6E$J8,OW%;:1&R6A&M,U8E,0^-TQG<)#/XONDY5 ?;E(JK.HS
M]KZHEC>*Z+48:(3.N#5-F(:%@E,,H\QP-D/>*UDLD-FP]P/%="M^WY[+/ER_
M+^VRUZ2X^1X+ACDHA8"5(&(P9;0=S2KV&F"5#UB94N<B*=)-%+2)ZYT B?L0
M+;W2QWJ-U>($,B;!23"'IA$!DP*09_JN 0DOW?/-A^8(-<D.JL;1DGOSSKA?
MU.'Z^GR%?3X3HF'<-$S,24@$##;8H)F+B@UL:!P\V:WXH:BRA5>M:HG[ $ZW
MW8,%2B"XE>Q;J,-%H*\1*=)\<)))E M]]UKPLJ;CZ.7H+UUJ>_0^W-D59+'.
M8(&*VT)7%D:JUVH3GH8.,(\ =PH 0@M<I")!7<?O3']//0)#',&4>UC^3OYT
M$79S^A8'5V+("R8/$$Y;;!6IXXI;XX._%G>[OW;G^K6<R2ECX561@9!1U932
MW';^UYIRPL$MD+*U#^484G<P"1L]V,:4I4D_]H^1,*W:.ER4FLT"I?D<E)T[
M(-71%SRJAG%QBK%-2_H===H*R,Q;< 3UE2Q3E(17S4^J&]B=:!U 3G083]TR
MV^JN9-:G;N4^*<(L7G^S_8H%(DIM/]>^0.UM$PFD:^U#2N'3BPZ5/:^YV<*=
M?SV0,;9AT/&KE69>Z'MI:"-P;69:L#$R&1J %:^.4A:\%A+G+:M0"_.*ZD G
M+3MB7S([V9L%;4$SH;167UH0AR>(3'16Q:J46[_=@[#A2$EX_3@^.'RDIH2?
MV;J9=H^*:W+D<Q(>GWQ+G!;&-)\;Q=XD]\;#*%")&J_;/4=MGP]F;^Q%S9&J
M.TKX&%Y]: XW>,LL[$#L+,6T)JN'&GT]_K'B>V\[CI?QENU%M!;2.8 %(FF$
MJTT8\U-LJ:.12@'!5].^J-A/J42F'K>6NN\]?DHF?K:1HQW.6=Q@2AMMDH;'
M643R.(%M)L??WJ"=2'96]KER[S6'SF<JI2FN"$R/HKFU1@[-I(W:#BI5K ZV
M_BH;DP,247HL<&N@(.WVM!&3TYY:9FY(9YAP7=HN4&XX2^T@IF7/;'D:L0^+
M#YL*\H7>21FGS:.V3XR=Y1*<N=?MDS&][$0.!,K)6)ZS9-,()KBJ+P#Z:KR#
MU%IK%U>:N!]=U307/M#(180L12&H+>3(1O*M8AUF(O-.OYJE'L\S-0K>5\7'
M%R7&$3];5DQPA4>+R[42)(#,%NG#U$M5M"/9]*]<T6AUY.S=>W=??HJ$[[$L
MR,[Q]^[-J]CPEAE8GC9+FYPL/#:Z=R+LX%2U<E?6N3E9MTKT%#687CR,/XB^
MGFXPK.:)T&BR79C"<7L\5#C, HW=&)/W-=E]E4<>Y .VI4.CLP1I&O%XP850
M\;)1Q56"H(?ZSAX'&Z7)"Q+'=[HE['CS9G*?6\(P28,%>A6:D/.9*9K9Y"@S
MHE8BA/+^PE//TVAGEK72;9@T^[RZ1^!B[U2'O65*@/+C7U^\9+=9]@,$+^A2
M[SBR;9JWP<(9F>]^W+XH*Z[H9=E3>['PN#OO'WM[,7*=GYV._6BZ[$X3L@24
MJ'.M6L:XJ.LTN3AMJUM$$E3IDWK2L?ICL.&0L1FWE-42HR&X"Y]J6_6TB'ZL
M=S;A%:URN/%3355,,D+]9HY\F8S0>KAD?. ;'<^H.+HB33F):D6DW%?#[9]_
MM1@J0..M6]5*'<')_O;N75O2K\'E24E9/IXB+Q>=;]9!=/BGFS%B^$,H(Q(S
M@KI%RDHETE-:?S-5CBL&'#X)&%*+YP^F'0UU.?51L,/446K+,G1 @U >C]_1
MB#6.,Q\XB3"T"[FBKFHJ57>H7-OZ%._OY9)AW(Y3'M-AS!W ,PHI,9/&14(F
M(!AV13?I7^P^CVA99M(E% ZR>V"$8MMDH@KF]^)TTG13%9!-AD8%5:2G]5L#
MSI=JZNO*:Z+?0&72P/+MI_E5'Z]Q5FS/*1CY'9G_6K \]'4ZSJDRCQ 9JHB&
M4O7O1V15,>4:*Q#GMA[)5)77G(IRM[@G&ZY8RQ2>[]8C[(<IH*_1JN/]6:#[
M58["KZCL1\J$(<Z"=BI#?P@IL)/6GD3N.H.:##E+N=L%?H\]0PT@1!0QY)Y?
M=-].)W-K&P<HYSRS<8L]?"-Q6,S9(^>Q<LC7MP6CT^6]6#28C!'QQ.Q&!SQ#
M>9K0KHQ.K$G)V TD?/1Q2(JLJ3[6PAN4ZJVZ'"^WK$P!1+<R%4*/J&$JH*U(
M:8;H<,,UXFD(WTVMT?MY0TIHBUS/&)WF0OH;"41YNS[O#CC\^7[*Y0K"N!5)
M[CX>9(LVH3W!10;<(LDKIK0$J=]/:5*=LC^Q)QU\\("\9#(^:J11K@E7_EB:
M"Q F(7?:>@IYB%='_]Z88C8*E=DHAGH['_NJ KW )78)Q5'L49R]I3(&I-,]
MJ.O-C<Y7_.OZ"XN<JT:6GK;H!B#?^>64KBWD?MF]/ULO#^\4[6?NH,7D4@BF
MX4@L4-.3V\U^:,M!QN%@(E+00]#=W![P,DF9%U69Z]I[Y]'>9RA%'3 Y@03!
MLCNMS#8G,5DJE:J"NDU<'HLU0B#<$A<63HAFG'M35*'.P7^K9Y=_?VC/M"#L
M "JE>10B CO@GB73ASX9F!%1G)XS#[^A,6K& A6D?>J2)*=4ZNT^V8-:I'-1
MUUL3D*2LZF)[N^YB5,X:TA]AJ)8>FM8$&E^L]\I^R!OOJQHOGKZL9?^\SHA4
MRG[UY&<>QL9 .%<QDA/6^*SQK.2 7>4XG%)8E96VMT.G3W"\^,8Z';G].UZ.
MX55)Q9?<(>$BTBPSGC2)2DOKGAIFY"6E-LL]U/ORTL;W1!A?R DB 3P]QH"5
M]JWM]]++%LE0S$LWN=^&J-$O][^5=25(JK%NSU?X6"_=ECKWFO(+$-JS;MA7
MB1%U3U# "3;E'[/7O'V=.W!7TYZ)H%7A HO H3F3#/.ZQ>R$F=YQT=90&0!"
M<VK7$ GR#\)%G)2R'>B4)UWCC?& !][857:1$J:Z;"\:!T<L(XE+.,Z2M82]
MXU_/TBS# A"!1F*RJK:\S]T/26#?W/T8GL5E^V&$!;K! DF-=Y"Q_"A]DE1D
MP@Q8;-HX^+FUX[Q>\(2SQN9:V*77H,FU=KCM<N[V(R\R$$%=O%Q=5XWA0QF=
MJ>VSNUA__\VZ69?8KVGS@Z?+--\6+EN.2Y1<?S*]EMU3LNR=$5I/"UOYI%@)
MWPW C4J'*MXNJ<Y^B+O_RU%? \W#9V:<"8:#0 C)B:U,*=MSO#A]Q@"M4_"R
MZT@*[RC/G?QSB[52>9HVUKPN9R@355PMN/=.9Z@"P(NGZL_60\&T7,$)N_>[
M#H7H[$M[_5LR_P@<*GG5M<XTRFDW4P70VSHSL :-K7/-)O+M3[URL"]L0?0W
M^69=M?BV,^T[7.9BW2\3&H&]4]!2Y*/6)IH^/1R9J$0=7L%+Q'U>+5E.:Q"Q
MPINFS'J]AWE1&"=L1R&5:=G$Z-"3CIX9+D53U6'0HD)_0/%>PLK'1Z%7 J\'
MU7(<\%$8R 9.^XDN0Z"MT\NGC NS(,QV9L^7B7=\L\BO&G-BR_%6^^66'B&*
MJ]MY0FY;"5FCOM!YWEQX?,'U%2J=>\Q[?_A5;!Z_ZI:,>>YH0U+WHI,$4PU]
M8-#?20QMT-]PV&^F6X_$#?5:Y7R$K$@ZL5/%YJW-K1HW8=70,2<JECFH-=="
M$'S?Y$F\JT0<K/QLUMQQ2_%:O]QUP[N,NZB.H"PR_0: )7_VU^$@F;8^@3M2
M39*T+3*E5"^J5P>E/]!_H.RBJ,?)&;C647*RW\.I[%DZ";./85%+VT??3(LA
M6RL=2NR4CS6Z<<U>H4 HX?7,"ZD3YJE.Y4"X?^@P7O_BE@;:<AA_'"5A/A(0
MK:2T@J@LF-(4Z39\D2@ZGAMF>FK1Z1( _N-K4[SM]B,8E]$6#*W"/G$-'>P]
M7:#Y=4:E@O&IONJ1O^ R.5*<S $>YH75;_=IMR%I-L;.3H[R=2U/*W?HLSO<
MY. =QK<>7%LX89)S5Q,#Z/KUCA-HO<S&@U1WR)<U%B@1L[;X(J<FBS]NZPA^
MQ/-%%Y@SA06".@%S+)!C^,P _-,B"R3) BV.6ER OKC$O$0O7_%M:<IE@;I&
MF9K?_CT74,-N!+% '?#-M:%^_:'G&/E@FW7-:S,#F#^']J'%]1F-&#)N.VCA
MYM.%R_ '.H5;CU]1W>%_,/@,XY-A.G[G%:!FMG8,TBD]$M)CQQ3X,4<_"\3M
MS@+A2AA^+%")@_&^$,.H+U&5.+\T=EF.LT"]_V#SE"G0P@+!_T&_+N/H]D\H
MM7^+^C87=L*TM@O3+(Z9^VG%:_^\8MQX[S>4V'] &8$9V<MNDY\(1%[XUS_T
M_8UC\;-86)[NAN[_GZDPYMG_"OJYGN:;J>!/8$_8G**VN.D?-L!_8-GN8__T
M=9H:F?27^?=^<I!M/H2]SE/ZX'<09&/SN^&K/]-G8^#LB<R^N8\$=,&,[7^S
ME-F6^S\A^'Y"I']+4",[']6,@U',T.\B(#^69&?,],\$L1$=/Q"X'PBC;XC0
M\>\1^F$T]L>2"S?SOZ4,^JTJZ+];_E<H_^3R_]##=NQ/,E'_*QG]GR8Q@9/_
M;WE^@="61Q3GI"]+5!WW\EIT.+QOA#_LMAF7)<*F=-]5\_X+@8_^Y2XUOEHE
M]Q)?/#<.H!.@[S0GRD]M>Q;G%*L^D"*]RS<Y*9SKPP)1BUB@>7:;-%W";)1C
M*(2S:]3!W&8KJLVIVNQVG(5?R7M/)!#M,8,T%HB ^:;:'K+!A*\O?B/;O2_$
MM<1GLTBY@X\%VD-FXK#;6_^0M&>&S?S;$*?MH)6;3Q=/8A[""HQ*6S#--2Q0
M/ID%"F6!OJ6F!OZ5@:&,LDVISY#?['::!;\<6/*9IA;#O[,B?*MA,9C=6D.V
MUK[%?#865FZU$;Y042^IP5# ;H;"UREL)OI_IXXM'&9>_9/6GTS^,_F?^,)_
MDOM/W/]BBP6LN)@8[/;FM[S[78#8%#":U@QU$B68PDUL,[\))'S7]T/MVF2_
M_HC'^I\"?XAZ^O.8?Z!8H.,AYECG2!8HP@<S]X<__WLE'@1_J\1?ZC__;<AM
M]B&:07@'N?+TNXO?Q?]1+_0:_N="?.4:ODD_A00LV2/3?]#_+GCZ9WOZ_Y5]
MQS8<LK7^%ZF:$,OT_XIZQ?^!^G\(()NZ>R";NA5D]8<[WY__2;S-D;AFZ_"O
MYOQK^/Y97=[?.>W[@]//F^+GQ/R1=N'@J#\H_162_I\WR%^)L?V>F+_J]V^2
M\._+N?[?E9/P]W*R0#_74/E>+N;Z>QZD:O=&G'>[@DELS,B3"^ZJ!I<B-%"_
MY\0J"/FQQOX'4$L#!!0    ( /J)=5I(1QRS'>T  +@$ 0 8    86YV<RTR
M,#(T,3(S,7@Q,&LP,#4N:G!GW+MY/)3_VS@Z0G:B[#$5I1+*DA*F""%-DGV9
MD&PA(=LP(?L6DK(6V;)EEV4FQI*$K&,?,Y2=F;+<S';N/M_G>7[G]7W..:_G
M=U[GKW.;]XO[?E_7];ZV][6\Y\:88,Q#CACHZNM"F Y!($S@#X0Q#=&&,!\Z
M]/<#7BS@AY6=E96%A963C>TP.S<G-S<7)Q<7#Z_ $1Y>?EXNKB-"1_B/'A,4
M%.3F$Q81.B8B<$SPV%\B3,P@#@LK!RLKQS$>+IYC_]L7XPN$G_V0 #.2F>D4
MY! _$S,_$Z,3 @7Y9&7ZYX+\Q\5T".3Q,!L[!R<7"%!_!'*(B9GY$ OS7Z[!
MV1!P'L+"SRIP\M*-PT>-[=E.>1]3#$MYSRZE5=TN>&^()*WD\#2<@U-(6$14
M[/09F;/GSBNK7%:]<E5-^Z:.KMXM?0.3^Z9FYA:65HX/G1XYN[BZ^?CZ/?,/
M" R*>!$9%1T3&Y>:]BK]=<:;MYGY!1\*BXI+2C_6U-;5-S0V?6[NP'9V=?=\
M[?TV/#(Z-HZ;F)PB$!<6?_Y:6EY9)?_^L[VSNP?L'_R5BPG"S/2?U_^E7/R@
M7(=86)A9V/[*Q73(_R\ /POKR4N'!6X8L]E['SVE&,9^3"OE?74[AY32/9*@
MP],A3B%I9<)I\E_1_I'L?R98^/\KR?Y+L/\EUQ2$FYD)-!XS/P0&H9GDQYV%
M_&M$$7_/_7@4N/ BZ"L!E<.LW_C02$?;*]CK6<N[W',9XZK<,(/,YZ[%CXX9
MZQSB/)O__/]70^O).??O,)<M43=)7L VF)8HWE?I5M-3:*$'Q2O=]D[?XSQ.
M/Y95\WDVK ,.C2M^4=PZ9;5>-;8OAT]98$#JO#:\O-^[W0,,"?O6%0\D,JQ>
MN?Z*@?O&!K*V66QO#$IA'P#\Y!9BL(3N9L^]C._[K;-FVUIW0@0GH,/H9H"9
MHKJ,9]^.\5(X$7^7?'M9[-?NC98^Q]Y;?WXPX]N"-7R"94PL,2D'K0%89NRE
M@SP^^P)5"0G+LL_H"ND1PQKT+%]_/#X,+T87;-Q-;(LJ/M0SF%=HQT'>U+IT
M(D0G.'E]EF)CYY[9JLE'WIRH/Z-I6E34]_,ME![XO8TYZ&)W$'\N?'R, *O3
M6Q\J1-X==AZK"Y :4;=\7&3A>4(\](?>2:C$G2!58[T:WYV(?;'*BU^\;X86
M=%X):.^[-19>&[$\Y='B/SZGUV)L9TQ1"OBUUP/E7$>8ROLE7M8;V5+'MSY,
M6)#!BU295\:@G7Q^W\:RFLAWC768 N^F0G*:JV2:00N4S/_?FN9<S:WJD_X/
MXM1JCS-IJ7U]GQ)Q;E'PZN'G$CJ">65 A.$/H9G5H,2B;'GI(QV>11:MO7PW
M;3L?4GA=9G@X9?-(#$@GE!NHM1[?#A&V&ZDW,K^9;C^Z7B%OIO]XMC8R_<:W
MM/KF ZC!\KFZ\?ECQK<5W\UF&-<Y?5[9^<"\7!G<CCK2JD06AW]&DQK:BH'P
M@2E"Q:.\.TV6J5?-MZ0$9;@5KU1&91E=NPBR^I+UF/'U?PWSXWC^?$2\_KS7
M)TSVU(TQ]/0OGB:!_>#+"U7(7YE&ZVR..H(VJY?#&K+>^#N+_#GL<XOKV#V_
MPG>'XLZ"8W"TGJ:DFSO 1=,=[G;O52]SV3QC,>5/7ST4ZK@N"\/F'5%7(=+,
MK4:4-8+A8_420O9>I5:3,Q=2+;_ZO/A'HB;-Z.&<G$JV&SJ"@X UD2\*Z>7S
MT1I V8WLO-UNB7 /D4CL^#8^G%0R#TUO2Q0*#OMAK'/L^=ERFFRGF%TS3MMH
MU$.%V?U<^+S5]YI 1=X2BO[47$_FCX('G.?K9XE3?6X)'$I]/WE;)<KG\M;'
M,B%G\_,I-M!6VC:JA<* 7-P/1;]BDCO6G:L2_UWQ;++HG(7CGY+%ML9X3TI,
MVI.O,_,/[[)LW_>&'U]K/B>DLZ/+<O\5Q%C'W+ ^>-_CB;^>@ %<0^03 S)I
M!+'(CXMS+_&H_M5_W'*E[?G@TG6!(=/%43F'^M<KF_;6+J]:TX29CC"EZB]#
MBERMVI):[ 5WLP*]2BP-.)*(XZ:IJNWMV',G?I\]-/N?MA'D: U[]#N!'.N3
M&-F]]:T(U/=Y=L_7[K$$YL,7#@4N22DS:1R[+X"WUOHIW12G*F&:S7S]Z)#E
M06.,<MOA7B\5#=T1>-TC=IGF',>$ZF752\PRPU52Y3'EY:(6#R]>9;G+7)(?
M!^H#'"6)HZ>,^3,OG5N.C-KZ]M>XX;OKEM9O+828TI\HS3[?V"E=_H_86WD0
M6>YIO&EOSL9J=9W]'=<QL] RHH2"EJ'_:+VLD<9?U\:9E#OH:0CZ\Z<&,UD=
M ]7U=YP\<4C_B\0RD\M'[+TZ:28_)IE/+U&)EO_A1_\V\C^_L;;N.R?^PL5:
MLDFTU*VRF $Y,8TY(#(@!QSO^)):3S,@K!!R7N<U<1J\ U:+B5/7+["<ZW?
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MFZ6.'R_G\/P*(P1C@#<ZC4]GV"5,4V[M;!D'X'>3@&BRXX)Y%%J,>CX3WZZ
M(DQ0]?U+ PKN//H<=96+)6;Z-:N-Q^+1;O<B0'MA%+@VOTVB16,9D+B#&0?G
MIM0]6YW6SZEZ5QUL"S<#ORQ('^#$R;4Z8/#N'A1P#3W3!/B1G3O0%T8<+EJO
MT<5,:UOY):LS+*\>SQNHL1O,02/6?NCQD^FPF"= U:Y3/-'W0 ,?:T\>':(5
MZ\R<S#SR3NIEZ-KQXV$C<4M+ +Z**C^,<6= C@)F/;I#.QM'.YM][]II.ZC>
MD70]\K8FU"?<>X0E;31S8QL3B>89JAL\9#F-5 7JL!UJHYFT5MRE'N4,\Z>.
MP;?MM%]Z9\M?[5W5+QP/%05,;(;0YU9JJ=> \D_(FZ-R.Q+&J<,SRO>T?H[J
M_'G"X9C]J_G8RN29.K ZKMKG3L7MA@&SI#(B6[MX,G3U@"T&J426W\3?\;AF
M5'W1T/["G%7WG+TCYNW]W!SV[2H-$FY#)82D^@4CJ:Z=#_CHVCZ#@PG>?D)$
MCOIFRE*4?&%)YMFAW#>+VVMV/0ME/%Q$%CR7TZBF&!4>BY9$6"-6'+C.LF5)
M'U8,M_G\E3:\)++J+C!"P(6A"$) !&$63H!V5K@;DBN+INJW_5\_V0R?3]76
M^C9?Q+%057PB\\U >MORP32.&J$]7'=.$X94;1CW\XJ1O$*R>T\HV;;TG+Y[
MV<N=EN<K?)8SW+^;SVP^MZ/U&J%G(Y',!P=&2 NWQM0M[1>VN( !_X:CTX#;
MFD'289$IDJ%B9$[@ZH?MI9(RM#APB< C5Z]4 <@L."?0)PO1"1&=JC 7H89$
M!N3"@J3+%Q&1 >\P(] M.GB8;^*07*4S <X+CVH9$/;;,;[7C'0\%L.'3]_-
M%[RNU_>\0./).^=#J;M6?V2IJ<ML/@P(RRH#\K)J@Y4!<:3AZ/$&E/-H ^!2
MV4H><Z6Z_>5H4A_1%!M08)YFV4IQ2K@@X'R7_?:5#M*5JU6&_SUJI=;X9*7R
MKV;.:4[F+WE10\EY!PL*!N-5+&,8E[7&S\.Q8$O5M#O[\/!(P3X#XB?#O-<6
M3!<L8$!X3OLS(#>+>S" ?#P#DC2NGLH\5?:[4&$3!8HQ_XYM0X"^^JNO;W^P
MES)-STW?<_ZW8@ZAF1P=*G@$:1]/%QSLNHV\FWI.)6+W&K+#N,A^D8I74&JT
MV1;$18<.4&<] .7NY$P5>'*N N!'@8(M#+2SN.D1#@GS*@U01;#&S6HO=6P]
M1E"^*B47\1GGW23WA"L/@@5@'=MZ%@'*'Y*_I#W6*MFQR5[L\CU+[DQ*Z .?
MO10XP6Z0+-R1RPL4D/1T *<JI!20[%WH4GTS,_1=P\7XOD<WGJ]2R*F?61Q9
M)',N#090"*$1"SF&7Z9>A0H _819\_:I!\-U?32!*W)+%AWI%VPN^PM*"UQJ
M5YDHT_8MWZ&:IDE\W8&R5:T'4JR1%TA;V-G@^VE8.R77BAT%;H2=RG?OL-0S
M":JS[5OK[EM3 (H@$Z$N1RKK.1HPCHB&"K6Z+J@F=&1NQ87C;3JB:X32?BXD
MJ?$>EIW%$#Y4,B#+KX ]!H1U"$6>(E11NBO*#,UG].K-;$08D!>Y>YM+ZT]"
M0JEC/V&D87/4M@$RF $)7\8 &\Y=%+W9Q- 5,%.8 >MI[NR_&9#:@J_[/Y=H
M7MHT'I^GM_3:S)?\J<<ZEK!/J$\!*6C"IOP#4GS;EU'Z]X<S#C-*G8&.T^^J
M2D$"_\;&;TRLOQJ\2R$VEXV,+B6-$!^*5;UP<BUW:*@.<WC9B+@H+$UG,;\C
M03F?/?R'&E6G^11X^AC>"8UU)YDA! 9)]P/D*12CG<AL2UIM;YI+=#]DD])V
M.&@IKHKD3_3OQCQ'5%>%A4JY'LR%R3POKXQLI$HE.QA];]AZNCHLNO>D*W8>
MU,X&3!CIZ24:8&W^PTM3"'DC:<2D[O6 <S0\1NU#W/WT,W>:5!;\Z1RD@?>4
M*Q-(X33"8)<*J3^MK.=IPS,&Q$W:P$G48V+5>Z30[_PW@Y%DTZ7B_<BO,!>O
M*51WLW-\O0OU*%E<[Q-]</C$:'2T'%7)_^-,J4OZI.>C2(,.CBLLVU_[[Y&%
M-SS(P=TH3DV!@#RLE7M L!Y9L+QFC2Y=-W1F;+C#H@^"OHFX:":+:]AR>_:9
MA,$&)<?Z)3K?)CEW>W%K?G82C*KUR"^_V%72'?M)5-/AAE3I/;4\JQBDPO %
MY%$"G&<YDZ\'P:U': F4\_!2OO:B[O6MV;U/:8[/9_(,7JU(IV-8IZFTF\9D
MKXW/1)KP%TFFH3JHB M:EJP7NR,>'XB$%[MD".BX<@<LK!MP%]D%WC:OI/>B
M)#5/!8STT*5)_HGK52KQ7-><6D>0UF!(VIA+X?DJP\.EIR8OX3/Q)^[W+G".
MM$07',N++ ",R&;B91HWZEW4]8Z8C@F0JYOMKZ1=2V+S;-VIN@G(5B2']Y:U
MVAT%^HE]L_=N!L</'KW2EO93Y&Y+80?)^\MV:>EZME@X[N?,8R+&'1;5+!,)
M>ZPP"5:,4VXVVA4!R5VR0@4GFQQ2RXV[C[ ,'&8-F4:<0=X=W\;'T95(?+%^
M7E$(@?=HTJ-W4^GAUA8=I=(OF&*9GM[:U].2'4;]NX/^*NV_TO4,49+L5C[-
MC7);M55Z\R<)X]\6"/NWV'3_,<:5J[H$WT@]/RAYZ;1BP9UDV1[4W-\8-R?[
MNWBA?["C$=Q/$4C=B 6>7P5\45%I+AYF/1O<'0OKI(68,*G$V8"J%MA_VR!M
MG NW?FC" B*(/S%8>&P%4<[SVS7Q>/_JY]/G3^6'EV%.$"_A/U>6J^?(G#FH
MS#M9L  54HT7WX61P2(Z=C2/3R_)=VB^@'B=2'@_*T_UVF_%[%ALY$Q4E;=*
MD3,6^#KXDO&<K7QD/LL?K7H@BH2%_B+/Y:_3Z"SI)Z^9O1U;'YZ52>+8KBQ>
M&&@K#OV!9H_OH)\$G,CGASNN+7MUOA:Z^"&+*%W2=U5D*5<6UEU5$+!%5,5N
MB;I!N=%GY OG/Z1<.!G7S73L_8ACX',T7/*%^>V/W1\\SNY1TS$2'4MQ2$M:
M$_HD5;EUM-7Z0\"6-AD3K;SA,@4O<$6+MQAZ206*H^HX]W6OOWOH7+J@L@RM
M$]X0)@>WXT6H^L67:[U(@U\.?)\T9)2OVHE]'GV\(_"U,"&#W\D>*]!Z8 ZM
MH@_8\>#4Y3X&F")/DVMZ.E0;$T/1T,;?K-E'7_<ZW=/7Z!;)=AYOKHJ#\FY7
MQ<U)C]?+Z=T MNR+UW1@=;YRFNLZQ3.1IG>+H!>?7RP(TUF>=044%( 3)L![
MBF/ E@V A3VG\A%EC>3[](;DO#;]*'!>6W?M>YD6!2]%%AK-+G7>C(^"S<NN
M*$S*$I?B0I61TA[P[B#6I6BDGE/(Y:RGC4(FEO$Y89:>I_1-+:1DJSS?1[OM
M+W7G<2%%B1IPG3%?A6B8,!JZIF:6)90B5$BX;'WN9WVBEO33BZ^V.IXK!LX[
M7Q%<A_*@SR9'2;*/M%XJIEX!\DJL)@I.V:Y^JNCO6TPUO#6\^!L^4FAOGM)^
M5N[Z?O)N/2!'0'  18-8/)\?7@@HV(W!^5W9\MV+-TO55UY#*:NG&B5)Q>B*
M7K^RRG=C<'DKVF.K @DKNE'ZO5'LU;.AT]_[AGYR,G\ZR,ZD[L;/2Z;8+]BB
MNH),BWMH?+:XTZY>5<J3A"C]I],-&68S]R6?YW:@WX-E2\]T/YO62!T6#/*7
MWSW>*&BDV&Z\>@K7[.)"Z_X)?72E5Z-7V1Q)3C!IPU0UR0?#8KQIKR>GDR\K
MM(W0',;3 RXW4F[9HK._4.7(BX[?$S8]U-11Y7:P\;T5\_^>5Q867R:[Y;>:
M_UN;].]M4T'J]6#34%TW'(RUD%:NJ5'<;3WK<$GR(V;R7"&M,.]9UXSP-Q;F
M$?%JQ/M_3XJ!_ECK#5F"?V>>1 #.$' FRWN8= MS>(=(]"?P""@F\%U@8^$K
M51G3NI.A<E"9_)TOD7H'+X#8O04\F#M)_Z&:1ZHY!:9=:[K =>+BY,_0P27/
M_8:M 26JQI6N$&^"0B)>*%28/G(7*0?D$'G8[.K&6U4NMSF765J*WZQVH<Y^
MFZ_^EGRN)H1]KP*1>%"90?XUC;WKCN=&GYX^$U&F76X=$M<M.*NL=UY<_BFZ
MJ>LN>503"L22HV\#L>4@S73Y8L=\^+OXTS4OK V]%+(P3_ M_EM9+_5NV J4
MB<4-)Z-Z['/5&9"&O4XX>\!(>]!;<E$:F:TC<[.NV;:K+3JJ<MUCP>SQX?#?
M.ASGCM-&IHMDBX$,RFVD/6FI*_GHU!I=JAHP)+3![EI[R.U4<=O,3B*^W#JD
MVP9/4<J-+GS(@&!A@&G=%N_*4\!Q(:0[FM!_0X5'2C_K:[#[Y7MWQK0"V:[T
M]D(>\*?E((Y33_W0/.5N53XU&$U7'WSOAD-YH$D_VL#X]GBKZ3*WW2/(5S;F
M'T&<94/-(R1;^KPX66GW"Y!(1"6$7B8-AOF]4>:1[0B_XIBN?BFP/.?.LP28
MG&?"*>V73!HWOAY&%]&RZ:?<81)H5M?,G@3UJX&$1,_=<^4[<HJ;<X;.YO>,
MWYI^>5"N:;]3E8D,)/5TY%X@V^1*#:FSD=,(NV7>KH*),VC^EQ;Q35)W8U)9
M,UX>8]H^U!:-Q1]S(.&P+8C#UDA%(.MRAH<]+3MMIJ/&-M#:8/&;TVP3<_M&
M6%+ZX#_[TI>?C._!/$<+ 3P4?<#\_JBZ,%&";WXW)]"S%H@:H,Z(3W\^U'S8
M[/$'MQ[7!>G2'<&#/%=OP;%RI2_MA!3!H6@_J1-TT_TM)Y)41Q3%P-:Y _3N
M5N-WKN9</DZ$?L\_&V)(>8P__ULU7NS, 6[4.'0(=[$[I8>4UQ,K!OE85M0)
M87X';2O@5W#)3VM!X+QKI\_^SXXPDO_G1QCWS;E(2\07^".>7N\S.B1/DKXV
MZ'B?:7Q<?>&SM/WEEH<)/CN"L_=5/$18CQG?^N>KKJQ3%TJ^+CS]=")BQJ3D
M'1]K,^V%)F3.IM];M6.#5[_(1SK)#/XVME?FUZ;[J+H,J:Q]CI64G2L"1ILH
MY389['"9=+-'Q<<+BE$B'FL)E_78KO;[W;_+%H/"\E/9*&?>/]84"O"VQSSX
M\W%JP9OM23O;>:7))[)#U@3G%]/$$V3"CPUX NN;3W1<^Q_T ,<IS:9N_8VY
MYH]GF=_6 ^Z$> 4H(F"*1VP*)C@W=3JQ^^.[_9HOQ;*B2R(BVY7^.K1L39$
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M\N=9+<7+=>XL$$8,@;9G[B3F1?M606:!U!!GLZ&J>]9<)<7LW T#L;*Z4@\
M=L.'_)G;L!@H,])Z87"R2I?TJ(!XS<.P^\!MPK:API_W04MK0\II&C%Y_MEM
M:*5[#]62<A7I"E01MR2!C*[+:/[AS7I,M/#<D9KZX:K33H9OG7C$;VU(&F0+
M6!]_R'W\T7.-!N@4EM =>R8L?\U.5CCW5%MU;:Y)T?)>30?W<J'$MYL=,U<?
M1[XJA22,=PUN:)/0@SUX4I0AL<G<3EBKZY75@$?JXG98Y8M0K;[I/GEQ=5#
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MEC@)]T=Z+T((!Z:N,I^@@7J++K=Y@]SZF]9L[V>HW:)\Q>SU?ARV6Y;:.L6
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M 1%=<VR-(4)LZ:<HEA?[.'2<3^H>+Y%^>7C3A7D,*4<QQ\.)?%RNH4J 1WF
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M@B?#Y\GDFC]X>>'^M-\G)<>=I\NPXOUY% . OE6&:2!V+6HG)2P (4X#O>"
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MX]&;A@+9SF17XF@&^10^IK&J4$5\(#FYQ'Y([I&4Z,3$UX>M$_-7HX]J2H)
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MJ7-J;9!8,'MY]VF$:27>.0JG2;IEIGT5R6@&RVJT^:#'VU<F&F02E_<K>*S
M#EEU;BF=I]\SCMW.=0JAYO20I(&"]E_+J"Q_/<8J5'VV:Z7D$V.UH96[JW3D
M"N(.29I\FP8*0<U!V(CR<RH=+Y\K&K@=;]M-I@]==YZ0,5P^8>AK7)J0]R'H
M.O1>Y%>"[1H#SL*H.9"SK&=GO$&D=8RQ2J]MEO=!%Y,.AF]^<6;RCM2^^^_'
M%P(FLQA]CAU=0U8N)A:.$B41\C@F6*L?-L+%Q7.@7UPX2 G]LS0T_JD[26[F
M%US0.N5[*:4.EPH=K+B%"@T4*>E35,HKBI\5'=7B]JP+OAQWC/Y'T'G=!T>O
M-]=!3@1^&VID'0SD<1!HA3C4X=\F]__H778U+?HD]./)A;4PAU8.'A!WK/0C
M!QJH-* Q;P82V<@%1$22>G)'RO3N0#+$ZM@H6$IDLWECGP8:F+L):^B/!+42
MC-:G@7S-1*RS[+?N+Y+8AK' 8J2-AG1_3\E657\]>[7YM]!K5>,35[..LICK
MD35)]FH9#NF*YR$L7A3'.WA]0DX)>DSCY,L;Z6S)/U1L&8E&G8^D0/35A9/^
MNPR]OQN%'91%>LA:,MKRIEBNG+(LZ,=1&"5G?N8KOEM!NDE00"S3]?M928N%
M[K5N%TBHLN12 491!W$_;?%:93!5"(?FKQP[00--67^;)"NYQ4K?YHE[B;7O
M9B.N[KX@A 5?PJ=O'#>V&S)-*ZIPNBK4*CEQ3^REB;RZ#_W()_9'4A]^%R)/
M4@?N-:'H$&?RQY>HEP@AZ-U4<=R [+I5N^B0OO=Q\[J/20]OG%2PJM,^MVM:
MCT]NM;C5QL='F!QZSY8BE!.&L8_+:9$Q+3?LE7$M]K[U4<!7Q/[FLB4RCP;Z
MHB1^;;O[Q-@X?'>Q=UOI2KEC;K)*19U9G7?\AW*-&VXN$C_4WM75,E^F6\:&
M\2GV*U\FLMPA.$?VR0'.T>'OLE@T?'+NXO4UM7L6O&[($\K<:GA_G%$(F9V)
MY!!OYRTY*C[7ML#Y,J[>2 2LE;+^%V%@SJ&HT*,0TKE4&NA!F[\-_ ,-]!<C
M_-FM5/?:IAO\7<O57KMJ)F_!9&WAE1]^8<]"^ZF%%\1TN';%D7\U[V!8ZX&J
MRO!.H6/13AE@1:[5!L]6QJBBG!( *;<-ZQGO*:WF"*@J#>N9<*1I.TYZR<;[
M#@QKJ4;[8^J,AY68GD\&C+4#<_8< :EKM5P=M1MF'$!/DSX /.X >N#;^(3^
MP^R :SG\AW\C@*#]ARJF[QVBE!P!R:(#%/JIQ5##M-Y.853M\FUK\[W"U*(=
M-  6G.L.>W$LRBDS:["W\))-F5S]Q'9].X?O[5;?.S_]X@N35Z6'L@ZAZZ/6
MZ]N?Q[/5_?2=^CX!:'@# ,;K4T ;*=4!VVP-G?3$-T>EA]Y#E>P3+P(,Y!_X
M+FLY)Z8>E5O54K)?'WKG-_3\!-\.MU<>BU],[=!S]4$\-GJ'!J)S*%FQY!W"
M;"O=E4ZLZ?_-QP&.C$=E!_C@D=33=03'IA,,4'8UZ[E)\>L7IB1&-XZ2M(+I
MJ<>R2,-M8>CK.T4.Y5>&#/.X(S)WNW'@PWWT7ZW6QRM+?#UF&E2UZ/@*437=
MY07Q^[.-10"6B-A&GK<G3-O59N<4V%YD+!O]4?H)_,AQ/]4YI^'6C'<VP:^[
ME56BN1.A0<GX<50MP[?PU-<5CKBN^@>C%K<L/Z!7U*Y0&.%AU#M.PY3G%B#(
M9F^ XX-&+4H*,#FUWR<KL1([;'&#?5$JE:KN*54';>T+KR[$S06OPDR&NP;"
MRI+%^[<O7LZ(_/$_'D;W?^.J?XC<5SQ) _U]@F0]<3:!D3JB@_QOCESTQY$M
M-,W:*8^X(LK';5=/H[H2$FZ[^OSCT=N+/6LP="FJ=< )AY8\&/U$AA*'ON7?
MJYD;A@V5%-4-UU:]DO%9M>8$OA_0GG$Z=;!< F[#ME<8AQ>]\/CUU^>'^[7Q
M>RV88<UPJCB J1#2^):=ODL0O#  0D>M9FHE)_8?K.851G7E-&)=0BS/!=:*
M 4:?GM.1;V:AATSUH+O)IV@@@.?(M>AK"#.O/4>N7Y\P-:DS52]AF+#U/[\2
M\R,:3\#/'!#=1X )Q_0A6$MZHNUIO:A,7[ODR+?:$!A2U00)VQAND<NETHL
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MHB=2V/V'"L)=::!.B3^;GA&VV=>W,1-0XA/,"]CV0\]I$@E" _%D :B'DPC
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MX9D]/S1R!2ORJVH2L&H!G:!F-.IW9!+)@AC,-O:Y')\3K^BF82=FJOWD]83
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MSH"0-I'-%;H!L4N&"23&K;P8O;?#.958W)<!H+ 'LA#UM6<E&(%F9'H7/-I
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M3BHS+U4F!>L3F%&S=2YGX>FK/U4DW 1DDO7.JD^&.F5RWM"Y#;Z]/,W;R.M
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MX"@-)(!L,AZ>EP]JI(>39@L_*XKBE/2,(V*5^]EK6%D*8T(HCLLT4"@P@WJ
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ME="IWR(UQ@FVE5.*([WM^J5>YJ3(*IG>\7N"I;4=; X6D[%'@Z0T/M+W6HJ
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M&#Y;N'&8,7+^P5^[9W;-V38(0)DL._GG_RB^N]$,KLQK@\1\@^"$B)&9_O*
M% 0^V'P$ML*R0"YLY\];&RM<\M7@-;J.7&IOT#KG<S^Q,=+LN69DDV0SK$JE
M QS)J4.-PI.WP]DI0=.0[..[%_9+;>J@-D_)_9(<;19C+Z' ]%>FZ:QK<.T7
M$+9H)QJ*?P8:!V!:+0[269CJAW(W'QS\?EQP\,!R!,N"]H1$0$[?,F[#OZ5
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MUPP,YW]@SX0XL<=E"0YN\\L=A37M9$=/FJ/C;:%Y1H76I8L/][^[MQP16!+
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M&(+@]JKL'Q"<9!.O/=8Q(IZ%NH\&;SHSFO[M >EBR/SY@J>J70!"\E^F*><
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MZ^Z\O-9N"N#MY?A@#"L==!S310<=B N= 62EA0[:YWQY;/1P;BUH/46QC8;
M\DGZMDA.$APZV'A+O3?=-^NSQX?'["F*/ /Q66@YH9TEUCDDHB51\PS).)X
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MA'TX2@=%\_7=_/%B4=Z#M!_'WC3 .).H$QR6SW[W;[D5Y%!5&% ZV?Q\[_9
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M587<[+BG<)"4W08QFK/X?X;0?[R =Q@$>,'GAMB"0_=#T4@Z"&94/@LFFCD
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M;7M+O[T$GASNVMO:0:86.90$>H^FI&SY:WZ/%$KD4W]][E.#6-J\JXD65_C
MOX>HN#(!;T'8T"!E3!/[FPHXZ#Z;;$4%SYY>1X@F:L*VQOX[Z\ $6(=D2##W
M-2BE$G;-31]P[*\-94@R]L9E098^'8QE_L^W\_T/'J[F$#=2UY<0#L(+OID<
M)^\"PT"X9^Y/*^LU3GO[/K)(_%EA2TE23',IK1&S^YPP1ZK!31U8$P33VMWT
MEA!K-N)K0Y/K\0_2$G[>U<WC60C>E&*,)DJNA7ZAR!**#Y8ZY$ZLH-EFN4UL
M;,5_E]E1"[(;'RF$_5JH&+#T BQO5)M41MNJ7()2[0/BT<_^$Z9ZPA:-D3K,
M"3RBBST"CB4A>4_(BA2=4?6C<YD0K4%E5L8VV0G?L9>STW![VF"JK,P2YVW'
MU,QVJ94_7DQIZ[CNAG+C$AOFH(@@6.(.\@0RRMVRN<*%0Z;]5>_E["!,((,?
M)\-F^60:^6<O*.A1-ODZY?)H"%SE^46*6XY=0+F$U(&I_?FT@)6(LGO4 >\U
M.TQ;]H29-I'[9:DO_'2W"ZX\1,\;UR.E/I9:NIAHQG?$6$7QLN(S-LW464U!
M:K:F<-[S1FY"]5SSA$=ZEA!1S*9R1B-R4W2Q@ZLEHS=&?G%_D[$L J3Y:'Z4
MG8'V'<N)XJ,85I(^1<^(U4:TI[]WQ_&/WY>W<:EY"N]:2'$Z[L7^8S+1V@K)
M,\^X&N>) +/+A0E#PN\2$Y/DXM+.+9_T^1(2GER[WOQ@;;5+?P/P\ENP9=@$
M)3I(T"7],AKP54+[XA[BV_ \5?:*-L/WAX=/5Q)[%ZH*:K=4W"WL*?.4Z:-A
MX7\3^3D/> (L__0$ZO_#$Y (OIAYH6*[2,&GL'^H4,+T_.'IZK%2O</_#>>>
M_,B!W+2NV"XY_Z?"#E+JU_R8YCU E998:G*SVU9.\9YI"M))NM/U%Q!WM_>E
MN)U=;RIDBK-J:RHV0#39_H6R?TD)L89^3_8M'/)5?F1496/TI8DYR_!&8Z9K
MQ?;A%]8'?,LQ2S^0 *:M )[5F"7HT\9,-[<V-$>(WNPN['?F_94Q^?XDM(\.
M#?14^NQA%55/<XTJ R]TZ/FY+EUTN_-1,\CT2>AP!87=GX!9\RSZ^1IA.RR,
M1GQ\,[7ON>^#M"%TK0G.(CE>Z*!5'ZS101<W+)V9J.NI1*74W(\D20?B';R&
MI'Y]DR0I)WX-C-#??^]Y<L'\_@ID.C#OX9X&1'3%2P#V?C#Y2W;5INO&A@W-
MZ=?+U)WJ'(^*"3LM;\;0<6&O[W .<V$98*C$9WO6R&(\3&K>*(?,BN'M7>0[
M34%:GP-DV$,4 (HOPAMEC_?(-/Y8#RMD&R9A!H5XAF4K,_7Q,WMFM6.R%GVL
M&'^.SI>HP& 1Q$@VD9*AV(SS,JL&GRH,DMQ?09_>C<^1[W3$]<:V?D\KLH#+
MB*'<%GTJ3;0"G 9>_D>$_N<;VLC(4ZOX+XKO0V>P5->!XDF&/U$NTNI@CHS6
M!PW]W8J"&NRB4N>$%5A!KNX]'50,TQ\LQIZ*7_Z_:OONN*:6;?\@'!L@!Z2(
ME*@H54"DUX"(B$@3 6F)"DJ)-.D0B(J"U @H*""A@U3I2@O2 B*]UY!$0$H@
MD19(2%XX]]UWWSO'^_N\>S_O]\=LLH?9.Y/9:[[KNV;V6LMM;/^1O1P=H,DW
M?'KP?[_ ^^?RZM5A@V:A'F\@9ZB(,Y*U0<Z[%%I[97;R[/,8[_-]$[_[BS8=
M(ZT33I* ^+C/BN%/DD?KO 5U<Y>.]HABK![PBVT6NUK<WEP.&3OA&0YZN5MD
M[OK^U+JJVX]ZU!=?Y_T3R6UJ=ERGO@^7<*(%;!X<V1WIE#GWV8CX-:%L)_XI
M,#?T83OE$O7>R#F*-;&:XBZPX15XW(!<U"F@-=YC'K6#ZVM.'5\[;^_=BK4%
M+1WO8:8(SE\O#JFW;:.4D</)%V_X_*2.OK^!ZLZG34DH[@ +;EN]".W!5/4@
M.Z#*0XJ*T28DO;HUY]^Q,N:4)>1(L%7=V&W'G%)$I[Q&&5\B+C>LHS7)BQJL
ML)<_S= 9V5__+>>'_S&/K:K'_F<:L3]RP;P9CF\N7#\9OV-DGY7PYJ77Y\0+
M#?DTZ]IYBPN5:>GGO,E6NGJN18K]70,F'[J,\F<NJ3S391"5XMVJU-$E*,,^
M?Y*R[ER"CWX==,KP&+^OQE>\[O I06MC^-SA2AD-U4(EK_QI8,[#QF=12W%.
M*ONOO0VEGS<-:<C@6U*ZA16ZL_N<8QVGR?+V[BEZV+TKT!^%4A7\,W?<?B.G
M)79)F!!0S;M^Z\WIY^#U61!@#KNU/%6=I.JN(*3-,.X/,ZC3'BZ*$,$U%CX\
MAO,R"2\P"4(0M33A$<(28@B.92#Y! 9K"FJ%\"!WDZN!!V'?RRJ<2\9X<'S4
M>@3.V_ Y\2<=D)Q Y8@6(WOAWDY>F@4.<]>[F;I-+:B(,2.TX9*1M%,!GQ@F
M?NT'^)P\_$5(1 D</1L[1 .II\&[^:4LJ^SL(R$_ET&187.K\HQ[55 Y7D*P
M'M%]U&X;)(U9F6SA3[; GZ0#+O<>L*P>&L^.(D\67O @E(,9]2:0!?N #I#-
M)0/9;:@"I-+,QQ_1V'KR!&(V759:?R3U4./)5DB%<;[?+2-_R_!V]5;G)NB^
MLB#3WMBP@I622'3E\:*D!---*W@L'2"2S?[%VDW"V_(Q,M$/\@(EWZLA1P$%
M2+50A!10!-87=$#23L]"32C2)_10X^'105;QYY9$-(M#UK5,_25S,XC8RW:<
MW*V%,F6QA;60)('?PK^@DSF,] +//_M/MX<P.D#XE7>Z%K4ZW]H3WMD3.$33
MF%OOPR17/Q;*^W]L_*V,:M$!JZ.Q?SM;^N.L_W#LKSR6FL[0 :]L?4&-T9EH
M:I7-8/%!>I1.Z3IX2?2'/RK^33215.T^ZBA^F6(\L!YUN-I/2XT4\:+:9+(5
MWYN?7_(M*?T(L0KID."HH?&$2@GF?<CB5/%T!6(> ,1N/R6N7(NXV:\P?E$:
M?^IBE'(GO($P@ABMI'$&< $CF@Y7#%D &EY7SZQ&K!MXG9W]COS0O'VH7NWK
M[[4-.TX33KO?25'\?KQVGVRDDN1L;TSU[#SV#R+ 30MW1GDG<W-J:I-(]E,W
M<AW#?4[$<9CJS(U$29GCS;W\3<QQF$G@MD<JUFT:SJDE].[129-7=G;6S29[
M6B=N1M+0!4MA2Y#;5%E2,8@S%.BL=3X"X,I;)%7P(X$C28\J>(DJE5-?';XW
M"H6^'+TCJBL8_['S@0@+L*!,E?P;]E@#$U;3JM7]^.127<^D->/!:JWA;N^?
M+[ZM*I;WC5(<ZGMQ72Q6 [I0=L7@FDF@>8*_T9970BSR89 ]MYDM\.B_Q3K_
MQX9=F6L9#\-D//YWD_&/>#P6W&;63W[E5G:P&_:FY)#[IGL:.)@.Z)/0!)6X
MCAI_KB6DR/@Y$1K< 6F[ES?[X/F-T#_%RWR%('_PX/"HT%G9WX4?'RHN4#K(
M0AR\HQP2QS;'/HY1!I/I@!5*_^&27\LOFVM*LO&'E8-EGQD0<'(R76E1;A'@
MM+:3P2[Y"\25AVG+YRFI[J_:>Q^HO\&J(OFV.[2O;E/:&_<I<YRT\A"H\;\.
MXQO 27.\4&TSY%FH!"F' L9UC.?&L-,!TFO?U<_$G-CU8] '\'O(J= QY#&-
M0(HYS)<(:HW5K(8?@VGUGTULLXF(RJJ<X4[N?E$;=7G<RE<ZS>E);^"D.!.R
M7*R]++).'Z&(> $14 ST]>"S6ZJAB0R6KG&+*' 5;-R=8WH['A,W(5(=N-B.
MFE)'PQFLP%WVY*2K=& )]=S'J@K[6[TJK>S2#TU_^SKGM.[+,A>V600YA7H@
M&PTZ3#6:6X^9Y$-0S4GY[<(\P_?U^]V+Q_H^#7V_+R,2DWG^N_!;E=Y@JQPR
M$&N<B2N;TL7-5N* QR"@IS #;*K4[53S"L?:SU_924*MZVQS9:;ZU0!7V'5R
M;3$45(WX8G2D55@R'70XH*QU[_UT5HN>G!WV]]9+*AJEJU$FX]EXCJCU!EV2
M.E:VK1%L;X46/C8"OKZ^MEV<G/(HW^>RYV'M+?2,3QD7V8HB M,A'Z-XDB4G
M1ZIE.6'"@X0M_BJI1=US2Q*>&8W%98C7$<SNQJ<>7S)D&J5A@$>;+OR G(3)
MDZ!S3?&!A>14LZ$U#:E2F_&V0?>:-QQOU LWGE^H0&?>^<$T$#J Y(1=Q52!
MVM=9[>R6:1S$%]G.3;Q$LM'HF+]7Q>Y.,6":(M=\A(5/2%LQ@GAZ$0?J"#FI
M0S)^2@%/S9*SUK^F4UI/+O&BG)Z7FY\_=$[WP37LJP:D<?5F<FM?N%K?ZA1%
M:CS XXL-B_!%TK7D_.((H_I/MK[#,FGA2)_G=[FLB29'#C6ID[%S;L';$4/X
M@08@16H%?D+K@H'OR;(8&1LI =M#I6P)K"])"S','9>#GAC_!@B-)[=>:V28
M0+YNLL8CB_T>Z]*.S]AO33!WN:[F'+,P8?GPG7D)DJ8E@\3Y/:68!OAC.2+H
M )<9?XN1 7S=6-Y(1G7ULT$NGM$+RX[OADNY_>Y!,H*&9R6)'BW^;N?:86YX
M(?6;L>=J4[!NU[(?%Q0:JF*5?[?=+'L!<F8%"82.[/D(GQY"/0QQ^@+62-^;
MA2+X5X1OF]X)?%2?$S?O^6!7FUDH0E=;N(RDC :>;%(-'3Z-^@**F%6$1]C(
M/E<(#M%M$Q:IJ3",GHJ.' &+.YSP+*H>3I"CVA&9OI*A.$14NAAIK TQ4=L.
MYRIUTW#(GK"%!HDAJNJ/#BX'<RC)G>OBW%5^1BH-CO"X^:[!80[Y$E,I2Y H
M8-R@+VP+&*4E0+(,<\HEAQD/3 M=F5V;5(A3Q<=^]I4ZO4G;6!2T,J#(4B^3
MRJ)"0>1U_"*B05TV3%:Q1TV:XRIQJRUS37K5(GYF$<TTD17-.GRO40^@3CN&
MQV-.!6":9S7#.D+%&TENM$A<48^HT!6R>'Q69,T);H!\#'ZVZ6/9&]1=$" @
ML5GM2/NI!H-,C/-C"'G,K+':\,=I$0V.LQ+G%@OC^\=&%/Z&FF![$N\0_N;L
M6>DY3?-FOQ2^UZAZ$F]JL&;?.ZJ^C_+1^J"[;CV/Z8 )AEF^OG^DZ2!Z5.)M
M.N![W<"5Y1WMX!Z>KYA6O#=QI[NBOI\/#7'2V7Y'<'*3[^N<A66>27RH?->C
MS]@H,&(;3E"G W36GZ/(YT= NS()L7L9F@M1&Q[AEAB^C%$91)NFX1?E.K,P
MWB7L>ZV?LUY*V.ZJH<Y<I;4Y@'<<%(3V@PM=("EV!\A;DH.A6!Q?9S1X<#VO
M_HCS3"/NTU6-Q5-F'>+SHV/:03T\<WB3_7SOWD9B,G";99@.V)5I5&[K)\]0
MV2*Q4RB.5KRLI/30LE]E5_X[E8WKL>>ME9"ISICX#F_=V+H,M3JI+ZA*AJAB
M]CA@!R&K1!FDK,MW&G:IEEST6\\.]:*][I>QFGF^U;"6;66_M9+$^F_R/6=$
M3G7(&;5\W=$.8N?!TRY5D"EBD;*I+77HUN 0 &KO?%#'FP)#GP^(7>>!Z<+$
MM$TS:\XEQI#.;F'*8*(2\?7ND1\6A3%+/N*00N:9'Z7F:"(9Y\%VK>EH/7$_
M_V5#&T8&!=78?G')_TG\=40:'JA<Z@UVV$=2C.F _F"L+.V8H@G-,"?;-_A@
M5+&AIVRIAL^DZ #RG5H:=^/KBGT$C3-8*O5N]OM9)Z3".TVY&/]2PS8_2)7Z
MREZ8L]I8J[B/KGJJ^):TB%G"_+V^SO..=1:R,8X%S)J_"=9-S@5K\F!K+(%5
M!0U/9J&HXRE#WR J.EG+5ZZ\VZU)]--6Z;TLU=]TH16_M!GM1=S>:/6SR4C>
M6<=!#:-?W@SXD<7O<'<"?3X^;EAE8O+'B98HHL<J'3#I3PO#'(,3#0KA/^V#
M0*WB6F>^Y-DC7OHWG6X<OIF]2L"F&D8'/ _XKI)B?>S1#@N;N6=%8[_0&Q[L
MV#:P*K/IDY+-8DMNY89 EVTLWZW++'W=GZ(_'NN0?VH)TW2@7!5MS%>J+X')
MI>KQ<::.;Q)$S.+F,Z:57[Y;>Z=+Z&4])!\3IB^6PCPIU0MIMHG?SQ A)=VG
M=4$XA"[%8AHV8/O[FG*S93"3,-S5[5$0L;2L0>J!)W_3*,SD@;=GS"<!6#E+
M^2OOM$7-HKZ_2HL/7DC6YTC#@%URZP^8+T=X'D1PANRWWG;8ZF<N<:N8:'.4
MJ'38P-%?^OW$V?*8N\<W7'P8XP'M@4N!R<8BTWX1 [Z7O:9 2R&NM]T)/D?J
MS<":6 %9Q  YX4N#63%,Z5,_"W(I?NFT<2;/D"C'7DW"_&M!?&'*CR:Q*>JM
M=%L@V<HFXOG%[.,8J+!X>=VGBP%3\[LG]9^.J?8</$S_3:LPN!-M"+4I3#Z(
MJV9D3@<DK PUB''$B1 -\R/7J"!0]+9A38CH:$ QL_?\0]7S+I=49C8V>N7^
M/D%Z&8+GB >3#>,F!A1!-,.2]4,35-_HMM$2O#0$.]\7\<2C2B_3Q9\X@WQ-
M&/\Y7<>1RO\U7=ZH9<94N%HO$-TVY1%=N5P3@5W(G2N25M"-?D[20@9ZR25[
MS;/)=QPBH%E.IFW8>?P9-%ZP%LTPK2M82>3IXE^0@T2&W:E:--6?@@+1MM9C
M-S<J_( 2.9<?=4S'[HJIG&M 4T#;[^F C)T6")7+%4E--KBV;RJ\H1?HT5IO
M$NM)CK5%!^4_*=T$2E0"(WRFQF4:^K#J>9]\I\9$W%TPG&Y:"CTX]EGF$8TC
M+IF[AA04ITMMY?0NLLU?US.Z=BAFH+ND],G:5MZY=?U6!^6WFH'[PVF>^BO(
M?*\BB-KR))P@OUTB]6V,=C*<8M55>W685/\UL6S/#,^_N;>MU1[(%\O1^CUN
M=$7'1' _GMG.R$W=!>G2/'OUOHY8\OMQ@8VA\_UX]PQ?[E\]JU*R"Y04SNZ*
M;3KK&GJD85#CV5E$JYKO?&-SJN>7ARF!W'DSTTQI^!1W7JLZYL$?96*D>21:
M F;H.<LZTB0\2885[LI!)^TWQ^[B%Z9)=N<XT_#'54J#&>.5_M_'Z\J+D;4G
M.RE2R20%L *<Y1%Q:S2,(T:C (W\,&4DBESP6@!*,\!SGY =JL\OVE#_B_'6
MWDGY]AQ)-O XO*;5Q80&89(QP'Q<L!<=P";=)/4E$!9Z;EF+O;%*KFR"KV6;
MSV^M+/%3IU.*]C6Y&":[Y*A'-$T#$NL=C^,KH!-NFPYLH ?1=P8]YC_=V3&(
M71=J^?!H,0-M?,0[V=:>:8TQ4J4,L73G'VOBPFO@K_X-^-490#KKP7:.?&Z]
M=3O]W,9)GZ8SU>G!1F_5FZ_GZ/=Z(5*%O%,$'^T<.!_^8J2;R/8>)"668136
M 4,VWNU"K(*(T=;VMK\!E=\M[&X8U(-$9SYU"*AVMOX!3C,\.-JY\OU,C%V3
M&ZL-V8$WYH&#<TH<HJ"Q!8U\?;W+I]!6Z#H@V,)0BF/R-EC;?0OS0MIE03;M
M[(#OI7GY#3?1U2=>:8[FWS>T@]_SH*F&$>BA)24\=FLQ?'5+3G8=V3::S/?[
M6]+ U<L=7RJG$Z1Z?H$]K]W+_L >CU;QT#,Z.0>(FGZZ<81MMP;.-FEGVWQV
M4L4WQ?I4$V'ZV6&Y=D^;W C"F<DW T.^?2\B\]\)K*[X9KL:B2- XH]KM7G1
M=@ )\1F& @AQNB.GEI<C_XH-YHWNWJ(]:TC6+=_/YK/YJ-912VPR.F\<3KKH
M$Z(GYNS/CE."9F5N+[(\8^K0*8W&L0"YQ.I?P=10Q.HWS:]"BLE97Q>P_'[4
M)DC\>4?!155ILBG>"9JA*?HKO>#?V@GSX@B?@?G[8RF-\)Z0A "_T0#IJP$"
M3-8Y?C-IW]?0-X\+/JK5]O6Q>F%W)W3H,,[\<#TQ\^XLK%PT^D,2:_IEO7$6
M7%6#Q .*-AJGJ=E@6$Q51.IPA04*)^8L<\XHA+2Y7>@6]_"[I?GA9V"&9MR!
M;VSD-H9'[%,%Z$0UQY$);9ZF40V3>[Z>WR9V894L T_DQE1+!?XL['^?+$G$
M&"U%Q!=;#3/?C.D E",*-2B=']7J9_*&\IF!HX=G," -/,_"$09%>>Q5!KN
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M24OH->0U;K/KWS@-Y8YG.";VF^K8;)C7?$P?Y9\_)CV<;B<UD\I/NU)B]2P
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M!U9NSN=F/_< OYF19;S,Q=+H .SEDXBBH>_5\&"E@JPHCI2_;M?KT@%G:N:
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M"*6'TXZ3<IES@3.3G!V*F0S8%QMI1[]S]YX1GY%N NF?2/J $O[5&C?^."Z
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M];1KE[W)7./C,/+[=?F1?%M0L[[B=?^I#Z>9G8P84^;S_:L1']?DS>K>[I"
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M/J#U."%DEQNZ>A\TCLN%OY55B! 049F\5\[)$<S>,P[-F#R/Z([D.?ZOPF+
M"":D^S)T*.\X5>9Y*U$U W/ *A#3UA'%*=6(H'Z):'UEY>_\,-+JTEP\Z:(1
MP1](1RT?)"UUUZ%KK- '422C%X0ET[BCRK<KH@VJP\Y/:PY%N=9&RQJFD/>N
M?6 =02XXV %=1)Z0,1O KI;$C-?O\$1XY/R=_^3YDZC2^/2O]_7 Q*D[C/%?
M H=8?&V1C5O]Z\EGH 87[+3$,)(*N$#$<$=]'.@.["Z@SN):I4MZ7,HNK>7R
M@PG1B##I3#HU*(X$"^I(&Q!O0<\S<A-MGT,"5!R0Q( 97;E;YC*L%Y>W6]3
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MQ[@BT?L^G?Z,U'=T*XC-]@99ZE>W*OF;L R>=A#.3-+':9/CEKIS764VIU4
MV[T4D&\;9;5CHD *$QN=>HV$172ED)5=P%^)_5*D -^#LJ1423=9SQ)DA,UQ
M/M1-^=T6K'YX>(+]"22H PC_"(R1N5FB E\>+NQRV'8J2A?3:VC$45',1!?>
MO+2!X"*"7<.V$K0DB7>60V VY-YNVX6?X7!YZ*\W:WRBPT1=414LF!7\ I[
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MB[]"#:(AS_!@% RK@EX' 2V#V UC@0$%9Z>"ZV;->XI;V9=S,S+I=+JTIN\
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M46QK"=41GZO H_._@XK],#0>;(IGB$%$S*/B8NAZ^^17>:=_U7GZY1CWO[T
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MN59+-NE* 4L->O/*QJ@7LA0]8']-70D*[NT4 OK1::EV3'AGE/N"S&8CAK=
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M1)SN]#7=%:[/)K02BET>ZH&>TE+VW.(+ #D=O@PIF8%</ANJ&ZNJC_XAJ_;
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MIH/YUJ'3$4.KHATXA:3VG33:S=7K\T3M<B!5DM'==R2 QFY2AX+A6J7RR).
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M,.6HDVWE&!Q6;7-;E5/ @MPCQUS0FU%K+"QF<#<% UG<(:B=EQ"?8\\]%FR
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M<\-G)CTNM:SY("%4-_H( =SRZ4+L6GB)P_1%\JKE*RES7Y\O_+@ 3:UJVRF
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MLBC).G>KESFB+6\F$G(6WV=EX$JR'!Y1-X!@")P_81-HP*D0;'%4#8Q=)TC
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M\Y; 3=Q)G$_N0$A@$9.V>TC0B)%47W_03P;UDP551EZ ^4P56O?HO$65#%O
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M%^:@;>TD41>@/CNA</7 25><?%YY?X3YB9%O]LDWU<L  +T3WQ=Z%Z$&>%9
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M+&9\PD4H4JE7#9^(T%]4=*,&?+H!+\R4VXP0]VI(\=K7'I+Q99$#G]6O,@W
M]\OY/#!DMZ\S2"^9/8C2-W.N+M>I./)AN'%IA?T5 :!7.5QLL8G:Y%"T7OU1
M^_:*V&@Z>< "YJR/_Y) L J7 YX;.18REA8=O8?5HET=-:83?<\PY!S]WO*B
MG^NK=CH*"K&=FGRLPBA6<Y&>QB>O=7HM1DG'7:K<WH\.ZHTR?*_"<#+P]@9?
MD'EC='$<A?LL4M1RS*8(HZS4 $:,GMRV+DMT$:F6EE]*.?[XKB2NZ2@.6KQJ
MMU42-II\KRYW"]6Y?'=4U%/XN=<')WZ3!RH?]-75!"(\'AHAL\>V&9_US\1-
M"))1\EJ>G/B2N6^ TX!GMO>:&8-F\1R#'C!J!S"=1[%?IZHWO'=.SR4X+U91
MV$7?3;:=C8+O)6T_K22<?OOX4] @N K2Q2'&- >FI;\[X>)LVMD#$7QT=R)>
MB%4)D?5](SAQDT)U.4;%74N#^\#)Q2EAKXH (-T0?I[(2B^4(/S$-(?=-3\Y
M(KXRI[?WJ2S'G'/VQ(=3]0+'"^S2'QI&Q8J+G"A(TG\\C9;?.! _DU/>7#U:
M;%5761NQ.:WZ+IF5+DI9E9,=.XLN5?F$=$0-(@5"E=06Y[27+L3#9\ "VHBT
MZI)ZM\]D;TYF/KQ\%G;MYMLNX?[1#K_2[1#$\1)EFU@TGJ\FK,4O(QC/NNG5
MJ3XL36O* ;?R.,-R.:'7.GJ9U[K O'V'HC)4X4'AMT\Y.X%^GM/C)[-+'<^;
M1*Z1;C&UYSR(-5@-*)#:V2V%I/7T$P"4PE.2ZY!ILZ7T+,2#Q8QP)?L<4],%
M\,:KV0[R12LFWR3Q6]Y.EQ"\ L&CU&6(L*75O!@\!UK6;+S4HT_2;*(274(
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MO;[7*C>P<N;+$4L/.023GF4K/2NZ;N!QI78M1F<Z?=P9[YAWDN;:4EFJO)L
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M1]E6#,EQD%!Z_JAX5$@BJJ<C6$Z01./B8PG7J!7KTW%@4L:TL)-_,89RS/'
MS4UQSU$9*OF+2HZ?L2B]!ZH(B]E6X5EOIAWSN+CM*:K7_3HL>FA)K]Y8D[:L
M.I\W>FI=_%NQRS03ZMEX$*5#X17?Z:30'SZ+-6/6C)\2;6YV*'WI")6ID>MB
M3KP6G&I?4-AM[OL.437*I]<R?6W@&[)I![=\,O2+Q:-)F#4L4M('@K$,X/)$
M60&3+TO>ND:]C/=)6LA >>VB2OR_+IQI=$<*W&D>#9#_V%TP8_*H.!MN$\W%
M)W?B)4FQ_+R[$]#-^WA,Q(@KCT_/Q.4S'[PP-W-Q%S64ROT[2?QP"]M0I,V
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M[07+'1WGWO7>6W>]^\_[XZR5WSXY^WS[V]_>YY>U<O;1)?7V2>_^\9MWO)E
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M#L&FADVB3V6E9A!]=:LR\35R.)HF)9++AC)-#&A14R(M3NVHRWB9Q!%-4^-
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M&5\PQ"!J->R9 %3;[C6"M !Z@"#/93$!_"<TI?L($[CG0Q/%;CRYA,!=8QG
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M'5H71[@-U47JFV4D6>&Q840,X8,T/.4L44_1I'MT4>NQ:-B%--=52VN,9.N
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M+=LM7%^AO9[^8I7S8H=LWZCZ1'Y.?5]VWHTGIY-F_!D/N]X%[4V,20F)"6I
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MXW5[5I'A/O^^"F^,D.8'BW>) +O2)IT+EX7C7YF=:8RM%=A9/Z,P/#[S1L
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MT6\*OSYM-2BR.AY\-1^GW7>J,&UOR%C8IC[FV9:C_S;T*W$ZEO(SF#DTA##
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M),!%4A#*]-X?HK5ERH?TC=M2D#I>,<@0S5Y#CKBX*RWEM#P10?#FQ\LKS2J
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MD9]XJ0WFU(HU441]P&D6M;3+NC[-F&IE:&%<HJ(Z[]WX?= <I.J,5\4M8&X
M*-8T$=Q,;P!'N%T[[_[8[@QV =;I^2KB42H3DWN8? :><P:",N?XS,&D5B+8
M@7*$='MQG$E>+4/FI#HR-\X6SALO__E?,U]HK>U@YJ^G5ZB)^SQJKKZ!.>)
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M*@R618ZN(LZK0&,X43\P&T>1(XB1^VSWSHX.SLVLS[@;YQR:.]D_(NM<-$.
MWJ3H2O @EO?Z/HO7ZE'4 Y#PJUMV*,>%:07QS?1(ZI3*#IXM-*@&:M&99/YQ
M5$[S\XX1B:-Q68 X"2>>6]^ME']6@ M\J4L'.D)>?!L_46 VSZU3V6?PF1CD
MH9S]J4W_Z.%?86TH0('LFJ[Z"P3%$]D#P<1LYV*2$$YG)/60_>W@Z;19SG[3
M3T?4J\F_6+U!%;EWP?=Q'S$K5FW3^&>KUE2@C\9P_;KEG0 [R>.6%&AK\@M
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MY<2-C].E&&3;JV>]PA2]0%= K>[RA-PFO'N)@:VAURMKJI+X##[5S@Z6;)X
M*_]PD@QH3X2@K@@''#T^I U#KP>>C9M&16E^R_]+QO=L\2U!W#H@*%$5C%R]
M?74+UMB<RM42&TQJ4:9]*<CH+U)V,GW&NR!-Q,R*&SYXW]_T:\.:P:>A4%+.
M'RM77SN<]A+G91=,TM#*D:^TS 6E#$)=3+FA/ G',JQ*PUQ.WW^(T'DW&S1K
MR(\2=_ROA219N)'5PN)$L'\>*-(8R]XJF?W3$E&R ++G_NR#]J<\XD-A&;),
MM1P\,NOX"JI9+R3\)5LOM7'\W3< ^M,.@CWFN "WZ7@4:HU_X3*:L(N<95:T
MT=-0R3O S4:)=:-ZWWB545Z")TSA3SVDJ!]5/D(F[\<@8C>_N)39F,)/D\S7
M'U\A#2 OE9^.4ZQU^,*#L5CFF*JG<.BAL03E+"!G6MKSQ7F.CZ\9HE,+YFAZ
M'Q20DKY5O5I60K!-C5H'CZ_</YD:9][KFR?G+R]OSS'#0L93'8[)U*]0FQL$
MK#248F%F ;J]-P# 7KMD$R8B=VU):*_G[$C>>\=KD4J&G5!^@_]J?9&434EF
M1XD5F;X_G.=H???PF@D4:#Z-E_EIN6@YK# 5:ZXP&?U1 *I#*MJ)W7]BP/A/
MZJYAU^]A#U#^:F0DW  3/(*"0:U-<-[C+&0@BHK!K8)/WLI<G('E1$,DI(^@
M8J-9,2N8<6NR#A0-\"E0=BPR$KCL4U/&DB2XO*UF=YQZ(?*4C-R!L\AYX[QO
M))+9U8H!NM<[ST6-^T&CP[1\"FA7XRL;RSHNS*9ES\Q6U[\+>-]_*0GZ8,VJ
M&!-_5GF5M\R7B-Q\+&YEO/!01Q:D[>]_#,]O95KJR)[]Y^SQI:-N.1KST612
M6#S(U@(.^\X=,?AJ4L@V4$>(28BK&<KOHS&Y.LC)-L[$""AC?(JTQQM?50+9
MP,\P6S&G9/&?)HPFP>*#;->)]K*9)5EPI_JO5Q.72'FT//I'U58ONWSCJ#QW
M\5Z#7X;QG(>'P.,(M$&+"X@K87/M:>_,6V_+--VE*H #7T$)5P@5 Z[CDA@D
MAS9&6IKW!<S$@;UL LMVDK<;,]P3RY3='"1"#P2=E4+Z-^2$MJS%H'UYJ\Z[
M'#4,B-B]1-K:>/WI!0M,G!5IPL R:)I-6#LQ*:VC=;'"FK)7#?RKGY&+PVST
MFAMGWM/./PT6*W1I,(MHRW_G3"]Y[!'XW@N!#E%#)6?%Q:$EAO$JN(4\T(>)
M7C.U[Y4[,T"I41A+MNTEVTI@+PU],GE9P3O69PM)K[(2*!V)^FUO/:<_6"'E
M%I"Q\F202ERZ<6[/]+2D7SM7!SQ!1_51K>/\.$EB&J=&_O%75]+?NYI=#-=/
M@KMR2'%UKK%K-X"'H$;+9EVRXG#HX>;94H$&<L"B?CR% (F OZ.7L>QX^J)7
M@1AU?BN&R?9:_$).VCQZ,A32$^":/TUW;54UNS4.Q-F=2+Y "18>&_)R<=K*
M:59%+*"E/A^)7YK/RAL4:;GXTGT=U4@)V^1>/_!P'I#-E7SK.#/U-6&2 -7Q
M$+*: R3$U:$5S'MD5V+D'5B<+X)SBYTE)<V^ZIE;J3K:BD0;]\LU,B;]VLFJ
M#9?F[/'1G3WO5:2%./5BU:/EB8-6.2BJH]%8RB8>K+CQ?'#5F0VT2]#M":#$
M;6%QB')TJ+216W?A.=@'%_BQ&)=V(<SD..* *A2N>"TT80^-\!784O3S\192
MOYO\U;N ,O#L$V[H!L#B*O^Q5-VK>'G'S#I&")8M=/2:V.XLFIPRH:=F\"&_
M71PE,=&]$!'\PTMN1W8B7$<U[N]KK'%,]YXL;/Z@+Q("4PFP:4N5E*^(BCF.
M"YI,GJ/-"O_-Z'= ?,F%<SF+Q2J&UQ_8]ECQ8,X*40LNEUJ:<!EP6I7^X6/:
MY@_Q47+JKG8TC,_7ZGY>58(%_; =AJ-N8(,\"Q"_*F9XNKC<V4NKN>+H<7O,
M4O*BY&B(AK?D*2L[2?6;Z6 1'"=BWJJZ9->*=Z)B_R1>R<EX?/ YNPY*)>4W
M9VF*7=2"VNO_CLR!HDTBP<Y9 '=]3N6:G#1,]]XB3OCUL?N[>]-D<5<_L8I>
MR,7/WYB 6[PDTE7&O1P8'>N(94%Z:MXHO'W>_#SH]4I7$1N+?@RUPE?1Z(]"
M-F[[^\V>:KV\<B\VV[;6(GMUJ?#".)DJ\*N6)ATMQ+S[-U_I]=I4"ZO';]Y3
M S_E/J^]*].U*(-4+@8'X2"0$IRY-I!__. T\:$I,JAPI\ZB;,2+-L9,M S2
M5A]Z P"5VTJ+$YBO-7:V2:U!N@<]"!=<6HY"*P3FIRJ.P,*?!-TKV_^\[2G9
M, >X6<W]4R-!>EJQ746TLX.<1[HD,99[,]:8.%PTW)1KIK%4ON5/F;'SDK6<
MFIGZZ_)?>7=R*%SQIE<_3VX 81W,\,=YH$RC<7$.$N<6^L(22V?F6%K?IE 7
ME6C#\W?/3#<$[N>V4"K=:XFW1GM$X+E+<06XS!X@Q[AX$-/^^X>9QP[&S?IZ
M'^+R2"S0[XR"$%P'O4^)1H#,UXC@_U;AR$*8E<M 86:I$N9+'CICI^8]4(06
MO+4SQ]'VK;Y%"*U8W0- GZ+$>Y,;0)<,\*%97U&?G$M W*?V9^G(&3)_+S**
MEP<X:HOWU"UW!MWB/UV=][OUR;6,' 2B!%G6MB+V#^6-4=M UCT@0^M4WDQ!
M)IG@HC'&G(^KM6&_![J54)H50N&7RP[D<LXE/_$@M=S1,QODJ5Q;8GF99<GY
MG/[<+QGQS.(Y(OPC+"O$*RG@#3$+ENKL.<:C9^$H>B:CO7Y-O!D71I_M5G:+
M:$*)MOKO^FG3/=W@IL424:*F1OF88\7YS#.U&+065B"'$2/9@:6#^Y4Y'54I
MVZR1*8ANO6JLB77+,/UN2_*$<7Y@(5&N+HGD(N ONAIQH/AF9M]=WJ9 U2]/
M?7,WJ7[@$*:T&S>R7[%=>34^P'(G)J7'F@5\%\7OIH8VQ7Y(+^HJ7KD!?+!4
M0';J4<Q >44XSKX(<''B# 0\"<0)-F\ -7Z=;,:KB@@VK6N::-61>+A>N87+
M_&*N<V =:VT2#8="O].G)R4"FH,,,C+]OKG[EJNQ3^7M75MRVL^L.,?J+0GY
MC9LB!\?V3YER GOJKJ9?^%N#1+][U2MUQ['%*B9^FO= <L08L7-.PBKYNX(?
MCIWHO&(S4IN[ 7#DNE!:O42:/+SS@C!$\SWPO6J ?6Z<C]8-X#YO-&I*L /%
MX6(0=%7(%2IM!&B-BQL.*:.ET>Q]_E&)VAHD.W #Z&QDIX6:]F9+9LR;OZIH
M]XQ";D I15J)JT1RELH1)]6SMET7ZB&G5)2J:]7T@Q_]@(G/9S9;8"XX!BW^
M,Y+\&X#:\4O5NA]1:8O(:%[QHSA(?7MX/HZAFWDDY%9^MZF"5==B(504^AA-
M7Q='2C,_$-KG_<!GS\+TJ_<YZM:>V/0$<:K(#!87(/?4@;C.,_N8>_"V)'4:
M> (U;<U.VCOBZ1#Y\__V:3&$RS]C"-=I.ZSV\\O;.\_A<=E;^)(6]/IZ=QG$
MD[;38%.;3M%]!U!F^SF,"K$R9]S50<[2R?DR]VW$2I=PA62J&]?8M[-=_>\?
MU F?O_HAG7CG 6#1XJ\EZPT 1H4(M"9VRN'/[&T1![).%D+)=%YI%9H4@@9)
M ;Q%(X+G6X?[[V>[*@,[8H*I:Z:YQZODE6WI\^DVJG+.AI\N-S+PF2W+0P)4
M[Y0<W@78@=_A^ OP]O68BUWFG,J?5MMF49/[OFST/C%K,O*ECWT'\^,36:L*
M;.77'RA)_ 9IG6EB1CY[X+G]?N#">CY1Y8'<Y)\]J>PA;RD,97"$;C/ZV_FS
MA:EO9-40\WE9TLT<R&!^#JK!IXIQG_/ZBDV7R)@.*=8.$E:_*_I %@B?D5K]
M>%/3N9G' <L-[4/NW>J\]F(/MN'TR(<]X[MNGJ%C;K&2P>!5 D::M#]+%;?<
MG([EW;=>[: !D77E/'2S[9&DMV(:+< ,6,PM=J<S1Z3SJ:28+=9\":TEX1Q4
M*^D,JT_G:8U="96U*L3J(I:EFJ=.G>PP![!1)V:A;?K>_L+(?J@*V8.O=6HB
M$<E)OO<I*71^W)+NQS4W*=U)\0ZF[?,TJ>-%\P5=MO%]_W=1PZ)V)W913"32
M<L'N65.@:VF<O9!O_,N]'BN.!DQV0IA]-87FT<! PU]8IPZ?Z%T3$[5V\TCN
M/UC8.W= #29S=2.RVW9-+JJ^TKPGH"/*8T9OLM[2*4]LY F"]:ED%ZU>B<G:
MBVY"?R[H1XM<O*C'%S^SW ,VCROVOST,_9<X_R#;H<LWBBW;[;;^0;WWUDZW
M)\ :&&1C2&)\T?3!$\PW&,.6D=\"("3NWY><,+KAC@-N3(,BI7)U+ONV]6R=
MM5:1.EB8MN=<[X??%^JI[E*W-HU>L>0D2I_@ 7:F,#-,6KY#%2Y6][IK_&28
MW=Q%JPFJ8+:@FSX,,^]8<N?F&N1XEK_(E%I;[.8&]KC*.1%.0*@$&1M.P^2&
MN:Q4*38CO5CU80QO&(5L/$2E6-C%0I7([X=6D)2"=2_5\?*846Q\*ZA8NVU:
M_IF-Q'5AP<(2OX5*<H@)W<@;4]H;@$_+8:\J;X2BXPH %XE@OS>UB:6+@%X_
MAT5L:=>V-1FF*3]6G3NED47FA/]^H_GH :6[\!Q9%]8EF&FZHUYB:QHNXE9H
MZI@19J&\N8,Q*>=-97_2NQ .5<U]=$3UN<[9K2_VC!G#&L 0<_*Q#!>CHV@Q
MP3WV+KKJW0T@6C4NW>W3V5EN,TK[C[GHO_B0_T';6P7%U47?@TUP=Y=.@KM#
MT$:"!PD$"-HA0' (WK@%".[N!-?@[A8@!'=MW.E&&Q^^F?I5S?P?IF:F:A[V
MTSU]S[EGG[WV6K=K[UN&1X)U<O8,L 2C(Y15OR.Z!NCH)E_7S>Y-G42ZC]'S
MAL^QKC+B1-1^J27CK8(VF:RH$(C2PX-ZP,MKM).Z_7>VK=4_[>2NDVQ(H&OG
M*Y$5PY$/D?PAXC0T%B1(&="SP&LZ4CA:9;F5YVF3Y5U3& -<XK%6G3S!F7]Q
MR/*+R<YV-QG+"I>[@X:[Z4X%?@RPCCST92V<LHJM<PUG!);K7WYW316$RC:'
MD';4MY_+]1-3OG%;ZD6AC,SK,<FV6;#,Q2>&"Q^G0(&$ZI6&?:5'Z9RG>156
M^MOD^K:P\H-Y?9]6@^6,[W">Y9VA$#WD/6>7+4((^K4";+R/%MR3GA+J+;MI
MP-Z%NVAH%;QTB FJ/]YMM:E#7=M7VZ@3([6\EL1$C5;UBB)!VLY!]?OFA^.-
MVA(-Q@$?[N#%V/U:Z7$74*5=:'+G65$F$_Q[6"O@E6+)6D\J]BF<ZN;X%]3'
M;POKX7V"'ARU\G:VPG71I=PF-?C'_%SCN!W)ORA"[UONW_X;M+D;=#9+);GX
MV&V/L0]<_Y5G J%&H'XZADF#WDJ/QXS*!</NIB/:J9$FWCH!3DI=O52SU^9+
MP8KF8\QASP#3=0Q(RE"Z13A:W:8$GXKPY+<$M=KVF..F6BLM2MML1P:U8UWG
MO+ZHD2&$O\EIO09Z#L)B8S4TU)<5$31T<:3?V51UV!A1_/80'Q R.&GN$=S.
M3J*H'!H7;<XGQ"-L6LWN<<^"^'JV1?7PWLBAG^PF2#^BGUD^9!=XO-NIPE1[
M$4X1L9/W!0-/1$.>K_M>FP1I0]_OV!2*C8\"B>D%P6(AV3[(.HTAO6M3!G^4
M#X3BC"1&>JQ17J->T-9.A0$MM5>#*?9MN[ZI8RU"EO")'ZNUT\^Y":WIF.[%
MI_J_>$6, FM4J;E3$@@BDBC_G:H0#GCND"!=_ N])T  96%5Y;E1%OWNC?-A
M!<NR$JLSN()1R1D0KN/CC;<$XH4)KU-PCBNDO?WE]\+\S,'XD)1N7P:8,R2B
M7T<4/TQP=-7A<^"<@>T:=2E.@@$9A*)"+ 95Z \/+Z/7RV-L9[]]3'O@WK33
M[4\/'KNN)&F]KOMED\**,XFJ=-F'OSC+3_F&^H_J1KR: 2ID -?K^B.LLPL>
M[/M6J0(1./=P."=ZW*K=\%>FU^;(P*(QW$+^9Z=WRH+4=[R)[_B")Y\TT$,.
MP;7<(5SMM'F6.I*OX4QADA$EAZW!R77%+^Z>?(F!8;$UV98\L_,%P]:8!*=@
M&6JG4\G&-=+I E@<;":V?DGVA1I:"&BV.$W<^NKIF,8K&6.*I\_G^XL#>\$U
M,?[BI% 0Z3Z567J9]*8#E@%$YNY@[^?X]6>['7_ET-'NM+FO1C_9](BQ #U-
MI;[#OB1=3;/ME6"CWS/<#@)1\KCR:Y;B1]B50B@A2Y^198:S2B_"2&>;A $T
M^'8O4S3]E_:K0]JYJZRH2CIFKPRR0'WN=.3T6BUZP;/M%T/B4Q_<T*STM@ZQ
M2G"Z6;:('X@1A(4/N--<'"YC[L;SKVV\#*@=*U>&N!>.3^+BUY;>T%B^>EN'
M^Y=R&<0OA";!]7\4[?YG[#LQ2^"-XLBGUY"8S8ZY@%\^G;C.4!N(L[I?@RPP
MIX2Z/$P\4RRPB^.G>R-Y3D>LS:$G"_)FUY+NAG _B BQZ='."46==^D ]ZX!
M)]-=NAK]K6H7;&3.-88YPO7TF<3<+'8_T#AF/0-0']#@R1GP8I6Y*UHD^3!@
MU(->N:&R?>X7VS,[(C$+-IJ:"TK%Y:C1F%0DL/ZD%!#Y2!\8W4F)((;ZIOE!
M)33V[T #8B2PT!!7L7N1!L7+[6E[Y65Q^,@$;;Q'.:8'?XTI7A\EA>;3GRZ2
MXTXJB)941%_<RMIA)V9$G_ NK<R* O0^H)+S-E[FGWC_Y\44'DP\Q">D0 K?
M !MCJJEV!:8,IM+BY?7.#+>F:U5'"E.'[V4CM46>/+J.<8M15A/HP\:<",(M
M596-H1/J?'U+%::Z%S5//EQF"8LH(5DSH#@F-:SQ9N91.6_1.K_<MICOLO)#
M/O(C\*6UNC,.,+^^WV]7RCO$)T^/V\3V45ORR.'J]JX9/(G<W@(0257KOKB<
M'PH.:M>&<L<\ P@*ZR>KZ\$A2[59<@F:;8UI7((AL9A<'',B5(K0>-XTLB]=
M[8"RC0:G+L*7#5H[VMSKUWL!M?LC/SQ$=6]3\MW*?%-CT;C6C%RZK"ECF4?(
MYR)DGC]FGR(++)T4T3JS\OTER2= WZI_WKG'M-.3= (',QC/@ES+QTQ/YG8E
M! Z$\%%GRXO3=OG;@C%,=608G3Z;ID"HKV7@:\'WTOM+8\>.SX!>8O--'^D1
MGR+^*"9TX:5WF%TB*J,928-\I"2Q[YA/K5F0+^KZP#4W_5[  %]QV.I0:'4Q
M7)R.MF[2]E10U6W-TC6D:6;MN+",G1 ')T"1/]'NHODU4O/CQWMNB'K_$_7T
M$ST84=Q7#?7*(82,W!@V3.^T!F[*-:93?P]>(G?!3_S>3?Q'0A[SNO5EIA3Y
MQ\0G3B,$?G\V>0O,5M]VS@__R@%7#SQ<NE3O6;AU!+3]F:N'_5:)\H_5*VA$
M"':/_5;_^BM?!DB&;"M<_>'MTEJ:CR-<TH%<.,3EQ'B05ML6K&@D;I<S)K2I
M<=3ED"H_:)*UHKOR BO^-CGH5\T@DRAU:'9201DBJAU;*,*NH/#P3[G+G"I5
M=]V?3SQX;J%?T=#44#URHOPLQH'60,H3+MMZ4/U^:\--D*#(59['JZ*$QQB!
M<6?L/#_>=*D1@L&*@C9[-C3U11<-]+_ AIB>' IO53CNXWBH@&.I-',?F,02
M8W>7HL[/C5.N_G/<S,/3IQSA54/O?C.+\4Z6!W9X:*BX#7<X7I3#]RY8,H3K
M0O5WAG9]8X*.EXK5U^PU9(ZR3NNZ'>V1TP6WW<Z-"@<R!+\4_#I,*&K3CE@-
MCA?'SZYD4J9?^!?OTXZ2 HH9G?00FC](K)T0)C8$)'Z!P0R#+GQ+3"_:_[[F
M2(3P!*3$OLV2\;%C#$?E.NI1S Q]S3PZC!( MO2=I$.=%W>%GJ$86+J![7-4
MX45!Y4;<Z7&W;HWSDRKB:6Z $SG3>O-H'B1QW:+]5J8L: ?3M,J4+6=]!]\_
MP9"ED1'2$ I39"1"$D 9NA0:VPG 6Q7V#+A6AJ.>1?N^/O#EGA(DSC_4>6*K
M#S5NF84F3UFZVO0G"S8VR)C)+R8GCI#C$]FN8-*C@Q]3.YE7'Y@1[B6'Z9)Y
M%9#1DZ7KO,U*9NDYSDKF>!]YS+<QQ".;_%1L?=C0" _S\!!ZTIL.$J1S6=]_
M2PV530/8N+J]2]FE>>L(K5[];VED 64&A<<I^H[-''/G8V]1XS&I,$EWEBA*
M[E?"S]H_PNXW@0.@A:'/,/=PLX:(39TZJ-6Q?1JM#E.;92J+VX=<#K=0UB24
MQI4J]K473A4E#H*!-LDJ2PT@R3>],;E*?G"0(IQFB69^KE;)Q-2FL+"@3DR!
M77Z@(#+VY]]EY4R+UUXQ)[P;1@Z;Y/Z71L+2-4\3;4UPM="24<(D^F4'AY(>
M@;.4+W@+D\O("9$ I5<=UN$ !/DF^G$'G/HC;"Y^$N*@-?->=#Z::$]^RK7<
M0,2B<;8J[80Q7M>G4Y8MX&V@V:=4*":JS>_9)P#D='XK.-)-DL8F!T>U"F*@
M9^?CL,&C+U>XI(0S\2=ZTRTN8W1!1TB3)GXTD/VX["4=$-Y+/LC"YGL=@J>6
M(=(-40Y]GN/AA5VPJXZK?!4._=09TT 3^I$:&NR?>@$^/;3-'$*S42K76O"=
M^8 K(!:;E+E?H) Q9HS6O;('GW5L?5O^H/L/$7!F%<^J$T9UPPMW"_!VO>?S
M_H#HVL"G/."#B"[WD4ORPS]0_5'5OUXS^25K42@+6+_VB-YK32;[\7/T*Z5A
M#3JVD>X@?L ZH2]3SY;/U_$>QX,4T>)@;\9K.S2#>XT8]^)#9V,CJ_ND$9PW
MG_ <*3F:;9%CZEER\;/];*/DSW0??SXQK:U;Z5(QOC#;HG@CH5/%[>3%\$!3
MM[ T;+P?Y3R73.U'/5W(WGXEWEI3WB9E"'%+'6=OC58XQYU9REQM0U+L1%2B
M<^,P5IWX80&;_1=*)61TH"$DI4]?-[*>^H38</KDRNCM$SWJ;-**R68Z_ZR>
M.@I0>3H7_R>GW[=GP,]?F^@_MWR01Z<Y<H;(YSQ[.IM8RVDM^^=^O\44[S=C
MZ_E;%H[%-=4--QCHJGT&1#?8V4 #,J1G&G!%Q(FA9WC6;HVBJQV%G3GNYIXI
M1,/NR:L<)DKFY\@)#%AXI$VZJR0:Z(/S+RSC+(9+DF/]B#T7;9H1WO2SP25S
MS>#"QA7:7%&YO;QKL=NLH]J\PAO_ZD+_Z15"=>OLU6%.W<J=0BAW_8F-,BPY
M!;I.N:[D9WEG\[G'=OG$+%+9W.9G%=Y^0;"R[[74OT^;G;7Y_GS>K&76HO.A
M'-P-/F1@O$.M?CH?+J^?>U[?GJ#Q?!\[RQ0KK?^/&MK_>[.*0XF@-,?K_FUX
M+C6H!B*\#7?]OY2/.(,)$_R"7 &@@YRG2'WXJV\A=GU6=#\NC+?@^$_O3V2;
M[KH>*1HV(T.TLII-UOSI,8F!_";R HNO_FQ8I'N2X<D"_*@8-4ZR,AS7_"E,
M,=?1IQ+0'W/^944]=E%%3?AA"@!.VJ+Q0%CR*VH8&^Z%4B1FF512VBNXB[1J
M+$AMI-$B(.F/?Z3IG3+#:]A_9=7$I!19 ^EI+Z1P8R__#)ZRB@<1WO(8.J&*
M?\FJ<#Q3W-$@1:D9^BB%\4<:5P1K"*%48A80QI!5?J 9C_.:L/D9T#"71$JI
M)O6@[T^?\E6&@%7DB5LY\).9>N*.A+5\/(\R^0?@=0M)6:3""')Q T":A;"_
MK:!'()<EACV,_T MEB/<*)9K76LN'P.9/>C\#@L03]1E17\:R,KU5N\?V2<*
M\1#C>L0L_5<G)?NUQ.&3OL=S;?4;RU=5>45ZJ@(?;&.;GP1-QSX'+O+>_TH&
M>O+WD+P?P?@\\ZBNGZV+R>)\4Q-YDXM1&&F*G;H\,8./[2^-%%I3;B8/=C9+
M./KP"><'#E)VOC];850G?TU2C#=<NRK?/:QR LC9?$M!K$\DVRJ$VF0ZEW?^
M4(^CK07L9T$FZE-^&LWZ=?\EG56$5Y%'%UX%W*)Y(HWI7BJ#)#\MS7^P7/X;
MK=1OOT5+D'UU4*OO<2A4%LI\QG/(/O3"YJ/(^W4ED6>(>_6YLBJ."".'<%?3
MU9R/*P< WLOW3"J6:Z]G,C;"P99:9^R<>^%;Y#KQW/=B@)Z[^551&6NW5K<7
MUK6J;PPN^9OP66:4TO[^TWRO7QW)G7#P@ZG+.GE#,<P]3/_#X@&/HMUDC-W$
MT/F3Z\U PXJPXP!GQW RF8:.# ^%VP#@4\,<9P.E/LMFVHP?25P2J?/83ZYU
MG@T7C0ZV;['#21=\$FRO3&6#!@!R'' B<MR<0FG&8T?)H=8 AF/_AUGQGO;9
M+:=HZ_9DF"$HU8[^ AU.NG>1BTW8.ASX*?FJM$#A^RLZ+QP=N<$*#K[S ;;^
M=YPQB3ZLIO%#_;$46S9!^'"*U"H_*L#LN;GL_83N#)7>E$2XS.F#-3:U8OV^
M]\_SW]<7#'S">YIB%(BORFZ<P1^O!)"(RD[LNKA+!%'O:WXG,[KYVX'$_1X]
M&QA&F; HOIF?1DT?'&F?0D-.9\*R"D KZBD7N3C<>"($&',']DJVY%_Y0&S[
M5&2-K^UU.%=T[$(7+G<P=SA_C[L>Z<<KT00K_W90K0?\0S9I%B0)VANY*LV2
MA?KWT$H7$5%)H5/F8ICK.(;2??-A?1NN+AYWX]@M*!XYP;. [+496"DJS$ D
M\BX7A<6LA\+0=;C,Z>%<A ;_C"[I&X;^^#;Z7QS1]&(/>Y$X-ZA?Z+M<'*_B
MJ(B2G?OTZ#EZB14YDM@.-;:_;=IZU[E<O#UC>E-],H<J2-D+N;BILX0S@5)#
M(D4?)AF(1?.DHUN.-!G\?]F][H3\V2R!!%3M3-F33;"TT"-B2)"&(-^FE*[N
M#^8_1'$%W'*3Q 6<XI,VD,5@K4N,]0?:-#X#DLMXY'1@R06;BY4.V^=[:H5#
MZ ?A^QG?(SQ+X]1E?H4#?G%8!GTE\L%C2[?3VR*J3V/>_8G?@9C=C0K,%-&P
MFIOK%::T-3/CW6/R%R>^CFZ8$1?Q*X:T#JOEURC6/ /,_LKDTK4=';\P"W ;
MG#OT*N.HY'7C!=&\&8_01J9*7/;5>4R,BX3,,V#@R*/:*.Q23#U5#_56_;ZO
MPR?XGJ6PW$KT[_5;E/HDNW %^P!MQ]T)=-?*9\"P#\SA,4)T[RG)2G"?=.]N
M_2%E'>T9L%!7Y7>@DV <\+^WH_P?HUGOUR5$"&M\%4;:@3\#[,C:C?:T*#9.
M).2\=/N9%J'8Y_)^LU?/@*H(8XXI/A[-(!OW7 SQU,D@KF.@?OR1O18?C2>2
M>K)F= D!SQ5)#"L>6K<$7(J0J.*=-[#PE>"IDV^2<.;BX"PH6,K<+8$">9\%
M8$F*V X/88A>:=0.DVP04Q[IHQ?8_0YT0/-_PU+ZSRWA'Z^,:&2RR'B#I)*:
MAY15X$;,K1E(%* Z7!_H1^7?*Y15&>.9K(23>NOVR/HAMPA+ P7G< &IYJHX
M@&R-9V\MSWRE>[-0WN3AW0T)4I07RCSY*Q"G#O^#;*5Q8Y.!R_ED)OX9<7I#
MVYN80AXQ6_,E/*]=_[<.K 15CT\%$[U"45*/+$8!WK5\7G%J5MZA&J3*.?J
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M,FP;K!_S-Y4&\(NN'BFAT&JTT.K %D7Q8/ZX1(?_$CU=MZU5V(2JW\ @X!D
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M[1YJ8@JT3#KW-S'?6.RS(.>^4?;__-9U!5U_[\'\K;ZE\VB;D]LRU[1![<H
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M8%N%J<F'Y5I638'S9[N4YF$H'3 >OXJ5M*+AI=F]*_^Y '7%9TY@U_+IN\>
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M+:J2,D1*G] ^<B=C^@37.G8S^8OF1 #KT(+@SX -XZP-_#!R]'ZJK,I(WF=
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MGXP*Y7%U@J9--B:<A">T;E*0U:#K3B#2+XFSZ8>XJD0@9;W=^W=/^#6*Q<\
MZ5R<_<)TRJ8A[!=.+#I;]WV>4-RQ*27;_[HR XQM$]?+GV\M<GG_W[SL$"VP
M^3=1QO/L;OTN4"' ^?J[H0Q&NL_1XXIV8!Y,>8\VV+('VD70EN2'?X@%ZKC6
M _56< <+_G7./T1^6@6_K)1RCQ[ITRL).:GR,,H55UHO7>EG $9R??&35&O
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MV%ACN8<-:E^%V@E._,X,#7'+IE:.<K;S@:,X=EAOKZNUCF'-]=C^=<%Q]C/
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MS+? T/OY83#?!5^QE_R6SB1)NR3D0>=V!AH)LKBKSBAZ!E@?/ -LNX@@7OU
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MB+H'4S3D@LK@?VH^YN0WV7FO7.*M.1=?R<Q4&S_#(SKZ&WN"-(P#X[0Q"+2
M0ZGS+"MB98=L,P@>W@IGJ35G>[[D<J5BU,KXTDIUN@F'$'N:!;=Y*72IWKXW
M[K5R0Z\DWD >K8+B\S74'9,KTU,1EQ"U@"/Y6N^?,3D=^\)EPZ6CC.@CBWN\
MZMF@L5G1O9H17"U^"1/0#F$@W%S1NZ'5[6.LE^_<QOAY:O^M*XW M(298:UZ
M]1SW>P=A"]'JYRR:RQ8))D3.U)7U5_L@!N?CC$/EN$B8*8H'W$FD;,4*)D =
MQ-B2>I=F&559C^RO<2A07+(,VQ>S3E '>[EDL:N*Y\/,1H.X;>S[20!-4-5#
MB2)W!Y[6V/.UC\,2YNF*9:BY(OK966;-N^P_*22C()%@#J(DS!P;%X'"5N!2
ME?%4VEA:!2B49^U+WD[FXT@:4TONSB5)CH6H'_C!$W6".F:I+XY9,*'J(I@6
MKVB!24F5#.]Y)R-8P5LF*]#5+RJ2;$MV$YPR0':[44$?"+R-M(^R8\<BHE3O
M(=%,QLIA)<BTE;K)!/$"BXJ?7O-\C#74"^UKR1Q1JT][-?V;C_)PDJ,>^PM.
M*]W309?;)G.34!)YC',+MY]&<I4_2WG'OF(FAAS5YB]FD/B>7^T!P1=@YU :
MX6B>BHUFK;>(&IAL#GZEHXW5G>[E;RCK+MT=+?&)&-'>QY=N;W%9 *4S7)_:
MR='^HBMSX%CBC=K3$E4XYGB]QXPS+')Y2.VDYZK2\AO;32,=CXO6&Y44#R[7
M0RUG[Z@YB,YMJ[;!"B ND+?I0AU+K"YL:G*<A0UPS-(=[/:'XOI4EZP?LHMV
MK8RSN6(!CR.NQ;0]>+*\%O< -!JU7I<%_F4'_O-[9TFX_X-IU5L-AH5S?A*+
MO@T:?FT/"LQ=FK/>1Z]'3W]-W^G-BO2_] $51RT4LRTA_Q#KJHLQS8H2&B\G
M3D,=_.AJA^^XTK_Z".MGT-,,P@QK4Y; A+#3D6I78':G60=@ELT5VRGQ SCO
M1N^1>UZP#DMK"'N;]H1PY]78M /^/77P"[^2GT<!T]]ZT6GKO(W[1=-]2RS#
M34C$'%M/&]\X3,_/72(+$X8CSHYOX888Y7QH&61&6:_QG[/340F3_;Q6Z6!S
MUFZ[#+9#R!_:1^Q<:EB!T+JT24[4>>;]@!5.ZS8TQ@[Q2;]CX! 4&XI9IPN[
M&0RH_<I%J!#T3K0)5B3@C98^EJ4HMK#&71'9\!IF\N))NFV21O'BDNW[I]\*
M<L2*?QD.<NCGB]AFTR]I9?'XEFF?5E:J7D>Y!QB-J8J70C>)]./N6^C9+C-?
M]. B__C[;X,ON,BO9GN9<*Y3_<P&93M7#56=)TXCV&"*F(9[6,$&5'&K;4 Q
M3""IUSO2L]!:O3F0X-/Y_<&MR"\7OE8.'!WEN;E3D;=,JBG S+_S3Q)HP'&<
M)];C07R^KEVC^,H5G5J9(<<2*PW5"$RY*X/PF-1Y4P.%$/]$LD.E9-H8=B\9
M88I"/V!?J539/J*VXOEOD_KQ.B[KWS$R*UNIH];?*J<^NUFJ-@$04;<$+JH,
MJ1N_?RZ%$CDG][/F\E!<=OC/]Z:,)<E_N?+[F.&*!06M"VA[E=Z%<%X'AUS_
MV#'PYF(X:BD*S"S1>@,[8$^[:/MUD0.[5I<1EP?%U;@H- O7U*3\FNV[RISN
MQ:@BF<Z=$"]S"R ["$-4;62RC'IXQ3@9U8_5EK&G!Y3-]9L)/XC1M%R8"<Z^
M]+,RKSRB,IJ#_;%,1L@-UPZB/,&@<0S^:(01O]/)R\\Y^<V.23GV(XH&_?"%
M-RS8S.=-+]^@D^=M=B,=+DUI.W&LX@JD1UA-TC=V1 N+[HW+A[:)8+Q#+WW@
M3744>R)N)F"=ZN1[-_2UVOY1, 7]30J [)"'!1-3U.L11;Q<AX&$BK==U2O<
M3,V4/BL)"<*=6=.D$4_*#W3C<RJ:#W>3.T)E[MWG79Y::J^*LV<@2N!'D(3#
M10$%3A685 W6NZS@Q\;4ZJ;BDFLF6W=T:)[.N7.FTM%T+7Y?J69?FJ\O=2W-
M@E:THF ,%7J@M^;WIP^JPL"83_O9<BVFM@K;*GUFU9%W?'WS8TS)4@->-VZ/
MZ ^]P&5C#]_*B3.98WISRG5R\;_[4OW-WA!YJC^E']-)#/<<OH77D3&UIIKM
M24/U'BJ>[QL,!M6V6J)B9-N)+%,PK0J;P#C-T:W""<FG%.Y"R13:CQ-PQ6(S
MID( HV>[O*O69(476G#0I#IUN.;+*XD'25!;;'.820@9!\4S3=>]DY7P'A(0
M253#*^;[PDVFW5NE/0,Q\&XU02R_-[W5@E:I(:T(53S_T22?A_22U*?+GSJ6
M+YR$(\&$Q*SS)&"&=9 $W!$ O-[]O_GONO5J&(!A5K;A?.ZLXK:,O8*%>9[6
MK*Q-PO8@L[(_'Q.Q;]V&AST;N,V*HM4$-X(N3/!]_M+0FFYYE8G\:4071<)"
M.$2D7!!_A#P@/[UHLDY,TR(!?<+G,K^<B!&DL4)A#[Y+PJX+X5YR)O^L8/MQ
M(-HH&/L3G>]::)F7_/BBY,?+SEUN5^K1[8 _.V;X?2;'&47XBYK6C_9DS3!.
M_4AGX.92H+CUAKD3<R%>B_UJ8Q;>/A-, K)N&!)/_^:(!(0>(4G T=X$"=B9
M@!.>!U]I.$T+XOQ!H(>_42!RG4"Z^C1C]GT]*HUJ:A<#R)62AJ\G)>WM*D$D
M65YCJ7 2>$6L5G<S;PO*GO(V/##/HJO0^NJ"(;.X*]/3*(Y'6C371%:IJ&Y<
M4N]YJ;5" L)?]<W404X.SM; 77#F^Q2Y\V^N)7W#EPU?J9JNH*EZFXO"4<U8
MB5!'B:Q"NZ/=[-H04T<O[<G.<Z;O*><:G4*N[73"W]C1XWF6R^QI?,$:;V]B
M3C_WBWDG]/,7!50_>9*HZ?1<9_.; < #D%\D<E)U-?7-'/S#,QA,4(6OC9B0
M ,0]$H = -94 T[H" SXG!6T>6^0"$95&1'AI=D04)8F69EGR4E?QC&36!K+
M0+9"RY:QNNY@?YH8Q.Q;*,G:5XHW1Y>@A@R6S*>ZTV.6CKV^4;S70]DWIBE%
M/(+@7(T(01@,"4C5U_L[WB(09+;J#1*@YI]U>AQ' F*-J$17$#,OEE.[EW@W
MVV2QD%?(R=;;I3=:4\UE[&VOMMPJK?X8>:T8R<P0+67W(BE+"U^-R>HD 5RM
M-,5XQ5XKZ&3KC6(W1=8RU?@48>3WG9CD,([[!^BA!UFSY%WM\+[,(A(0E$<"
M5M[!N]1] XBP?Z"?#2+')YQ0.BO'%F%2VWE!F,*T/!C[F'P:X2;J@\-SM%K.
ML_AW]9IB=Q-74\W$YD677_;X=]M7FW<TJM'K8P; 5'V@-X5?; VT'5H^/N5%
M&[)1KL#3'[/W^KP\\O>TY0OZSLMK5V_UCUTB:JG"/Q!M_NF<UMT<IX;7*X==
M:\![04)-5:4]BF,>*2&_-.IE-="2@ *N>*+K71\IB6$=*AZI:_5-)RP$=BSX
M-4$:Z4H"*.:&<O#/#PYXU&9L#?)M(#(ZHI&*WVR"+;Y:>U.^B-J (.%_MOJ/
M<.<1V0[#$>O_%NYY_#U,4J<].8'!"0FF<-[(P?N/KB9R::3K1$"Y6Y+XRX>[
M/X-;^\B!9T!Y%5/02!N C>N^H=+'B0B?VNFNIR/O>2Y1J+VP_,35)X7%DWF(
M2>4=E"6*:3?!"-Y)Q. \<?^H+Q%0'PD @8Y>_#/'E4>H\1=O841_Q^7,G(;6
M?3&P=3!2>YGH-_T\U)+_: ;]5>/(_()T._<T%RKKQUMD4321;PZ_9XY9FH69
MG!]*WEP4./BF.\WJT3;E%,EOL;"B2NDH!+WV/#_J'?$,<O#N>@D)6"HF ?BU
MBR?JOGZ1).#V/WV+;Y  0)6\X'=*^E!]</7F5'/%=FUJX;9W<F45TV"3TZ/5
MKY4?[O<>J3-*,;O=?7%LOA6.2;V#042JJC@AI7GC4.PY#1/B<T;-S[_?^:F=
M'3-K_+T[VJ+<D^5FTJLA5W <D9><J/H/U+-A< P6C/W7>@"5;L3GK*X1-FBF
MX*=)536GU]W^Y<J+N?T!GLQ5@8R:"39:5[4YV4S#I%1S$3[S:S#PB3),%4.[
MR)EZ$X,97^IZOLFT8=':Z.EV6*2H!;I"UXIS"R7RU($)<J#P^B2<^%W0\=H?
MS_DD(.P59EL6)VX(/AB $*^K\U"VG%5-FP!6,*=JT\I\ULOUE-'PDLU\8*[I
MGMP1=TM7G87P(*-/,-=HV4<L?&L(,]>7R8(I"I='7 JLTL;4-=:.7=7[_=YN
M%G19?=0O\K*/9@2%H_>#9=B/H@8T.7*2XH.^X:NL@[\E5S!QM(W3K,O2Y>WV
MPSCPL4PPXPK.!N_@E:>6+!GF8Z$66>3KF7,2^'TXRT$H#7H)-D]$'RU]'!I-
M"V?YXH-QZO3)8LS&$HYAAVK7ZD-1=4V91)2V>X/6FHK&TS%V!V_#^.;L1S(T
MJU/JI]D$I8$+/S;=0/E_<_S\C&OVX(.9A6K5?Z-V\F]PQZR9E2[PQ39:Z+%]
M%$'6U1,U9-A5ENW[=J@U99NCXO"Z+Y_9\X3>GD&I:.$G K&&\K^.J;9Z,--=
MRBRQ20[(==84_P5$Q$I C.:FWYQ1L' 85##1+%'_%<NM%AFTD?2KJ*S_+"U#
MO#,(Y !QF.@[K?D[OUD[+8M3&6*'BU:X L"2W?[)[SB]%G8^7MD31T)Y^6>L
M'\R.:S]G9FI)?"8][ H&"$P5&VTBU1\,6AO"NX^C-IL_6[A,IR3.VT0DBA,?
M&Y=E2W='W;M0 JQR9TR":T'AAH2F3?CAYEF4==4@>%\2,/@ORB-K*2'P8V*K
M,,V&X8J<8K<[C*%=.LIW&56%Q6]1,%!J7LIS)K_RZK#\BQ8N"'.IHGS)I<$?
M] $>4+R17M>]Y-9H>V@5I-8C2/&>UVYT-YBE>H^RE 1@$*W_3N#&\#,VQF @
M_Y[H?E4]'C^8;F/#HXG<LQO'DJG++;8^ME.M6K3^!=VRJM.X),I$14N*X-K=
M<[=D0BF6R7H"0&^(M'C9]MFIK#)G96Y_=UQ6SDUDF7D45+>GZ-;:2O"51ZVR
M3*TQZZK5Y7%X>R)O;U#?/_V1_SE8_YU=:8B<Q!$XB$COHEQP^(:@G&X[G,<>
M\FA:UJ"ZDV>5_E9-"_7#);Z&9/;[@TSU97;$(?M+DD&<SG; F7KPG<5;WTQ[
M*E?F*OK[ [2\P!:?*!JQ:IF,\+O,KZ;M374Y_1F>!"!1\)41$S#N3W5I$23/
M. X^DO(OW&_WPFO".ZO SG8\HW59-'V":<A395L^@X:ZUL8Z^A_]G+T8)MHH
MVPNYF-7=G.8]VZ+0($Y\0(=5!3$OSU('ZA4 =7*X[EI28$)7*J.>PS-0.>E-
M47S^<PK_GLTT07+GS-F_@HS (&#_^T0M&+6#DH"+AUU+>_\*BB1!<N1L7F'!
MW^>A?I&/%5?)G4F0DW^7(*E$MO5P$O#O9\5^J>BWD;X=T*LDQU+XWVT)G\FU
M7=E_DKPP^=BO*OG_4E)Q_ZFU_GC\_SY,[]^&R9X-.PO&ULK6/],1/$O55?K,
M[4#UV.]_UC\K^HT*384<,SQF+98F 7?_H)8<@:B+>V-OYJX$G9W.^&+]-=R#
M&$-\1X:^;YX"[]+ >UP.##<]$Z,:9YY$#9</>RM *^[A$97[*K:WQFY<M$BZ
MT\3YQCGTI_;#=S5NW@/N'P$AJBN-O[2ILN_9Q$41;@<6X)<Z.-U;HU+2"X8F
M?+3_?$]:H]THE+ GK&IN^[_>-,%+@]W/QCKF.,T10S+@<SJBW\;NJXI(N(ZW
MJ6F">^H?!WL^R@ ?;PCXQ;]=YP?*T.H@:?3==)=*9+JAP(MOT5K9)5'T>8-@
MD6U#.3(V@PNKXZ"!^8FA)G/*'/YURF#.>R\RC$$?"D1L3%+7V'F<R<K;H['Z
M+RE*Z!;S17\&7Q.ZJ[ X07:E<T\W@D>/%]C/OZ#P>L/P4E&HDH<_$+%\."2L
M5.3 \;7CH$=^XA.[TN7OY-71Y%.Q^]FL5!GIRB(43X*9OESA*!)NWXCBJ@!D
MG>4>2'A.)<<]G= $J)B!8$>_ IHW_$;,"+D<=3OG<\R_1^1^SAJ,/0LLZ;E.
M+I3NJVZNHHE$J],Z:M)2HZ/>A$0SRNM %C>,5V83+69Z%9!:8\%7F7HXI+^>
M&YR^.);Q6**IP^9EX6FB[.!C\#V3:VB BDNK C@?"1@O*UH9;ZK$M1N_'E9.
M!V( P8PO^DHA9<-:8Q_JC,+X]WZKT_"Q<.1K,;Y4DOMIU'=YU238)A8X-B*7
MH>(8NE:_F%5!^RH6:D0Q[,?[#NA]I'_]<?O/^ Q>?;Z^[P?95.NJXQ/H?)-V
M>UWO,>E7ZI2&!=>*;Y@EM:F,U@>S(Z3=O+,;%UX9+SO(C=% O)S)$+(^J.1/
MC2/KAO/J$'&IU4Q_HW.4%&/CR3?E"LBR*6/UY3(41.8\Q][Q? E?4:=[RG8U
M+2-67Z\E,R3=H4.(_=B((D#]*3>G >B!806$?1C@6TPW,%17>T?&/."9V376
M>JC5391I3@)6KGZYH.Z_%D>U1L6R/GL_O@/U.]EB\>J+086;V9?6UR2*YLUM
MS^3BR74,HF?I1)@-?GSSH8W;4X[OB=+QHC5_[HR3@*_56!_BP/EU8KR%$54M
M?H>HZ]$%.3YM(P%C(J[?14?^/+DOH(C,.@U:@F\PUPT$C8//2@?N>*IRA_,@
MLZ+2=9:0>#O/69DG)W/S:&6&6U+#B+9Z74C(9X"+PHBJ;M2>O@B=<Z+E4H)#
M2^(TIYGN0F0*<RHB)"P#5YQ9WIVXRR_!R$];7F:]A3!DXSU0.^?PJ4BG;C]4
MHFL@DUW="YZ!J[+54>ZE!BP<-5^S7W4(10''(?_SS"V(&K\_!S-W^HWC)P&C
MB>9I WUSF*J[^'TM@D#];<1,$@G0U+%S(:,@-/'6DG%HSL 2<VT\FS]O&30>
MNN-&G<6U;K/JI4^U/YW)@_(, =+'"7,<Q>H2@=>\C9DG]-K!5@#+)>@7^Z@
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M<O0^Q3?(PFF#60JT'_%G?;[%Q9-C!^$VHO!4_AKU2T>3@R(JP.LKAYR#QV4
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M"#%M/E86QLY.OS+C@.VP.'T=D+>MBV#4+1>O7ZV/[T:Y$7EL->FE,Z)4"O^
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M'IIX_5Q(?>Y3YRX_3PU8SCE<J_6&&"AE FLA;(:PYA20YLMY/+.+['):-+,
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MF!^9_9&3\FGR,0'RQKSHB[\ T/>822<>?GX&3G<1B:I8-$>H%$%?WGJ3035
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M_Y9&0A>:VTA>M"!;UD$R%%^[J),2DAN<O=G&^C&(1,KAIW>]#"R1KIHLK_&
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M47Q==9,XR<*XS)JFUA72>)UV#W3Y1B_,@(,FU5!G<ZY=MWQ4B:W[8QDO"[;
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ME-21S^/$;WG]CAV#VI:N'$XW'GH_0.P+HR:_F2[/%_\XMG23JO%S,VH)^KV
M_5=>T<2G V_'"H6ITCK-*5L2T>Z8,T5'/=5>2SF'>VRT[#1H;OK#V>FUJ!U8
M'L+EE[<[A08!TL.I%>U]^MGE[HO,KMF7Z5,(NA[?DDAKIA$P?SDR9;.FM2+#
M7]KQ37+7/S1')XUVQ2![E)E7;/P'U[83E$R6_0&>W5H,;F8J:#KR3YQP9/ED
M6N=PZAQT>Y+E> L_@6/;D2(D8OS>M]A\!= :-=_P.\,=?BB#J-%6)YP%YTWE
MZB\B:9T= E4#!]LDK5-?&&M[#2048>IL]](5Q\>XH%OXR4T]*&$2&U2M;Z[
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M$?.FZ1T)'X*(GNW5@])$<%O,E'"<$-6'XK<+2M.Q5L@N6\A$&P\,!2XC>6
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M=TB9FSGL>\I#FK <KE_3:LO@>2Y,0X\$VP:9-7++_)?/F8[NS',@4:MQPO*
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MF;9T\O,_C3\8>\EY[AP0U?OM!R[K860QDBW@@U?OFGM=BJ7]+-'+N?N^3OB
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M_J?A[2M%\%VEP?/66!VS*\H#N^>%0 C)X]_M2"".U@CAAC6**-0B(@PJJ!@
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M<6PMOLA999S9R$$AMO"!B3@]LUR7@4&;3K@Z_/<7NJ;W::9;;RUFP<!TSPP
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MZ[\ML*@G'.1CO6OIBVQMGN?+42J3]:4G+HRJ=3D=[7.9T6WN=/TN*VOPWGH
MC2 ??(Z$CL:NQ": NQSM#<,._P!:W+N<O$Q>,3(^2!G[IK-T^"2^D,:*QCSN
M"CH/QI.3>I+DSEO'OC.X\+Z=:7%O:B]GGN%54SC:#P2*W?M#2:6Q9 !M1L(?
MNG%6]3TN&*18VC\P#E<+GRS_ $JH\8$93:'=V"D+T&/ZT0'.4'!)*S1/:NLE
MC;N)-TN,E/:H_L^Z6,D!L'#$]"?K4UK;D6ZG<"IY *_=.?7/-6O($MWB)0T9
M 8CH1ZTNK)6QHVEY%>1-""&D7Y74]2.V*YKQ)X*AF268/M9AC ;'YBMO7K39
M*DMM$4(7)>,5SGB#Q:=/BMTU&!/(D=8T9F^<L3@#I_C6:;OH72YD]&>=W'A#
M4-'O7R9+RU=O,"X^Z,=JL642^(;82.@$<9R(N=P(-=[I?BS3)]2DTN"_MKG4
ML;4B=2H(]-W3/YUIM%$0WFVZ0D_=6->2/7/\ZZ;RB^6:-W7YNIS'AZWPWVCY
MMK_*!TX%=7;M(DBN-NY&!!'7UJQ'9V4297#HIQM'0L?2H;I88VP"VX,>V./2
MLI3]H[G-S-L]9HHHKW#C.+\96.D6VHR:K?N!.+3R%'MEB/U)KC8];31]"#);
M-)#(WEH!W)[FM_QWX3U'6O%L%\N9-.@MHP( <;Y [D_H5KE-9L[F+S+5\I>3
MR_)!U5!VXKTJ48RBE<:;,]-4E^TOY=O&GFC:=O5:T_"OA&[AGOFEG"SR@>29
M&SSZ?E79^%/AI:Z;:))?DW-TP!;'"BH_B1);Z-HA%G"JWY(\M@O3'>JEB+R=
M.'4EKFW.*^/WBA_"/AJQM'G9V9?G)]1T->*?"B'7?%VL[XK>6[0OS*3QMSV-
M=9XMTS7/B5';1ZNP0J-I<+@8'0UZW\&/A[+X.T$O/<;"V1'MX4#/!KN@XX6@
M^:SDR'>4K(U8_",VEK;RQP']VNYG8@D-_A5JS\36MEJK3:C*UN[J(R[(0A;Z
MUT4M]'I<<23R!@V?F)YK \90?V]X*NELE#L>0 .M>+S2G921NM$<9K_B2.T\
M57EQI]Q-+)*F?D/"J!SBNB\.>-G\01P1PEP\,9>1G&02!W->>?"K1M;TG7$C
MUBS"V@E($DO).??N*]3N?!<EJ+B2PD%O&Q+-&G\0]*[:RIQM!_>)2+4GBG2H
M=&%[+(LTCC;M09?=Z8JO;KH^G:/!=RZ: '.2/+^?<:C\&^'K(1W%R]NPG#$;
M9UR ?45U%M8BX*37"#>!\J]A7')J.B8)Z:[F?HOAW2DN/[0M;3RI'S@LN#^5
M,UK1[*"1KDP*A(+/(JYKI ,#BLGQ%?O8:<TD=LUX6(0Q)U.:Q4W*5VPB['F.
MK6^I6$T*Z7 ;V.[D!+'L,YQGTKU73]-@AMH@;6.-]H+ *.#WJAI6E-%HL463
M V_S$!ZIWP:UK1)XX\3R+(WJHQ6E2HYZ!)W9E^(M.-[$8DMU9F7:)CCY,U!I
MG@?3--5&C@'GI@^9WS6M=RLUPD(4E3@EAVIEK:3PW5PTEPTL+XV*3]VHYY)<
MJ9-C#,T6IZZMO=QH#$IRF>_8T6KVFMV=UII<N QV CD =,56\6W2:3>17\>G
M2.\#@-.IPN#Z_G5W09H;VYEN$CV>:,H5' JVO=NC4\2\:^#M<FU6/3])M4N$
M#A)3_$N?>M3P]\%]8@U.S:XU"33V"DJ4;/(]:]?\/V+I?7,D[*TRN02!@G/<
MUJ75Y&;C[-&0UU@LH;M[UU/%U$N2)C**;N>7:C\/AX3M8]1GOI+Z;?F>:3I@
M^U'B#5O#6LV,-E810R7#.K':O)Q6[XB76=2:72YH8FMV3<) > 3T&:RO"_P]
ML-"U2*.8JVHF'<%!XSZ54:GN\TY:KL'+8FTO5?"6E6EQITFHK:2W&-^YMN&]
MJYC5OA'>^+=,O7BU**\1S_HS@XP![U6^)?P1U3QS/<R644=FI7(R<%F'>O0O
MAKX/U#1?!MA9:HQAU"'[YCDR*R]O.G)RC+<TM%QL]SQ6'X2ZAX&N%-[/'+=3
M\Q-NS@#L?RK4^%O@37=)^*6BZI>Q2K;LTY8MTP89 N/Q(KWCQ1X?36]-9%C1
M[J, Q._8BL7P;97*WWFW]^MU(A,<2?=*G!! 'TKH^N2G3:?:QFH([BBBBO)&
M<SX]O!9Z0 3$&FD6-?/4E<G)Z#Z5\U?%#P!X=\21VB7NERR!R\\UR+21X ?7
M?M*C\2*]_P#B_JUEI.@6S7P7RY;J.)&8D;7;=@@]C]:\QO\ 6M+M]*MYHH[V
M5I9VALEM4-S,TG<(HXSWW$C%?%YTHU*OLJB3C:_G?U/I\JK5,/!U*;L[GY]Z
MKX%T?Q1>2)X"\!^*]>GAG='N[6WD:WMRI(.,A0_?[IXQ7J'P'^!U^;]M0T[2
MYM.MWRC7FLQ2;891@LYBPK2 DXQN49'WC7NWQJ\?:_X&^ WB7Q.UM;36MC##
M(-"BDV9M]X$WGRKR['<Q*(0.2"3S7H'PR\2VWCWP''K/A"1X-$GA06D8C$B%
M< Y X( X [ # %>//+Z<H1C2NUYML^FEG^.E3E&;6IR'@#1+/X:7NN7+71UJ
MY@C6'[>8RDZ1[<-G:I  +':J]!C)/6O5I=0B:R,]O)\J*N^ZGB8C>!D$,?O9
MX&3TKGD\/VUC*]K"$DO\/',]O*'@BF;D>8H(PW\6&.<5RUA\0M2O[N30=)BN
M[?4[&9;:\OI=(F:R<XR1%,/W>.>I8X/8UQ4IU<*G"HM/(\:I"&)?/'<ZCQQI
M>?#UPMQ")8[E)# @G"-OZX#," <^O7I7E'ASQ!:66LZ=H?VJXNO$SW!N+:S<
M2/\ Z,H(D=<8 7D;CD@5Z)X5\*Z9X;\*W%C;62PS.\E[Y=P[+%Y[L68[CEL%
MLD_R KG?&NBVD?AF35)/+_M"&&1K9XH660_,,LCHZL6+#)^8=<$'I6TN2;<X
MO?L72;A%QD>B0:=I5O AO;NWY8S23N5"@D9+#)Z'/X5C:%XQ\,:?XCAGUAM)
MMKWYH+<S2))((R<* 2<C<!SZ\5F7'BRU^RZPNJ6UO(-)F6$0W&V=Y@0-DF 3
MLW,2,GG((-<W\/+.[\>0WMY+IT&D*9F2UANE##C())&-N"/3KQ4>TM)*EH_S
M%[-2@Y57H=A\<='M?CK\*?%'AG21?#4+J!CIA@@PD<\!#1R*Q "C>%&<]*X#
MX7?%?1OBIX3TC5_&.M:1HGB6QNO(NO#=Y<QQ2V-W;'9(7)<%VRI8$KC!X'>O
M0O%VL:A\*?",FH:A=ZIXI>UA'FVVDVR_OB>2!&<X]1AL@"ODGX?_  JU?XI^
M+M6U_P 2V$7@WX>Z]K$M_:^$QY,&I7DK  -(Y&Y8R1N*+SR?K7JU,0Y4&L0N
M6W7I^!QTJ$5*\7[K^\]6\6?M.M\4_%47@_X<QZT]A;3RMJ'B:TMUE67 PUO:
MY'J23*1D8P <UZ1X \-^'1-<&VLK^1[<CS+B^+EXY !E S8VMW( IOAVV@TB
MT@T'PEX1$L4;NKZE)<"*&U=8^?GVLP8CC"KT!R>]6-)^'WB_6KB![SQ-96%O
M;RYEL]%MY2SAESCS9"2P _V17)64JTH<JTT-8RA0BX[,Z7Q7X9BL= >U 5H(
MU:;S)I<+$#DY7 R#U''3O7FWB2(:!I=K9P:E"X=/GO+>)?M)C8;@IW'#'&1E
M1S7(?M&Z?=>!M6T^#PAX@\0:GK%_92%HI[D2QLJE01&BQY5QDDD>G-?/%G'X
M]L?B-IMQ;ZK::O$DR32RR<^0-V%##/#Y.-O4=2*\S%U8TJDJ,6EIWV/H,!@J
ME:BL3S?)GUUX0NCX$BO+*72=7O=+9\Y=/->92H'F( !_$1\I[#(/45)JC6FK
M:-<"*ZO=.7889;)T\IRP;&<GYB>?H.U0^%?B!J-U;V\&H^(CO9C&!=6^$7!_
MB;H>3[=JYYO GCR34+[[!K=C=QS$N\4Y=0BJ21Y8QT''7)![UEAZM+$TU[#7
MOJ<]2G*G5?M59_@>AZ%X6T'PG9W":C;2731,S@S7KSK;F7"E=S$[2>N% ]S5
M76?AA:W%D0D":M8?:5N392".:&+:#\I#!BQXZ@>U5/ NLZ[X;\.-%XITFY\0
M:M'"#+>VXMP9F9B%"Q@J5P" !@^O>L3Q+\;;07:6D&FZ[87EM<?9?+N]"O%=
MB.P*1%6!8\%3WKO<6EM>WWGG*3<VKG17FD:SJ-WIMEHNFZ3INDK!YUQJ&GP^
M7($)X@BCP-TASDMD!0.A)KI?#MSIMWJ%[H>AZA>'4K:/?)+=0>;G'!CW'&[Z
M _C5+P[X_P#"FK&/0=1U@66J,AGFCF4Z==*X;( CE"$@<#.T@XY-9TFA>(O!
MFHZIK^HZQHVI:/<W"21-J3)9G38!U^<*!(2>2<\]JU]G[1*26QBY\J<9'IT6
MU;".Z)_?;@%$T83> .B@].^>IKG?$<^N:I:3+X>U2STFX$B2S/JB&ZC\H<RH
M@4J 2/XLG'I5*U^(VEWC6=MX>\0R:Y9;\RM@722@\E8YE(((/;GCI6OK$<?B
M.*ZL+J*[ALKB%HX[BP(>1,CECQE&]"5..]=52,K)19QP:^T<A=>*9M;UR6*P
MCN+ZXT]6A:U211:IYH#AI&.1N*] ,C!]:X72H]0\/^.-=NDE:^75O)5[56V+
M!(@QO VG=N&,\ #;WKO-'\,VGAO3KG3?"UZNKRDEIK[56$TS7 .=SD!%+ _P
MJHZ50\0^!=+OK'3=FIW<4B;I+JZ+_OV?[S;E'(_#D>^:\2M"4FTV>Y1JPAK;
M0]1^ KQMJ'B<1^8BDV[^2W 3)ES@8&.0<_2O7Z\2_9GU>SUJTUJXL+M=3M&2
MW,>HHA03KNFP"K ,&7&#D=Q7MM?H6114,NIQ7][_ -*9\GF;YL7-^GY(*\]O
M-(?5]0NA,ZQ6ZRDCS/O$Y[8X%>A5Y5:>)H-6NK[3I4DB99YE&9!E@'(R!7?B
MYPBHJ3LWL<^'C)J3CT+DFBO>E!'>RR6RCYO+EV\CT('-:%HD/VE UX6BQM",
M OS>N>M5M(TZ"S>18[B3!&5DE<?+^E7KOPK'?6L8DD)V'>K1':V?7-8QIR2O
M8VG-?"V+J<?F+YJ*EPJ@-M^]D <XQU^E0:+/#JNGBY$=Q:2ME?+E^1NN,X[4
MLUC*MHH)D9BNP,\FQCZ'@<5A>(IK70(8KZXURZTTR.L"B60>3O/K\HSG'WB:
MSG4E1]]["251<J-^Y\N&S99I@^S(,3$$$=R2>E8.E:D'\0&"!%C18,0SE>)L
M=5]B,@_2L36=3\3VLIBT_38-8B^4E9)FB4LQY;<H(VA>=N"3ZUKW,-CIN@I+
MK%DEH4E4HL;B0!OX2.!^ Q7(\4JC]HM$CJ5%P7*]6=%JNM&UT\W4Z-$D1^8[
MQC'=N/7K@^M>2:I\>;;3?%=II]MI9U"*0HD\]LSJZECA,J%(P,]SSNSQ7H^E
M>,= ^(&BK]A4WD+D@&6(@$*<$].A(KD/%GPQT#3-1T9['1YC<76HQ2NT#LJH
M P)R0..W'>L,4L34Y)X::Y;ZET%AX\T,1!\W0[B_@&K*URJM&G(<N?\ 5CT.
M./K531_%OV^.>"2<!XY"C-$"RR8YR,<?CTS6Q9ZU#_PD-WI4J^;;.,QNPSSC
MYE/Z5PM_X+DT[Q2;W1W6R62X\UK-6WI,A3:Q[", X[-WXKKKSDW&5+7O8YZ?
M))N,].QXY^V^+X?#ZPU2SAA\VSNE74'>'?(+)@2SJA(Y#8..Q%>Q?LX_#_1?
M!GP*\*^'-&U+^U].MH-ZWC*$,V\EV+ 9QRU<WX^^%%GXS74F\0W&I26T,;A+
M:*\\N*5 #L^1 -W&>#7RW\"?C%XP^$_C*U\)_P!IOJWA*)F065PF)K-%[1'^
MZ PZ@=Z\)XGZG5DZZLIGT<<)4Q^%5/#N\H7;/O'4TMO#NO:<GG+%!>JRF$\;
M"HX8=L8XYKD?%GPBCGTB\?18;6UU!I?/M;H#JQ/S9SQD],^]>FZ==V?B;0XY
M8Y"!)&&W+U7(]#TK,N()[#?:)= D?.6*\E3WVBOH'AZ6)I*4E=/8^;IUZE"?
M*G9HY'P7J%MX:T^32;_SH+R%RQCFD5RX8YW ]<=L>U5X?"=II7Q#U;4[)%B_
MM,()U$@5975>" !]X#N>M<EXQ\36_A3Q:EI9ZA:WRI))-'9-<+YDK;<R0KDY
M!4 L,Y]*UM/^)?AO4=4L;>TU1(;V\4P)'=G!D"\[!VSR<'\Z\>%>*ER3M>.Q
MZKH5%^\BG:1UNE76E7NI7MO;:C;3W(D"S11-&S1-V4A>1GWJ3Q-JG]DK X61
M;42;)-B@A2!DY'ICL*\HT/X3^ _!/Q?U#5O#\4^G>.-0B^URQN\CQRIDJ2L>
M0C\YR <C@X KU^'4C%X?F;4&CLY5)\R5G #*21NP#QQBO3I5Y5$]+'#6BE/F
M6I5-S%]KM)(XO/:3$K*TA3Y,9W XZ^U:<GGP1+<06\DZ,Y:0;AYL8[9)_+\J
MBN+!5TZ$1SB>)X08]ZYQQQ[G->76WQ3O]+\=V'A*4_V??ZHDXL1.CO;ET&>#
MP>F>"<UM4KJ@ES=3&%)UF^7H>W:)JQU.VEDF,;!01YH< D@]"O;'KWJGK6EV
MFMZ>\?F[ED4A)8W 8-ZCW!KGY+J;P\OVF6^MX9CB/]ZX1&?&=JDG[Q]^:V=,
M\2&?1C<203VKL"5AFV@H<>Q.0.M=L)Z)/<Y'!Q=T8M[X(N_$VJ:=<R:E<0W&
MDL6,*_+YC$85SC\>O%:EMXENAM=DD1]N")8RASDC./3 [5XM\8/B?\2?"GQ&
MTFY\->&H]8T(Q"">19U"2HQ'S''*NO/M@FO8M.N;B_$%Y%;KY$\6YI$*L8\#
M[I'?G/3TKS_;PE.4(:-;_P# .Z="<:<:E39E>34%GU=IBS%(L,9<Y*AN.?09
M%=1%);7,387<@P 5[?C7,P6EE+*+DS^3<Q!HER/*5L_,<>N.OX5<MIGTZ]A,
MLHN8[H$C:,C=@'@_3FNVC4=O?>YSS@G\*/0K50D"*O   J:H;4@PJ1T('\JF
MKTEL>>]&<[XZN1:Z*C%MNZ=$!QZYKY_^,7B]K2\\-:3:M'::G?7BK;M*2I8*
M06..XP>G>OH+QS"D^A,' .) 03V/.#7@OCSX:6?Q"O-%U1I9(M5T.8S6L@8[
M1TR"/?%>;B+.4[KI^/0[\-.$91<NAV$F^<JJ<N%R^SY><5C>)89S;6C0B184
M!+JH_4^U4--M-6M]>GDN)"(,<;N*TYR+R>42LSP!BJX^Z,=>_K6E*'L>5O4Y
MIOGYKE/PP]VD<\:E_L; 8=N 2>N#WK<DN%LU421N99&"*J1ENN>?8<'D\5%I
M05Y&B"%8L  XX#>OUJ[>P&.=79VP 04[$\8/^?6LJLU.=[6*AM8@CM=DOFJY
MSG. 00!4UP@N&C"D@KEG)' &>*;; QM("=O.<9X I;E?(1I <IT8'-0VV$F)
MJEP+"PFDB9_.(VJH7D]>M-MMYBCRN=_S'<<8_"I[5XKMV#,5 YY.XT\H\3^8
MP5E3@#/)-3=*/+8E#B=S$LY*9S@=.E4;R"6[MPL4GE#.,XR2*O%&*9;&6[>G
M%-C1=V",L, #/&:A7AJ#.9E\RSF2W)(*'/)P?J:Z>6=YFA;:'8J 21CK[USW
MBWQ59>%M/2>]B:;S)/+1$7+'IGK6OI6I6^KZ5!<VYW)(N^,-QC/8BNFK&4H*
M;6@0LI$KJ1O)3:5/W3_2KVC2^8QB! 0?,V>01BJ%W%YG#$J<?* >3]*;,QM(
MR7& HYP.G'>L;7+DGS6B:ERWVLR$E8Q&"<'O56PNS92I)&N58;2I/7Z5F0Z]
M;SP,(U82*2&(XR3VJ[;IYDZ;B4C(R=@Y!Q4JUK%2C;<T2\.H7D[,#&-O()S@
MXK.D.Z; 3: <D <$>OYU;MY$BN1YA#+C:P(^]GI31(EO=JP<X# ,&X)'TJ+V
M=B9*R&2"6TA195# ]&S]U?:K6EM*L^47[ZCY#V'J*@N[B.^MH7# R#Y-N>.O
MI4MM$'DMVC!#D@$YXX.,#VI/343^$Z&UWB,B098#MQ7-W0M[#4'^T0AX2.<X
M[]^:Z:3[H (9NI'M7/:PXFO416&X+@G&0?;'M40U9,6[')6OP[TRRU^+6H%>
M-A(7$98'YN_..E;GB2&6[U))+=V*H 3CH#Z'%:]R1<6EJKRQ;\L -W(_6JEJ
M@>=H]S"1AM5NH/N:ZI5IU'>;N)12=S0L)8)[ -,BI(O#GIT]:CU%Y9YHC#(J
M*& #!2V>YX_2H;[398(PT!5R0 <OU;/_ .JH5WAE)(^_P,CBN=63-4K'K5%%
M%?0'(8&L7SR:Q;6$/#JGVAW[*N2!GZD&N&UO2I[GQ,FHC4(]XD55"C@"M+QQ
MXEM='\526TKO'//8(JE?0NXJ#P?X9GEMKN82$(QS$3SN-=]./)'G8]U8]&6=
M!&3O&$7+'TKS36_B/I%ZNHQ/&;N%$9%9!SGVK%^*%KK]GX7OKB*[-BOEMYC+
MW^E>+?#?4KNXL)[F7Y8=IC#R\JW/6NC#813BZC>A,WR-'9> /$<U]<O+=02I
M8+\F]U^Z2:]JM%22TM?.U!([="N"6QN]J7P-X2L8-"MYY(XY7N )3M^[S70Z
MAI-FUMM^RK(1RJ =ZPQ%:$Y6BMAQ;ZE.;0XKF^%U/+NM8N8H^@R1Z]ZO)IAD
MMC:D>7">Z^GI5I+99;:%'4J  =A[&K+,$4DD =<FN%R;'<R/^$9LPD?F9?RG
M$BL3@@CI6I%(CQY0AU]1S7&>+_B#HFE6TT4UUOE9?NPM7'WWQ:M](T%4LHR1
M+RLCG+ 'J:WC0J5%>P'<>(=>TZXNH;6/4TMI(FWR%#P!V!_&O-_VAOVP?!?[
M,^@Z5J_B6VU34+"_E-NMQI5N)5CD R%<EAC(SCZ&N4BN8=<2[\LRO=%\[<8#
M5Y=\<_@['\7/AYKGAC5"ZO=Q[[1ICDVTR\I(/H?T)KKE@_=M?5"4D]"[IO\
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MSN .!S4=A)/<HZQ%(RK8R1R<CT_"MVUA5FD)&P\#T_&LF[&#W)0-R_+7/ZE
M\4CR.A&YB"1U^E=$I*-@D $5AZK=2RW7R*-B_,%R/F]ZB+UN6T01:>LHFC=
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MX>/)3:,9ZM)'U-X061/"^F[4$7[I<1M_"/2MW/I@XK)\*1W$.B6T5RGENB@
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MO9%+7GVIXS/;[O\ 5E1A?F8;.,<=:]"73K6VO8=-AL8-*MYCY$<EG;K')+M
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MPQ^RKX@\3ZAI\=RZ:-82Q17,<IA*(KN I*KDYP#G& =V!WK[%^ W[%&C?"-
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MDT]!,T=/TLWT'E7HA^SSQE/)!Z=<&O@S]H7]G/Q!?MJC:;IJW]G!.[(T*98
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MY!Y4+WG^MF6-=H5E.6R>3G':OR9T&\MO#&MV,FGEY=8C'FD1.R!"6Z#'JO\
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M<$17C<4<^G3//&:X#X;:=H5ZDE^NM6\^BQ79F\[[1YZ-,ZX8(KLRH ..F3V
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M=!O$@5HK:]@42--*"P=3P4Q@C![YKY$L_AEX*U37=0\7:CJ@LTOK1D?2+.8
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M?+;NSTG3K3:RA)=A!!#;>I[C/^-:6H6[-9,5!DD'*XX.:S;61[>\CP-R]"P
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MB"]@TBS*SY>W%S+)E44@?ZN,<*YYRV.17R G[0WQ @OOMEOJUT\T@4[PSJK
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MC EV$1][BU4*QDEPWO=8.SVZBFT39N&Y&Q1.WSC4C=^4_N4V9VWR>'?G9;T
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M3JQ6JG!-I@D2"QL%(C\B2U)#8O"A)H&B"Y7:RLHB!+>B =O_WNK@=/Z.Z*Q
MB6Y$2X>IT.?!([FMMRFE'JA5.?$_G3.G=$6JU:*EHR9YQ6:9!T(\/#@](P5[
MMJ\ 7&Z8GAQP<*/9BO^U/J;R6\)]*Z<=@&)Y_I!7OD*NRQD<AP2512#F@O8P
M1&QL55OASKN$174M^=/GA2PSKU*GJ^>*B*CV=F)8I:KFS3\=L!O<H11)TM,6
MRP1W1R83*T_N$98O5!PU-CML.6PXC.P7&N4^S=JP!S'6<>K%&MBLU#9!S9EN
M#6]:-_/^EYG3MK+S08J:-98QO2'TU:^5FK:>B AY>R$*K.:=UZJ'%I+/E.Q
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M.$X$6W6\?]((8XZR?6*%9\6W'@6QA@;<@3N^%W_J%"HQVN$^,AK!VL58YZK
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MEX-W,.K[3MY.%_,E&$\U8LN><%P3T>PA1=!T/V^]N/?EI5./]7/G!EUJX!6
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M8U!Z"@<IJ9MK,W>@LLJ@PF.458N6O: 2)-M_-$OK)*)G\-IE6;)9B^5L$LI
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M\WECPN+<3G?AK88)N:6Q'8B A(&L5ZZVG-\_#[1=G=/3<^<G*XE"DCL>5<"
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MUW. _2](+6>1BAK2I81H.-WN90,*FA^OFSW[OMB$H,K^Z\H=A;$!?]R^=*S
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M-6P 1K99=NN/:;V%' R4MVDPR5O8X%.956J!Q@HWCYB=S5TKQ(_ZY"ACSK7
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MYF5_QS*4G\I8;EIE#V@!.+S=%TR0G KY*;G =?YE#[L7BC4R^;D..#+8):J
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M.L;&-!L EJ5TAW$5M.]+& =_\>GL!\(G@#4>6V(\V:[TLQ%49\#5*JE9N!7
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M928^%-I19JZD4B0%D)>4H(<%24Y><=DD7F7F&:4-;L_SZ]&T1]-;^R%#0I8
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ME;_WZI?.7V8Z'(,6L[9^#A_7W=0Y:!NLD? WU?HX5.^W^I0*ZDT,]@F6((U
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M,C R-#$R,S$N>'-D4$L! A0#%     @ ^HEU6@O-39/F#   RZ@  !4
M         ( !+Q0  &%N=G,M,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M /J)=5I4K[,&?BL  !:\ @ 5              "  4@A  !A;G9S+3(P,C0Q
M,C,Q7V1E9BYX;6Q02P$"% ,4    " #ZB75:M!@]6>QK   G]08 %0
M        @ 'Y3   86YV<RTR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @
M^HEU6BPE1C4E2   PSP% !4              ( !&+D  &%N=G,M,C R-#$R
M,S%?<')E+GAM;%!+ 0(4 Q0    ( /J)=5I:D< VA8@# $PF'  5
M      "  7 ! 0!A;G9S+3(P,C0Q,C,Q>#$P:RYH=&U02P$"% ,4    " #Z
MB75:6T/[1&EG  !#;P  &               @ $HB@0 86YV<RTR,#(T,3(S
M,7@Q,&LP,#,N:G!G4$L! A0#%     @ ^HEU6@,G8U SX0  ;?8  !@
M         ( !Q_$$ &%N=G,M,C R-#$R,S%X,3!K,# T+FIP9U!+ 0(4 Q0
M   ( /J)=5I(1QRS'>T  +@$ 0 8              "  3#3!0!A;G9S+3(P
M,C0Q,C,Q>#$P:S P-2YJ<&=02P$"% ,4    " #ZB75:<16M*!ZH  !EN
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M.60Q+FAT;5!+ 0(4 Q0    ( /J)=5I\?'MEV0,  )H.   8
M  "  >F3"@!A;G9S+3(P,C0Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4    " #Z
MB75:FN]UFV@(  ";+P  &               @ 'XEPH 86YV<RTR,#(T,3(S
M,7AE>#,Q9#$N:'1M4$L! A0#%     @ ^HEU6L'PE;4A!0  R!<  !@
M         ( !EJ * &%N=G,M,C R-#$R,S%X97@S,F0Q+FAT;5!+ 0(4 Q0
M   ( /J)=5K,IO[]\1<  .:,   7              "  >VE"@!A;G9S+3(P
F,C0Q,C,Q>&5X-&0U+FAT;5!+!08     $@ 2 -4$   3O@H    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>anvs-20241231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anvs="http://annovisbio.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="anvs-20241231.xsd" xlink:type="simple"/>
    <context id="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_CLI8H38dPUa4BbOr2SOSqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_f4FMnm-LBE-CzSoyhuwWBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_d8L9-mdvUEO7pQR41LiAvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hOaMIkWJtUezSLsczgZ1uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_QubN3dDRukWsMAmcsNrjCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_xdwCJRelz0CJeBLUaRigFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_15mDcFyvlE6Gb641ZNdHLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bxePodlwPkegkSAB4FKMNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_AedzWyGjZUykRExAVLXYGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mYYWaz1_-0mHQD-w2xRyvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_FuwYvmh-q0yc-mYoMixFEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputConversionPriceMember_naW-EsPsskqjwTlzZs5cbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputConversionPriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_anvs_MeasurementInputSuccessRateMember_3aP8WPBeZ02voCIQpI_gMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">anvs:MeasurementInputSuccessRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_j7VLWFmUpEe9bDHG0DciDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_hMBXSD_r90OcUkje1xs0Kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6DnXcoTVUU-mi30CGoncNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9YgeSUKYHkinaLnDH3gT8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zUAgBq5SJEGx67d7VE9u4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6THFqqlMJEyIsnWSUyL9qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_28BkIxJtwUCxsN3Its458Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cpOE3CFuPkqOfWlu_Xn-hw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KVeVvbTwK06JZJKM4d21ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qdFrnkmd3UOa2tLKqyPiAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_bukzSMYfYkGUxtewxBU0ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_pDfDkGHDXUSTWmxUhrtBpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_wwvOa88X1UO_ZTYRVgaRLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_pJBku7_aCk68MVRcc7xViA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:PerformanceBasedVestingConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_OeMNROUv0EC2j9VxF13eMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_WHvnc8vNT0mnAJbraAi9IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_zW8RAM-bpUWV473IHWZYTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_12_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_VGsJvkPfqEiFabjsYECyuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-12</instant>
        </period>
    </context>
    <context id="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_RldmCmC-GEOG6BsKRZ7jHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hvDUBjTlvU2jxBxrBfn9yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CG9ka-YnN066FFG9Jtzx0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_SrizNFCLl0OrRUDzrcGBsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anvs:EquityIncentivePlan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_61vShh9zukuFEQnE9vaedw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_c12N8aDCj0a8T1KQPkPjgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_drKyELhDW0-wlU15l7Zyuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_gvgCPSCuP0eTU2Ad-DzdLg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BZvwU0W_1kq5dnznbxqBTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_CS9mE9iYf0ibvclFxHcf3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_drOFZ18jkU62ofbq5FTKag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-27</instant>
        </period>
    </context>
    <context id="As_Of_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_F4sV-r5ZzEW1HxbvXiPFTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:April2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-07</instant>
        </period>
    </context>
    <context id="As_Of_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_SkKKchrYf066v4UUAPqRkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:March2023AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-04</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_2_1_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_a5jUEWlNeEGGlp00_fXhKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:December2024AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-02-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_VTb1RU6T3Eu-Tbi6TLPZEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023EquityOfferingAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_q2MkFPGZKUeQUuTkMa5JVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">anvs:GeneratedIn2017AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hoAfWhIToE-9kc4wkiIxvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1b7gLnM7l0uyFch569QwTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RRJXAsbbukC8dIuM3xSztw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b1p2M5EkZEWd2ktBcLEmYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_ZJ9I8gAzMkiGCrkd6nMsRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_Tk2BdOkQEki6zZ7xcxRKFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anvs:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_YF4qvTY1HkiAlLoVQFqtXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anvs:ServiceBasedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_JiqWi9fSuEijFwv_zoQINA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_DplnVEhr1UKyMZzvd2jAOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_eDlqgmZOK0uV7d1yioA33g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_OUKphoR9A0ai9gK2FT1JGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sZy1RM1ObEShrxOTqRKePw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023EquityOfferingAndWarrantIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_gHIzv_4Whk2YABqPEYSDww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qXOmV3N2BkWavNqKGoaRZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_MQP1-VikVEKX6PVp5fZJKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GmXKWrDQdku8NRf1skZHOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_EkA9YeMGEkWI79aNnSvkJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ETg7vggNp0yISA331JxRTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_Ce1DhVkEO0ycmzDj2jbxSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MarkWhiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_iJ4ofV9Y8E6ZohLjT2mgzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MariaMaccecchiniMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_leZDo1RgDkCmAdE8soyXPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:ClaudineBruckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MarkWhiteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:MariaMaccecchiniMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anvs:ClaudineBruckMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_rJgoRibFTU2F1Wv9IExzHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_18_2025_MpjKojjXkUSsMLNgxf4KXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2025-03-18</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_M2DYJkhLdUG7ok90TpIEwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5yKKJ3mp6ECf-Gc5Bz4Sqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_sqRyLfV0qkCQCwu5h2544Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_10_31_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_qlq2NUmLmkOmub_e008yZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-31</startDate>
            <endDate>2023-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ks4SJs0ZpUGHrUcFBn_hhg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-03</startDate>
            <endDate>2025-02-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_KsBP2tMOlkaHzf39vA3zUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_fOusTvtxKkyURMPwViHpkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-03</instant>
        </period>
    </context>
    <context id="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-15</startDate>
            <endDate>2024-03-21</endDate>
        </period>
    </context>
    <context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_xPM3GLi0RUOkXjtpjkTGoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_NgTaNPhJI0e6-e-ecoGs3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_dh8V_0GTe0Kam8Xht2ZFqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:SecondaryOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-03</startDate>
            <endDate>2025-02-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:December2024AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_27_2023_To_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_Ole6j-8tB0ajoZW3rv8oMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:November2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-27</startDate>
            <endDate>2023-11-27</endDate>
        </period>
    </context>
    <context id="Duration_4_7_2023_To_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_6Rvkzj0uGUq7zP-I43U2RQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:April2023PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-07</startDate>
            <endDate>2023-04-07</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_IQdTVBbE1kuTFDb_-zrMqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:March2023AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-04-04</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anvs:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anvs:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_ZVroRH_FcESsW5ndUBJ8dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_aMlHarrTRUOw2ZPEPhIpaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_26_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_4nudJCrUe0q5HzKyVLPtIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-26</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_NZ9r7_BupkiL0YsEGFb8kg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_25_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_C7P9lxm6_UawTNSEnjwUvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementFixedPurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-25</instant>
        </period>
    </context>
    <context id="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_jFh9SfTd8kas9xGVihV0Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementCommitmentSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-25</instant>
        </period>
    </context>
    <context id="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-25</instant>
        </period>
    </context>
    <context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_Myild4X83kmqgHCD5Jm5Sw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementFixedPurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <context id="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_KwF1UY3e6UWazmxYxCohhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-25</startDate>
            <endDate>2024-04-25</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_7gg9fooLjEmkcRZFmQ-9wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">anvs:WarrantsClassifiedAsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="As_Of_12_11_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_HZ8IW9wPyES6tf53JMU46Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:December2024AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-11</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anvs:March2023AtMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001477845</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q">
        <measure>anvs:lease</measure>
    </unit>
    <unit id="Unit_Standard_Vote_iNruACJbWkCS-x51NTwMZQ">
        <measure>anvs:Vote</measure>
    </unit>
    <unit id="Unit_Standard_D_Rt3F2Dcobk-KrJxikqwA4w">
        <measure>anvs:D</measure>
    </unit>
    <unit id="Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug">
        <measure>anvs:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      id="Hidden__sY3U0j3JEOClaX1AU374Q"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      id="Hidden_nehVYZIkkkyD86UwvBXiAw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_gyAUU2VwqkCQhdTRxalVsA_2_1">0001477845</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_b2qcEykNfUOP0IJNRr4LKg_3_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_n7aXXn1u4E-qkHV9JFFxiQ_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_tzDbAOWPv0qBVZRnKBykiQ_5_1">false</dei:AmendmentFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_l-woCN51Gkqe22neOrHPUA_6_1">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Hidden_mZLC-SsCREWJ1bGnJlH22Q"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Hidden_zf0wHy7OGEOHuqg2Y_k6EA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Hidden_gpFqkFDn5Ui6GHkc9wqiBw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Hidden_-uopdWwNhE2Q_pRJNT2atw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:FederalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      id="Hidden_7SaK4QnVyEqfJCs42II-wQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      id="Hidden_0nCDzmrS8USk-QqhIbWFcA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Hidden_lTTopYnhakCO6SzZjzlPOA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">10519933</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Hidden_AHJWVzGiNUeXAwXQV8zhFw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">14141521</us-gaap:CommonStockSharesOutstanding>
    <anvs:NonCashFinancingCostsIncludingChangeInFairValueDerivative
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      id="Hidden_TFrxFG3gykmZYKFhjgO8zQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"
      xsi:nil="true"/>
    <anvs:CashPaidForFinancingCostsDuringPeriod
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      id="Hidden_Qc2Tvi8YB0WWjmj0gWXuNQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Hidden_cLJWlZQJJUG8Jg1dho1-lA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
      contextRef="As_Of_6_30_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_CLI8H38dPUa4BbOr2SOSqg"
      id="Hidden_IDmi6EBxm0ykocQlpvyy7w">http://fasb.org/us-gaap/2024#MonteCarloModelMember</us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList>
    <us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q"
      id="Hidden_MYnYPWwqd0e83MnNL4wIWQ">http://fasb.org/us-gaap/2024#BlackScholesMertonModelMember</us-gaap:WarrantsAndRightsOutstandingValuationTechniqueExtensibleList>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Hidden_sH-lbMPWqkOGFnPa1im7Pg"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w"
      id="Hidden_nIEprH3FlECzxDG_jmJGRg">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <anvs:NumberOfWarrantsIssuedDuringPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA"
      id="Hidden_x2mt2vNGpkmX_I7rt27w1w"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q"
      xsi:nil="true"/>
    <anvs:ConversionOfWarrantsNumberOfWarrantsConverted
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA"
      id="Hidden_hS9S4DOFWEOzsGyH4QCjfA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q"
      xsi:nil="true"/>
    <anvs:NumberOfWarrantsIssuedDuringPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA"
      id="Hidden_IEv4e_C0VEWG-Y-PNjt6jw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_9eZXt5Ywl0uO0vJowqUXtQ">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_ho0Avlfvb06nrVGBr0DKSA_0_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_5OIHGWzMWE-WVBwsSru6nw">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_T9knyJHAA02hYSsb__Tj0Q">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_FLySWt_Un0afHqhICwvYiA_4_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_GZeUfGFdI0mitYBlQKNqXw">001-39202</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_-xmQCWfBwkaerbJ-VKNhZQ">ANNOVIS BIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_nAI_A6fkuk2Ek5j4Kjv46A">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_Xm9KrUqyxEme6yLSjumAdw">26-2540421</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_O6DO-bYmhkuFMGReE6eKWQ">101 Lindenwood Drive, Suite&#160;225</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_EPS2jNIT70CHJK--uatUYg">Malvern</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_m8KrTe8WeUm7Lpr8rl0m0w">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_NYT9HaE1mEaG8O90qGON_g">19355</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_3svz2M9SIUmK-GVQT47KJw">484</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_BATpVdljj0SkeNtKRpoZPw">875-3192</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_JRXQjKhL4kOq9UTGvLTxmA_2_0">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_sYFOH76wbEyoS9m8e9YyNg_2_2">ANVS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_5wujyYyaUk2TsEOSWFIPnQ_2_4">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_LGbQ87MKeEqOAzNLJKlIMg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_7Zb2jABfuESJOz0E3mY2OA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_3m9gmA0UfUeEVQoavu5H7Q">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_mJvwBoSacUSIc1IfLeElDA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_Z4X18ggrGkeyPqO9Nlnrhw">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_HF9hq8zWc0uGXiyRm-HNNA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_gmkHL0apEUGVaT6qkwYtzw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_JkKsR_kr7EuTxt4fnBwwIQ">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_zqRr-28dw0Cd0-S0JR6wWw">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_ve949k9u80uznf4o7QuTzA">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_sij5EfAxEEqCyqKMWGTSpQ">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2024_rJgoRibFTU2F1Wv9IExzHg"
      decimals="0"
      id="Narr_uzBbE5PjXEGeEnY-gZ3nhA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">51312050</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_18_2025_MpjKojjXkUSsMLNgxf4KXw"
      decimals="INF"
      id="Narr_KP9ixp7tdkGYQNcGYg_zeA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">19486231</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_b63bLuuEQECPOyz--fYLCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;"&gt;Certain portions, as expressly described in this report, of the registrant&#x2019;s proxy statement for the 2025 Annual Meeting of the Stockholders are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb__b0TTGRydUaETLhlmCQFXQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company&#x2019;s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations. The Company references the National Institute of Standards and Technology Cybersecurity Framework to help identify, assess, and manage cybersecurity risks and has adopted and tested a formal cybersecurity incident response plan. As part of our risk management process, the Company engages a third-party provider to conduct periodic maturity assessments. The Company stores data in cloud environments, with security appropriate to the data involved and has adopted controls around, among other things, access and acceptable use, backup and recovery and vendor risk assessment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity program is managed by the Annovis Incident Management Committee (the &#x201c;AIMC&#x201d;). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company. From time to time, we engage this vendor to monitor our environment, which includes an outsourced security operations center. We may also from time to time engage partners for periodic penetration testing and vulnerability assessments. We intend to continue to work to formalize our cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations, or financial condition, although we may be materially affected in the future by such risks or future material incidents. See &#x201c;Risk Factors&#x2014;Risks Related to Our Business Operations&#x2014;Disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations&#x201d; for additional information regarding cybersecurity risks.&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_ejCZZKc_A0Kttijcmw8q9g">The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company&#x2019;s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_Xwciqb9VSUecfxpSlcqgDg">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_awz1nfz-Qke0nv6h7W5w9Q">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Group_MAkmTSKySE6UwMNLn2chsw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our cybersecurity program is managed by the Annovis Incident Management Committee (the &#x201c;AIMC&#x201d;). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_LGmN2N-CtUiI7BUXULHklQ">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_tULMHvAjyUuZ4yfiMzQiIg">Annovis Incident Management Committee</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_0V-WIdET50WBSzIxspel7w">Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_T1N-C0xI-0-LJriRiTzwoA">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_WpWYeuvycE2jPDUWUPOmJw">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_8uKUODbKEECYWwWphZ1aEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Roles and Responsibilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Cybersecurity is an important part of our risk management processes and an area of focus for the Annovis management and Board of Directors. We continue to invest in cybersecurity and enhance our internal controls and processes, which are designed to help protect our systems and the information they contain.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Our Board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The Board has delegated to the Audit Committee the responsibility to oversee the integrity of the Company&#x2019;s information technology and cybersecurity risks and to assess the risks and incidents relating to cybersecurity threats. While our Board and Audit Committee oversee cybersecurity risk, management, through the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually. Additionally, the Audit Committee regularly meets with members of the Company&#x2019;s internal audit function to discuss risk management activities, compliance, best practices, and other related matters.&lt;/p&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_PcagFlT33EOfod4oBkvmYw">Board and Audit Committee</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Group_vGPGrH4-EUeWOQmSC89u0w">the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_WUUBSL0he0mgTHyDakhZ2Q">AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_-xOA9b_oWEawCuKw7onboQ">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw"
      id="Tb_AZfLcVbpC0WRVBz9jvrZzg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Name and Title&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Action&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Date&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Aggregate Number of securities to be sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Plan Expiration Date&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Maria Maccecchini,&#160;CEO &amp;amp; Director&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Adoption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;17-Dec-24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Rule 10b5-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;270,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;16-Sep-26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Claudine Bruck, Director&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Adoption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;17-Dec-24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Rule 10b5-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;21,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;31-Dec-25&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Mark White,&#160;Director&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Adoption&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;17-Dec-24&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;Rule 10b5-1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;51,426&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;30-Sep-26&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw"
      id="Narr__ObGNECrf02PTBwEmGfwzw">Maria Maccecchini</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw"
      id="Narr_KLs44pzbbkeJboIWwQoDew">CEO &amp; Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw"
      id="Tc_ybgv80D-NkGToYEIwRMOjg_2_1">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw"
      id="Tc_5S_Ct9I16k-TxpBIzIYfqA_2_2">17-Dec-24</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_iJ4ofV9Y8E6ZohLjT2mgzg"
      decimals="INF"
      id="Tc_R0SaoOnd4keKo-cRg_qoJw_2_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">270000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MariaMaccecchiniMember_T0534M_QAUW0cANc7zcKXw"
      id="Tc_H66Ab4f4mESniNLjUs0EHw_2_5">16-Sep-26</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw"
      id="Narr_hl8Lsh2FUEygYpChCwCavw">Claudine Bruck</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw"
      id="Narr_m6ePN7UNcUGJ3tqPn32lKQ">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw"
      id="Tc_xfr4NfZyGk2p0YdUmKcGHQ_3_1">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw"
      id="Tc_uqg95aJH6k6P490w_08MXQ_3_2">17-Dec-24</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_leZDo1RgDkCmAdE8soyXPw"
      decimals="INF"
      id="Tc_Ulirflvd40-h0-zn040hGA_3_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">21426</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_ClaudineBruckMember_Kp22c0qBmU2nwWtibbyxlw"
      id="Tc_qNbKySPvnEKpVSxK9w_VsQ_3_5">31-Dec-25</ecd:TrdArrExpirationDate>
    <ecd:TrdArrIndName
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA"
      id="Narr_J_tBfNWV3kmjShadweRPrw">Mark White</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA"
      id="Narr_kRIvNWVmsEar-UynUDsDmw">Director</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA"
      id="Tc_lG6E1yeXOkaahYnmT6r_Ww_4_1">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA"
      id="Tc_p5fArviih0GMgW2t94qyuA_4_2">17-Dec-24</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="As_Of_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_Ce1DhVkEO0ycmzDj2jbxSg"
      decimals="INF"
      id="Tc_cRR5ixkHLESvXP0C-90WeA_4_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">51426</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="Duration_10_1_2024_To_12_31_2024_ecd_IndividualAxis_anvs_MarkWhiteMember_7Zi36wzD_EONHoLGJeKwaA"
      id="Tc_tVGLLWDIy0eKzX7ybUeFLQ_4_5">30-Sep-26</ecd:TrdArrExpirationDate>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_vTEG5hLyGUqJX-onutFJWg">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_hBDQMOOKOE6tGBs_zboWZQ">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_LCX9LwxUjkig-HEUe137Lw">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_xTKiXVH0IEm5utC4fkqWug_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">10551916</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_yxKQZ8ATBUilys5cFEJzDw_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5754720</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_zoRDbhuV3E2_9DaQOhb-eA_7_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3373717</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_B2xXhmNCGUeaIKn0PAvJlw_7_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4453544</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_-fJW6ZisP0mC2uK4fyQnXQ_8_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13925633</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_BpiU7dtJoUeyrea7CEGthQ_8_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">10208264</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_XsuzLj6390yI7f2TxnBBXQ_11_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2305974</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_mXsse8YrWUyRFtiR5dVvZw_11_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1292837</us-gaap:AccountsPayableCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_Xvpxi1qpdkOExCRyGcANbQ_12_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1575013</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_WXuGuaFcIEu-j6LJXLnU6Q_12_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2986273</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_wqojjvD0ek6FvexVh3JGvg_13_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3880987</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_ZgC3gtWgI0u4e4BlOp49Zw_13_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4279110</us-gaap:LiabilitiesCurrent>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_vsW4KCuokkyJLzjUYdk4FA_15_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">737000</anvs:WarrantLiabilityNoncurrent>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_vOaQL750dEaUAHQTDSGxVg_15_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13680000</anvs:WarrantLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_aER42V7yVkiA6uGCSfoOLQ_16_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4617987</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_5agQ9jlQPEW2rMYbugYBfQ_16_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">17959110</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Narr_DuWQVtF3UU-Hsb7YUbH4dQ"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_LSmlXMdvbUqwSmPX9lkejQ"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Narr_TUehyiNOV06qs36Pr1OkYA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_bZpGJqoceky4Kxkae7vqUg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Narr_AsrARDHjZ0GrvAmMCsu9Uw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_iCM_Zy0kUEWKG8vWOSXI2w"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Narr_SjpeJxvjUEiwqG4znBGUpg"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_F0tuYz6aSEuYFOdgeJakeA"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Narr_KlEIdhbpT0OSt7mE7unaoA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_R_lQZADQ7kqzkXHO7bpVbA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_hldh8T_uRUSDOSnephNAAQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">14141521</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Narr_mFzN1qQdrkWAk-wfZ1hRdg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">10519933</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_wgK_jfRWFUqM6MsjjceyYw_20_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1414</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_WgTghecSkEeAk-N_1qqbTg_20_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1052</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_QnoFcYa7tEqXGKX9ryJp9g_21_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">144155694</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_wxnpJKbDnke-AEhpCqftoA_21_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">102507189</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_UFXwBOH-zEmw3dPup1rALA_22_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-134849462</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_9j9xwJgHUUaZ7djhxtS_HQ_22_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-110259087</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_Sl0XjoBqK0G_JVvYRhuRsA_23_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">9307646</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_chggbXaAYUu3-9gsjIew0A_23_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-7750846</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_ssqaSkYOS0O1ffxkLHpJVg_24_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13925633</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_6L8tjagfs0GKNOs-8QP7hg_24_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">10208264</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_qJ1T_MAClEmS9Zw-Q7wOeQ_4_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">19995447</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_RK9gQEbwAk2_3RupDO-u2A_4_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">38790603</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_Or6WTwjBVUqb8hBSbxXZjQ_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">6699481</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_pe7ioVNAyEOFQ6j3SEJ26w_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">6244408</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_F4SDBO4FzU-JitskOfD-mA_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">26694928</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_vc2pXWYUPUmLLppeIW4kag_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">45035011</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_GL__h5RBEUS15ObLLLcaoA_7_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-26694928</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_avwvPrW22UmtJSTBGuIRZQ_7_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-45035011</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_-rslyupWQ0W4hbjVqUjkGA_9_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">331849</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_LVqlhor5WEqWr2Nj5SgF_A_9_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">667898</us-gaap:InvestmentIncomeInterest>
    <anvs:FinancingCostsFromIssuanceOfShares
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_ECLMZvQnn0-BzHi0kJEFdA_10_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1853189</anvs:FinancingCostsFromIssuanceOfShares>
    <anvs:GainLossOnChangesInFairValueOfWarrantLiability
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_o93JXnC6f06tZwK2AylFeA_11_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3625893</anvs:GainLossOnChangesInFairValueOfWarrantLiability>
    <anvs:GainLossOnChangesInFairValueOfWarrantLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_qw6AQ-D4xUqZ67JJXicFAA_11_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-11837200</anvs:GainLossOnChangesInFairValueOfWarrantLiability>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc__wIAPg9-Hk28_dg1Iq5jaA_12_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2104553</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_K6xSO2npQ0usj5hBrfjxKw_12_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-11169302</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_WHBDJEPj60SNnPDYGMIVMA_13_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_tS_HjhFdwEGx9t-BFlhopQ_13_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_wY5xhyTDZkKVRjw11qG4Sg_15_3"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="2"
      id="Tc_uvANdMN5SUmhJw_xJinP2g_15_6"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-6.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_KTgooy1m5EWfa3HrfEOVfA_16_3"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="2"
      id="Tc_nzxVhpsaLUShX4-3z1eGUA_16_6"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-6.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_sHc_lUQfqECSg2c6rFBIJQ_18_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">12182475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_3w4nY36q-kGBCGGLBxurtQ_18_6"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">9023138</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_i1GGZrXka0yuSqvHuEapuA_19_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">12235444</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_jDnT7hQ8ykqoX9sQSZ833g_19_6"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">9023138</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A"
      decimals="INF"
      id="Tc_YsL1IVTeFU2-KWLdoidb8w_5_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">8163923</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A"
      decimals="0"
      id="Tc_wenbNeSaSkKOpM4UxJGRkw_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">816</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_cpOE3CFuPkqOfWlu_Xn-hw"
      decimals="0"
      id="Tc_6Z2237vO4kWWJqPQQ8YxDA_5_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">82377488</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_28BkIxJtwUCxsN3Its458Q"
      decimals="0"
      id="Tc_EgPN17s1XESvjdGyU-APyg_5_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-54054774</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_gHIzv_4Whk2YABqPEYSDww"
      decimals="0"
      id="Tc_7u4hH1oMBEmrKhM1GZgldA_5_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">28323530</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"
      decimals="INF"
      id="Tc_O5Amq599ykycXShQ_QSVuw_6_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">59897</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"
      decimals="0"
      id="Tc_d2eiSL9Ag0eZtlJdZkgA6A_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">6</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w"
      decimals="0"
      id="Tc_-HJNbLMWOkONJgE3DebvDg_6_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">8379</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_nqbeu-bwlEWmwvaRx_3WZQ_6_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">8385</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w"
      decimals="0"
      id="Tc_66OnjXVg20-zJIra7LzzBQ_7_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4628406</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_aoiDQF1lTkC-tUQIVRTMNQ_7_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4628406</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <anvs:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"
      decimals="INF"
      id="Tc_25dQDaDDm0ujzIckt09WQA_8_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">50000</anvs:StockIssuedDuringPeriodSharesWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"
      decimals="0"
      id="Tc_SnyyD_OVQkGVeLNZLSkxJA_8_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w"
      decimals="0"
      id="Tc_5BPVNfoCYEWM3qqFnr8RKg_8_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1056196</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_7qkoGM5qt0-xwYpUbhMC-w_8_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1056201</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"
      decimals="INF"
      id="Tc_jUNQQ_xrS0u3WLRzEcNvMQ_9_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2246113</anvs:StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability>
    <anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Bf920OuFDk-O9I5tD3SVkA"
      decimals="0"
      id="Tc_VGuX7VSYQ0KGqvngOFYp3w_9_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">225</anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability>
    <anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_KgoUYb5ihkGxtclLJD3Q5w"
      decimals="0"
      id="Tc_IqlIfEeVrEuRZ_KLaCUFjQ_9_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">14436720</anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability>
    <anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_Rsgw_iOVTkOqneNzi5plAw_9_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">14436945</anvs:ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_b1p2M5EkZEWd2ktBcLEmYQ"
      decimals="0"
      id="Tc_KH-LqvKYn0uKd2rJVjp-Wg_10_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_GeLlIbZFHUiWMotIzKNl8Q_10_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qdFrnkmd3UOa2tLKqyPiAg"
      decimals="INF"
      id="Tc_xeHZ_O2AJkqNX8NrL6wPDw_11_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">10519933</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_qdFrnkmd3UOa2tLKqyPiAg"
      decimals="0"
      id="Tc_THZ6FDPdB0uoPJBKRp_PGQ_11_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1052</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_6THFqqlMJEyIsnWSUyL9qw"
      decimals="0"
      id="Tc_TXVeoQ6B-EOtT_bTZnIxww_11_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">102507189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_zUAgBq5SJEGx67d7VE9u4A"
      decimals="0"
      id="Tc_Duz8ie88N0aNiAoq7qv7Bw_11_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-110259087</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_YtIwz7b2SkKOPlry5gAgZw_11_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-7750846</us-gaap:StockholdersEquity>
    <anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="INF"
      id="Tc_cKQHxAzPXke29ruqX_f7iQ_12_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">220339</anvs:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod>
    <anvs:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="0"
      id="Tc_ATc1mXeSkE6IKjiWi32iqA_12_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">22</anvs:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions>
    <anvs:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"
      decimals="0"
      id="Tc_vbHT_rXPAUKajRxt1tnBeQ_12_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-22</anvs:StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"
      decimals="0"
      id="Tc_6LsLeit-rUCBiSekr37Mzw_13_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3836770</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_ZvxVA1pTGEq66uWskJltLQ_13_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3836770</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <anvs:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="INF"
      id="Tc_AnQkPU1QGEiuIj3WkkeMvw_14_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">891667</anvs:StockIssuedDuringPeriodSharesWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="0"
      id="Tc_stlXvQhCxkK7DoxGmWs3xg_14_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">89</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"
      decimals="0"
      id="Tc_zaEWnKHl-UyDCeD-2OzbHA_14_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">17342022</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_-Y31fYVbHEG72tl4PhjseA_14_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">17342111</anvs:StockIssuedDuringPeriodValueWarrantsExercised>
    <anvs:StockIssuedDuringPeriodSharesEquityDistributionAgreement
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="INF"
      id="Tc_RWKsCMB4B0yEMjqKUE--0A_15_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">26788</anvs:StockIssuedDuringPeriodSharesEquityDistributionAgreement>
    <anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="0"
      id="Tc_zOPqa2WPpUiBsma9slfAhg_15_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3</anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"
      decimals="0"
      id="Tc_Mcc-lxMl4U-e0wkZSsxiNA_15_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">156766</anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_g46RUfzFkEWdvNxGdVzC0w_15_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">156769</anvs:EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:StockIssuedDuringPeriodSharesEquityLineOfCredit
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="INF"
      id="Tc_PSCWOoAAdkaELUgpyWs2LA_16_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2051428</anvs:StockIssuedDuringPeriodSharesEquityLineOfCredit>
    <anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="0"
      id="Tc_6XJHnuZAt0Ktf6sS7NNaXg_16_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">205</anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"
      decimals="0"
      id="Tc_k1J94S0GV0SZ760ARUOpXw_16_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">16438012</anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_6EnNcD8_S0CVlk_VVV0gag_16_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">16438217</anvs:EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:StockIssuedDuringPeriodSharesRegisteredDirectOffering
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="INF"
      id="Tc_rzG60fkKOkqMamHijx6SsA_17_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">431366</anvs:StockIssuedDuringPeriodSharesRegisteredDirectOffering>
    <anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_iJZKM-ORL0CIsBhQ4BrYgA"
      decimals="0"
      id="Tc_nj--_fpwRku2qm4H67uEvw_17_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">43</anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Rf6aKLX-2E2XsdWByERIgg"
      decimals="0"
      id="Tc_UwjSq5drh0qZz1GZnUyF-Q_17_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3874957</anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_Cmz2-jw-5UOyHuMWK0tyOw_17_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3875000</anvs:RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_RRJXAsbbukC8dIuM3xSztw"
      decimals="0"
      id="Tc_KVaGMR0OI0iMEGyVGx8rBQ_18_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_SLz9lemAO0GgOsI6Qcok9Q_18_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590375</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KVeVvbTwK06JZJKM4d21ew"
      decimals="INF"
      id="Tc_eHqsqPZ9nEGe3rqZtVwOZg_19_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">14141521</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_KVeVvbTwK06JZJKM4d21ew"
      decimals="0"
      id="Tc_pRWULPa3lUKMBEGUebcTKg_19_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1414</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9YgeSUKYHkinaLnDH3gT8A"
      decimals="0"
      id="Tc_hW0lYdYsBUCmXYwi43AMRw_19_9"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">144155694</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_6DnXcoTVUU-mi30CGoncNQ"
      decimals="0"
      id="Tc_GfnKcsypYUy0hM13u9RXRA_19_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-134849462</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_8sBgTGqTOUKvUzEYw8DkUQ_19_15"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">9307646</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_6fmCQGSCy06jeFH4f0E30w_4_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590375</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_T0RLH1D35UmnsM2e7QYa7A_4_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_ufGguxb5iEio7VcGkOu3Yg_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3836770</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_gkifeqH70kid6YvjURPdjA_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4628406</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_Eesi0Ur8dEadga0gRlcGZg_7_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-3625893</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_hZmsClEPe0-6bQhKxeG4Gw_7_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">11837200</us-gaap:FairValueAdjustmentOfWarrants>
    <anvs:NonCashFinancingCostsIncludingChangeInFairValueDerivative
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_XxNxmfW4Sku_e4Xtd-kibA_8_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1803189</anvs:NonCashFinancingCostsIncludingChangeInFairValueDerivative>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc__i14K6PJRkGWPQUkevuyYQ_10_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-1079827</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_EF49sNSIr0OhjwvLx1gtbQ_10_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-3190832</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_RxYQ7a5F-U6-pQxJ1DE-4Q_11_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1013138</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_hhs60V6nv02KoMHZPYHv8A_11_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-2668417</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_rLQcPAa2XkWupzocSeE7uA_12_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-1411260</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_I_kQ86TI5k-An7wrWN-5kA_12_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-751012</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_zNPWxDNU2EWhitIwwNMXsg_13_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-21894604</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_75xt4gQ52UWFoxJqgjPuwg_13_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-39967304</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_GVtpGtmdtU-TE4HUrOSKMQ_15_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">18666797</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_3FlHcTO_k0CU2nmGd9HwpA_15_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">16885946</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_D0ovMEBEnEe6umrqd3FHdQ_16_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">8025003</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_vpAomu_q2E2ZyN_6XvrqUg_16_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">450000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_BGejPE9WW0qlkoroQNXHJA_17_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">8385</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_S2ZoVWWoY0G86HkTY4_QnA_18_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">26691800</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_vm7SygZSG0ysOKEooGjqqA_18_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">17344331</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_POHs2imFt0qYI5cR8w5CHw_19_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4797196</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_xtA08qww6EWxmqnmL893Yw_19_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-22622973</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_59QwpxS0K0S4gh6BujCRKw_20_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5754720</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_gHIzv_4Whk2YABqPEYSDww"
      decimals="0"
      id="Tc_cqNFsq8mB0i_iuXWu76qXw_20_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">28377693</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_kqX9eKoAxEOij83CObWnJA_21_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">10551916</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_8tsRQnfv_k-r0XMlUe6j0A_21_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5754720</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <anvs:NonCashTransactionValueOfConsiderationWarrantExercises
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_3RIsgNRtg0OqPksij2de_g_23_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">9317108</anvs:NonCashTransactionValueOfConsiderationWarrantExercises>
    <anvs:NonCashTransactionValueOfConsiderationWarrantExercises
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_8zUP7pVVqEm6FsIRZfnRgQ_23_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">606201</anvs:NonCashTransactionValueOfConsiderationWarrantExercises>
    <anvs:CashPaidForFinancingCostsDuringPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_OOTLmgrwqk6-e2lzxEvBRg_24_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">50000</anvs:CashPaidForFinancingCostsDuringPeriod>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_2ya8qszncEOFP2UEqUUpJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(1)&#160;Nature of Business and Management&#x2019;s Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Annovis Bio,&#160;Inc. (the &#x201c;Company&#x201d; or &#x201c;Annovis&#x201d;) was incorporated on April&#160;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#x2019;s disease (&#x201c;AD&#x201d;) and Parkinson&#x2019;s disease (&#x201c;PD&#x201d;). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company&#x2019;s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Going Concern&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#x2019;s future operations are dependent on the success of the Company&#x2019;s efforts to raise additional capital.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#x2019;s primary source of capital has been the issuance of common stock and warrants to purchase common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Since the Company&#x2019;s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2024, the Company had cash and cash equivalents of $10.6 million and an accumulated deficit of $134.8 million. The Company&#x2019;s net loss was $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company&#x2019;s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company&#x2019;s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2024, combined with cash raised in the first quarter of 2025 in connection with its December 2024 ATM with OpCo and February 2025 stock offering with ThinkEquity, is not sufficient to fund operations for the period through one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company&#x2019;s ability to continue as a going concern. Management&#x2019;s plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management&#x2019;s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, management concluded that such plans do not alleviate the substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="-6"
      id="Narr_D81ivNpGvkO953Wo8vXxIw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="-5"
      id="Narr_ZaiNUliM-0KLkWqDdkZeUw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">10600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="-5"
      id="Narr_Kn7b2skhjUStOVhINb2t9Q"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-134800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="-5"
      id="Narr_YRBVz9_QCEG82S_eUmG6Kg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="-5"
      id="Narr_YIW-0ztlUU-gqa2wg7ivdg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56200000</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="-5"
      id="Narr_nvyKQ8VGeUmVRu_e3BhifA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-26700000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="-5"
      id="Narr_VwbRFiuhPEOynoFxgdWNSQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-45000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_CbbHt9xrd0aBVTPrTywZ4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(2)&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Basic and Diluted Net Income per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Issuance Costs Associated with Equity Issuances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Issuance costs incurred in connection with the Company&#x2019;s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (&#x201c;ELOC&#x201d;) Purchase Agreement are expensed as incurred as prescribed by ASC 815. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&#160;Derivative Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 &#x2013; &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;. An embedded derivative &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;that requires separation is accounted for as a separate liability or asset from the host agreement.  The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 &#x2014; Stockholders&#x2019; Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;zero&lt;/span&gt;&lt;/span&gt; because the ELOC facility had been exhausted and all shares from the equity line had been sold. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(h)&#160;Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;1,250,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock and (ii) warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;1,250,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock at an exercise price of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$9.00&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; per share (&#x201c;Canaccord Warrants&#x201d;). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#x2019;s control or not deemed to be indexed to the Company&#x2019;s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(i)&#160;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company&#x2019;s contracts with its vendors and are realized in the ordinary course of business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(j)&#160;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(k)&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model represent Management&#x2019;s best estimates and involve a number of variables, uncertainties, assumptions, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;and the application of Management&#x2019;s judgment, as they are inherently subjective. If any assumptions change, the Company&#x2019;s stock-based compensation expense could be materially different in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model for stock options are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term. &lt;/i&gt;As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the &#x201c;simplified&#x201d; method, as prescribed in SEC&#x2019;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility.&lt;/i&gt; The expected volatility is based on historical volatilities of Annovis and similar entities within the Company&#x2019;s industry for periods commensurate with the assumed expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate.&lt;/i&gt; The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividends.&lt;/i&gt; The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(l)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.      &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(m)&#160;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt; &lt;i style="font-style:italic;"&gt;(Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2023-07&#x201d;) on an annual basis, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, &lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.  See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(n) Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; &lt;i style="font-style:italic;"&gt;(Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company&#x2019;s financial statement disclosures, but it does not anticipate material impacts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&lt;/i&gt;&#x201c;ASU 2024-03&#x201d;&lt;i style="font-style:italic;"&gt;)&lt;/i&gt;, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. &lt;span style="white-space:pre-wrap;"&gt;The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.  &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccounting
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_QmMAGxwZBkqWBeAb3Go64w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to U.S.&#160;GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_Q9MM7Zcry0eCF2eQiu2vYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_akrr3GrH4Em5lSYnW7Rqtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="INF"
      id="Narr_0WCv9nLf90-shOm6FwbptA"
      unitRef="Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_CLJX_8J43kuJw42iMIeEfw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Basic and Diluted Net Income per Share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_9GocUodF3UisAqaqASVHBg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(e)&#160;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company&#x2019;s financial condition, results of operations, and cash flows.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Narr_sWOYE78BP0Ct8cDe8IjaOg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">250000</us-gaap:CashFDICInsuredAmount>
    <anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_4PqnW7uJpUuC_mqaAlspDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(f)&#160;Issuance Costs Associated with Equity Issuances&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Issuance costs incurred in connection with the Company&#x2019;s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (&#x201c;ELOC&#x201d;) Purchase Agreement are expensed as incurred as prescribed by ASC 815. &lt;/span&gt;&lt;/p&gt;</anvs:IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock>
    <us-gaap:DerivativesEmbeddedDerivatives
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_xmaX4EfZZE2gixtY7njRdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(g)&#160;Derivative Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 &#x2013; &lt;i style="font-style:italic;"&gt;Derivatives and Hedging&lt;/i&gt;. An embedded derivative &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;that requires separation is accounted for as a separate liability or asset from the host agreement.  The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 &#x2014; Stockholders&#x2019; Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;zero&lt;/span&gt;&lt;/span&gt; because the ELOC facility had been exhausted and all shares from the equity line had been sold. &lt;/p&gt;</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_4MeJwfQBcUObxjSYJ7H1xQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(h)&#160;Common Stock Warrants&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;1,250,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock and (ii) warrants to purchase an aggregate of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;1,250,000&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; shares of common stock at an exercise price of &lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$9.00&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; per share (&#x201c;Canaccord Warrants&#x201d;). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#x2019;s control or not deemed to be indexed to the Company&#x2019;s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. &lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA"
      decimals="INF"
      id="Narr_QSLKZ1gN1kWdycpkIr4c1Q"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw"
      decimals="INF"
      id="Narr_MJtSBJgDg0qmbivpT6uWzg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw"
      decimals="2"
      id="Narr_XSxOlsqMe06H8wfrDtF1Iw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_pTBC1l1RrEWmWfNdTxN3dg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(i)&#160;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company&#x2019;s contracts with its vendors and are realized in the ordinary course of business.&lt;/p&gt;</us-gaap:ResearchDevelopmentAndComputerSoftwarePolicyTextBlock>
    <anvs:IntangibleAssetsPatentCostsPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_D7Uv7Fy4XUGUN0NrkLGOVg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(j)&#160;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="background:#ffffff;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.&lt;/span&gt;&lt;/p&gt;</anvs:IntangibleAssetsPatentCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_4SQNkCl-aUWAcpqvI7Ygkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(k)&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation&#x2014;Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model represent Management&#x2019;s best estimates and involve a number of variables, uncertainties, assumptions, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;and the application of Management&#x2019;s judgment, as they are inherently subjective. If any assumptions change, the Company&#x2019;s stock-based compensation expense could be materially different in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The assumptions used in the Company&#x2019;s Black-Scholes option-pricing model for stock options are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Term. &lt;/i&gt;As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the &#x201c;simplified&#x201d; method, as prescribed in SEC&#x2019;s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Volatility.&lt;/i&gt; The expected volatility is based on historical volatilities of Annovis and similar entities within the Company&#x2019;s industry for periods commensurate with the assumed expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Risk-Free Interest Rate.&lt;/i&gt; The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Expected Dividends.&lt;/i&gt; The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_0Qq5gBsvJESLEK9fPGMTqw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Narr_hvMnx9x9hEiyNEcWSUZwIg"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_azsBqmodskOTiNPqfBQqxw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(l)&#160;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject to the provisions of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.      &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_eA-aBXOCaU-EvYZy5T7m1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(m)&#160;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt; &lt;i style="font-style:italic;"&gt;(Topic 280): Improvements to Reportable Segment Disclosures&lt;/i&gt; (&#x201c;ASU 2023-07&#x201d;) on an annual basis, which requires public entities to disclose information about their reportable segments&#x2019; significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, &lt;i style="font-style:italic;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.  See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(n) Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In December 2023, the FASB issued ASU No. 2023-09, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; &lt;i style="font-style:italic;"&gt;(Topic 740): Improvements to Income Tax Disclosures&lt;/i&gt; (&#x201c;ASU 2023-09&#x201d;), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company&#x2019;s financial statement disclosures, but it does not anticipate material impacts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;i style="font-style:italic;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (&lt;/i&gt;&#x201c;ASU 2024-03&#x201d;&lt;i style="font-style:italic;"&gt;)&lt;/i&gt;, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. &lt;span style="white-space:pre-wrap;"&gt;The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.  &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_psXdKsjBeEWI-adUvnYmeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(3)&#160;Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures certain assets and liabilities at fair value in accordance with ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level&#160;3&#x2014;Valuations based on unobservable inputs and models that are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total assets measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Fair Value Measurement at  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not transfer any financial instruments into or out of Level 3 classification, during the year ended December 31, 2024 or 2023. &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;"&gt;Canaccord Warrants&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The common stock warrants issued in connection with the Company&#x2019;s equity financing in November 2023 (&#x201c;Canaccord Warrants&#x201d;) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company&#x2019;s control or not deemed to be indexed to the Company&#x2019;s stock. The Canaccord Warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense), net in the statements of operations until the warrants are exercised, expired, reclassified, or otherwise settled. From their date of issuance until the period ended June 30, 2024, the fair value of the Canaccord Warrants was estimated using a &lt;span style="-sec-ix-hidden:Hidden_IDmi6EBxm0ykocQlpvyy7w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Monte Carlo&lt;/span&gt;&lt;/span&gt; simulation model, given the performance conditions outlined further below. However, during the quarter ended September 30, 2024, the Company determined that certain performance conditions could not be met and that going forward, their use as inputs for determining fair value was no longer appropriate. As such, after the period ended June 30, 2024, the fair value of the Canaccord Warrants is estimated using a &lt;span style="-sec-ix-hidden:Hidden_MYnYPWwqd0e83MnNL4wIWQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Black-Scholes&lt;/span&gt;&lt;/span&gt; option-pricing model.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in both a Monte Carlo simulation model and a Black-Scholes option-pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on an implied asset volatility calculated and believed to be reasonable for the Company over the holding period remaining. The risk-free interest rate is based on the market yield of U.S. Treasuries over a term commensurate with the remaining term to expiration. Any changes in these assumptions can change the associated valuation significantly.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Number of warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Phase III data probability of success&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Term (time to expiration in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Redemption hurdle price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company&#x2019;s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days&#x2019; prior written notice, at any time after:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company&#x2019;s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson&#x2019;s Disease; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the date on which (a) the closing price of the Company&#x2019;s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$14.25&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and (b) the average daily trading value (&#x201c;ADTV&#x201d;) of the Company&#x2019;s common stock is equal to or exceeds &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, for &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; consecutive Trading Days. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson&#x2019;s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met. As such, the probability of success and redemption hurdle price inputs were no longer used in the Black-Scholes option-pricing model outlined above for the year ending December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The Warrants were exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. See Note 7 &#x2013; Stockholders&#x2019; Equity (Deficit) for additional background.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_O-4cS8kHhkGNfUsdc72mLQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Measurement at &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total assets measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 491,006&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Total liabilities measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;Fair Value Measurement at  &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Carrying Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Level 3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total assets measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,136,677&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total liabilities measured and recorded at fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA"
      decimals="0"
      id="Tc_qXFf6q3HTk2rXHlNNFNClQ_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">491006</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qXOmV3N2BkWavNqKGoaRZw"
      decimals="0"
      id="Tc_D0t0mDEUhUONrc0n6ASgxA_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">491006</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA"
      decimals="0"
      id="Tc_AOcLimvqAEyzGqYXwfXgRg_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">491006</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_qXOmV3N2BkWavNqKGoaRZw"
      decimals="0"
      id="Tc_ByAqj5Otu0myQZNggtC_Ig_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">491006</us-gaap:AssetsFairValueDisclosure>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA"
      decimals="0"
      id="Tc_fMVAM4eQFkO8juuUN3DmAA_8_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">737000</anvs:WarrantLiabilityNoncurrent>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_M2DYJkhLdUG7ok90TpIEwQ"
      decimals="0"
      id="Tc_c1BVM7InqES7ae4KAsyx2Q_8_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">737000</anvs:WarrantLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA"
      decimals="0"
      id="Tc_eSdvyxiVo0-8_zOqEbJHew_9_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">737000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_M2DYJkhLdUG7ok90TpIEwQ"
      decimals="0"
      id="Tc_YUmw9_EbYkWsnU0egISkbA_9_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">737000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA"
      decimals="0"
      id="Tc_LJ6zmM-HlUaAEfcPr_2vMg_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5136677</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_MQP1-VikVEKX6PVp5fZJKQ"
      decimals="0"
      id="Tc_Fehse2exuUq622TyZnIWJw_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5136677</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA"
      decimals="0"
      id="Tc_PYQQQ5oEv0y5zOtk0RvwAw_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5136677</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_MQP1-VikVEKX6PVp5fZJKQ"
      decimals="0"
      id="Tc_zDD5fcveEUedE0gnoVkwug_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5136677</us-gaap:AssetsFairValueDisclosure>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA"
      decimals="0"
      id="Tc_mZVQuF0Ku0Kp90l0ePHoUg_8_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13680000</anvs:WarrantLiabilityNoncurrent>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5yKKJ3mp6ECf-Gc5Bz4Sqw"
      decimals="0"
      id="Tc_jXayop0hjUmRgBQnMem51w_8_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13680000</anvs:WarrantLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember__xl3VXMBkEW-EmMBovZcyA"
      decimals="0"
      id="Tc_qzZg3B6eCEiej4aLrIjwig_9_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13680000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5yKKJ3mp6ECf-Gc5Bz4Sqw"
      decimals="0"
      id="Tc_X1zR7_N8lkaYx0juVVlf_w_9_12"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13680000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_FinancialInstrumentAxis_us-gaap_WarrantMember_ZJ9I8gAzMkiGCrkd6nMsRg"
      id="Tb_yGbzEJrX10i2gpRrA4h7ng">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Closing stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.03&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Number of warrants outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 308,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Phase III data probability of success&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 60&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Term (time to expiration in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.84&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Redemption hurdle price&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.25&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk-free rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_xdwCJRelz0CJeBLUaRigFA"
      decimals="2"
      id="Tc_qD-EHwj9UES1AO8D3VnUow_2_3"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExercisePriceMember_FuwYvmh-q0yc-mYoMixFEA"
      decimals="2"
      id="Tc_8REf8WIBskGegv3r-B4ywA_2_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_f4FMnm-LBE-CzSoyhuwWBg"
      decimals="2"
      id="Tc_Ft6YPQHz70ipwmpWnIiqcA_3_3"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">5.03</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputSharePriceMember_15mDcFyvlE6Gb641ZNdHLg"
      decimals="2"
      id="Tc_4HvzKenH3k2aTExxJC30dA_3_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">18.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_OUKphoR9A0ai9gK2FT1JGw"
      decimals="INF"
      id="Tc_J_LHWXm3FkqIb9tl5D6TKA_4_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">308333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_sZy1RM1ObEShrxOTqRKePw"
      decimals="INF"
      id="Tc_wrwJQee5mUyUgihWYikKkQ_4_6"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_anvs_MeasurementInputSuccessRateMember_3aP8WPBeZ02voCIQpI_gMg"
      decimals="2"
      id="Tc_VjwTwVL0sUO6stfjyIfz7Q_5_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_hOaMIkWJtUezSLsczgZ1uw"
      decimals="2"
      id="Tc_dPPTcggzT0mu7-XtC6S-wA_6_3"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputPriceVolatilityMember_AedzWyGjZUykRExAVLXYGw"
      decimals="2"
      id="Tc__3d5GVLR60qBixNDPCfhlw_6_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.55</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_QubN3dDRukWsMAmcsNrjCQ"
      decimals="2"
      id="Tc_N15_S1yJ2kKsCkHRFQuC3Q_7_3"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">3.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember_mYYWaz1_-0mHQD-w2xRyvw"
      decimals="2"
      id="Tc_P7RHYElR8keYJMOYA5eh_w_7_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">4.84</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputConversionPriceMember_naW-EsPsskqjwTlzZs5cbA"
      decimals="2"
      id="Tc_W6upCxcZrUKh4yiIFc4fHQ_8_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">14.25</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2024_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_d8L9-mdvUEO7pQR41LiAvg"
      decimals="3"
      id="Tc_zZ63hGwPE0KUbJBCMvT3bA_9_3"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.043</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="As_Of_12_31_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputRiskFreeInterestRateMember_bxePodlwPkegkSAB4FKMNQ"
      decimals="3"
      id="Tc_F_3xUhuoAkm7yWrhHfRhiQ_9_6"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.039</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"
      decimals="2"
      id="Narr_AwAgUiCdJ0ef-xPkh1V9kQ"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <anvs:ClassOfWarrantOrRightRedemptionPricePerShare
      contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"
      decimals="3"
      id="Narr_2LQboc7bvU-4kxVmlH31Bw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.001</anvs:ClassOfWarrantOrRightRedemptionPricePerShare>
    <anvs:WarrantsThresholdPeriodOfNoticeForRedemption
      contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_qlq2NUmLmkOmub_e008yZg"
      id="Narr_6X7k6wW1jECSyDPwQPP1Eg">P30D</anvs:WarrantsThresholdPeriodOfNoticeForRedemption>
    <us-gaap:SharePrice
      contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"
      decimals="2"
      id="Narr_utyCAlQi7Um3z2sbN5SxIQ"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">14.25</us-gaap:SharePrice>
    <anvs:AverageDailyTradingValue
      contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"
      decimals="0"
      id="Narr_NrVG2_U_Xk2AmZKzRgLd1A"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2000000</anvs:AverageDailyTradingValue>
    <anvs:ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded
      contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_qlq2NUmLmkOmub_e008yZg"
      decimals="INF"
      id="Narr_WRwrzocHxUCa3savkHhZBg"
      unitRef="Unit_Standard_D_Rt3F2Dcobk-KrJxikqwA4w">2</anvs:ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"
      id="Narr_Ds6eVKWWl0eeKaE1Z0VWTA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_yXdkoXOuqUmCKWd6GJ2d5w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(4)&#160;Prepaid Expenses and Other Current Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,998,811&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,391,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 346,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,455&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,098&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,373,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,453,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_BWrTCP0jcUeI6Ep3K88uJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Prepaid expenses and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid clinical expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 2,998,811&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,391,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 346,313&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 23,455&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prepaid insurance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21,098&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 18,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Security deposits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 7,495&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 20,796&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total prepaid expenses and other current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3,373,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,453,544&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <anvs:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_z39v_TfzQkyP750LpCqD_g_3_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2998811</anvs:PrepaidResearchAndDevelopmentExpenseCurrent>
    <anvs:PrepaidResearchAndDevelopmentExpenseCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_AdOxja32m0OXY61g5u1BQg_3_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4391219</anvs:PrepaidResearchAndDevelopmentExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_5KcpNur4kEqfHQZFQegsjQ_4_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">346313</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_-utUy42iWEalmA9u6MeOwg_4_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">23455</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_zZg8awRnLEmIvKSAZFTi2w_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">21098</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_fVvZu0EVjkeB4sTMN2rZqA_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">18074</us-gaap:PrepaidInsurance>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_BR26F0Tuj0Sb13vZIxIW-A_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">7495</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_fr2nUqQ_oUWJfhsxJFvTLQ_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">20796</us-gaap:SecurityDeposit>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_p22wIs7mAEujBrZlrapV9w_7_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3373717</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_a2iDv650IkOWt2eRDfbfbQ_7_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4453544</anvs:PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_DhjGtlBZ20qP6g142OVuAw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(5)&#160;Accrued Expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 948,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,645,589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 364,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,848&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 261,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,575,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,986,273&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_TZKe8-4XtkCCIYq-U4GmaQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Accrued expenses consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued clinical expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 948,695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,645,589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 364,717&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,848&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued professional fees and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 261,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 243,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,575,013&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,986,273&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <anvs:AccruedClinicalLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_K5gtFvCKLkqJyFRCqtIYaA_3_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">948695</anvs:AccruedClinicalLiabilitiesCurrent>
    <anvs:AccruedClinicalLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_ktj1rZ6vFUW80wPF1nVPgA_3_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2645589</anvs:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_oZuipQU1LEeMwKSa0g7r1Q_4_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">364717</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_huShGDO1306b4XBJEkqSoA_4_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">96848</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_inHK2f3DYkaB1Tjmq8V2Rw_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">261601</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_xPRR5UuBlkmHdysmdsLtIA_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">243836</us-gaap:AccruedProfessionalFeesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_xdIWu3zNW02UAz2UqVscfg_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1575013</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_HiMYzsHFd0ayIIjF1HOGtg_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2986273</anvs:AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_PZFyYbITMEOCN_dAyt_7Lw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(6)&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a)&#160;Research &amp;amp; Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company has entered contracts with CROs and CMOs related the Company&#x2019;s clinical trials.  The contracts require upfront payments, milestone payments, and pass-through cost reimbursements, to be made. While the contracts are generally cancellable with (written) notice, the Company is obligated to make payments for services rendered through the termination date of the project with any applicable CRO/CMO.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b)&#160;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company maintains one short-term lease associated with occupying its corporate headquarters. Total rental expense was $0.1 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Employment Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has an agreement with its Chief Executive Officer that provides for severance payments upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreement was estimated to be $1.1 million&#160;at December&#160;31,&#160;2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;Litigation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#x2019;s liquidity, financial condition and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;For both the years ended December 31, 2024 and December 31, 2023 the Company did not have any pending legal actions deemed to be material.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <anvs:NumberOfShortTermLeases
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_euBDri2pC0SW7HW-7IcKXg"
      unitRef="Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q">1</anvs:NumberOfShortTermLeases>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="-5"
      id="Narr_6zvBV-f4_EWZi3hdP5PEQg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="-5"
      id="Narr_tVBV60S160eJK7SmbzSC0Q"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">100000</us-gaap:OperatingLeaseExpense>
    <anvs:MaximumAggregateSeverancePayments
      contextRef="As_Of_12_31_2024_srt_TitleOfIndividualAxis_srt_ChiefExecutiveOfficerMember_NgTaNPhJI0e6-e-ecoGs3g"
      decimals="-5"
      id="Narr_oDbtIoEUVkGye0sIeBLdKQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1100000</anvs:MaximumAggregateSeverancePayments>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_JTYhfhAaJ0uCnYvA9TA2pA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(7) Stockholders&#x2019; Equity (Deficit)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(a) Overview&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company&#x2019;s initial public offering (the &#x201c;IPO&#x201d;) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are two classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 is designated as common stock and 2,000,000 is &lt;span style="-sec-ix-hidden:Hidden_sH-lbMPWqkOGFnPa1im7Pg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;preferred&lt;/span&gt;&lt;/span&gt; stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(b) Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Dividends&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Liquidation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;Voting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(c)&#160;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of December 31, 2024 or December 31, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;(d)&#160;IPO Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In conjunction with the closing of the Company&#x2019;s Initial Public Offering (&#x201c;IPO&#x201d;), the Company granted its underwriters 0.1 million warrants to purchase shares of Company common stock (&#x201c;IPO Warrants&#x201d;) at an exercise price of $7.50 per share, which was 125% of the IPO price. The IPO Warrants have a &lt;span style="-sec-ix-hidden:Hidden_nIEprH3FlECzxDG_jmJGRg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five-year&lt;/span&gt;&lt;/span&gt; term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders&#x2019; equity. At both December 31, 2024 and December 31, 2023, 2,400 of the IPO Warrants were outstanding. No IPO Warrants were exercised during the years ended December 31, 2024 or 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(e)&#160;March 2023 ATM&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 31, 2023, the Company, entered into an At the Market (&#x201c;ATM&#x201d;) Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d; or &#x201c;March 2023 ATM&#x201d;) with BofA Securities, Inc. (&#x201c;BofA&#x201d;) and ThinkEquity LLC (&#x201c;ThinkEquity&#x201d; and, together with BofA, the &#x201c;Sales Agents&#x201d;), as sales agents, pursuant to which the Company could offer and sell, from time to time through the Sales Agents, shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;), having an aggregate offering price of up to $50.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to termination of the Sales Agreement, the Company sold 0.7 million shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7.6 million before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(f)&#160;April 2023 Private Placement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 7, 2023, the Company sold 0.1 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $1.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(g)&#160;November 2023 Equity Offering and Warrant Issuance&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (&#x201c;Canaccord Warrants&#x201d;) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#x2019;s control or not deemed to be indexed to the Company&#x2019;s stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Issuance of Canaccord Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,449,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of 50,000 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (606,201)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,837,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,625,893)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of 891,667 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,317,107)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(h)&#160;Warrant Summary&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had the following common stock warrants outstanding:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&#160;or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;IPO warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 29, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Canaccord warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (891,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;November 2, 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(i)&#160;November 2023 Private Placement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;On November 27, 2023, the Company sold 0.2 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $6.10 per share, for aggregate proceeds of $1.3 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(j) March 2024 Registered Direct Offerings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 15, 2024 and March 21, 2024, the Company entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, the Company issued 0.4 million shares for net proceeds of $3.9 million in registered direct offerings.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(k) April 2024 ELOC Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 25, 2024, the Company entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of the Company&#x2019;s common stock. The term of the agreement was until the expiration of the Company&#x2019;s active S-3 Registration Statement, unless earlier terminated or exhausted. Due to certain pricing and settlement provisions, the ELOC Purchase Agreement qualified as a standby equity purchase agreement and included an embedded put option and embedded forward option. The Company therefore accounted for the ELOC Purchase Agreement as a derivative measured at fair value, with changes in the fair value recognized in the statements of operations within other financing costs. The Company initially recognized a derivative liability of $1.7 million related to the purchased put option at inception of the ELOC Purchase Agreement. The Company then expensed the difference between the discounted purchase price of the settled forward and the fair value of shares on the date of settlement as a noncash financing issuance cost. The Company recognized $1.3 million of noncash financing costs during the year ended December 31, 2024 related to the discounted purchase price of the settled forward and the underlying fair value of the shares issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon execution of the ELOC Purchase Agreement, the Company agreed to issue to the ELOC Purchaser 33,937 shares of Common Stock as commitment shares (the &#x201c;Commitment Shares&#x201d;). The fair value of the Commitment Shares was $0.5 million, which was expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The Company also incurred issuance costs of $0.1 million, consisting of legal costs incurred in connection with the ELOC Purchase Agreement, which were expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The ELOC Purchaser agreed that during the term of the Purchase Agreement, neither it nor any of its affiliates would engage in any short sales or hedging transactions involving the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the ELOC Purchase Agreement, on any business day (the &#x201c;Purchase Date&#x201d;), if the Company&#x2019;s stock price is greater than or equal to $5.00 per share, the Company could direct the ELOC Purchaser to purchase common stock. The ELOC Purchaser&#x2019;s committed obligation under any single Fixed Purchase could not exceed the lower of 25,000 shares of Common Stock or $250,000 (&#x201c;Fixed Purchases&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company could also direct the ELOC Purchaser, on any trading day in which the Company submitted a Fixed Purchase notice for the maximum amount allowed for such Fixed Purchase, to purchase an additional amount of the Company&#x2019;s common stock (a &#x201c;VWAP Purchase&#x201d;). The ELOC Purchaser&#x2019;s committed obligation under any single VWAP Purchase could not exceed a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) 30% of the trading volume in the Company&#x2019;s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date (&#x201c;VWAP Purchase Maximum Amount&#x201d;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company could also direct the ELOC Purchaser, on any trading day for which a VWAP Purchase had been completed and all of the shares had been placed, to purchase an additional amount of the Company&#x2019;s common stock (an &#x201c;Additional VWAP Purchase&#x201d;). The ELOC Purchaser&#x2019;s committed obligation under any single Additional VWAP Purchase was the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (&#x201c;Additional VWAP Purchase Maximum Amount&#x201d;). The applicable pricing structure for each purchase type is outlined below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The purchase price per share for Fixed Purchases (&#x201c;Fixed Purchase Price&#x201d;) equals 95% of the lesser of:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the daily volume weighted average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s Common Stock on the NYSE for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The purchase price per share for VWAP Purchases (&#x201c;VWAP Purchase Price&#x201d;) equals 95% of the lesser of:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the VWAP during the applicable VWAP Purchase Period during the applicable VWAP Purchase Date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The purchase price per share for Additional VWAP Purchases (&#x201c;Additional VWAP Purchase Price&#x201d;) equals 95% of the lesser of:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date; and &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In addition to the commitment shares referenced above, a total of 2.0 million shares of the Company&#x2019;s common stock were issued under the ELOC Purchase Agreement during the year ended December 31, 2024, for net proceeds of $14.6 million. The facility was fully exhausted during 2024 and no further shares are available to issue as of December 31, 2024. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following is a roll-forward of the ELOC derivative liability from date of execution to December 31, 2024: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at April 25, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,697,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Settlements and changes in fair value of ELOC derivative liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,192,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at June 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 505,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Settlements and changes in fair value of ELOC derivative liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (62,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at September 30, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 442,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Settlements and changes in fair value of ELOC derivative liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (442,500)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fair value at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;(l) December 2024 ATM&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 11, 2024, the Company entered into an Equity Distribution Agreement (&#x201c;Distribution Agreement&#x201d;) with Oppenheimer &amp;amp; Co. Inc., (&#x201c;OpCo&#x201d;) relating to the sale of shares of the Company&#x2019;s common stock. In accordance with the terms of the Distribution Agreement, The Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as agent or principal.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year-ended December 31, 2024, the Company sold 26,788 million shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <anvs:NumberOfClassesOfStockDesignated
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_aZYonHsct0y5ecBeXMWAsw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2</anvs:NumberOfClassesOfStockDesignated>
    <anvs:CommonStockAndPreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_t0HCOHvVe0q8u73ZdJGJwg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">72000000</anvs:CommonStockAndPreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_mQDQIqHJgEmgTLjZESgIRw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_9s08Q9fIFU6h3NIVxs0ejg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">70000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr___laxYrVNUmJ5gzft8bsng"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2000000</us-gaap:PreferredStockSharesAuthorized>
    <anvs:NumberOfVotesForEachShareOfCommonStock
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Narr_tGvUYXsk1EWqcz3Q2rnItA"
      unitRef="Unit_Standard_Vote_iNruACJbWkCS-x51NTwMZQ">1</anvs:NumberOfVotesForEachShareOfCommonStock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_fHoxrrmeT0yrgm4f7KpiTg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Narr_gxps20pko0WPFEzbNMf-Hw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w"
      decimals="-5"
      id="Narr__LaNXL0tVkuMcrng8lQiQQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w"
      decimals="2"
      id="Narr_yTfoupuR-EKa4U3rEfnWFw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <anvs:PercentageOfExercisePriceToShareOfferingPrice
      contextRef="As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w"
      decimals="2"
      id="Narr_cnWH11o32EOzwzy9M8bkog"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">1.25</anvs:PercentageOfExercisePriceToShareOfferingPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng"
      decimals="INF"
      id="Narr_SPqsTvoSZEmCmTaTfjmmuQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA"
      decimals="INF"
      id="Narr_eRSkNG2PQ0GJ3T9rUWnfTg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <anvs:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_7gg9fooLjEmkcRZFmQ-9wg"
      decimals="INF"
      id="Narr_0H63oquw4UyuwRUZryDIRA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</anvs:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <anvs:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_unTK9_ZPhUqTY5xqBgY3dA"
      decimals="INF"
      id="Narr_igS9_KYQok6YSu8lgUTIvw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</anvs:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ"
      decimals="INF"
      id="Narr_CVkGciS4UE22bP11ntKprw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <anvs:AtMarketEquityOfferingCommonStockAuthorizedValue
      contextRef="As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ"
      decimals="-5"
      id="Narr_L1wi9xnM7EOCcrvzK26faA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">50000000</anvs:AtMarketEquityOfferingCommonStockAuthorizedValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_31_2023_To_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_IQdTVBbE1kuTFDb_-zrMqw"
      decimals="-5"
      id="Narr_PsmbNpj0C0ObyGeYVDF30Q"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_SkKKchrYf066v4UUAPqRkQ"
      decimals="2"
      id="Narr_6YvBhNP1C0O5mg5x_bFT9g"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">10.88</us-gaap:SaleOfStockPricePerShare>
    <anvs:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_31_2023_To_4_4_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_IQdTVBbE1kuTFDb_-zrMqw"
      decimals="-4"
      id="Narr_kvyzhbXCXE2-yN-HT6vNRw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">7600000</anvs:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_7_2023_To_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_6Rvkzj0uGUq7zP-I43U2RQ"
      decimals="-5"
      id="Narr_wbcWet4x20OZRwKTbvVhfw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_F4sV-r5ZzEW1HxbvXiPFTA"
      decimals="2"
      id="Narr_OkLQHH8WTEedgn6fZmbGew"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">12.61</us-gaap:SaleOfStockPricePerShare>
    <anvs:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_7_2023_To_4_7_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_April2023PrivatePlacementMember_6Rvkzj0uGUq7zP-I43U2RQ"
      decimals="-5"
      id="Narr_NgwkzEjlwkuwy4ysnlpV-A"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1100000</anvs:GrossProceedsFromIssuanceOfCommonStock>
    <anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_O2tjUjZ63kq4NfMwWsvLow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (&#x201c;Canaccord Warrants&#x201d;) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company&#x2019;s control or not deemed to be indexed to the Company&#x2019;s stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Issuance of Canaccord Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,449,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of 50,000 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (606,201)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#212529;"&gt;Change in fair value of warrant liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,837,200&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability at December 31, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,680,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value of warrant liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,625,893)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Exercise of 891,667 warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,317,107)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrant liability at December 31, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 737,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA"
      decimals="INF"
      id="Narr_oXu4gOW5b0aq3bImbwhyKA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw"
      decimals="INF"
      id="Narr_o7wY3msp40S62Ye6fu7TRA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw"
      decimals="2"
      id="Narr_UVMHD8swFkqZI0fOGkjWTQ"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw"
      id="Narr_LiG6GXn_GUe5deH7s3MCFw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_31_2023_To_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_3cLMgH7h90-8VTwO_frBfA"
      decimals="-5"
      id="Narr_JdWBrcrFjUWKlj61OPGT-g"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">6800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw"
      decimals="0"
      id="Tc_A17qsEMG7kWF8gX6ytMu8w_1_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2449001</anvs:WarrantLiabilityNoncurrent>
    <anvs:ConversionOfWarrantsNumberOfWarrantsConverted
      contextRef="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ"
      decimals="INF"
      id="Narr_di9CdQsJ50ukDwqST9CsmQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">50000</anvs:ConversionOfWarrantsNumberOfWarrantsConverted>
    <anvs:IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants
      contextRef="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ"
      decimals="0"
      id="Tc_sMEeh4dSdkeZSHTkyWaN_w_2_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-606201</anvs:IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_11_1_2023_To_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_GxKy89pBdUiXe4Qr3gU5nQ"
      decimals="0"
      id="Tc_bfgLrAGyV0iABzpyim53oQ_3_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-11837200</us-gaap:FairValueAdjustmentOfWarrants>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_sqRyLfV0qkCQCwu5h2544Q"
      decimals="0"
      id="Tc_NP8xCeFc6UW4zI63Lqz2RQ_4_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13680000</anvs:WarrantLiabilityNoncurrent>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA"
      decimals="0"
      id="Tc_LOFm2j34rEShoTLnJ2mc3Q_5_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3625893</us-gaap:FairValueAdjustmentOfWarrants>
    <anvs:ConversionOfWarrantsNumberOfWarrantsConverted
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA"
      decimals="INF"
      id="Narr_T0Qym4GXqUmK81ktBgSIrg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">891667</anvs:ConversionOfWarrantsNumberOfWarrantsConverted>
    <anvs:IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA"
      decimals="0"
      id="Tc_hKg25v-oI06NbAj6Mr88Wg_6_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">9317107</anvs:IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants>
    <anvs:WarrantLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q"
      decimals="0"
      id="Tc_ag4eVItPmkekFDIC1EWZBA_7_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">737000</anvs:WarrantLiabilityNoncurrent>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_pDXO4LdpA0O0ZPZh2FgbMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had the following common stock warrants outstanding:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Outstanding&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercised&#160;or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;price&#160;per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expiration&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Classification&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Granted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Expired&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;IPO warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Equity&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;January 29, 2026&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Canaccord warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Liability&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,200,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"&gt; (891,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 308,333&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;November 2, 2028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng"
      decimals="INF"
      id="Tc_vz0vaspnWEemAWApXcg-RA_4_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA"
      decimals="INF"
      id="Tc_ocX4sCgjxE2JSSfZYbGv7Q_4_10"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2400</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_vDkCA98XHkSMwMCqvTDFZA"
      decimals="2"
      id="Tc_y-8e4eKtYkmZe28AaeFBQg_4_13"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">7.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_sqRyLfV0qkCQCwu5h2544Q"
      decimals="INF"
      id="Tc_kFLoXCgQqkiTsrQsgtzzmA_5_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1200000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <anvs:ConversionOfWarrantsNumberOfWarrantsConverted
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_TZ8wGWKjzkONa6Roh5fOOA"
      decimals="INF"
      id="Tc_as5eG-jTdESCnZKcX1pCcQ_5_8"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">891667</anvs:ConversionOfWarrantsNumberOfWarrantsConverted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q"
      decimals="INF"
      id="Tc_QpqPIEXJ-k-7E2L6l_oSyQ_5_10"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">308333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q"
      decimals="2"
      id="Tc_COteFyIwUE-WbCnD0nQF6Q_5_13"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_27_2023_To_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_Ole6j-8tB0ajoZW3rv8oMQ"
      decimals="-5"
      id="Narr_2KjV3M1EQUmJ1XAPE0t3WA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_drOFZ18jkU62ofbq5FTKag"
      decimals="2"
      id="Narr_1acsP8UdAEW_j6zExGiHyg"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">6.1</us-gaap:SaleOfStockPricePerShare>
    <anvs:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_11_27_2023_To_11_27_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023PrivatePlacementMember_Ole6j-8tB0ajoZW3rv8oMQ"
      decimals="-4"
      id="Narr_4A0WKRG_WEqf_aHrV0guug"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1300000</anvs:GrossProceedsFromIssuanceOfCommonStock>
    <anvs:NumberOfSaleOfStockTransactions
      contextRef="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew"
      decimals="INF"
      id="Narr_abvsQzY_OUSuHOcjDns2DQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2</anvs:NumberOfSaleOfStockTransactions>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew"
      decimals="-5"
      id="Narr_n8reVvdpW0GMnGI8PeHmbA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew"
      decimals="-5"
      id="Narr_4Sp_C6pVukWRrJqQxFFShg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <anvs:CommonStockPurchaseAgreementSharesAuthorized
      contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog"
      decimals="INF"
      id="Narr_jAzSYmbpZkKpB0mAhSgdNQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2</anvs:CommonStockPurchaseAgreementSharesAuthorized>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog"
      decimals="-5"
      id="Narr_fXb4VcGwyUGkl1nsV23doQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1700000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <anvs:NonCashFinancingCostsFromIssuanceOfShares
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_xPM3GLi0RUOkXjtpjkTGoQ"
      decimals="-5"
      id="Narr_7CKgE8z8-kmiCmacXtInPg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1300000</anvs:NonCashFinancingCostsFromIssuanceOfShares>
    <anvs:CommonStockPurchaseAgreementTotalCommitment
      contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_jFh9SfTd8kas9xGVihV0Yw"
      decimals="INF"
      id="Narr_-sPXYz3CA0aNi_31XtUHCA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">33937</anvs:CommonStockPurchaseAgreementTotalCommitment>
    <anvs:CommonStockPurchaseAgreementTotalCommitmentValue
      contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_NZ9r7_BupkiL0YsEGFb8kg"
      decimals="-5"
      id="Narr_jBo75y6ar0-E1RCxsWGj2Q"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">500000</anvs:CommonStockPurchaseAgreementTotalCommitmentValue>
    <us-gaap:ProfessionalFees
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementCommitmentSharesMember_VTb1RU6T3Eu-Tbi6TLPZEw"
      decimals="-5"
      id="Narr_utco3D1JsECvS6ElJ7564A"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">100000</us-gaap:ProfessionalFees>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog"
      decimals="2"
      id="Narr_EfLOirszWUyVpVR0cKNriw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">5</us-gaap:SaleOfStockPricePerShare>
    <anvs:CommonStockPurchaseAgreementTotalCommitment
      contextRef="As_Of_4_25_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_C7P9lxm6_UawTNSEnjwUvQ"
      decimals="INF"
      id="Narr_WWVBJrn7GEaLwyLLrSjDkw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">25000</anvs:CommonStockPurchaseAgreementTotalCommitment>
    <anvs:CommonStockPurchaseAgreementTotalCommitmentValue
      contextRef="As_Of_4_25_2024_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_C7P9lxm6_UawTNSEnjwUvQ"
      decimals="0"
      id="Narr_eFchJ_y7s0Sh7fDg5tAsAg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">250000</anvs:CommonStockPurchaseAgreementTotalCommitmentValue>
    <anvs:CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g"
      decimals="2"
      id="Narr_8wVmyCg1OE2uLZO4br-1-Q"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">3</anvs:CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice>
    <anvs:CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g"
      decimals="2"
      id="Narr_rZwzBZlMsk6puB3kghHGDQ"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.30</anvs:CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume>
    <anvs:CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_KwF1UY3e6UWazmxYxCohhw"
      decimals="2"
      id="Narr_3Lp3hwPP9kWnHLaa3_uIcw"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">3</anvs:CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice>
    <anvs:CommonStockPurchaseAgreementPurchasePricePercentage
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementFixedPurchaseMember_Myild4X83kmqgHCD5Jm5Sw"
      decimals="2"
      id="Narr_7tH6vitzskmubXZW1fKYDQ"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.95</anvs:CommonStockPurchaseAgreementPurchasePricePercentage>
    <anvs:CommonStockPurchaseAgreementPurchasePricePercentage
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember_2vnd0TLBDkOaUDTQ5uUq3g"
      decimals="2"
      id="Narr_KnhheG0-REK7Ymz4sx4_oA"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.95</anvs:CommonStockPurchaseAgreementPurchasePricePercentage>
    <anvs:CommonStockPurchaseAgreementPurchasePricePercentage
      contextRef="Duration_4_25_2024_To_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember_KwF1UY3e6UWazmxYxCohhw"
      decimals="2"
      id="Narr_er8Iu4HnaU2R-a221PVLlw"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.95</anvs:CommonStockPurchaseAgreementPurchasePricePercentage>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_hMBXSD_r90OcUkje1xs0Kw"
      decimals="-5"
      id="Narr_hPQMAVDs4UyPFtiNDSzgnQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_hMBXSD_r90OcUkje1xs0Kw"
      decimals="-5"
      id="Narr_gazuGztm20qjkbcmU9vrBw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">14600000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog"
      decimals="0"
      id="Tc_lGxezDs1Z0iMzCsFBeTirg_1_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1697500</us-gaap:DerivativeLiabilitiesNoncurrent>
    <anvs:FairValueAdjustmentOfDerivativeLiabilities
      contextRef="Duration_4_26_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_4nudJCrUe0q5HzKyVLPtIw"
      decimals="0"
      id="Tc_qKOYVeJw8EGW_ENwHZ88Cg_2_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1192500</anvs:FairValueAdjustmentOfDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_eDlqgmZOK0uV7d1yioA33g"
      decimals="0"
      id="Tc_MtqXG_vzdU2ut3XH4ZIAVA_3_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">505000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <anvs:FairValueAdjustmentOfDerivativeLiabilities
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_aMlHarrTRUOw2ZPEPhIpaw"
      decimals="0"
      id="Tc_2wyEoX1Az025OS_lU814xQ_4_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">62500</anvs:FairValueAdjustmentOfDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_DplnVEhr1UKyMZzvd2jAOg"
      decimals="0"
      id="Tc_iRfoO3p-rkOXI4Y6yZKVuQ_5_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">442500</us-gaap:DerivativeLiabilitiesNoncurrent>
    <anvs:FairValueAdjustmentOfDerivativeLiabilities
      contextRef="Duration_10_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_ZVroRH_FcESsW5ndUBJ8dg"
      decimals="0"
      id="Tc_-jksFCxY0UyHU_XkM7WuwA_6_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">442500</anvs:FairValueAdjustmentOfDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_JiqWi9fSuEijFwv_zoQINA"
      decimals="0"
      id="Tc_38dsLiTZY02GN8jm01irBg_7_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <anvs:AtMarketEquityOfferingCommonStockAuthorizedValue
      contextRef="As_Of_12_11_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_HZ8IW9wPyES6tf53JMU46Q"
      decimals="-5"
      id="Narr_z_9FSoykpUuUaqevgSPwTA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">50000000</anvs:AtMarketEquityOfferingCommonStockAuthorizedValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw"
      decimals="INF"
      id="Narr_gpQFYjs3FUenHVaL9XwsJQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">26788</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <anvs:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw"
      decimals="-5"
      id="Narr_QIW-s4d3LkOdOYjawouulQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">200000</anvs:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_l3-QgLezUEK56PFSmYolqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(8)&#160;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective upon the closing of the Company&#x2019;s IPO on January&#160;31, 2020, the Company&#x2019;s 2019 Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) became effective, succeeding the Company&#x2019;s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 12, 2024, the 2019 Plan was amended to increase the number of shares authorized from 2,000,000 to 3,000,000. As of December 31, 2024, the 2019 Plan contained 354,299 shares available for future grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board, except when they are below previously approved thresholds allowing the Company&#x2019;s CEO to grant awards on a discretionary basis. The Company&#x2019;s stock options generally carry a maximum term of 10 years after date of grant and are exercisable in cash, or as otherwise determined by the Board. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,510,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,414,867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,326,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,213,539&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,836,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,628,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In Thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,954,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 17,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 870,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (300,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (189,248)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,336,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,824,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $5.16 and $7.39, respectively. During the year ended December 31, 2024 the Company received no cash proceeds from the exercises of stock options. For the year ended December 31, 2023, the Company received $8,385 cash proceeds from the exercises of stock options. As of December 31, 2024, there was unrecognized stock-based compensation expense related to unvested stock option awards, related to service-based options of $2.4 million, which will be recognized over a remaining weighted-average period of 1.0 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the years ended December 31, 2024 and 2023, the Company issued 870,494 and 367,329 options, respectively. Under the grant agreements for the 2024 stock option grants, 382,282 of the options vested immediately and 468,212 of the options vest in substantially equal quarterly installments over two years from the date of grant. There are also 20,000 stock option grants that vest as consulting services are performed and awards are earned. Under the grant agreements for the 2023 stock option grants, 94,624 of the options vested immediately, and 272,705 of the options vest in substantially equal quarterly installments over two years from the date of grant. All of the options have a 10-year term prior to expiration.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The assumptions utilized in the fair value calculations for stock options granted during the years ended December 31, 2024 and 2023, respectively, were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average expected option term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Related Party Transaction&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;During the year ended December 31, 2024, the Company issued 20,000 non-qualified stock options to a member of its Board of Directors in consideration for the member&#x2019;s agreement to serve as a consultant to the Company. The options were issued in one tranche, at a grant price of $5.27 per share. 8,069 of the awards became vested during the year ended December 31, 2024. &lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2018Member_WHvnc8vNT0mnAJbraAi9IA"
      decimals="INF"
      id="Narr_xUMejuiwhEeko_fplfkDdw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_1_2021_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_RldmCmC-GEOG6BsKRZ7jHA"
      decimals="INF"
      id="Narr_MW3hdYtBdEyxgPBkAnS4sA"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_6_12_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_VGsJvkPfqEiFabjsYECyuw"
      decimals="INF"
      id="Narr_JxvRv-LM6UuHQ1teP6gmug"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_zW8RAM-bpUWV473IHWZYTw"
      decimals="INF"
      id="Narr_JLfQXlW1H0OnKCgnhttwUQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">354299</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_SrizNFCLl0OrRUDzrcGBsg"
      id="Narr__KSUpA8_1k2Bt72Oc5GJbA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_CEEslxFJpU6DNpROhNwFbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the&#160;years ended December 31, 2024 and 2023 was as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,510,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,414,867&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,326,326&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,213,539&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3,836,770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,628,406&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_gvgCPSCuP0eTU2Ad-DzdLg"
      decimals="0"
      id="Tc_EfPlOpf-y0q7iT1sADGOhg_4_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2510444</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_CS9mE9iYf0ibvclFxHcf3Q"
      decimals="0"
      id="Tc_qfcFExYY9EytFWukloul1Q_4_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2414867</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_drKyELhDW0-wlU15l7Zyuw"
      decimals="0"
      id="Tc_UVqUVbW_q0ubUZMIfK6s7A_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1326326</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BZvwU0W_1kq5dnznbxqBTQ"
      decimals="0"
      id="Tc_goNSsf2SskiIgyaV6v8SiA_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2213539</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_eiBsSVvKSEuf2IKcKmeqLA_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">3836770</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_AD9elYj_B0iixujaG2QZoQ_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4628406</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_pF8sDXjakEaFWve35xHS0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table summarizes the Company&#x2019;s stock option activity:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(In Thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,954,774&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 13.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt;6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 17,863&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 870,494&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (300,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 3.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 570&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (189,248)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 20.61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 2,336,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 11.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December&#160;31,&#160;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,824,122&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 12.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 6.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,298&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="INF"
      id="Tc_yp-CnhVA_kePJEceVdmF8g_7_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1954774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="2"
      id="Tc_hhvkvSllnkSgTzqg-6YMrA_7_5"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">13.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      id="Tc_2M8gbdLitkK0dEdsO3spJQ_7_7">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="-3"
      id="Tc_k6tD9L4Gv0CLw7-NmM3-eA_7_10"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">17863000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="INF"
      id="Tc_giiNWqe59EGh05TcgWpGwQ_8_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">870494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_JdZo7G8JEUmZsvcAFeYLcg_8_5"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">6.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="INF"
      id="Tc_MYQqoeDDvEGi6u0xv9iu2A_9_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_1qF47NV95E-se17smOxP3Q_9_5"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">3.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="-3"
      id="Tc_OGPBWWrv_0uIR7EtwKjLJQ_9_10"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">570000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="INF"
      id="Tc_4lAhwdu7pk6olljWPB7VUQ_10_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">189248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_tnAmacDie0aoVFJfjklBbg_10_5"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">20.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Tc_yjnaNohni0ugT3eU2CKqSw_11_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2336020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="2"
      id="Tc_LLIu8pJY_kah8IfTEDf5sg_11_5"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_Q_Yq8WQ2IEK-4Qry-1Qcvw_11_7">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="-3"
      id="Tc_mUsGU-MQ2E2hCiGy2Qvn7w_11_10"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1298000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="INF"
      id="Tc_l3VdcxnJdUWfFAmd8szOsQ_12_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1824122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="2"
      id="Tc_NXYEeXKu9k6SavoyQmcyqA_12_5"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">12.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tc_Da0wWLZ4vEuWO1TWXU345A_12_7">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="-3"
      id="Tc_OTzBFnY-qEqtIb51RPbh0Q_12_10"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1298000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Narr_pOCOiyl28kG_-iQcvDXcgg"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="2"
      id="Narr_TuHidDg_u0e5v2HvO8pZdw"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">7.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Narr_5x1wQ8hYhkuhP-UAKR1LMQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Narr_DMJEqZ4mhUqYrB7pvsKxoA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">8385</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_Tk2BdOkQEki6zZ7xcxRKFQ"
      decimals="-5"
      id="Narr_bxV4grRy9k67-_3LN8D4mA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_anvs_ServiceBasedOptionsMember_YF4qvTY1HkiAlLoVQFqtXg"
      id="Narr_dXVHJqvbI0qlOua6rVmh3g">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="INF"
      id="Narr_ukPe2r-5eE6641R3h94O1g"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">870494</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="INF"
      id="Narr_-vH-Wqn_B0Wd_9RVnzr5gQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">367329</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_wwvOa88X1UO_ZTYRVgaRLA"
      decimals="INF"
      id="Narr_5WJ8ZvI4s0mBztSTuASlQg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">382282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_61vShh9zukuFEQnE9vaedw"
      decimals="INF"
      id="Narr_obCU2l4prkOsVN7LaHDBxg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">468212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_61vShh9zukuFEQnE9vaedw"
      id="Narr_56hJSO8exEyJvuV2USIOhw">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_VestingAxis_anvs_PerformanceBasedVestingConditionsMember_pJBku7_aCk68MVRcc7xViA"
      decimals="INF"
      id="Narr_9JX-vGLI1E65viwVYLVRUQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_OeMNROUv0EC2j9VxF13eMQ"
      decimals="INF"
      id="Narr_g4G-bugfVEOdl_P7TMbstg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">94624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_c12N8aDCj0a8T1KQPkPjgA"
      decimals="INF"
      id="Narr_5zspahtyo0GEYjfVBAy08Q"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">272705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember_c12N8aDCj0a8T1KQPkPjgA"
      id="Narr_Eswnv-B_BU2MnDqWms_ADg">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Narr_bsEw1QGgaUmpo8DgtWSSPw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_yiA16hibj0aDPOQapllMzA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4.17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average expected option term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 120&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw"
      decimals="4"
      id="Tc_joyh8rYp80urzRompmylDQ_3_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A"
      decimals="4"
      id="Tc_ptXT5IpcH0G5O6So8aeImA_3_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.0417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw"
      id="Tc_LP4-2WE6W0eGJqt2guo6jQ_4_2">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A"
      id="Tc_0OGJAFNaMkCtrmAKMskagA_4_4">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_LAkBkCl5NUauejfB571yPw"
      decimals="2"
      id="Tc_fuEwyShDKESaAPD_4ta36g_5_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">1.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2023_To_12_31_2023_srt_RangeAxis_srt_WeightedAverageMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_TGr5SKwBOke2-vN60p0L0A"
      decimals="2"
      id="Tc_Ibzd6z47A0ij0eUYIA-Z2Q_5_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">1.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_hvDUBjTlvU2jxBxrBfn9yg"
      decimals="2"
      id="Tc_jN5uJX6xZUO9OYEsAaiHrA_6_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CG9ka-YnN066FFG9Jtzx0g"
      decimals="2"
      id="Tc_w_rrfNchgkKmUUd-W4Jnuw_6_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_pDfDkGHDXUSTWmxUhrtBpg"
      decimals="INF"
      id="Narr_yXXEyx4L3kCBXPu3t2PDFg"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">20000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_pDfDkGHDXUSTWmxUhrtBpg"
      decimals="2"
      id="Narr_ffT7COWgEU23gST2AMnxug"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">5.27</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2024_To_12_31_2024_srt_TitleOfIndividualAxis_srt_DirectorMember_us-gaap_VestingAxis_anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember_bukzSMYfYkGUxtewxBU0ew"
      decimals="INF"
      id="Narr_aKmrnVvev0CE_b4_5hoszw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">8069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_v1L7uT0G8EW20MhXPz-u8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(9) Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has reported a net loss for the&#160;years ended December 31, 2024 and 2023, and the basic and diluted net loss per share attributable to common stockholders are the same for both&#160;years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share &#x2013; Basic:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,590,375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average common shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,182,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic net loss per common share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.02)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6.23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share &#x2013; Diluted:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,590,375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Less: gain from change in fair value applicable to dilutive liability-classified warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,625,893)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Numerator for diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,216,268)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Denominator for basic net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,182,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Plus: incremental shares underlying &#x201c;in the money&#x201d; liability-classified warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Denominator for diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,235,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Diluted net loss per common share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.31)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6.23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,336,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,954,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,202,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_d6HLT-IoNUeeue5ZEHhZww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share &#x2013; Basic:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,590,375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Weighted-average common shares outstanding, basic&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,182,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Basic net loss per common share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.02)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6.23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Net loss per share &#x2013; Diluted:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (24,590,375)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Less: gain from change in fair value applicable to dilutive liability-classified warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,625,893)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Numerator for diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28,216,268)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Denominator for basic net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,182,475&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Plus: incremental shares underlying &#x201c;in the money&#x201d; liability-classified warrants outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 52,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;   Denominator for diluted net loss per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,235,444&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,023,138&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Diluted net loss per common share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.31)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6.23)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_ElbTNkIwgEOQ_5gmEOsx-w_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_rD6rma5w_0i2Vk36vi-W0Q_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_lR0jkmlsW0O-9PqETc0S3A_8_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">12182475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_Sd4xNFaVTk6-9-BIndwuoA_8_6"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">9023138</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_ZmUbzqp4y0ShSu3wx39dwA_9_3"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-2.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="2"
      id="Tc_BQg9e8TR5ECTkf-V22RkGw_9_6"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-6.23</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_MxlCYJGQME6UwKYZ_aJ1OA_13_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_orKzN5WNfESLmvdeBFfiMg_13_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_IsGiSpZmuUaXATLaG-YEqw_14_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-3625893</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_KleS4OMgGEm9dvvCzG1RLQ_15_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-28216268</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_jtacJWsZvUadL6oZXF6FZw_15_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_JzbbjrxP4UKgpjaghVHR8g_17_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">12182475</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_oCKlNKFkSkSHkXRPLuLmrA_17_6"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">9023138</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_5Hebx7WEtkeEYrHeTtcuYg_18_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">52969</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Tc_y-sc5TjEkEGbklT-Tkhi0Q_19_3"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">12235444</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Tc_17Bz9mD_WE-HU2KKUxrxcw_19_6"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">9023138</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_tBvNehq9hE-i_MTEHrsitQ_20_3"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="2"
      id="Tc_tBvNehq9hE-i_MTEHrsitQ_20_3_2"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-2.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="2"
      id="Tc_T1PgaMNzOEuN74Ad_DMM6g_20_6"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-6.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="2"
      id="Tc_T1PgaMNzOEuN74Ad_DMM6g_20_6_2"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">-6.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_KpvIkuVGtEOmj-hfytE28w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,336,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,954,774&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,202,400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w"
      decimals="0"
      id="Tc_YOSOVaVa9EaMhSFwK4tVEg_3_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2336020</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_ETg7vggNp0yISA331JxRTQ"
      decimals="0"
      id="Tc_C0TWBcJmP0CfEKPiRiJ_tA_3_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1954774</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_GmXKWrDQdku8NRf1skZHOw"
      decimals="0"
      id="Tc_-wsSFV1GWUiDnjiWdS8Wvg_4_2"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">2400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_EkA9YeMGEkWI79aNnSvkJg"
      decimals="0"
      id="Tc_VI1YOt4VyEi5Wntmwoeobg_4_4"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1202400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_10nsTLkOnEap71jrw-xqVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(10) Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The federal and state provision (benefit) for income taxes was&#160;$0&#160;for the&#160;years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2024 and 2023 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, change in rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value of warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets are comprised of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,634,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,607,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,390,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,245,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,137,406&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,334,494&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Section 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,802,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,793,442&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,198,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,132,475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 76,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,240,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,127,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,240,555)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30,127,594)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had U.S. federal net operating loss (&#x201c;NOL&#x201d;) carryforwards of $54.1 million which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million which may be available to offset future income tax liabilities and will expire beginning in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2024 and 2023 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company recorded a net change in valuation allowance of $7.1 million and $11.7 million in the&#160;years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2024, the Company had federal research and development tax credit carryforwards of $5.2 million available to reduce future tax liabilities, which expire beginning in 2028.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections&#160;382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections&#160;382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company&#x2019;s tax&#160;years from 2021 to the present remain open for review. All open&#160;years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the tax authorities may adjust the tax attributes upon their examination of the future period in which the attribute was utilized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="0"
      id="Narr_NMlX6XlqAki3kmLhVr4HFA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Narr_KYfY0hMtS0ivR0y1eHGkYQ"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_Lqs2y-_pGUqcoBszfcL3wg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the&#160;years ended December 31, 2024 and 2023 is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal income tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 3.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State and local tax, change in rates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt;0.0 &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in fair value of warrants &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (20.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Effective income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 0.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc__jeZiRzBOEeHwv8BXS2_wA_4_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_EJFBopEwfESFoX52dRfIUg_4_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_WQUsO4_NnEOUUtNVv3Fpcg_5_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.04</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_FzfNsNxCHUKF-PCjqTFV8A_5_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_5vFGwl_dhEmf3I_ocqP1kg_6_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_AgyfgibOfUeqrRmzwnE5_Q_6_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">-0.035</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_Cx-D6S7k-UWRKc-22ixR-w_7_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_fb0WtJejC0uoOVUi5mWgOQ_7_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc__11y7jl_106xYzWTF4qJtQ_8_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.043</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_710FhQVJxUibooxlOIDhAA_8_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_Cn6UEH8GwU2GpGkRlXyEag_9_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_E7uejL07_kSVuhPfhNvV4Q_9_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_oEA4kMv8vkGuu5fYh5cboQ_10_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_scDqicZTN0mzLcHdTvG8LQ_10_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_RTYEd6wHB0CoGKvO_GAioA_11_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">-0.289</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_z3lAIguMOUGURgUEjM3BGQ_11_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">-0.207</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="3"
      id="Tc_1HB32Q5ExEi3lNUjJdx8LA_12_2"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="3"
      id="Tc_bzEqx6uJd0-0GBOvKQdUBg_12_4"
      unitRef="Unit_Standard_pure_ylN5xi-l6E-4ihGyJQV1nQ">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_MDAfMcFoN0KqmneavXg9jg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets are comprised of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 13,634,896&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 9,607,158&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,390,635&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,245,472&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized R&amp;amp;D&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,137,406&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,334,494&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Section 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 12,802,738&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 10,793,442&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;R&amp;amp;D credit carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 5,198,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 4,132,475&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 76,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 14,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 37,240,555&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 30,127,594&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Less valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37,240,555)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (30,127,594)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred taxes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_UtyLZQcw30iOo_-W-Cc1dQ_3_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">13634896</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_4Osnvwn3K0Sw-yvN319eNw_3_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">9607158</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_wVejGrDABECAg58ElvpY7Q_4_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4390635</anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment>
    <anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_T0AMKxOpbkO5cjYnW7ZGJw_4_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4245472</anvs:DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_aR-MexVzvEWyY4vLZDyRzA_5_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1137406</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc___Ihqa_RUkCm9Y1xgeX_pg_5_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1334494</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_tFQ-Szw_80ukldp5xVGdOQ_6_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">12802738</anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures>
    <anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_VxX6EIHGHkaASTqNqNwuWg_6_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">10793442</anvs:DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_T32wF8siQkuDEAUMhtSrPA_7_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5198123</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_eJqIzegR2kKBeP30joI_fQ_7_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">4132475</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_hfEp0hU0nUyosTgyGNaI3w_8_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">76757</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_x2pqIH2JlEqHWHiGV6sNgA_8_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">14553</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_GuWQIwUeykiJVQF1B-ZkKg_9_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">37240555</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_uv8-P_KpJkadVlKcnGGvsw_9_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">30127594</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_NzkmX4ts6UeRKUEzYxO5Ow_10_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">37240555</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_64wtvH8dYE-FcU0qzBlGfA_10_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">30127594</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Tc_9G55xtyVaE6_Z0o34knp1g_11_3"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww"
      decimals="0"
      id="Tc_gOIrwivLa0Sw-lBrVR0YuA_11_6"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_1b7gLnM7l0uyFch569QwTQ"
      decimals="-5"
      id="Narr_eG7_KkVExUiOIdzSZ-2C6Q"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">54100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxPeriodAxis_anvs_GeneratedIn2017AndPriorMember_q2MkFPGZKUeQUuTkMa5JVg"
      decimals="-5"
      id="Narr_6jnfkjjGVkiU1Zd1vNeZrA"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_hoAfWhIToE-9kc4wkiIxvA"
      decimals="-5"
      id="Narr_af6yqCjhI06JRgQWoJICRw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">56600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="-5"
      id="Narr_yFYaebNRkEGfsNgW7hspKw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">7100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_ANZ0bpwmrEa6DHxfYotu5A"
      decimals="-5"
      id="Narr_fMmYO5WFuU-7b00LQWGKLg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">11700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2024_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_j7VLWFmUpEe9bDHG0DciDQ"
      decimals="-5"
      id="Narr_zcVe1syDXkOg2HFsfyUHjg"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">5200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA"
      decimals="0"
      id="Narr_d9W-X9bXlkWJ8I16kSK9_A"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      decimals="0"
      id="Narr_2bUfs75wZE-jm6cm4C10gw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <anvs:ResearchAndDevelopmentAmortizationPeriodTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_fOusTvtxKkyURMPwViHpkQ"
      id="Narr_0edVWphNEkyOXvdh9rjDhQ">P5Y</anvs:ResearchAndDevelopmentAmortizationPeriodTerm>
    <anvs:ResearchAndDevelopmentAmortizationPeriodTerm
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeTaxAuthorityAxis_us-gaap_ForeignCountryMember_KsBP2tMOlkaHzf39vA3zUA"
      id="Narr_pR19sC_3skujyjo_6eHVWg">P15Y</anvs:ResearchAndDevelopmentAmortizationPeriodTerm>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_ajk1E3lrMkidXIEFIWhQkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;(11) Segment Information&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2008. The Company&#x2019;s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. This presentation is consistent with how the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on net loss as reported on the statements of operations. The CODM uses net loss to monitor actual operating results, assess cash runway, and benchmark against the Company&#x2019;s competitors. The measure of segment assets is reported on the balance sheets as total assets. The Company&#x2019;s assets are held in the United States.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company&#x2019;s segment information as reviewed by the CODM:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Program expenses related to clinical-stage product candidates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,723,518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,104,702)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Program expenses related to preclinical and discovery programs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (568,214)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (583,154)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel-related expenses (including stock-based compensation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,525,586)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,444,920)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative professional and consultant fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,687,276)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,152,485)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&#xb9;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,190,333)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (749,750)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 331,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 667,898&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other non-cash income (expense) items&#xb2;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,772,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,837,199)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,590,374)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;&#xb9; Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;&#xb2; Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_s0tpbpm24k6C_IfEbTl_SQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;When evaluating the Company&#x2019;s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company&#x2019;s segment information as reviewed by the CODM:&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Program expenses related to clinical-stage product candidates&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,723,518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35,104,702)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Program expenses related to preclinical and discovery programs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (568,214)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (583,154)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Personnel-related expenses (including stock-based compensation)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,525,586)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,444,920)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative professional and consultant fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,687,276)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,152,485)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment items&#xb9;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,190,333)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (749,750)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 331,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 667,898&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other non-cash income (expense) items&#xb2;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,772,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (11,837,199)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (24,590,374)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (56,204,313)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;&#xb9; Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt;&#xb2; Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.&lt;/span&gt;&lt;span style="font-weight:normal;background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <anvs:ProgramExpensesRelatedToClinicalStageProductCandidates
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_yK8K5UyBRE-mVnWr68hU-A_3_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">16723518</anvs:ProgramExpensesRelatedToClinicalStageProductCandidates>
    <anvs:ProgramExpensesRelatedToClinicalStageProductCandidates
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_Q4nF-B81uEG5nQ8x0C52rw_3_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">35104702</anvs:ProgramExpensesRelatedToClinicalStageProductCandidates>
    <anvs:ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_L4XD--dj-0GAoNRReuCv8A_4_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">568214</anvs:ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms>
    <anvs:ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_Mn7imuau9UmQv8acOOWItw_4_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">583154</anvs:ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_L0ELPV-sQES9bHhQeBm6rA_5_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">6525586</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_nsTJS1ImpUuzMedHV_rFog_5_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">6444920</us-gaap:LaborAndRelatedExpense>
    <anvs:GeneralAndAdministrativeExpenseProfessionalAndConsultantFees
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_1xZfmNlaDku3qoefyCFO2g_6_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1687276</anvs:GeneralAndAdministrativeExpenseProfessionalAndConsultantFees>
    <anvs:GeneralAndAdministrativeExpenseProfessionalAndConsultantFees
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_SvymXOfdaUWmCSjFhLfzIQ_6_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">2152485</anvs:GeneralAndAdministrativeExpenseProfessionalAndConsultantFees>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_nyVEovh_506zN88fkzKUVw_7_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1190333</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_mmJDkhLQlkOWew1nhA076g_7_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">749750</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_SxdVjTWrgkePz8aZd9sMeQ_8_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">331849</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_yVSGHuxhdE-a2A8AK-YxGg_8_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">667898</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_xn5WtOmQR0KkES8eRMd8rQ_9_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">1772704</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_qvvyCUEy30Clijy4hPRorQ_9_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-11837199</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A"
      decimals="0"
      id="Tc_xVx_RPdRPE219MLxapWcqA_10_2"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-24590374</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2023_To_12_31_2023_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_jHyJk8DGak2uf7FsjrWESw"
      decimals="0"
      id="Tc_aNvY_Dqt2k-pf0viuRRrPw_10_5"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">-56204313</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg"
      id="Tb_wKhI6fmBkUO4edwP7kWh7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;(12) Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subsequent to December 31, 2024, the Company sold 0.1 million shares of its common stock under its ATM with OpCo, which the Company entered into in December 2024. The Company received net proceeds of $0.5 million after deducting commissions and fees.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the &#x201c;ThinkEquity Warrants&#x201d;), at a per unit price of $4.00 (the &#x201c;Offering&#x201d;). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. The Company has agreed to suspend sales of its Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_2_1_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_a5jUEWlNeEGGlp00_fXhKg"
      decimals="-5"
      id="Narr_HQbYw2qHhE2FIWPcwX_SKQ"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_1_1_2025_To_2_1_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_a5jUEWlNeEGGlp00_fXhKg"
      decimals="-5"
      id="Narr_C8AYIII7UEG2XsuAGoeU2g"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <anvs:SaleOfStockNumberOfUnitsAuthorizedForIssuance
      contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg"
      decimals="-5"
      id="Narr_PG3at6Iqe0Wcqk0v__Z3-Q"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">5300000</anvs:SaleOfStockNumberOfUnitsAuthorizedForIssuance>
    <anvs:NumberOfSharesIncludedInEachUnit
      contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg"
      decimals="INF"
      id="Narr_eTfpqZGp2E6CAQwnHKiUug"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1</anvs:NumberOfSharesIncludedInEachUnit>
    <anvs:NumberOfWarrantsIncludedInEachUnit
      contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg"
      decimals="INF"
      id="Narr__qXlNUwImUacWSVBH5jBmw"
      unitRef="Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q">1</anvs:NumberOfWarrantsIncludedInEachUnit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg"
      decimals="2"
      id="Narr_8zEIN5U6J0G1eKtsZvGGqg"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">4</us-gaap:SaleOfStockPricePerShare>
    <anvs:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_dh8V_0GTe0Kam8Xht2ZFqA"
      decimals="-5"
      id="Narr_yN8B3h0RpkWMUKxjVBYYvw"
      unitRef="Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A">21000000</anvs:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_bTxUgUMD7U-OqPd01NWvXg"
      decimals="2"
      id="Narr_M41DdH_XvE6ymphnzTr4oA"
      unitRef="Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <anvs:WarrantTerm
      contextRef="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_anvs_SecondaryOfferingMember_dh8V_0GTe0Kam8Xht2ZFqA"
      id="Narr_BqSLh64bvUiWUhAYHOCl_A">P5Y</anvs:WarrantTerm>
    <anvs:SaleOfStockAtMarketOfferingTemporarySuspensionTerm
      contextRef="Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ks4SJs0ZpUGHrUcFBn_hhg"
      id="Narr_JgEfJYf8jkSYi7NQ3biTVA">P6M</anvs:SaleOfStockAtMarketOfferingTemporarySuspensionTerm>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
